Document 6B882Qnwpyy6LgKZxwgd9bjRE

Bio-Statistician/MathematicianThis witness will be identified in the near future. At that time a curriculum vitae will be supplied. This witness will describe the mathematical/statistical model which will be used in the presentation of the figures to which the witness will testify. The theory subserving the testi mony is that the multi-faceted presentation of symptoms and signs and test results in the same veteran makes a random compo sition of such an array extremely unlikely in view of the relative in-frequency of each facet of the array. As such, this testimony will be used in the generic and specific proximate causation areas. 12387 HENDERSON & GOLDBERG, P.C 1 6 1 2 Frick Building Pittsburgh, PA 1 5 2 1 9 Thomas W.- Henderson Theodore Goldberg Robert L. Jennings, Jr. Joel Persky Antonio D. Pyle Thomas W . White February 27, 1984 t/" Ms. Nancy Petrilla U.S. District Clerk U.S. District Courthouse 225 Cadman Plaza Brooklyn, New York 11201 Re: MDL No. //381, Agent Orange Product Liability Litigation Dear Ms. Petrilla: Please find enclosed for the Court file, Plaintiffs' Compliance with Guideline No. 34 on Plaintiffs' Government Causation witnesses which are to begin being deposed on March 1, 1984 in Washington, D.C. Also... please find ..anpInspH an additional rn-nv _nf P1a-In ff4 ' Ex p and ed Summaries on the following Plaintiffs' Cansai-lnn Kvrwart-s which I > pronuLs.ed Magistrate Shindlin she would receive before Wednesday., \ February 7Q..lQR./i_ Apparently, the original court copies were missing some pages. I apologize for this inconvenience. Please be advised that by copy of this letter and the enclosed documents I have notified all parties on the attached service list of the filing of said documents with the Court and I have served the U.S. Department of Justice, Ms. Gretched Witt, on or before noon, February 27, 1984, with the enclosed documents as per our agreement. Thank you in advance for your kindness and cooperation in this matter. cc: Enclosures Ms. Gretchen Witt See attached Service List Alison Pettiette Hand Delivery V HENDERSON & GOLDBERG, P.C. 1 6 1 2 Frick Building Pittsburgh, PA 1 5 21 9 ; Thomas W . Henderson Theodore Goldberg Robert L. Jennings, Jr. Joel Persky Antonio 0 . Pyle Thomas W. White February 27, 1984 HAND DELIVERY M s . Gretchen Witt Mr. Arvin Maskin U.S. Department of Justice 521 12th Street Room 824 Washington, D.C. Re: MDL No. 381, In re: Agent Orange Product Liability Litigation Dear Ms. Witt: Enclosed please find Plaintiffs' Outlines in conformity to Page 34 of the U.S. Guidelines and Order of the Court in the above.entitled and numbered cause on each Plaintiffs' Government Causation Witness whose deposition is to be scheduled and taken on or before March 15, 1984. With regard to the listed documents for each of Plaintiffs' nine witnesses, we will supplement within 7 days of each deposition any other documents Plaintiffs' may wish to have the witness review prior to his/her deposition. However, as to Janet Springer, the list of documents is complete. This will confirm the deposition of Ms. Springer beginning Thursday, March 1, 1984 at 9am at the Hyatt Regency Hotel in Washington, in a conference room. Thank you for your cooperation in this matter. Very truly yours, Alison Pettiette Thomas Henderson' ' Enclosures cc: Ms. Nancy Petrilla, U.S. District Clerk See Attached Service List 12383 PI.AlTf I F F 'S GOVSRiitlEKT CAUSATIO:! W I T M E D S E S Teruim U. Ilouk A. Center for D'.sease Contr ol (CDC) Atlanta. GA B. Bc'tth factual and ^sae.t teat iwony Is sought C. Gaateral Events iiuy fc C".Jai icnow 1edgc of the hict ory o f lic >ic idc - .1c 1ud ino : pjjuy in G b#U *M- no t in J . S . limited iinu to, cb road; Cl ind u otri.a I xy osu V o an cl Cixp '3sior.s; (2; rag 1st ra Uion r*^ r,4 D , '3t-T vrii. the Department of k*gri* r* u .1 . V '2 nd c.ny o t ar gover::men agene .! s i:j - -`5 an U /- c a - - Lhr. D o.f .h u 'an 11-i - A::'.y act u a ; ;;0:.`l dge of the IkiStC r y o i T, or !; . c Z_c.. a c p . c. a. Li 'J in ;he U.S. ar d a b v o ad : .1 ... V in E , b j,t Ti ^ l i m i t e d t o , i i , u . s . X Jl l; a --j use 0 r A g fc-. nt Or nge and othc r p h s * C\" u - C - ,.1 r Jn V r tl iin.:, C --) change 3 .1 . t he ii i S - 1 c * cq u ir GTCants oi herl ..oI d e 3 it ' t h e u,, r*c\S g ov c '11o-fce rum of p rr f* i.7 sn ;.:lr*v d 3 its agencies riA.EPA, and inc lu din CJIIi ; and o: ci:..y %, ou .. c d C n n .k11 iust-ial and o iher h um.vr> n. ZV'i - Ci to /. D > 2 ,4 ,5 -T in :he U f . ar.c:[ Sec Answer and Sun :I.ccantsl Answer of P l a i n t i f f s 1 to' Dof r :riants * "nterrc.gctoi-y Ho. 19 attached : hereto and inccrpcrated herein for all pur poses re: events or occurrences which these ca.cation witnesses may be expected to give any factual information they may have regardin the safc'etc outlined in said Answer. Huaar: Rick A s oc a s a c n t cf Eupcsu ra to 2 ,4-- D , 2,4, i~T and dioxins and any factual knowledge in support thereof. D. Expert T ee ti mc ny 1} Tost icon;.- is sought in witness' pe rs ona l and official capacity. 2) ' .'Meet Matter 2 ,4-D , 2,4,5 * T , TCDD !s and d i ox i n s ; Agent .Or ar. l! 11 (also rhiue, B l u e , Pink, Greer.,' and T u r p i rzaiotj sf^iH /'"'N 7 S'" ;*, y S. and related chlorophenols and human risk aaiicssnent regarding exposure,, .eluding, but not limited to, cue or more of the following cubj set ar-oas: a) C h e m i s t r y / E ; t: Manufacture c> X d-a. -Xc. y d) M od es of Hr. e ; Pate in the Environment (Humans f Plants', Artmain)_ Slate of Art/State of Medical and Scie -tifi Literature 1) Liana P h y s i o l o g y / S t u d i e s //. A;...ni l PL'a.ic.togy/Studiec 3 ', E-.n... St*. Ins L-piC- cn 1o ..egy/Eiostatistics L. Plants, arrimais, h m an s Cate or Epidemiology 1 ) 1 c.preductive Epidemiology Acau't - Health Efra'-ir 3) witness will be naked opinions about bctl. published an/or eu-go i n -; studi. 4) 3 .ritac.cs will b t asked opinions about any studies or research witness has personally performed cr actually participated in. j.e s witness will be ashod opinions about other governmental studies. fitness is exported to review the following dosuiacscr prior to giving testimony : St';, E1A , Research 'and revolopaient. Health Assessment Docum ent ou -Dibs.:' ir, for the Offices q l: -Air' u-lty,' Plena in y 'ar.cl ar.darc-sv, pVepared 'by the Enviroiiaeat.al Criteria and A 3 aas site Office, Cincinnati, Ohio 45218 ( July -- 12371 EPA, Rennerch and Development, Health and Environmental Effects Profile for; Tetra Pcnta, and Hcxaehlcrodibenr.o-p-dioxins, for the Office c Sol i d .Waste and Emer gency Response, by the Enr_.:cntaental Criteria and Assessment Office, Cincinnat Ohio 45240 (Jcnu 1983). ) EPA, Research and Development, Ambient Water Quality Criteria for 2 ,3,7,8 TC DD, pre pared for Office of Water Regulations and Standards, Ivy the Environmental Criteria and Assessment Office, Cineinnat Ohio mSPiS (July 1903).. ETA, Re se a r ch and Deve lo pme nt , Dioxin.., Industrial Environmental Research Cine:* vmeti Ohio (1978). copy o .. there dr cum ont s ,s a si:r.ah- d . h. Major Alvin T,cung x. Dr. Rodney Eovoy Kenneth V. Therein n. David T. Buzzaiii o. Dr. Michael Gross g-.. Dr. Renee stringham r. Dr- Van Miller :r ............ '* ........ ) SUPPLEMENTAL BSWLR IX; im^ERRQg.JORY NO. ID SlainSiffs r:"t preliminarily that the extant Order on producing fa-t witnesses rtates that f:._t vr :nesses are not due until Karel 2, 1984. Hcwsvc:.', laintiffs nrxy o;J.i one ox* ntrrx. of .die fol .owing persons (or these iron* vr "ions categories Listed tele*:) at Urns of t . rl. to testify as to factual knowledge they ma / have including: Ranch Hand ?e:-: onnol: Thorne persons will testify tc their Icnowlec'ga of t & Ranch Hand Operation,- Ranch Hcnderr:-1 exposure to Agent Crar.; i. no/or taio,.-:lodgo relating to the spraying, testing, and e 'foots c Agent Or-cngs cn htensns. Makers of the LI a. trrad forces: These persons mag- testify tc the circumstances and conditions surrounding'the spraying of Agent Orange. Perrons nrasent :x- Vietnam during tfcs sespe.rure period in questioi-."1931-197?. including. }-rt not limited to, military and paramilitary personnel of * 11 3... Net: Zealand and Australia, v:ho have knowledge < the spraying operatione of idio herbicides, the exposure o:' he Plaintiffs' class, the lazarac acocrapanylr.g any such exposure, tbs Plaintiffs' themselves, and tiie Defendant company representatives present in Vietnam to cversr.. the deliveries and spraying operations of the !. --bioidos thev mrxuifactured. 4 Person.:; together with their c.=manstrative and documentary evidence who gave testimony 1 ;hich will form the substance of their testimony herein) at the EPA Cancellation Hearings of 2,4,5-T (1379-1901 yr.xsr F:TTA, including but r.o.t limited 12373 Dr. Roy Albert or. K. Diana Courtney 'bert i. Brnirrhmni^ *3N Any current or previous employee, contractor, uubccntractrr, in-housc. car private consultant of etch of the Defendants or any other person who lias factual knowledge of how ctioxins v/orj: upon plants, animals, and/or humane. i" ftny (Cinarr. iat or previous employee, rentrector, subornitrac:or, iu-tarso ar private consultant of each of the defendants or any other person who has factual kna-zledgo of any statist os concerning '-he effects of dioxins upon plants, animals, ai. Vor ;v humans. Any cccrrit or previous employ.., ccnt.rc.ctor, suboentactor, itt-haasa or private consultant of each of do Defendants or anv ctlr;.. parse : including, out not limited to, msnbers of E&\ arid other gaver :cientai are c;-.5,who has factual lonowledge cf * fallowing incidents: a. . Love Canal b. iniSS Beech, Mir.s r.ri c. Sevesco, real" d. BAiT USS3, IS'il - Badiorh u Cerrearry) o.. r.ucSacticr. risliaps and/or explosions r. .nee ISliS at -.ny of the plants of aiy cf :;ho Defer/-:,its manui?...tu:ciiTi5J TC?, 2,4-D, 2,4,-`dL' phenol, chlorin'., roe-tic acid, benzene, sodium hydroxide, potassium hydroxide, ar/./or ;tusnt Orange, including mishaps in the g -okaying, ar/. f ';nrpcrt-h.g :f the Defendants' products f' if:: u. : Anted L'crucs bases for eventual shipment to Vietnam. f. Sprevir of Viotna-.: fret: 13,, 1/71, Any c f -ant or prr-v.ous enplcyae, cc.^rarn-.or, subcontractor, in--hour... c: private nsultnnt of each of ti:r. r fendants or any other person who has factual kac:v ."ga cf any surveys, teste, epidemiological studies of any kic/l relating to the effects cf sjosure to Agent Grange, 2,4-D, 2,1,5-T or any constituent thereof inc.ludr'iia the stcc-r.dsry by-product known r.s dioxins. 1/: Any person with factual Icicwledgo of how decisions are fade within- the United Cistes yc/ornmonfparticularly the decision to t:se and. to continue to use phenrxy herbicides in Vietnam, particularly Agent Orange; any person with factual knowledge cf government procurement contracts and the invitation to bidders, particularly those pc./sons who negotiated the gewsrnnent contract: for ail phenacy herbicic.s (agents v.hite, blue, purple, pink, green, orange 1 and v.lfcn the individual defendants repre.- sentavives Joetueon 1911-1 r72,, -U- 12374 '/"V / !7&' 15. Any person with factual knowledge through any surveys, tedcs, epic-aniologica] studies or otherwise undertaken by. any state government, any private public or foreign evaporation, the U. 1. Congress or the government of any nation concerning the chemical cccr,pound;-, 2 , 1 , 4 , 5-T, dioxins, or related chiorenhenla relating to the creation of dioxins, the detection of dic:cin:i, the dangers of 'dioxins* esqposurs, and/or the tcadLcity, carcinogenicity, fstctcxieity, teratfigenicity . acute and/or chronic effects on plants, animals and the htroan popula.fcion 25.. Any end all persons listed in the Chemical .cythe by Alastair Kay as having factual taowiadga regarding 2,4,5-T, 2 and- fir: -j-mtarainant dioxins. 17. 21 worker ocapcncaticn carriers for the Defendants ar.d dccuEesata-bion or a.ll occupational exposures filed since '925 which '.acdcncc industrial injuries or diseases at the TCP, 2,4,5-1, 2,.4-Dr, Phenol, packaging, n d h r r u v p o r a f c i e n plants c~ the Steferfkotc. IB. Ary ssa al1 current or pricr wcrJcars compensatici ciaimvnts cf th Dcferdmto who airred relevsnt occupaidonai <rcposures ano/or ri'cvant ocovpaticr.nl ir.juries or.1/ :r diseacas and/or cynrotams r U n reievent nlrnt.: .liutai in Anewer tu Lio. 19 (sub IV! abavo. 19, Any and all narrhor : ->f t a y. C. House of R&presentati/es Ctamdttee ...i lunar,-. bie Panic:-: of the E?k actions .'1583) and/o:, any person toge'hou with tha:r documentary and deccnstrativs evidence giving t ...rtieeny a 1: e.aid hearing {which will fern the substance cf their tost: r.my liarein- on the failure of the EPA to take prarnpt and effective action to 'ban the production of 2,4~D, 2 ;4,5-T, end .its contaminant eicidns. 20. Any and aJJ. persons haviry .ewiedge o.. relevant facto regarding the financial status of the Defendants and their ability to respond in punitive dasryas, including, but not limited to, their past, present, and future p:c fits and earnings in the "sited States and abroad nines 132"> through and including the present iron the sale of die products rrs.de the basis of this lawsuit, .i.e., 2,4-D, 2,4,5-T, p'lenoxy herbicides and the relevant herbicide market. hi. Any and all person:: having imovriedge of relevant facts regarding .the ownership interests of the Defendants nd their ability to reepor.'. in punitive oarages. itcl'iding, fcv.. .,,oi limited tc,dsfendants! domestic snd foreign subsidiaries, joint. /enturers, licensing r.grascents, ar.d/cr ether public or private corporations in the U, S. and breed, in rhich those defendants c m a sub stantial fir.uncial interc ut since 1325 t'-vouch and including the prevent,, .2375 V. I 2.:. Any and ail persons listed by Plaintiffs1 hi both original and rat:,idea witness licer., as etpert witness {medical, scientific **r causation', , geventtant witness,. government causation witness, defendants5 employees and/or related parsonnai and/or any witnesses listed by all Defendants, may ba called at tinti of trial to cress: it fact*-al : .ToirmaAion as t.> any issue involved in this case. 21. Any and ail members of the scientific and/or medical ccnra.nify who ha-Te knowledge of lv.-.lovaut facts,- including i n f e c t i o n ci; m y of the. previously listed subjects in tils Answer, including, lent not liiaited to : a. David Kriefaei.. Ph.D. b. Dr. Alan Poiane. Tir. `nul BA.0A -.u. Dr. C.. Popps r. Dr. Cortei, BASS' f. Di:. K. --I. i-V.rom: .1 g. Dr, *j, *.h Alvin Ali.t i-jurilyn Auigrrhut 21. Any ancl oil perrons clic :::.o fv.ct*:.nd knowledge ronceming ilia individuo I representative L-laintiifffs damages, including, but not li .' or to, tie 1 Hewing: a. Any and 11 med'caJ. parse ns who have examined, observed, treated and/cr tasted the Plaintiffs7 for injuries diseases and/or related Aysi-.a.l sr.d emotional conditions t. in resulted from Plaivli o.. " gestro to Arant Orange, and/or puenexy herbicides, their constituents, secondary byproducts, wastes., residuals and r-ntsminants. b. Any erd nil hospital personnel where Plaintiffs have bsen confined for treatment .relat' ig to tie:.:: exposure to defendants* products in Vietnam. o. Any and ail perrons with knowledge of tha economic losses, psychological and/or infcangibb damages sustained by y*-ur Plaint*'ffr: as result > Miei: iir! -ics and diseases ..usuiting i .so their .'-roosure to Defendants * on :ducts in Vietnam A;.y a :d all parse:u; with knoveedge of the past,, present and/or future eerne tic losses your Flo:, itiffs have or will sustain in 'die future as a re e f 1 of tlv:.i" f ss of wage earnings unf/cr v/vj.gc,3 earning capacity r',:s"-it:.ng from the injuries and diseases made the basis of this ?." /suit which''sre caused by1 T\*'..mtrfrs exposure to Defendants5 preducts 1`" Vietnam. 12376 -<"W /^ mpw \ J ` Z a , Unito; Slates -nviro'-.iiicn- : Prelection A*},.rio*/ !?nsiienHe .'ioit**,il I- 1 .tri' i r.'::oiv !.nc.nnii' OH 45ZC3 ri Diorans iX. 0*}0%J7i7& '1 7~> PLAIN TIFF'S COVE P:.'MRHT CAUSATION WITNESSES I . 0ebciscs Muker j eu EVA, Washington, D.C. IV. Eotfa fi c `:ua.I and c;:per;: t e s t i mo n y is sought. C. Cstioral Events Pre-1951: A.ny factual knov/iedge of the history of herbicide spraying in U.S. and abroad; i n c l u d i n g b u t not l i mit ed to, (1) induatri. expo su res and explosi on s; (2) registration 2 ,4~D, 2, 4.5-T with the De pa rt m en t of Agricui- tire and any other g o v e rn m e nt agencies b; ary and/cr ell f tic Defendants; 196 '.-fro s n::t : Ar.y factual knew! edge of the history of L'-rbiciie spraying in the U.S. and abroad; i n c l u d i n g , but net limited to, (1) U.S. m i l i t a r y use of Agent O r a n g e ant. other pher he rbicide" in Vietnam; (2) changes in the ; istrat .on rc.qr irements of herbicides wit: U.S. government and its agencies Includin; Icnoviobf of FIFE A, FDA,E? A, and OS rIA; an: ( any knowledge cf indust riel and other human ex posures to 2 :4--D , 2,4 ,f - T ir. the U.S. and abroad; See n s e and. Su pp lemental Answ er of Plaintiffs' to Defendants' Inte rro g a t o r y No. 19 attached hereto ar.d inco rp ora te d h e r e i n for ail pur poses re: events rr o c c u r r e n c e s which these causation witnesses may be expected to give any factual information they may have regard: the subi acts outlined in said Answer, Human hi A s se s s m en t of Ex posure to 2,4-0 > 2 r.4 ,5-T ar.d .'levins and any factual k n o w l e d g e in support t .iereof. Expert Testimony i: Testimony ir sc capa c1 -y . in witness' personal and of fiait ?^ Subject Matter 2,4 D . 2,4 ,.5-T , TCDD s and dioxins; Agent Ora (also White, Elue, Pi.nkr Oreen, and Purr and related c'nlorophenols and human r isk assessment regarding exposure Including, bun noi: U n i t e d to, >ue cr 3 0 re c . the followung subject areas: a ) Ch e ini s tr y / B i0 che 1 1 s t ry 0 ; M a n u f a c t u r e a n d /or Pro duct : 1. c ) i. f.' l i C j. y ) M o de s of Human, Er.psui e ) Fate in th Environner. 1 ( L iu t i, m s , P I act s , Animais) f ) Stata of A r t / S t a t o . 0 f M e d i c a ' and Scienti Lit arature *\ Plant Physio'or;7/ Stud ics An:., al Physiology/Studies . H ut _u Studies 3) Epidar ..0 10 e ;7/E i0st ct i st i c s 7. Plants, animais, humans ) 0au a ar Hvid er, c i o gy -y Lapa odvetiva Epidemiology h; d.VGrs' Heal th Effects 3) e." j w i t n e ss will be atkad op in i o ns ab-* ut both p u bl is hed ,r.:id/or ou -g e i ng otudi..s. 4) Y a s , uitncf,3 will be asked op in i o ns about any studie or research witness l as personally perf :rmod or actually p a r t i c i p a t e d in. rs > ) Yes. wif.nacr. will be asked o p i n i o n s about ot her g o v -ornaienta 1- .studies. 6) Yes. w i tn es s is e x p e c t e d to re v ie w the f o l l o w i n g d o cu me nts prior tr giving t a n t i m o n y : Sre , Research and Development , Health Ae_sessraeat Documant: on D i o x i n n_lor th 1. f fi c eo o f A ir 0u a l ity,' Pla n nin r- 'and _ da , pf epaged by the ISr.viroumeni.al C r i t e r i a end 1' 0 as sin Of fie*- , Ci nc innati, Ohio 45140 ( j u lv 1 1 0 ?79 E P A . Renaai'ci. i:nv Dcvelopuent, II- i.th and linvi r a 1 Ei fecto Profile for; Tec Pent.-', and H e x a c ..lorodiL er.r.o-p-uioxir.s for the O f fi c e of Solid Wistc and lime:: gency ilesponpo, by the Environmental Criteria and Assessment Office, Cinein Ohio 45240 (June 1383). EPA, research and Development, Ambient Water Quality Criteria for 2,3,7,8 TCDD, pro pared for Offic e of Water R e g - 1at ions L\\.j Standards, by the Envisoni-entnl Criteria and A s ::a n ament Iff ice, Cincin Chic 45243 (July 1383). EPA, Research and Development, Dioxins, Industrial Environmental Research Ciucin:ia..i , Ohio (1978) . copy of these do" .msnts ..s a t t a c h e d . SL-PLOffiMTK. ANSWER TO INt ET 'OYi'ORY NO. 19 Plaintiffs note preliminarily tliat the extant Order on producing fa- witnesses that fact witne: ;es are not-duo until March ' 1934.. However, Plaintiffs may caji one or more of the following persons (or those Yrav. various'categories listed b e ) at time of trial to testify as to factual ;newiedge they may have, including: i. Ranch Hard Persona:.*.: these persans will testify tc their knowledge of the Ranch Hand Operation, Ranch. Handers exposure to Agent Crange, and/or hicwledge relating to the sp: lying, testing, and effects of i'gont C range on hiuians. M-'iinbers of O. ; .ace., .-'ore.j: These persons mo testify to the circumstance.? ana c.:editions .-urrounding the : raying of Agent trance. 1. Persons present in Via:c:am during the closure peried in question 2.SS1--L272, including.. but not limited to, ir<~ j.t-;ry and paramilitary personnel of the U. C., lew Zealand _nd Australia, who have knowledge of idle cpraying operations of the herbicides, the exposure cf the Plaintiffs1 class, the hazards ecccmpanyiug any such exposure, the Plaintiff-;' ..hentselver;, and. the Defendant company representative:: piftseni: ii. Vietnam ioversee 'he deliveries rnd spr "(no operation?-: of the herbicides they manufactured. 4. Persons together \.-Vdi their demonstrative and documentary evidence whe gave testimony (which will form the substance cf their testimony herein} at the EPA Cancellation Hearings of 2 ,4,5-T (1979-1S30) under FIFR.V including but not limited :rrt a. <b ... c. d. e. f. g. h. i. j, Dr. Roy AlbertDr. K. Diane Courtney Robert K. Baughman, Ph.D. Dr. Clav Axeiscn Dr. Renats Kimbrough Dr. Dawn G. Goodman Dr. Kirk T. Kitchin Dr. Fonal.6 Thomas Dr. Rainer Frentzei-Eeyms Dr. Matthew Keseison, Harvard k. Major Alvin Young l. Dr. Rodney Bovey m. Kenneth V. Thamein n. David T. Buzzelli o. Dr.Michael Gross p. Dr. Renee Stringham r. Dr. Van Miller Any current or previous employee, contractor, in-house or private consultant of each c? the Defer. Yes or ary other person who has !mov:1edge of the rnanufacti m y processes, chemistry, occupational exposure and/or -jxicity of 2,4--D and/or 2,4,5-T or related dilcrophenols; irx uding, but not limited to- laborers;, operators; supervisors; ontract adrair.istrators? q u a l i t y control personnel; engineer ; (process, chemical, mechanical and/or safetv). Any cuz rent or previou 5 cnployee,. contractor, subcontractor, in-hou: :& cr private cc isvf.hanh. of each of the Defendants cr any cd >er parser, who h :.s trowiedga of the possible means <. - ----.1. -- 1-VJ- .otic proteccin from the has or Is of diaxizis' exposure; including, but not limited to, laborers, operators, sapervi sors, contract a.minis trators, quality control personnel, engine; s (process, civ ...cal, mechanical and/cr safety) . Any currant, or previous crplevee, contractor, subcontractor, in-house cr private consultant c ' each of the Defendants or any other person who has krowla/ce of the means to warn those who might be exposed, to use the herbicides in question, particulariy Agent Orange, includine, but not limited to, laborers, operators, supervisors, cor.react administrators, quality control personnel, engineers (process, chsnical, mechanical and/or safety). Any current or previou employee, contracted, subcontractor, in-house or private cot zultant of cadi of the Defendants or an* other person who has factual, knowledge of any other manufacturing processes which could reduce the risks of exposure to Agent Orange and/or other phenoxy herbicides being contaminated with dioxins and further reduce, 'die risk and hazard to human health of any such exposure. Any current or previous employee, contractor, subcontractor, in-house tr private consu.ltar.-f. of each of the Defendants or any other perron who has factual new!edge of cononiratorial conduct of tdie Dc. .ndants, individually and/or duplicative eff r is (acts which are erailel in nature) which tended to or did in fact result in ;aisleading the public and the fJnited States government iron gaining knowledge of 'die danger.-.; attendant from exposure to Agent Orange and ether phevzoziy herbicides. 12382 ir Cr^. 10. Any current or previous employee, contractor, si;' xsntrs or, in-house or private consultant of each of the Defendant., or any other person who has factual cncwledge of hoi-; dioxi work upon plants, animals, and/or humans. Any current or pre-levs employee, c:..;.tractor, sufccontr. in-bouse or private consul.tant of each of the Defendan any other person who has ..'actual knowledge of any stat ooncecning tha effects of dioxins upon plants, animals humans. nr, r ,cs ld/or 12. Any current or previous employes, contractor, subcontac r, in-house or private consultant of each o f t h e Defendant or any other pe.:on including, but rot limited to, members of ?A and other get emmsntal agencies, who has factual Icnowiedge c 'oris following incidents: a. Love Canal b. Times Beach, Missouri c. Sevescc, Italy d. BASF (1953, 135': - Sadi. ;che in Germany) tv Production mishaps end,--y; or'p.'ooicn.s silica 1925 at ai the plants of any of the Defendants manufacturing, T 2,4-D. 2,4,5-T phenol, chlorine,- acetic: acid, benzene hydroxi.de, potassium hydroxide, and/or Agent Orange, mishaps_in the packaging, and transporting of the Dei products to the U. S. Armed Forces bases for eventual to Vietnam. f. Spraying of Vietnam from 1951-1972. of sodium c udin.g i-iants1 . hipmant 13. Any current or previous employee, contractor, subcontrac r, in-house or private concul'tant of each of the Defendants r any other parson who has factual torwiedge of any surveys, tv tc, epidemuo.logiaal studies of any kind relating to the effec s of exposure to Agent Orange, 2,4-D, 2,4,5-T or any conntituf. it thereof including the secondary by-predu known as dioxins. 14. Any person with factual knowledge. of how decisions are made within the United States government, particularly tiie decision to use and to continue to use phone:g/ herbicides in Vietnam, particularly Agent Grange; any person v.ith factual knowledge of government procurement contracts and toe irritation to bidders, particularly those persons who negotiated toe government contracts for all phenory herbiciats (scents white, blue, purple, pink, green, orange I and II) with the 'individual defendants! repre sentatives between '351- 1372. 11- 15. Any person with factual lr.ov/1edqe through any surv 3, tests, epidemiological studies or otherwise- undertaken by -iiy state government , any private public or foreign corporat 3n, the U. Congress or the government of any nation concernin' the chenca compounds, 2 ,5-D, 2,4,5--T, dioxins, or related chib :cphonols relating to the creation of dioxins, the detection )f dioxin:.;, (lie oangers of die.wins' exposure, and/or the toxicity, arcinogenicity, fetotoxicity, teratogenicity, acute and/or c'ironic ffects on plants, animals and the hiraan population. 16. fey and all person., listed in The Chemical ffcvche ' Aiastair ttw, as having factual !uiov/le'ge regarding 2,4,5-T i,4-D, and its contaminant dioxins. 17. Ail worker csnpansaf.ion carriers for the Defendant and docu mentation cf ail occupational exposures filed sine 1925 which evidence industrial injuries or diseases at the TC 2,4,5-T, 2,4-D, Phenol, paricaging- and/or transporatic:. pla- s of the Defendants. 10. Any and aid terrant o.: or ior workers, co mensa tion t .irnanss of tiie Defen.dc r'- '-.'ho c?.am -a.1 relrvant occupational er ,-sures and/o relav.m oc.-.ut.rtiourd irrVtries and/or disease;:; and,- .- symptoms a the rc.lo.VFHt dents l. st.. 1 j.n nr.swor to No. 19 (sul above. 19. fey ar:d all numbers of the U. S. douse of Represent eves Contnittoe or. Oversights Review of the E?A actions .983) and/cr air/ person together with their documentary and demo trativo evidence giving testimony at said hearing (which wi form th substance cf their testimony herein; on the failure .; the EF i to take prompt and effective action to ban idle prod; :icn of 2,4,5-T, and its contarminant dioicins. 2 0 . Any and all persons having knowledge ov relevant fat ; regarding the financial status of the Defendants and their ab: ity to respond in punitive damages, inducing, but not line sd to, their past, present, and future profits and earnings in tl United States atnide abnroada since 192:" thnrougehn anda incliudciung thne pres nt ftran the ssaa]le of the produces made the basis of this lawsuit, i.e., 2!,,4-D, 2,4,5-T. phenoxy herbicides and the relevant irbicide market. Any and all persons having knowledge of relevant fac\ ; regarding the ownership interests f the Defendants and their *bility to respond in positive damages. including, but not limi' d to, defendants' domestic and foreign subsidiaries, joint nturess, licensing agreements, --nd/or other public or private corporations in the u. S. and abroad, in which these defendants own a subsi antial financial interest since 1923 through .and including the oresent. -12 e. Any and all persons w?tn knowledge of past, prc and/or future reasonable ;nc necessary costs of doctors, hospitals, nursery care, medical equip drugs, and any other related medical services r< ed or to be rendered in the future to Plaintiffs a; result of their injuries and disease resulting;, their exposure to Defendants' products in Vietrv ' f. Any and all persons with knowledge of the physic disfigurement (past and present;, physical and i .al impairment (past and present), physical pain (p: an.l present} and mental anguish (past and present) v ,,ft Plaintiffs have sustained as a result of their o. osura to Defend:sits' products in Vietnam and which in reasonable probability Plaintiffs will continue ) sustain for an indefinite time into -the future i : beyond the cate of th::; trial. rtespsctfuJ.lv sub .tted; rm f\ , ' Ujj-.rf~y-.izi j t O Z i Thcnas W. Header: .1, Esquire Allison Pettiett". Esquire CERTIFICATE OF SERVICE I hereby certify that a true and correct copy of the oregoing Supplement to Plainti-ff's Int arrogatories wara mailed Federal Ex ress to hr. William itrehley, Kelley, Drye A Warren, hr. Gene Locks, Plai .tiffs' fifenagarisnc Corraratt.ee Agent Orange Office, with copies to personally servo tie remaining Defendant.:.: at the Tuesday depositions and Ms. Nano/ Petrilla, TJ.S. District Clerk.-U.S. Courthouse, 225 'teaman Plaza, Brooklyn, Maw York 11201 this 2Gth day cf February, 130- y^\ ^ -- -v ' J* 1 t.. ^ * \JJLl -:-j t a - ^ Al li f.on Petv.iette ii 12385 -14- r > ~r\ (J o t' i Srarws `'lviftn.nfit.il f' rr.i'-r'iort - lenr.v iT r, Jnv'luoaiiTH lustrial En\ nmuMt:. :..:noronrv Ciiir.innati ( ' 45263 tH vi .. -V V ' -1 'v'1 12386 P L A I N T I F ? ;S GO VERNMENT C A U S A T ION WITHES,'3ES Jiiaet Springer EPAj Washington!, D.C. B. Both factual and expert te stimony is .ough C- General Events ire-1^61: iny factual knowledge of the. h herbicide spraying in . S . and including j -at not limited to, exposures and explosions ; ( 2) : 2 ,4-Z', 2,4,S--T with the Dcpartr culture and any oth :r govemmei any and/-.r all cf Che Defendant. ry of road; ) industrial istraticn of t of Agriagencies by 1961 prsent.; An y fcctusl I-nowl'cdge or t'i h a t Tici do cprxying in the .3 . iv.ciud i..,,, but uct limited to, Kilitary use of Agent Orange an ucrbici...cs tu Vietnam; (2) chan gistraclon rc.yaireaents of herb J.Ci. gcverncext and its agencia haow 1 adgo o f FI IRA.,. F D A ,EPA, an ar.y knowledge of industrial and exptaures to 2 ..4-D ,-2 ,4 .!'-T in t abroad uistory of i abroad; ) II.T-. otl:er phene a in the >ides v:ith the Including JSHA; and (3] ther human i 0. C . and See Answer and Supplemental Answer of Plai: If S : t Defendantr. ' Interrogatory Nc.'l: ttachcd ' oxreto and inccrpora red h e re i n i all purposes re: events or occurrences /hich these causation witnesses nay be expec ed tc give any factual informa'tion they map lave regardin; the subjects outlined in said Ar. rer. Ilirasn Risk Ascesumeut of Exposure to 2,4-D. ;,4,5 -T and ioxinr and any factual kuowledg in support th c:veo f . D Expert Testimony 1) Testimony is sought in w i t n e s s ' persona' and official cayaciv. . 4oL. J Subject hatter 2,4--D, 2,4,-T, ^CDD's and dioxii T/II (also W h i t e , blue, Pink, Grc Agent Oran; and Purpli and.related e h l o r o p h e n o `3 and human risk assessment regarding exposure, including, but not limited to, one or more of the following s bject areas: a) Chemi stry/Biochemistry 'k'- \ b) Manufacture and/or Production c) To xic ity d) Mo des of Human Exposure e) T4.,' C~*t e in the Environment (Humans, Plants, Animals) f) .Oi-<W_ate of A r t / S t a t e of M edical and Scientif Literatur ' 1 Plant Physiology/Shudic nL.\ Animal P h y s i o l o g y /Studies ->J Hunan Studies O *' ideurology/' Bio statistics i) Plants, animals, hur :na o4. Cancer Epidemiology n * Reproductive Epidemiology wr.,s Ac /ersa Health Effects 3) Yes, witness will be asked opinions about both published and/or on-going studies. 4) `res, witness will be asked opinions about any ctuc_cs or res2"v:h witness has personally performed or actually p a r t i cipated in. ' ,.1 5} Yes, witness V7ill be asked opinions about other governmental studies. 6) Yes, witness is expected to review, the following documents prior to giving testimony: See. F.?A, Research and Development, Health A s s e s s m e n t Document- on- -Dioxins for the Of fic as- o f A i r Q u a l i t y . P l a n n i n g 'and -itan d a rc*s", ^pirepare<T rby ! the ;':iviron :ent.al C r i t e r i a and Assassmer Of f ic C i nc i n n a t i , Oh i o 45243 ( July 19-f 12383 .... ' "ilV,':< 'Vy'.. '.. ,.i 4. v '' /"v 1J"-S; >' - / *'*-''* fr.'.'yl' -iv. , * .i.-sV. ' <t J ' ,,*1 > .'V' k EPA, Research and Development., Health and;, Environmental Efiects Profile for; Te Penta, and Hexachlorodibenzo-p-dloxin for the Office of Solid Waste and Erne geney Response, by the 13nvirom.i ntal Criteria and Assessment Office, Cinci Ohio 45i'.`>8 (June 1983). EPA> .iese;.rch and Developroeat, Ambient Water Quality Criteria fot 2*3,7,8 TCDD, pr pared for Office of Watar Regulations and Standards, by the Environmental Criteria and AaseaGnent Office, Cinci 0;:io 432<.->r. (July 2983). EPA , Rcnea-cl and DaVcloptrjia.nC , Dlo:cinnr ii i .i.1.'ij. i'llivIlfuni iut ai uaMuu.i:l. C i .innuti, Ohio (1978). A copy of these documents is attached. ' " ",i :V.f vi V- .. . --'--V. k` ..!. -,.-;'y .'.'.K'.J "'V' '; 4 .?':?&&[*%$ 4 " r'1-, '' . ,..... .. :-f -, - ZJ*::. f- .s '- '"i . r '. ::: .... ..:. "' . .v's -, -i- .. .'a ' . . ;/ V,.' . "; a :iv':-a' ;w ' . ViV ' ' ' ; -'X':' :i .: W;-y .' -V.t-`<vv d .*; . ;V' ' .. .12339 nUPi-LSMgff/U ANSW5R TO INTERROGATORY NO. 19 . .. O ' Plaintiffs note preliminarily that the extant Order on producing fact witnesses states that fact witnesses are not due until March 2, 1984. However, Plaintiffs may call, one or more of the following persons (or these from various categories listed below) at time of trial to testify as to factual krcr.iledgo t h y may have, including: Ranch Hand Personnel: 'Fnese perse:s will testify to their knowledge of the Ranch Car.:: Operation, Ranch Handers' exposure to Agent Grange, and/or low/ledge relating to the spraying, testing, and effect:; of Agent Grange on humans. Manburs of the C. 3. iwrasu Dorcas: These persons may testify to the cirar.;stsr.ces ced conditions surrounding the spraying of Agent Grange. Perseus present in. 'Vietnam during the exposure period in question 196.V 1972, including., .but not limited to, military and parrr.ulitaiy person:. :;L of the id, N* Zealand and Australia , who liave kr.rwlGdgn of tho spraying operations of tlie herbicides, the exposure of the Plaintiffs' class, the hazards aoconrporyir.cj any sued: exposure, the Plaintiffs' themselvas, and the .Defendant company representatives present in Vietnam to oversea the deliveries and spraying rperations of the herbicides they manufactured. Parsons teg ';her v.ltl tiieir dcmcnr.trative and documentary evidence who gave testimony (which will form the substance of their testimony herein) at the 3PA Cancellation Hearings of ?.,4,5-T '1979-1980' under FIFRA, including but not limited t.C; a. Dr. Roy Albert: *b. /Jjmm K. Diane Courtney - c. Robart K. Baughman... Ph.D. / d. Die Olav keelson e,, Dr, Senate iiirbrcurh >. Dr. Dawn G. Gcodr"... 9- Dr. dirk T. Kitchiii h. Dr., Donald Theme.' 2 . * Dr. S:i..n?r Fren'csel--Bevrae j- r M-rktliSv: Msselscn, Harvard Y 1--.,V*l;-. i. <: :. Ma. jar Alvin Young i. Dr. Rodney Povey m, Kenneth V. Therein a. David T. Euuzelli o. 'Dr.. Michael Gross p. Dr. Renee Stringhnm r. Dr. Van' Milier i. Any current o;: previous employee, con-tractor, subcontractor, in-horse or private consultant of each of the Defendants or any other person who has knowledge of the manufacturing .recesses, chemistry, occupational esrpesure and/or tojcicity cf ,--D and/cr 2,4,5-T or related chiorophenols; including, bat not limited to, laborers;, operators; supervisors; rntract adrinistraters? quality control personnel; engineer^ {process, chemical, r.edianioa.1 and/or safety). Any current or previous employee, contractor, subcontractor in-house cr private .snsuitant of each of the Defendants or c-ny ether person who las hnov/ledge of the possible means of prc^hiactic so tec-cion from, the hazards of dioxins' exposure; including, or'., net limited to, laborers, operator's, supervisors; contract cdmir.i:'trators, quality control personnel, engineers (process, chemical, media:deal and/cr safety';. . . 7. Any current cr p:nviou..j <....ployca, contractor, subcontractor, in-house or private consultant cf each of tiio Defendants or any ether person who lias loicwiedga cf the means to v;am those v/ho might be exposed to use of tijs herbicides in question, particularly Agent Orange, including, but not limited to, laborers, operators, suparvisors, contract administrators, quality control personnel, engineers (process, chemical, metiianical and/or safety). 1. Any current or previous employee, 'u.itractor, subcontractor, in-house or private consultant of each cf the Defendants cr ajry other person who has factual knowledge of any other rmufacturing processes which could reduce the risks of exposure ` to Agent Orange and/or other phenoxy herbicides being contaminated with dioxins and further reduce the risk and hazard to human health cf any such exposure. 9. Any -Torrent or previous employes, contractor, subcontractor, in-heir:a cr private consultant of each of the Defendants or- any cviie.::- person who has factual loiowledgs of conspiratorial conduct of the Defendants, individually and/or duplicative eiforts (acts which are parallel in nature) which tended to or did in fact result in misleading the public and the United States government from gaining knowledge of the dangers attendant from exposure to Agent Grange and othor phenoxy herbicides. 12391 -10- ... g'W/ *V:. 'v` f* 10.. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person who lias factual .aiowledga' of how dicacins .work upon plants, animals, end/or humans. ,. , .. . :'/ y. . 11. Any current or previous employe, contracter, sufccontractor, in-house or private consultant of each of the' Defendant:; or any other parson who hi 3 factual knowledge of any statistics oonoeming the effects of dioxins' upon plants, animals, and/or humans. 12. Any current or previous employee., contractor, suLcontactor, in-house or private consultant of eacli of the Defendant.-? or any ocher person isiciuding, but rot limited to, members of EPA and other govor.cmental agencies. v:ho has factual knowledge of the following incidents; a. Love Canal b. Times Beach, Missouri c. Sevesco, Italy d. BASF (.1953, 1951 - Badische in Germany) e. Frccucticr. vishapo and/or explosions since 1325 at a 7 of the plants of any of the oiler,"ants ltianufacturing, T'. 2,4-D, 2,4,5"'.? phenol, cltorino, acetic acid, fcansene.. sodium hydroxide, potassium hydroxide, and/or Agent Grange, nicluding Irish-ps in the packaging, and tear,"-porting of the Defendants' products to the rj. s . Armed Forces `oases for eventual shipment tv Vietnam. f. Spraying of Viettra 'free. 1951-13.2. L .13 Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any ether person who has factual knowledge of any surveys, tests, epidemiological studies of any kind relating to the effects of exposure to Agent Orange, 24-D, 2,4,5-T or any constituent thereof including the secondary by-product known as dioidns. 14. Any person with foetus! kr o.-ledge of how decisions are made within the United Steves government, particularly the decision \:o use and to continue to use pkanoxy herbicides in Vietnam, particularly Agent Grange; any person with factual knowledge of y vtexsnsnt procurement contracts and the invitation to bidders, . particularly those perrons who negotiated the government contracts for ail phenoxy herticictes (agents white, blue, purple, pink, green, oi.vnge I and XI) with the individual defendants repre sentative;.; bscveen 1961-1972, 12392 tr 15.. Any person with factual knowledge tltrough any surveys, tests/" epic,u:.u.clexical studies or otherwise undertaken by any state gover.rnent, any private public or foreign corporation, tine U. S. Cong.;ess or the government of any nation eonoermng tile chemical compounds, 2,5-D, 2,4,5-?, dioxins, or related chioronhenole relating to the ersc.tion of dioxins, the detection of dioxins, tile dangers of dioxins' exposure, and/or tile toxicity, carcinogenicity,, fetotoxicit.y, teratogenicity, acute and/or c.ircilc , rfect: cn plrots, anrials and tlie human population. 1.6. Any and all persons listed in The Chemical Scythe v ALasteir 2ty, a;., having factual Itiowledge regarding 2,4,5-1 2,4-D, and its contaminant dioxin.':. 17. .Hi worker compensation couriers for .the Defendant.; and dccujirr.taticn of all occupational exposures filed since 1925 which evidence industrial injuries or diseases at the TCP, 2,4,5-f, Phenol, pac-aging, and/or fransporntion pl?--i;s of ti--t nafunchnt 19. Any and all current or rrior worker:- ocmoe-isatian claimants cf the Defondants who claim.:./ relevant -.ccupaticnal e"'oosures rnd/f relevant <m '-'pntic; -?.! 3r:juries and./or diseases a.!'.'. r syi.Mtu.is the rcl ..vvvl giants list :d. in Ar..-sv..'r to Wo. 19 (sub IV; above. 19, Any and all members of the U. S. licuse of Representatives Conmittcs <--ri Oversights ?evi. of the EPA actions (1933) and/or any person together vf.th their I'.oaimentary and derm nstrative evidence giving t?.stiivov;y at said hearing (which will form the .'.)bst-:r.co of Vhair tost:.:iony herein) on the failure cf the EPA tc- take, preopt and effective action to ban the production of * 2 ,4--D, 2,4,f--T, and its contaminant dioxins. 20. Any aid ail persons having locwiec'ge of relevant facts regarding the financial status cf the Defendants and their ability to respond in pur.:tivo dsrtsges, including, but not limited to, their pi.?';, present, and future profits and.earnings in the United States ar.d abroad since 1925 through and including 'the present from the sc Vo of tbs product.';; made the basis of this lawsuit, i..e., 2, -- D, 2,4,5--?, phenexy herbicides and the relevant herbicide market. 2.1. hv.y and all persons having knowledge cf relevant facts regarding the ownership interests cf ti'.e Defendants and their ability to respond in punitive damages, including, lout not limited to, defendants' domestic and foreign subsidiaries, joint venturers, licensing agreements, and/or. other public or private corporations in the CJ. r>. and rh-roan., m v-hic:h Jhese refendants own a substc'.rsti.al financial 'ntes'st. since 1925 through and includir j the uresent. 123 e. Any and all persona with knowledge of past, present and/or future reasonable and necessary costs of doctors, hospitals, nursery care, medical equipment,' . drugs, arid any other related medical se: "d.crso rendered or to be rendered in the future to Plaintiffs as <_ result of their injuries ana disease resulting iron their exposure to Defendants' products in Vietnam. f. Any and all parsons with knowledge of the physical disfigurement (cast and present}, physical and mental impairment (past and present), physical pain (past and present/ ~.ne mental anguish (post end present) vjhi.cn Plaintiffs have sustained as a result of their exposure to Defendants* products in Vietnam and which in reasonable probability Plaintiffs vjv.1 1 continue to sustain for an indefinite time into idea future far beyond the data of this trial. respectfully submitted, / Uj- jfa. rjXTFj lira:. VI. Menci-v "n, Esqidre Allison Pettiet Esauire CZRIOIOGATS OF SSbvICE I hereby certify that a true arc correct copy of the foregioing Gupnlatent to Plaintiff's .Interrogatories were mailed Federal Express to Mr. William IOroirloy, Kelley, Drya s Warren, Mr. Gene Locks, Plaintiffs' ifepfc -ament Co.triff.ee Agent rrange Off.ice, with copi.es to personally serve the rsnaifcixig Defendants at '-'.a Titesday depositions and Mn. Nancy Petrilia, U.f.. 'istrici Clerk, U.S. Court ouso, 225 Cadian Plaza, Brooklyn, New York 11201 this 1.0th day of February, 1984. s\ v ix i ^ r r ^ U x f o n t X c illison Pettiette 12334 r\ ni ... , 7.r:v .' -cicni*!- ifuciion -i.. ..idustiwl(nvironrru!i'<.i ! JO'jratorv Cim: ruiU O h 4 5 2 '.3 rti:vii::iltt,wiu`iinn-( . JT'-O. p'Q \a/ '\ J j J O 12395 PLAIN T I F F 1S GOVERNMENT CAUSATION WITNESSES Peter Infante t A. Na ti o na l I n s t i t u te for Occupafri c n a l Safety & Health, Ua3h E. Bo th factual and expert t e s t i m o n y is sought. C. .General Events Pre-1961: Any factual k n owl ed 'c of the histor y of herbicide spraying in U.S. and abroad; including, but not limited to, (1) industrial e x po su res and ex pl osions; (2) r e gi str at ion of 2 , A - 0 : 2,',5-T with the Depa r t m e n t of A g r i culture an:' any other g o v e rn m e n t agencies by any and/or ail of the Defendants; 1 9 6 1 - p r e s e n t : Any ia-.cu-.l k n o w l e d g e of the hi sto ry of h e r bi c i d e spr ay inx in the rr q and abroad; includit g , but net limited to , (1) U.S. mill t n r y v.s 2 f Agent C-rar. go tn d other pher !li:-b ."< : Jn V 'et-.mn; (2" char- gas in t . : gistra'.lo:. 7: vjc .'.remer.ta c.. herb icldea with U ..3 . g- '.-erncent and its agencie'" including k n o w l ed g e of FIFRA, FDA,ERA, and OCHA; and (3) any knowledge of incustsic,1 and other human exp os ure s to 2 2,4, 5-T in the U.S. cud abroad- See Answer and Supplemental Answer of P l a i n t i f f s ' to D e f e n d a n t s ' I n t e r r o g a t o r y No. IS attached hereto a '' i n c o r po r a t ed h e r e i n for all pur poses re.. events or o c c u r r e n c e s w hi c h these c a u s a t i o n w i t ne s s e s may be ex pe c t ed to .ive any factual information they may have r-gardin. the subjects outline d in said Answer. H um an Rick A s s e ss m e n t of Ex po s u re tc 2.4--D, 2,4.5-7 and diox:.ns and any factual k n o w l e d g e in support thereof, D. Expert Test im ony 1) Testimony is sought in w i t n e s s ' p e r s o n a l and off ici al capacity. ?.) Subject Hatter 2,4-D, 2 , 4 , 5-T, T C D B 'e and dioxins; Agent Oran I/II (also White, Blue, Pink, Green, an-' Purpl and related chlorophenols and human risk assessment regarding exposure, including, but not limited to, one or more of the following subject areas: a) Chemistry/BiocIvemi-v;:r\ b) Manufacture and/or Production c) Toxicity d; Modes of Human Exposure e) 1'ate in the Environment (Hue:ans, Plants, Animals) f) State o': Art/State of Med i c al and Sclent: Literature I) Plant P h y s iology/St\ lies 1) . Animal Physiology/Studies d; H u ma n Studies g) Eyidr:miology/Bior t a t i c t i c c 1) Plants, animals, h u ma n s r../>.*j, C a nc er E p i d e m i o l o g y -c j> R e p r o du c t i ve E p i d e m i o l o g y h) Advcr ;e Hea lt h Effec ts 2} Yes, witness will be asked opinions about both published and/or on-going studies. Ay 1c s , witness will be asked opinions about any s'udie or research witness has personally performed or actually participated in. 5) Yes, witness will be asked opinions about other governmental studies. 6) Yes, wi t n e ss is ex pe c t ed to r e vi e w the following documents prior to giving testimony: bee, E P A , I^eGj^jtrch and " e v el opine n t , Health An sea ament 'Document- on' D lcx ins for the Offices- of Air Quality,' Plannin., `and Standards , prepared 'by the Environmental Criteria and Acsessmc Office, Cincinnati, Ohio 45268 ( J u l y 1 t oC pi->' v.^riy-. y ':' '% r> V r , EPA, Research and Development, I 'aith and Environnental Effeets Prt ile for; Terra Penta, and Kexachlo rodib ;zo-p-d ioxins> for the Office cf Solid ;:ce and Emergency Response, by the E ironmental Criteria and Assessment fice, Cincinn.it Ohio /52A3 (June 1983). EPAj Research ani Development, Quality Criteria for 2,3 pared for Office of Wate and Standard.:, by the En Criteria and Assessment uhio 45 7:48 (July 1933). -.blent Water ,8 CDD, preRegulations ronman:al ifice, Cincinnat A copy of EPA, Research and Development, '.crins, Industrial Environmental Research :innati - Ohio (1978). :eae documenta is attached. 123 b t A r\ & t^ 11i- f`-1 ! '-fp !' -'1' id M ( i `A- Sft i SUPPLEMENTM, ANSWER TO INTERROGATORY NO. 19 Plaintiffs note preliminarily that the extant Order on pr xSucimg fact witnesses starts that fact witnesses are not cue until ..larch 2 1984. However, Plaintiffs may call one or more of the following persons r those from arious categories listed belcw) at that; of -trial to testify ;. to factual 1-trcwiedga the" may have, Including; 1. Ranch Hand Personnel: These persons will testify to their 'uiowledcje of the Ranch. Hand Operation,- Ranch Handers' exposure to Agent Orange, and/cr lo.cv/led o relating to the spi .ying, testing, and effects of Agent Orange on humans. 2. Members of the U. 0. Armed Forces: theca parsons may testify tc. the circumstances and c ; .ditions surrounding the spraying of Agent Orange. 2. Persons present in Vietnam during the exposure peric-. in question 1961-1972. including, but not limited to, military and paramilitary personnel of the U. S., New Zealand end Australia r who have knowledge of the .spraying operations of the herbicides, the eqpccurc cf the Plaintiffs11 class, the hazards acoanpanying any such exposure, the plaintiff -! themselves, and the Defendant canpany representative present in Vietnam tc oversee the deliveries and spraying operations cf the herbicides they manufactured. 4. Persons together with -heir demonstrative and documentary evidence who gave testimony (which will form the substance of their testimony herein) at the EPA Cancellation Hearings of 2,4,5-T {1979-1980) under FILto P Dr. Ito" Albert; >-b. Dr. K. Diane Courtney - c. Robert K. E-aughraar., Ph..D. a d. Dr. 01av AxeIson e. Dr. Renate Kimbrou/'i .LC,. Dr. Dawn G. Goodman g- Dr. Kirk T. hitebin h. Dr. Ron old T otaas i. Dr. Rainer Frentzel-Eayms j# Dr. Matthew Mesalson, Harvai 12399 -9- ! ; .7* ... -io k. Major Alvin Young l. Dr. Rodney Bovey m. i'enneth V. Therein n. David T. Buzzelii o. Dr. Michael Gross p. Dr. Renee Stringnani r. Dr. Van Miller Any current or previous employee; contractor, subcon actc;:, .un-fiouse or private c0nsu.lv.3 nt : each of the Defend .its or any other parson who has know! ja of the manufactur ig processes, chemistry, occupatir ...al '-xposure and/or 1 -deity of 2,4-D ard/or 2.4,5-T or related chlorophenols; incl Ling, but not limited to, laborers;. operators; supervisors; < .exact administrators: quality control personnel; engineer: {process, chemical, mschmical and/or safety) . Lvny current or previous employee, contractor, subcontractor, inr-house cr private consultant of each of the Defendants or any c-th.r person wiio has iuicwlodga of the possible mean .of prqdjiactio protection f.vcr. the hazards of dioxins' expo sure: including, but not limited to, laborers., operators, supervisors, contract administrators, quality control personnel, engineer, (process, chanical, mechaiv ial and/or safety}. i. Any crjrrevit cr previous employee, cov.oractcr, subcontractor inrheuse or private consultant of c-ach .of the Defendants or any other person who has knowledge cf the means to wan. these v:ho might bo exposed tc use of the herbicides in question, particularly Agent Orange, including, but not limited to, laborers, operators, supervisors., contract administrators, quality control personnel, engineers (process, chemical, mechanical and/or safety). Ou Any current or previous employee, contractor, subcor.tractor, in-house or private consultant of each of the Defendants or any other person who has factual. iciCwledge of any other manufacturing processes which could reduce 'the risks of exposure to Agent Orange and/or other phenoxy herbicides being contaminated with dioxins and further reduce the risk and hazard to human health of m v such exposure. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other perse: who has factual knowledge of conspiratorial conduct of the '<3sfeivdants, individually and/or duplicative efforts (acts which are parallel in nature) which tended to or did in fact result in mj.sleac!Lng the public and the United States government from gaining knowledge of the dangers attendant from exposure to Agent Orange and other phenoxv herbicides.. 12400 -10- 0^ 10. Any current or previous employee, contractor, subcontractor, in-l*ruoe cr private consultant of each of the. Defendants,or any ther per:.on who has factual knowledge of hew dioxi: r work upon plants, animals, and/or humans. 11. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendant, or any other person who lias factual knowledge of any state ics oonoemi.r.g the effects of dioxins upon plants, animal's, rml/or huanans. 12. Any current or previous employee, contractor, subcontac ;r, \ in-heuse or private consultant of each of the Defendant or any other person including.- but not .limited to, rasnbors of PA and other governmental agencies w o has factual icncwiedge c idle following incident:: a. Love Canal b. Timas tea'll, Missouri c. Sevssco, Italy a. BAS? (1553- 1924 Badischo- in Ger..rrr/> n Production mishaps and/or explosion:; since 1925 at a:: of the plants of any of the Defendants iRar^ofacturiiig, ft ', 2,4-D, 2,4,5- ? phenol, chlorine, acetic acid, benzene, sodium iTydroxi.de.. potassium hydrcuLde, and/or Agent Orange, including mishaps in the packaging, and transporting of the Defend nits' products' to the U. S. /ted Forces bases for eventual shipment to Vietnam.' f. Spraying of Vietnam from IS51-1972. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants ir any ether person who has factual knowledge of any surveys, tests, epidemiological studies of any kind relating to the effects of exposure to Agent Orange, 2,4-D, 2,4,5-T or any constituent thereof including the secondary by -product known as diox is. 14. Any parson with factual knowledge of hew decisions are made v.dthin tlie United States government, particularly tiia decisi to use and to continue to use phenoxy herbicides in Vietnam, particularly Age. t Orange; -any person with factual knowledge of govemriient procurement contracts and the invitation to bidders, pa rticularly those persons who negotiated the government contrac for all phenexy herbicints (agents white, blue., purple, pink, craan, orange I and 7.1] with the .individual defendants repre sentatives between 1961-1971. -11- A S't 15. Any person with factual knowledge through any surveys,, tests, epidemiological studies cr otherwise undertaten by any state government, any private public or foreign corporation, the 0. S. Congress or the government of any nation concerning the chemical compounds, 2,5--D , 2,4,5--T, dioxins, or related chlo phenols relating to the creation of dioxins, the detection : dioxins, the dangers of dioxins' eseposure, and/or the toxicity, carcinogenicity; fetofcoxicity, teratogenicity, acute -and/or chronic c ^ects on plants, animals and the human population. 16. JteT/ and ai.l -arsons 1:'.ted in '.he Chemical Scrythe by 'lastair Bay, as having factual knowledge regerding 2,4,5-'-?, .HD, and its contaminant dioxins. 17. M l worker compensation carriers for die Defendants .and docu mentation cf ail occupation?.! exposures filed since 1915 which evidence industrial injuries or diseases at 'the TCP, 2,4,5-T,'' 2.4- D, Phenol, pedarging, and/'er t .ensporation pi-ants of the Defendant: ,, 10. Any and nil current'cr prior v.or.b. crr.rx-nsat.ion claimants of the Defender:-'-s who olaiir.td re :-vc: .occupational exposures and/or relevant occrpaticr.nl injuries inl/cr diseases and/cr symptoms at tV.are?.evei:.f. plr.fslisted in uuowor to No. 19 (sub 17) above. 19. Any and ail members f the S. i_-r.ee .f Reprsentatives Ocnsnittae c:i Oversights It. -iev; r the ?A :tions (1SC3) and/or any per.. r.\ together with their documentary : id demonstrative evident-: giving ter. i ny et said nearing (which will form the siibsta.se cf '-.licit testimony herein) on the failure of the EPA to take premp- and effective action ho ban the production if 2.4- D, 2,4,5-T, and its contaminant dioxins. 20. Any and all parser havnng knowledge of relevant facts regarding the financial status of the Defendants and their at -lity to respond in punitive damages, including, but not limited to, their past, present, and future profits and earnings in tile united States and abroad iroe 1921 through and including the present fron the sale cf the products race the basis of this lawsuit, i.e., 2,4-c, 2,4..5-'..'. phenoxy herbicide:: and the relevant herbicide market. 21. Any and ell persons havii g krsswledge of relevant facts regarding the ownership interests cf the Defendants and their ability to respond in punitive damages, including, but not l/nited to, .fer.dantc: dcmentic and foreign subsidiaries, joint venturers, licencing agreements, and/or other pubi-.c or private corporations i . :ho U. G. and abroad, in which these defendants own a sub stantial financial interest since 1925 through and including the "resent. -12- 1n Any and ail persons listed by Plaintiffs1 in h-oth original and afforded witness lists,, as expert witness (medical, scientific or causation).. government witness,. government causation witness, defendants1 employees and/or related personnel and/or any witnesses listed! by all Defendants, may be called at time of 'trial to present factual information as to any issue involved in this case- Bny and all members of the scientific and/or medical oonraunit..' wte have inowladge of relevant facts, including information . css.' of -tire previously listed subjects ii. this Answer, including, but :ot limited v;o: a. Ssvid Ifriehsi, Ph.i . !b. L:.t Alan Polar.! v. iDr.. Vaul Gaidar: 0AS7 d Ur. C. Paces e. iDr. Osttel, liAid it. Dr. E. 2. .fcDcr/ssil g. Dr. K. S. Kh:-.r:a h. Alvin .Alv'. i. Marilvn 2 incarhut Any and ail rev ...ns who hove indrviduai repr*ss e n t r \\\ rot limite-.:?. 4. the fed hewing; tarTd.tfic. * r*-a <Tt. Any and cl?. 1vr`i--ni porte; ?avo caeami: treat: d. one.' >r teote1d the it. and/or relat .n . .al and Lifv.1 1fce:r: :anburies, assesses lr:o! coo.nvdlitions which rsulte fixza Plaintiff-e-exposure to Agent Grange, and/or phenoxy herbicides, their constituents, csoarv'ary by-products, wastes, residuals r d ro:vtc:rnF:.-.-'*.s. b. Any and ell hospital parrs;:-*---I -where Plaintiffs have been confined for treatverd: relating tv> '-heir e^rposure to pefendants' n w v i m j t j s i VViif te' -t.nr aanmi. c. Any and all persons with kncwlndga of the sconanic losses, psydiologicai and/or intangible damages sustained by your Plaintiffs as a result of their injuries and diseases resulting from their exposure to Defendants' products .in Vietnam. d. Any and all persons with kneviedgo cf the past, present rnd/cr fuf.ure economic lessen your Plaintiffs hr.ne or will sustain in the future rs a result r; f-heir loss of wage enmings and/or wages earning capacity resulting from th~ injuries and diseases ma''o the basis < 1 t h i s ?.av/sr:'-. v;hbch were caused -t v Prair.-t: ffs exocuure to Defendants' o-xduct.'-* in .ietnsm. 12403 r^. PLAINTIF?'.S GOVERNMENT CAUSATION WITNESSES D. Diane Courtney fr EPA Washington, D. A* feth- factual and csrert t e s t i mo n y is scngi '. C. Gen er al Events ?re-- IS I: Any factual knowl- dgn el the Listory o herbicida sprayir.g n U.5. and e.broad; inc ludinj , but nst !.:.i.hcd to , (1 ) indu : exposuras and exp losio .-; (2 ) reg rtrat: 2,4-D, 2 , A ,5-T t;A.;h tho Dspartmen o i. culturo ar.d any other g-nvuvnaent ugenci any and/c r all o the De fende. 'tb ; o c - /--r r-r CtlUi1- ..-,.. of the u ir.tcry of .trl'Li cid j>r::ying in -he U .3. and ror.d ; inducir. but not limited to, (1 ) TU`/"> r 1 iary " 2 .7 A3 eat Or an ge end r. e r pl v I orbi-' i in victncm; (2 ) changes in Llic gusto ...'un r'u.-ireeats of fcsrbicidas vit ' U. S. government and its agencias includi nr. hr.oviedge cf F173.A. FLA, EPA and OCHA.; and . r.- ' know", edge cl industrial and ether ione . c::csV.re s t ~ 7. .1-.0 .. '1,4,5 - Y in the U .S . and abroad' Seo Anuo. Lappicimental Answer cf Plaintiffs' to f*p*]*r Interrogate ;:y No. 1 9 s,Ciac bed tr: a d incorporated herei a for ali. pu r- s re: events ~.c occurrences which these ation itiicsseu Euy be expected to c*v UpWf\, iti^ti ... :.""rtnat icn they Easy have regard;. ubp ec'ts outline-' in said Answe r . rsr.ont of Expo s'?re to Z , h -J>, 2,4,5 -T and dioxins and factual Laouledge ir. support ihercof . D . xpe ::t T est ime nv 1 ) Testimony sc it.ht in witr. car acity. `?*>/ f!;h ie :t Matts V.' c 4-.). " A S-v Ttr-i) :s and dioxii.s; Agent Ora: 7 (alno Whit*; >Ai --*0y and related chlotophenoi.j and ii man risk' assessment, regarding exposure, .ncluding, but not limited to, one or more of the following subject areas: a) Chemistry/Biochemistry b) Manufacture and/or Product!' n c) Toxicity d) Modes of Human Exposure c) Fate in the Environment (Hu. ar :, Plants, An LmaIs) r) :ltat of Art /State cf Medical and Scientif 1 L ':era are 1 Plant Physiology/Studies >. .nimai Physiology/St .'.dies ^ . i 'ill ftfcudiaB 3 ) Epidemiology/Biostatistics 1) Plants, animals, humans 2) Cancer Epidemiology 3) Reproductive Epidemiology h` A d v e m e Health Effects 2) Yes, witness wi.l . be asked opinions about both published and/or on-going studies. 4} Yes, witness will be asked opinions about any studies or research witness has personally perf ormed or actually participated in. 5) Yes, witness will be asked opinions about other governmental studies. 6 ) Yes, witness is expected to rev lev/ the. following documents prior to giving testimony: See, EPA , Res earch and Development, Health Assessment Document on Dioxins for the 0ffices of Air Quality, Planning 'ana "Standards ",*"^1p?epared by the Environmental Criteria and Assessment Office, Cincinnati, Ohio 45248 ( July 1982 12406 ( f ' surribiE^rrAi a n s w e r t o interrogat o r y n o . 19 Plain-tint's not'-: preliminarily tfiat tlie extant. Older on producing fact v-utnesses states that fact -/itnesses are not due until March 2, 1984, However, Plaintiffs may call one or more of the following persons (c those fresn various categories listed below) at time of trial to testify a: to factual knowledge they nay have, including: 1. Ranch Hand Personnel: These persons will testify to t air iarowledgc of the Ranch Rand Operation, Ranch Handers' -.gposure to Agent Orange, ar.d/or knowledge relating to the sore l.:?, tenting, and effects of Agent Grange on humans. Mi-sbers o:: tl'.n U. G. Armed forces: These parsons may .ertify to the circumstances and conditions surrounding the sp ayiug of Agent Orange. 3. Persons pro sent in Vietnam during the exposure period 1 question 1961--1972,. including, but not limited to, mil fary and paramilitary personnel of the U. G., New Zealand a i Australia, who have JaiowLedge of the spraying operatio? 3 of. the herbicides, the exposure, of the Plaintiffs' class, :he hazards accompanying any such exposure, the Plaintiffs themselves, and the Defendant company representatives present in Vietnam to oversee the deliveries and spray, ic operations of the lierbicides they manufactured. 4. Persons together with their demonstrative and docuaentcry evidence who gave testimony (which will form the substance of their testimony herein) at the EPA Cancellation Hearincs of 2,4,5-T (1979-1980) 'nde?; 7IFRA, including but not limited to: a. >-b. - c. d. e. f. g. h. i. j" Dr. Roy Albert- Dr. K. Diane Courtney Robert K. Baughman, Ph.D. Dr. 01av Axelson Dr. Renate Kimbrough Dr. Dawn G. Goodman Dr, F irk T . Kite'in Dr. Donald Thomas Dr. Rainer Hrentzel'-Boyme Dr. 'lattheS MeseIcon, Harvard -9- 12407 (' k. Major Alvin Young l . Lr. Rodney Eovey m. Kenneth V. Themsin n. David T. Buzzelli o. Dr. Michael Gross p. Dr. Renee Stringham r. Dr. Van Miller S_ Any current or previous employee, contractor, subcontrictor, in-house or private consultant cf each of the Defends os or any ether person who has knowledge of the manufacturirg processes, chemistry, occupational exposure ant!/or to: Icity of 2,/--D and/or 2,4,5-T or related chlorcphenols; including, but mot liirlted to, laborers;, operators; supervisors; contract adr.iiniistrotors; reality control personnel; engineers .process, chemical, mechanical and/or safety). 5. tef current or previous or.ploves, contractor, subcontractor, its-house or private consultant of each cf the Defendants or am-- other person who has knowledge of the possible meaas of yr.-vhi. .it; protection from tho hazards of dioxins" cavposure; iiicduii. . but not 1imitec. to, laborarc, operators, supervisor.:... *ra;?xacf. administrators, quality control parsonr.oi, engineers (process.- chemical, mschani^l and/or safety) . 7. Ar.y current or previous employee, contractor, subcontractor, XTr-house or private consultant of each of the Defendants or any other person who h o knowledge cf the means to warn those who might be exposed to use of the herbicides in <-uestion, particularly Agent Grange, including, but not limited "o, laborers, operators, supervisors, contract administrators, quality control personnel, engineers {process, chemical, mechanical and/or safety). 8. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person who has factual knowledge of any other manufacturing processes which could reduce the risks of exposure to Agent Orange and/or other phenoxy herbicides being contaminated with dioxins arid further reduce the risk and hazard to human health of any such'exposure. 9. Any current or previous employee, contractor, subcontractor, inr-bou.se or private consultant of each of the Defendants or any other person who has factual knowledge of conspiratorial conduct of tho Defendants, individually and/or duolicative efforts (acts which are parallel in native) which tended to or did in fact result in misleading the public and the United States government from gaining krcwledgo cf tlie dangers attendant iron exposure to Agent Orange end. other phenoxy herbicides. -.10- 10. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendant;.; or any oL icr pstson who has factual knew ledge of how diox.v.s work upon plants, animals, and/or humans. 11. Any current or previous employee, contractor, subcontractor, im-!icnise or private consultant of each of the Defendants or any other person who has factual knowledge of any statistics concerning the effects of dioxins upon plants, animal's, and/or Ih'tijbnnrMtii-^im 12. Any current or previous employee, contractor, sufccontactor, in-house or private r .-.nsultant of each of the Defendants or any ocher person ..nciudirig, but not limited to, members of EPA and other governmental agencies, wiio has factual knowledge of the following Incidents: a. Love Canal b. Times Beach, Missouri c. Sevesco, Italv d. BASF (1953, 1j 54 - Badisd'o in Germany) e. Production mishap:.: and/or explosions since 19213 at any of the plants of .any cf tiie 'Defendants manufacturing, TCP, 2,4-D, 2,4,5-T phenol, chlorine, acetic acid, benzene, sodium lTydroxi.de.. potassium hydroxide, and/or Agent Orange, including mishaps in the packaging, and transporting of tiie Defendants' product.; to tiie U. 5. Armed Forces bases for eventual shipment to Vietnam. f. Spraying of Vietnam from 1961-1972. 13. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person who has factual knowledge of any surveys, tests, epidemiological studies of any kind relating to the effects of exposure to Agent Orange, 2,4-D, 2,4,5-T or any constituent thereof including the econdary by-product known as dioxins. 14. Any person with factual knowledge of how decisions are made within tiie United States government, particularly the decision to use and to continue to use phenoxy herbicides in Vietnam, particularly Agent Orange; any person with factual knowledge government procurement contracts and the invitation to bidders, particularly those persons who negotiated the government contracts for all phenoxy herbicides (agents white, blue, purple, pink, green, orange T. and 11} with the individual defendants repre sentatives between 1961-1372. -11- 12409 ( k 15. Any person wiri factual knowledge through a m surveys, tests, epidemiological studies or otherwise undertaken by.,any state government, any private public or foreign corporation, the U. S, Congress or the government of any nation concerning the chemical compounds, 2 ,5-D, 2,4,5-T, dioxins, or related chlorouhenols relating to the creation of dioxins, the detection of dioxins, the dangers of dioxins' exposure, and/cr the toxicity, carcinogenicity, fetotoxicity, teratogenicity, acute arc/or chronic effects on plants, animals and the human population. 16. Any and all parsons listed in The Chemical Scythe by Alastair Bay, as having factual knowledge regarding 2,4,5-T, 2,4-D, and its contaminant dioxins. 17. Ail worker compensation carriers for the Defendants and docu mentation of all occupational exposures filed since 1925 which evidence industrial injuries or diseases at the TCP, 2,4,5-T, 2.4- D- Phenol, packaging, and/or transporation plants of the Defendants. 13. Any and all cat rent or prior workers compensation claimants of the Defendants who claimed relevant occupational exposures and/or relevant occupational injuries and/or diseases and/or symptoms the relevant plants listed in Answer to No. 19. (sub 17) above. 19. Any nd all members of the U. S. House of Representatives Committee or. Oversights Review of the EPA actions (1983) and/c any person together with their dccurxintary and demonstrative evidevice giving testimony at said hearing (which will form the substance of their testimony heroin) on the failure of the fill to tab. prompt ami effective action to ban the production of 2.4- D, 2,4,5-T, and its contaminant dioxins. 20. Ary and ail persons having knowledge of relevant facts regarding the financial status of the Defendants and their ability to respond in punitive damages, including, but not limited to, their past, present, and future profits and earnings in the United States and abroad since 1925 through and including the present frar the sale of tine products made the basis of this lawsuit, i.e., 2.4- D, 2,4,5-T, phenoxy herbicides and the relevant herbicide market. 21. Any and all persons having knowledge of relevant facts regarding the ownership interests cf the Defendants and their ability to respond in punitive damages, including,but not limited to, defendants' domestic and foreign subsidiaries, joint venturers, licensing agreements, and/or other public or private corporations in the U. Z. and abroad, in which these defendants own a sub stantial financial interest since 1925 through and inciudin.: the present. 12410 I \ r- r IS. Any person with factual knowledge through any survt a, tests, epidksniological studies or otherwise undertaken by ry state goviarnroent, any private public or foreign ociporat ^ . the U. S. Congress or the government of any nation concern:' n the chemical compounds, 2,5-D, 2,4,5-T, dioxins, or related chi nhenols relating to the creation of dioxins, the detectior dioxins,.the dangers of dioxins' exposure, and/or the toxicity. > rcinogenicity fetotoxicity, teratogenicity, acute and/or chronic c fects on plants, animals and the human population. M . Any and all persons listed in The Chemical Sc.-the b; Alastair Hey, as having factual knowledge regarding 2,4,5-T, "2.4-0, and its ccntuninant dioxins. 17. All worker compensation carriers for the Defendants ind docunsantation of all occupational exposures filed since 1925 which (evidence industrial, injuries cr diseases :t the TCP, 2,4,5-7, 2lT4-D, Phenol, packaging, and/or tronsporaticn plat u of the Dsfe. 'ants. 13. Any and all current or prior workerscesraeneation claimants of the Defendants who claimed relevant occupational exposures and/or relevant occupational injuries and/or diseases ar.d/> r syraptans af the relevant plants listed in .'.nswav to Mo. 19 (sub .17} above. 15. Any and all members of the TJ. S. Rouse c? Representative's Camrnittee on Oversights Review of the EPA actions {1933) and/or any person together with their documentary and demonstrative evidence giving testimony at said hearing (which will form .the substance of their testimony heroin} on the failure of the EPA to take prompt and effective action to ban the production of 2.4- D, 2,4,5-T, and its contaminant dioxins. 20. Any and all persons having knowledge of relevant facts regarding the financial status cf the Defendants and their ability to respond in punitive damages, including, but not limited to, their past, present, and future profits and earnings in the United State and abroad since 1925 through and including the present iron the sale of the products made the basis of this lawsuit, i.e., 2.4- D, 2,4,5-T, phenoxy herbicides and the relevant herbicide roar.i-.et. 21. Any and all persons having huav/leace of relevant facts regarding the ownership interests of the Defendants and their ability to respond in punitive damages, including, but not limited to, defendants' domestic and foreign subsidiaries, joint venturers, licensin''' agreements, and/or other public or private corporation', in the n. S. and abroad, in which these defendants own sub stantial fin-uncial interest since 1925 through and including the present. -12- 12411 (f 22. Any and all persons listed by Plaintiffs' in both^cri'inal and mended! witness lists, as expert witness (medical, sc entific or cau^sation) , government wiuness, government causati witness, defendants' tanployees and/or related personnel and/or any witnesses .minted by all defendants, may be called at time of trial to present factual information as to any issue involved n this ca: 2. 23- &sy and all members cf the scientific and/or medical immunity wham have knowledge of relevant facts, including infer .'cion am any of die previously listed subjects in this Answer, including, tot not limited to: a. David Kriebel, Ph.D. lb-. Dr. Alan Poland c_ Dr. Paul Goldmann, BAS? dL Dr. C. Roppe e. Dr. Oettol, BASF f. Dr. E. McDonnell g. Dr. K. D. Khiera h. Alvin Ain1. i. Marilyn Fingerhut 24. Any and all persons wise have factual knowledge conce. ing the individual representative Plaintiff's damages, indue ng, b u : not limited to, tl o fcHexing: a. Any and all medical persons who have examined, observed, treated and/or tested the Plaintiffs' for injuries, diseases and/or related physical and emotional renditions v.' .ch resulted from Plaintiffs1 exposure to Agent Orange, and/or poenoxy herbicides, their constituents,- secondary ly-products, wastes, residuals and contaminants. b. Any aid all hospital personnel where Plaintiffs have been confined for treatment relating to their exposure to Defendant"* products in Vietnam. c. Any and all persons with knowledge of the economic losses, psychological and/or intangible damages sustained by your Plaintiffs as a result of their injuries and .diseases resulting from their exposure to Defendants' products in Vietnam. d. Any and all persons with knowledge of the past, present and/or future- economic losses your Plaintiffs have or will sustain in the future as a result of their loss of wage earnings and/or wages earning capacity resulting from, the injuries and discuses made the basis of this lawsuit which v;ere caused by Plaintiffs exposure to Defendants' products in Vietnam. -13- J>Zl s i [r o i n * u S*w in*-..ucoj^Aac \ iMjcas-'U BS'Sr hO iim u - U.O Ajoiiijr-qr-i :i-: vaJ'oOV.ij-,liij: ujiu| A3U.lhv uno }).' i.'IUVU1U0JIA'J^ U.-IIUP VW &' ?L A iN T IF ? 'S GO V7?.R ITM EH T C.AU 0 AT I O IT W I TITE S S E S Th: 1 Tj .7. i. VJi *A Center for li sease Sa Z et y and Health , . 2k.;_3a fee teal. ano c:: rV* GeneTal EverX PV;..10'6 '' : Any facti::1 knarIedge of the history of C Z1. d P spv ay i in U.S. and abv a a o -, iZ - x u .1i but Z?tZ limited to, Cl) inoustr xpe b . a ec and ex p i o cions; (2) regi c <' t7 tz _;io r: - ' i - D - - ^ .5-T v ith the Department - - ^Z-"s.* _ 7.*"y*r*. < ir :I a n y r th o r g o v e r n m e n t a g a n c i o s b* rt 11 V and 4 - a 1 1 c he Do fondants; 1951 Z Z " " j.` k r. o v .-le d g e c f t h e h i y t o r y o n i - b . . i l o ;. p r a y i n g i n t a : U . 1 . a n d a l r o a 1 ; l:z r : 'j. d i . " : b t n o t l i m i r e d t o , Z D D . c Zb. - . . '*' ':Z` *J V , e : A g u t f r a n g e a n d . o t . h r X "7:1v. b i z * i w i ' clc:' I lZ ^ c ^ n e r (2 ) ch a n te s in . h e . s z: ~ V. 1 o a r e n u i r - : - : u c r . r . c o f h e r b i c i d e s v; i H b s 'i-t ' C*ZIC ..w. b agencies _nc ltd leg edge oi ..:ERA, F!A, EPA, and OSH /i* and 7" - 7*/a I^c o i indurti* ia1 and otha r *.".;u:zi -- r* cQ >-D , 1 d ,5-T it. the IT fine ep. Arevrar and Scopieuenta 1 Answer cf Plaintiffs' to Oaf and ant r : Interrogatory lie i-aretr a::.' incorporated herein for all pur poses re: events or occurrences which fees* causation witnesses may be expected to give any feet uni in fern:at ion they nay have re gar t'r.; 3coi ects outlined in said Answer. ITAnaan 1x.:r Asosr: vaant of Expo eraro. to 2,4~D, 2 5-T an ditfit t end any far tirai knowledge in sunpor ::hor V V * Expert 1est imo ir. 1 > Tostir.'.^ny i.? sc uglifc in witter-,.;' personal and offre capacity. Z) Subject Matter ,4-r , 2 A .o -- i TGDD 3 end die:::,ns ; i g e n t 0 : i / r.i no White lue. Pink, G r e e n : a n a P ur S it'S I *V ;u' " a a 3,7..-g y - i'.von..,;.v;;..u^ a <I. P_s '>7rpb :JnjrIS'i / xp `0 FFF/- "j j - -y3 ~t :::: I-: r."f IF.:-;7 ;; -x'-o "yzx vk ,;F:; ; V . "if *:.Lt ui1 w ^3-._' ;.i\' ' ....Xj.jXi'>t .iV.u ;ps : r.'.... ...op;: ' T*n -- . .:>3^ 7s::: zv.-. P ; .:r.;: 14 -v-- i; -.- * '.-r - ? 3 .. '.ii.: *?A." '7' A f 7 I-- - . .i . "S'.1-:, "" .1 ' /_v B .o 3 "p : 3p :t\ *r. , J'- pr: :y. l-'? *" 1, ' t - 7 U " 's w .JW ypoq :. / W ` X L .1 .**'--1.4.- : y . A .1 71137.7 lr D..v;:y.::ip ..t?O " ......- j,- r"" r; T.iU ... .-1. : .;; - y ; *1 af ..j r;o" :;iv.7 r :iw: n? ;'Jvo" ;'[ c'.'.'.iU" :: .-, - ;;pr ; op- ; . \-, :x 3C `*V.J y .r:v.vt 1-i. w .. .... *.-r-r * 'T *. .1'' :" ;v . 'pf'/. J : -j :r:; s \ t: s -. : ' " t ;; -3 MS : 5 :';::'.-pr. - 3 7..1 JLi ;> .1 r ; es . 1 ?JO 0 . t :o d :;3 SF ... .. w- .<.J0>0 . J i l j T.V ;: ;; T , D 1i d C ^ ^ V U :: *W :>.V. 3 1' * ---tu.5/?'^'`--i-S 'u-*.--`y.; *&,!'!it**'i**"*-3a>''**' 'i 3r\':. r - . V [Research and g^'cf? Research ana D^y a1opment^%glox iris`,-; i R C U S t ra l:E|n_^____ Ciac innat i Ohia:( - .-K^Vj^SafeS^^ taen ts i * ;:t-*cS1dv^$' > -- . i-*.- i'-'-`v'r--''c^v-':VJ-.v'~i.v*SS>'J-.f; 'jMt'. -1v>: i'!:~r~t`V -,, ---, . :t v -- - j-.- -i- <-- '2'S:? --. ^=r*---= Tf 3LTPLEMENTAT. ANSWER To IKTERROrATDRY No 19 Plaintiffs notn pre.liininar.13y Hint. the extant order or* prod-wing fact witnesses states that fact witnesses are ncv. due until March 2, 1984. However, Plaintiffs may call cne or more of the following persons (or those ran various categories listed beim) time of trial to testify as to factual knowledge they rray have, including: 1. Bench Hand Personnel: These persons will testify to their taro.ledge c h a Ranch Hard operation, Ranch Handers' exposure to Agent 'range, cri/cr kr.a;iedg3 relating to the spraying, testing, and effects of Agent Orange on humans. 2. Ibarters c.f the V, s. fumed forces: These persons may testify to the circuast-anceo anc conditions surroundirjg tha spraying of Agent Grange. 3. Persons present in Viet'.an erring the exposure period in question iSCl-l?'/t, including, tut not limited to, military and paramilitary v rsonnol of the it S., New Zealand and Australia, who have knowledge of the rpraying operations of the herbicides, the exposure of :-. Plaintiffs' class, the hazards accrrpanyir.g any such, exposure, the Plaintiffs' thsmselver, and the Defendant ccspany representatives present in Vietnam to oversee the dr.liveries aid spraying operations of the herbicides they manufactured. 4 Per.:.3ons to.-ether ntr. 'heir demonstrative and documentary evidence vix gave testimony 'which will form the substance of their testiirony herein) at the EPA Cancellation Hearings of 2,4,5`-T: {li'`;?"-1980) under F3PBA, including but not limit--, ta: a. Dr. Roy Albert: b. Dr. 4. Diane Cbuxtnsv c. Robert. K. Bauchman, Fh.D. d. Dr. Oiav Areison e. Dr. Ren.ite Id-Through f. Dr. Dawn G. (V.'odnv'n g* Kirk T. Kitchin 4 Ujl Ronald Tbcraas . Or. Rainer Frentzel-Eevrae J L::. Matthew Merelson, Hex 12417 _0_ 10. Any current, or previous employee, contractor, subcontractor, in-housc. or private consultant of each of the Defendant i or any other parson who lias factual knowledge of how cl:o:o is work upon plants, animals, and/or humans. 11. Any current or previous erp: oyee, cor.tractor, cuboontr; itor, Cl i n it i i i,ii iii 11 i,t>iUI i i'i 11 M i I i mi l*i i ii i 11 ! 'I any other person v.vo has knowledge of the possible means of prcpljiactic protection fran the hazards of dioxins1 exposure; including, but net limited to, laborers, operators, supervisors, contract adrr nistraters, quality control personnel, engineers (process, chemical, mechanicf.il and/cr safety). 7. k ' current or previous employee, contractor, subcontractor, it -house or private consultant of each of the Defendants or any other perron who has knowledge of the means to warn these who. might be exposed to use of the herbicides in question, perrticrlirl'- Agent Orange, including, but not limited to, `.ct*T7mrn, c.j,->r<vt/3rn, vip^r-vi r:nrr., -nti-fc\*ftfc uitvti.itJlrif` 1, y u lity control personnel, engineers (process, checaical, mechardcal and/or safety). Any currant or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person -'110 has factual inowledge of any other manufr.cturi-p:nscesses vihich ciuld reduce the risks of eicposure to Agent Orange and/or other phcricxy herbicides being contaminated wj.th dioxins and further reduce the- risk and hazard to human health of ;iy sv-.-.h exposure. "nv cur*reT,+- or '*i/~i*ir* `fai ,_J CO ls. Any person with factual knowledge through any sur. :ys, tests, epidemiological studies or otherwise undertaken b? any state goveusnant, any private public or foreign on pore on, the U.;S. Congress or tine government of any nation concern?... the chemical ocnoounds, 2,5-D, 2,4,5-T, dioxins, or related civ ronhenolr relating to the creation of dioxins, tine detectio: of dioxins, tine danger:. of dioxins' ezrposure, and/cr the toxicity carcinogenicity, fctotoricity, texakogericity, acute and/or chroni- affects o:i plants, animals and the human population. 16. Any and ill parsons listed in The Chemical Scythe y Alastoir. Kay, as having iaclual krov/lcdge regarding 2,4,5- 2,4-D, and its contaminant dio;.-ins. V). All Morkoc.nny.'-T'.kir c vrir'rr: ;'-^r t'v n*|Vnx1an< and n civ .I'o:itati.cn of u.U. oscupn -ierv.. . .posne c filed sin 1923 which evidence industria.7 injtries or diseases at tine T:... ; 2, 4,5--T, 2,4-D, Phenol, packaging, and/cr transgoraticn pia. hs of the Defendants. Ar.y r:.d all 0'.:.-rent or ,:.icr worker: compensation ..arnants the. aa undents w:o cla..' red relevant ;ccupaticnal e xisures -. Mr tele1;ant '-c..upatio- ul ;./uric:: ard/- : diseases an: .r syrrptems the ro' oVctik 1:'c .in Answv n Mo. 19 (si 17) above. 19. Any and all members of the u. S. Heuse cf Represent;.fives Ccomittee on Oversights Review of tla EFA actions \1933) and/or any person together v?ith the: r documentary and derrnstrative evidence giving tostirony at said hearing (whicln will form the substance of their testimony herein) cu tlie failur: of the r to taka prompt and effective action to ban the prer. action of 2.4- D, 2,4,5-T, and its contaminant dioxins. 20. Any and all persons h.-reg knowledge of relevant frets regarding the firuiroiai status of the Defendants and their ability to respond in punitive damages, including, but not limited to, their past, present, and future profits and earnings in the United states end abroad through and including the present from the sale of the products made the basis of this lawsuit, i.e., 2.4- D, 2,4,i-T. phenory herbicides and the relevant herbicide market. Any arc. all. persons having Icnowledge of relevant facto regarding the ownership interests of the Defendants and their e'-llity to respond in punitive damages, including, but not limited to, defendants' domestic and. foreign subsidiaries, joint venturers, licensing agreements, and/or other public or private corporations :'n th L S. and abroad, in which these defendants own a sub stantial financial interest since 1925. through and including the present. 1.2419  'Vv/5 -.'l :4 PN * -/TV 22. Any and ail persons listed by Plaintiffs' in both original and amended witness lists, as expert witness (medical scientific or causation), government witness, government causation witness, defendants' employees and/or related personnel and/or any witnesses listed by all Defendants, nay be called at time of trial to present factual in"o;.Tiiation as to any issue involved in this case. 23. Any and all members of die scientific and/or medical ccnaunity 'h o have knowledge of relevant facts, including information cn an;' of the previously listed subjects in this Answer, including, but not limited to: a. David Kriebei, Ph.D. b. Dr. /dan Poland c. Er. Paul Gcldmann, EAsr d. Dr. C. Ratpe e. Dr. Oettel, FAS? f- Dr. E. E- McDonnell g. Dr. K. S. Khiera h. Alvin AJ i- Marilyn, I-ingerhv.t 24. Any and all persons -wiio 1: a. factual, Incwledge cor earning the individual representative Plaintiff's damages, including, but r. a limited to, the following: a. Any and all medical parsons who have- examined, observed, treated and/or tested the Plaintiffs' for injuries, diseases and/or related physical, ar.d emotional conditicnr which resulted free. Ilaintiffr.* exposure to /.gent Orange, and/c phenoxy herbicides. their constituents, secondary by-products, wastes, residuals and contaminants. b. Any and all hospital person: cl where Plaintiffs have been confined for -treatment relating to their exposure to Defendant." ' products in Vietnam. c. Any and all persons with knowledge of the economic losses, psychological and/or in-tangible damages sustained by your Plaintiffs as a result of tlieir injuries and diseases resulting from ti.eir e:q?csure to Defendants* products .In Vietnam. d. Any and all persons with knowledge of the past, present and/or future economic losses your Plaintiffs have or will sustain in the future as a result of their .loss of wage earnings ana or wages earning capacity resulting from the injuries and diseases made tlie basis of this lawsuit which were caused by Plaintiffs exposure to Defendants' product.? .in Vietnam. -13- / 9 ") < q . Aiiy end all persons with iovowledge of past, present nd/or future reasonable and necessary costs of doctors, hospitals, nursery care, medical equipment, drugs, and any other related medical services rei>:erei or to be rendered in the future to Plaintiffs as a result of their injuries and disease resulting iron their exposure to Defendants' products in Vietnam. f., Eagr and ail persons witli ituowledge of the physical disfig.remenh (past and present), physical and mental impairment {past and present), physical pain (past and present) and mental anguish (past an present) which Plaintiffs have sustained as a result of their exposure to Defendants* products in Vietnam and which in reasonable probability Plaidstiffs will continue to sustain for an indefinite time into the future far beyond tiie date of this trial. Respectfully submitted, Thermic !v. Henderson, Esquire Allison Pettiette. Esquire i hereby certify that a true and correct copy of the foregoing Ellison Pettiette 12 A Z Z l'Z l i 89 "SS. MC; tlfcUUJ.r 7 oieior: .Jiciu:iihjiaij3 i>:msni'i; K/iUO-i.AO(! i'swswy A*:i. h r uo SjC; dujujO i PLAINTIFF'S GOVERNMENT CAUSATION WITNESSES Donald Earne3 A. ____ E P A , Hashingt on , D .d . j___________________ B. Beth .actual and expert testimony is sought. C. General Events Pre-1961: Any factual knowledge of the history of herbicide spraying in U.S. and abroad; including, but not limited to, (1) industr exposures and explosions; (H)registration 2,4-D, 2,4,5--T with the Department of Agri culture and any other government agencies any and/or all of the Defendants; 1951-present: Any factual knowledge of the history o herb iti.de spraying ir. the U.S. and abr.. a d ; i n c l u d i n g , but not limit ed to, (1) U.S. military use of Agent Orange and other pro he rbicides in Vietnam; (2) changes in t'. a gistraticr. requirements of herbicides wit; U.S. government and its agencies including kn owledge of 77.FRA, FDA,EPA, and OSLIA; end any knowledge of industrial and other kune exposures to 2,4-h, 2,4,5-T in the U.S. an abroad; See Answer and Supplemental Ans we r of Plaintiffs' to D e f e n d a n t s ' In te rrogatory No. 19 attached hereto and incorporated herein for all pur poses re: ''.vents or oc cu rrences which the. causation witnesses ma y be expected to giv any factual information they may have regar the subjects outlined in said Answer. Human disk Assessment of Exposure to 2,4-D, 2,4 ,5-T ar. dioxins and any factual know led ge ir suppor ti:e reo f .. Eu 'er:: Testimony 1} T est ir ->ny is sc u gh .: in witness' personal and offir a acity . 2.) Subject Matter ,4-"\ 2 f'-T, TCnr,'a nml dioxina ; P I/I I (aio o w h it a , Blue, Pink, G r a u n , aud Pu 12723 and related chlorophenols ana human risk assessment regarding exposure, including, but not limited to, one or more of the f o ll ow ing s u b 1'oct areas: a) Cham .stry, B i o c h e m i s t r y b) M a n u f a c t u r e an d /o r P r od u c t i o n c) T o x i c i t y d) M o d e s of H u m a n E x p o s u r e e) Fate in the E n v i r o n m e n t (Humans, Plants, Animals') f) .State of A r t / S t a t e of M e d i c a l and Scienti Literature I ) Plant Ph r-\ J Animal P kv sic 1og y /Stu d 1a s ^ , H u m a n St g) ;\c 'm'iolt-gy /'Br 1) Plants, **. C a a c e E 3) Re v-" -clue A d v e r s e H e al t h Eff cts 3) Yes, w i t n e s s wi l l be aske.cj o p i n i o ns about both p u b l i s h e d and/ o: on--going st u d i e s . 4) Yes, witter w i l l be asked op in ion s about any Studie or research witness has personally performed or a c t u a l l y part 'oipeted in. 5) Yes, wi. ie.ee w i l l tv asked o p i n i o n s about other governmental studies. 6) Yes, w i t n e s s is e x p e ct e d to re v ie w the f o l l ow in g documents prior to giving testimony:: Coe , ETA, Ree car eh and Developinent,_Hoal<* h A c s e s o m e n t D o c u m e n t on P 1 b x i s s o r t 'ne O-fj; f i e vs_ o A i r 0 u . J . j L t v , P l a n n i n g ' and *titan-'ar?c ,__ pfesared `by the Envir-'n-enou-.l C r i t e r i a and As sec cm Office, '.ncinnati, Ohio 45243 { July 1 EPA , Re;;scrch and Development, 11 nltl; and E n vi r o nm ent al Efloots P a 1e for; Tot ?enta , and Hexaclilorodi b.e'.izo-p-dioxins for the Office of Solid Waste and Emer gency Response, by the En .ironmeV.tal Criteria and Asses sm ent C.'fice, Cincin Ohio 45248 (June 1983). EPA, Research and Development, A abient Water Quality Criteria for 2,3 ,8 TODD, pre pared for Office of Wate Regu i.atio .s and Standards, by the Er .ronnonta Criteria and Assessment fice, Cincin Ohio 45240 (July 1933). E?A, Research and Development, jicrins. Indust ial Environmental Research Cincinnati, Ohio (1978). copy of th e document!" *s attach ed . 12425 SUPPLEMSWrAL ANSWER 'Ll. IlJTEffl&i&'iUy No. ID Plaintiffs note preliminarily that the extant Order on ting fact witnesses states that fact witnesses are not due until Marcl 984. However, Plaintiffs rosy call cne or more of the foliating person: those from various categories listed below) at time of trial to testif3 ;o factual knowledge they may have, including: 1. Ranch Hand Personnel: These persons will testify t ;mewledge of the Ranch Kara Operation, Ranch Hander to Agent Orange, and/or Irncwledge relating to the s testing, and effects of Agent Grange on '-.-mans. iir cposure Lng, 2. Members of hie ti S. Anned Forces: These persons m to the circumstances an:'. conditions surrounding the of Agent Orange. octify aying 3. Persons present in Vietnam during `the exposure peri' question 1961-1372, including, but rot limited to, it- and paramilitary personnel of the U. 13., New Zealand Australia, who have knowledge of the spraying ccaret, tiie herbicides, the exposure of tire Plaintiffs' clas: hazards accompanying any such exposure, the Plainbif -ihsmselves, and the Defendant company representative: present in Vietnara to oversee the deliveries and spr; operation:, of the herbicides they manufactured. .ary \ 3 Of die' ,g 4. Pc'.-sons t-"ether wit.i tlieir demonstrative and documsi evidence who gave testimony (which will f o m the .cut: of their testimony herein) at the ERA Cancellation Hr of 2,4,fj--T (1379-lSOG] under F3FRA, including but not to: .ncjs mited a. - b. - c* dm 1JL i. Dr. Roy Albert: Dr. 1. Diane Courtney Rober K. Baughman, Ph.D. Dr. Oiav Axelson br. Reuate Kimbrough Dr. Darn G. Goodman Dr. Kirk T. Kinchin Dr. Ronald Thcnas Dr. Rainer Frentcel-rayira Dr. Mattliew Mecelr.cn, Harvard 1242S -9- rx *-*IL. k. Major Alvin Young l. Dr. Rodney Bovoy m. Kenneth V. Themein n. David T. Buzzelii o. Dr. Michael Gross p. Dr. Renee Stringham r. Dr. Van Mii'er 5. Any current or previous employee, contractor, sub in-house or private consultant of each of the Defi airy other person who has knowledge of the manufac processes, chemistry, occupational exposure and/o: 2,4-D and/or 2..4,5-T cr related chlorophenols; i: not limited to, Laborers;, operators; supervisors; administrators; quality control personnel; engines chemical, mechanical and/or safety) . actor, as or 1 icity of ing, but erect .process, 6. Any current or previous employee, 'contractcr, sub; in-house or private consultant of each of the Daf. any other parson who lias iincwiedgo of the possibL prcphiactie protection from the hazards of dioxin.including, but net limited tc, laborers,, perator: contract administrate:, s q u a l i t y control personne (process, chemical, mechanical ar.d/cr safety) . ractor, its or ns of ensure; parvisers, 7. Any currant or previous employee, contractor, suber in-house or private consultant of each of the Defe: any ether person who has luiowledge of tho means to who might re exposed to use of the herbicides in qi particularly Agent Orange, including, tut not limit laborers, operators, supervisors, contract adminisi quality control personnel, engir-eers (process, chc meciiai',;.cal and/or safety-. -actor, ts or e those ion,' to, ->rs, 8. Any current or previous employee, contractor, subcc in-house or private consultant of each of the Defer any other person who has factual knowledge of any c manufacturing processes which could reduce the risk to Agent Orange ar.d/or other phenoxy herbicides bei with dioxins and further reduce the risk and hazard health of any such exposure. actor, .'cs yc ;r >f exposure contaminated human 9. Any current or previous employee, contractor, subcc-. 1CCOj~ j in-house or private consultant of each of the Defeat ,ts or any other person vino has factual laicwledge of cons; .-irate al conduct of tiie Defendants, individually and/or duplicative ; arts (acts whi.ch are parallel in nature) which tended to or die o fact result in misleading the public and the United Dtatr Tovemmont fre.n gaining knowledge of the dangers'attendant frex posure to Agent Orange and other phenoxy herbicides. 12427 -1.0- 10. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person v/ho has factual knowledge of how dioxins work upon plants, arumais, and/or humans. 11. Any current or previous employee, contractor, subcontract .or, in-house or private consultant of each of the Deft-dents or cur other person who has factual knowledge of any statis ics concerning the effects of dioxins upon plants, animal's, nd/or humans. 12. Any current or previous employee, contractor, subcontacfor, in-house or private consultar. of each of the Defendant.f or arc/ other person including, but i. t limited to, nembers of .IPA a d other governmental agencies; who has factual knowledge of the ' foHaving incidents: a. lavs. Canal b. Tinies Beach, Mic:aouri c. Sevesco, Italy cl. BASF (1953, 1.): 1- - Endischo in Germany) e. Production r.rLshans and/or e:c?lcsicns since 1921 at any of tile pic .as of any c:i the Defendants manufacturing, TC"': 2,4~D, 2,4,5--? phenol, chlorine,, acetic acid, benseno, sodium hydroxide, .potassium hydroxide, and/or Agent Orange, including mishaps in the padcaging, and 'transporting of the Defendants' products to the U. S. Armed Forces rases for eventual shipment to Vietnam. f. Spraying of Vietnam front 1961-1972. 11. Any current c-r previous employee, contractor, subcontractor, in--hotre cr private consultant of each of the Defendants or any other person rho has factual Icnorledge of any surveys, tests, epidemiological studies of any hind relating to the effects of exposure to Agent Grange, 2,4-D, 2,4,5-T or any constituent thereof -:ncluding the secondary by-product known as dioxins. 14. Any person with factual knowledge of her decisions are made within the United States government, particularly the decision to use and to continue to use phenoxy herbicides in Vietnam, carrticularly Agent Grange? any parson with, factual knowledge of goverrraent procurement contracts and th-;. invitation to bidder.':, particularly those persons who negotiated tine government ccntjracts for ail phenoxy herbicio':.: (agents white, blue, nirp-ln, pinlc, green, orange I and II;. with the individual defendants repre sentatives between .1961-1972. 12428 -ii- 22. Any and all persons listed by Plaintiffs' in both original and amended witness lists, as expert witness (medical, scientific or causation) , government witness, government causation witness, defendants1 employees and/or related personr l and/or any witnesse. listed by all Defendants, may L.a called at time of trial to present factual information as to any issue involved in this case. 23. Any and all members of the scientific and/cr medical community who leave kiwledga of relevant fact?, including information cn any of the previously listed subjects in this Answer, including but not limited to: a. David Kriebsl, Ph.D. b. Dr. Alan Poland c. Dr. Paul GoldiruC:, BASF d. Dr. C. h-.ppe e. Dr. Gettel, BASF f. Dr. E. 2. McDcnnell g. Dr. K. 0. Khiera h. Alvin Ale i. Marilyn Finger-hut 24. Any and all person." wb _ have factual Icnowledge.concerning trie individual representative Plaintiff:s damages, including, but not limited to, die following: a. Any and ail medical persons who have examined, observed, treated ard/or tested the Plaintiffs' for injuries, diseases and/or related physical and emotional conditions vliich resulted from Plaintiffs-' aseposure to Agent Orange, and/or phenoxy herbicides, their constituents, secondary try-products., wastes, residuals and ooriiaminants. b. Any and air hospital personnel where Plaintiffs have been confined for treatment relating to their exposure to Defendants products in Vietnam. c. Any and all persons with Ixcvledge of the economic losses, psychological and/cr intangible damages sustained by your Plaintiffs as a result of their injuries and diseases resulting from their exposure tc Defendants' products in Vietnam. d. krr and all persons with Icnowledge cf the past, present and/or future eccncnac losses your Plaintiffs have or will sustain in the future ::n a result of their loss of wage earnings and/or wages earning capacity resulting from the injuries and diseases made the basis cf this: lawsuit which were caused by Plaintiffs exposure to Defendants' products in Vietnam. 12429 -13- e. Any and ail persons with Knowledge of past, prand/or future reasonable and necessary cos'.s o doctors, hospitals, nursery care, medical jui drugs, and any rther related medical serv. .s or to La rendered in the future to Plaint: _fs result of their injuries and disease resulting their exposure to Defendants' products in Viet f. Any and ail persons with knowledge of the pays, disfigurement (past and present), physical and impairment (past and present), physical pain present) and mental anguish (past and present) Plaintiffs have sustained as a result of their to Defendants' produces in Vietnam and which i: reasonable probability Plaintiffs will continue sustain for an indefinite tine into the fucurc beyond the date of this trial. red t el and in jsure Respectfully su ted, C iW -( itt:o Teonas w. Render .n, Esquire Allison Pettiefct- Esquire CERTIFICATE CF SERVICE I hereby certify that a true and correct copy of the re sing Supplement to Plaintiff :s Interrogatories were mailed Federal E ess to Mr. William Krchley, Kellc Drye & Warren, Mr. Gene locks, Pla: :iff. ' Management Ccnsnittea Agent Orange Office, with copi. .3 to persona ,.y serve tiie remaining Defendants at the Tuesday depositions and Ms. Nanc Petrilln, J.S. District Clark, U.S. Courthouse, 225 O.cman Plaza, Brooklyn New York 11201 this 20th day of February, 1904. in Allison Peif.iette 12430 -14- paaa*VBB\^j V.T^^ S**1- ai-' `JuttaJ J S ri'r'; `tvtronm . un Pm -ijctiuf a qo n r.v usinai r'-.vimninenia! rrv );rn lo rv . tiA li O H <-'S< Si rttS*'i:tt4 -a*. a D i o x i n <c v^ >\\. ,.0 r>-% I P LAINTIFF*S G0VEHNM3N"' CAUSATION WITNESSES Umberto Saffiotti National Car-car Institute, Washington, D.C. B. Both factual and expert testirony is sought, C. General Event.; Pro-1961: Any factual knowledge of the history of herbicide spraying in U.S. and abroad; including, but not U n i t e d to, (1) industrial exposures and explosions; (2) registration of 2.4- D, 2,4,5-7 with the Department of Agri culture end a n y 'other government agencies by any and/cr all of the Defendants; 19C 1-y ..asent: ..ny factual knowledge of the history of herbicide spraying in the U.S. and abro.*-: i; including, bud cot limited t o ; (!) U.S. military uc i of Agent Orange and ether whenherbicides in Vietnam; (2). changes in the ru_ gi3t-ration requirements of herbicides with the U.S. government and its agencies including knowledge of FTFRA, F D A ,E P A , and OSHA; and (3) any knowledge - f industrial and other human exposures t: 2,4-D, 2,4,5-T in the U.S. end abroad; t See Answer and Supplemental .newer of Plaintiffs' to Defendants' Interrogatory No. 19 attached hereto end incorporated herein for all pur poses re: events or occurrences which these causation witnesses may be expected to give any factual information they may have regarding the subjects outlined in S 3 i d Answer. Human Risk Assessment of Exposure to 2,4-D, 2,4,5-7 and dioxins and any factual knowledge in support thereof - D. Expert Testimony 1) Testimony is sought in witnes s ' personal and official capacity. 2) Subject '.-latter , 2.4- D, 2,4,f--7, T C D D 's and dioxins; Agent Or any I/II (also White, Blue, Pink, Green, an. Purple 12132 ' ' .-V. and related chlorophenolr and huaan risk assessment regarding exposure, including, but not U n i t e d to, one cr more of the following subject areas; a) Chemistry/Biochemistry b) M a nufacture and/or Productioii c.', Toxicity d) Modes of human Exposure e) Fate in the Environment (Humans, Platts, Animals) f) State of Art/State of Medical and Sclenti Literature 1; Ilar.t P h y s i o l o g y / S t u d i e s 2) animal P h y s i o l o g y / S t u d i e s 3; ilu a n Li::;* los ) E p id am io 1c gy /B i out at i st i c s 1) Plants, .anivais, humans 2j Cancer Epidemiology 3) Reproductive Epidemiology h) Adverse Health Effects / 3) Yes, witness will be ashed opinions about both published and/or on-going studies. ') Yes, witness will be asked opinions-'about any studio. or research witneaa has pornr-nally performed or actually participated in. 5} Yes, witness will be asked opinions about other governmental studi '... 6 ) Yes, w i t n e s s is expect ed to r e v i e w the fol lo wi ng documents prior to giving t estimony See, EPA, R esearch and Development, -Health Lssessmerit Document- 'on 'DiOxins for the 0 f1 ices- of Air Quality , Planning `ar.d ^'iTag.d'Hrdr., pfeparecT'by the Environmental Criteria and Assassin Office, Cincinnati, Chic 45248 ( jv.ly 1 12133 to ' yi 4 i :V: % . .i :>' ' . '.. .- . ''* ^T"V v" ; . . . , : '.Vi.; ... . -, -'-I- Tv'- ifi. EPA, Research and Development, Health and Environmental EfCects Profile for; Tet Pent a and .liexach *orodibeuzo--p-dioxins for the Office of Solid Waste and Eme r gency Response, by the Environmental Criteria and Assessment Office, Cincin C?iio 45248- (June. 1983). EPA, Research and Development, Ambient Water Quality Criteria for 2,3,7,C TCRD,. pre pared for Office of Water-Regulations and Standards, by the Environmental Criteria and Assessment Office, Cinein: Ohio 45248 (July 1983). EPA, Research and Development, Dioxiis, Industrial Environmental Research Cincinnati, Ohio ;i973). A copy of.th-rse dccuacnts is attached. ;' :; -AU.\ i. y 41 V'i .14 }?' ' \ <7 . ::;.>? -.y. -V.vA r.z.vr: .. .; . .. ;vvr. ifi! 12434 .-A? ( *r> ''jV "**''. fa /liVJl . - *u ' *4A h `v ns#* /f J-'"">. .$85 '. SvUw- ''tir SUPPLEMENTAL ANSWER TO INTERROGATORY KO. 19 , Plaintiffs note preliminarily th-.t the extant Order cn producing fact witnesses states diat fact witnesses are not due until Mavch 2, 1984. However, Plaintiffs may call one or more of the following parsons (or there from various categories listed !xiw) at time of .trial to testify as to factual Icncwladge they may have, including: 1. Ranch Hand Personnel: Tiieta persons will testify to their knowledge of the Ranch Hand Operation, Ranch Handers' exposure to Agent Orange, and/or knowledge relating to the spraying, testing, and effects of Agent Orange on humans. 2. Member.: cf the U* 5. Armed Forces: These persons may testify to the circumstances and conditions currour.c.:n.g idle spraying of Agent Orancs. 3. Persons prorent in Vietnam during the exposure period in question 1561-1372, including, but rr..t limited to, military and paramilitary personnel of the U. S., New Zealand and Australia, who have jnowledcc cf the spraying operations of the herbicides, the exposure of tiie Plaintiffs' class, the hazards accompanying any such exposure, the Plaintiffs' themselves, and the Defendant company representatives present in Vi etnam tc oversea the deliveries and spraying operations of the herbicides they manufactured. .'> <* -V ' . Persons together with their demonstrative arid documentary evidence who gave testimony (which will form the substance cf their testimony herein) at the EPA Cancellation Hearings . 2,4,5-T (1379-1980) under FTFRA, including but not limits to U-'. * i- 'V. _ C. d. e. f. gh. i. j- Dr. Roy Albert: Dr-. K,, Diana Courtney Robert K. Baughman, Fh.D. Dr. Olav Axeison Dr. Renate Kimbrough Dr. Dawn G. Goodman Dr. Kirk T. Kitchin Dr. Ronald Thomas Dr. Rainer ? renteal-Eevma Dr. Matthew Mese-lson.. Harvard mm-- x&t' - f -9- h 1 2 -', (o f 7^ k. Major Alvin Young 3.. Dr. Rodney 3ovey ra. Kenneth V. Therein n. David T. iiuzzelli o. Dr. Michael Gross p. Dr. Renee Stringiiarn r. Dr. Van Miller 5. Any current cr previous employee, contractor, subcontractor, in-house cr private consultant of each of the Defendants or any other person who has knowledge of the manufacturing processes, chemisury, occupational expo.sure and/or toxicity of . 2,4-D and/or 2,4,5-T or related chlorcphsnols? including, but not limited to, laborers?, operators? supervisors; contract administrators; quality control personnel; engineers (process, clionicai, mechanical and/or safety}. 6. Any current cr previous employeef contractor, subcontractor, in-house or private consultant cf each of the Defendants or any other person who ass knowledge cf tie possib* .means of yrcplgiackic crctecai'vr; from the hazards of '.rucLn' exposure; includin':, brt rot liraited to, laborers, operators, supervisors, contract administrators, quality control personnel, engineers (process, clerical, mechanical and/or safety). 7. Any curr ent or previous eaolcyee, contractor, subcontractor, in-house or private consultant cf each of the Defendants cr any other.' person who Ires knowledge of the naans to warn those wiio might he szeposed to use cf the herbicides in question, partiad-rrly Agent Orange, including, but not liin.ited to, laborers, operators, supervisors, contract administrators, quality control personnel, engineers (process, chenical, mechanical and/or safety'-}. 8. Any currant or previ-.us employe:':, contractor, subcontractor, in--house or private consultant cf each of the Defendants or any other person who has factual. Iincwledge of any otlier manufacturing processes which could reduce the risks of exposure to Agent Orange and/or other phenoxy herbicides being contaminated with dioxins and further reduce the risk and hazard to human health of any such exposure., 9. Any current or previous employee, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person who has .factual knowledge of conspiratorial conduct of the Defendants, individually and/or duplicative efforts (acts which r~n parallel in nature) which tended to or did in fact result in misleading the public and the United States government frem grimr.g know]edge of the dangers attrrdant fresa exposure t o Agent orange and other phenoxy herbicides. -10- 'rS k'V/f' 15. Any person with factual knowledge through any surveys, tec epidemiological studies or otherwise undertaken by any state government, any private public or foreign co. poration, the U. S. Congress or the gt /emmenb of anv nation concerning the chemical eompoundo, 2,5-D, 2,4,5-T, dioxins, or related chloronhenols :, rje., relating tc the creation of dioxins, the detection of dioxins, the dangers of dioxins' exposure, and/or the toxicity, carcinc.genicitv, fefcotoxicity, teratogenicity, acute and/or chronic effects on t ,, f 1 .. 10. .'ny current or previous srployae, contractor , subcontractor, in-housa or private consultant of each of the Defendants or . any ether person who has factual knowledge of how dioxins work t^on plants, animals, nd/or humano, 11. Any current or previous amloyeo, contractor, subcontractor, in-house or private cor.rud.tant of cadi of the Defendants or any other person who lias factual knowledge of any statistic.-: concerning the affects of dioxins upon plants, animals, and/or humans..... ~ 12. Any current or previous f~ ~loyea, contractor, subcontactor, in-house or private consultant o'- each of the Defendants or any other person including, but not -.inited tc, members of SPA and o f 'er government?' agencies who factual knowledge of the a. Love Canal b. Times Beach, Missouri >,... c. Sevesco, Italy 'd. BASF (1953, .1954 - Badir- nhe An Genrsr- ; - . . o. Production mishaps and/or explosions since 1925 at any of the plants of any of the Defendants manufacturing, TCP, 2,4-0, 2,4,5-'? phenol, chlorine, acetic cid, ben2ene, sodium lydrosdde, potassium hydrcxi.de, ard/or Agent Orange, including mishaps in the packaging, and trar -porting of the Defendants' products to tlvs U. n. Armed Force; bases'for eventual-ellipment to Vietnam. f. Spraying of Vietnam from 19Q-1972. 13. Any current or previous erployce, contractor, subcontractor, in-house or private consultant of each of the Defendants or any other person who has factual knowledge of any surveys, tests, epideuiological studies of any kind relating to the effects of exposure to Agent Orange, 2,4-D, 2,4,5-T or any constituent thereof including the seccudary by-product known as dioxins 12437 14. Any person with factual knowledge cf how decisions are made within the United States government, particularly the decision to use and to continue to use phenoxy herbicides ir Vietnam, -If-iiigarl> &/-- ----- `1 7 *f'-~"' S Pi~<rr 1 :* I H 22 Any and all perse is listed by Plaintiffs' in both original and amended witness lists, as expert witness (mee .cal, scientific or causation), government witness, governmen! causation witness, defendants' employees and/or related persorau . and/or any witnesses listed by all Defendants, may be called at tnva of trial to present factual information as to any issue involved in this case. 23. Any and all members of the scientific and/or medical ccnmiiity who have taxrwiedge of relevant facts,, including information on any .f the previously listed subjects in this Answer, including, but not limited to: ! O a. David Kriebei, Ph.D. b. Dr. Alan Poland c. Dr. Paul Goldmann, BASF d. `Dr. C. Rapps e. Dr. Oettel, BASF f. Dr. E. E. McDonnell g. Dr. K. S. Khiera h. Alvin Aim i. Marilyn Fingerhut 24. Any and all persono who ha a f.,uLu-'i knowledges concerning the individual representative Plaintiff's damages, including, but not limited to, the following: a. Any and all medical persons who have examined, observed, treated and/or tested the Plaintiffs' for injurj.es, diseases and/or related physical and emotional 'conditions which resulted from Plaintiffs' exposure to Agent Orange, and/or phenolherbicides, their constituents, secondary by-products, wastes,, residuals and. contaminants. b. Any and all hospital personnel where Plaintiffs have been .\ confined for treatment relating to their exposure to Defendants' ..` products in Vietnam. c. liny and all persons with knowledge of the economic losses, psychological and/or intangible damages sustained by your Plaintiffs as a result of their injuries and diseases resulting from their exposure to Defendants' products in Vietnam. d. Any and all persons with knowledge of the past, present and/or Ti .:i future economic leases your Plaintiffs have or will sustain in the future as a result of their loss of wage earnings anchor wages earning capacity resulting from the injuries and diseases made the basic of this lawsuit which were caused by Plaintiffs exposure, to Defendants' products in Vietnam. i 1.2438 United Stares Environm ental Protect:; .1 A t'iirtcv Research & Development Industrial Environmental iLaboratory Cinc::rni:i OH 'JE26 /*> L C-; ,, /^ -~tJ rffiv % -jn*r ' ; jp ; > 4 X ^ ' im r ' ' -W. <** . S ^ `T '. '!$*, vp*v - r ^ v . V> i / i 1j* iV i -Jt 12433 :.u6 relatad chlorophnnols n.nd 'matan y ar.socsment rcgaring e-pocare, inclr b'i': not iiuited do, one ov r,sore of tu o1 ?. T.-iin g au b \oct a"o.a .o: dh en i at r"/Bloc h cirir;t ry iar.::_'act:urri sn/or 1Jr o d " ion .-..'/v ionicitv 'i) i' es .-tunan F.xrsc :i:r v) :a ir tbo .uvirosaciit (Humane Animo. Is) . :cto nte of Medioal and Lt.-acrcsure -/ Blant "'-.yciology/otad ir.s Ar.ir:nl Payaiolcfiy /Sfcuies J} dan-a.: d'rvdic-a * o.* ?*'.'.`'ir.{b.-.'.O.i ?.? .*>- .>r. animis - hir a-:ai 2T *'.*in" Ipicasi.-Lology - : ide.'..-.io 1 p * h ::Ii Ejiocti x O .J... f. .-j--* op.Vaioao a..-:-ub i; fea! -~ d/r en go:`::g etaclias r.vv *o c* -A l:ac! opAnisas about a o :i w id n eco fea.s p e r s o n a l l ; p *}.> pe ;ti c.i o ir. ..e 1.j.1 be feed opinic-nr n i ---.t c .10 1 s11:d ie . . *'w.`i *-TTT- C:Z 0d do ::ev:;aw ida fe 11 ri:;.,ya . pr te yi- ir. as'-.isor-': ;oe , r.I \j ferjs r.refe an J j-ev e1o pean i: 11 :.r.r.o ns aoat Do ca-m ent -on-'Tixos:in s O f :;ic-ca- q::: A-ir'Qv.-ltv-, 'P .1snn: "sV-nuil'bttc - p r eparad by tfen Enviar nueriutl Criteria and. Office, i'-'acina v.ti , Ofeio 4524 ' ti :,r./.7.j'.n:i':'r3 gcveiviikht ga.g .-a '.'Iun w ::t ;;s s ?fs -..1ari *_ia_;qor* 4 . Cantar for Dis ..ns : Contro.'. (CDC) A t l a n t a , GA 3. doth l.ro an'! :t: tcat:.!-'.ny io sought. C. Cc::y...l : : < J l: ir.1!: h a ;uledg '. of th e history o r iC rpraying in 0 . B . and ab:, oad ; :..nc,,u'...Innr; b u a o . t limited to, (1 ; il(u t -# *''J snd e : : p l o s i c n s (!; regio.::; j.C Xo .5-.' riti: t!i Hep 3. ..nr:.C aJ A C .1 .'.r.y or he:: gcvernncnt a ?a.::?:icc all cf tha Dafendanr .: '*i. ..... -siO. .... jwlo .'..r'jJ r, r ?:1:o h 1ot. ;*V v.7 .; `V opr r.y;.i:g i;' C - - S . .:. : :.fc:;oa-d ; ..i'_iiu.;.-.;ii5: b-t not lini "t.oh ,.. T`i 7. ' ''..0 0 A i.g:at C V*?: .r\ snd othe r ph-no .1 -i Acida." It \2) 'oI:m g os in i:h;. 'jv. '* c '. Cu.m, rs :. ' ur-cu c13 c ? *\ erbiai-ies v,- _.. c . g v n r : neat :.n*l its age::uies ilici -.i.o --`-`L " :'UA, FDA *P/. ; and C3K.A S C.1 S. ;-.uy hr.owladgc :1 lilduSt ICJ. ti1- end ntiier hur.an :;j.rrrr . sc i .A*-or ::.,h n '*i. in the U. - a:ac loro u rr tt; . . o i . ; i p,v - ' ^ . -i p !L eim.entrh Arerei; Ih-.t-orrogatc ri --**| iucorp tod< herein :;c r all pur" a s <2a r ?: ; e v e n t j or oc ^ ^ r> f* i r f* !' rt e / cf-r-r.t:7r.n T47.ti-asses ".ty bo e:ipectad tc give any ta .tua ` in '1cruaticn th ny :aay have regardi r.'ui Uj;or- 'zj.?.ncl: ,iii ;c.id Answer. t .:;.:.i ;r- - ,, U ?**:Y C f Sr re to 1 .i--D , .1.4 S-T and ,v}*.>;tV. ..;; `i'.v uny rcutnal un owledge in crppor-v. -* no art To S t i c . ; r%-*:CS:-u~i-Y r.3 sought ia .'it ne su * oar cnr * C7 . and off:.e it N C :r - hi, .-.. - -.; CC: .i's c i i o : A,'ouu i ;a ;o 'hit a lina, .. i.nli, G r e e n , .-v 1 ,?u::p. V/i4,sX-r A c .>py o enr ,;h cn i .;cv c 1 o puent , e.-itii i-.:-. nvire ruer.'' Profila*; ** .e <*r Ca 1. - -U ..W w fo :: Totr P e n t e , a n d c:;a ::lorod ib en :o - p - d ie x i n s . for the Office, ci Joiid Waste end Suer- g cviey Rsspcr.se, b y the Environi-.-cr.tal Irileric and rsessiaant Office viacinr;: O7._o 4 S 240 '.Tare 19Gin \U!V- ' .. V "'> .Vrch ,d DeveLr rincnt, Ai.';uJ.oi'.2" Q A.i i: Cr ir o ri a for 2 .3,7 TU i-.V.-, p '-';' for O f f i c e of Jai ar UeG'.il ..Us.1 :.la-.-ciard-, b y :!c E:ivivi.V2,*to 0 f --- 9 C.;i o 4 5 ."4e U u _ y 1 9 G 3 : - I,: L'i'. n p.'^eut:, Dioxine ; e::t a .1 P.esear :h .i'.*' i fi i r*i * .9 s <i.4 i.iT-xu-i cotad a ns h -v . t o iwrawSGarroay i;o. 10 Plrintiff ; n : ' i a p r o l : m ;."7 ten,. t-jr*o cactani C-rdor on prccucing rrec rvasres state-: that fret vLtnassss arc r2.: tea u.rfil ite:te 2 , IOC4. Idverar, Plaintiffs .ray call one or rere : f. ten following persons (or those from various categories listed ]y ~ .h :xs'. at trJ.tr..; or trial to osctify as to ff Jtual knrv/l&3ge they ty have.. 5..alt-liny. 1 . Ranch iiarid Pomona -mu 'Thooo ;.-arsons wi.Il testify tc titer kncvdedge cl tee lm.h Karr; Operation, itench Harders* e'-ipssnr:: to Agent Orange, r,wo: Inowlodge rel .ting to the spraying, testing, .ml off-rote of Ayanh (ranga on l.raans. 2.. ftsofoers tf tea R. Innsd For.cos: these perrons way testify to teo ntect-teteacc-.- ec.5..con1 itl.anr snrr -nding the spraying of Agent invagn. 1 . Par.-.-ono yrem:.t i.. "r m u m .or.r.g te.. ci:>asur*' perio.. :a quasti-M llcl-...1 .. incivd;' ,g, -.,,c-.': iicLtca to.. rtemtai and. pa; ' .ary rerro: m.l of tie U. 'few tealem. or.I Aitenralin: 1... Inn: i m k y ;of teo spraying operations or. the imbioiic ;.mpcrvre cf ten litentiffs5 class, ten hnoardo mm.yvotenc any sud. oteocnra, tea Plaintiffs? teemselves, mo. .la rteenimt errpony rmrerantatives .resent it: 7int:rr: tc oversea tire callv'e.ries and spraying operations -1 . ie imiterides -'-hoy rmr:lcr.tiered. Drrsovr vomte: :cite ter:.:/ darrmirtrahive and dccnmsntarv trvidante rlo gave tai/lrv (which v*i'l form -/he subsrai^e of tie:..: t_teJ.r.o:v-herein) at ten '..V,Cancellation Heaxiro o ,.,.C .1, {1171teffO) rafter Ftete . *ncludi:ig but not ii.dtea `j . . a. r.?:o.. tev* 1. . Dr. n. Diene Oe^rtr.rv m Pecart !'.. Pmtensn, Iltet d., Dr, tew tecel.r:.n O., or. m a m Iterbrrvgn D.r. 7- t.c "coir' i 0 . Dr,. tel; t1. ;*_-y.:ihi.: h. Dr, Ronale thrmar i. Dr. Frir.rr Dr l/ml-reyn.e *j* Dr.. 17.7'i.m 17 miser. r.arv:v:t IO > * i\ i'lCLJ*CU /viVCS) -010.-" 1 . D r . ' fto d r.s y lo v o y a . K e n n e th V . T h e ra e iii a , D e v x d ff . B u r r e l l : , u . U r. M ic h a e l G ro s s p . D r . B ence S trin g i^ -iii .:, C r . V a n M i l l e r 5 . Ar*y c u r r e n t c r p r e v ia --u o p l - : / o c , o l v t r a c t o r . s u h c c n .tr r .c to r , ir .- d e u c e o r p r i o r .he c r n c u it r .- v t o f e a c h o f th .r D e fe n d a n ts c r a r*y o t h e r p a rs o n o h o In s h c w la d g a o f t h e rn e n 'ila o b u r lie r f r s c o n c e s , d '< c r .i '.s t r 7/ . ^ c c u p r t i o n a i e x p o s u r e a n d / o r t c x i c i t y . . l 2 , -'-*U a n d , o r d d i r : c r v a l e t e d . lo : : o p lia n o .'..o ; d e l u d i n g , h a t n u t l i m i t 2 d ^ ; . .1c h a r e r a ; . e p o r a t o r u ; s u p e r v i s o r s ; c o n t r a c t a i i i i n 5 . s t r r ; . h c r s ; 'p r o l h v p e n i i o l - e r s e r n e l ; e n g i n e e r s ( p r o c e s s , c fe a a ic a l, ro e s h e ..' m l o r - '/o r c u ih t y i , C. A ny c m . _ : . . o v i . : : : r? .y l y c r.. rc e .lrs c to r. e v b c o r tr a r tc r , in - h o u s e o r rr.vnv. ;n o r s u l t r o t o l e t c h o f d i e D e fe n d a n ts c r a n y o t h e r p r a t e r . i f -; L a e ! r .....l e f a a o f t h e p c s s i b i n r c s s n e o f o r q o ld r e tic g r e t - r : ic n .1 s t ; -h r. h a tre d s o f d ic r h v r e x p o s u re ; : i i e i u d i r ; .t : r t ; r h 1: 1 .r e d t o , l a b o r e r s , - p a r a t o r s ; s u p e r v i s o r t ; c o n t r a c t : lr i i: t v re;. ' - p u '.iit y c r .v x e X p e r s o n n e l, e n g in e e rs p r o c e c , c/:r::'- ' . v-e: r:vi o r . l r . ' . f o r s a f e t y ) . A n y cv.-.:.: o f . ; c r o . ' i . s s; _t r p 2s , . a : . n t . c a t o v . s u b c o n t r a c . : o r , i i -h o u s e r r g a iv a 'a - co r.. v ..w ...: c l ; w l o f id le d e fe n d a n ts c r a n y e t l.r v ra e a a r - n s ;a.v :w la d g a c:: t h e r e a m t o w a rn th o s e w hv r i e l . ' o - p .'o rr ' o a v o f i r e h e r t i r i l e s h i q u e s tio n , p a r c i c t l - : I p h a ;.:;.': 'r . r . v p e , r o d r i n g , b u t r o t lit i t e d t o , l a b o r e r s . . - c o o -- . '. ;v .g c '-a v e rs , c o n t a c t a d n in is t r a t o r s , q u a l i t y c o n t r o l p e r s o n n e l , ...*y i n s e r s y r o o r r s , c h e r d c a l . ra o h a ru n o l a n d /' c s h ir t y ) . 3 . A n y c u r e no o r p ...v ; a s c ist/ o v e r . o a . n t r a . .. c r , s u b e o a t r r t o r , in -h o r.re c r r r iv a t o c m e r it h i: o f each. o f t i e D e fe n d a n ts o r a n y e th e r p evs er. r l o h a s f o r t r a l h ic v lL e c re f a n y o th e r i h n u f n r b a l a a p c o . r a -.; : i . o h c h ~ a c l r e e : f t r o t . i s o f c r e r r s , t o 7-~e. O r - * ..g o e n d . ' ; : . . t i e r " h a .o : / h e r b : ' . i d e a o o . i n g u o n t c u x l r s u e d a h a h i ca.tr....; e r r . h r . I- - : : t i i o : .* io '.c s r r h r s o r d t o h v x v in h e e lth o r err* s f - y r . 9 . ? jy o u r r e r f r : p ro v ir u s a rp lc .-rr':. r a n tra -: h e r, s u b c o n tr a c to r, i n - h o u s e o r o r i.v u iv r . c - - . . c a l f . r u t *.': e a r b . c f t h e D e f e n d a n t s o r snp-r o t h e r ^ a r e a -.dir 1 c s t r r l J i r r . l r l p e , . f c o n n n irc f.o ri." .'-. c a n d r d . c f the o^erlc.rtn r .l'/" d u p .lic a tiv a e ffo rts (.rots whir '-. : p s r a l l s 1 i: ir/r.:' . lei fovcisf to o r did in font re si.. f I s l s o l - r ;; ' ,.' 1 I t 'rile d .States govern sent c i i .' . a i'.c'c.....cl; . of optss r t t r r o o n t i .'t n exrc .s.r:: t ; her n t C oo.r e ond ot!' . v ;'e.. : ' ' ::rb; :i; .os. 12444 I. ilry narrent or prate eu ci.picyen, canhrr-Utov, subcontract- r, irHicusa or private co -subo rt of cooli of fis Defendants or ony ocrer porsen who ir -5 incineri Ki.,r;ledgo of how diclino work upon oleres, arJ-meJ-s, encl/or rosne;"3. 11. tey crurent or prvenu:> sr:playee, contractor, subcontractor, iiv-bousa cu privato consultent of each of die Defendants or any otter pareen elio .on factual dev.edge of any statistico concerning file effects of devins upon plants, sternal's, and/or humans, 12, any currant cr previe-: ; f l u y e s , contractor, rte-ccntachor, irt-house or private c^nrraltsr.t of cadi of the Defendants or ;..y ether perse.. inchrlteg, :nv re': liraiton ..or 'nemters of EPA a 1 other gcvonursental n-jonnioo, tex ten frutve. . lunvledge of the following teoiidantau a- Lore Co.nl b. Mires Bertel; 1-ltefcV A c. lav--- .0 , "only e- P recau tio n u l s t e r s m l1/ :: : naie- rie. `.lu re 1525 e t any o f th ? p iv o ts o f er.y o f to e tote .te ite r 0 .. .te n d r i n g , 1CP, ':Mir 2M ivo 'C, M l .ri.,.;, ..ode /...id.. macana, sodium :ute:n.teda, ontoreoV-v. liter :lcic, end/ur : rout Drange, ineiiidirg nishrpu ;te the roroeging.. :y tevisportiio; of tire Defendants' prete.M s to ,,; ; te, lo Aisne-' `orces hasss for eventual ehipnent to Viatnrv;.. t. rte.T.yiug "7 5"M. ,:ra or,. I M l - i f . M .2. Anv tornarte or previous sirteoyco, rond-actor, sutcontrcrtor.. in M e s a or* privet a.advent of etch of tee Dfendants or any of m :w:scu who : .; futeudL kcod-sd* of a: y surveys, tests, car V cMloMo-'l ri udir : rf " * tete M l M g a the ff'r;t-3 of Vope.. ut.; La o/j-d-h A-v.,.ya; .A'O-O, t,-. ;.r oi.y ecu .tituen:: r'.iarccf Molul.Lr the suero tea Ir-'-prochtct Icrowr. as dictesis. 1/ Ary era. .. with fr.-Jim.. uic.jlsd-oe *f hcv decisions are iraca \,dtein the U M ted Clot'eu rovantnant, prte/icndarly '-ha decisi' uo uso o.:c `o continue te use -heneo 'te:,h i d las iu Vietnam, p?::tio?J.a.-lv teent ":r.r a--- carro. 'tete. f- etua.l knowledge gevate.uret pr-.-cuvAV/vh co. ? 00; arm 'he te/olation tr bilde: jerlicularly Mo,. : pn \ .-1:; /'? n y '' 'ter' l o gc'vot' Tir-rt ron' for elf. phone:?/ hate-lu.:ou [ Ml ar. s nh:.':.:, blu , purp>ie, pink, -..lar., orarne If.. ; ill; rite in .teMM >&1 tetec.vtent:; repr- mb- lunar tetuoen .1G 1:2145 Any person with factual l:nowiedc?a through any surveys ; tests, spidcmoic-gics 1 studioc m: c-lvrcra 3 under::rlcen by any state ycvorn.'.2nt, era/ pii sto public or foreign corporation, Lbs . S, 'iOi'gresr. or toe gov. orront of '.ny ns tier. concerning the charaical ccccuns, 2,5'"D, .V-.-f'*'!'.- dirdrra;, or related alorc phenols relating to tlm creation of c"::.oxir.s> he detection c: dioxins, the dangers of dioxins} cpcoure.. and/or die toxicity, corcincgcnicitv ; fetotoraicityc taarafc-.gcjnicitry.. acute and. or chronic effects on. plants, aniicals and tin human population 15. Any arrl ail purons listed in The d.jgnicsl. Scythe by Alastair Eay, as baring factual r-Twlcdga regarding 2,1,.r -1. 2-ID, :,v..l its UDnter.f.:'ar dira::!:ran 1?. AL:. workc ccnp.n: :nfi.. o r e . r s for tiro Defendants era.i cracurcuntaticc: .f 1.1 coupe tioral <measures filed since 192!; ciie; ericcn . industriel. innr.cs cr diseases at the CF, ?..f,.f '?, 2,4-D. fir a.:-? . uaararacvs, x.'>:r c m raperat'on slants cf die Dfendrais.. Any and VI- 0 . _.r r.ra.-:r.Sct:ion ci..ixncU;tc of li'3 . if~/'ZL\ \'WO i.. rarar sieve ct vupnlionnl exposroran rs.d/..-: relevant - "A"? ' m- ,-v;".b" .- ~ ! s--r. ;vxl/or ::,yinrl 'he cel.. ; ` - ;c . . . v -v v.. 1 Id .sub ill .-.ioAra. Any v.l i.y.\ J.V of . . 1. f. .. Ct :; ; prasentatives dcviTtl-tea cyht :t. . of 'm : A rations (1383! and/or ri y .-rs.c 1iogc-'- v.*i; id. . ch encan 1-7 and dame:-strutis: evict:v a g:..vine foe ticon;. . ......iy. y.-.. - 'which vri11 !c-rs: 'he /"WTCbu-! .. '' c : t k .t ; '*r-C*''*1 irarein; m the failure of the Did be take y;c:.cpi r.nd. -eff rclive eclien to ban (die production of ') M .t ^/. tw"*-. . ^.. /. i its .contaninanl ci- sir c : tv arid all. persons h ./ii ; :x-r-.viedge: 0:f relevant facts regarding tic. finnccl.al stats.s Of 'tiio Dcfcnc entra red their ability *rreapend in pUT-ltiVO ..nf....>. grc, including , but not liiiu.ted tc, -ra-i: pact, present, end .brtrrrra profits and earnings in the United State:. and slccad sinn *'i' 1trough -and including the present firasn 'die cale of ihe prelects ranis the irnsic ci this lawsuit, i.c., 2.4-D, 2,4,1 1'.. rlvrar.. ? hcraoicilec and ti e relevant herbicic market. Any "cd all pert one havr no lvra/ic..is or relevant facts regarding 'he rvercoip inter \sir. -Nf lira Defer, arris and their ability to respond in punitive damage.. jLrc.li,'riug, !v,t net liraited to. defendants1 daraccfi- am" feesip.\ si bciciiaries, joint venturers, license <7.g?:-'sracnt:j,. end/c :: other -ublic or private corporation-, in the . U. usd a h r , : - m which t.csse defendants own a sub stantial freer::iai if- us.. Inno 1125 ierrrough and inci;;ding wra sresent. 12446 ! `-'y 1 persorr' '..usted Ly Pa:.stiffs' -'ll both crioinal and .rudcd tnaus :vs cscjXirt .'itnom n<;U:nl, ti.C:u; cr causation).. ge a-...me..': ritnoss,. yovu.mn.nt enusatic iwitness, deiendant-d awplGyscs: and/or rn.lr.tr personnel ;nd/or any witnesses listed by all Defenderte, m m be exJ.lx.l at fciir.u of trial to present factual i:dentation as to noy intro involved 1 i this casa. 23. Any anil all rumens of tito scientific and/or medical .omunity who h.-'s bncv/lacga of relevant facts, including inforr otion on XTy o the jrev usuy listel subjects in this f.mv: ., irxludinc, hot not ..':..it::.'i b f..r David j., . .j . b. Lr. hi.TjI- . c. Dr. Paul 1-C.-V d. n--x* ...< -rv: e. Dr. *r !? Hr. c. Dr. ... Moibsro:-; . ..1-.-u--c..*, h. Alulu -lii,: 'L* Mr.ti.y1*::. .s rhai 2A, Any o:' r.V oerrom \ir m u . lovcuul iumledye ccncerr ng 'ha ndivid'ul u y uso..'.ni: .o 12.ai hifi;o durugn , including.- Id: no': Ir-P.i 'rrl ; y. tho d o: :u;;; a. Any ano l. rmilrul. parser:: o',o huive examinod/ observed, treat: 1 end/.::: tasted 'is 1laiivtiffs ' f-:: injurie.".. disease" and/or minted rluuicc.. and evxt.lonol conditions vi oh resulto fren ilaiotiffn erge-suro to P r u t Orange r and or fneno:"/ xdr.u: dos, uisir :onm ihueros, u m n d e r y by err.ducts, wastersuirais si so ;.aa. ruta. i:, tsy m u all hespiru. n n o n o I vr- a Plaintiffs have buen confined ir hroatuont relating -te. .their cc<posure to Defendants' oronots iu vietmu. ' -i"./ ci'/. aj. y,,u.v_b\v v.v,h. rroved m of the oosnonc losses, psychologic.:.! and/or i im.uble erroagos sustained by your Plaintiffs as a result t? thoir injuries and distases resulting iros: their enoosuro to .jeiV.rde.rt:';* rrxduchr in Vietnam. o.. 2xy and sil .r: vos v;..rh bnwledya o.T the ystt, present and/or fui-re '" sao loo-ou y m r Plaintiffs .tara or will su/uu ir. the fute :i result u n i r los:'; of wage earnings and/or '..ages earning capacity r itir.y from the injuries sad disea; ,-c made the basi.s cf this lav/suit v;'r!oh were caused by Plaintiffs cvxcovrc to Defendants' prod-.vats ' . Vietnam. 12147 i \ o. Any aid all parser's wrlth kre.i.ei.gc of past, present trd/or future reasonable a:vd rucaesnry rests of dc .-iters.. Iospitalr:, nursary os:.-a, rnefliccl oqui.prnsivt, .`'.rags, .tad c .ty ether related medical serv. c:as rendered or to be rendered. in the future to Plaintiffs as a result of their :...:juries r i disease resulting freru their e"pOL.;-:.'.-c to Defendants' prr.durb: in Vietnam. f . Any aid. alt. pc: :e.on:; with knowledge of the physical disric^-enni: Igast r:\-.C. present), physical ant! mental iu.pairra:i: t at ., nv.-i! present' f physical join {pt.r/c and present- c no tur.frl anguish (.jest and pro. ant) widen IfLaiu.tr.fur larva e-nf.. ..cl a result of there: exposure to iaicriurt:.;5 y:::,cunts :_n Vietnam c..:d whiih in reasonable pros- bili-'-y Plaintiffs 'til eentinne to r:ustr.ir. far an indefiriha hisie .into the future for hoy: no tin >. ;ho of this, trial. rte3f.2Ctf-.il..y; subr:i.ttud; 1 1 t ^--.--.-hifefcferii'Q lucsics W. licrderscr. Esqif.ro Aliinon Pattiette- liruirr "'1C-: 1 barely rer.J.fy rat t hrir: :_,v'. oup_ of the foregoing irpplrsaeno to .Isi.. riff *s lot-. .nyafnr: o tore tailed Federal Express to . or. orllirnr K'reMo;;. K e l l ! t :y; h. r's .ran, Mr. Gene Lodes# Plaintiffs' Mma'''arsr.i Cca\:it rt. Lgrsnt Leery.; ufiiro.- w'.iV1.copies to personally serve the rdraining tsicv.l.o; p; r.r. via v --.-sdry 1 rosrhv.'rr; and Ms. Nancy Pctrilla :j.:t. Pistri:; .11 1 .,;. y VJr *. - rac- h..as..;, hrcoklyn.. New Yob: iltV this rOri; cl-..y of rebLun*y., lit ' j tt.:~ r.;\.y - l i a l u - d l lili :.on lattiett a 12448 V L '. ':jA L'^UfiJ S u .c; r- nvjfonjn;:..t; \ \ " ;;e*ior* a ;jncv :<luswir>tr.ivt.xonicnt.T. joor.'Kocv ir.cjr.ny;0!: 526J ftesoarc.t & svt!ku>nti: ;t 7";a% a u o x ] t:5 ..--'V V ".`V i 'X.ts . .rrt*. 'V. S-jwS .^ X iO vCJ f"-X " ..,,:# ' W ' " ! T /' "U;U > 5M V-. j. -w ^ .* 1"^^"> - * Xr \ \ ^*4^ .*&*t**s.S3, r *>*- *! .-i '1 J:' J v-r UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK "AGENT ORANGE" PRODUCT LIABILITY LITIGATION MDL NO . 381 ; -X 0 O VI ^t a ..' //J' DEFENDANTS LIST OF FACT WITNESSES SUBMITTED PURSUANT TO THE SCHEDULING ORDER FOR THE COMPLETION OF DISCOVERY '"V I iI !^ BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, P .C . 33 W ashington S treet Newark, N ew Jersey 07102 (201) 622-7400 \ UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ---------------------------------------------------------------------------X In R e "AGENT ORANGE" PRODUCT LIABILITY LITIGATION X MDL NO . 381 DEFENDANTS LIST OF FACT WITNESSES SUBMITTED PURSUANT TO THE SCHEDULING ORDER FOR THE COMPLETION OF DISCOVERY BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, P.C . 33 W ashington S treet N ew ark, N ew Jersey 07102 (201) 622-7400 12451 DEFENDANTS LIST OF FACT WITNESSES SUBMITTED PURSUANT TO THE SCHEDULING ORDER FOR THE COMPLETION OF DISCOVERY On behalf of all defendants, and pursuant to the Scheduling Order For The Com pletion Of D iscovery d ated January 10, 1984, counsel for Thompson Chemical Company hereby subm its the following list of potential witnesses to be called a t tria l, a tta c h e d h e re to as Schedule A. These w itnesses shall be called to testify as to the issue of the government contract defense. F urtherm ore, a tta c h e d h ereto as Schedule B, defendants hereby submit a list of witnesses presently scheduled to be deposed at a future date. Therefore, defendants reserve the right, after these witnesses are deposed to determine whether or not these individuals shall be called upon a t trial. Each individual defendant also reserves the right to submit an additional list of witnesses on their own behalf which they may choose to call upon to testify. D ated February 29, 1984 Respectfully submitted, BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, P.C. Newark, New Jerse y 07102 (201) 622-7400 Attorneys for Defendant Thompson Chem ical Company RIVKIN, LEFF, SHERMAN & RADLER 100 G arden C ity Plaza G arden C ity, New York 11530 Attorneys for Defendant The Dow C hem ical Company 12152- 'TirTA7XTT U V Ar T T O n T t M T X V IT41UJ 1 CA, V J. 4^111AJ. . 405 Lexington Avenue New York, New York 10174 (212)682-4567 Attorneys for Defendant Monsanto Company ARTHUR, DRY & KALISH, P.C. 1230 Avenue of the Americas New York, New York 10020 (212) 841-9300 Attorneys for Defendant Uniroyal, Incorporated KELLEY, DRYE & WARREN 101 Park Avenue New York, New York 10178 (212)808-7800 Attorneys for Defendant Hercules Incorporated SHEA & GOULD 330 Madison Avenue New York, New York 10017 Attorneys for Defendant Uniroyal, Incorporated CLARK, GAGLIARDI <5c MILLER 99 C ourt S tre e t White Plains, New York 10601 (914) 946-8900 Attorneys for Defendant T H A griculture <5c N utrition Company, Inc. Schedule A Andrew W. Anderson 1311 Thomas Run Road Belaire, Maryland 21014 Gordon A. Anderson 102 Hickory Lane Naugatuck, Connecticut Robert J. Anderson 3624 North 36th Road Arlington, Virginia 22207 Robert L. Andreoli 25 Eighth Avenue Iron River, Michigan John Angel Box 78 Yellville, Arkansas Kenneth Arndt, M.D. 330 Brookline Avenue Boston, Massachusetts Louis B. Arnoldi 512 North Overlook Drive Alexandria, Virginia John C. Atkinson 1222 Merchant Lane McLean, Virginia 22101 Dr. Joseph D. Avellino 2219 South Broad Street Philadelphia, Pennsylvania 19148 Carl Gwin Baker 19408 Charline Manor Road Olney, Maryland John D. Baldeschwieler 619 South Hill Avenue Pasadena, California William F. Barthel Route 2 Mount Vernon, Iowa Richard R. Bates 2810 Pheasant Lane Clarksburg, Maryland Frank L. Bauer 600 Grant Street Pittsburgh, Pennsylvania *Russell H. Betts *Weldon Bills Peter S. Bing, M.D. 7900 W. Pico Boulevard Los Angeles, California Donald J. Birmingham 19811 Wedgewood Drive Gross Point Woods, Michigan Warren R. Bontoyan 3910 Meeting House Road Perry Hall, Maryland 21228 Rodney William Bovey Dept, of Range Science Texas A&M University College Station, Texas 77343 Lester Boyer Edgewood Church Road Frederick, Maryland Harold Brown 101530 Third Street, N.W. Washington, D. C. Major William Andrew Buckingham,Jr Department of Political Science U. S. Air Force Academy Colorado *At the present time, addresses on these witnesses are unavailable; however, they will be supplied as soon as possible. 1 2 '54 Schedule A - Page 2 John L. Buckley P. 0. Box 263 Whitnes Point, New York George W. Connell Route 2, Box 626 Warrenton, Virginia Levi T. Burcham 4701 Crestwood Way Sacramento, California Katherine D. Courtney, Ph.D. Environmental Biology Division EPA Environmental Research Center Dr. Edward James Burger, Jr. Research Triangle Park, N.C. 27711 2233 Wisconsin Avenue, Suite 324 Washington, D. C. 20007 Nicholas H. Cox 2516 East Cass St. Jack E. Burton Joliet, Illinois 204 Vivian Lane San Antonio, Texas Robert E. Cox 203 East Belerest Rd. Charles E. Bushey Bel Air, Maryland 374 South Peoria Circle Aurora, Colorado 80012 W i l l i a m J. Crawford 524 Margaret Dr. Dohrman H. Byers Fairborn, Ohio 12060 Lawnview Avenue Cincinnati, Ohio William Murlin Creasy 3910 Molly Rd. Theodore Carroll Byerly Pine Bluff, Arkansas 71603 6J Ridge Road Greenbelt, Maryland Eugene Cutright 1474 Maplewood Dr. John F. Callahan, Sr. Macon, Georgia 31210 2612 Green Road Baldwin, Maryland Roswell G. Daniels 226 West Edgewood St. David M. Cawthorne Morton, Illinois 61550 P. 0. Box 293 Forest Hill, Maryland Robert A. Darrow 7613 Baltimore-National Pike Milton K. Christensen Frederick, Maryland 21701 1089 Clubhouse Boulevard New Smyrna Beach, Florida Thomas R. Dashiell 304 Thomas Ave. Frederick, Maryland 21701 Joseph F. Coates 3738 Kanawaha St., N.W. Delmore, BG Fred J. Washington, D.C. 1600 S. Eads Arlington, Va. *George.Collins* Joseph Amadeo DiPaolo 6605 Melody Lane Bethesda, Maryland 20034 *At the present time, addresses on these witnesses are unavailable; however, they will be supplied as soon as possible. Schedule A - Page 3 Will i a m W. Dorrell 8600 Pine Cliff Drive Frederick, Maryland *Dr. Hans Falk Paul Doty 4 Kirkland Place Cambridge, Mass. Francis Gene Douglas 3101 South 54th St. Kansas City, Kansas Henry N. Doyla 5303 Augusta St. Bethesda, MD. Lee A. DuBridge 1730 Hornet Rd. Pasadena, California Robert H. Duguid 107 South Lyndbrook Rd. Bel Air, Maryland Sigmund R. Eckhaus 4208 Colonial Rd. Pikesville, Maryland Fred I. Edwards 5206 Worthington Drive Bethesda, Maryland William A. Fenner 2713 Roffin Road Hopewell, Virginia 23860 David Firestone HFF 426 200 C. Street S.W. Washington, D.C. 20204 Henry Fischbach. 5627 Bradley Blvd. Alexandria,. Virginia Lawrence Fishbein 3203 Misty Lane Littlerock, Arkansas 72207 Oscar G. Fitzhugh . 4208 Dresden St. Kensington, Maryland John Stewart Foster 2737 Sinton Place Pepper Pike, 44124 *John Frawley Dr. Kenneth Endicott . 11317 Broad Green Drive Potomac, Maryland Herbert G. Fredericks 2414 Diana Road William B. Ennis, Jr. Baltimore, Maryland 1131 S.W. 74 Terrace Plantation, Fla. 33317 Seymour L. Friess 6522 Lone Oak Court Graydon C a s p e r .Essman Bethesda, Maryland 11 Holcomb Drive Williamsburg, Virginia Verne C. Fryklund, Jr. 6805 Broyhill St. Donald W. Falconer McLean, Virginia 22101 115 Kline Blvd. Frederick, Maryland 21701 Donald W.. Fuhlhage Rural Route 1 Tonganoxie, Kansas * At the present time, addresses on these witnesses are unavailable; however, they will be supplied as soon as possible. 12 C5 6 Schedule A - Page 4 James Gardner 1616 Arlington Drive Salt Lake City, Utah 84103 Major Robert M. Gastineau,. M.D. 2381 Rexford Drive Pittsburgh, Pennsylvania 15241 *Perry Gehring John H. Gerety, Jr. North Entrance Friendhsip Inn P.O. Box 1885 Klamath Falls, Oregon *Thomas Gervason William Godel 711 Ledo Park Dr. Newport Beach, Ca. 92660 John Gordon Nathan Gordon 4990 Sentinel Drive Apartment 301 Bethesda, Maryland 20816 Dr. Herschel E. Griffin 11274 Pabelln Court San Diego, California 92124 David Henry Groth General Paul Donal Harkins 65104 Northport Drive Daillas, Texas 75230 At the present time, addresses however, they will be supplied Benjamin Harris 11323 Gienarm Road Glenarm, Maryland ' E. Ross Hart 1160 Chain Bridge Road McLean, Virginia 22101 Wayland J. Hayes 2317 Gold Club Lane Nashville, Tennesse Harry W. Hays 3900 Watson Place, N.W., Building A Washington, D.C. 20016 Apt. 2G Albert E. Hayward. 5716 Jefferson Blvd. Braddock Heights, Maryland 21714 Robert J. Heaston 8231 Stonewall Drive Vienna, Virginia 22180 James A. Hebbeler 821 Park Court Palm Harbor, Florida Harry Heimann Brunildo Antonio Herrero 616 Lake Hollingsworth Drive Lakeland, Florida Garnett Higginbotham Division of Food and Color Additi\ FDA 200 C Street, S.W. Washington, D.C. 20204 Donald F. Hornig 16 Longfellow Park Cambridge, Mass. these witnesses, are unavailable; soon as possible. Schedule A - Page 5 Richard G. Horton 208 East Ring Factory Road Bel Air, Maryland 21014 Philip Charles Kearney Building 050 BARC-West Beltsville, Maryland William Horwitz 9830 Cherry Tree Lane Silver Spring, Maryland 20901 Surgeon M. Keeny, Jr. 3600 Albermarle St., N.W., Washington, D.C. Riley D. Housewright 147 Fairview Avenue Dr. Marcus M. Key University of Texas Health Frederick, Maryland Science Center, at Houston Harry Otto Huss P.0. Box 20186 Houston, Texas 77025 Route 1 Box 352 Uhrichsville, Ohio 44683 Dr. Henry A. Kissinger 435 East 52nd St. Kent R. Irish New York, New York 1604 Rock Creek Drive Frederick, Maryland Michael Klein 1800 South East St. Lucie Blvd. Keith H. Jacobson 740 Beall Avenue Rockville, Maryland Building 10-306 Stuart, Florida Dr. Bernard J. Jandorf Dayton L. Klingman 2028 Forest Hill Drive 6017 Baywood Avenue Silver Spring, Maryland 20903 Baltimore, Maryland 21209 Albert Christian Kolbye Marc Jeffries 4802 Fort Summer Drive 2108 Hyden Ct. Bethesda, Maryland Fallston, Maryland 21067* Wesley Rudolph Koster Dr. William Jurgelski 105 Northlake Dr., Apt. 215A Office of Health Hazard Assessment Orange City, Florida 32763 National Institute of Environmental Health Science William George Kratz Research Triangle Park, N.C. 27709 935 North Capitol *A b r a m Saul Kaplan Many, Louisiana 71449 George M. Lawton 1388 Almond Ave. Ronald Joseph Kassel Livermore, California 222 East Belcrest Road Bel Air, Maryland * At the present time, addresses on these witnesses are unavailable; however, they will be supplied as soon as possible. IO/ o .) \ Schedule A - Page 6 John S. Leary, Jr. 2002 Sea Cove Court Nassau Bay, Texas Douglas H.K. Lee 421 Wood Duck Drive Sarasota, Florida Jane Lewis 5125 Temple Hills Road Temple Hills, Maryland 20748 Dr. Douglas Lindsey 1501 North Campbell St. Tuscon, Arizona Gordon J. MacDonald 20 Occom Ridge Hanover, New Hampshire Harold Noble MacFarland 2320 Harrah Manner Drive Pittsburgh, Pennsylvania 15238 Dr. Arthur H. McCreesh 1317 Saratoga Drive Bel Air, Maryland 21014 Harold Joseph Magnuson, M.D. 12305 Fernando Drive San Diego, California 92128 Walter W. Melvin 413 Bobolink Court Fort Collins, Colorado 80526 Edward A. Metcalf 906 Wellington Rd. Baltimore, Maryland 21212 Lester L. Miller 437 Blueridge Drive York, Pennsylvania Charles E. Minarik P.O. Box 682 West Harwich, Mass. Ian Alastair Mitchell, M.D. 110 Parmele Blvd. ; Wrightsville Beach, N.C. Francis W. Morthland 5602 Garrett Rd. Durham, North Carolina Donald W. Norberg 9153 East Stanford Ave. Englewood, Colorado 80111 Dr. Harold T. Magnuson 12305 Fernando Drive San Diego, Cal. 92128 Dr. Arthur H. M c C reesh 1317 Saratoga Drive Bel Air, Maryland 21014 William D. McElroy 9651 Black Gold Road LaJolla, Cal. 92037 Robert S. McNamara 2419 Tracy Place Washington, D.C. Vincent McRae 12000 Old Georgetown Rd. Rockville, Maryland John F. O'Leary Route 1, Box 213 Queenstown, Maryland 21658 Peter G. Olenchuk 6801 Baron Rd. McLean, Virginia 22101 Normand E. Olivier 31 Mosher St. South Dartmouth, Mass. Boris J. Osheroff 13102 Camellia Drive Silver Spring, Maryland 20906 12459 Schedule A - Page 7 Arthur Joseph Pallotta 601 Abbott Lane Falls Church, Virginia M a j . Gen. Jacquard H. Rothschild 2323 N. Central Ave. Phoenix, Az. 85004 Laverne A. Parks 322 E. Garden Green Port Hueneme, Cal. 93041 Dr. Jack Phillip Ruina 28 Hawthorne St. Cambridge, Mass. 02138 *Vernon Perone Umberto Saffiotti 5114 Wissioming Road Bethesda, Maryland Lawrence M. Petrucelli 5600 Cedar Parkway Chevy Chase, Maryland Samuel Sass 17 North Read Street Bel Air, Maryland 21014 Alan P. Poland 2918 Nottingham Way Madison, Wisconsin Paul Aaron Possick 46 Winding Way Woodcliff Lake, N.J. Melvin M. Rabstein 4401 Gulf of Mexico Drive Long Boat Key, Florida Eberhardt Rechtin 1665 Cataluna Palos Verdes Estates, Cal. Kennard A. Reynard 2496 Cedarwood Drive Adrian, Michigan Bernard Schwetz 1101 30th Street, N.W. Suite 205 Washington, D.C. 20007 Robert A. Shade 199 Rooster Drive Eagle, Indiana Warren C . Shaw 1907 Edgewater Parkway Silver Springs, Maryland Carleton G. Shead 1406 Flying W. Trail Helotes, Texas 78023 *John R. Shoemaker Merl Ringenberg 612 Rock Spring Road Bel Air, Maryland Ralph T. Ross Room 330A Administration Building U.S. Department of Agriculture Washington, D.C. Seymour D. Silver 2920 Strathmore Ave. Baltimore, Maryland Dr. Van Murray Sim 1615 Toll Gate Road Bel Air, Maryland *At the present time, addresses on these witnesses are unavailable; however, they will be supplied as soon as possible. 12'iBO Schedule A - Page 8 Dr. Thomas C. Simmons 2706 Bynum Hill Circle fD a 1 A i > .Tl-L.J- M a >*tt 1 JT -l.CiJ.HwA Charles H. Townes 1988 San Antonio Ave. Berkeley, California ^ Anthony N. Sinclitico 1800 Willann Road Baltimore, Maryland 21237 John L. Traub 610 West Baker Ave. Abingdon, Maryland Marshall Steinberg 927 Jaysmith Street Great Falls, Virginia Thomas A. Treglia *Dr. Jesse L. Steinfeld John Wilder Tukey 115 Arreton Rd. Princeton, N.J. Herbert E. Stokinger William Martin Upholt 525 East Indian Drive Silver Springs, Maryland William W.. Stone 434 Sanahelena Drive Solana Beach, California Cyrus Robert Vance One Battery Park Plaza New York City Marshall Stubbs 2001 Columbia Turnpike Arlington, Virginia Wayne E. Vandeventer Walter Edward Sultan Filiberto Vargas 1203 Springwoods Terrace 6165 East I Lift Ave. Fallston, Maryland 21047 Apartment 308 B Denver, Colorado 80222 William H. Summerson 5108 Brittany Drive South Henry L. Verhulst St^ Petersburg, Florida 5917 Walton Rd. Bethesda, Maryland Steve S. Szabo 20 Milrose Lane Frank J. Vocci Monsey, New York 6009 Winthrope Ave. Baltimore, Maryland 21206 General Maxwell D. Taylor 2500 Massachusetts Ave. N.W. D orothy M. Ward Washington, D.C. 345 Homeland South Way Baltimore, Maryland 21212 *At the present time, addresses on these witnesses are unavailable however, they will be supplied as soon as possible. rS * p " Schedule A - Page 9 Paul C. Warnke Cummings, Burlington, Rubier, Acheson & Shaw Washington, D.C. John T . Weimer 1500 South Vie w Rd. Bel Air, Maryland 21014 Frank H. Westheimer 3 Berkeley St. Cambridge, Mass. 02138 William Childs Westmoreland Box 1059 Charleston, S.C. 29402 Jerome B. Wiesner 61 Shattuck Rd. Watertown, Mass. Jerome Wilkenfeld 5757 Owensmouth Ave. Woodland Hills, California Donald Whittam 10308 Brookmoor Drive Silver Spring, Maryland 20901 James H. Wills 9706 Bellevue Dr. Bethesda, Maryland Herbert F. York 6110 Camino De LaCosta LaJolla, California Dr. Mitchell Zavon Occidental Chemical Corp. P.O. Box 728 Niagara Falls, New York 14302 Walter Leo Zielinski, Jr. 12705 Darnestown Rd. Gaithersburgh, Maryland 20878 /--vc SCHEDULE B DEPOSITIONS SCHEDULED AFTER FEBRUARY 29, 1984: 1. Donald Barnes 2. General Stanzwick 3. Julius Johnson 4. Harold Kinney 5. Debdas Mukerjee /--N 6. Elmer Wheeler 12'83 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In R e "AGENT ORANGE" PR O D U C T LIABILITY LITIGATION MDL N O . 381 DEFENDANTS LIST OF FACT WITNESSES SUBMITTED PURSUANT TO THE SCHEDULING ORDER FOR THE COMPLETION OF DISCOERY BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, P.C . 33 W ashington Streert N ew ark, N ew Jersey 07102 (201)622-7400 A ttorneys for Defendant Thompson Chem ical Company UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product Liability Litigation DEFENDANT DIAMOND SHAMROCK CHEMICALS COMPANY'S PRELIMINARY LISTING OF FACT WITNESSES___ Pursuant to the Special Master's Final A m e n d e d Recommended Scheduling Order, approved by the Court on January 10, 1984, defendant Diamond Shamrock Chemicals Company ("Diamond Shamrock") sets forth below its preliminary listing of fact w i t n e s s e s w h o m a y give live t e s t i m o n y at trial in s u p p o r t of Diamond Shamrock's claims and defenses. This listing does not address deposition testimony that may be used at trial, which will be identified as part of preparation of the pretrial order. In accordance with the Scheduling Order and the Magistrate's P r e t r i a l O r d e r No. 9, D i a m o n d S h a m r o c k r e s e r v e s the r i g h t to supplement and amend this preliminary listing. Name and Present Address Description of General Nature of Testimony Dr. Donald J. Birmingham 19811 Wedgewood Drive Gross Point Woods, Michigan Testimony concerning research and i n v e s t i g a t i o n of c h l o r a c n e by 0.S. Public Health Service in the i950's and 1960's, including visits to Diamond Shamrock's former Newark plant. Robert L. Chonoles Diamond Shamrock Chemicals Company Berry Avenue at Route 17 North Carlstadt, New Jersey 07072 Testimony concerning manufacturing operations at Diamond Shamrock's former Newark plant, including: the removal of dioxin from tric h l o r o p h e n o l ; a n d the U.S. P u b l i c Health Service study of the Newark workers in 1968-69. Sigmund R. Eckhaus 4208 Colonial Road Pikesville, Maryland Testimony concerning United States' program for the construction of an Agent Orange manufacturing facil ity, and c o m m u n i c a t i o n s w i t h pr o ducers of Agent Orange in connec tion with that program. Dr. Marcus M. Key University of Texas Health Science Center P.O. Box 20186 Houston, Texas 77025 Testimony concerning research and i n v e s t i g a t i o n of c h l o r a c n e by U.S. Public Health Service in the 1960's including visit to Diamond S h a m rock's former Newark plant. Jane Lewis 5125 Temple Hills Road Temple Hills, Maryland 20748 Testimony concerning the procure ment and production of Agent Orange pursuant to the Defense Production Act, including directives and priority ratings issued by the United States. Dr. Alan P. Poland 2918 Nottingham Way Madison, Wisconsin Testimony concerning medical study of the workers at Diamond Shamock's former Newark plant in 196869, and research and investigation of trichlorophenol, 2,4,5-T and dioxin at. National Communicable Disease Center in the 1 9 6 0 's. Dr. Paul A. Possick 46 Winding Way Woodcliff Lake, New Jersey Testimony concerning medical study of the w o r k e r s at D i a m o n d S h a m rock's former Newark plant in 196869. -2- Name and ]Z<?gent .Addcesg Warren C. Shaw 1907 Edgewater Parkway Silver Spring, Maryland Description of General Nature of Testimony Testimony concerning DSDA regula tion of *2,4,5-T under F I F R A in 1 9 5 0 ' s a n d 1 960's, a n d U.SDA research and investigation con cerning health effects and efficacy of 2,4,5-T. F. Gordon Steward Diamond Shamrock Agricul tural Chemicals Inc. P.O. Box H Tuscaloosa, Alabama 35404 Testimony concerning manufacturing operations at Diamond Shamrock's former Newark plant, including: the development, installation and operation of a method for removing dioxin from trichlorophenol; the D.S. Public Health Service study of the Newark workers in 1968-69; and the p r o d u c t i o n and s h i p m e n t of Agent Orange pursuant to contracts with the United States. Dated: New York, New York February 29, 1984 Respectfully submitted, CADWALADER, WICKERSHAM & TAFT ByUjtArrtuty & A^ A Member of the Firm Attorneys for Defendant Diamond Shamrock Chemicals Company One Wall Street New York, New York 10005 (212) 908-7000 -3- AFFIDAVIT OF SERVICE STATE OF NEW YORK ) ss. : COUNTY OF NEW YORK ) MICHAEL M. GORDON, being duly sworn, deposes and says: 1. I a m n o t a p a r t y to t his action, am o ver 18 y e a r s of age and reside in New York County, New York. 3. On F e b r u a r y 29, 1984, I s e r v e d the a n n e x e d dant Diamond Shamrock Chemicals Company's Preliminary Listing of Fact Witnesses on each of the persons named on the annexed list by depositing a true copy of same enclosed in a postpaid properly addressed wrapper, in an official depository under the exclusive care and custody of the United States Postal Service w i t h i n the S t a t e of N e w York. The copy to D a v i d J. Dean, Esq. w a s sen t by Federal Express. A copy was also sent by Federal Express to the Agent Orange Plaintiffs' Management Committee, 26 Court Street, Suite 905, Brooklyn, New York. Sworn to before me this z r day of February, 1984 Commission 12488 s e r v i c e LIST roR defendants Leonard L. Rivkin Rivkin, Leff, S h a m a n a Radiar (for DOW CHEMICAL) 100 Gardan City Plata Garden City Haw York 11530 Morton G. S i l b a m a n Clark. Gagliardi t Millar (for T H AGRICOLTORE t NUTRITION COMPANY INC.) Tha Inna of Court 99 Court Straat Whita Plains, Nav York 10601 John C. Sabatta Townlay a Opdika (for MONSANTO) 405 Lexington Avanua New York, New York 10174 William Krohlay Xallay Drya a Warran (for HERCULES, INC.) 101 Park Avanua Nav York, Naw York 10178 John M. Fitzpatrick Dilvorth, Paxton, Xalish a Lavv (for HOOKER PLASTICS a CHEMICALS CORP.) 2600 Tha Fidelity Building Philadalphia, Pannsylvania 19109 Richard Goldstain Shaa a Gould 330 Madison Avanua New York, Nav York 10017 Thomas Back Arthur, Dry a Kalish, P.C. (for UNIROYAL) 1230 Avanua of tha Americas Nav York, Nav York 10020 David R. Gross Budd, Larner, Kant, Gross, Pieillo a Rotanbaum (for THOMPSON CHEMICALS) 33 Washington Straat Newark, Nav Jersey 07102 Arvin Maskin Department of Justice (for THIRD PARTY DEFENDANT OSA) Safavay Building 521 12th Straat, N.W. Washington, D.C. 20530 L. Kevin Sheridan Executive Assistant U.S. Attorney Eastern District of Nav York United States Courthouse 225 Cadman Plaza East Brooklyn, Nav York 11201 COPIES OF ALL DOCUMENTS MUST BE SENT TO:__________________ Clark of the Panel Judicial Panel on Multidistriet Litigation 1120 Vermont Avanua, N.W. Suita 1002 Washington, D.C. 20005 FOR PLAINTIFFS Victor J. Yannaeone, Jr. Yannacone 6 Yannaeone Post Office Dravar 4109 Patehogua, Nav York 11772 Stephan J. Sehlagal Sehlegal a Trafelet, Ltd. One North LaSalle Street Suita 3900 Chicago, Illinois 60602 Benton Musselvhite Lav Officasof Benton Musselvhite, Inc. Suita 517 609 Fannin Houston, Taxes 77002 Thomas Henderson Baskin 6 Sears Frick Building - 10th Floor Pittsburgh, Pannsylvania 15219 David J. Dean, Esq. Dean, Falanga 6 Rosa 1 Old Country Read Carla Place, Nav. York 11514* 1289 DISTRICT COORT EASTEMi; DI STRI CT OP NEW YORK . > 7-%/\ -.V^ c >.'..'`V:r.;'.'''"./r-i-../'-*;,';'~ ;;:i'; "AGEN T ORANGE" - ' ^ X ^ ^ P r o d i ^ t Liability Litigation >: ' /V/, - '/ ), - v;>;; ts * 0' r ^ `;v' :liPi i'i' -vbiNSi^ .-:.- ^ -v--^v'Z.` ^ ':- MDL NO. . D E F E N D A N T DIAMOND SHAMROCK' S .OBJECTIONS, TO .P L A I N T I F F S ' P R ELIMINARY.LIS T _OF : 7 ^ POTENTIAL DEPONENTS PRESENTLY OR FORMERLY' .i.:,-.;v x>: ^ ^ - " V `v7>:-.y; '*........ "'"* .r. _ - * 5*tV. J L ^ . i 'i S l 'AN'fc-- >..l-V'.'. ;\(1`/:\'''' ;: ';i"'':f,.v "'.jji-v.*:'*'' i S M S i...v.'.'!;., J.'`'I.''* ;:':i ' ':> r<. ' "'1 ',"',. . *-,, k" "...'-'.>: ,? ;->'<>'4./; ^.V.y v ' ^ x V ;;Sr 7; !-S..?.-^*'.V '<V ^-v'- i. `i . i V ' s i K * ... V;,-,*$/.V--' '' `Ti - C , ' r'^l; j7X". ..^ V .it .;;.,yj_ .:7-:0 :f '{ZQwk-r n 77 r w r n - w r r * n t T A * / / T A- r T T ' r:% ;'-'V c^"-_'? .' k '.-L'T; ' A PARTNERSHIP INCLUDING PROFESSIONAL C O RPO RATlO Ni'.jt^iKi^V''- *.- - ~ ... 7/ -; r.`: One Wall Street ' -- New Yotfe,7N^;i0005.7 ... % . 'j ' . ' (212) UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ---------------------------------------- - In re : "AGENT ORANGE" : Product Liability Litigation : ---------------------------------------- - MDL No.381 DEFENDANT DIAMOND SHAMROCK'S OBJECTIONS TO PLAINTIFFS' PRELIMINARY LIST OF POTENTIAL DEPONENTS PRESENTLY OR FORMERLY _________________________________________________ xlimiflaxy_i.ai.emB Pursuant to the direction of Magistrate Scheindlin at the F e b r u a r y 9, 1984 p r e - t r i a l c o n f e r e n c e , d e f e n d a n t D i a m o n d Shamrock Chemicals Company ("Diamond Shamrock") sets forth below its o b jections to plaintiffs' p r e l i m i n a r y list of p r esent or former Diamond Shamrock employees who may be deposed by plain tiffs, served on February 9, 1984 ("Plaintiffs' List"). Diamond Shamrock requests, however, that consideration of its objections by the M a g i s t r a t e be deferred pending receipt and review of plaintiffs' "priority" deposition list. I !] I li Since the c o m m e n c e m e n t of deposition discovery in the "Agent Orange" litigation in 1982, plaintiffs have deposed nine p r e s e n t or f o r m e r D i a m o n d S h a m r o c k e m p l o y e e s on s u b s t a n t i v e 1271 i issues. An additional three employees have been examined pursuant to Pretrial Order No. 57. On December 12 1983 counsel for plaintiffs confirmed in writing that their deposition discovery of D i amond Shamrock would be g_ompleted by the examination of five additional former employees: Richard Marrese, Donald Purdy Cy Perkins, James King and Stanley Honour. See letter from Edward J. Gorman to Michael M. G o r d o n d a t e d D e c e m b e r 12, 1983 (Exhibit A hereto). Dr. M a r r e s e and Mr. Purdy were e x a m i n e d on D e c e m b e r 13, 1983 and J a n u a r y 5, 1984, r e s p e c t i v e l y . The d e p o s i t i o n s of Mr. P e r k i n s and Mr. King were both tentatively scheduled, and then postponed at plaintiffs' request for various reasons, including ill health j I of plaintiffs' counsel. The d eposition of Mr. Honour re m a i n s j unscheduled. j Now, only 12 weeks before trial, plaintiffs have , identified ten former Diamond Shamrock employees that they may w i s h to depose, in_addiiiDD_ii3 the three witne s s e s p r e v i o u s l y requested and remaining to be scheduled. Thus, if their List is accepted at face value, plaintiffs seek at the last m i nute to double the number of Diamond Shamrock depositions taken in this litigation. Their List similarly more than triples the number of outstanding depositions to be scheduled, in total repudiation of plaintiffs' most recent assurances to Diamond Shamrock. P l a i n t i f f s ' u n an n ou n ced new "wave" o f D iam ond Sham rock d e p o sitio n s, in the fa ce of recen t r e p r ese n ta tio n s to the con tr a r y , w ould s e r io u s ly and u n f a ir ly p r e ju d ic e Diamond Sham rock's own p r e - t r i a l p r e p a r a tio n s . I n s te a d o f th e th r e e r e m a in in g -2- 12472' depositions agreed to in December, Diamond Shamrock would now be c o m p e l l e d to l o c a t e and p r e p a r e for d e p o s i t i o n s of 13 f o r m e r employees, most of w h o m reside far from New York and are unlikely | to agree to travel here for their examinations. The strain on the resources of Diamond Shamrock's counsel that would result at this critical stage of the proceedings is obvious. Absent a compelling explanation for plaintiffs' failure to apprise D i a mond j Shamrock of their intentions and to pursue scheduling of Diamond j Shamrock depositions during the past several months, plaintiffs should not be p e r m i t t e d to sidetrack D i a m o n d Shamrock's trial preparations in the few precious weeks remaining before jury selection. In fairness to plaintiffs, Diamond Shamrock recognizes that plaintiffs themselves estimate that only a fraction of the deponents they have listed will actually be examined. Plaintiffs have also stated their intention to submit by February 15, 1984 a "priority list" that is expected to contain only one-half to oneq u a r t e r of the n a m e s set f o r t h in their o r i g i n a l list. JSfifi tr. at 9214-15. Accordingly, Diamond Shamrock requests that con sideration of its objections to the num b e r of form e r D i a m o n d Shamrock employees identified as deponents in Plaintiffs' List be deferred to p e r m i t receipt and review of plaintiffs' p r i o r i t y -3- 12173 list, and discussion of that list between counsel for Diamond Shamrock and plaintiffs. Dated: New York, New York February 14, 1984 Respectfully submitted, Diamond Shamrock Chemicals Company One Wall Street New York, New York 10005 (212) 908-7000 -4- /l JAM AICA O FFIC E 9 0 -2 4 SU TPH IN BLVD. JAM AICA. N .Y . I 1 4 0 6 (2 I 2) 6 6 8 - 4 1 14 PE T E R M. J . REILLY EDW ARD J . DORMAN PE T E R M. J . REILLY . JR . MARK O. SO K O LO FF RICHARD E . CH ESN EY DONALD E. LAMPSON E L IZ A B E T H M . O 'N E IL L LAW O F F IC E S O 'H a g a n . R e i l l y & G o r m a n . P . G REILLY BUILDING 4 4 4 MAIN S T R E E T P . O . B O X 7-3 IS L IP . N. Y. I I 7 6 1 NEW YORK O FFICE 12 2 E A S T 4 2 N D S T R E E T NEW YORK. NEW YORK 1 0017 ( 2 12) 6 9 7 - 4 2 7 0 OF COUNSEL ( 6 16) 6 8 1- 8 8 8 7 H EN R Y J . O 'H A O A N - D EC TS 19 7 8 EDWARD O . DOUGHERTY - DEC*D 1977 OEOROE W. KELLY ALLAN M. KAPLAN RICHARD F . PO H L (ADM. P E N N . BAR) EDWARD F. HAYES. Ill December 12, 1983 Cadwalder, Wickersham Taft, Esqs. One Wall Street New York, New York 10005 Attention of Michael M. Gordon, Esq. RE: In re "Agent Orange" Product Liability Litigation MDL No'. 381 Dear Mr. Gordon: This will confirm our telephone conversation of December 8, 1983 wherein you advised that Mr. S. S. Savage is deceased and Mr. S. B. Honour, still shares this earth with us although his exact whereabouts are unknown. Presently scheduled for depositions are Mr. Marrese, Perdy, Perkins and King. As you know Mr. Fiorella has written to Mr. Lex Creamer regarding his deposition but to date we have not heard from this gentleman. What we are looking for is a witness with knowledge of the various South American episodes involving chloracne and the use of 2, 4, 5,T. I doubt if we will hear from Mr. Creamer. If you will be kind enough therefore to arrange to have Mr. Honour presented for deposition, he, in addition to those gentlemen mentioned above,will complete our discovery. Thank you for your cooperation, I remain Very truly yours CC: Albert Fiorella, Esq D. Russo, Esq. EDWARD J . GORMAN 1 - 0 AFFIDAVIT of s e r v i c e STATE OF NEW YORK. I : ss.: COUNTY OF NEW YORK ) JEFFREY SAPER, being duly sworn, deposes and says: 1. I am not a party to this action, am over 18 years of age and reside in Queens County, New York. 2. On February 14, 1984, I served the annexed De Diamond Shamrock's Objections to Plaintiffs' Preliminary List of Potential Deponents Presently or Formerly Employed by Diamond Shamrock on each of the persons named on the annexed list by depositing a true copy of same enclosed in a postpaid properly addressed wrapper, in an official depository under the exclusive care and custody of the United State Postal Service within the State of New York. The copy to David J. Dean, Esq. was sent by Express Mail. A copy was also sent by hand to the Agent Orange Plaintiffs' Management Committee, 26 Court Street, Suite 905, Brooklyn, New York. Sworn to before me this 1984. MICHAEL MACXIN GORDON Notary PubBc, State of New York _ _ No. Sl-4MS9fl5 qualified In New York County 0 corion E*p; SERVICE LIST FOR DEFENDANTS Leonard L. Rivkin Rivkin, Leff, Sherman t Radler (for DOW CHEMICAL) 100 Garden City Plaxa Garden City, Hew York 11530 Morton G. Silbernen Clark, Gagliardi t Miller (for T H AGRICULTURE fc NUTRITION COMPANY, INC.) The Inns of Court 99 Court Street White Plains, New York 10601 John C. Sabetta Townley t Updike (for MONSANTO) 405 Lexington Avenue New York, New York 10174 William Xrohley Xelley Drye 6 Warren (for HERCULES, INC.) 101 Park Avenue New York, New York 10178 John M. Fitzpatrick Dilworth, Paxson, Xalish 4 L e w (for HOOKER PLASTICS & CHEMICALS CORP.) 2600 The Fidelity Building Philadelphia, Pennsylvania 19109 Richard Goldstein Shea l Gould 330 Madison Avenue New York, New York 10017 Thomas Beck Arthur, Dry t Xalish, P.C. (for UNIROYAL) 1230 Avenue of the Americas New York, New Yozk 10020 David R. Gross Budd, Larner, Kent, Gross, Pieillo & Rosenbaum (for THOMPSON CHEMICALS) 33 Washington Street Newark, New Jersey 07102 Arvin Maskin Department of Justice (for THIRD PARTY DEFENDANT USA) Safeway Building 521 12th Street, N.W. Washington, D.C. 20530 L. Xevin Sheridan Executive Assistant U.S. Attorney Eastern District of New York United States Courthouse 225 Cadman Plaza East Brooklyn, New York 11201 COPIES OF ALL DOCUMENTS MUST BE SENT TO: _________ Clerk of the Panel Judicial Panel on Multidistrict Litigation 1120 Vermont Avenue, N.W. Suite 1002 Washington, D.C. 20005 FOR PLAINTIFFS Victor J. Yannacone, Jr. Yannacone 6 Yannacone Post Office Drawer 4109 Patchogue, New York 11772 Stephen J. Sehlegel Sehlegel 6 Trafelet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Benton Musselwhite Law Offices of Benton Musselwhite, Inc. Suite 517 609 Fannin Houston, Texas 77002 Thomas Henderson Baskin 6 Sears Frick Building - 10th Floor Pittsburgh, Pennsylvania 15219 David J. Dean, Esq. Dean, Falanga 6 Rose 1 Old Cotintry Road Carle Place, New York 11514' 1 3 3 3 N E W H A M P S H IR E A V E , N.W . W A S H IN G TO N , D .C . 2 0 0 3 6 (2 0 2 ) 2 9 3 * 6 3 0 0 TWX: 7 1 0 *6 2 2 *1 9 3 4 A P A R TN ER SH IP IN C L U D IN G P R O FE S S IO N A L C O R P O R A T IO N S Jffy.S S ty e n : ( S 2 ) 0 S -7 0 0 CABLE a d d r e s s : l a b e l l u m TE LEX*. 1 2 9 1 4 6 /6 6 7 4 6 8 R A P IF A X : (2 1 2 ) 2 6 9 - 2 3 2 1 2 4 9 R O Y A L P A LM WAY PALM BEACH, FLA. 3 3 4 6 0 (S O S ) 6 8 8 - 9 5 0 0 TWX! 8 1 0 -9 8 2 -7 6 2 6 February 14, 1984 Honorable Shira A. Scheindlin United States Magistrate United States District Court Eastern District of New York United States Courthouse 225 Cadman Plaza East Brooklyn, New York 11201 Re: In re "Agent Orange" Product Liability Litigation, MDL No. 381 Dear Magistrate Scheindlin: Pursuant to your direction at the February 9, 1984 pre-trial conference, I enclose Defendant Diamond Shamrock's Objections to Plaintiffs' Preliminary List of Potential De ponents Presently or Formerly Employed by Diamond Shamrock. Very truly yours MMG/mam Enclosure BY HAND cc(w/encl.): Clerk of the Court*^ Service List 127S UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re j. (f 1. Charles Baron, M.D. 2 . Deborah Anne Barsotti, Ph.D. 3. Ronald Codario, M.D. 4. Arthur W. Galston, Ph.D. 5. John Garofalo, M.D. 6 . Lennart Hardell, M.D. 7. Maureen C. Hatch, Ph.D. 8 . Alastair W.M. Hay, Ph.D. 9. Herbert Kay, Ph.D. 1 0 . Ronald H. Kerman, Ph.D. 11. Marvin S. Legator, Ph.D. 1 2 . Alan Scott Levin, M.D. 13. Peter Orris, M.D., M.P.H. Marvin A. Schneiderman, Ph.D. 15. Ellen K. Silbergeld, Ph.D. Ij5. Raymond Singer, Ph.D. 17. Theodor D. Sterling, Ph.D. Biostatistician/Mathematician (Additional) Exhibit "A" Exhibit "B" Exhibit "C" Exhibit "D" Exhibit "E" Exhibit "F" Exhibit "G" Exhibit "H" Exhibit l.j.f Exhibit " J " Exhibit "K" Exhibit "L" Exhibit "M" Exhibit "N" Exhibit "0 " Exhibit iipn Exhibit " Q " Exhibit "R" PLAINTIFFS'' MANAGEMENT COMMITTEE Thomas W . Henderson, Esquire 12479 1--1 01--01 Dr. Charles M. Baron, M.D., is a p h ysiatrist p r a cticing in Philadelphia, Pennsylvania. His c u r r i c u l u m vitae will be supplied. Dr. Baron will testify as to the p e rformance and interpretation of various tests in the veterans. These will include an eltroencephalogram on both sleep and waking states with nasopharyngeal leads. He will also perfrom electromyograms, nerve conduction velocity tests, and somato sensory evoked potentials of the upper and lower extemities. Dr. Baron will then testify as to the mechanisms by which toxins produce the changes noted in the tests and what the various tests are capable of determining as to the medical status of the patient. Then he will relate the results obtained in the testing of each plaintiff examined, give opinions as to the causation of those results where possible from the evidence revealed by the tests, and state the prognosis for the individual plaintiff for further d e t erioration in test results and/ o r for the individual's condition as a whole. 12480 Dr. Deborah Anne Barsotti is an Assistant Professor of Toxicology in the Department of Pharmacology and Toxicology of the Philadelphia College of Pharmacy and Science in Phila delphia, Pennsylvania. Her curriculum vitae is attached. Dr. Barsotti is a toxicologist who has done substantial personal investigative work with halogenated aromatic hydrocarbons. This category of chemicals includes various biphenyls and dioxins, and specifically includes tetrachlorodibenzo-prdioxin (TCDD). She will testify as to the relative chemical stability and lipophilicity of these chemicals as well as their resistance to degradation, and will testify that these qualities are what account for the perceived and documented bioaccumulation of the chemicals in the human system. Dr. Barsotti will emphasize the difference in results b etween ch r o n ic and acute exposures to these chemicals, testifying as to the varying types of responses to acute and chronic exposures. Dr. Barsotti wil l discuss her own w ork as well as review the literature in these areas, noting differences in routes of administration, and in the species and genetic strain of the animals involved. She will explain these variations and where they permit extrapolation of results from animals to humans. In particular, Dr. Barsotti will also testify as to the similarities in response to these chemicals by rhesus monkeys and by humans, and will explain how the similarities permit extrapolation in this instance. Dr. Barsotti will also discuss reproductive toxicity, 12481 teratology and post-natal toxicity, including instances where no gross or clinical signes of maternal toxicity could be detected. CURRICULUM VITAE DEBORAH ANNE BARSOTTI ADDRESS: Homs - 4818 T r i n i t y Place Phil a. , PA 19143 215-724-5387 Business - Phil a. College o f Pharmacy & Science Dept, o f Pharmacology & Toxicology 43rd & Kingsessing Mall Phil a. , PA 19104 215-596-8978 CITIZENSHIP: USA BIRTHDATE: September 1 4 , 1949 MARITAL STATUS: M arried; no c h ild re n EDUCATION: Humboldt S ta te U n iv e r s it y Areata, C a lifo rn ia - 1967-1972 Bachelor of Arts Biology-Medical Technology Humboldt S ta te U n iv e r s it y A reata, C a lifo rn ia - 1972-1973 Graduate School Coursework: Electron microscopy Endocrinology Instrumentation U n ive rs ity o f Wisconsin Madison, Wisconsin - 1973-1980 Doctor o f Philosophy Pathology Thesis T i t l e : Gross, C lin ic al & Reproductive Effects o f P o ly c h lo rin a te d Biphenyls (PCBs) in the Rhesus Monkey EXPERIENCE: Phil a. Co llege o f Pharmacy & Science P h ila . , PA - January, 1983 to Present Asst. Professor, Dept, of Pharmacology/Toxicology In s t r u c t B io lo g ic a l Methods in T o x ic o lo g y , Toxicology I I I & Techniques in Electron Microscopy Advise undergraduate students Faculty adv iso r f o r Tox Club Member, Advisory Committe f o r fo u r graduate students Conduct independent research *831 r> :C -y. A s s is ta n t S c i e n t i s t - J u ly , 1982 to January, 1983 P roject Associ ate - June, 1980 to June, 1982 U n iv e rs ity of Wisconsin Dept, o f Pathology Madison, Wisconsin uuui u m ated m u ltifa c e te d project.?; in v o lv in g over 120 rhesus monkeys exposed to low le v e ls o f to x in s ( h a lo - genated arom atic hydrocarbons) and in te g r a te d the c l i n i c a l data and observation s with the residue analyses o f tis s u e s and f l u i d s o b tained by gas chromatography (GC) and con firm ed by mass spectrometry (MS). Supervised the c l i n i c a l and reproductive e v a lu a tio n s as well as the care o f lab o rato ry animals. Developed d a ta management and word processing systems u t i l i z in g o n - s i t e computers and t i e - i n s to a Sperry Univac 1100 to s o r t , c o l l a t e and s t a t i s t i c a l l y e v a lu a te data. Conducted gross necropsies and m icroscopic e v a lu a tio n s and prepared necropsy reports. Research Assistant - 1976-1980 U n iv e rs ity o f Wisconsin Dept, of Pathology Madison, Wisconsin Conducted radioimmunoassays f o r serum progesterone and e s t r a d io l f o r use in evaluating the reproductive parameters in rhesus monkeys. Performed c l i n i c a l assessments on la b . animals in c lu d in g hematology and c l i n i c a l chem istries. Supervised and evaluated data and prepared r e p o rts f o r con tra c tu ra i work. Separated c e l l u l a r fr a c tio n s o f tis s u e homogenates by u l t r a c e n t r i f u g a t i o n and assayed homogenates and r e s u l t a n t f r a c t io n s f o r content o f various components. Provided animal husbandry f o r rhesus monkey and r a t c o lo n ie s . Supervised u n i t members on protocols f o r e x p e rim e n ta tio n and proper methods o f conducting basic l a b o r a t o r y analyses. Pre-Doctoral Fellow - 1974-1976 U n iv e rs ity o f Wisconsin Dept, of Pathology Madison, Wisconsin Stocked and organized a la b o ra to ry f o r the c l i n i c a l and r e p r o ductive analyses of laboratory animals. Prepared protocols fo r long-term feeding studies in the laboratory animals including those fo r gross, c lin ic a l and reproductive assessments. Developed radioimmunoassay procedures f o r serum proges terone and e s t r a d i o l . Conducted metabolism and d i s t r i b u t i o n studies in r a ts and rhesus monkeys using r a d io la b e le d isomers o f halogenated arom atic hydrocarbons and o th e r chemicals. Laboratory Assistant - 1970-1972 Humboldt S tate U n iv e r s it y Student Health Center Areata, California Duties included assisting in routine c lin ic a l laboratory p ractices involved in u r in a ly s is , gonococcal screening, VDRLs, h e te ro p h ile s f o r mononucleosis, t h r o a t c u ltu re s and pregnancy t e s t s . AWARDS/HONORS: N ational Sea Grant Graduate Student o f the Year - 1976. PROFESSIONAL SOCIETIES: American Society f o r Prim atologists M id-A tlantic Chapter, Society of Toxicology SEMINARS/MEETINGS: P a rtic ip a n t - Federation o f American Societies f o r Experi mental Biology (FASEB), A t la n t ic C i t y , NJ, A p r i l , 1976. Topic: " E ffe c ts o f p o ly c h lo r in a te d biphenyls on re p ro duction in the primate". P a r t i c ip a n t - American A s so ciatio n o f P a th o lo g is ts and B a c t e r io l o g i s t s , Boston, MA, March, 1976. Topic: "The A s so ciatio n o f T ran s p la c e n ta l and Mammary Movement o f PCBs w ith In fa n t M o r b id it y and M o r t a l i t y " . I n v i t e d Speaker - 9th Annual Sea Grant A s so ciatio n M eeting , Los A ngeles, CA, November, 1976. Topic: "Toxicology o f PCBs in the A dult and I n f a n t Rhesus Monkey". P a r t i c ip a n t - FASEB, Chicago, I L , A p r i l , 1977. Topic: " E ffe c ts o f p o ly c h lo r in a te d biphenyls in nonhuman prim ates". P a r t i c ip a n t - American Chemical S o c ie ty , 11th Great Lakes Regional Meeting, Stevens P o in t, WI, June, 1977. Topic: "Responses of i n f a n t primates to i n t e r u t e r i n e and neonatal exposure to polychlorinated biphenyls". I n v i t e d Speaker - Community Meeting on PCBs, U n iv e r s it y o f Wisconsin, Parkside, March, 1977. -3 - 12485 P a r t i c ip a n t - In te r n a tio n a l Symposium on Pathobiology of .Environmental P o llu ta n ts , S to r r s , CT, June, 1977. Topics: "Pathology o r rhesus macaques (Macaca m u la tta ) exposed to t e tr a c h lo r o d ib e n z o - -d io x in (TCDD)" and "Exposure o f p o ly c h lo rin a te d biphenyl (PCB) to i n f a n t rhesus macaques (Macaca m u latta)". I n v it e d Speaker - Community Meeting on PCBs, Door County, WI, September, 1977. I n v ite d Speaker - 45th Annual Convention o f A s sociation o f Midwest Fish and W i l d l i f e Agencies, Milwaukee, W I, J u l y , 1978. Topic: "Consequences o f d i e t a r y PCB consumption in rhesus monkeys". I n v i t e d Consultant - Symposium on PBB L i t i g a t i o n , Traverse C i t y , M I, J u l y , 1978. Topic: "PBB t o x i c i t y in the rhesus monkey". In v ite d Speaker - Smerkee's Conservation Club, Sheboygan, WI, F eb ru ary, 1979. Topic: "PCBs and t h e i r e f f e c t s on rhesus monkeys". P a r t i c ip a n t - FASEB, D a ll a s , TX, A p r i l , 1979. Topic: "Residual e f f e c t s o f p o ly c h lo r in a te d biphenyls on a d u lt nonhuman primates and t h e i r o f f s p r in g " . Expert Witness - State of North C arolina, H alifax County; testim ony on t o x i c i t y o f PCBs, June, 1979. P a r t i c i p a n t - Sea Grant Symposium on Toxic M a te r ia ls and t h e i r E f f e c t s on Marine Resources, Madison, W I, J u l y , 1979. PUBLICATIONS: B a r s o t t i , D. A. and Van M i l l e r , J. P . : Reproductive assessments o f rhesus monkeys housed in c lim a te c o n tr o lle d co n d itio n s . Amer. J. P r i m a t o l . , submitted 1983. B a r s o t t i , D. A .: Long term rep ro d u ctive assessment o f rhesus monkeys exposed to c h lo rin a te d biphenyls (A ro c lo r 1248). Fd. Cosmet. T o x i c o l . , submitted 1983. B a r s o t t i , D. A. and Van M i l l e r , J. P. : Accumulation o f a commercial p o ly c h lo rin a te d biphenyl m ix tu re (A ro c lo r 1010) in a d u lt rhesus monkeys and th e ir nursing offspring . Toxicology. In press. Bowman, R. E . , Heironimus, M. P. and B a r s o t t i , D. A . : Locomotor h y p e ra c t i v i t y in PCB-exposed rhesus monkeys. N e u r o to x ic o l. 2 : 2 5 1 -2 5 8 , 1981. B a r s o t t i , D. A. _, Abrahamson , L. J. , M a r la r , R. J. and A l l e n , J. R. : The e f f e c t o f clim ate c o n tr o lle d housing on the re p ro d u c tiv e p o t e n t ia l o f the rhesus monkey. J. Reprod. F e r t i l . 5 9 : 1 5 - 2 0 , 1980. -d - I24SG B a r s o t t i , D. A. and A l l e n , J. R . : Health im p lic a tio n s o f A ro c lo r 1016 on nursing rhesus monkey i n f a n t s . T o x ic o l. A p pl. Pharmacol. 5 2 :1 3 5 , 1980 (Abstract). A l l e n , J. R. , B a r s o t t i , D. A. and C arstens, L. A . : Residual e f f e c t s o f p o ly c h lo r in a te d biphenyls on a d u lt nonhuman primates and t h e i r o f f s p r i n g . J. Toxicol. Environ. Hlth. 6 :5 5 -6 6 , 1980. A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J. P .: T o x ic o lo g ic a l e f f e c t s o f A r o c lo r 1016 on nonhuman prim ates. EPA Report # 6 8 -0 2 :2 4 6 4 , 1980. B a r s o t t i , D. A . , Abrahamson, L. J. and A l l e n , J. R. : Hormonal a l t e r a t i o n s in female rhesus monkeys fed d ie t s c o n tain in g 2 , 3 , 7 ,8 -t e t r a c h l o r o d i b e n z o l - d i o x i n . B u l l . Environ. Contam. T o x ic o l. 2 1 : 4 6 3 -4 6 9 , 1979. B a r s o t t i , D. A . , C a rstens, L. A. and A l l e n , J. R . : Residual e f f e c t s o f p o ly c h lo r in a te d biphenyls on a d u lt nonhuman primates and t h e i r o f f s p r i n g . Fed. Proc. 38:1119, 1979 (A b s tra c t). A l l e n , J. R . , B a r s o t t i , D. A. and Lambrecht, L. K . : Reproductive e f f e c t s o f halogenated arom atic hydrocarbons on nonhuman p rim a tes . New York Academy o f Sciences, 320:419-427, 1979. A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J. P . : Pathology o f rhesus macaqques (Macaca m u la tta ) exposed to t e t r a c h lo r o d ib e n z o - - d io x in (TCDD). I n t e r n a t i o n a l Symposium on Pathology o f Environmental P o l l u t a n t s , National Research C o u n cil, 346-355, 1979. A l l e n , J. R . , Van M i l l e r , J. P. and B a r s o t t i , D. A . : T o x ic o lo g ic a l responses o f nonhuman primates to 1 , 2 , 4 , 6 ,7 ,8 -h e x a c h lo r o d ib e n z o - -d io x in (HCDD). T o x ic o l. Appl. Pharmacol. 47:17 9, 1979 (A b s tra c t). C a rs te n s , L. A . , B a r s o t t i , D. A. and A l l e n , J. R . : Exposure o f p o l y c h lo r i n ated biphenyl (PCB) to i n f a n t rhesus macaques (Macaca m u l a t t a ) . I n t e r n a tio n a l Symposium on Pathobiology o f Environmental P o l l u t a n t s , .N atio nal Research C o uncil, 339-345, 1979. S c h a n tz, S. L . , B a r s o t t i , D. A. and A l l e n , J . R . : T o x ic o lo g ic a l e f f e c t s pro duced in nonhuman primates c h r o n ic a lly exposed to f i f t y p a rts per t r i l l i o n 2 , 3 ,7 ,8 -te tra c h lo ro d ib e n z o -p -d io x in (TCDD). T o x ic o l. Appl. Pharmacol. 46:18 0, 1979 (A b stract). A l l e n , J. R. , Lambrecht, L. K. and B a r s o t t i , D. A . : Some general e f f e c t s o f polybrom inated biphenyls in nonhuman p rim a tes . J. Am. Vet. Med. Assoc. 173 1 1 :1 4 8 5 -1 4 8 9 , 1978. Lambrecht, L. K. , B a r s o t t i , D. A. and A l l e n , J. R. : Responses o f nonhuman primates to a polybrominated mixture. Environ. Health Perspec. 23:139147, 1978. A l l e n , J. R. , B a r s o t t i , D. A . , Van M i l l e r , J. P . , Abrahamson, L. J. and L a l i c h , J. J . : Morphological changes in monkeys consuming a d i e t c o n ta in ing low l e v e l s o f 2 , 3 , 7 , 8 - t e t r a c h l o r o d i b e n z o - - d i o x i n . Fd. Cosmet. , T o x ic o l. 15:401-410, 1977. 4 * ' t v * - * 1 -VO -J A l l e n , J. R. and B a r s o t t i , D. A . : Responses o f in f a n t primates to i n t e r u t e r i n e and neonatal exposure o f p o ly c h lo rin a te d biphenyls. American Chemical So c i e t y , Proceedings o f 11th Great Lakes Regional Meeting, June, 1977 (Ab stract). A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J. P . : Reproductive dysfunc t io n in nonhuman primates exposed to d io x in s . T o x ico l. Appl. Pharmacol. 4 1 :1 7 9 , 1977 (A b s tra c t). Norback, D. H. and B a r s o t t i , D. A . : E ffe c ts o f p o ly c h lo rin a te d biphenyls in nonhuman primates. Fed. Proc. 3 6 5 :3 9 6 , 1977 ( A b s tr a c t). B a r s o t t i , D. A . , M a r la r , R. J. and A l l e n , J. R . : Reproductive dysfunctions in rhesus monkeys exposed to low le v e ls o f p o ly c h lo rin a te d biphenyls (A r o c lo r 1248). Fd. Cosmet. T o x ic o l. 1 4 : 9 9 -1 0 3 , 1976. B a r s o t t i , D. A. and A l l e n , J. R . : The ass ociation o f tra n s p la c e n ta l and mammary movement o f PCBs w ith i n f a n t m o rb id ity and m o r t a l i t y . Amer. J. Path. 82:21a, 1976 (A b s tra c t). A l l e n , J. R. and B a r s o t t i , D. A . : The e f f e c t s o f tra n s p la c e n ta l and mammary movement o f PCBs on in f a n t rhesus monkeys. Toxicology 6 :3 3 1 -3 4 0 , 1976. A l l e n , J. R . , B a r s o t t i , D. A. and C a rstens, L. A . : Residual e f f e c t s of sho rt te rm , low le v e l exposure o f nonhuman primates to p o ly c h lo rin a te d biphenyls. Toxicol. Appl. Pharmacol. 30:440-451, 1974. - 6 .- 12488 Dr. R o nald Corderio, M.D., is an internist practicing in Philadelphia, Pennsylvania. His c u r r iculum vitae will be supplied. Dr. Corderio will testify that he is currently engaged in the private practice of medicine as an internist. He will testify that he personally: has examined and/or treated over five hundred Vietnam veterans for complaints related to Agent Orange. He will testify as to the type of interview he has conducted with each veteran, the type of tests that each veteran should have performed, and the clinical significance of positive or negative findings on each of those tests. He will also discuss how toxins, and specifically Agent Orange, can cause changes in each of the tests and what such changes portend for the individual. Dr. Corderio will next discuss some of the available medical literature in both animals and humans to further validate his own work. Dr. Corderio will then outline in detail the results obtained from his own extensive investigation into Agent Orange toxicity based upon his examination of more than five hundred veterans, and will present those conclusions which he feels are reasonably appropriate based upon an analysis of his investigative work. With this material as background, Dr. Corderio will then proceed to present the test results which have been obtained for each court-approved representative veteran plaintiff. He will interpret each of the test results in terms of those individual plaintiffs. Finally, he will testify on generic causation and specific proximate causation in relation to each representative veteran plaintiff. He will also testify as to prognosis for each representative veteran plaintiff. ARTHUR W. GALSTON, Ph.D. Dr. Galston is Eaton Professor of Botany, Department of Biology, at Yale University. His Curriculum Vitae will be supplied. Dr. Galston is a plant physiologist and has personally observed the effect of the spraying of Agent Orange on the Vietnam ecosystem, i.e. the devastation of the Vietnamese countryside. Dr. Galston has been in Vietnam on four occasions between 1971 and 1982, and will describe those observations while in Vietnam, with such pictorial evidence as is available. Dr. Galston will testify to the potential and actual effects of phenoxy herbicides and their contaminants, both in Vietnam and elsewhere, including the United States and Sweden, and other places. The testimony will include the chemistry and the mechanisms of action of such chemicals on plant life. In addition, Dr. Galston will testify to the fate of Agent Orange and other phenoxy herbicides and their contaminants, especially TCDD, in the environment generally and in Vietnam in particular. Dr. Galston will testify to the persistence of such chemicals on plants, in water, and in soil, such that exposure to the phenoxy herbicides and their contaminants, especially TCDD, by the veterans in sprayed areas in Vietnam is presumed. The bases or grounds for Dr. Galston's testimony as to any facts and opinions expressed are a review of the scientific literature and his personal research and experience. Dr. John Garofalo is a immunologist practicing in Philadelphia, Pennsylvania. His curriculum vitae will be supplied. Dr. Garofalo will testify to the performance of certain tests on the veteran plaintiffs and their wives and children and to the interpretation of those test results. Specifically, he will be conducting phenotyping assay tests for, among others, B-lymphocytes, K cells, T-lymphocytes, T-helper cells, T-cytotoxic cells, and T-suppressor cells. The purpose of these tests is to determine antigen levels, antibody levels, and the presence of a viral defenses and immune surveillance systems, and to identify various types of cells that may be indicators of and/or precursors of malignancy. Not only will the tests determine the presence of such factors, but they will also include functional assays of each. 12492 LENNART HARDELL M.D. Dr. Hardell is employed by the University Hospital in its Department of Oncology in Umea, Sweden, where he specializes in internal medicine and oncology. His work includes diagnosis, treatment, and evaluation of possible causes of cancer, and education of medical students. Dr. Hardell will testify to several epidemiological studies which he and colleagues have conducted in Sweden. This research includes investigations concerning the relationship between the risk for different types of cancer and exposure to phenoxy herbicides and chlorophenols. The research has been published in the medical and scientific literature. These studies utilized the case-control study as the vehicle for investigation. Certain methodological aspects, such as selection of cases, selection of controls, assessment of exposure, and statistical methods, were considered; and then utilization was based upon thoroughly considered aspects of bias, all of which were well controlled. Specifically, these studies, four in number, involved soft tissue sarcomas, malignant lymphomas, and colon cancer. Highly statistically significant risks of soft tissue sarcomas and malignant lymphoma were found, whereas no association was found for colon cancer. In point of fact, the negative finding for colon cancer strongly supports the statistical significance of the increased risk demonstrated for soft tissue sarcomas and malignant lymphomas, i.e. a presumed causal relationship between exposure to phenoxy herbicides and human cancer particularly of soft tissue sarcoma and malignant lymphoma. Dr. Hardell has also seen in his clinical practice basal cell carcinoma of persons previously exposed to phenoxy herbicides, with no other known confounding variables. With respect to those cases with soft tissue sarcoma, malignant lymphoma, and basal cell carcinomas, Dr. Hardell will testify that the presumed exposure to Agent Orange caused, in significant part, such neoplastic processes. The bases for Dr. Hardell's testimony as to various facts and opinion include: educational background; professional training and experience; review of the applicable medical and scientific literature; personal research; and a review of the pertinent medical data of the relevant representative plaintiffs. 12434 -2- MAUREEN C. HATCH, Ph.D. Dr. Hatch is Assistant Professor of Epidemiology at Columbia University, School of Public Health, in New York City. Her Curriculum Vitae will be supplied. The subject matter about which Dr. Hatch will testify is reproductive toxicology and its specific applicability to miscarriages and congenital malformations (birth defects) in the wives and children of Vietnam veterans. Dr. Hatch will testify at length to the data collected in Vietnam regarding untoward pregnancy outcomes. Dr. Hatch is one of two investigators who are to publish that portion of the International Symposium held in Ho Chi Minh City in January, 1983 having to do with reproductive toxicology as a result of exposure to Agent Orange and other phenoxy herbicide spraying in Vietnam. The results of these data demonstrate a statistically significant increase in certain congenital malformations, e.g. cleft palate, limb deformaties, and anencephaly, as a result of paternal mediated reproductive effects. The exposure of the fathers was to the spraying of Agent Orange in Vietnam. The mothers were not exposed. These human data are coupled with positive, consistent animal data. For example, such studies where males were exposed indicate the following; the male gonads, are a target site of 2,3,7,8-TCDD action; at the endocrinological level, there has been demonstrated a major effect, i.e., AHH receptor in male gonads; which very nicely provides a mechanistic linkage; and finally, abnormal biochemical and morphologic characteristics of the sperm have been likewise demonstrated. ALASTAIR W.M. HAY, Ph.D. Dr. Hay is a lecturer on Chemical Pathology, Department of Chemical Pathology, Old Medical School, University of Leeds, Leeds, England. His partial Curriculum Vitae is attached. Dr. Hay will testify to a broad spectrum of matters related to Agent Orange, phenoxy herbicides, and their contaminants, including dioxins, especially 2,3,7,8-TCDD. Dr. Hay will discuss in detail his knowledge of the various phenoxy herbicides and their contaminants, including but not limited to the various aspects of: chemistry; biochemistry; manufacture and/or production; fate in the environment, animals, and humans; modes of exposure, i.e. absorption, ingestion and inhalation, specifically by the veterans who served in Vietnam; toxicity; and the state of the medical and scientific literature at various times since at least 1957 forward. The medical and scientific literature, attendance and participation in various symposia, review of various documents of certain defendants, personal research, and experience form the bases of whatever facts and opinions to which Dr. Hay will testify. Dr. Hay's testimony regarding the medical and scientific literature will include an exposition of the definitions and explanations, and their applicability to the troops exposed in Vietnam, of the phenoxy herbicides and their contaminants, in the following areas: plant physiology; toxicology; neuro-toxicology, both neurological and psychological; epidemiology; immunology; mutagenicity; teratology; reproductive toxicology; and carcinogenicity. 12 m More specifically, the phenoxy herbicides, including Agent Orange, 2,4-D and 2,4,5-T, and their contaminants, including dioxins, especially TCDD are highly toxic, neuro-toxic, immuno-suppressive, teratogenic, potentially mutagenic, and certainly carcinogenic. As a carcinogen, e.g. TCDD, it has no safe level and indeed any single exposure may prove to result in human cancer many years later; said in another way, there is no "no effect" level that can be established. Dr. Hay will testify to examples of the grounds which support the above, including: knowledge of spraying Agent Orange, especially its effect on the Vietnamese countryside; the purpose and historical tracing of the animal studies; historical tracing of the human data, including the various industrial incidents since 1949; references to specific documents, such as the EPA Dioxin document (presently in Draft form); various cancer epidemiology; pertinent teratology epidemiology; various studies of the Vietnamese, especially in area of reproductive toxicology; and those reports of the symptoms and diagnoses of the U.S. Vietnam veterans. 12497 -2- Name: D.O.B.: Alastair Watt Macintyre HAY 21 April 1947 Marital Status: Married Children: 1 son (Tom) Place of Birth: Glasgow, Scotland Nationality: British Degrees: B.Sc.(Hons), Chemistry IIA - London 1969 Ph.D., Biochemistry, London 1973 Home Address: School House, Arthington Lane, Arthington, Leeds LS21 1PE England. Work Address: Department of Chemical Old Medical School, University of Leeds, Leeds LS2 9NL England. Pathology, Place of Secondary Education: Gifford Technical High School, Bulowayo, Zimbabwe (formerly Rhodesia) Present Appointment: University lecturer in Chemical Pathology since April 1979 (University of Leeds) Leeds, England. Former Appointments : Research Fellow - Zoological Soc of London September 1972 - November 1977 Research Fellow - University of Leeds, Department of Animal Physiology and Nutrition December 1977 - March 1979 PUBLICATIONS Books "(i.) Alastair Hay. The Chemical Scythe: Lessons of 2,4,5-T and Dioxin. Plenum Press. 265pp. August 1982 (ii) Sean Murphy, Alastair Hay and Steven Rose. No Fire: No Thunder. The threat of chemical and biological warfare. Pluto Press. (To be published in January 1984). 135pp. Scientific Papers Some 50 scientific papers including: (i) Hay, A.W.M., Mawer, E.B., Hassan, A.G., Crawford, M.A., & Stevens, P.A. The role of essential fatty acids in vitamin D dependent calcium absorption in the intestine. Proc. of 5th Vitamin D Workshop. Williamsburg USA now in Vitamin D, Chemical, Biochemical and Clinical Endocrinology of Calcium 12498 2 Metabolism. Walter de Gruyter. Berlin. 1982 pp309-311. (ii) Hay, Alastair. Vitamin D: Sunlight and precursors. Nature. 2 9 7 , 364 (1982) (iii) Hay, A. Herbicides, Trichlorophenols and soft tissue sarcomas. Lancet I, 1240, (1982). (iv) Hay, A. It kills weeds, but what about people? New Scientist. 94., No. 1314. ppl58-161 (1982). (v) Hay,A ., Murphy, S., Robinson, J.P., and S. Rose. The poison cloud hanging over Europe. New Scientist. 9_3, No. 1296 pp630 635 (1982) . (vi) Hay, Alastair. New Pathways for clorinated dioxins. Nature, 294, 514-515 (1981). (vii) Hay, A. Experimental Toxicology and cytogenetics: an overview. In "Herbicides and War" to be published by Stockholm International Peace Research Institute. (1984) A. Westing, Ed. (viii) Hay, A. The Mutagenic properties of 2,3,7,8-Tetrachlorodibenzo-p-dioxin in "Chlorinated Dioxins and Dibenzofurans in the Total Environment. Vol II" Edit, by Keith, L.H. et al to be published in 1984. Other Publications I have written some 90 odd articles for the News, News and Views and books review section of the scientific journal Nature since 1976. 12499 Dr. Herbert Kaye, P h . D . , is a p s y c h ologist in the D e p a r t ment of Psychology at the State University of New York at Stoneybrook, Long Island and a visiting Associate Professor in the De partment of Psychiatry at New York University Medical Center. His curriculum vitae will be supplied. Dr. Kaye will testify concerning the significance of a battery of q u a n titative neurophysiological tests called neurometries will which be performed on the veteran, wife and children plaintiffs. The procedures were developed in part by Dr. Kaye in conjunction with medical and psychological researchers from this and other coun tries. He will testify that neurometries, on which he has written extensively, is a sophisticated battery of electrical tests in use for about fifty years, which are highly efficient in determing cortical EEG and evoked responses. Dr. Kay will explain the model used in the computeriza tion against which the test results are compared and will explain . how deviations from normal produce certain effects. Dr. Kaye w ill also discuss the m e c h a n i s m by which toxins produce these altered responses, and what effect those altered re sponses have upon the individual veterans at present, and the prog nosis for any additional changes or deterioration in the future based upon an assumed bioaccumulation of the toxic materials in the system. In doing so, he will rely on his experience in diagnosing many Vietnam veterans exposed to Agent Orange. r.n 0 RONALD H. KERMAN, Ph.D. Dr. Kerman is Associate Professor, and Chief, Cellular Immunology, Clinical Immunology Laboratories, the University of Texas Medical School at Houston. His Curriculum Vitae is attached. Dr. Kerman will testify that 2,3,7,8-TCDD in particular causes, among others, immuno-suppressive effects, as reported in the literature regarding the various animal species studies. Specifically, TCDD has been demonstrated to suppress T-cell mediated immunity in such species. This effect likewise has been demonstrated in humans by Bekesi, specifically an alteration of mature T-cells. Dr. Kerman will testify that the special scientific discipline involved is immuno-toxicology which has been defined as "the undesirable effects of an inappropriate response of the immune system". The bases for the facts and opinions to which Dr. Kerman will testify include a review of the applicable medical and scientific literature, his educational and professional background, and his work in connection with the Texas Agent 0range Study. Dr. Kerman will discuss the following in his testimony: the immune system, with its organic, cellular, and humoral components - most especially with regard to the latter, T-helper cells, B-cells, plasma cells and immunoglobulin production; immune response, both beneficial and harmful; the various experimental studies, particularly those demonstrating atrophy of the thymus, weight loss, depletion of lymphoid organs, lymphopenia, cutaneous type delayed hypersensitivity (skin thickness) and altered bacterial immuni ty. 12501 Dr . Kerman will testify that on the basis of the above a person exposed to TCDD might have increased predisposition to increased infection and neoplasm (cancer). CURRICULUM VITAE Ronald H. Kerman, Ph.D. DATE OF BIRTH: June 10, 1943 PLACE OF BIRTH: Chicago, Illinois NATIONALITY: U.S. C itizen SEX: Male EDUCATION: 1965 1967 1969 U niversity of Illinois, B.S. (with Honors) U niversity of Illinois, M.S. University o f Illinois, Ph.D. in Immunology HONORS: 1965 1967-1969 1967 1969-1971 1970 Bachelor of Science with G eneral Honors in the College Recipient of Public Health Service Predoctoral Traineeship Phi Sigma National Biological Honorary Recipient of Public Health Service Postdoctoral Traineeship Society of Sigma Xi RESEARCH AND PROFESSIONAL EXPERIENCE: 19831981- 19771977-1980 1974-1977 1973-1977 1972-1973 1969-1971 Associate Professor D epartm ent of Pathology, and Chief, Cellular Im munology, Clinical Immunology Laboratories, The Uni versity of Texas Medical School a t Houston Associate Professor Departm ent of Surgery, and Head, Histocompatibility and Immune Evaluation Laboratories, Division of Organ Transplantation, The University of Texas Medical School at Houston Member, Program in Immunology, G raduate School o f Bio medical Sciences, The University of Texas Health Science Center at Houston Assistant Professor D epartm ent of Surgery, and Head, Histocom patibility and Immune Evaluation Laboratories, Division of Organ Transplantation, The University of Texas Medical School at Houston Assistant Professor D epartm ent of Surgery, Loyola University Stritch School of Medicine, Maywood, Illinois Research Immunologist Chief, Immunobiology Research Laboratory, Research Service, V. A. Hospital, Hines, Illinois Assistant Professor D epartm ent of Microbiology, Jefferson Medical College Postdoctoral Fellow, (Immunology) Children's Hospital of Philadelphia and The University of Pennsylvania School of Medicine Curriculum Vitae Ronald H. Kerman, Ph.D. 2 PROFESSIONAL SOCIETIES: RESEARCH INTERESTS: RESEARCH SUPPORT: 1974-1978 1976-1979 1976- 1980 1977- 1978 197719771983-1984 OTHER ACTIVITIES: The Transplantation Society (Editorial Board, Trans plantation and Member, Symposium Com m ittee) American Association of Immunologists American Association for Cancer Research New York Academy of Sciences American Society of Transplant Physicians (Member, and Vice Chairman, Scientific Studies Committee) Society for Experim ental Biology and Medicine International Society for H eart Transplantation American Association for the Advancement of Science American Society for Histocom patibility and Immuno- genetics (Chairman, Finance and Audit Com m ittee, and Member, Laboratory A ccreditation Committee) Immunologic response to allotransplantation and malignancy Evaluation of immunocompetency Co-principal Investigator: Bronchogenic Carcinoma: Immu nologic P rofile, Radio and Im m unotherapy - V.A. M edical Research G rant No. MRIS-8121-08. $213,000 Co-principal Investigator: Immunotherapy Adjuvant to R adiotherapy of Head and Neck C ancer - V.A. Medical Research G rant No. MRIS-8121-06. $73,814 Co-principal Investigator: Factors Influencing Immuno com ptence in Human Transplantation - V.A. Medical R esearch G rant No. MRIS-3068. $68,770 Principal Investigator: Functional and Surface Receptor D ifferences of Human T-lymphocyte Subpopulations General Research Support Funds, The University of Texas Medical School a t Houston. $5,000 Principal Investigator: The Role of HLA Typing in R enal Transplantation, ESRD Program , No. 450068. $377,400 (last year) Principal Investigator: Immune Monitoring for the Diagnosis of Renal A llograft Rejection, ESRD Program , No. 450068. $544,800 (last year) Principal Investigator: Immune Evaluation of Veterans Exposed to Agent Orange. Texas Veterans Agent Orange A ssistance Program , IAC(83-84)1266. $93,352 Special C onsultant in Immunology to the Epidemiology and D isease C ontrol Study Section, NIH C onsultant in Immunology and H istocom patibility T esting to the D epartm ent of Laboratory M edicine, M.D. Anderson Hospital and Tumor Institute Editorial Board, Transplantation Review of manuscripts for the journal Human Immunology Review of manuscripts for the journal Transplantation Review of manuscripts for the journal H eart Transplantation Book review er for Journal of American Medical Association L iterature Reviewer for The American Association of Clinical H istocom patibility Testing -- AACHTion News 12504 Curriculum Vitae Ronald H. Kerman, Ph.D. 3 G rant Reviewer for the Kidney Foundation of Canada G rant R eview er in T ransplantation Immunology fo r T he March of Dimes - Birth D efects Foundation O utside Review er of R esearch Proposals in Immunology fo r the Research and Development Committee, The Vet erans Administration Research Service Invited P articip a n t (as a testin g laboratory) in The Third A m erican HLA Workshop Invited P a rticip an t (as a testin g laboratory) in The Eighth International H istocom patibility Workshop "Relevance of DR typing to renal allograft survival" Invited P articip a n t (as a testin g laboratory) in The In te r national Transfusion and T ransplantation Workshop Invited P articipant (as a testing laboratory) for the Ninth International H istocom patibility Workshop Invited P rese n ter a t an NIH Workshop, "The B iological Relevance of Immune Suppression as Induced by G enetic, Therapeutic and Environmental Factors" Invited P a rticip a n t (as a testin g laboratory) in the In te r national Collaborative Transplant Study Laboratory Inspector for Clinical Laboratory A ccreditation in H istocom patibility for The A m erican Society fo r His tocom patibility and Immunogenetics and The College of American Pathologists Chairman, Finance and Audit Com m ittee for The American Society for Histocom patibility and Immunogenetics Member, Symposium and A ffiliations Com m ittee, The Transplantation Society Member and V ice-Chairm an, Scientific Studies C om m ittee, American Society of Transplant Physicians M ember, Acquired Imm une D eficiency Syndrome (AIDS) Working Group for the Houston Area Chairman, Organizing Com m ittee and Host for The Fourth International Immune Monitoring Symposium: Im munological Evaluation and Monitoring of the Transplant R ecipient (1983) Member, Organizing C om m ittee for the International Sym posium on R elevant Immunological F actors in C linical Kidney T ransplantation, H eidelberg, West Germ any, 1985 Member, UTM3H Admissions Interview C om m ittee' Member, UTMSH Admissions C om m ittee Member, Medical Review Board, Organ Transplantation C en ter, UTMSH Member, C om m ittee on S ubject Selection for The U niversity of Texas System Agent Orange Study Member, S teering C o m m ittee, Program in Immunology, UT-GS3S Chairm an, By-Law s C o m m ittee, Program in Immunology, UT-GSBS Course D irector, "M ethods in C ellular Immunology," a P ro gram in Immunology C ourse, UT-GSBS 12505 BIBLIOGRAPHY Ronald H. Kerman, Ph.D. Publications 1. Kerman, R ., Segre, D. and Myers, W.L.: A ltered response to pneum ococcal polysaccharide in offspring of immunologically paralyzed mice. Science 156:1514, 1967. 2. Kerman, R., Segre, D. and Myers, W.L.: The role of immune and n atu ral specific antibodies in immunologic paralysis and immunity of mice to pneumococcal polysac charide Type m . J. Immunol. 104:655, 1970. 3. Kerman, R. and Segre, D.: A nti-pneum ococcal polysaccharide Type EH hem olytic plaques in mice: C ellular response in immunity and immunologic paralysis. J . Immunol. 104:1262, 1970. 4. Kerman, R. and H arris, T.N.: R esistance to denaturation by periodate of a dialyzable histocom patibility antigen. Proc. Soc. Exp. Biol. Med. 141^:179-183, 1972. 5. Kerman, R.H., Harris, T.N. and Harris, S.: Preparation of a dialyzable histocom pati bility antigen from balb/c mice. Proc. Natl. Acad. Sci. 6^:223-227, 1972. 6. Sm ith, R.A., Kerman, R ., Ezdinli, E. and Stefani, S.: A modified assay for th e detection of human adult active ro sette forming cells. J. Immunol. Meth. 8:175-184, 1975. 7. Kerman, R. and Stefani, S.: Immunological evaluation of p atien ts with solid tum ors before and a fte r radiotherapy. In Crispen, R.G. (ed.): Neoplasm Immunity: Mecha nisms, pp. 109-120. University of Illinois Press, 1976. 8. Stefani, S., Kerman, R. and Abbate, J.: Immune evaluation of lung cancer patients undergoing radiation therapy. Cancer 37:2792-2796, 1976. 9. Stefani, S., Kerman, R. and A bbate, J.: Serial studies of im m unocom petence of patients undergoing radiotherapy for malignancies of the head and neck. Am. J. Roentgenol. 126:880-886, 1976. 10. Kerman, R.H. and Geis, W.P.: Total and active T -cell kinetics in renal allograft recipients. Surgery 79:398-407, 1976. U . Kerman, R., Sm ith, R., S tefan i, S. and Ezdinli, E.: A ctive T -ro se tte form ing cells in the peripheral blood of cancer patients. Cancer Res. 36:3274-3278, 1976. 12. Kerman, R., Smith, R., Ezdinli, E. and S tefani, S.: U nification and technical aspects of total T, active T and B lymphocyte rosette assays. Immunol. Comm. 5(7-8):685694,1976. 13. Dodson, M.G., Kerman, R.H., Lange, C.F., Stefani, S. and O'Leary, J.A .: T and B cells in pregnancy. O bstet. Gynecol. 49:299-302, 1977. 12506 Bibliography Ronald H. Kerman, Ph.D. 2 14. Kerman, R.H. and S tfani, S.: PHA stim ulation of lym phocytes from p atien ts with lung cancer. Oncology 34:10-12, 1977. 15. Kerman, R.H. and Stefani, S.: Radio and im m unotherapy of lung cancer: A 1 Tw+r>\r /*\ 1 m m n n t T rr*er p o r i . i l l v ^ n s_p__e_n , TK> . U . J \_ iXNT 8- 0__p_i15L_S.n i i i i i m U n i i . y ~ o O i l u l U H i O r pp. 29-35. Franklin Institute Press, 1977. 16. Stefani, S. and Kerman, R.H.: Lym phocyte response to PHA before and a fte r radiation therapy in patients with carcinom as of the head and neck. J. Laryngol. Otol. 91:605-609, 1977. 17. Kerman, R.H., Ing, T.S., Hano, J.E . and Geis, W.P.: Prognostic significance of th e active T-RFC in renal allograft survival. Surgery 82:607-612, 1977. 18. M arshack, M., Toto, P. and Kerman, R.H.: Delayed hypersensitivity in the h am ster cheek pouch. J . Immunol. Meth. 15:325-330, 1977. 19. M arshack, M., Toto, P. and Kerman, R.H.: Im m unotherapy of chem ically-induced tumors in the ham ster cheek pouch with dinitrochlorobenezene. J. D ental Res. 57:625-630, 1978. 2 0 . Stefani, S. and Kerman, R.: Prognostic significance of pre-therapy delayed hypersen sitivity and T -cell levels in p atien ts with lung cancer. In Nieburgs, H.E. (ed.): Proceedings of the Third International Symposium on the D etection and Prevention of C ancer, Vol. 1, P a rt II, pp. 785-797. M arcel Dekker, Inc., 1978. 21. Geis, W.P., Iwatsuki, S., Molnar, Z., Giacchino, J.L ., Kerman, R.H., Ing, T.S. and Hano, J.E .: Im m unoblastic pseudo-lymphoma in renal allo g raft recipients. Arch. Surg. 113:461-466, 1978. 22. Dodson, M., K legerm an, M., Kerman, R.H., Lange, C., Tessier, J . and O 'Leary, J.: Bechet syndrome: With immunologic evaluation. O bstet. Gynecol. 5D.621-625, 1978. 23. Dodson, M.G., K legerm an, M.E., Menon, M., K erm an, R.H., Lange, C .F. and O 'Leary, J.A .: Establishment and characterization of a squamous cell carcinoma of the vulva in tissue culture and immunological evaluation of the host. Am. J. Obstet. Gynecol. 131:606-619, 1978. 24. Kerman, R.H. and Geis, W.P.: T-RFC m onitoring of CMI events in renal allo g ra ft recipients. Transpl. Proc. 10(3):633-635, 1978. 25. Kerman, R.H., Ing, T.S., Hano, J.E . and Geis, W.P.: P redictive value of activ e T-RFC in renal allograft survival. Transpl. Proc. JJD(3):637--638, 1978. 26. Kerman, R.H. and Stefani, S.S.: E ffe c t of BCG im m unotherapy on the activ e T and to ta l T-RFC in patients with lung cancer. C ancer Immunol. Immunother. 4:41-47, 1978. 27. Kahan, B.D., Kerman, R.H. and McConnell, R.: Com bination of immunological and radionuclide techniques to diagnose allograft rejection. Surgical Forum. 29:364-366, 1978. 12507 Bibliography Ronald H. Kerman, Ph.D. 3 28. S tfani, S. and Kerman, R.H.: Prognostic value of th e immunologic profile in inoperable lung cancer patients tre a ted by radiation. In Muggia, F. and Rozencweig, M. (eds.): Lung C ancer (Progess in C ancer R esearch and Therapy), Vol. 11, pp. 465470. Raven Press, Inc., New York, 1979. 29. Kerman, R.H.; Identification of human T and B lymphocytes. In Natelson, S., Pesce, A .J. and D ietz, A.A.: Clinical Immunochemistry: Chemical and Cellular Bases and Applications in Disease, pp. 12-20. American Association for Clinical Chem istry, 1979. 30. Kahan, B.D., Floyd, M., Oka, T ., Van Buren, C.T. and Kerman, R.H.: Im m unological techniques in clinical renal transplantation. I. Cross-M atch Methods, Jap. J . Trans plant. 14:1-13, 1979. 31. Kahan, B.D., Floyd, M., Oka, T., Van Buren, C.T. and Kerman, R.H.: Imm unological techniques in clinical renal tran sp lan tatio n . II. Imm unological M onitoring P o st allografting. Jap. J. Transplant. 14:14-25, 1979. 32. K erm an, R.H., Floyd, M., Conner, W., M cConnell, R., McConnell, B .J., Van Buren, C.T. and Kahan, B.D.: Combined immunological and radionuclide techniques to m onitor ren al a llo g raft rejectio n . Transpi. Proc. JL1:1229-1231, 1979. 33. Geis, W.P., Giacchino, J.L ., Buckingham, J.M ., Bansal, V.K., Iwatsuki, S., Kerman, R.H., Ing, T.S. and Hano, J.E .: Does suppression of T-RFC determ ine in vivo immunosuppressive e ffe c t of ATG? Transpl. Proc. 1_1:1433-1434, 1979. 34. Kerman, R.H., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved a llo g raft survival of strong immune responder-high risk recipients with adjuvant ATG therapy. Transplantation 30:450-454, 1980. 35. Kerman, R. and Kahan, B.D.: Clinical histocom patibility testing in renal transplanta tion: Potential keys to alloimmune specificity and reactivity. In Reisfeld, R. and F errone, S. (eds.): C urrent Trends in H istocom patibility, Vol. 2, pp. 201-226. Plenum Press, 1981. 36. Kerman, R.H. and Kahan, B.D.: Assessment of immune param eters of transplant recip ien ts on immunosuppressive therapy. In Dean, J . and Padarathsingh, M. (eds.): Biological Relevance of Immune Suppression as Induced by Genetic Therapeutic and Environmental F actors, pp. 82-97. Van Nostrand Reinhold Co., New York, 1981. 37. Kerman, R.H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prolonged a llo g raft survival of strong pretransplant immune responders treated with ATG. Transpl. fro c . 13:332-335, 1981. 38. Kerman, R.H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: C orrelation of non specific immune monitoring with rejection or impaired function of renal allografts. Transplantation 32:16-23, 1981. 39. K erm an, R.H ., Floyd, M., Van Buren, C.T., and Kahan, B.D.: Prediction of cadaveric allograft survival based on pretransplant nonspecific im m unocom ptence. Transpl. Proc. 13:1533-1535, 1981. 12508 Bibliography Ronald H. Kerman, Ph.D. 4 40. Kerman, R.H., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Serial m easurem ent of nonspecific immune param eters of chronically hemodialyzed renal failure patients. J. Clin. Immunol. 1:163-168, 1981. 41. Kerm an, R.H.: New developm ents in tran sp lan tatio n immunology. 1 1 I C L - 1 IU C L Bulletin 33(6):281-286, 1981. 42. Kerman, R.H.: E ffect of blood transfusion on renal allograft survival: Immunological considerations. Am. J. Kidney Diseases 2:125-127, 1981. 43. Kerman, R.H. and Kahan, B.D.: Immunological evaluation of transplant rejection: Pre and postoperative indices detecting immune responsiveness. In Hayry, P. (ed.): P resen t and Future Trends in Clinical Transplantation. Ann. Clin. Res. 13:244-263, 1981. 44. Kerman, R.H., Van Buren, C., Payne, W., Flechner, S., Agostino, G., Conley, S., Brew er, E. and Kahan, B.D.: Influence of blood transfusions on immune responsive ness. Transpi. Proc. 14:335-337, 1982. 45. Kahan, B.D., Van Buren, C.T., Lin, S.N., Ono, Y., Agostino, G., LeGrue, S., Boileau, M., Payne, W. and Kerman, R.H.: Immunopharmacologic monitoring of Cyclo sporin A -treated recipients of cadaveric kidney allografts. Transplantation 34:36-45, 1982. 46. Ono, Y., Kerman, R.H. and Kahan, B.D.: N atural cell-m ediated cy to to x icity and suppressor activ ity for n atu ral cell-m ediated cytotoxicity in long-term renal tra n s plant patients. Transplantation 34:103-107, 1982. 47. Van Buren, C.T., Kerman, R.H., Agostino, G., Payne, W., Flechner, S. and Kahan, B.D.: The cellular ta rg e t of Cyclosporin A action in man. Surgery 92:167-174, 1982. 48. Kahan, B.D., Kerman, R.H., Agostino, G., Friedm an, A. and LeGrue, S.J.: The action of Cyclosporin A on human lym phocytes. In White, D.J.G. (ed.): Cyclosporin A, pp. 281-293. Elsevier - Biomedical Press, Am sterdam , 1982. 49. Agostino, G .J., Kahan, B.D. and Kerman, R.H.: Suppression of mixed leucocyte culture using leucocytes from normal individuals, uremic individuals and allograft recipients. Transplantation 34:367-371, 1982. 50. Kerman, R.H., Conklin, R., Cahall, D., Van Buren, C.T. and Kahan, B.D.: CMV and renal allo g raft survival. In Eisenstein, T. and Friedm an, H. (eds.): Host D efenses to Intracellular Pathogens, pp. 517-519. Plenum Press, Inc., New York, 1983. 51. E ttenger, R.B., Kerman, R., Jordan, S.C., Warshaw, B.L., Harris, R. and Fine, R.: Sensitization following donor-specific transfusions for living related renal transplan tation. Transpl. Proc. 15:943-945, 1983. 52. Van Buren, C.T., Kerman, R.H., Agostino, G., Flechner, S., Payne, W., and Kahan, B.D.: E ffect of cyclosporine on im m unoregulatory cells of renal allograft recipients. Transpl. Proc. 15:527-530, 1983. 12509 Bibliography Ronald H. Kerman, Ph.D. 5 53. Kerman, R.H., Van Buren, C.T., Payne, W., Flechner, S. and Kahan, B.D.: Monitoring T cell subsets and immune events in renal a llo g raft recipients. Transpl. P roc. 15:1170-1172, 1983. 54. Flechner, S., Kerman, R ., Van Buren, C.T., Payne, W., and Kahan, B.D.: The use of cyclosporine and prednisone fo r high MLC haploidentical living related renal tran s plants. Transpl. Proc. 15:442-445, 1983. 55. Agostino, G., Kahan, B.D. and Kerman, R.: D etection of nonspecific suppressor cells from normal individuals, uremic patients and allograft recipients. Transpl. Proc. 15:724-728, 1983. 56. Kerman, R.H., Agostino, G., Van Buren, C.T., Payne, W., Flechner, S., Conley, S., B rew er, S. and Kahan, B.D.: E ffe c t of blood transfusions on g ra ft survival and immune responsiveness. Transpl. Proc. 15:1022-1025, 1983. 57. K erm an, R.H., Van Buren, C., Payne, W., Flechner, S., Agostino, G., Conley, S., Brew er, 8. and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune p aram eters affectin g cadaveric allograft survival. Trans plantation 36:50-54, 1983. 58. K erm an, R.H., F lechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclo sporine improves allograft survival in im m unologically high-risk renal allograft recipients. Transpl. Proc. 15:1909-1911, 1983. 59. K erm an, R.H., Van Buren, C .T., Payne, W., F lechner, S., and Kahan, B.D.: Immune monitoring of renal allograft recipients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. Transpl. Proc. 15:1971-1973, 1983. 60. Kerman, R.H., Payne, W., Van Buren, C.T., Flechner, S., and Kahan, B.D.: D etection of host presensitization to donor alloantigens utilizing a comprehensive immune crossm atch. Transpl. Proc. 15:1815-1816, 1983. 61. Flechner, S.M., Payne, W.D., Van Buren, C., Kerman, R., and Kahan, B.D.: The e ffe ct of cyclosporine on early g raft function. Transplantation 36:268-272, 1983. 62. V erani, R .R., B ergm an, D., and Kerman, R.H.: G lom erulopathy in acu te and chronic rejection: U ltrastructural characteristics and relationship to graft survival. Am. J. Nephrol. 3:253-256, 1983. 631. K erm an, R.H.: E ditorial: Influence of HLA A, B and DR antigen m atching in transfused cadaver renal transplant patients. Cleveland Clinic Quarterly 50:216-217, 1983. 64. K erm an, R.H., Flechner, S., Van Buren, C.T., Payne, W. and Kahan, B.D.: Immuno logical monitoring of renal allograft recipients treated with cyclosporine. Transpl. Proc. 16:2302-2305, 1983. 12510 Bibliography Ronald H. Kerman, Ph.D. 6 65. Van Buren, C., Kerman, R., Agostino, G., Flechner, S., Payne, W.D., and Kahan, B.: E ffe c t of cyclosporine on im m unoregulatory cells of renal allo g raft recipients. Transpi. Proc. 16:2293-2297, 1983. 66. Kahan. B.D.. Van Buren. C.. Flechner. S._ Pavne. W.D.. and Kerman. R.: Cvcloannrinp immunosuppression m itigates immunologic risk fa c to rs in renal allotransplantation. Transpl. Proc. 16:2469-2478, 1983. 67. Flechner, S.M., Van Buren, C., Kerman, R.H., and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal transplan tatio n . Transpl. Proc. 16:2689-2694, 1983. 68. Flechner, S.M., Van Buren, C.T., Kerman, R., and Kahan, B.D.: The e ffe c t of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. Transpl. Proc., 1983 (In press). 69. Flechner, S.M., Kerman, R.H., Van Buren, C., and Kahan, B.D.: Successful trans plantation of cyclosporine treated haploidentical living related renal recipients w ithout blood transfusions. T ransplantation, 1984 (In press). 70. Kerman, R.H., Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: C orrelation of visual, 51cr-release, and flow cytom etry crossm atch results to graft survival. Transpl. Proc., 1984 (In press). 71. Rogers, A.J., Kerman, R.H., and Kahan, B.D.: The pharm acokinetic and immunobiological activ ity of cyclosporine in man. Transpl. Proc., 1984 (In press). 72. Van Buren, C.T., Flechner, S.M., Kerman, R.H., Vaughn, W., and Kahan, B.D.: Cyclosporine improves outcom e in high risk cadaveric renal allograft recipients. Transpl. Proc. 1984 (In press). 73. Kerman, R.H., M anner, C., Ford, K., and Hoots, K.: Com prehensive immune evaluation of 78 hem ophiliacs. Ann. N. Y. Acad. Sc. 1984 (In press). Bibliography Ronald H. Kerman, Ph.D. 7 A bstracts and Presentations 1. Kerman, R ., C lark, J . and Wheelock, E.F.: M ononuclear in filtra te into an air pouch: A new in vitro cell m ediated immune assay. Fed, Proc, 32:973, A tlantic C ity, New Jersey, April 1973. 2. Wheelock, E .F ., K erm an, R.H ., C lark, J . and Toy, S.: Cell m ediated im m unity in dorm ant friend virus infections. Proc. Am. Assoc. C ancer Res. JL4:68, A tlan tic C ity, New Jersey, April 1973. 3. S tefani, S., K erm an, R. and A bbate, J.: S erial studies of im m unocom petence in head and neck cancer patients undergoing radiotherapy. A bstract, American Radium Society Meeting, San Juan, Puerto Rico, May 1975. 4. Kerman, R ., S tefan i, S. and Geis, W.P.: T o tal and activ e T -cell dynamics in renal allograft recipients. A bstracts of the American Society Transplant Surgeons, Chicago, Illinois, May 1976. 5. Kerman, R., S tefani, S., Sm ith, R., Ezdinli, E. and. Geis, W.P.: Immunological evaluation of patients with solid tumors and hem atological malignancies. Presented a t the 1975 C ancer Symposium, Neoplasm Imm unity: Mechanism, Chicago, Illinois, Septem ber 1975. 6. Stefani, S., Kerman, R. and Abbate, J.: Immunological evaluation of patients with bronchogenic carcinom a. Presented at the American Society of Therapeutic Radi ology, San Francisco, California, October 1975. 7. Stefani, S. and Kerman, R.: D eterm ination and prognostic value of immunocompe ten ce in p a tie n ts with lung cancer tre a te d by radiotherapy. A bstracts of th e Third In ternational Symposium on D etection and P revention of C ancer, New York, April 1976. 8. Geis, W.P., Vaz, A.L. and Kerman, R.H.: Steroid sparing e ffe c t of ATG in high risk renal allograft survival. Presented at the American Society of Transplant Surgeons M eeting, Chicago, Illinois, May 1976. 9. Kerman, R .H ., and Geis, W.P.: Prognostic significance of the activ e T -cell in renal allograft survival. Presented at the American Society Transplant Surgeons Meeting, Chicago, Illinois, May 1976. 10. S tefani, S. and K erm an, R.: BCG and radiotherapy, in bronchogenic carcinom a: Prelim inary report. Presented at the American Society of Therapeutic Radiology, ..Atlanta, Georgia, O ctober 1976. 11. K erm an, R. and Geis, W.P.: T-RFC m onitoring of CMI events in renal a llo g raft recipients. Presented at the Sixth International Congress of the Transplantation Society Special Session Immunological Monitoring of Transplant Recipient, New York, August 1976. 12. Kerman, R. and S tefan i, S.: Radio and im m unotherapy of lung cancer: A prelim inary re p o rt. P resen ted a t the 1977 Chicago Symposium: Im m unotherapy of Solid Tum ors, Chicago Illinois, February 24-25, 1977. 12512 Bibliography Ronald H. Kerman, Ph.D. 8 13. Stefani, S. and Kerman, R.H.: Relevance of immunologic analysis for patients with inoperable lung cancer treated by radiotherapy. Presented a t an NCI sponsored Symposium "The Second C onference on Lung C ancer T reatm en t," a t Airlie House, Virginia, May 22-24, 1977. 14. Kerman, R.H., Ing, T.S., Hano, J.E . and Geis, W.P.: Prognostic significance of active T -R F C in renal allograft survival. A b stracts of F irst In tern atio n al Symposium on Immunological Monitoring of the Transplant R ecipient. London, Ontario, June 8-10, 1977. 15. Kerman, R.H. and Geis, W.P.: T -R F C m onitoring of CMI events in renal allo g raft recipients. A bstracts of F irst In tern atio n al Symposium on Imm unological M onitoring of the Transplant Recipient. London, Ontario, June 8-10, 1977. 16. Ezdinli, E., Simonson, K., Icli, F. and Kerman, R.: E ffects of single vs. m ultiple agent therapy on cell-m ediated im m unity. P roc. A m er. Assoc. Clin. Oncol. 18:355, Denver, Colorado, May 1977. 17. Geis, W.P., Iwatsuki, S., Molnar, Z., Giacchino, J.L ., Kerman, R.H., Ing, T.S. and Hano, J.E .: Im m unoblastic pseudo-lymphoma in renal a llo g raft recip ien ts. P resen ted a t the W estern Surgical A ssociation, Las Vegas, N evada, November 15, 1977. 18. Kerman, R.H., Roesler, H. and Kahan, B.D.: Specific stim ulation of active T -R osette form ing cells by 3M KC1 solubilized antigen. Fed. P ro c., 1978. Presented a t the FASEB-AAI Meeting, A tlanta, Georgia, June 1978. 19. Kerman, R.H., Floyd, M., C onner, W., McConnell, B .J., McConnell, R. and Kahan, B . D.: C orrelation of active T -R F C and spontaneous blastogenesis with decreased renal allograft function. A bstracts of the American Association for Clinical H istocom patibility Testing, Boston, M assachusetts, June 1978. 20. Kerman, R.H ., R oesler, H. and Kahan, B.D.: Increased activ e T-RFC with in vitro stim ulation by soluble donor antigen. A bstracts of the Amer. Assoc, of Clin. Histocomp.. Testing, Boston, M assachusetts, June 1978. 21. K erm an, R.H ., Floyd, M., C onner, W., McConnell, R ., McConnell, B .J., Van Buren, C. T. and Kahan, B.D.: Combined immunological and radionuclide techniques to m onitor renal allo g raft rejection. P resen ted a t th e VII In tern atio n al Congress of The Transplantation Society, Rome, Italy, Septem ber 1978. 22. Kerman, R.H.: Invited speaker to a special workshop "Immunological Monitoring of the T ransplant P atients", VII In tern atio n al Congress of The T ransplantation Society, _Rome, Italy , Septem ber 1978. 23. Kahan, B.D., Kerman, R. and McConnell, R.: Combination of immunological and radionuclide techniques diagnoses allograft rejection. Presented a t the American College of Surgeons, San Francisco, C alifornia, O ctober 1978. 24. Michelson, J ., McConell, Kerman, R. and Kahan, B.: Association of acute rejection episodes in renal transplant p a tien ts with scored results of com puter analyzed data. Presented at the Southwest Society of N uclear M edicine M eeting, March 16, 1979, San Antonio, Texas. 12513 Bibliography Ronald H. Kerman, Ph.D. 9 25. Kerman, R.H., M acek, C. and Kahan, B.D.: Increase in 3 d ifferen t E -ro se tte m arkers on human T cells following PHA activ atio n . Fed. Proc. 38 (No. 3, P a rt n):1282. Presented at the Annual M eeting of The American Association of Immunologists, Dallas, Texas, April 1979. 26. Kerman, R.H.: Immunological considerations in renal tran sp lan tatio n . C linical Oncology Grand Rounds, M.D. Anderson H ospital and Tumor In stitu te, Septem ber 1979. 27. Kerman, R.H. and Kahan, B.D.: Assessment of immune param eters of transplant recipients on immunosuppressive therapy. P resented a t an NIH Workshop on "The Biological Relevance of Immune Suppression as Induced by G enetic Therapy and Environmental Factors," Williamsburg, Virginia, November 1979. 28. Invited p articipant in a working cadre for the NIH to develop a "Consensus On Immunotoxicology" for the National Toxicology Program, November 1979, Research Triangle Park, N.C., NIEHS, NIH. 29. Kerman, R.H.: H istocom patibility testin g in transplantation. Pathology Grand Rounds, St. Luke's Hospital, January 1980. 30. Van Buren, C.T., Kerman, R.H. V anBuren, D. and Kahan, B.D.: C orrelation of immune responsiveness with n u tritio n al indices in chronic ren al failu re p a tie n ts. Presented a t the American Society for Parenteral and Enteral Nutrition, Annual Meeting, Chicago, Illinois, January - February 1980. 31. Kerman, R.H.: Immune monitoring of renal allograft recipients. Surgical Grand Rounds, University of Miami School of Medicine, March 1980. 32. Kerman, R.H.: P re- and postoperative immune monitoring of allograft recipients. Medical Grand Rounds, Division of Dialysis and Transplantation, Children's Hospital of Los Angeles, April 1980. 33. Kerman, R.H. and Semchuk, R.: Delineation of a radioresistant T cell subpopulation. Fed. Proc. 39(3):945. Presented a t the Annual Meeting of The American Association of Immunologists, Anaheim, California, April 1980. 34. Kerman, R.H.: E ffe ct of heat on the ability of human T cells to express the active T and to ta l T receptors. Fed. Proc. 39(3):1137. Presented at the Annual M eeting of The American Association of Immunologists, April 1980, Anaheim, California. 3-5. K erm an, R ., Peddada, L. and Kahan, B.D.: C orrelation of hyperacute rejection with .LDA and CDA vs. 51C r-labeled donor T and B cell ta rg e ts. P resen ted a t The American Association for Clinical Histocom patibility Testing, S t. Louis, Missouri, April 1980. 36. K erm an, R ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allo g raft survival of strong responder-high risk cadaver recipients with adjuvant immunosuppressive therapy. Presented at the Annual Meeting of The American Association for Clinical H istocom patibility Testing, April 1980. 12514 Bibliography Ronald H. Kerman, Ph.D. 10 37. Kerman, R., Conklin, R., Cahall, D. and Kahan, B.D.: Association of cytomegalovirus and renal allograft survival. Presented at the meeting of the American Association for Clinical H istocom patibility Testing, St. Louis, Missouri, April 1980. 38. Kerman, R., Floyd, M., Van Buren, C.T. and Kahan, B.D.: D elineation of donor specific and nonspecific pretransplant immunocomptence as a predictor for LRD allograft survival. Presented a t the Meeting of The American Association of Clinical Histocom patibility Testing, St. Louis, Missouri, April 1980. 39. Kerman, R.H., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allograft survival of strong immune responder-high risk recipients with adjuvant immuno suppressive therapy. Presented a t the annual meeting of The American Society of Transplant Surgeons, Chicago, Illinois, May 1980. 40. Kerman, R.H., Floyd, M., Van Buren, C.T. and Kahan, B.D.: C orrelation of nonspecific immune monitoring of renal allograft recipients with rejection and impaired renal function. Presented at the Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, May 1980. 41. Kerman, R., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prolonged allograft survival of strong pretransplant immune responders treated with ATG. Presented at the VUIth International Congress of The T ransplantation Society, Boston, M assachu setts, June 1980. 42. Kerman, R., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prediction of renal allograft survival based on pretransplant non-specific immunocom ptence. Presented a t The Second Internatio n al Symposium on Immunological Monitoring of the Trans plant R ecipient, Leiden, The N etherlands, Septem ber 1980. 43. Kerman, R.H., Floyd, M., Van Buren, C.T., McConnell, B .J., McConnell, R. and Kahan, B.D.: Delineation of renal allograft rejection and impaired renal function by serial measurement of non-specific immune param eters. Presented at The Second International Symposium on Imm unological Monitoring of th e T ransplant R ecipient, Leiden, The Netherlands, Septem ber 1980. 44. Kerman, R.H. and Kahan, B.D.: Increased expression of the active T-RFC receptor as a m easure of allosensitization following in v itro stim ulation of recip ien t lympho cytes by soluble donor HLA antigens.- P resen ted a t The Second International Symposium on Imm unological M onitoring of the Transplant R ecipient, Leiden, The N etherlands, Septem ber 1980. 45. Kerman, R.H., Floyd, M., Van Buren, C.T. and Kahan, B.D.: C orrelation of HLA A,B . and DR typing to cadaveric and living related renal allo g raft survival. P resented at The Second International Symposium on Imm unological M onitoring of th e Transplant. R ecipient, Leiden, The N etherlands, Septem ber 1980. 46. Floyd, M., Kerman, R., Woo, J ., Van Buren, C.T. and Kahan, B.D.: R elationships of beta-2-microglobulin metabolism, immune reactivity and renal allograft rejection. P resented a t The Second In tern atio n al Symposium on Imm unological M onitoring of the Transplant R ecipient, Leiden, The N etherlands, Septem ber 1980. 4'n b?i Bibliography Ronald H. Kerman, Ph.D. 1 47. Kerman, R.H.: Immune monitoring of renal allograft recipients. Surgical Grand Rounds, University of Chicago, June 1981. 48. Kerman, R.H., Van Buren, C.T., LeGrue, S .J. and Kahan, B.D.: Imm unopharm acological monitoring of cadaveric renal allograft recipients receiving Cyclosporin A. Presented at the Annual Meeting of the American Society of Transplant Surgeons, Chicago, Illinois, June 1981. 49. Kerman, R .H ., Conklin, R., C ahall, D., Van Buren, C .T. and Kahan, B.D.: CMV and renal allograft rejection. Presented a t a Symposium on Host Defenses to In tra cellular Pathogens, Franklin Plaza Hotel, Philadelphia, Pennsylvania, June 1981. 50. Schoenberg, L.P., Kahan, B.D. and Kerman, R.H.: The use of Cyclosporin A as immunosuppressive m edication in renal tran sp lan tatio n . P resen ted a t The N ational Kidney Foundation, Inc., Washington, D.C., November 1981. Amer. J . Kidney Diseases, Program for Clinical Dialysis and T ransplantation Forum, p. 29. 51. E ttenger, R., Kerman, R., A rnett, J., Jordan, S., Warshaw, B., Harris, R., Wassner, S. and Fine, R.: Sensitization following donor-specific transfusions for live-related renal transplantation. American Society of Nephrology, Washington, D.C., November 1981. 52. F lechner, S., Boileau, M., Payne, W., Van Buren, C., K erm an, R. and Kahan, B.: The use of Cyclosporin A in strong immune responder, high risk renal tran sp lan t re c i pients. American Urological Association, Kansas City, Kansas, 1982. 53. Kerman, R., Van Buren, C., Payne, W., Flechner, S., Agostino, G., Conley, S., B rew er, E. and Kahan, B.: Influence of blood transfusions on immune responsiveness. Presented at The Transfusion and Transplantation Conference, Los Angeles, Cali fornia, January - February 1982. 54. Agostino, G., Kahan, B.D. and Kerman, R.H.: Suppression of mixed leucocyte culture using mononuclear leukocytes from normals, urmies and allograft recipients. Pre sented a t the Annual Meeting of The American Association of Immunologists, FASEB, New Orleans, Louisiana, April 1982. 55. Agostino, G .J., Kahan, B.D. and Kerman, R.H.: M easurem ent of suppressor cell statu s in p o te n tia l allo g raft recip ien ts. P resen ted a t th e Annual M eeting of The American Association of Clinical Histocompatibility Testing, San Francisco, Cali fornia, April 1982. 56. K erm an, R.H.: Invited p resen ter at two workshops on 1) Imm une monitoring of ..a llo g r a f t recip ien ts and 2) The e ffe c t of transfused blood and blood products on uremic hosts. Presented at the Annual M eeting of The North American Transplant C oordinators O rganization, San Antonio, Texas, May 1982. 57. Kerman, R.H., Van Buren, C., Flechner, S., Agostino, G., Conley, S., B rew er, E. and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune param eters affecting cadaveric allograft survival. Presented a t The Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, June 1982. 12518 Bibliography Ronald H. Kerman, Ph.D. 12 58. Agostino, G., Kahan, B.D. and Kerman, R.H.: Suppression of mixed leucocyte culture using leucocytes from normal individuals, uremic individuals, and allograft recipients. Presented at The Annual Meeting of The American Society of Transplant Surgeons, Chicago, Illinois, June 1982. 59. K erm an, R.H.: Invited p re sen te r a t a workshop on "Human T lym phocyte subpopula tions: T heir role in rejectio n and immunosuppression." P resen ted a t the In tern atio n al Congress of The Transplantation Society, Brighton, England, August 1982. 60. Kerman, R.H.: Invited p re sen te r a t a workshop on "M echanisms responsible for blood transfusion effects." Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 61. E ttenger, R.B., Kerman, R ., Jordan, S.C., Warshaw, B.L., Harris, R. and Fine, R.: Sensitization after donor-specific transfusions for live-related renal transplantation. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 62. Van B uren, C.T., Kerman, R.H ., Agostino, G., Flechner, S. Payne, W. and Kahan, B.D.: E ffe c t of cyclosporine on im m unoregulatorv cells of renal allo g raft recip ien ts. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 63. Kerman, R.H ., Van Buren, C .T., Payne, W., F lech n er,.S . and Kahan, B.D .: M onitoring T cell subsets and immune events in renal a llo g raft recip ien ts. P resen ted a t The International Congress of The Transplantation Society, Brighton, England, August 1982. 64. Flechner, S., Kerman, R., Van Buren, C.T., Payne, W. and Kahan, B.D.: The use of cyclosporine and prednisone fo r high MLC haploidentical living related renal tra n s plants. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 65. Agostino, G., Kahan, B.D. and Kerman, R.: D etection of nonspecific suppressor cells from normal individuals, uremic patients and allograft recipients. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 66. Kerman, R .H ., Agostino, G., Van Buren, C.T., Payne, W., F lechner, S., Conley, S., Brew er, E. and Kahan, B.D.: E ffect of blood transfusions on g ra ft survival and immune responsiveness. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 67. Kahan, B.D., Kerman, R., Payne, W.D., Flechner, S. and Van Buren, C.T.: Immunopharmacologic studies of cyclosporine-treated renal allograft recipients. Fifth T ripartite Meeting, Society of University Surgeons, Salzburg, Austria, Septem ber 1982. Bibliography Ronald H. Kerman, Ph.D. 13 68. Kerman, R.H., F lechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclo sporine improves a llo g raft survival in immunologically high-risk renal allo g ra ft recipients. Presented a t the Third International Immunological Monitoring Sym posium, K eyB iscayne, Florida, N ovem ber 1982= 69. K erm an, R.H., Van Buren, C.T., Payne, W., F lechner, S., and Kahan, B.D.: D etection of host presensitization to donor alloantigens utilizing a comprehensive immune crossm atch. Presented a t the Third International Immunological Monitoring Sym posium, K eyBiscayne, Florida, November 1982. 70. Kerman, R.H ., Payne, W., Van Buren, C.T., F lechner, S., and Kahan, B.D.: Imm une monitoring of renal allograft recipients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. Presented a t the Third International Immunological Monitoring Symposium, Key Biscayne, Florida, November 1982. 71. Kerman, R.H.: Invited plenary speaker at the First Annual Meeting of The American Society of Transplant Physicians, "Optimizing immunosuppression: Mode of action of cyclosporine." Chicago, D ecem ber 1982. 72. Kerman, R.H., Van Buren, C.T., Payne, W., F lechner, S., and Kahan, B.D.: Cyclo sporine improves a llo g raft survival in im m unologically high-risk renal a llo g raft recipients. Presented a t The Annual Meeting, N ational Kidney Foundation, Clinical Dialysis and Transplant Forum, Chicago, December 1982. 73. Kerman, R.H.: Role of immune evaluation in clinical m edicine. Clinical Immunology Grand Rounds, The Children's Memorial Hospital, Chicago, Illinois, December 1982. 74. Kerman, R.H.: Immunologic effects of toxic m aterials. Presented at Toxicology Clinical Update, University of Texas Medical Branch, Galveston, Texas, January 1983. 75. Kerman, R.H.: C yclosporine im proves allo g raft survival in immunologically high risk renal allograft recipients. Presented at Pathology Grand Rounds, University of Pittsburgh School of Medicine, February 1983. 76. Kerman, R.H.: Immune evaluation of renal failure patients and allograft recipients. Presented at Surgical Grand Rounds, St. Louis University Medical C enter, St. Louis, Missouri, March 1983. 77. Kerman, R.H.: Immunological evaluation of hemophiliacs. Presented at a Symposium on C urrent Problem s in the M anagem ent of H em ophiliac C om plications, H ouston, Texas, April 1983. 78. Flechner, S., K erm an, R.H., Van Buren, C.T., Payne, W., and Kahan, B.D.: Successful transplantation of high mixed lymphocyte culture haplo-identical living related donors using cyclosporine and prednisone. Presented at the Annual Am erican Urological Association, Las Vegas, Nevada, April 1983. 79. K erm an, R.H., F lechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Imm unolo gical monitoring of renal allograft recipients treated with cyclosporine. Presented at The F irst International Congress on Cyclosporine, Houston, Texas, May 1983. 12518 Bibliography Ronald H. Kerman, Ph.D. 14 80. Van Buren, C., Kerman, R., Agostino, G., Flechner, S., Payne, W.D., and Kahan, B.: E ffe ct of cyclosporine on im m unoregulatory cells of renal allograft recipients. P resen ted a t The F irst Intern atio n al Congress on Cyclosporine, Houston, Texas, May 1983. 81. Kahan, B.D., Van Buren, C., Flechner, S., Payne, W.D., and Kerman, R.: Improved outcom e of 150 renal allografts in immunologically high risk recipients tre a te d with cyclosporine. P resented a t The F irst In tern atio n al Congress on Cyclosporine, Houston, Texas, May 1983. 82. Flechner, S.M., Van Buren, C., Kerman, R.H., and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal transplan tatio n . P resented a t The F irst In tern atio n al Congress on Cyclosporine, Houston, Texas, May 1983. 83. Flechner, S.M., Van Buren, C.T., Kerman, R., and Kahan, B.D.: The e ffe c t of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. P resented a t The F irst In tern atio n al Congress on Cyclosporine, Houston, Texas, May 1983. 84. Kerman, R.H., Flechner, S., Van Buren, C.T., Payne, W., and Kahan, B.D.: Cyclo sporine immunosuppression overcomes immunologic risk factors for recipients of cadaveric renal allografts. Presented at the Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, June 1983. 85. Flechner, S.M., Kerman, R.H., Van Buren, C.T., and Kahan, B.D.: The high risk haploidentical living related recipient: Transplantation without blood transfusions and steroid withdrawal using cyclosporine. Presented at the Annual Meeting of The American Society of Transplant Physicians, Chicago, Illinois, June 1983. 86. Kerman, R.H.: Relationship of immunocomptence of hemophiliac patients and acquired immune deficiency syndrome (AIDS). P resented a t the Gulf C oast Hemo philia C hapter Meeting, Houston, Texas, O ctober 1983. 87. Kerman, R., Van Buren, C.T., Flechner, S., and Kahan, B.D.: C orrelation of visual, 5 1 cr-release and flow cytom etry crossm atch results to g raft survival. Presented at The Fourth International Symposium: Immune Monitoring of The Transplant Re cipient, Houston, Texas, November 1983. 88. Rogers, A .J., Kerman, R.H., and Kahan, B.D.: The pharm acokinetic and immunobiological activ ity of cyclosporine in man. P resen ted a t T he F ourth Intern atio n al Symposium: Immune Monitoring of The Transplant Recipient, Houston, Texas, November 1983. 89. K erm an, R.H., Manner, C., Ford, K., and H oots, K.: Com prehensive immune evaluation of 78 hem ophiliacs. P resented a t th e New York Academy of Sciences Symposium on Acquired Immune D eficiency Syndrome, New York, New York, Novem ber 1983. 90. Kerman, R., Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: DRW6 and- DR3 phenotypes correlating with immune response. Presented at the Annual Meeting of The American Association for Clinical H istocom patibility Testing, Chicago, Illinois,' November 1983. 12519 Bibliography Ronald H. Kerman, Ph.D. 15 91. Van Buren, C .T., Flechner, S.M., Kerman, R .H ., Vaughn, W., and Kahan, B.D.: Cyclosporine im proves outcom e in high risk cadaveric renal allo g raft recip ien ts. Presented at the F irst Meeting of The European Society for Organ Transplantation, Zurich, Sw itzerland, November 1883. 92. Kerman, R.H.: Cyclosporine immunosuppression for renal transplantation. Presented to Sandoz Pharm aceuticals, Inc., East Hanover, New Jersey, December 1983. 93. Kerman, R.H.: New horizons in tran sp lan tatio n : Influence of cyclosporine on renal transplantation. Invited presenter at the Western Dialysis and Transplantation Society, Park City, Utah, January 1984. 94. Sterling, R .P., Bradley, B.B., Khalil, K.G., Kerman, R.H., and Conklin, R.H.: Compari son of biopsy proven pneumocystis pneumonia in acquired immune deficiency syndrome (AIDS) p atien ts versus renal allo g raft p atien ts. P resen ted a t The Society for T horacic Surgeons, San Antonio, Texas, January 1984. 95. Rogers, A .J., Kerman, R.H., and Kahan, B.D.: Correlation of immunopharmacokinetic profiles of cyclosporine-treated allograft recipients and rejection. Presented at The Society for University Surgeons - Residents' M eeting, Chicago, Illinois, February 1984. 12520 MARVIN S. LEGATOR, Ph.D. Dr. Legator is Professor of Environmental Toxicology, University of Texas Medical School at Galveston. His Curriculum Vitae will be supplied. The subject matter of Dr. Legator's testimony will include: the teratogenic and carcinogenic effects of TCDD, as well as its mutagenic potential; the multi-system effects of TCDD at extremely low concentrations; the demonstrable effects, both gross and more subtle, of TCDD on animals; the extrapolition of the animal studies to humans, that is, the inherent, intended predictive aspects of the animal data to man; and finally to his work as a geneticist with respect to reproductive toxicology, i.e. male (Vietnam Veterans) - mediated birth defects and certain untoward pregnancy outcomes. Dr. Legator will testify to the extreme toxicity of dioxins, particularly 2,3,7,8-TCDD. Specifically, his testimony will indicate that TCDD is a complete carcinogen based upon certain animal studies, and that as a carcinogen, there is no safe level and does not have therefore a so-called no effect level. With respect to that, Dr. Legator will describe the extra ordinary precautions which are taken, and the fears of the researchers, in connection with the laboratory use of TCDD. In addition, Dr. Legator will testify to the reproductive toxicological effects, i.e. birth defects, and miscarriages of the children and wives of the exposed Vietnam veterans. The animal data in this regard are positive and consistent and provide a mechanistic linkage which confirms the Vietnamese epidemiological study of Hatch and others. Specifically, therefore Dr. Legator will testify that the miscarriage of Mrs. Dan G. Jordan and the congenital malformations of the children of Dan G. Jordan, as well as those of Kerry Ryan, daughter of Michael F. Ryan, were caused by the presumed exposure of representative plaintiffs Jordan and Ryan to phenoxy herbicides and dioxins - specifically 2,3,7,8-TCDD -- while serving in Vietnam. The bases or grounds for such facts and opinions include Dr. Legator's: educational and professional experience; personal researches; review of the applicable medical and scientific literature; and a review of the medical records and/or data of the Jordan and Ryan families. -2- ALAN SCOTT LEVIN, M.D. Dr. Levin is engaged in the practice of medicine in San Francisco, His Curriculum Vitae is attached. Dr. Levin will testify that phenoxy herbicides and their contaminants, including dioxins, most especially 2,3,7,8-TCDD, cause an assortment of immunological responses, i.e. immuno-toxicity, which predispose persons exposed by absorption and/or ingestion and/or inhalation - to such chemicals to a whole host of adverse health effects, such as: chloracne or other skin rashes; various neuro-toxic effects; reproductive effects; and neoplasm. In connection with the carcinogenic effect, Dr. Levin will state there is no safe level for this or any other carcinogen, and that a single exposure several years earlier can result in human cancer many years later. The bases for such facts and opinions expressed herein by Dr. Levin include: review of the medical and scientific literature, including both animal and human data; his personal researches; his clinical experiences; and his personal knowledge of the defoliation of Vietnam by such phenoxy herbicides and dioxins, with such chemicals in the presence of the veterans and their presumed exposure thereby; and review of all pertinent medical data of the representative plaintiffs. Dr. Levin will discuss the following in his testimony: the immune system, with its organic, cellular, and humoral components - most especially with regard to the latter, T-helper cells, B-cells, plasma cells and immuno globulin production; immune response, both beneficial and harmful; the various experimental studies, particularly those demonstrating atrophy of the thymus, weight loss, depletion of lymphoid organs, lymphopenia, cutaneous type delayed hypersensitivity (skin thickness) and altered bacterial immunity. In addition, Dr. Levin will discuss the following and their significance: immunology as molecular biology; chemical-induced immune disregulation; T-cells (lymphocytes from thymus) acting as immune modulators, (for which again there is no "no effect" level); immune surveillance; the similarity of the immune, neurologic, and endocrine systems and their significance in the area of immuno-toxicity; the relationship of immune disregulation caused by chemicals and carcinogenicity. Dr. Levin will then testify to the causal relationship of the various Agent Orange/dioxin related adverse health effects of the representative plaintiffs, including: chloracne; neuro-toxic effects, both neurological and psychological; reproductive toxic effects, both miscarriages and birth defects; and such neoplastic processes as soft tissue sarcoma, as here a rhabdomyosarcoma, lymphocytic lymphoma and basal cell carcinoma. -2- V\ ^' C CURRICULUM VITAE Alan Scott Levin, M.D, .Born: High School: College: Graduate School: Masters Thesis: Medical School: Internship: Fellowships: Specialty Board Certifications: Military: Marital Status: January 12, 1938= Chicago, Illinois. Austin, Chicago, Illinois University of Illinois, Champaign-Urbana, Illinois 1956-1960 B.S. Chemistry in L.A. with Honors. University of Illinois (Chicago Medical Center) M.S. in Biochemistry, 1963. Metabolism of Serum Albumin in Rats with Cirrhosis of the Liver, 1963. University of Illinois (Chicago Medical Center) M.D. 1964 Alpha Omega Alpha Honor Medical Society, 1963 Children's Hospital Medical Center, Boston, Mass. Traineeship Grant, Harvard Medical School 1964 Research Assistant, Children's Hospital Boston, 1965. USPHS Hematology Training Grant, University of California San Francisco, Medical Center 1969-1971 (Pediatric and General Immunology). American Cancer Society Faculty Research Award, 1971-1974 1. Certified Diplomnte American Board of Allergy and Immunology, 1975. 2. Certified Diplomate American Board of Pathology-Clinic Pathology, 1977. 3. Fellow in the American College of Emergency Physicians 4. Fellow College of American Pathologists. 5. Fellow American Society -of Clinical Pathologists. 6 . Member American Academy of Allergy. 7. Member American Association of Clinical Chemists. USN attached to USMC as Flight Surgeon 1966-1968 Viet Nam Campaign ribbons and unit citation, Navy and Marine Corps Commendation, First through Fourth Air Medals Bronze Star Medal with Combat "V", Silver Star Medal, Honorable Discharge November 1969. M a r r i e d to V e r a S. B y e r s , Ph.D., M.D. No c h i l d r e n . fL P.V i~yl12ht \rJ> f Acad ernie Appointments : Adjunct Instructor in Pediatrics University of California San Francisco Medical Center 1971 - 1972 Assistant Professor of Immunology in Dermatology University of California San Francisco Medical Center 1972 - 1978 Adjunct Associate Professor of Immunology University of California San Francisco Medical Center 1978 - Director of Laboratory of Immunology University of California and Kaiser Foundation Research Institute Joint Program Project San Francisco, California 1971 - 1974 Director of Division of Immunology Western Laboratories 2945 Webster Street Oakland, California 1974 - 1977 Medical Director MML/Solano Laboratories 2920 Telegraph Avenue Berkeley, California 1977 - 1979 Medical Director Levin Clinical Laboratories, 326 6 th Stree-t San Francisco, California 1979 - 1981 N Inc. Private Practice of Medicine 450 Sutter, Suite 1138 San Francisco, California, 94108 1981 - Member, Medical Quality Review Committee, ^4 Board of Medical Quality Assurance State of California 1982 - *i r*. * * o X &O&O I ALAN SCOTT LEVIN, M.D. BIBLIOGRAPHY (Abstracts not included) 1. Levin, A.S., and Jeffay, H.: Metabolism of serum albumin in rats with cirrhosis of the liver. J. Lab & Clin. Med. 63: 776-783, 1964. 2. Klemperer, M.R., Gotoff, S.P., Alper, C.A., Levin, A.S., and Rosen, F.S.: Estimation of serum beta 1-C globulin concentration: Its relation to the serum hemolytic complement titre. Pediatrics 36: 766-769, 1965. 3. Alper, C.A., Levin, A.S., and Rosen, F.S.: Beta-IC-globulin: Metabolism in Glomerulonephritis. Science 153 (3732): 180-182, 1966. 4. Vyas, G.N., Levin, A.S., Fudenberg, H.H.: Intrauterine isoimmunization caused by transplacental passage of maternal IGA. Nature 225: 275-276, 1970 5. Levin, A.S., Pipkins, M.O., and Fudenberg, H.H.: A rapid.radioimmunoassay for measuring nanogram levels of antigens. Vox. Sang. 18:459-466, 1970. 6. Levin, A.S., Spitler, L.E., Stites, D.P., and Fudenberg, H.H.: A gene tically determined cellular immunologic deficiency: Clinical and laboratory responses to therapy with transfer factor. Proc. Natl. Acad. Sci.L'SA 67: 321-328, October, 1970. 7. Stites, D.P., Levin, A.S., Austin, N.E., and Fudenberg, H.H.: Immuno biology of Human Lymphoid Cell Lines. Immunoglobulin biosyncheseis in cultures from Hypogamma-globulinemias and Paraproteinemia. J. Immunol, 107: 1376-1381, November, 1971 8. Levin, A.S., Fudenberg, H.H., Hopper, J.E., Nisonoff, A., and Wilson, S.K.: Immunofluorescent evidence for control of synthesis cf variable regions of light and heavy chains of IgG and IgM by^the same gene. Proc. Natl. Acad. Sci. USA 63: 169-171, 1971 9. Fudenberg, H.H., Wang, A.C., Pink, J.R.L., and Levin, A.S.: Studies of an Unusual Biclonal Gammopnthy. Ann. N.Y. Acad. Sci. 190:501-506, 1971. 10..Levin, A.S., Fudenberg, H.H., Pete, L.D., and Sharp, G.C.: IgG levels in Cerebrospinal Fluid of Patients with Central Nervous System Lupus. Clin. Immunol, and J. Inmunonath. 1: 1-5, 1972 11. Spitler, L.E., Levin, A.S., Huber, I!., and Fudenberg, H.H.: Prediction of Results of Transfer Factor Therapy in the Wiskott-Aldrich Syndrome by Monocyte IgG Receptors. In Proceedings of the Sixth Leukocvte Culture Conference. Academic Press, Inc., New York and London, P.795-803, 1972. ( 12. Spitler, L.E., Levin, A.S., Stites, D.P., Fudenberg, H.H., Pirofsky, C.S., August:, E.R., Stiehm, W.H., Hitzig, H. , and Gatti, R.A. : The WiskottAldrich Syndrome Results of Transfer Factor Therapy. J. Clir.. Invest. 51: 3216- 3224, 1972 13. Spath, P., Garraty, G., Levin, A.S., Petz, L.D., Fudenberg, H.H.: Immunhematologische Vernderungen bei Cephalosporin-therapie. Verhandlungen der Duetschen Gesselschaft fur innere Medizin, Vol. 78, 914-916, 1972. 14. Fudenberg, H.H., Spitler, L.E., and Levin, A.S.: Treatment of Immune Deficiency Disorders. Amer. J. Pathol. 69:529-536, 1972 15. Stites, D.P., Levin, A.S., Lauer, B., Costom, B.H., Fudenberg, H.H.: Selective "Dysgammaglobulinemia" with elevated serum IgA and chronic salmonellosis. Amer. J. Med. 54:260, 1973 16. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: Agammaglobulinemia and Lymphopenia without infection: A demonstration of immunologic unknowns. Amer. J. Med. 54: 371-377, 1973. 17. Raubitschek, A.S., Levin, A.S., Stites, D.P., Shaw, E.B., and Fudenberg, H.H.: Normal Granulocyte Infusion Therapy for Aspergillosis in a Patient with Chronic Granulomatous Disease. Pediatrics 51-230-233, February 1973 18. Wybran,'J., Levin, A.S., Spitler, L.E., and Fudenberg, H.H.: Rosette Forming Cells, Immunological Diseases and Transfer Factor. New England Journal o: Med. 228:710-713, 1973. 19. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: Human Lymphocyte Transfer Factor in "Methods in Cancer Research", H. Busch (ed.) Acad. Press. Ill 5th Ave., New York, N.Y., 59-106, 1973. 2 0 . Levin, A.S., Spitler, L.E., and Fudenberg, H.H.': Transfer Factor Therapy in Immune Deficiency States. Ann. Rev. Med, (invited Review) 2_4: 1973 21. Levin, A.S., Spitler, L.E., and Fudenberg, H.H.: Immune Deficiency States. Introduction to Clinical Allergy (cd.: B. Feingold) Charles Thomas, Springfield, Illinois, Chapter 19, 346-359, 1973. 2 2 . Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: The Wiskott-Aldrich Syndrome. In the Science and Practice of Clinical Medicine. J.M. Dictschy, L.E. Early, H.H. Fudenberg, A. Renold, C.A. Sanders, and J.P. Sanford (ed.) New York, 1974. 23. Spitler, L.E., Levin, A.S., Fudenberg, H.H.: Transfer Factor. Clinical Immunology Volume M. (ed. R.A. Good . Bach), 2: 153-175 , Academic Press, N.Y. 1974. 24. Fudenberg, H.H., Levin, A.S., Spitler, L.E., Wybran, J.E., and Byers, V.S Therapeutic Uses of Transfer Factor. Hosnital Practice 9:95-104 1974 \ 25. Levin, A.S., Transfer Factor Therapy: Current Status. So. Med. Journal (invited editorial) 68^ 1465-1466, 1975 26. Fudenberg, H.H., Byers, V.S., Levin, A.S., and Hackett, A.J.: Additional evidence for viral etiology of certain human tumors in A.A. Gottlieb, M.D., Fundamental Aspects of Neoplasia. New York: SpringerVerlag, 1974 27. Fudenberg, H.H., Byers, V.S., and Levin, A.S., : Immunologic Evidence for a Viral Etiology of Certain Malignant Tumors, in Perspectives in Virology (Gustav Stern Symposium), New York, February 4-5, 1974. 28. Levin, A.S., Byers, V.S., Fudenberg, H.H., and Wybran, J .: Immunologic Parameters for monitoring immunotherapy with tumor-specific transfer factor. Trans. Assoc. Amer, Phys.,_87, 153-158, 1974 29. Fudenberg, H.K., Byers, V.S., Levin, A.S., and Hackett, A.J.: Immunologic Evidence for a Viral Etiology of Certain Human Malignant Tumors. Ann. N.Y. Acad. Sci. (In Press, 1975) 30. Wybran, J., Levin, A.S., Fudenberg, H.H., and Goldstein, A.L.: Thymosin: Effects on Normal Human Blood T Cells. Ann. N.Y. Acad. Sci. 249:301-307, 1975 31. Carter, J.B., Ponce, B., Byers, V.S., Barr, G.D., Fudenberg, H.H. and Levin, A.S.: Standardization of tissue culture conditions for spontan eous thymidine-2l4c incorporation by unstimulated lym.phocytes : Circadian rhythm in Human Lymphocytes. J. of Allergy and Clinical Immunology 56, 191-196, 1975. 32. Byers, V.S., Levin, A.S., Hackett, A.J., and Fudenberg, H.H.: Tumor specific cell mediated immunity in household contacts of cancer patients. J. of Clin. Invest. 55-500-517, 1975. 33. Levin, A.S., Byers, V.S., Fudenberg, H.H., Hacket^ A.J., Johnston, J.O., and J.E. Wybran: Osteogenic sarcoma: Immunologic' parameters before and during therapy with tumor specific transfer factor. J. Clin. Invest 55: 487-499, 1975. 34. Levin, A.S., Spitler, L.E., and Fudenberg, H.H.,;' Transfer Factor 1. Methods of Therapy, (end Int. Coni, on Immunodeficiency in Man. St. Petersburg, Fla. 1973), in BIRTH DEFECTS: Original Article Series (Editors: D. Bergsma and R.A. Good), Sinaucr, Assoc., Inc., N.Y., 1975. 35. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: Transfer Factor II. Results of Therapy. (2nd Int. Conf. on Immunodeficiency Disease in Man, St. Petersburg, Fla., 1973), in BIRTH DEFECTS:. Original Article Series (Editors: D. Bergsma and R.A. Cood) , Sinauer Assoc., Inc., N.Y., 1975. I 36. Fisher, J., Byers, V.S., Shafrin, M., and Levin, A.S.: Relationship of Cu and Zn levels to metastatic events in human bone sarcomas. Cancer, 37, 356-364, 1976. 37. Spitler, L.E., Levin, A.S., and Fudenberg, H.K.: The Wiskott-Aldrich Syndrome: Immunological Studies in Patients and Family Members Cellular Immunology, 19, 201-218, 1975. 38. Byers, V.S., Levin, A.S., Hackett, A.J., and- Johnston, J.W.: Quantitativ Iramunofluorescent Studies on the Tumor Antigen Bearing Cell in Giant Cell Tumor of Bone and Osteogenic Sarcoma, Cancer Research, 35:2520 2531, 1975. 39. Jones, L.W., Levin, A.S., and Fudenberg, H.H.: Glomerular Antigen Comple Associated with Transitional Cell Carcinoma. Surgery, Gynecology and Obstetrics 140:896-898, 1975 40. Kaplan, M.A., Byers, V.S., Levin, A.S., German, D., Fudenberg, H.H., and LeCam, L.: Circadian Rhythm in Human Lymphocyte Function. J. Allergy and Clinical Immunology: 58 I, 180-189, 1976. 41. Spitler, L.E., Levin, A.S., and Wybran, J.: Adjuvant Immunotherapy for Malignant Melanoma with BCG and Transfer Factor. Cellular Immunology 21, 1 - 19, 1976. 42. Levin, A.S., Byers, V.S., Hackett, A.J., Johnston, J.O., and LeCam, L.M. Tumor Specific Transfer Factor Therapy in Osteogenic Sarcoma, Immunotherapy in Cancer, Proceedings of ITR-C'nicago, 1975. 43. Byers, V.S., Levin, A.S., Hackett, A.J., Johnston, J.O., and LeCam, L.M. Tumor Specific Transfer Factor Therapy in Osteogenic Sarcoma, A Two-Year Followup Study, Annals of New York Academy of Science, 277, 621-627, 1976 44. Byers, V.S. and Levin, A.S., Tumor Immunology, in Basic and Clinical Immunology: Eds. Caldwell, J., Fudenberg, H.H., .-^tites, D.P. and Wang, A.S., Lange Books, 1976. 45. 'Levin, A.S., Byers, V.S., LeCam, L.M., and Johnston, J.O., An Unusual Metastasis in an Osteogenic Sarcoma Patient on Tumor Specific Transfer Factor Therapy, Transfer Factor, 537-542, Academic Press, 1976. 46. "'Byers, V.S., LeCam, L.M., Hackett, A.J., Johnston, J.O. and Levin, A.S.: Familial Incidence of Breast Carcinoma Immunity - A Statistical Survey. Cancer Immunology and Immunotherapy. 2, 163-172, 1977 47. Byers, .S., and Levin, A.S.: Tumor Antigen Density on Osteogenic Sarcoma Cells in Vitro. Cancer Research. 37, 3173-3183, 1977. 12330 Chun. Shi-Han, icoc , C.R., Giblett, E .E ., Levin, A.S.: Adenosine Deaminase Dfi Lenc : Another Family with a "Silent" .Ada Allele and Norasl Ada Act in Two Hetcrozygotes. American Journal of Human Genetics. Vol 642-644, 1977.' ' 49. Marmor, M.D., Nelson, J.W., Levin, A.S.,: Copper Metabolism in American Retinitis Pigmentosa Patients: British Journal of Opthalmology. Vol. 62. 163-171, 1973. 50. Byers, V.S.,. LeCam, L., Levin, A.S., Johnston, J.O., and Hackett, A.J.: Osteogenic Sarcoma: Immunotherapy of Clinically Disease Free Patients with Transfer Factor: Long-Term Follow-up. Cancer Immunology and Immunotherapy - 6_. 243-251, 1979. 51. Byers, V.S., Levin, A.S.: Poison Oak III: Genetic Restriction in T Cell Mediated reactivity-Journal of Clinical Investieation.-Submitted. 52. Newman, B.R., Byers, V.S., German, D., and Levin, A.S.: Variability of Lymphocyte Function by Serum Factors. Journal of Clinical Laboratory Immunology 2, 151-154, 1979. 53. McGovern, J.J.,Jr., Lazaroni, J.L., Saifer, Phyllis, Levin, A.S., Rapp, D.J., Gardner, R.W.: Clinical Evaluation of the Major Plasma and Cellular Measures of Immunity. Journal of Orthomolecular Psychiatry. Vol. 12, No. 1. , 1933. 54 . Eyers, V.S., Baldwin. R . L e v i n , A.S., Embleton, M.J , and Price, M.R.. Monoclonal Antibodies: Their Use in the Diagnosis and Treatment of Cancer - In probability Models and Cancer, pp. 15-3^. L . LeCam and J, Neyman (Eds.) North-Holland, 1932. 55. Binder, R.L., Callaway, E., Levin, A.S., Stites, D.P.: Relationship between Creatine Phosp'nokinase and Immunoglobulins in Unmedicated Caucasian Schizophrenics. Biological Psvchiatrv. In Press. 1983. 56 McGovern, J.J.,Jr., Rapp, D.J., Levin, A.S.: PhOmol Provokes Abnormal Immune Response During Double-Blind Testing. J .'A,M.A . Submitted 1983. 31 ( ALAN SCOTT LEVIN, M.D. BIBLIOGRAPHY (Abstracts Only) 1. Alper, C.A., Levin, A.S., and Rosen, F.S.: Turnover of an I complement component. J. Clin. Invest. May 1965. labeled 4 2 Levin, A.S., Petz, L.D., Fudenberg, H.H.: Immunoglobulins and C Levels in Normal and CNS-SLE 'Cerebrospinal fluids using new micro radio immuno assays. Abstract presented ASCR Western Regional Meetings. 3. Levin, A.S., Stites, D.P., Spitler, L.E. , Sa'nud, M.A. and Fudenberg, H.H. : Induction of "delayed hypersensitivity" in Wiskott-Aldrich pacient by transfer factor. Clin. Res. 18:426, April, 1970. 4. Vyas, G.N., Levin, A.S., and Fudenberg, H.H.: Isoimmunization to human IgA in pregnancy. Clin. Res. 18:157, April 1970. 4 5. Levin, A.S., Petz, L., and Fudenberg, H.H.: IgG and C levels in CSF of patients with active CNS-SLE. Clin. Res. 19:137, June 1971 6. Levin, A.S., Fudenberg, H.H. , Hopper, J.., and Nisonoff, A.: Immunohistologic investigations of a Biclonal Camopathy: Detection of identical antigen in variable regions of IgG and IgM producing cells. Presented at ASH Meeting, San Juan, P.R. Blood XXXVI (6), 831, 1970. 7. Spitler, L.W., Levin, A.S., Stites, D.P., and Fudenberg, H.H.: Current status of transfer factor therapy in Wiskott-Aldrich Syndrome. Presented at ASCI Western Regional Meetings, Carmel, Jan. 1971 Clin. Res. XIX (j) 162, 1971 8. Levin, A.S., W'einer, R.S., Fudenberg, H.H., Spath, and Petz, L.: Granulocytopenia caused by anticephalothin antiboMies. Clin. Res. XIX (2) 424, 1971 9. Levin, A.S,Spitler, L.E., Stites, D.P., and Fudenberg, H.H.: Molecular intervention in genetically determined cellular immune deficiency disorder J. Clin. Invest^ 50:59a, 1971 10. Spitler, L.E., Levin, A.S., Fudenberg, H.H., Huber, H.: Abnormal monocyte IgG receptors in the Wiskott-Aldrich Syndrome. Sixth Annual Leukocyte Culture Conference. Academic Press, 1972. 11. Spitler, L.E., Levin, A.S., Stites, D.P., Pirofskv, Fudenberg, H.H.: Transfer Factor Therapy in Mucocutaneous Candidiasis. Sixth .Annual Leukocyte Culture Conference. Academic Press, 1972 12. Wybran, J., Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: The Rosette Forming Cell as an Indicator of Successful Transfer Factor Therapy in Immuno Deficiencies. Clin, Res. XX (3), 1972 i p K '12 1*J%. Levin, A.S., Spicier, L.E., Wybran, J., and Fudenberg, H.H.: Treatment of Osteogenic Sarcoma with Tumor Specific Transfer Factor. Clin. Res. XX (3), 56S, 1972. 14 . Spider, L.E., Levin, A.S., and Fudenberg, H.H.: Immunologic Evaluation of Patients with Micocutaneous Candidiasis and Results of Transfer Factor Therapy. Clin. Res. XX (3), 519, .1972. 15. Spitler, L.E., Levin, A.S., Blois, M.S., Epstein, W., Fudenberg, H.H., Hellstrom, 1., and Hellstrom, K.E.: Lymphocyte Responses to Tumor Specific Antigens in Patients with Malignant Melanoma and Results of Transfer Factor Therapy. J. Clin. Invest. 16. Wybran, J., Levin, A.S., Spitler, L.E. , and Fudenberg, H.H.: Tne Human Rosette Forming Cell, Transfer Factor and Prognosis of Cancer. Clin. Res. XX, (3) 635, 1972. 17. Fcnes, D.U., Mogerman, S.N., Spitler, L.E., Stites, D.P., Shinefield, H.R., Fudenberg, H.H., and Levin, A.S.: Graft Versus Host (GVH) in A Di George Patient: Probable Accelerated Induction of T Cell Competence. Clin. Res. XXI (2) 309. 18. Mogerman, S.N., Levin, A.S., Spitler, L.W.,'Stites, D.P., Fudenberg, H.H. and Shinefield, H.R.: Transfer Factor Therapy in X-Linked Recessive Severe Combined Dual System Immune Deficiency Disorder (SCID). Clin. Res. XXI (2) 310. 19. Carter, J.B., Pence, 3.E., Stites, D.P., Levin, A.S., German, D.F., and Fudenberg, H.H.: Spontaneous Thymidine' - 2--*-'4 C Incorporation by Unstimulaced Normal Human Peripheral Lymphocytes In_ Vitro: Tissue Culture Conditions and Quantitative Measurements. 2 0 . Carter, J.B., Ponce, B.E., Stites, D.P., Levin, A.S., German, D.E., and Fudenberg, H.H.: Circadian Cycle of Spontaneous Thymidine-2*-^ C Incorporation by Unstimulated Normal Human Peripheral Lymphocytes In Vitro. ----------------------- A.v .X 21. Fones, D.W. , Levin, A.S., Mogerman, S.M., Spitler, L. E., Stites, D.P., Shinefield, H.R., and Fudenberg, H.H.: Graft Versus Hose Followed by Host Versus Graft: Evidence for Accelerated Induction of T-Cell Competence. s' 22: Levin, A. S',vSpitler, L.E'., Wybran, J., Byers, V.S., and Fudenberg, H.H.: Treatment of Osteogenic Sarcoma (OS) with Tumor Specific DiaLysable. Transfer Factor (TF). Clinical Research. 1973 23. Levin, A.S., Byers, V.S., Fudenberg, H.H., and Wybran, J.E.: Immunologic Parameters for Monitoring Immunotherapy with Tumor Specific Transfer Factor. Clin. Res. 1974. 24. Gardner, R.D., Byers , V.S., Levin, A.S., and Fudenberg, H.H Frozen Human Lynphoc ytes: Dissociation between Tumor Specif ic Cytotoxicity and Mixed Leukocyte Reactivity (MLC Reactivity) 25. Byers, V.S., Levin, A.S., and Fudenberg, H.H.: Detection of Tumor Specific Immunity in Normal Household Contacts of Tumor Bearing Patients. Clin. Res. 1974. 26. Levin, A.S., Byers, V.S., Johnston, J.O., Hackett, A.J.,and Fudenberg, H.H.: Host-Tumor Relationships in Giant CellSarcoma of Bone (GCS): Measurement by Quantitative Immunofluorescence. Clin. Res. 1974 27. Fudenberg, H.H., Byers, V.S., Levin, A.S., and Hackett, A.J.: Evidence for Viral Etiology of Human Hypernophroma and Osteosarcoma. Perspectives in Virology. In Press, 1974 28. Levin, A.S., Byers, V.S., LeCam, L., and Johnston, J.O.: Evidence for Regression in Osteogenic Sarcoma Induced by Tumor Specific Transfer Factor. 2nd International Workshop on Transfer Factor. Frederick, MD., 1975. 29. Hackett, A., Springer, L., Levin, A.S., and Fink, M.: Transmission and Scanning Electron Microscopic Studies on Osteo Sarcoma Before and After Transfer Factor Therapy. Cancer Research 16:193, 1975 30. Levin, A.S., LeCam, L.M., Hackett, A.J. and Johnston, J.O.: Osteosarcoma (O.S.): 5 Year Followup of Epidemiology and Tumor Specific Transfer Factor Therapy (TSTF). Clin. Res. 1976 31. Levin, A.S., LeCam, L.M., and Agraz, J.M.: Dip-Stick Method of Quanti tative Immunofluorescence. Clin. Res, 1976-, 32. Newman, B.R., Byers, V.S., Levin, A.S., and Jerman, D.: Circadian Influences on T. Lymphocyte Function Mediated by Serum Factors. Clin. Res. 1976 33. Levin, A.S., Kassel, S.D., and Flam, M., A New Diagnostic Index: Collagen Disease vs. Malignancy vs. Infectious Disease. J.A.M.A. 237, 1916, 1977. 34. Levin, A.S., and Baldwin, R.W. : Solid Phase Fl'uoroimmunoassay to Detect Serum Immune Complexes. 6th International Congress on Immunofluorescence, Vienna, Austria. 1973 3-5, Levin, A.S., McCovern, J.J.,Jr., Miller, J.B., LeCam, L.L., and Lazaroni, J.: Non-Anaphylac tic Food Allergies Mediated by Immune Complexes: Ann. Allergy, Abstract in Press. 1981 12534 Dr. Peter Orris is an internist practicing in Chicago, Illinois. His curriculum vitae will be supplied. Dr. Orris will testify as to the clinical aspects of the diseases in the representative plaintiff veterans. His testimony will be based upon a medical records review and an analysis of various; test results that will have been performed upon the repre sentative plaintiffs. Dr. Orris will also testify on generic causation and specific proximate causation in relation to each representative veteran, plaintiff. He will also testify as to prognosis for each representative veteran plaintiff 12535 Marvin A. Schneiderman, Ph.D., of Bethesda, Maryland, is a statistician and epid e m i o l o g i s t who is the former Chief of Statistics and Epidemiology and the former Director for Science Policy of the National Cancer Institute and is currently a consultant. His c u r r iculum v i t a e is attached. Dr. Schneiderman will testify concerning mathematical models, statistics, and epidemiology in the area of cancer. He will first discuss the epidemiology of dioxins and their contaminants to human cancer insofar as it relates to soft tissue sarcomas, and particularly the EPA peer review.group conclusions in regard thereto, stomach cancers and lymphomas. In that regard, he will discuss the relationship of exposure to the time the disease appears, the so-called latency period. He will also discuss the multiplication of base rates in the production of such cancer. Next, Dr. Sch n e i d e r m a n will present a multi- s t a g e model of cancer induction. He will discuss age relationships and the stage of cancer development as they are affected by dioxins and their contaiminants or other materials. He will also present certain pertinent animal data and discuss it as a predictor for human experience. He will also testify that TCDD is more toxic than many other carcinogens, including being more carcinogenic by a factor of 4 or 5 than benzene, for example. He will also explain the concept of risk assessment and how judgments as to such are capable of being made with regard to humans. This will include discussion of a mathematical model for association of the multi-faceted presentation of symptoms and signs in the same veteran to exposure to Agent Orange as a causative factor. 1 iC/ He will also discuss the population incidences of these rare cancers, presenting a comparison of the onset ages for them in the general population with the ages of onset for the cancers observed in the Vi e t n a m veterans. He will also discuss the relationship of cancer induction to immune deficiencies or deficits. He will place special emphasis upon lymphomas and soft tissue sarcomas and explain how the ex perience with transplant patients validates his opinions in this regard. Finally, he will discuss the question of a threshold in the induction of cancer. This will include testimony to the effect that there is no "safe" dose for a carcinogen and that a single exposure may cause cancer. He will also discuss the disease-producing behavior of generalized carcinogens, i.e., the chance of a single carcinogen leading to cancer at multiple sites. E<J?v0 *{9 M A R V I N A. S C H N E I DERMAN Dr. S c h n e i d e r m a n is a C l e m e n t A s s o c i a t e s Senior S c i e n c e Advisor w i t h p r i n c i p a l r e s p o n s i b i l i t i e s in biostatistics, epidemiology, risk assessment, and health surveillance. He has more than 30 years of e x p e r i e n c e in cancer research ana related subjects, and he is the author of more than 130 sc i e n t i f i c p a pers in areas of biostatistics, epidemiology, risk assessment, and science and regulatory policy. During his career with the National Cancer Institute (NCI), he was, successively, Associate Chief of the Biometry Branch, Associate Director for Field S t u d i e s (Epidemiology) and S t a t i s t i c s , and A s s o c i a t e D irec t o r for Science Policy. In this last position, he was one of the pr i n c i pal advisors to the Director of the Institute. Dr. Schneiderman is a member of the adj u n c t faculty of the G e o r g e t o w n U n i v e r s i t y Graduate School, and Professor of Biostatistics at the Uniformed Services University of the Health Sciences. He has held teaching positions at the University of Pittsburgh Graduate School of P u b l i c H e a l t h and the U n i v e r s i t y of Miami (Florida), as well as at the Georgetown University Medical School. He was also a Rockefeller Public Service Fellow at the London School of Hygiene and Tropical Medicine. He has served on a number of e xper t a d v i s o r y c o m m i t t e e s and is or has been an associate editor of Cancer Research, B l o o d , Journal of the National Cancer I n s t i t u t e , B i o m e t r i c s , S t a t i s t i c s in M e d i c i n e , A m e r i c a n Journal of Industrial Medicine, and a number of other scientific journals DEGREES P h . D . , Statistics, American University, Washington, D.C., 1961 M.S., Statistics, American University, Washington, D.C., 1953 B.S., Mathematics and Statistics, City College of New York, 1939 NON-DEGREE EDUCATION Harvard University Graduate School of Business, 1945 Management sciences, economics, statistics Ohio State University Graduate School, 1946-1947 Economics London School of Hygiene and Tropical Medicine, 1959-1960 Epidemiology, medical research involving humans, controlled trials, biostatistics SCHNEIDERMAN, page 2 1983-present 1981-present 1980-present 1975-present 1980 1978-1980 1970-1978 1967-1978 1966-1975 1960-1970 1960-1965 1959-1960 1955-1959 1948-1955 1939-1948 EMPLOYMENT HISTORY Senior Fellow, Environmental Law Institute, Washington, D.C. Professor (Division of B i o m e t r i c s ) , Department of Preventive Medicine, USUHS, Bethesda, Md. Senior Science Advisor, Clement Associates Associate Professor, Graduate Faculty, Georgetowi University Expert Consultant, Office of the Director, Natior Cancer Institute (NCI), National Institutes of H e a l t h (NIH) Associate Director for Science Policy, Office of the Director, NCI Associate Director NCI, Field Studies and Statist Program, Division of Cancer Cause and Prevention. NCI Adjunct Professor, Biostatistics, Graduate School of Public Health, University of Pittsburgh Clinical Associate Professor, Medical Statistics, Georgetown University Medical School Associate Chief, Biometry Branch, NCI Professorial Lecturer, Georgetown University Medical School Rockfeller Public Service Fellow, Statistical Research Unit of the British Medical Research Council, London School of Hygiene and Tropical Medicine Mathematical Statistician and Acting Chief, Therapeutic Trials Section, NCI Mathematical Statistician, Biometrics Section, NCI Private Industry, Military Service (USAF), Other Federal government agencies SCHNEIDERMAN, page 3 HONORS Distinguished Lecturer, Lawrence Livermore Laboratories, Univer sity of California, 1982 American Conference of Government Industrial Hygienists, Symposium Speaker Award, June, 1982 Samuel Wilkes Public Lectureship, Princeton University, 1980 Keynote Lecturer, Society of Occupational and Environmental Health, 1979, North Carolina Public Health Association, 1980 Environmental Defense Fund, Public Interest Science Award, 1977 Distinguished Service Award, Department of Health, Education and Welfare (DHEW), 1974 Superior Service Award, DHEW, 1968 Rockefeller Public Service Fellow, London School of Hygiene and Tropical Medicine, 1959-1960 Phi Beta Kappa, 1939 SELECTED ADVISORY COMMITTEES Committee on Toxicity Data Elements, National Academy of Sciences, 1981-present S u b c o m m i t t e e on the G e o c h e m i c a l E n v i r o n m e n t in R e l a t i o n to Health and Disease, NAS/NRC, 1980-present Science Evaluation Board, National Health and Medical Research Council of Australia, 1980-present .American Cancer Society, Analysis and Projections Committee, 19-76-1978, Institutional Grants Committee, 1980-present Science Advisory Board, Howard University Cancer Center, 1979present (External Review Committee) Cente r for S c i e n c e in the P u blic Interest, Board of Directors, 1983-present Food Safety Council, Board of Directors, 1978-1982 Advisory Committee, Biomedical and Environmental Assessment Division, Brookhaven National Laboratory, 1978-present SCHNEIDERMAN, page 4 Advisory Committee, International Cancer Research Data Bank (CIDAC), Franklin Institute, Philadelphia, 1981-present Task Force on-Heart Disease Epidemiology, National Heart, Lung, and Blood Institute, 1979-1980 Science Advisory Board, National Center for Toxicological Research, 1974-1979 Ad Hoc Subcommittee on Asbestos-Related Health Problems, Armed Forces Epidemiology Board, 1978-1979 International (American) Chairman, U.S./U.S.S.R. Working Group on the Epidemiology of Cancer, 1973-1979 Committee on Maritime Hazardous Materials, National Academy of Sciences, 1978 Committee to Coordinate Tox i c o l o g y and Related Programs, DHEW, 1978 President's Biomedical Panel, 1975-1976 Consultative Panel on Hazards of Chemical Pesticides, National Academy of Sciences, 1974-1976 Chairman and Executive Secretary, Committee of Presidents of Statistical Societies, 1973-1976 Board of Directors, American Statistical Association, 1972-1974 International Council, International Biometric Society, 1971-1973 Immunology-Epidemiology Segment, Special Virus Cancer Program, NCI, 1969-1971 Advisory Panel on Carcinogenicity of Pesticides, Secretary's Commission on Pesticides and Their Relationship to Environmental Health, 1969-1970 Chairman, Subcommittee on Medical Biostatistics, American Thera peutic Society, 1967-1968 Subcommittee on Biologic Effects of Atomic Radiation, N A S / N R C , 1964-1965 SCHNEIDERMAN, page 5 SELECTED SOCIETIES American Association for Cancer Research American Society for Preventive Oncology (Founding Member) American Statistical Association (Fellow) Biometric Society (International) International Epidemiological Association Royal Statistical Society (Fellow) Washington Statistical Society American Association for the Advancement of Science (Fellow) International Statistical Institute (Fellow) Society for Occupational and Environmental Health SELECTED PUBLICATIONS Schneiderman, M.A. Standard setting: Implications of sensitivity and a search for an ethical base. In: P r o t e c t i o n of the Sensitive Individual, Annals of the American Conference of G o v e r n m e n t I n d u s t r i a l H y g i e n i s t s , 3:133-138 (1982) Schneiderman, M.A. A personal reminiscence (Austin Bradford Hill). S t a t i s t i c s in M e d i c i n e 1:307-308 (1982) Schneiderman, M.A. Discussion of "Some Aspects of Cancer Epidemi ology" by Abraham Lilienfeld. Biometrics (Supplement) 38:161-165 (1982) Davis, D.L., Bridbord, K., and Schneiderman, M.A. Cancer p r e v e n tion: A s s e s s i n g cause, exposure, and recent trends in mortality for U.S. males, 1968-1978. Teratogenesis, Carcino genesis and Mutagenesis. Pp. 105-135 (June 1982) Schneid e r m a n , M.A. T r ends in cancer m o r t a l i t y and incidence in the U n i t e d States: Is the future clear or clouded? In Mike, V. , ed. S t a t i s t i c s in M e d i c a l Research. John Wiley and Sons, New York. Pp. 71-107 (1982) S c h n e i d e r m a n , M.A. D e s c r i p t i o n and r e l i a b i l i t y of trends in ''= cancer incidence. In Magnus, K. T r e n d s in C a ncer Incidence. H e m i s p h e r e P u b l i s h i n g C o r p . , W a s h i n g t o n , D.C. Pp. 1-2 (1982) Schneiderman, M.A. Cost-benefit, social values and the setting of occupational health standards. In Lee, J.S., and Rom, W.N eds. Legal and E t h i c a l D i l e m m a s in O c c u p a t i o n a l Health. Ann Arbor Science, Ann Arbor, Michigan, p p . 191-205 (1982) SCHNEIDERMAN, page 6 Peto, R. , and S c h neiderman, M. , eds. Quantif ication.. of O c c u p a tional Cancer: B a n b u r y R e p o r t No. 9. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1981) . Davis, D.L., Bridbord, K . , and Schneiderman, M.A. Estimating cancer risks: P r o b l e m s in m e t h o d o l o g y p r o d u c t i o n trends. In Peto, R . , and Schneiderman, M . , eds. Quantification of O c c u p a t i o n a l Cancer: B a n b u r y Report No. 9. C old Spring Harbor Laboratory, Cold Spring Harbor, New York. Pp. 285315 (1981) Schneiderman, M.A. Summary comments. In Crandall, R . W . , and Lave, R . , eds. The Scientific Basis of Health and Safety Regulation. The Brookings Institution, Washington, D.C. Pp. 297-299 (1981) Schne i d e r m a n , M.A. R e g u l a t i o n of carcinogens in an imprecise world. Ann. N.Y. Acad. Sci. 363:217-232 (1981) Schneiderman, M.A. Extrapolation from incomplete data to total or lifetime risks at low doses. Environ. Health Perspect. V. 42, Pp. 33-38 (December 1981) Schne i d e r m a n , M.A. T o x i c Su b s t a n c e s in Our E n v i r o n m e n t - C a n we manage them so that they don't manage to harm us? H e a l t h F o r u m 81, The C o a l i t i o n for Health and the E n v i r o n ment, W a shington, D.C. (1981) S c h n e i d e r m a n , M.A. E p i demiology: W hat Can it Tell Us? P r o ceedings of the Conference on Environmental Risk, New Orleans, Louisiana, D e c e m b e r 10, 1980. The E l e c t r i c Power Research Institute, Palo Alto, California, EPRI EA-2064, Project 1316-6. Pp. 369 - 3-89 (October 1981) S c h n e i d e r m a n , M . A . , Nisbet, I., and Brett, S.M. A s s e s s m e n t of Ri s k s Posed by L o w Levels of Asbes t o s in the General E n v i r o n m e n t . Berichte: B u n d e s g e s u n d h e i t s a m t . No. 4, 1981. D i e t r i c h R e i m e r Verlag, Berlin. Pp. 3/1-3/28 (1981) Schneiderman, M . A . , and Levin, D.L. Needs, problems and prospects in cancer epidemiology. In Levin. D.L., ed. Cancer E p i d e m i o l o g y in the U.S.A. and U.S.S.R. U.S. D e partment of Health and Human Services, P H S , Bethesda, Maryland. NIH Publication No. 80-2044 (1980) Schneiderman, M.A. The Relationship Between Diet, Occupation, the Environment and Cancer. Proceedings: US/Egypt Symposium on the Biomedical Effects of Technology Transfer, Cairo, E 9YPt (February 9-13, 1980) (In Press: Environmental Health Perspectives) SCHNEIDERMAN, page 7 S c h n e i d e r m a n , M.A. S c i e n t i f i c Issues in a N a t i o n a l Cancer Policy. Proceedings of the 4th Toxic Control Conference. Government Institutes, Inc., Washington, D.C, Pp = 95-107 (1980) Schneiderman, M.A. The uncertain risks we run: Hazardous materials. In Schwin, R.C., and Albers, W . A . , Jr., eds. Socie t a l Risk A s s e s s m e n t . P l e n u m Press, N e w York. Pp. 19-41 (1980) Schneiderman, M.A. What's Happening to Cancer in our Advanced Industrial Society? Have the Risks been Overstated? Keynote Address: Society for Occupational and Environmental Health, W a s h i n g t o n , D.C. (In Press: Proceedings) (December 3-5, 1979) Blokhin, N.N., and Schneiderman, M.A., eds. Epidemiology of Cancer in the USSR and USA. Meditsina, M o s c o w (Russian) (1979) S c h n e i d e r m a n , M.A., DeCoufle, P., and Brown, C.C. Thresholds for environmental cancer: Biologic and statistical consider ations. Ann. N.Y. Acad. Sci. 329:92-130 (1979) Schneiderman, M.A. Alpha, beta manitonne-- a new industrial material with unknown'benefits and risks. In Carcinogenic Risks/Strategies for Intervention. International Agency for Research on Cancer (IARC), Lyon, France. IARC Sci. Publ. 25:237-239 (1979) Schneiderman, M.A. The Links Between the Environment and Health. Proceedings: National Conference on the Environment and Health C a r e Costs, U.S. House of R e p r e s e n t a t i v e s (August 15, 1978) Biersteker, K., and Schneiderman, M.A. Epidemiologic Aspects of Drinking Water-Health Relationship. Proceedings of the Health Effects C o m mittee of the NATO committee on c h a l l e n g e s of M o d e r n Society. Bonn, W. G e r m a n y (April 23- . 27, 1978) Schne i d e r m a n , M.A., Mason, T.J., and Hoover, R. Cancer, geography, and geology-- a problem for interdisciplinary cross-fertili zation. In G e o c h e m i s t r y and the Env i r o n m e n t . Vol. 3. N a t i o n a l A c a d e m y of Sciences, W a shington, D.C. (1978) Schneiderman, M.A. Legislative possibilities to reduce the impact of cancer. Prev. Med. 7:424-438 (1978) 125 SCHNEIDERMAN, page 8 Schneiderman, M.A. Water and epidemiology. ed. Safe Drinking Water: C u r r e n t and Proceedings of the National Conference the Future. Pp. 111-148 (1978) In Russell, C.S., Future Problems. on Resources for Schneiderman, M.A. Extrapolating animal and microbiological tests to humans. In Coling, G., ed. Environ m e n t a l Cancer (Causes, Victims, Solutions). Proceedings of a conference of the U r b a n E n v i r o n m e n t Coalition, Inc. Pp. 9-11 (1978) Schneiderman, M.A. Environmental Factors and Cancer Prevention. Marcel Dekker, New York (1978). (Third National Symposium on Detection and Prevention of Cancer, New York (April 26-30, 1976) Schneiderman, M.A. Risk assessment of the health effects of water chlorination. In Jolley, R.L., Gorchev, H., and Hamilton, D . H . , eds. Water Chlorination-- Environmental Impact and Health Effects. Ann Arbor Science Publications, A n n Arbor, Mich. Vol. 2, pp. 509-515 (1978) Schneiderman, M.A., and Brown, C.C. Estimating cancer risks to a population. Environ. Health Perspect. 22:115-124 (1978) Schne i d e r m a n , M.A. E i g h t y per c e n t of cancer is related to the environment. Laryngoscope 88:1-16 (1978) Schne i d e r m a n , M.A. Tim e Tren d s in Cancer: U n i t e d States, 1953-1973. Laryngoscope 88, Supp. 8:1-6 (1978) Fears, T . R . , Scotto, J., and Schneiderman, M.A. Mathematical models of age and ultraviolet effects on the incidence of skin cancer among whites in the U n i t e d States. Am. J. Epidemiol. 105:420-427 (1977) 'DeVesa, S.S., and Schneiderman, M.A. Increase in the number of c a n c e r deat h s in the U n i t e d States. Am. J. Epidemiol. 106:1-5 (1977) Schneiderman, M.A. The numerate sciences-- epidemiology and biometry. JNCI 59:633-644 (1977) Schneiderman, M.A., and Levin, D.L. Epidemiology of cancer and tobacco use: Trends and trend indicators. In Steinfield, J., Griffiths, W . , Ball, K . , and Taylor, R . M . , eds. S m o k i n g and Health: II. H e a l t h C o n s e q u e n c es, E d u c a tion, Cessation Activities, and Governmental Action. Proceedings of the Third World Conference on Smoking and Health, New York. Pp. 73-84 (1977) SCHNEIDERMAN, page 9 Schneiderman, M . A . Health effects-- a scientific and.statistical analysis. In Miller, M.L., ed. P r o c e e d i n g s of the F i r s t To x i c S u b s t a n c e s Law Seminar. W a s h i n g t o n , D.C. .(1977) Levin, D.L., and Schneiderman, M.A. Cancer. In Miller, S.S., e d . S ymptoms. T h o m a s Y. Crowell, N e w York (1976) Fears, T.R., Scotto, J . , and Schneiderman, M.A. Skin cancer, melanoma, and sunlight. Am. J. P u b l i c H e a l t h 66:461-464 (1976) Schnei d e r m a n , M.A. C a r c i n o g e n e s i s as an end point in health impact assessment. In Anderson, E.C., and Sullivan, E.M., eds. Impact of Energy Production on Human Health: An Evaluation of Means of Assessment. National Technical I n f o r m a t i o n Service, Springfield, Va. Pp. 65-74 (1976) Schneiderman, M.A. Sources, resources, and tsouris. meni, J.F., ed. Persons at High Risk of Cancer: proach to Cancer Etiology and Control. Academic N e w York .(1976) In FrauAn Ap Press, Hoel, D . C . , Gaylor, D . W . , Kirschstein, R.L., Saffiotti, U., and Schneiderman, M.A. Estimation of risks of irreversible, delayed toxicity. J. Toxicol. Environ. Health 1:133-151 (1975) Mantel, N . , and Schneiderman, M.A. Non-parametric interval estimation of relative potency for dilution assays, includ ing the case of non-monotone dosage response curves. B i o m e t r i c s 31 : 6 1 9 - 6 3 2 (1975) Mantel, N . , and Schneiderman, M.A. Estimating "safe" levels-- a h a z a r d o u s undertaking. Canc e r Res. 35:1379-1386 (1975) Schneiderman, M.A., Mantel, N., and Brown, C.C. From mouse to m a n -- or how to get from the laboratory to Park Avenue and 59tn Street. Ann. N.Y. Acad. Sci. 246:237-248 (1975) Schneiderman, M.A. How do you know you've done any better? Cancer 35:64-68 (1975) Schneiderman, M.A. Digestive system cancer among persons sub jected to occupational inhalation of asbestos particles: A literature review with emphasis on dose response. Environ. Health Perspect. 9:307-311 (1974) Schneiderman, M.A. Safe dose? The problems of the statistician in the w o r l d of trans-science. J. Wash. Acad. Sci. 64:6878 (1974) 12546 SCHNEIDERMAN, page 10 Fears, T . R . , and Schneiderman, M.A. Pathologic evaluation and the blind technique. S c i e n c e 1 8 3:1144-1145 (1974) Elashoff, R.M.. , Sobel, M. , and S c h n e i d e r m a n , M.A. A p roposal for economical first stage screening for tumorigens with a p o s s s i b l e "joint action" bonus. In Pratt, J.W., ed. Statistical and Mathematical Aspects of Pollution Problems. Marcel Dekker, New York (1974) Van Belle, G., and Schneiderman, M.A. Some statistical aspects of p o l l u t i o n and protection. Int. Stat. Rev. 41:315 (1973) Wynder, E.L., and Schneiderman, M.A. Exogenous hormones-- boon or culprit? JNCI 51:729-731 (1973) Gehan, E . A . , and Schneiderman, M.A. Experimental design of clinical trials. In Holland, J.F., and Frei, E., eds. Cancer Medicine. Lea and Febiger, Philadelphia. Pp. 499519 (1973) Schn e i d e r m a n , M.A., and Mantel, N. The Delaney clause and a scheme for rewarding good experimentation. Prev. Med. 2:165-170 (1973) Schneiderman, M.A., and Levin, D.L. Parallels, convergences, and d e p a r t u r e s in c a s e - c o n t r o l studies and c l i n i c al trials. Cancer Res. 33:1498-1503 (1973) Graham, S., and Schneiderman, M.A. Social epidemiology and the p r e v e n t i o n of cancer. Prev. Med. 1:371-379 (1972) Scotto, J., and Schneiderman, M.A. P r e d i c t i n g s u r vival in terminal cancer. Br. Med. J. 4:50 (1972) Schn e i d e r m a n , M.A., and Levin, D.L. T r ends in lung cancer: Mortality, incidence, diagnosis, treatment, smoking and u r b anization. C a ncer 3 0 : 1 3 2 0 - 1 3 2 5 (1972) Johnson, R.E., Thomas, L.B., Schneid e r m a n , M.A., Glenn, D . W . ., Faw, F., and Habermann, M.D. Preliminary experience with total nodal irradiation in Hodgkin's disease. Radiology 9 6 : 6 0 3 - 6 0 8 (1970) Schn e i d e r m a n , M . A . , and Scotto, J. C o m p u t e r - I n v e s t i g a t o r I n t e r act i o n s in S m a l l - S c a l e C l i n i c a l Trials. P r o c e e d i n g s of the Fifth Scientific Meeting of the International Epidemiol o g y Asso c i a t i o n , Primosten, Yugoslavia. Pp. 449-467 (1970) 12347 SCHNEIDERMAN, page 11 Gold, G.L., Shnider, B.I., Salvin, L.G., Schneiderman, M.A., Colsky, J., Owens, A.H., Krant, M.J., Miller, S.P., Frei, E., Ill, Hall, T.C. , Spurr, C.L., McIntyre, O.R., H o o g s traten, B. and Holland, J.F. The use of mechlorethamine, cyclophospha mide, and uracil m u s tard in neoplastic disease: A c o o p e r a tive study. J. Clin. Pharmacol. 10:110-120 (1970) Schneiderman, M.A. How to read the drug literature-- or any other organized collection of numbers from experiments. Mod. Med. 37:92-96 (1969) Malmgren, R.A., Bennett, J . M . , DelVecchio, P.R., DeWhitt, S.H., Feld, M . , Kazam, E . , and Schneiderman, M.A. Evaluation studies of p e r i p h e r a l blood leucocyte changes in malignancy. Acta Cytol. 13:149-153 (1969) Schneiderman, M.A. Q u a n t i t a t i v e thinking in m e d i c i n e -- b i o s t a tistics. (Using n u m b e r s to mark the route from cause to effect and back.) In Cantor, P . , e d . T r a u m a t i c Medi c i n e and Surgery for the Attorney. Matthew Bender, New York. ?p. 419-477 (1969) Givelber, H . , DiPaolo, J.A., and Schneiderman, M.A. The influence of' actinomycin D on survival of x-radiated RF mice. Cancer Res. 28:2484-2488 (1968) Pipberger, H . V . , Schneiderman, M.A., and Klingeman, J.D. The love-at-first-sight effect in research. Circulation 33:822825 (1968) Carbone, P.P., Spurr, C . , Schneiderman, M . A . , Scotto, J., Holland, J.F., and Shnider, B. M a n a g e m e n t of p a t ients with m a l i g n a n t lymphoma: A comparative study with cyclophosphamide and vinca alkaloids. Cancer Res. 28:811-822 (1968) Hall, T . C . , Nevinny, H.B., Holland, J.F., Maldia, G., Schneiderman M.A., Salvin, L . , Shnider, B.I., Gold, G.L., Frei, E., Ill, Carbone, P.P., Colsky, J., Franzino, A., Grob, D., Matiasevic, D . , Olson, K.3., Horton, J., Owens, A., Santos, G.W. , Chalmers, T.C. , and Krant, M.J. Comparison of antimetabolites in the treatment of breast and colon cancer. JAMA 200:770-778 (1967) Schneiderman, M.A. The Shin Tokaido to developing new treatments in medicine: Unbiase d n e s s . In Harris, R.J.C., ed. P r o ceedings of the 9th International Cancer Congress. SpringerVerlag, Heidelberg. Pp. 194-198 (1967) Bull, B.S., Schnei d e r m a n , M.A., and Brecher, G. S e m i - a u t o m a t i c d i l u t i o n s y s t e m for the h e m a t o l o g y laboratory. Am. J. Clin. Pathol. 47:549-553 (1967) S C H N E I D E R M A N , page 12 Schne i d e r m a n , M . A Mouse to man S t a t i s t i c a l p r o b l e m s in b r i n g i n g a W i.V* 11 A 4- r> 1 in i/-a VJiJ.nj.vCi trial. In LeCam, L., and Neyman, J., eds. Biology and Problems of Health. Univer- sity of C a l i f o r n i a Press, Berkeley. Vol. 4, pp. 855-866 (1967) Schneiderman, M.A. Non-objective art and objective evaluation of cancer c h e motherapy. In Brodsky, I., and Kahn, S.B., eds. Cancer Chemotherapy. New York, Grue and Stratton. Pp. 67-76 (1967) Spurr, C.L., Carbone, P.P., and Schneiderman, M.A. Comparative e v a l u a t i o n of c y c l o p h o s p h a m i d e and vinca a lkaloids in lymphomas. Proceedings of the 57th Annual Meeting of the A m e r i c a n A s s o c i a t i o n of C a n c e r R e s earch 7:67 (1966) Myers, M.H., S c h n e i d e r m a n , M . A . , and Armitage, P. Bo u n daries for closed (wedge) sequential t-test plans. Biometrika 5 3 : 4 31-437 (1966) Schneiderman, M.A. Experimental design considerations in m u l t i c l i n i c trials. In R a d o u c o - T h o m a s , C., exec. ed. I n t e r n a tional Encyclopedia of Pharmacology and Therapeutics. P e r g a m o n Press, Oxford. Vol. 2, pp. 617-636 (1966) Schneiderman, M.A. The value of controlled trials. In Hayward, J.L., and Bulbrook, R.D., eds. C l i n i c a l E v a l u a t i o n in B r e a s t Cancer. London, A c a d e m i c Press. Pp. 249-259 (1966) Cutler, S.J., G r eenhouse, S . W . ,.C o r n f i e l d , J., and S c h neiderman, M.A. T h e role of h y p o thesis testing in c l i nical trials. J. Chron. Dis. 1 9 : 8 57-882 (1966) Bourgeois, L.D., Hart, L.J., Herman, L.G., Schneiderman, M.A., and Young, V.M. Effect on varying preincubation and diffu sion times and antibiotic disc susceptibility testing. In Day, R.A., ed. A n t i m i c r o b i a l A g ents and C h e m o t h e r a p y -- 1965. W a v e r l y Press, Baltimore. Pp. 283-288 (1966) Sctmeiderman, M.A., and Krant, M.J. What shall we measure on whom: Why? Cancer Chemother. Rep. 50:107-112 (1966) Dawson, J.M., Hall, T.C., Schneiderman, M.A., Shnider, B.I., Owens, A.H., Andrews, J.R., Baxter, D.H., Brenner, S . , Hunter, C., Levene, M.B., Sheehan, F.R., and White, G. The o b j e c t i v e e v a l u a t i o n of change in tumor size in lung cancer patients with non-measurable disease. Cancer 19:415-420 (1966) SCHNEIDERMAN, page 13 Schneiderman, M.A. Looking backward: Is it worth the crick in the neck? Or: Pitfalls in using retrospective data. AJR 96:230-235 (1966) Bull, B.S., Schneiderraan, M.A., and Brecher, G. P l a t elet counts with the Cou l t e r counter. Am. J. Clin. Pathol. 45:678-688 (1965) S c h n e i d e r m a n , M.A. How can we find an optimal dose? Toxicol. A p p l . Pharmacol. 7, Supp. 2:44-53 (1965) Schneiderman, M.A. The optimal dose and the ranking of drugs. J. O r a l Ther. Pharmacol. 2 :118-119 (1965) Carbone, P.P., Krant, M.J., Miller, S.P., Hall, T.C . , Shnider, Colsky, J., Horton, J., Hofley, H., Miller, J.M., Frei, E.J., III, and Schneiderman, M.A. The feasibility of using r a n d o m i z a t i o n schemes early in the clinical trials of new chemotherapeutic agents: Hydroxyurea (NSC-32065). Clin. Pharmacol. Ther. 6:17-24 (1965) 3. Schneiderman, M.A. The proper size of a clinical trial: "Grand ma's strudel" method. J. N e w Drugs 4:3-11 (1964) Schneiderman, M.A. Defensive design of clinical trials. In Sternberg, T.H., and Newcomer, V.D., eds. The Evaluation of Therapeutic Agents and Cosmetics. McGraw-Hill, New York. Pp. 66-73 (1964) Sch neiderman, M.A., Myers, M.H., Sathe, Y.S., and Koffsky, P. Toxicity, the therapeutic index, and the ranking of drugs. S c i e n c e 1 4 4 : 1 2 1 2 - 1 2 1 4 (1964) Schnei d e r m a n , M.A. Is it really bad? A p r o p o s a l for the to x i c i t y - t e s t i n g of drugs. J. Soc. C o s m e t i c Chem. 14:227232 (1963) Sch n e i d e r m a n , M.A., and Armi t a g e , P. C l o s e d sequential t-tests. Bio m e t r i k a 49:359-366 (1962) Brecher, G., Jakobek, E.F., Schneiderman, M.A., Williams, G.Z., and Schmidt, P.J. Size distribution of erythrocytes. Ann. N.Y. Acad. Sci. 99:242-261 (1962) Sch n e i d e r m a n , M . A . , and Armitage, P. A f a mily of closed s e q u e n tial procedures. Biometrika 49:41-56 (1962) Schneiderman, M.A. The clinical excursion into 5-fluorouracil. J. Chron. Dis. 51:283-295 (1962) SCHNEIDERMAN, page 14 Schneiderman, M.A. Controlled clinical trials: Monday's count d own for T u e s d a y ' s launching. J. N e w D r u g s 1 :250-255 (1961) Schneiderman, M.A. S t a t i s t i c a l p r o b l e m s in the screening search for anticancer drugs by the National Cancer Institute of the U n i t e d States. In Q u a n t i t a t i v e M e t h o d s in P h a r m a c o l ogy. North Holland Publishing Co., Amsterdam. Pp. 232247 (1961) Zubrod, C.G., S c h n e i d e r m a n , M.A., Frei, E . , III, Brindley, G., Gold, G.L., Shnider, B . , Oviedo, R . , Gorman, J., Jones, R . , Jr., Jonsson, G., Colsky, J., Chalmers, T., Ferguson, B., Dderick, M . , Holland, J., Selawry, O., Regelson W . , Lasagna, L . , and Owens, A.H. Appraisal of methods for the study of c h e m o t h e r a p y of cancer in man: C o m p a r a t i v e therapeutic trial of nitrogen mustard and triethylene t h i o p h o s p h o r a m i d e . J. Chron. Dis. 11:7-33 (1960) Leiter, J., Wodensky, I., Bourke, A.R., and Schneiderman, M.A. Screening data from the Cancer Chemotherapy National Service Center screening laboratories, III. Cancer Res. 19:488575 (1959) Leiter, J., and Schneiderman, M.A. Screening data from the Cancer Chemotherapy National Service Center screening laboratories. Canc e r Res. 19:31-279 (1959) Schne i d e r m a n , M.A. M a t h e m a t i c a l m o d e l s in the r e g u l a t i on of granulocyte production. In Stohlman, F., Jr., ed. Kinetics of Cellular Proliferation. Grue and Stratton, New York. Pp. 259-264 (1959) Brindley, C.O., Markoff, E . , and Schneiderman, M.A. Direct o b servations of lesion size and number as a method of following the growth of human tumors. Cancer 12:139-146 (1959) Freireich, E.J., Schmidt, P.J., Schneiderman, M . A . , and Frei, v E. , III. A c o m p a r a t i v e study of the effe c t of transfusion of fresh and preserved whole blood on bleeding in patients with acute leukemia. N. Eng. J. Med. 2 6 0 :6-11 (1959) Armitage, P., and Schneiderman, M.A. Statistical problems in mass screening program. Ann. N.Y. Acad. Sci. 76:896908 (1958) Frei, E. , III, Holland, J.F., Schnei d e r m a n , M . A . , Pinkel, D., Selkirk, G. , Freireich, E.J., Silver, R.T., Gold, G.L., and Regelson, W.A. A comparative study of two regimens of c o m b i n a t i o n c h e m o t h e r a p y .in acute leukemia. B l o o d 13: 1126-1148 (1958) . . tri X /v o o .i. SCHNEIDERMAN, page 15 Schneiderman, M.A. Epidemiology of carcinoma of the.breast. Med. Ann. Dist. C o l u m b i a 27:275-280 (1958) Silver, R.T., Beal, G.A., Schneiderman, M.A., and McCullough, N.B. The role of the m a t u r e ne u t r o p h i l in b a cterial infections in acute leukemia. Blood 12:814-821 (1957) Stohlman, F., Jr., Brecher, G., Schneiderman, M.A., and Cronkite, I The h a e molytic effect of ionizing radiation and its r e l a t i o n ship to the hemorrhagic phase of radiation injury. Blood 12:1061-1085 (1957) Brecher, G . , Schneiderman, M . A . , and Williams, G.Z. Evaluation of an e l e c t r o n i c red blood cell counter. Am. J. Clin. Pathol. 2 6 : 1 4 3 9 - 1 4 4 9 (1956) Olivier, L . , and Schneiderman, M.A. A method for estimating the density of aquatic snail populations. Exp. Parasitol. 5:10 9 - 1 1 7 (1956) Stohlman, F . , Jr., and Schneiderman, M.A. Application of the c r ^ tech n i q u e to the study of e x p e r imental hemolysis in the dog. J. Lab. Clin. Med. 47:72-37 (1956) Cutler, S.J., Schneiderman, M.A., and Greenhouse, S.W. Some s t a t i s t i c a l c o n s i d e r a t i o n s in the study of cancer in industry. Am. J. P u b l i c H e a l t h 4 4 : 1 159-1166 (1954) Prehn, R.T., Main, J.M., and Schneiderman, M.A. Factors influ encing tumor distribution among the mammary glands of the mouse. JNCI 14:895-904 (1954) Olivier, L., and S c h n e i d e r m a n , M.A. A c q u i r e d resistance to s c h i s t o s o m a M a n s o n i infection in laboratory animals. Am. J. Trop. Med. H y g . 2:298-306 (1953) Brecher, G., Schneiderman, M.A., and Cronkite, E.P. The reproduc ibility and c o n s t a n c y of p l a t e l e t counts. Am. J. Clin. Pathol. 23:15-26 (1953) Heston, W.E., and Schneiderman, M.A. Analysis of dose-response in relation to m e c h a n i s m of pulmonary tumor induction in mice. Science 117:109-111 (1953) Plum, C.M., Clemmesen, J., and Schneiderman, M.A. In vitro study of bone m a r r o w v. e r y t h r o p o i e s i s of bone marrow from cases of pernicious anemia and leukosis. Acta Med. Scand. 143:237-248 (1952) 12 SCHNEIDERMAN, page 16 S c h n e i d e r m a n , M . A . , Mantel, N., and Brecher, G. T h e effect of rejection procedures on the accuracy of blood counts. u* v_.xj.ii* ira Lnuj.. 4-UJ ! Schneiderman, M.A., and Brecher, G. The relative freq uency of sparse cell elem e n t s -- an application to reticulocyte blood counts. Biometrics 6:390-394 (1950) Brecher, G., and Schneiderman, M.A. the counting of reticulocytes. 20:1074-1083 (1950) A time saving device for Am. J. Clin. Pathol. Williamson, C.R., and Schneiderman, M.A. The use of mass x-ray survey films for heart d i s e a s e case finding. Mass. H e a l t h J. 30:7-14 (1950) Di 1 c iic n J-* J 1 1__________ I J o iijje ry e iQ , "p n i _ t'n .u ., is an environmental scientist and toxicologist who is the Chief Toxicologist for the Environmental Defense Fund and a Research Scientist in the Reproductive Toxicology Laboratory of the National Institutes of Health in Bethesda, Maryland. Her curriculum vitae is attached. Dr. S i l b ergeld will testify as to the scientific models for TCDD toxicity. She will emphasize the receptor model, its role in physiology, how to detect receptors and how to link receptors to function. She will discuss how receptors recognize TCDD by virtue of structural "fine-tuning". She will testify as to the existence of receptors in humans and in their various organs, together with the implications of their presence for TCDD potency. She will also discuss the extrapolations which are possible between animals and humans. She will further testify as to the mechanisms of toxicity including the sensitivity of the reproductive system, both endocrine and gonadal, to the receptor-mediated effects of TCDD. Finally, she will discuss the consequences of receptor inter action with TCDD insofar as that interaction produces results involving RNA-DNA, AHH induction, and heme synthesis regulation, among others. In the field of neurotoxicity, she will discuss the experimental and clinical studies with particular emphasis upon dose-response mechanisms, acute versus chronic exposures and 12554early versus long latency effects. She will also discuss the biochemical and morphological effects of TCDD, the electro physiology involved and the effects of TCDD on such things as cognition, mood, and affect. She will also emphasize the basic mechanisms of toxicity on both the central and peripheral nervous systems, specifically dealing with the role of altered porphyrin synthesis on the nervous system. Three aspects of this problem will be discussed: First, the effects of decreased cellular energy supply on neuronal activity and viability; second, the effects of decreased heme systhesis on the integrity of myelin; and third, the neuroactive properties of certain porphyrin precursors. 12555 CURRICULUM VITAE Name: _ -Ellen Kovner Silbergeld Date and Place of B i r t h : July 29, 1945. Washington, DC Education: 1967 - A.B. 1972 - Ph.D. Vassar College Johns Hopkins University Chronology of E m p l o y m e n t : 1967 1968- 70 1969- 71 1972-75 1975 1975-79 1979-81 1982 Instructor, California International Summer Program, Uppsala Sweden Secretary and Program Officer. National Academy of Sciences. National Research Council, Washington. DC "Nader's Raiders", Center for the Study of Responsive Law. Washington, DC Postdoctoral Fellow in Environmental Medicine and Neurosciences, Johns Hopkins University. Baltimore. Maryland Assistant Professor. Department of Environmental Medicine, School of Hygiene and Public Health, Johns Hopkins University Staff Fellow and Head. Unit on Behavioral Neuropharmacology. Experimental Therapeutics Branch. NINCDS.NIH Chief, Section on Neurotoxicology, NINCDS.NIH Chief Toxics Scientist, Environmental Defense Fund, Washington, DC Guest Scientist, Reproductive Toxicology Section. Pregnancy Research Branch. NICHD.NIH Other Professional Appointments: Consultant. NSF Energy Program. 1974-1975 Member. Nutrition Foundation National Committee on Food Additives and Hyperkinesis. 1975-1980 Member. USDHEW-FDA Committee to Coordinate Toxicology and Related Programs. 1977-1981 Member, US Delegation of the Joint US-USSR Health Agreement on Environmental Health. 1977-78 Member, Society for Neuroscience Committee on Social Issues. 1978 Member. OECD Chemicals Program Ad Hoc Expert Review Committees on Reproductive Toxicity and Neurotoxicity. 1982 - 12556 Member, Member. Member. Member. Member. Member. US Delegation to OECD Expert Meetings on Existing Chemicals, 1983 Hazardous Waste Task Force and Hazardous Waste Facilities Siting Board. State of Maryland, 1983 Govenor's Blue Ribbon Panel on Binghamton. NY. State Office Building. 1982 Executive Committee. Science Advisory Board. US EPA, 1983 Board on Toxicology and Environmental Health Hazards. National Academy of Sciences. 1983 Public Policy Committee. American Society for Neurochemistry, 1983 - Professional Society Memberships: American Public Health Association Society for Occupational and Environmental Health Society for Neuroscience Association of Women in Science American Association for the Advancement of Science International Brain Research Organization American Society for Neurochemistry American Society for Pharmacology and Experimental Therapeutics Engineering Society of Baltimore Other Activities Secretary-Treasurer, Society for Occupational & Environ mental Health. 1983- Editorial Board: Neurobehavioral Toxicology. 1979American Journal of Industrial Medicine. 1980Neurotoxicology, 1981Environmental Research, 1983Hazardous Waste. 1983 - Participant. NIH Consensus conferences, 1979 and 1982 Expert consultant on lead poisoning. U.S. Secret Service. 1979-81 Chairperson. Society for Occupational and Environmental Health Special Committee on El Paso Lead Poisoning. 1977-1979 Preceptor, NIGMS Pharmacology-Toxicology Research Associateship Program. 1977-1981 Graduate board examiner. University of Pittsburgh and University of Toronto Lecturer, continuing medical education courses in environ mental medicine (Johns Hopkins) and occupational medicine (NIOSH) 2 \n E l e c t e d c o u n c i l l o r . NIMH-NINCDS A s s e m b ly o f S c i e n t i s t s . 1979-1981 E l e c t e d r e p r e s e n t a t i v e . NINCDS EEO C o m m i t t e e . 1 9 7 7 - 1 9 8 0 C o - ^ o r g a n i z e r , Women i n N e u r o s c i e n c e Member. S o lo w ey L e c t u r e s h i p s e l e c t i o n c o m m itte e , NIH, 1 AOA 1 no 1 J.7 0 U -1 7 0 1 E n viron m en tal H e a lth C o n su lta n t, O il. Chem ical and Atom ic Workers U n ion. AFL-CIO. W ashington. D .C .. 1970 R e v i e w e r . EPA d o c u m e n t s on l e a d , m a n g a n e s e . m ercury, d io x in , r is k a s s e s s m e n t, and e x p o su r e . 1981- Ad Hoc M ember, O c c u p a t i o n a l S a f e t y and H e a l t h S t u d y S e c t i o n . NIOSH, 1 9 8 3 - M e m b e r , NIMH C o m m i t t e e o n F r o n t i e r s o f N e u r o s c i e n c e . 1 9 8 3 G rants r e v ie w e r . N a tio n a l F oundation - March o f Dimes; N ational S cien ce Foundation: N u tritio n Foundation: T h ra sh er F o u n d a tio n ; H e r e d it a r y D i s e a s e s F o u n d a tio n . NIH M anuscript review er. L ife S c ie n c e s . Biochem ical Pharm acology. Environm ental Journal Pharm acology. S c ie n c e . N eu rotoxicology. N eurobehavioral T oxicology T eratology. Pharmacology B iochem ical B eh avior. P rocs. S o c iety Experim ental B io lo g ic a l M edicine. Experim ental N eurology, etc. Honors and Awards: G r a d u a t e d summa cum l a u d e , 19 6 7 e le c te d to Phi Beta Kappa. 1967 undergraduate academic sch o la rsh ip . 1963-1965 Woodrow W ilso n N a t io n a l F o u n d a tio n F e llo w , 1967-1968 Leverhulme and F u lb r ig h t F e llo w sh ip s to U n iv e r s ity of London, 1967 N a tio n a l S cien ce Foundation Graduate T ra in eesh ip . 1968-1972 P u b lic H e a lth S e r v ic e R esea rch F e llo w s h ip to Woods H o le, 1970 R ock efeller Foundation predoctoral research fello w sh ip . 1971-1972 NIH p o s t d o c t o r a l f e l l o w s h i p i n e n v ir o n m e n t a l h e a l t h scie n c e s, 1972-1972 Joseph P. Kennedy, J r . F e llo w sh ip in n e u r o sc ie n c e s. 1974-1975 Pharm aceutical M anufacturers A sso cia tio n Foundation Research S ta r te r Award. 1974-1975 N a tio n a l Academy of S c ie n c e s Exchange F e llo w to Y u g o sla v ia , 1976 George M iller lec tu r esh ip in environm ental stu d ie s. U n iv e r s ity of I l l i n o i s , 1984 P rofessional In terests: Neuropharm acology & T oxicology Environm ental Risk A ssessm ent 3 12558 BIBLIOGRAPHY ELLEN KOVNER SILBERGELD A. SCIENTIFIC PUBLICATIONS 1. S ilb e r g e ld . E.K.: D ie ld r in : E f f e c t s of chronic s u b le th a l exposure on a d a p ta tio n to thermal s t r e s s in a freshw ater fis h . Environ. Sci. Technol. 7:846-849, 1973. 2. S i l b e r g e l d . E. K . : and G oldberg, A .M .: A le a d -in d u c e d beh avior d i s o r d e r . L i f e S c i . 1J_(9): 1 2 75-1283, 1973. 3. S i lb e r g e ld , E. K . : Blood g lu c o s e : A s e n s i t i v e in d ic a t o r of environm ental s t r e s s in f i s h . B u ll. Environ. Contam. Toxicol l l( l) : 2 0 - 2 5 . 1974. 4. S i l b e r g e l d , E. K ., F a l e s . J . T. and G oldberg. A .M .: Lead: Evidence for a p r e ju n c tio n a l e f f e c t on neuromuscular function. Nature 247:49-50. 1974. 5. S i l b e r g e l d . E. K ., F a l e s , J. T. and G oldberg, A .M .: Lead: The e f f e c t s o f i n o r g a n i c le a d on th e n eurom uscu lar junction. Neuropharmacology 13.:146-157, 1974. 6 . S i l b e r g e l d , E. K. and G o l d b e r g . A . M . : L e ad i n d u c e d b e h a v i o r a l d y s f u n c t i o n : An a n i m a l m o d e l o f h y p e r a c t i v i t y . Exp. N eurol. 42:146-157, 1974. 7 . S i l b e r g e l d . E. K. and G o l d b e r g . A . M . : H y p e r a c t i v i t y : A lead induced behavior disorder. Environ. Health Persp. 7:227-232. 1974. 8 . S i l b e r g e l d , E. K. a n d G o l d b e r g . A . M . : P h a r m a c o l o g i c a l a n d neurochemical in v estig a tio n s of lead induced h y p e r a c tiv ity . Neuropharmacology 1.4:431-444, 1975. 9. M o r r i s o n . J . H . . O l t o n . D. S . . G o l d b e r g , A.M. and S i l b e r g e l d , E. K.: A l t e r a c t i o n s in consummatory b e h a v io r o f m ice produced by d i e t a r y e x p o su r e to i n o r g a n ic l e a d . D e v . P s y c h o b i o l . 8.( 5 ) : 3 8 9 - 3 9 6 . 1 9 7 5 . 10. S i l b e r g e l d . E.K.: Neurochem ical and p h a rm a co lo g ica l s t u d i e s o f c e n t r a l n e r v o u s s y s t e m l e a d t o x i c o l o g y . In. Carnow, B.W. ( e d . ) : H e a l t h E f f e c t s o f O c c u p a t i o n a l Lead a n d A r s e n i c E x p o s u r e . USDHEW. PHS, CDC, NI OSH. W a s h i n g t o n . D .C .. pp. 74-85. 1976. 4 531 C- O 1 1 . S i l b e r g e l d . E . K. and C h i s o l m . J . J . , J r . : L e a d poisoning: Altered urinary catecholamine m etabolites as i n d i c a t o r s of i n t o x i c a t i o n in mice and c h ild r e n . S c ie n c e 192.1153-155, 1976. 1 2 . F i t z g e r a l d , R. S . . G a r f i n k e l , F . , S i l b e r g e l d . E. K. and L o s c u to ff, S.C .: F actors in the in t e r p r e t a t io n of mouth o cclu sio n pressure during measurements of c h em o sen sitiv ity . Chest 70(1):145-149. 1976. 1 3 . S i l b e r g e l d . E . K. and G o l d b e r g . A. M . : H y p e r a c t i v i t y . I n G old b erg, A.M. and Hanin. I . ( e d s ) : B i o l o g y o f C h o l i n e r g i c F u n c t i o n . Raven P r e s s . New York. pp. 6 1 9 - 6 4 5 . 1976. 14. S i l b e r g e l d . E. K . : I n t e r a c t i o n s of lead and c a lciu m on th e synaptosom al uptake of dopamine and c h o l in e . L i f e S c i . 2 0 (2 ):309-318, 1977. 1 5 . C a r r o l l . P . T . , S i l b e r g e l d , E. K. and G o l d b e r g , A. M. : A lt e r a t io n of c e n tr a l c h o lin e r g ic fu n c tio n by chronic lead a ceta te exposure. Biochem. Pharmacol. 2^:397-402. 1977. 1 6 . S i l b e r g e l d , E . K. a n d P f e i f f e r . R. F . : D i f f e r e n t i a l e f f e c t s of three dopamine a g o n ists: Apomorphine. b r o m o c r ip tin e and l e r g o t r i l e . J. Neurochem. 2 8 :1 3 2 3 -1 3 2 6 . 1977. 1 7 . S i l b e r g e l d . E. K .: Na+ r e g u l a t e s r e l e a s e o f Ca++ sequestered in synaptosomal m itochondria. Biochem. B i o p h y s . R e s . Comm. 77. ( 2 ) : 4 6 4 - 4 6 9 , 1 9 7 7 . 1 8 . S i l b e r g e l d . E. K . . A d l e r , H. S . and C o s t a . J . L . : Subcellular lo c a liz a tio n of lead in synaptosomes. Res. Comm. Chem. P a t h o l . P h a r m a c o l . 1 7 : 7 1 5 - 7 2 5 . 1 9 7 7 . 1 9 . G o l d b e r g . A. M. a n d S i l b e r g e l d . E . K . : A n i m a l m o d e l s o f h y p e r a c t i v i t y In. H a n i n . I . a nd U s d i n , E. ( e d s . ) : A n i m a l M o d e ls o f P s y c h i a t r y and N e u r o l o g y . Pergamon P r e s s , New York. pp. 371-384. 1977. 2 0 . S i l b e r g e l d . E. K . . A d l e r . H. S . . K e n n e d y . S . and C a i n e . D. B .: th e r o l e s of p r e s y n a p t ic f u n c t i o n and h e p a t ic drug m etab olism in the hypotherm ic a c t i o n s of some n o v e l d opam inergic a g o n i s t s . J. Pharm. Pharmacol. 2 9 :6 3 2 -6 3 5 . 1977. 5 12560 21. S i l b e r g e l d . E. K . : Neuropharmacology of h y p e r k in e s is . In V a l z e l l i . L . a n d E s s m a n . W. B . ( e d s . ) : Cu r r e n t Developments in Psychopharm acoloav. v o l. 4, pp. 181-214. 1977. 2 2 . S i l b e r g e l d . E. K. an d A d l e r . H. S . : S u b c e l l u l a r m e c h a n i s m s of lead n eu rotoxicity. Brain Res. 148(2):451-567. 1978. 2 3 . S i l b e r g e l d , E. K . . C a r r o l l . P. T. and G o ld b e r g . A. M . : N eurotoxicity of lead: A review of experimental stu d ies. Proc. I n te r n a tio n a l C onference on Heavy M etals in the Environment. U n iv e r s ity of Toronto P ress. Toronto. Canada, pp. 213-228. 1978. 2 4 . S i l b e r g e l d . E . K. a n d C o s t a . J . L . : s y n a p t o s o m a l c a l c i u m m etabolism s tu d ie s by e le c t r o n microprobe a n a l y s is . Exp. N eurol. 63_:277-292. 1979. 2 5 . C a i n e . D. B . . K e b a b i a n , J . . S i l b e r g e l d . E. K. and E v a r t s . E.: Advances in the neuropharmacology of Parkinsonism. A n n . I n t . Med. 90. ( 2 ) : 2 1 9 - 2 2 9 . 1 9 7 9 . 26. S i l b e r g e l d , E.K. and W a lte r s. J . R . : Synaptosomal uptake and r e l e a s e of dopamine in s u b s t a n t ia n ig r a : e f f e c t s of GABA a n d s u b s t a n c e P . N e u r o s c i . L e t t . 2 _ : 1 1 9 - 1 2 6 , 1 9 7 9 . 27. W alsh, M.J. and S i l b e r g e l d , E. K. : Rat r o t a t i o n m o n ito r in g for pharmacology research. Pharmacol. Biochem. a Behavior 10:433-436. 1979. 28. Hruska. R . E . . Kennedy. S . , and S i l b e r g e l d . E.K.: Q u a n tita tiv e a sp ects of normal locom otion in r a ts. Life Sciences 25/.171-179. 1979. 2 9 . H ruska, R.E. and S i l b e r g e l d . E. K . : Abnormal lo c o m o tio n i n rats after b ila te r ia l in tr a s tr ia ta l in jectio n of kainic acid . L ife Sciences 25.:181-193 , 1979. 30. S i l b e r g e l d . E.K.. Hruska. R . E . . Weir. R .. and Kennedy, S.W.: Dopaminergic and s e r o t o n e r g ic e f f e c t s of ergot d r u g s . I n : F u x e , K. an d C a i n e , D . B . . e d s . D o p a m i n e r g i c E rgot D e r i v a t i v e s and Motor F u n c t i o n . Pergamon. Oxford, pp. 223-235. 1979. i l . Lafferm an, J . A . . and S i l b e r g e l d , E.K.: E r y th r o s in B in h ib it s dopamine tran sp ort in rat caudate synaptosom es. Science 205:410-412. 1979. 6 32. S i l b e r g e l d . E.K.. M i l l e r , L . P . . Kennedy, S . . and Eng. N . : L e a d , GABA a n d s e i z u r e s : e f f e c t s o f s u b e n c e p h a l o p a t h i c lead exposure on s e i z u r e s e n s i t i v i t y and GABAergic f u n c t i o n . E n v i r o n . R e s . .19.: 3 7 1 - 3 8 2 . 1 9 7 9 . 33 . S i l b e r g e l d . E.K. and H ru sk a. R . E . : E f f e c t s o f e r g o t d cu y on s e r o t o n e r g ic f u n c tio n : b ehavior and n e u r o c h e m istr y . Eur. J. Pharmacol. 58:1-10. 1979. 34. S i l b e r g e l d . E.K. and Hruska. R. E. : E f f e c t s o f k a i n i c a c id on b e h a v io r a l and b io c h e m ic a l a s p e c t s o f c h o l i n e r g i c f u n c t i o n . In: Chase, T . N . . W exler, N . S . . and Barbeau, A ., e d s . . Advances i n N e u r o lo g y , V o l . 23 ( H u n t i n g t o n 's D is e a s e ) . Raven. N . Y . . pp. 633-644, 1979. 3 5 . S i l b e r g e l d . E. K. and H r u s k a . R . E . : L i s u r i d e an d LSD: Dopam inergic and s e r o t o n e r g i c i n t e r a c t i o n s in the "serotonin syndrome". Psychopharmacology 5:233-237, 1979. 36. S i l b e r g e l d . E.K. and Hruska. R. E. : Tremor: R ole of s t r i a t a l c h o l in e r g ic neurons and the e f f e c t of in tra stria ta l kainic acid. Neurosci. Letters 15:235-242. 1979 . 37. S i l b e r g e l d , E.K. and G oldb erg, A . M . : Problems in ex p erim en ta l s t u d i e s of lead p o is o n in g . In S in g h a l, R.D. and Thomas. J. A. ( e d s . ) : Lead T o x i c i t y . B a ltim o r e : Urban and Schw artzenberg. pp. 1 9 -4 2 . 1980. 38. Hruska, R.E. and S i l b e r g e l d , E.K.: E str o g en trea tm en t enhances dopamine receptor s e n s i t i v i t y in the rat striatum . Eur. J. Pharmacol. 2:397-400, 1980. 39. S i l b e r g e l d . E. K. , G o l d s t e i n . G.W.. and W o lin sk y . J . : E lectron probe m icroanalysis of iso la te d brain c a p illa r ie s poisoned with lead. Brain Res. 189:369-376, 1980. 40. S i l b e r g e l d , E. K. , Hruska. R . E . . M i l l e r , L . P . , and Eng. N . : E f f e c t s o f l e a d in. v i v o and in. v i t r o on GABA ergic n e u r o c h e m i s t r y . J . N e u r o c h e m . 34.: 1 7 1 2 - 1 7 1 8 , 1 9 8 0 . 41. Hruska, R.E. and S i l b e r g e l d . E.K.: In c r ea se d dopamine recepton s e n s itiv ity after estrogen treatment using the rat r o ta tio n model. Science 208:1466-1468. 1980. 42. Hruska, R.E. and S i l b e r g e l d . E.K.: C o r t ic a l neuroch em ical changes after in tr a str ia ta l in jectio n of kainic acid. Brain Res. 191:572-576. 1980. 7 12562 43. Hruska. R.E. and S i l b e r g e l d . E. K. : E f f e c t o f e r g o t d e r i v a t i v e s o n p o s t - d e c a p i t a t i o n c o n v u l s i o n s . Commun. P s y c h o p h a r m . 4.: 5 7 - 6 2 . 1 9 8 0 . AA Urne lra T.n^mer04 1 4 U U U U 4V 4J | U U 441II*M 4 I u ir\A C i 1 K r c t l t? ir Hypophysectomy prevents the s t r i a t a l dopamine receptor s u p e r s e n s i t i v i t y produced by c h r o n ic h a lo p e r id o l t r e a t m e n t . E u r . J . P h a r m a c o l . 6J5 : 4 5 5 - 4 5 6 ( 1 9 8 0 ) . 45. S i l b e r g e l d . E.K. and Hruska. R. E. : Neurochem ical in v e s t ig a t io n s of low l e v e l lead exposure. In: Needleman, H . L . . e d . . Low L e v e l Lead E x p o s u r e : The C l i n i c a l I m p lic a tio n s of Current R e se a r ch . Raven. N . Y . . pp. 135-157,1980. 46. Hruska. R.E. and S i l b e r g e l d . E. K. : I n h i b i t i o n of [ H ] s p ? r o p e r i d o l b i n d i n g by in. v i t r o a d d i t i o n o f eth an ol. J. Neurochem. 35.:750-752, 1980. 4 7 . S i l b e r g e l d , E . K . , and Lamon. J . M. : R ole o f a l t e r e d heme s y n t h e s i s i n l e a d n e u r o t o x i c i t y . J . Occup. Med. 22:680-684. 1980. 4 8 . H ru sk a. R. E. . Ludmer, L. M. , and S i l b e r g e l d . E. K.: C h a ra cteriza tio n of the s t r i a t a l dopamine receptor s u p e r s e n s i t i v i t y produced by e s t r o g e n trea tm en t of male r a t s . N e u r o p h a r m a c o l . 19.: 9 2 3 - 9 2 6 . 1 9 8 0 . 4 9 . S i l b e r g e l d , E. K . : D e t e c t i o n o f n e u r o t o x i c i t y u s i n g n e u r o c h e m i c a l m e t h o d s I n : R. M. G r y d e r and V. H. F r a n k o s , ( e d s . ) . The E f f e c t s o f Foods and Drugs on th e Development and F u n c tio n of th e Nervous System : Methods fo r P r e d i c t i n g T o x i c i t y . FDA ( N o . 8 0 - 1 0 7 6 ) , W a s h i n g t o n . D . C . , p p . 9 9 - 1 0 5 . 1980. 50. S i l b e r g e l d . E. K . : E r y t h r o s in B i s a s p e c i f i c i n h i b i t o r of h i g h a f f i n i t y 3H -o u a b a in b i n d i n g and i o n t r a n s p o r t i n r a t b r a i n . N e u r o p h a r m a c o l . 20.: 8 7 - 9 0 . 1 9 8 1 . 51. S i l b e r g e l d . E. K . . and C ain e, D. B .: Animal models o f p a r k i n s o n i s m . P h a r m a c o l . T h e r . 12.: 1 5 9 - 1 6 6 , 1 9 8 1 . 5 2 . G o u d s m it . J . . Rohwer, R. G . . S i l b e r g e l d , E. K . . and G a d j u s e k . D. C .: H y p e r s e n s i t i v i t y o f c e n t r a l s e r o t o n i n r e c e p to r a c t i v a t i o n in s c r a p i e - i n f e c t e d ham sters and the e f f e c t s of s e r o to n e r g ic drugs on sc r a p ie symptoms. B rain Res. 220: 372-377, 1981. 8 12563 5 3 . H r u sk a , R. E . , and S i l b e r g e l d , E. K.: I n h i b i t i o n o f n e u r o tr a n s m itte r b in d in g by e r g o t d e r i v a t i v e s . J. N e u r o s c i . R e s . 6.: 1 - 1 1 . 1 9 8 1 . 54. S i l b e r g e l d . E. K=. Lamon, J. M .. B r a d le y . D . . Hruska, R . E . . P itm a n . K . , H e s s . R. A . , and Frykholm . B. C . : Heavy m e t a l n eu r o to x ic ity ; porphyrinopathic mechanisms. Procs. I n t e r n a t . Symp. o n H e a v y M e t a l s . WHO-EEC-EPA. A m s t e r d a m , pp. 561-564. 1981. 55. Chisolm. J. J . , and S ilb e r g e ld . E.K.: Increased e x c r e tio n of hom ovanillic acid in children with increased lead a b s o r p t i o n . P r o c s . I n t e r n a t . Symp. on Heavy M e t a l s . WHO-EEC-EPA. A m s t e r d a m , p p . 5 6 5 - 5 6 8 , 1 9 8 1 . 5 6 . W e ir , R. L . . H r u sk a , R. E . . and S i l b e r g e l d , E. K.: B i n d i n g of a n tip a r k in so n ia n erg o t d e r iv a t iv e s to the dopamine r e c e p t o r . P s y c h o p h a r m a c o l . 75.: 1 1 9 - 1 2 3 , 1 9 8 1 . 57. S i l b e r g e l d . E.K.: N eurochem ical and io n ic mechanisms of l e a d n e u r o t o x i c i t y . I n : ( V e r n a d a k i s , A . , a n d P r a s a d . K. N . , ( e d s . ) . Mechanisms of A ction of neurotoxic Sub stances. Raven. New York, pp. 1 - 2 4 . 1 9 82. 5 8 . H r u s k a , R. E . . P i t m a n . K. T . . S i l b e r g e l d , E. K . . and Ludmer, L. M .: P r o l a c t i n i n c r e a s e s th e d e n s i t y of s t r i a t a l dopamine r e c e p t o r s in normal and h y p o p h y secto m ized male r a ts. L ife Sci. 10: 547-553. 1982. 5 9 . H r u s k a , R. E . , L u d m e r . L. M . . P i t m a n , K. T . . D e R y c k . M . . and S i l b e r g e l d . E. K . : E f f e c t s of e s t r o g e n on s t r i a t a l dopamine r e c e p t o r f u n c t i o n in male and fem ale r a t s . Pharmacol. Biochera. Behav. 16: 285-291, 1982. 60. S i l b e r g e l d , E. K . , and Anderson. S. M .: A r t i f i c i a l food c o l o r s and c h ild h o o d b e h a v io r a l d i s o r d e r s . B u l l . N.Y. A c a d . Med. 58.: 3 7 5 - 2 9 5 , 1 9 8 2 . 61. M o r r i s . S. J . , S i l b e r g e l d . E. K ., Brown. R. R . , and H ayn es. D. N . : E r y t h r o s i n B (USFD&C Red 3 ) i n h i b i t s c a l c i u m t r a n s p o r t and ATPase a c t i v i t y of m uscle s a r c o p la s m ic r e t i c u l u m . B i o c h e m . B i o p h y s . R e s . Commun. 1 0 4 : 1 3 0 6 - 1 3 1 1 , 1982. 62. S ilb er g e ld , E.K.: Current sta tu s of neurotoxicology, basic and a p p lie d . Trends in N e u r o s c i. 8.:291-294, 1982. 9 12564 63. S ilb e r g e ld , E.K., Anderson. S . M . . and M orris. S . J . : I n t e r a c t i o n s o f e r y t h r o s i n B ( U . S . F. D & C Red 3) w i t h r a t c o r t i c a l membranes. L ife S c i. 3.1:957-969. 1982. 64. S i l b e r g e l d . E. K . . H ruska, R. E . . B r a d l e y . D . . Lamon. J . M ., and Frykholm, B. C.: N e u r o t o x ic a s p e c t s of p o r p h y r in o p a t h ie s : lea d and s u c c i n y l a c e t o n e . E nviron. Res.. 22:459-471. 1982. 65. S i l b e r g e l d . E. K.: E xp erim ental and environm ental n e u r o t o x in s : c o r r e l a t i o n of b e h a v io r a l and b io c h e m ic a l e f f e c t s . I n L e v y . M. a n d S p i e g e l s t e i n . A. ( e d s . ) B e h a v io r a l Models and t h e A n a l y s i s o f Drug A c t io n E l s e v i e r - N o r t h H o lla n d . Amsterdam, pp 2 9 7 - 3 1 5 . 1 9 8 2 . 66. DeRyck. M .. Hruska. R.E. , and S i l b e r g e l d , E.K.: E str o g en and h a lo p e r id o l-in d u c e d v e r su s h a n d lin g - r e la t e d c a t a l e p s y in male r a ts . Pharmacol. Biochem. Behav. 17:1027-1035. 1982. 67. S i l b e r g e l d . E. K.. Lafferm an. J . . and F in k e l. T .: In v i t r o t e s t i n g f o r n e u r o t o x i c i t y . In: K o l b e r . A . . Wong, T . K . , Grant. L.D.. Dewoskin, R . S . . and Hughes. T.J. (e d s) . In V i t r o T o x i c i t y T e s t i n g o f E n v ir o n m e n t a l A g e n t s . New York, Plenum, pp 4 7 3 - 4 8 6 . 1 9 82. 68. S i l b e r g e l d . E . K. , and Lamon. J . M. : E f f e c t s of a l t e r e d porphyrin s y n t h e s i s on b ra in n e u r o c h e m istr y . Neurobehav. T o x i c o l . T e r a t o l . 4.: 6 3 5 ~ 6 4 2 * 1 9 8 2 . 6 9 . H r u s k a , R. E . , W e i r , R. L . . P i t m a n . K. T . . and S i l b e r g e l d , E . K . : E r g o t d e r i v a t i v e s a r e p o t e n t d r u g s a t CNS a m i n e r g i c r e c e p t o r s : c o r r e l a t i o n s to b eh a v io r and a g in g . In: A g n o li. A .. Trabucchi. M .. and Spano. P. F. ( e d s ) . Aging B r a i n and E r g o t A l k a l o i d s . New York. Raven, pp 2 1 5 - 2 2 6 . 1983 . 70. S ilb erg eld , E.K.: Experimental stu d ies of lead n eu ro to x icity : Im plications for mechanisms, dose-resp on se, a n d r e v e r s i b i l i t y . I n R u t t e r . M. , a n d R u s s e l l - J o n e s , R. ( e d s ) Lead V ersus H e a lt h . London, John W ile y , pp 1 9 1 - 2 1 6 , 1983 . 71. S ilb e r g e ld . E.K.: E f f e c t s of lead on rep rod u ction : a r ev iew of e x p erim en ta l s t u d i e s . In R u tte r , M .. and R u s s e l l - J o n e s . R. ( e d s ) Lead V e r s u s H e a l t h . London. Joh n W ile y , pp 2 1 7 -2 2 7 . 1983. 10 --------- 12565 72. S ilb erg eld . E.K.: In d irectly acting neurotoxins. Acta P s y c h i a t . S c a n d . 67. S u p p l . 3 0 3 , 1 6 - 2 5 , 1 9 8 3 . 73. M attison. D.R.. Takizawa, K .. S ilb erg eld , E.K.. N i g h t i n g a l e , M . S . , J e r i n a , D .. and Y a g i, H.: G e n e t ic s of o v a r ia n b e n z o (a )p y r e n e , m etabolism , o o c y te d e s t r u c t io n , and im paired f e r t i l i t y . In Rydstrom, J . . M o n t e l u i s , J . , and B e n g t s s o n , M. ( e d s ) E x t r a h e p a t i c D r u g M e t a b o l i s m a n d C hem ical C a r c i n o g e n e s i s . Amsterdam. E l s e v i e r , pp 3 3 7 - 3 5 0 . 74. S ilb ergeld . E.K.: L ocalization of lead: im plications for mechanisms of n e u r o to x ic ity . N e u r o to x ic o l. :193-200, 1983. 11 - -t n w `if* ..n> b IN PRESS: S ilb e r g e ld . E.K.: B ehavioral t e r a to lo g y of lead . In Yanai. J. (ed) Behavioral T eratology. E lsevier/N orth Holland. S ilb ergeld , E.K.: N eurotoxicity of lead. Blum, J. (eds) Neurot o x i c o l o g y . Dekker. In Manzo. L. and F ow ler. B . F . , and S i l b e r g e l d , E.K.: Mechanisms of m etal t o x i c i t y . In N riagu. J . . and H ornig. D.F. (ed s) Changing G e o c h e m i c a l C y c l e s o f M e t a l s an d I m p l i c a t i o n s f o r Human H ealth. B erlin. Springer Verlag. M a ttiso n . D. R. , and S i l b e r g e l d . E.K.: O ccu p ation al r i s k s to r e p r o d u c t i o n . In O s o f s k y . H. ( e d ) A d v a n c e s i n G y n e c o l o g y and O b s t e t r i c s . B a lt im o r e . W illia m s & W ilk in s . S ilb e r g e ld . E.K.: M itochondrial mechanisms of lead n e u r o t o x i c i t y . In N a r a h a s h i. T. (ed ) C e l l u l a r and M olecular Mechanisms of Environmental N eu rotoxin s. P r e s s . NY. i n p r e s s . Raven S ilb e r g e ld . E.K.: Review of o c c u p a tio n a l h e a lth s t u d ie s on P C B s . I n K u i p e r , H. ( e d ) P C B s . M a r c e l D e k k e r . i n p r e s s . S i l b e r g e l d . E . K . : E f f e c t s o f PCBs i n O c c u p a t i o n a l P o p u l a t i o n s . In V i s s e r . R. ( e d ) P C B s . Amsterda m, E l s e v i e r . M a ttiso n . D . R . , and S i l b e r g e l d . E.K.: R eprodu ctive t o x i c i t y o f TCDD. I n L o w r a n c e , W. ( e d ) D i o x i n s . R o c k e f e l l e r University Press. IN PREPARATION: S i l b e r g e l d , E. K. , and M a tt is o n , D. R. : E f f e c t s of t h r e e p o l y c y c l i c arom atic hydrocarbons on f e r t i l i t y in fem ale mice: A life tim e study of the e f f e c t s of sin g le -d o se treatment. S ilb erg eld . E.K.: A Textbook in N eurotoxicology. 12 12567 B. ABSTRACTS 1. S i lb e r g e ld . E. K . : E f f e c t s of lea d on neurom uscular f u n c t i o n s : In v i t r o evid en ce for s i t e of a c tio n a t the presynaptic l e v e l . Fed. Proc. 32.:275, 1973. 2 . S i l b e r g e l d , E. K. and G o l d b e r g , A. M . : L e a d p o i s o n i n g : a n animal model of h y p e r a c tiv ity . Pharm acologist 15.:143, 1973. 3 . S i l b e r g e l d , E. K. a n d G o l d b e r g , A. M . : cholinergic-am inergic in tera ctio n s in lead induced h y p e r a c tiv ity . Pharm acologist 16.:335. 1974. 4 . G o l d b e r g , A. M. a n d S i l b e r g e l d , E . K . : N e u r o c h e m i c a l a s p e c ts of lead induced h y p e r a c t i v i t y . Trans. Amer. Soc. Neurochem. p.185. 1974. 5 . S i l b e r g e l d . E . K . , C a r r o l l . P . T . a n d G o l d b e r g . A. M. : Monoamines in lead -in d u ced h y p e r a c t iv it y . P harm acologist 13:203, 1975. 6 . G o l d b e r g . A. M . . C a r r o l l . P. T. and S i l b e r g e l d . E. K. : Cholinergic aspects of hyperactivity. F ifth Internatl. Meeting for Soc. Neurochem., 1975. 7 . P f e i f f e r . R. . and S i l b e r g e l d . E. K . : D i f f e r e n t i a l b e h a v io r a l and n e u r o c h e m ic a l e f f e c t s of. t h r e e d o p a m in e rg ic a g o n is t s . N eu rosci. Abst. I_I:720. 1976. 8 . S i l b e r g e l d . E. K. a n d M i l l e r . L. P . : L e a d i n t o x i c a t i o n : changes in s e iz u r e t h r e s h o ld and gamma-aminobutyric a c id fu n c tio n . Neurology 4.(27) :405, 1977. 9 . A d l e r . H. S . and S i l b e r g e l d . E. K . : I n t r a s y n a p t o s o m a l i n t e r a c t i o n s of lead and ca lciu m in dopam inergic n e u r o tra n sm issio n . P h a rm a co lo g ist 19.(2) :40, 1977. 1 0 . S i l b e r g e l d . E. K. and W a l t e r s , J . R . : D o p a m i n e u p t a k e and relea se in substantia nigra: E ffec ts of gamma-aminobutyric a c id and s u b sta n c e P. P h a r m a c o lo g is t 19.(2) :544. 1977. 11. S i l b e r g e l d . E. K .. M i l l e r . L. P . . Kennedy, S. a n d .E n g . N . : Lead and s e i z u r e s : R o le o f gamma-aminobutyric a c i d . Neurosci. Abst. I l l :1039. 1977. 1 2 . A d l e r . H. S . C o s t a , J . L. an d S i l b e r g e l d . E. K . : X - r a y m ic r o a n a ly s is in n eu roch em istry: L o c a l i z a t i o n of an 13 ^ l elemental neurotoxin and manipulations of mitochondrial Ca++. Neurosci. Abst. ITI:1235. 1977. 13 Baring. M. D . , Wa lters, J . R .. Silbergeld. E. K.. Eng. N.. and L a k o s k i , J ILXI .- UT?i-.P i-.FO f l tL. nWfJL systemic apomorphine on firing rates of dopamine cells in rats with striatal kainic acid lesions. Neurosci. Abst. 4. 267. 1978. 14. Hruska, R. E. and Silbergeld. E. .: Ergot drugs inhibit spiroperidol and serotonin receptor binding. Soc. Neurosci. Abst. 4.: 425, 1978. 15. Silbergeld, E. K., Hruska. R. E., Walters. J. R., Kennedy. S.. Eng. N.. and deSantis, S.: Effects of intrastriatal kainic acid on motor behavior in rats. Soc. Neurosci. Abst. 4: 49. 1978. 16. Kennedy, S., Hruska. R. E., and Silbergeld, E. K.: Serotonergic-dopaminergic effects of ergot drugs. Soc. Neurosci. Abst. 4.: 426, 1978. 17. Silbergeld, E. . Hruska, R. E., Lamon. J. M . . Frykholm. B. F.. and Hess. R. A.: Neurotoxic mechanisms in porphyria and lead intoxication: Possible role of a-aminolevulinic acid. Clin. Res. 27:307A. 1979. 18. Lamon. J. M . , Silbergeld. E. K.. Frykholm, B. F.. and Hruska. R. E.: Extra-erythropoietic heme metabolism in lead intoxication. Clin. Res. 27: 299A, 1979. 19. Silbergeld. E. K.. Hruska. R. E.. Lamon. J. M . . Frykholm. B. F., and Hess. R.A.: The effects of lead (Pb) on hepatic heme synthesis and drug metabolism. Pharmacologist 21.: 209. 1979. 20. Silbergeld, E. K . , Hruska. R. E.. and Lafferman, J. A.: Actions of lead (Pb) on GABAergic neurotransmission: Discrepancies between in vivo and in vitro effects. Soc. Neurosci. Abst. 5.: 416, 1979. 21. Lafferman. J. and Silbergeld, E. K.: Erythrosin B (Food, Drug and Cosmetic Red No. 3) inhibits dopamine uptake in rat caudate s y n a p tosomes: a kinetic study. Soc. Neurosci. Abst. 5. 562. 1979. 22. Hruska. R. E. and Silbergeld, E. K . : Increased dopamine receptor sensitivity after estrogen treatment. Soc. Neurosci. Abst. 5.: 73 (1979), No. 236. 14 12569 23. Silbergeld. E. K . . Hruska. R. E.. Schwarcz. R.: GABA in the basal ganglia: effects of selective lesions. Brain Res. Bull., 4: 696, 1979. 24. Weir. R. L., Hruska. R. E. and Silbergeld. E. K . : Effects of dopamine agonists on 3H-spiroperidol receptor binding. Soc. Neurosci. Abst. 5: 81, 1979. 25. Hruska, R. E.. Ludmer. L. M . , and Silbergeld, E. K.: Prolactin increases the number of striatal dopamine receptors. Pharmacologist 22:220 (1980), No. 338. 26. Silbergeld, E. K.: Erythrosin B: ouabain-like actions of an artificial food dye in rat brain tissue. Pharmacol. 22.: 198, 1980. 27. Hruska, R. E., Ludmer. L. M . . and Silbergeld. E. K.: The striatal dopamine receptor supersensitivity produced by estrogen may be mediated through prolactin. Soc. Neurosci. Abst. 6: 441. 1980. 28. Chisolm. J. J., and Silbergeld. E. K . : Increased excretion of homovanillic acid (HVA) in urine by young children with increased lead absorption. Neurosci. Abst. vol. 6^508. 1980. 29. Silbergeld, E. K.. and Anderson, S. M . : Erythrosin B: specific inhibitor of high affinity [3H]-ouabain binding and ion transport in rat brain. Neurosci. Abst. vol. 6.:56, 1980. 30. Silbergeld. E. K . . Anderson. S. M . . DeRyck. M . . C h ro n w a l l , B., and Morris, S. J.: Neurotoxicity of an artificial food color (erythrosin B): methods for rapid testing. Abstr. 8th Meeting Internat. Soc. N e u r o c h e m . . p. 238, 1981. 31. Ptiman. K. T.. Hruska, R. E.. Ludmer. L. M . , and silbergeld. E. K . : Prolactin increases the density of striatal dopamine receptors in normal and hypophyse.ctomized male rats. Soc. Neurosci. Abstr. 7: 217, 1981. 32. DeRyck. M . . Hruska. R. E.. and Silbergeld, E. K.: Estrogen potentiates haloperidol-induced catalepsy/akinesia in male rats. Soc. Neurosci. Abstr. 7: 217. 1981. 33. Silbergeld, E.K.: The biochemical basis of lead neurotoxicity. Abstr. Ann. Mtg. A A A S , Toronto. 1981. 15 12570 34. Hruska, R. E.. Pitman. K. T., Ludmer. L. M . . DeRyck, M . . and Silbergeld. E. K . : Comparison of the biochemical and behavioral effects of estrogen in male and female rats. So-Cr Neurosci. Abstr. 7: 218, 1981. 35. Silbergeld, E. K . , Morris, S. J., and Anderson. S. M . : Erythrosin B and N a ,K - A T P a s e : receptor-like interactions with brain synaptic membranes. Soc. Neurosci. Abstr. 7: 105. 1981. 36. Silbergeld. E. K . : Basic and applied neurochemistry of hazards. Abstr. Annual Meet. A A A S . Washington. D.C., p. 63. 1982. 37. Silbergeld. E. K.: Neurotoxic implications of altered heme synthesis in lead poisoning. Neu r o t o x i c o l . 3/.119-120, 1983 . 38. Silbergeld. E. K . , Nightingale. M. S.. and Mattison, D. R . : Effect of oocyte destruction by polycyclic aromatic hydrocarbons (PAH) on fertility of DBA/2N (D2), C57BL/6N (B6), and (D2 x B6) FI mice. Soc. Gynecol. Invest. A b s t r . . p. 51. 1983. 39. Silbergeld. E.K., Nightingale, M.S.. Godlove. K . . Malley, J . . and Mattison, D.R.: Reproductive toxicity of polycyclic aromatic hydrocarbons (PAHs) in female mice. Pharmacol.. 21:655. 1983. 40. Mattison. D.R., Takizawa. K . . Silbergeld. E.K., Nightingale. M.S., Jerina, D., and Yagi, H . : Genetics of ovarian benzo(a)pyrene metabolism, oocyte destruction, and impaired fertility in inbred DBA/2N and C57BL/6N mice and D2xB6 FI heterozygote mice. Abstr. Internat. Conf. Extrahepatic Metabolism of PAHs and Carcinogenesis. 1983. 41. Mattison, D.R., and Silbergeld, E.K.: Occupational exposures and pregnancy, Abstr. 15th Ann. Cong. Col. Soc. Obstet. Gynecol., Bucarananja, Columbia, 1983. 42. Mattison. D.R.. Nightingale. M.S.. Shiromizu. K . . Takizarva K . . Silbergeld, E.K., Kay. H.H., and Swartz. W.J.: Ovarian toxicity. Abstr. 15th Ann. Cong. Col. Soc.. Obstet. Gynecol. Bucaramanga, Colombia, 1983. 43. Swartz, W . . Silbergeld. E.K.. Malley. K . , and Mattison. D.R.: The effects of benzo(aJpyrene on urine ovarian function and fertility. Abstr. Amer. Assoc. Anat., in press. 1984. 16 ----- 12571 OTHER PUBLICATIONS REVIEWS Silbergeld. E.K.: "Lead in Man and the Environment" for Trends in Pharmacological Sciences. 1981 Silbergeld. E.K.: "Hazardous Waste in American" for Quarterly Review of Biology, in press Silbergeld. E.K.: "Nutrition and Brain Function" for Trends in Neurosciences, in press OTHER Silbergeld. E.K.: "US Lead Program Vital" (editorial) Clin. Chem. News. February. 1983. page 4 Silbergeld. E.K.: "Where do we go from here?", in Legator. M.S. (ed) Community Health STudies: A Guide for C i t i z e n s . Johns Hopkins Press. Baltimore. MD. in press Silbergeld. E.K.: "Health Effects" in Environmetal Defense Fund. Dumpsite Cleanups: A Guide to the Superfund P r o g r a m . Washington, DC. 1983 Silbergeld. E.K.. and Highland. J.: "Ghost Dumps" (letter) Science, 2 1 6 :462. 1982 Silbergeld. E.K.: "Cancer Policy: Has the Dust Settled?" Environmental Forum. 2.:25-29, 1983 Hall. K.L., and Silbergeld. E.K.: "Reappraising Epidemiology" Harvard Environmental Law Review. 7:441-44.8, 1983 17 12572 Dr. Raymond Singer, P h . D . , is a neurotoxicologist and neuropsychologist practicing at Occupational Health Consulting, Inc., of N e w York, N e w York. Dr. Singer's cur r i c u l u m vitae is attached. Dr. Singer will prepare reports concerning each of the veteran plaintiffs. These reports will be based upon personal interviews and review of appropriate test findings performed by himself and/or by others. The personal interview will consist of a thorough account of the v e t e r a n 's b a c k ground and current and historic symptoms. It will also detail the educational and occupa tional background of each veteran. Various neuropsychologic tests will be given and d iscussed w ith p a r t icular reference to whether:: any deficits or changes noted are due to the results of any toxic chemical exposures. Neurophysiologic tests will also be given or reviewed and interpreted, with particular emphasis placed upon nerve conduction velocity findings, and the results will be set out and discussed, with particular reference to whether the findings are related to toxic chemical exposures. To the extent warranted, Dr. Singer will relate any findings to A g e n t O r a n g e exposure. Dr. Singer will also testify to the effects of toxic chemical exposures as they have been studied in a number of research efforts in both animals and humans. He will discuss the findings reported in various populations exposed to toxic chemicals 12573 and particularly to TCDD through the mechanism of industrial ac cidents. He will also discuss the findings concerning demyelination of the fatty sheaths surrounding the nerves and the "dying-hack" neuropathy which has been associated with toxic chemical exposures. Dr. Singer w i l l also discuss the results of his own wor k in relation to occupational exposures to TCDD, and will explain how his results are consistent with those obtained from tests per formed on the veterans here, and how those results are consistent with causation by phenoxy herbicides and their contaminants. 12574 RESUME Name: Raymond M. Singer Born: August 20, 1950; Philadelphia, Pennsylvania Address: 415 East 85th Street, #10H New York, NY 10028 (212) 744-1728 Ph.D. M.S. B.A. EDUCATION AND DEGREES Washington State University Washington State University University of Rochester 1978 1975 1972 Psychology Psychology Psychology PROFESSIONAL ORGANIZATIONS Certified Psychologist, New York State Board of Psychology Member, American Psychological Association Member, National Academy of Neuropsychologists Member, Society for Occupational and Enviromental Health Member, American Public Health Association Associate Member, College of Toxicology PROFESSIONAL EXPERIENCE 1983 1983 1982 1982 1982 1981 - 1982 1979 - 1981 1978 - 1979 1978 1979 Adjunct Instructor, Mount Sinai School of Medicine Department of Community Medicine, New York City Consultant, New York State Department of Social Services, Office of Disability Determinations President, Occupational Health Consulting, Inc. Clinical Psychologist, Private Practice, New York City Reviewer, The American Journal of Industrial Medicine Fellow, Mount Sinai School of Medicine, Department Community Medicine, Enviromental Sciences Laboratories, New York City NIH Post-Doctoral Fellow in Environmental Epidemiology, Mount Sinai Medical School of Medicine, New York City NIH Post-Doctoral Fellow in Biological Psychiatry, Millhauser Laboratories, New York University Medical Center, New York City Clinical Psychology Intern, Park East Psychological Associates, New York City 22^7"" Dr. Raymond Singer December 5, 1983 1972 - 1978 Teaching and Research Assistant, Department of Psychology, Washington State University, Pullman, Washington PUBLICATION AND PAPERS Singer, Raymond. Peripheral nervous system assessment in the evaluation of toxic chemical exposure. Paper to be presented at the 12th Annual Meeting of the International Neuropsychological Society, Houston, February, 1984. Singer, Raymond. Neural indicators of phenoxy herbicide exposure. Paper presented at the 1983 Annual Meeting of The Society for Occupational and Environmental Health, Washington (D.C.), December, 1983. Singer, R . , Valciukas, J . , and Lilis, R. Lead exposure and nerve conduction velocity: The differential time course of sensory and motor nerve effects. Neurotoxicology, 4, 2, 193-202, 1983. Presented at the' XI Triennial World Congress of Pathology, Jerusalem (Israel), September, 1981. Singer, R . , Moses, M . , Valciukas, J., Lilis, R . , and Selikoff, I.J. Nerve conduction velocity studies of workers employed in the manufacture of phenoxy herbicides. Environmental Research, 29, 297-311, 1982. Presented at the XX International Congress of Occupational Health, Cairo (Egypt), September, 1981. Valciukas, J. and Singer, R. The embedded figures test in epidemiological studies of environmental neurotoxic agents. Environmental Research, 28:183-198, 1982. Lilis, R . , Valciukas, J . , Singer, R . , et al. Assessment of Lead Health Hazards in an Autobody Shop at an Automobile Assembly Plant. Report to the National Institute of Environmental Health Sciences, June, 1981. Valciukas, J., Lilis, R . , Singer, R . , et al. Lead exposure and behavioral changes: Comparisons of three occupational groups with different levels of lead absorption. American Journal of Industrial Medicine, 1:421-462, 1980. Singer, R. The Neuropsychological E v a l uation of Patients Affected by Occupational Neurotoxic Agents. Invited address, New York State Psychological Association Convention, New York City, May, 1980. 12576 Dr. Raymond Singer December 5, 1983 Valciukas, J . , Lilis, R . , Singer, R . , et al. Neurobehavioral studies of painters. Presented at the International Symposium on Occupational Health Hazards Encountered in Surface Coating, Handling of Paints in the Construction Industry, Stockholm (Sweden), October, 1979. Manuscript submitted, Archives of Environmental Health. Singer, R. The role of the psychologist in the prevention of myopia. Paper presented at the annual meeting of the American Psychological Association, New York, New York, September, 1979. Singer, R. The Camphill approach to the education of the retarded person. Symposium presented at the annual meeting of the American Psychological Association, New York, New York, September, 1979. Singer, R. The behavioral etiology of myopia. Paper presented at the annual meeting of the Eastern Psychological Association, Philadelphia, Pennsylvania, May, 1979. Singer, R. The relationship between visual refractive error and interests, values, personality, academic performance, and reading. Doctoral dissertation, Washington State University, 1978. Singer, R . , Young, F., and Rokeach, M. Values as predictors of visual refractive error (in B a r r o w E s k i m o s ) . Paper presented at the Western Psychological Association Convention, Seattle, Washington, April, 1977. Singer, R. Can myopia be prevented? Invited address - Presented to the Washington State University Chapter of Sigma X I , February, 1976. Singer, R. The association of personality and myopia. Papers presented at the Western Psychological Association Convention, Sacramento, California, April, 1975. Young, F., Singer, R., and Foster, D. The psychological differentiation of male myopes and non-myopes. American Journal of Optometry, October, 52, 10, 679-686, 1975. 12577 THEODOR D. STERLING, Ph.D. Dr. Sterling is Professor in the Facility of Interdisciplinary Studies and Department of Computing Science, Simon Fraser University, Vancouver, British Columbia, Canada. His Curriculum Vitae is attached. Dr. Sterling is a mathematician, statistician, and epidemiologist; as well, Dr. Sterling is intimately familiar with existing data and analyses concerning the effects of phenoxy herbicides and impurities, e.g. 2,3,7,8-TCDD> contained therein. Dr. Sterling has devoted much of his teaching and research to the collection and analysis of data and their use for scientific inference. Dr. Sterling will testify that there exists a considerable body of medical and scientific evidence which demonstrates that the preparations of 2,4,5-T and 2,4-D are toxic, teratogenic, and carcinogenic. Further, there is no credible scientific evidence of a no effect level; said another way, as a carcinogen, there is no safe level and therefore a single exposure years ago may be responsible for human cancer which develops today. In addition, Dr. Sterling will testify that there is ample evidence that exposure to 2,4,5-T is teratogenic in humans when the mother is exposed, and convincing evidence is now extant that the outcome of pregnancy is influenced by exposure to the father alone. Most especially, Dr. Sterling will testify of the incidence of subjective symptoms and/or medical records documenting such symptoms. These symptoms are those which have been compiled by the National Center for Health Statistics, and will be compared, to the extent available, to those symptoms of the Vietnam veterans, particularly those of the representative plaintiffs. The purpose will be to ascertain the incidence of such symptoms in the general population so as to analyze statistically the symptoms of the plaintiffs. The product of such overall incidence will be calculated to examine the possibility or likelihood of such a constellation of Agent Orange/dioxin related symptom complex to occur in a random fashion. The bases or grounds for the facts and opinions of Dr. Sterling's testimony are: educational and professional background; publications regarding the subject phenoxy herbicides; review of the applicable medical and scientific literature; attendance and participation in various symposia dealing with the scientific issues in question; training as a mathematician, statistician, and epidemiologist; and training and experience in the computer sciences. -2- CURRICULUM VITAE Theodor D.Sterling EDUCATION B. A. (CUM LAUDE) , 1949. M.A., 1952* University of Chicago; Ph.D., 1955, Tulane University. PROFESSIONAL AFFILIATIONS Present: Professor, The Faculty of Interdisciplinary Studies and Department of Computing Science, Simon Fraser University. Previous: Visiting Professor, Department of Statistics, Princeton University, (78). Chairman, Department of Computing Science, Simon Fraser University, (72-77). Professor in the Department of Applied Mathematics and Computer Science, Washington University, St. Louis, Missouri (66-72). Also Joint appointment as Professor in the Department of Sociology (66-68), and Visiting Professor in Computers and Humanities, Hebrew Union College, Cincinnati, Ohio (68-70). Professor of Biostatistics and Director of the Computing Center, College of Medicine, University of Cincinnati, Ohio (58-66). Previously instructed in the Department of Statistics, Michigan State University and Department of Mathematics, University of Alabama. PROFESSIONAL ACTIVITIES ACM Committee on Scientific Freedom and Human Rights; President of the Computer Science Association cf Canada (75-80); Chairman, Ombudsman Committee, Canadian Information Processing Society (73-80); Chairman, President of Biological Information Processing Organization (64-65); Chairman, CIPS Special Interest Groups, Humanization of Information Systems (73-80) ; Chairman, SIGCAS Committee of Information and Public Policy (72- ) ; President of Missouri Chapter, American Association of Workers for the Blind (70-72) ; Member of the Panel for Biology, Management, and Social Sciences of the Mathematics Association of America (62-67) ; Chairman, Committee on Professional Activities of the Blind of the Association for Computing Machinery (63-71); Chairman, Ad Hoc Committee on Accreditation, Association for Computing Machinery (66-67); Committee on Radiation Dosimetry, American Association of Physicists in Medicine (66-69); National Lecturer for Association for Computing Machinery (72-3, 75-6). EDITORIAL ACTIVITIES: Associate Editor - Canadian Journal of Statistics (73-78) ; Editorial Board - International Journal of Biomedical Computing (69- ); Computers and Applied Mathematics (73- ), Humanist in Canada (73- )- 12580 GOVERNMENT AND OTHER SERVICES: (Consultant/adviser, now and previous): (In Canada) Canadian Standards Board; Environment Canada, The Royal Commission (B.C.); Consumers Association of Canada; Society for Professional and Environmental Control. (In U.S.) NIH: PHS; EPA; FTC; SRA; 0,S. National Academy of Science, National Research Council; American Lung Association; Natural Resource Board (Wisconsin); Environmental Defense Fund, MECCA (Minnesota); Citizens. Against Toxic Sprays (Oregon) . (In Kuwait) - Ministry of Health- PROFESSICNAL SOCIETIES: Can. Inf. Proc. See.; Can. Comp. Sci. Assoc.; Assoc. Comp. Machinery; Amer. Math. Assoc.; Math- Soc. ; Inst. Math. Stat.; Amer. Stat. Assoc.; Biometric Soc.; N.Y. Acad. Sci.; Amer. Assoc. Phys- Med.; Assoc. Res. Opthamology. HONORS AND AWARDS: Fellow, Amer. Assoc. for Advancement of Science; Fellow, Amer. College of Epidemiology; Fellow, Amer- Stat. Assoc.; Fellow, Car. Com. of Scientists and Scholars; Sigma Xi; Pi Nu Epsilon, Mo rrison Cressy Award in National Science; University Res earch Professor ( 1 9 8 0 - 1981) 12581 BIBLIOGRAPHY Theodor D. Sterling Book s A Guide to PL/1 and Structured ?rog ramni in g . doit, Rinehart ana Winston, February, 1969. Second edition - 1976. Third Eaition 1 980. Essentials cf PL/1. Holt, Fiinenart and Winston, January, 1573. Visual Prosthesis - The Interdisciplinary Dialogue. (Editor), Academic Press, March, 1971. Computing and Computer Science with PL/1. dacmi1lan , January, 1970 . Computing ana Computer Science with Fortran IV. Macmillan, January, 1970. Introduction to Statistical Data Processing. Prentice-Hall, Ju n e , 1966. Advances in Biomedical Computing Applications (Editor), Annals of The New York Academy of Science, Vol 123, 1966. Computers and the Life Sciences. Columbia Press, December, 1965. In preparation: People are Trouble: The Human Side of a Com p u t e r i z e d Society. Concepts of Machine Computation. 12582 Articles 1984 The Economics and Politics of Building Illness: The NAS/NRC Report on Indoor Pollutants. International Journal of Health Services 14(1): 43-5 3. Second Thoughts: On Filtering Information About Occupation, Smoking and Disease. Journal of Chronic Diseases. (In press) Computers and Society. In Adriana Davies, (ed.) The Canadian Encyclopedia. (In press) Investigations on the Effect of Regulating Smoking on Levels of Indoor Pollution and on the Perception of Health and Comfort of Office Workers. Proceedings of workshop on Effects and Exposure Levels, Geneva, Switzerland, larch 15-1 7 , 1983. (In press) The Emerging Key Role of White-Collar Computer workers Vis A Vis Organized Labor. Technology and People. (In press) What is the Most Advanced Technology on Earth Today and for What is it Used? In Gallup, G. and Ncrirack, C.T. (cas.) . America Wants to Know: Ihe Experts' Answer Ro o k , New York. A w Publishers, Inc. (in -hress) 1}._9M ' CJ)<QJ 19 33 The health Effects of Low-Dose Radiation on Atomic workers: A Case Study of E m p l o y e r - D i r e c t e d Research. In Navarro, V., and Berman, D. (es.), Health ana Work Under Capitalism: An International Perspe ctive. Baywood Publishers, New York, NY. pp. C,_k 1 Concatenation. In A. Ralston and E. Reilly, Jr., (ed.) Encyclopedia of Computer Science and Engineering (second edition). Van Westrand Reinhold Company, New York. pp. 395-396. Programming. In A. Ralston and E. Reilly, Jr., ( e d .) Encyclopedia of Computer Science and Engineering (second edition). Van Nostrand Rainhold Company, New York. p p . 1194-1217. Statements. In A. Ralston and E. Reilly, Jr., (ed.) Ency c l o p e d i a ot Computer Science and Engine e r i n g (second edition). Van Nostrana keinhola Company, New York, p p . 1404-1407. Trap. In A. Ralston ana . Reilly, Jr., (ed.) Encyclopedia of Computer science ana Engineering (second edition) . Van Nostrana Rein nolo Company, e w York, p p . 1534-1535. Corporate Planning and Technological Change. The TWU Transmitter, Special Issue V (5) : 5. Euildiny Illness in the W h i t e -Coilar Workplace. la ter national Journal or health Services 13:277-287. Possible Eifocts on Occupational Lung Cancer from Smoking F.elatac Chan g e s in the Mucus C o n t e n t of the Lung. Journal ot Chronic dise ases. Jo (10) :669-b76 . The Impact or Different V e n t i l a t i o n Lighting Types on building Illness: Canadian Journal or Public Health. (E. Septemter/Cctober. Levels -.mu >'auorescent An Experimental Study. Sterling, senior author) Unemployment Follows from the Chan g e s in T e l e c o m m u n i c a t i o n s . T e l e c o m m u n i c a t i o n s Workers Union T r a n s m i t t e r IV (3): 9. Air Quality in Puolic Buildings with Health Related Complaints. ASHRAE Transactions 89(2). Perceived vs Actual 7<isks: The Problem of Multiple Con f o u n d i n g . In Covello, V., Flamm, W., Rodricks, J., and Tardiff, R. (eds.) The Analysis of Actual Versus Perceived Risks. Plenum Publishing Car?., hew York, pp 203-212. New Healtn Hazaras in Scaled Buildings. American Institute or Architects journal, April, 86:64-67. Existing Data Systems: How Useful Are They? In Chiazze, L. Jr., Lundin, F.E. and Watkins, W. ( e d s . ) , Methods and Issues in Occupational and Environmental Epidemiology. Ann Arbor Science Publishers, Inc., Ann Arbor, Michigan, pp. 51-61. Prevalence of Disease in Wives of 3iue-Collar Workers: C o m p a r a t i v e otuay. in i-niazze, l . or. r1*.UHmU.4 A Y1*10 Ua4>l/i nuwAXi ^i o^ f W . (eds.), Methods and Issues in Occupational and Environmental Epidem i o l o g y . Ann Arbor Science Publishers, Inc., Ann Arbor, Michigan, pp. 165-176. 1932 Unionization of Professionals in Data Processing: An Assessment of Recent Trends. Communications of the ACM 25(11): 807-816. Health Effects of Chlorophenol Wood Preservatives. International Journal of Health Services 12(d): 559-571 . Job Discrimination Based on Exposure Considerations and Smoking. In Lee, J. and Rom, w . (eds.) Legal and Ethical Dilemmas in Occupa t i o n a l Health. Ann Arbor Science Publishers, Ann Arbor, Michigan, pp. 379-387. The Case tor Entirely Removing the Gas Range from Indoors. Proceedings of International Symposium on Indoor Air Pollution, Amherst, Mass., Oct. 13-16, 1931. Indoor byp r o d u c t Levels of Tobacco Smoke: A Critical Review or the Literature. JAPCA, "arch 32: 250-259. What is Ahead tor Lab o u r / M a n a g a m e n t in Data Canadian D atasystems Id (5): 90-99. Processing?. C r i t i q u e V. The Health Effects of 2,4,5-T. In Harnik, P. voodoo Science, Twisted Consumerism. Center for Science in the Public Interest. Washington, D.C. 93-49. 1981 Does Smoking Kill Workers or Working Kill Smokers? R e p rinted in Feinberq, H.G. (Chairman) Litigation and Settling Occupational Disease Claims. New York Law Journal, New York. October. Humanizing Computer Information Systems. Reprinted in Murray Gruber (ed.) Management Systems in the Human Services. Temple University Press. Philadelphia, PA. 287-299. Setting the Stages for Labour Unrest in the Canadian DP Industry. CIP5 Review, July/Oct. Voi. 5(4): 36-37. 85.tnC<t What EFT Will Hear, to the Consumer. CIPS Reviw, nay/June. Vol. 5(3) 16-17 Ve n t i l a t o r y F u n ction Changes Over a workshift. Br. J. ot I n oustrial Medicine. 36 : 1 52-135 . (H. Diniich, senior author.) Unionization and its Implications. Proceedings of the Second Annual Office Automation Conference, March 23-25, 1981, Houston, Texas. Possible Risks to Human Lunas from Magnetometric Dust Clearance Exp e r i m e n t s . Journal of Applied Physics, Vol. 52 (3, Part II) 2575-2577. Use of Gas Ranges tor Cookinc and Heating in Uroan Dwellings. Journal of the Air Pollution Control Association, February, Vol. 31 (2) 162 -165. E n g ineers Throa ter; Domination or 0? Jobs. TIPS Review, Jan./Feb. V o l . 3(1): fc-b. 19 80 The Health Et fects of Lou -level ot Ionizing Paoiation: A D i a l o g u e . In Rom , W .II. and Archer, W.E. (eds.) , Health I m p l i c a t i o n s Of New Energy T e c h nologies. Ann Arbor Science Publishers, I nc ., Ar.n Arbor, Mien. Pages 150-164. Stressing Design Rather Than Performance standards to Ensure Protection of Information: Comments. In iloffman, W. (ud.), Computers ana Privacy in the Next Decade. Academic Press, Inc. 1 0 2-1 C 7 . Smoking, O c c u p a t i o n and R e s p i r t or y Disease. Report to the American Lung Association, Occupational Health Task force Meeting, April 9, 1980, C l e a r w a t e r , Florida. The Social Impacts of Electronic Fund Transfers, The Financial Post, Sp e c i a l Report, March 8 , 1960, si 1 The Health Effects of Low-Dose Radiation on Atomic workers: A Cas e Study of Employ er--Dir ected Research .' In ternational Journal of Health Services, January, 10(1): 37-46. C o v e r - u p at Hanfora: The Effects of Low-Dose Radiation. Humanist in Canada, Spring (No. 52) XII, No. 1: 5-d. The Computer Ombudsman, A Possible Model of A ccoun t a u i l i t y Among Professionals, Transactions of Society, 17(2): 31-35. 12586 1979 Statistical Problems in M u l t i - V a r i a t e (Etiological) Surveys. Canadian Journal ot Statistics, 7 (2): 205-21 5. The Mutual Relationship Between Smoking, Occupation and Disease. Proceedings of the XIX International Congress on Occupational Health. Supplement to vol. 30. Consumer Difficultie s with C o m p u t e r i z e d Transactions: An Empirical Investigation. Communications or the ACM, May, 22(5): 283-285. Carbon Monoxide Levels in Kitchens ana Homes with Gas Cookers. J. Air Pollution Control Association, iiarch, 29 (3): 238-241. What Consumers say About Computer Errors, Canarian Datasystems, 11 (12) : 64-67. What Happens When Magor Errors Are Discovered Long After An Important Report Has Eeen Published?, Invited talk to the Annual Meeting of the American Statistic Association, Washington, D.C., A ug u s t , 1979. 1978 Computers in Developing Nations: A C a u t i o n a r y Tale. Reprinted in Personal Computing. February, 27-jl. Smoking Patterns fcy Occupation, Industry, sex, and Race. Archives of Environmental Health. November, 33(6): 313-317. Processing Errors Among the Public: Their Frequency ana Crigin. Proceedings of the Session '73 C a n a d i a n Computer Conference, CIPS, Edmonton, Alberta. May. Does Smoking Kill Workers or forking Kill Smokers, International Journal ot healtn Services, 6(3): '437-452 .. Follow up: New Evidence C o ncerning Smoking ana Health, Med. J. Australia, 65: 384-387. Frequency of C o m puter Related Errors Among Holders of Credit, Charge or Dank Accounts, CIPS REVIEW, June, 5: 17. High Level Language Programming. In Belzer, J., Holzman, A.G., ana Kent, A. Encyclopedia of Computer Science and Technology, Marcel Dekker, 9: 257-283. Humanizing Info rma Li or. Systems. In aelzer, J., riolzman, A.G. ana Kent, A. E n c y c l o p e d i a of Computer Science and T echnology, Pa r c e l DekJcer, S : 361-37 1 . Natural Language Compilers and Interpreters in hadiation Treatment Planning or Nous Pardons Anglais 'Setter Than Jede Anaere Sprache. In V. hosenaw (?.a) , Computers in Hadiation Therapy: Proceedings of the Sixth International C o n g r e s s on the Use of C o m p u t e r s in Radiation Therapy, University oi Goettingen, Goettingen, FRG. 19 77 Com p u t e r s in lev eloping Nations: a Cautionary C o m m u n i c a t i o n s of the ACM. December, 20 (1 2): 971 -972. Tale. New Evidence Conc e r n i n g Smoking and Health. Medical Journal of Australia, October, 2: 53B-S42. Fold, Spindle and Mutilate. Humanist in Canada, -arch. 40/15-20. Exposure to Pollutants in Enclosed " L i v i n g '' Environmental Research, February, vol 13: 1-13. Spaces. 2 ,4 ,0 -T .... T e r a t o g e n i c Em D r o y o t o x i c , Fetogenic, Mutogenic, Acres U .S .A . , 7/7. Smoke Gets in lour L'yes. iiuaanist in Canada. U2 : 2-b. 1 97d Humanizing I n f o r mation Systems. Datamation. Decern b e r . Smoking C h a r a c t e r i s t i c s by Type of Employment. J . Medicine, November, 1b (11): 7 4 3 - 7 5 4 . Occup. Do *e Need A Computer Ombud s m a n ? Canadian Datasystems, August, 62-64. . Programming. In Ralston, A., and Meek, C.L. (Editors), E n c y c l o p e d i a of Computer Science, P e t r c c e l l i - C h a r t e r , Ne ork, pp. 1127-1166. Statements, Ralston, A., and Meek, C.L. (Editors), Encyc l o p e d i a of Computer Science, P e t r o c e l i i - C h a r t e r , New '/ork, pp. 326-1 329 . A Single-Track Universal Curriculum for Computing Science. INFOR, February, 14: 1, 40-62. Kan Against Himself - Biological Dangers from the Use of Herbic i d e s . Humanist in Canada, February, IV (3): 2-7. Addit i o n a l C o m ments on the C r i tical Assessment of the Evidence Bearing on smoking as the C a u s e or Lung Cancer. American Journal of Public Health. February, Vol 6b (2) : 161-164. R e l a t i o n of Place of Birth and M i g r a t i o n in Cancer Mortality in the D.S. - A study of Ohio Residents (1959-1967), reprinted in the 1976 Year Book of Cancer. iy 7b Humanizing Computerized Information Systems: Guidelines ana Their Implications. Science, December, Vol 190: 1168-1172. A C r i tical Reassessment of the Evide n c e Bearing on Smoking as the Cause of Lung Cancer. American Journal of Public Health. September, Vol 65 (9) : 9 39-953 . A C r i tical Review of Reports on the Effect of Smoking on Sex and Fertility. Journal of Sex Research. August, Vcl 11(3) 201-217. Lung Cancer Among black a n i white Migrants In the U.S. Et i o l o o i c a l C o n s i d e r a t i o n s . Journal -ji the National Medical A s sociation, J a ic n , Vol 1 7 ( 1 ) : IJ - 1 11 , 1Od . (7 .F . M a nc uso , s e riio.r author.) 19 79 Relation of Place of firth anu Migration in Cancer Mortality in the 'J . s . - A r t u d y of Ohio ,- e s i tents 9 3 3 - 19 b 7) . Journal oi Chronic Diseases. Vol 2 7 : 0 5 9 -4 7 /1 . (7 . f. K ancuso, senior author.) Guide l i n e s ior h'u n.an iz i no Ccmr-uti;-r lie:. Infer nation Systems: Report from Stanley House. C o m m u n i c a t i o n s oi the ACM. November, Vol 17 (11): 609-613. (Reprinted m AEDS Journal, Vol 10 (1), Fall 1S 76: 1-10. Teaching Simulators of Ideal Teaching Machines. S1GSCE Bulletin, ACM. June, Vol fc(2 ) : 45-56. A Proposal tor a New C u r r i c u l u m A p p r o a c h . University Aft ,.1 is . Simon Fraser University, Eurnaoy, 3.C. May, pp. 6-7. Ideal Teaching Machines -- A Solution to the Pedagogic Language. C o m m u n i c a t i o n s of tne ACM. April, Vol 16: 207-208. 12589 The 'Jse of an Information System to "liuaanizs" Procedures in a Rehabilitation Hospital. International Journal of -io-Eedicai Computing. Vol 5: 1-5 7 . Information for Public Policy. Conputsrs m i Society. Vcl (i): 2 . (Invited editorial). The Simon Eraser One-Track. Universal Curriculum for Computing Science. SIGSCL Bulletin, ACM. February, vol 6 (1) : 28-32. I9 7 3 The Statistician vis-a-vis Issues of Public Health. The American Statistician. December, Vcl 27(5): 212-217. Extending the General Fieli Equation to fit the Dose Distributions of a Variety of Therapy Units. Sritish Journal cf Radiology. Vol 46: *83-990. (J. .einxam, senior author.) Air Pollution and Smokinq. Environment. Voi 15(b): 3-5, 25-26. Dynamic l/icplay or naci ct her a oy Plans Dsin Films, iaaiology . June, Voi 107: 639-691. Coirputer-Procucea Humanists and tne Ccni.u ter Community. Humanist in Canada. vol 25: h . Computing and the humanization of Medici r.tj. Interr.aticnai Journal or riomedical Computing. t u t o r i a l , July, Vol 4(3): 159. 197 j Difficulties ci Searuring the effects of Air Pollution vs the Effects of Smoking. Presented at the 139th Meeting cf the American Association for tne Advancement of Science, ,,acesler 1972. A Versatile System for Three-Dimensional Radiation Dose Computation ana Display, 3T P . Computer Programs in 3iomedi cine. Voi 2: 178-1 92 . (J. weinkam, senior author.) Fitting the Cenerai Field L'gu t i on to tr.-? jio mens Gai:;matron 3 . Technical Report on Research Agreement No. 1051/CF for the In tern aticnal Atomic Energy Agency, Vienna , Austria. The Incidence of Lung Cancer in the U.S. Since 1955 in -elation to the Etiology or the Disease. American Journal or Public Heaitn. February: 152-158. 12590 i y 7i A critical Assessment of the Evidence on the Cigarette Smoxina Lung Cancer Relationship. Presented at the 138th Meeting of the American Association for the Advancement of Science, Symposium on Smoking and health Now. Philadelphia, December, 1971. Difficulty of Evaluating the Toxicity and Teratogenicity of ^ 2,4,5,-T from Existing Animal Experiments. Science. December, Vol 174: 1358-1359. Some Thoughts on Treatment Strategy. Computers in Radiotherapy (proceedings of the uth International Conference on Computers in Radiotherapy, Glasgow, September 1970). Edited by A. S. Glicksman, ;i. Cohen, and J. K. Cunningham. Puolishea as Special Report No. 5 (1971) by the British Institute of Radiology, London . Three-Dimensional Treatment Plan Display on Computer-Produced Films. Computers in Radiology, op. 12-14. A Review of the Claim that Excess 'lorbiaity and Disability Can Be Ascribed to Smoking. Journal of the American Statistical Association. Vol t-b (334) : 251 -257 . A Critical Reassessment of the Evidence Bearing on Smoking as the Cause or Lung Cancer. Special Report on the Washington 'university Project on the Review of Crucial Data Searing on the Emox in u and Health Issue, St. Louis. Robot Data Screening, An Intelligent (?) Data Search Technique. AGARD Conference Proceedings No. 94 on Artificial Intelligence, 2-1-d-r, Tecnnitdi Editing and Reproduction Limited, Loncon. Comment on Smoking Dogs. Letter to the Editor. Archives ot Environmental health, vol. 22: 631-032. 19 70 Problems in Determining if a Commonly-Used Herbicide (2,4,5-T) Has an Effect on Human Health. Proceedings of the Sixth Berkeley Symposium on Mathematical statistics and Probability, field at the Statistical Laboratory, University of California. University ot California Press, pp. 479-494. Experience with a "Universal" introductory Course in Computer Science. Proceedings of SIGCSE Technical Symposium on Academic Education in Computer Science, NovenDer 10, 1970. Houston, Texas. SIGCSE Bulletin, Vol 2(3), Association tor Computing Machinery, New York. 12591 Robot Lata icreeiunq, An Automatic Search Technique, Rio-Medical Computing. Voi 1: 61 -74. (From the Proceedings of the Conference on Statistical Computation, University of Wisconsin, April, 1969 .) Report on Prog ress in the . * i .h t ua1 Prosthesis The New OutiooK for the 31 i nd . Feoru j I'y , Voi 64: 41-4 6. 19 69 Automatic Data Screening: A Practical Solution to the Multivariate Problem in Clinical Data. Annals of cue hew York Academy or Sciences. Vol 161: 6 32-ouO. A Comment on "Air Pollution -- The Industrial viewpoint" . Journal of Occupational Medicine. July, Vol 11: 31-je3. Robot Lata screening -- A Ubiquitous Automatic s ear ch Technique, in nil ton , C n . and Helder, J. A . ("d ) t statistical Computa tier., Academic Pre ss, Mew Yor<t. PP . 319-333. Me asurir.t; t j . r^4 ^ ^ 1 Air 'oliati 1t ;n r san do rii ait y . Archive s of Environmental Health. April / voi 1 3: -ob-u9u . 19:>S Computer Interlace, Incut Metnocs, a 5.- Presentation of Results. Role or Compii ti. re m ra lictherapy , In t rn ational A to ic Inert y Agency, Vienna. Pape r Vo. 16, p p . 136-141. Opti mi ration as a joint Result of Planning ana Implementation. Role or Ccapu ter s in nadi ot.no rap y , in tec national Atomic Energy Agency, Vienna, pp. 163-167. Display Devices tor Computer Translatai Irailie. ?rocaeai n as Conference on New Processes for a m i l a Ma nu rac tu r e , 196c, Center ter sensory hies Evaluation ana Development, nassaenusets Institute of Technology. February, pp. 14-20. 19 67 Automation of Radiation Treatment Planning, VI: A General Fie la equation to Calculate Percent Deptn Dose m the Irradiated volume of a Cobalt 60 Beam. British Journal or Radiology. Voi 40 : 46 3-UbB . Urban hospital Morbidity and Air Pollution: Second Report. Archives of Environmental Health, vol 16: 362-374. 12592 A New Direction in Rehabilitation Through Advanced Instrumentation and Computation. Journal of the American Medical Association. Vol 200(7): 625-629. .ihe Use of Computers in Therapeutic Radiology, Summary Report of an International Conference heia in Camd ridge, England, June 19 16 (Editor) . r n t i s h Institute of Radiology, London. final Narrative. Report, Training of the a n n a for Professional Computer Work. Department of Health, Education, and Welfare, HD-1 5-5-67-C.. . 1966 Robot Data Screening: A Solution to Multivariate Type Proclems in the biological ana Social Sciences. Communicatons of the ACM. Vol 9(7): 529-532. A Biologically-Oriented Computer Language. Armais of the hew York Academy of Sciences. Vol 128(3): 755-755. (S. V. Pollack, senior editor.) Cancer Therapy - Computation ana Visualization Distributions ir. External Beam Therapy. Journal Diseases. Voi 15: 523-539. of Dose or Chronic Use of the Computer to Teach Introductory statistics. Communications of the ACM. Vol 9 : 274-27b . Computers : No Longer a Big Bargain Comuuters ana Automation. Vol 15 : 1-4. author .) tor Uneducated (3.V. Pollack, U se rs . 3 1 niGr. The Selection, Training, and Placement of Blind Computer Programmers. Report or the Association for Computing Machinery . Is Medical Diagnosis a General Computer Proolem? Journal of the American Medical Association. Vol 196(3): 281-266. Lefogging the Issue: California has discovered that laws can's control auto exhaust fumes. Barron's, May 2, pp. 5, 14-15. Urban Morbidity and Air Pollution: A first Report. Archives of Environmental Health. Vol 13: 150-170. The Blind as Computer Programmers. Rehabilitation Record. Vol 7(1): 7-1 u . Role of Statistics in the World of Computers. Annals of the New York Academy of science. Vol 12 8 (3): 1108-1115. The Role ot tne 31 ina in Data Processing. Presented at Third Annual Conlerence on Computer Personnel Research Group, held at 'ashin cton University, 1965. Reprinted in Com outers and Automation. Voi 15: if-27. Proceedings on the P raille Research ana Development Conference, Sensory Aids, Evaluation and Development. Massachusetts Institute t Tocnnoiccy, ovsnbnr, 19i>6. 19 65 Automation cf Radiation Treatment Planning, v: Calculation un a Visualisation of the Total Treatment Volume, British Journal pi r.&Gicloqy . Vol 5B : y 0 1-- 12 . Roaot Data Processing Techniques tor Multivariate Epidemiolccical Predictions. Annals o t the Mew York nca ce.my ot Science, vox 12 6(2): 779-79'. The Role of the Blind in Data Processing. Procedures oi Third Annual Computer Person noi Hesaarcn Conlerence, June 1'-b5. (11. H . Gotterer, ec..; Computers in Personnel Research Group, Silver Spring, Da.; pp . a 1- 35 . Computation ot 1.adia tion Dosajes. In Stacy, R. no Gasman, B., (td .) , Computers in 'ioracd ica 1 Research. Academic Press, hew York, Voi 1 (Chapter Id). Toward on Ur.de re r<.c ua te "a tnem a tics r.esoarenerr: in the riuias oi oioloqy une Proceedings. Vci id(1): 5-9. Proc r .lin : g r F u tu rr. Medicine. t r.ratior Careers tor the: Elina in Electronic Data Processing. Electronic Data Processing. Occupational Outlook quarterly, voi ?(!): 1- . Lmployire;nt Potential tor the Elina in Computer Hc-iatr-u Fields. The International Journal for Rancation of the Blind. October, pp . 1- 5. The t i m e in DP. ACM Commi tree on Professional Activities ot the Blind. 1?11u Mathematical Analysis of Lead Burdens. Archives of Bnvironmental Health. 8: uu-51. Design and Operation oi a Medical Computing Center. Annals of the e w York Academy of Science. Vol 115(2): 59 1-599 . (F . Saengsr , senior author) . Planning- Radiation Treatment on the Computer. Annals of the New York Academy ol Science. Vol 115(2): 976-997. Professional Computer Work for the Blind. Communications of the ACM. V cl 7 (4) : 226-211 . Computer Wcr?; as a Profession for the Blind. Journal of R e habilitation. Vol it: 20-21. Epidemiology of Disease Associated with Lead. Archives Environmental health. Vol 8: 133-248. 'latnomatical Analysis Lead Burdens. Archives of Envir o n m e n t a l Health. Vol 8: 44-51 ot of Automation of Radiation T r e a t m e n t Planning, IV: Derivation ot a M a t h e m a t i c a l Expression for the Per Cent Depth Dose Surface ot Cobalt 60 Beams and V i s u a l i s a t i o n of Multiple Field Dose Distributions. British journal of Radiology. Vol 37(439): 544-550. Locating Placenta Praevia. Procedures or the Rochester Confe r e n c e on Data Acquisition ana Processing in Biology and Medicine, New York, 1963. Pergamon Press, New foric, pp. 103-111. 19 6 3 Do M a l i g n a n c i e s Result : rcn Diagnostic and Therap e u t i c Radiation? Genetics {a the .-.`pi ac-rdo ioyy of Chronic Disease, U.5. Dept, of h e a l t n , Education rind Welfare, 'pp. 2oS-i7l . MEDCOMP, Part 1, Statistical Systems. Medical Computin': Center, University of Cincinnati, Ohio. Boron, Cadmium, Chromium, and riicxel in the Blood ana Urine. Archives ot Environmental Health. Vol 6: 236-295. (H. Imbus, senior author.) Potential Hazard ot Exposure to Lead. Archives ot E n v i r o n m e n t a l Health. Voi fc: 255: 272. (R . Kehoe, senior autnor.) Carcinogenic Effects o f T1JI Compared with X- Irraoiation - a Review. Health Physics. Vol 9: 1371-1:64. (6. Saer.ger, senior author.) A u tomation ct Radiation T r e a t m e n t Planning, III: A Simplified System ot Digitizing isodoses and Direct Print-Out of Dose Distribution. British Journal of Radiology. Vol 36: 522-527. Intra v e n o u s Methotrexate (Amethopterin) Therapy in the Treatment of Acute Leukemia. Pediatrics. vol 31 : 834-339 . (J. Perrin, senior author.) Autonation cf Radiation T r e a t m e n t Planning, II: C a l c u l a t i o n or Kon-Convergent Field Dose Distributions. British Journal ot Radiology. Vol 36(427) : 63-67. Rotot Treatment Planning. Procedures ct m e h o c nester Con ter e nee on Data Acquisition ana Processing in Biology and Medicine, hey Yo l k , 16 6 2 . Peroamon Tress, New York, p p . 23 3- 319 Robot [a ta Screening . Procee d i n g s ot lne Hoc ne s t.e Data Acquisition ana Processing in Biology and Medicine, hew York, 1962. Perca.ton Tress, New jerk , p p . 31-2^2. 17 62 O c c u p ational Exposure to Organic Lean Compounds. Archives oi Environmental Health. Vol 5: 532-636. (R. OeTrivixie, senior a u t h o r .) New Developments in Chronic Disease Spidemiciog y : Competing Risks ana Eligibility. American industrial hygiene Association Journal. Vci 2o : 6 3 3 -0 4 6 . Kaaiatiou trini- r-1 o 1c :y . Cancer, vc 1 1 u t j. Comparative Ctuoies environmental ;-tai:h. senior author.) of Certain Lead ALxyls. Archives ot 0 5: 515-32 , a :3-6 c . (E . ci ngham, 19M A Practical Procedure for Automating radiation Treatment Planning. British Journal ot Haciioioqy. Voi ad : 7 6-7 33. Epidemiclogical Methods ana Community Air Pollution. Archives or Environmental health. Vol 3: 267-275. (J. Phair, senior author.) Competing Causes ot Deatn in Coal :ar 'orders, lettering Report. 19 60 C e s i u m -137 Retention and Distribution in x-Irraaiateu Rats. U.S. Army Medical .research Laboratory, fort Knox, Kentucky. Report No. 504. (G. Keriakes, senior author.) Seasonal Variations in the Birth ot the Mentally Deficient? American Journal of Public Heiltn. Vol 50: 555-^65. 12596 The Lean Content of the Atmosphere. Presented at the b3r a Annual hee tinc of APCA , May 1960 , Cincinnati. (J. Cholax, senior author.) What is so Eecu liar About Acceptirig the Ps yc nolc gicai Reports, vol 7: 3fa3-3 faa . U 11 Hypo tn es is? Neoplasia Following Therapeutic Irradiation for B n lqn Conditions in Child ho o d . Radiology. Vol 74: 839-904 (t Saenoer, senior author.) 1959 Fuolic Decisions ana Their PossiDle Effects on inferences Drawn from Tests of Sign ificance - or Vice-Versa. Journal of the American fatatisticai Association. Vol 54 : L *-/ 0 1 u Pulmonary Function in Children, I and 11 . Journal or a 11 er a y . Vol 30 (s) : 514 -5a 3 . (I . L . Herns te in , sen ior author.) Tables of Pulmonary Function Values in Children Ages o to 14. Kreger Printing Co., Cincinnati, Ohio. (I. L. Rernstein, senior a u t h o r .) The Anor r-xiger. ic Action of Doxtro-Arapn at amine Gulfate upon fees m o nest on.st- s or Pilfering otrenutn. Journal of Comparative ana Physiological Psychology. vol 52: 179-182. (P. Siegel, senior author.) Sources of Contextuel Constraint Upon oris in Sen te nets . Journal of Experimental Psychology. Voi 57: 171-lhU. (H . Adorn, senior author.) 19 57 Effect or Irrelevant Drive on Extinction of bar-Pressing. Fs yc no 1or;icai Reports. Vo 1 1 : fa1 5- 1a . A Central surveillance System deasurement Model, Part I, II. Frcyrct " rc!.: ;ar. Z34 o , 7.91"-, diversity or dionium. A General Survey of Statistical Decision Theory. Project Michigan Z915, University of o i cmqan. Bio-Statistician/MathematicianThis witness will be identified in the near future. At that time a curriculum vitae will be supplied. This witness will describe the mathematical/statistical model which will be used in the presentation of the figures to which the witness will testify. The theory subserving the testi mony is that the m u l t i - f a c e t e d presentation of symptoms and signs and test results in the same veteran makes a random compo sition of such an array extremely unlikely in view of the relative in-frequency of each facet of the array. As such, this testimony will be used in the generic and specific proximate causation areas. 12598 AGENT ORANGE TESTIMONY DAY 8 MOYER V DOW 66SS1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re Agent Orange Product Liability Litigation X MDL 381 (All Cases) SPECIAL MASTER'S RECOMMENDATION RE APPLICATION OF PHYSICIAN/PATIENT PRIVILEGE TO MEDICAL AND WORKERS' COMPENSATION RECORDS OF DOW EMPLOYEES Plaintiffs, Vietnam veterans and members of their families claim that they suffered injuries as a result of the veterans' exposure to herbicides manufactured by the defendant chemical companies and supplied by them to the United States government for use in the Vietnam War. The case has been certified as a class action for all liability and compensatory damage issues pursuant to Rule 23(b)(3) of the Federal Rules of Civil Procedure and for determination of punitive damage issues pursuant to Rule 23(b) 1 ( B ) . See In re "Agent Orange" Product Liability L i t i g a t i o n , P.T.O. 72, --- F. Supp.--- (E.D.N.Y. Dec. 16, 1983), writ of mandamus d e n i e d , No. 83-3065, Slip Op. (2d Cir. January 9, 1984). Pursuant to the discovery rules of the Federal Rules of Civil Procedure, plaintiffs are seeking from defendant-Dow Chemical Company ("Dow") the medical and workers' compensation records of its employees who have made claims against Dow arisincr out of allecred industrial exposure to Dhenoxv herbicides from 1953 to 1970. Dow argues that these records are privileged by reason of a Michigan statute which prohibits physicians from disclosing information acquired in attending any patient. Dow further bolsters its argument by reference to Michigan Public Health Code 333.5611 which requires employers to file written reports of occupational disease claims made by employees and which expressly denotes such reports "non-public" and exempt from disclosure. See MCL, Public Health Code 333.5611. Both sides have extensively briefed the issues including which law should apply to a resolution of this dispute. After careful consideration, it is the Special Master's recommendation that Dow produce, under an appropriate protective order, the requested records to the plaintiffs, with the names, addresses and information identifying individual employees redacted. The following memorandum sets forth the reasons for the Special Master's conclusion. Introduction Rule 26(b) of the Federal Rules of Civil Procedure provides for the discovery of any matter, not privileged, which is relevant to the subject matter of the litigation. While the court always has discretion to limit discovery, see Fed. R. Civ. P. Rule 26(c); Apicella v. McNeil Laboratories, I n c . , 66 2- - 12718 FED 78, 82 (E.D.N.Y. 1975), generally, if the item being sought 1 R r p l P v a n t +"n t * h p c n h i P n l - m a f t o r r\-f t h e-------------------------------------------------------- ww W-- J Ww w tttw w w w -. w - 1-. i- .w-t--.i- a3 s a-.wf i-. pw - n,-. sa--n H.s- --n nw+w- privileged, it is discoverable. Relevancy for discovery purposes is treated mor e flexibly than under the Federal Rules of Evidence, Rule 4 0 1 V and includes anything that appears "reasonably calculated to lead to the discovery of admissible evidence". Fed. R. Civ. P. Rule 26(b)(1). Clearly, the records sought by plaintiffs here are relevant for discovery purposes, and may themselves constitute admissible evidence. Plaintiffs seek those medical and workers' compensation records of Dow employees who claimed to have suffered injuries by reason of industrial exposure to phenoxy herbicides from 1953 to 1970. Such records m a y show that phenoxy herbicides cause certain types of injuries; they may also show what Dow knew concerning the product it manufactured for the government, which may help plaintiffs to refute defendants' government contract defense.**/ However, if such records are *Rule 401 of the Federal Rules of Evidence defines relevant evidence as "evidence having any tendency to make the existence of any fact that is of consequence to the determination of the action more p r o b a b l e ... than it would be without the evidence". **The government contract defense has been described by Judge Pratt as having three elements. To prevail on the defense, a defendant must show: 1) that the government made the specifications for "Agent Orange", 2) that the product manufactured by a defendant complied with these specifications in all material respects and 3) that the government knew as much as or more than the defendant about the hazards to people that accompanied use of the p r o d u c t . In re "Agent Orange" Product Liability Litigation, 534 F.Supp.1046, 1055 (E.D.N.Y. 1982) -3- 12719 privileged they are outside the scope of Rule 26 and are not u i^ om uA ua v v c tA a uV k 1i c . ,x i i4u & Aeaxi t ? x-a M ^M MtD 4u c X y A m 4 xs> wtlau e u i i t>r>i. I 1 A * * /a x /vjw cA u m iw \^ 1Aauy ae ea medical and workers' compensation records are protected from disclosure by reason of the physician/patient privilege. I. Rule 501 of the Federal Rules of Evidence Rule 501 of the Federal Rules of Evidence deals with the subject of privilege and provides that: Except as otherwise required by the Constitution of the United States or p r o v i d e d by Act of Congress or in rules prescribed by the Supreme Court pursuant to statutory authority, the privilege of a witness, person, government. State or political subdivision thereof shall be governed by the principles of the common law as they m a y be interpreted by the courts of the United States in the light of reason and experience. However, in civil actions and proceedings, with respect to an element of a claim or defense as to which State law supplies the rule of decision, the privilege of a witness, person, government, State or political subdivision thereof shall be determined in accordance with State law. The Rule, especially its second sentence, attempts to establish a relationship between federal courts and state law-making bodies. Saltzburg, Federal Rules of Evidence Manual, at 229 (3d ed. 1982); See Berger, "Privilege, Presumptions and Competency of Witnesses in Federal Court: A Federal Choice-of-Laws Rule", 42 B r o oklyn L.Rev. 417, 436 (1976). However, commentators to the Rule, as well as courts applying it have not always agreed on what it means. See Saltzburg, Federal Rules of Evidence Manual at 229. -4- 12720 One approach to construing Rule 501 calls for a federal court sitting in diversity to apply the forum state's law on privilege. S e e , e . g . , Samuelson v. S u s e n , 576 F.2d 546; Super Tire Engineering Co. v. Bandag, I n c . , 562 F.Supp. 439, 440 (E.D.Pa. 1983). This result is hardly startling since, under the principles of E r i e , state law would normally be expected to supply the rule of decision in a diversity case. See Pollitt v. Mobay Chemical C o . , 95 F.R.D. 101, 104 (S.D.Ohio 1982); 2 Weinstein's Evidence 501[02] at 501-21; Berger, s u p r a , at 448. If the privilege rules of more than the one state were involved, e.g., where the communication sought to be protected was made in a state other than the forum, the federal court would look to the choice-of-law rules of the forum state to determine which state's substantive law would be used for resolution of the privilege question. See Klaxon Co. v. Stentor Elect. Mfg. C o ., 313 U.S. 487, 61 S.Ct. 1020 (1941); see, e . g . , Mazzella v. Philadelphia Newspapers, I n c . , 479 F.Supp. 523 (E.D.N.Y. 1979). At least one commentator, however, has argued that Rule 501 directs the federal courts to apply a federal choice-of-law rule in cases where state law supplies the rule of decision and more than one state's privilege law is implicated. Berger, "Privilege, Presumptions and Co m p etency of Witnesses in Federal Court: A Federal Choice-of-Laws Rule", 42 -5 - 12721 Brooklyn L. Rev. 417 (1976). Cf^ Mitsui & Co. (U.S.A.) Inc, v. Puerto Rico Water Resources Authority,- 79 F .R .D . 72 (D .P .R . 1978)(District court in Puerto Rico applied an interest analysis test to determine whether the Puerto Rico accountant-client privilege should be used to protect information sought in depositions of accountants in New York, which does not recognize the privilege). See also, Apicella v. McNeil Laboratories, I n c . , 66 F.R.D. 78 (E.D.N.Y. 1975). In Apicella, a products liability case based on diversity jurisdiction, the court refused to permit disclosure of a newsman's sources even though the forum state did not recognize the privilege. The court balanced relevancy of and need for the material sought against the state's policy regarding protection of news sources and federal constitutional interests. It hel d that even though the forum state had no privilege for newsmen, the parties' request for the journalist's sources should be denied in view of other factors weighing in favor of protection of those sources, such as the adverse effect disclosure would have on First Amendment rights, the ability of the journalist to obtain information from his sources in the future and the fact that the parties had not demonstrated need for the material. Although Apicella was a diversity case, the court did not slavishly follow the state 6- - 12722 law which, it wo u l d appear, would hav e resulted in disclosure; instead it fashioned a balance test to determine whether the material would be protected from disclosure by a privilege. U t i l i z i n g a balance test in this case, it seems clear that Dow's employee medical and workers' compensation records are not protected from disclosure. The need for the requested material far outweighs any interest in absolutely protecting these records from disclosure, especially where the names, addresses and other identifying information concerning individual employees are redacted. Even under the first approach, however, this result would hold because, it is submitted, federal common law will govern the instant privilege question, and under federal common law, as will be shown below, no physician-patient privilege exists. A l t h o u g h jurisdiction in this case is founded upon diversity, the recent learned and provocative opinion on choice of law of the newly-assigned trial judge, Chief Judge Jack B. Weinstein, suggests that, rather than applying its own law, each state w o u l d look to federal common law or national consensus law to supply the rule of decision at least with respect to the product liability, government contract defense and punitive damage issues. See Preliminary Memorandum on Conflicts of Law, P.T.O. 87, dated January 12, 1984 at 5,6 ("PTO 87"). -7- 12723 In its very detailed analysis, the Court distinguished between federal law applying by its own force, for example, when jurisdiction is founded upon the existence of a federal question, and federal substantive law applying because a state chooses to apply it. See PTO 87 at 8-10. As an example of the latter, the Court noted that in deciding what state policy and law ought to be, a state often looks at federal law; drawing upon federal decisions, statutes and executive orders, a state might incorporate federal substantive law into its own substantive law. Id. at 9. In examining the question of what law should apply in this multidistrict litigation. Judge Weinstein looked at the choice-of-law rules of the states in which the transferor courts sit. See PTO 87 at 2-3, citing Klaxon v. Stentor Electric Mfg. C o . , 313 U.S. 487, 61 S.Ct. 1020 (1941) and Van Dusen v. Barrack, 376 U.S. 612; 84 S.Ct. 805 (1964). He concluded that, regardless of which choice-of-law methodology was used, each state, "because of its inability to identify and select any other state's law to be applied, as the rule of decision, would seek to divine what the national rule of decision with respect to product liability law would be so that such law would appropriately reflect the national and international characteristics of this case". PTO 87 at 33. 24- s 19 7 The Dow employee records which plaintiffs have requested relate to the products liability and the government contract defense issues, see supra at 3. As to both, Judge Weinstein has t e ntatively determined federal common law or national consensus law applies. C f . In re "Agent Orange" Product Liability L i t i g a t i o n , No. 83-3065, Slip Op. at 1091 n.2, (2d Cir. January 9, 1984). (The Second Circuit noted that although there is no federal question here> it has not yet been determined what law might apply to which issues and implied that federal law might apply to certain issues, such as the government contract defense). Pursuant to Rule 501, then, for purposes of resolving the instant privilege problem, it appears that, since state law does not supply the rule of decision with respect to those issues, the court should look to federal common law to determine whether Dow employee medical and workers' compensation records are protected from disclosure by a physician-patient privilege. See Scott v. M c D o n a l d , 70 F.R.D. 568, 571 (N.D.Ga. 1976). II. The Balance T e s t . At common law no physician-patient privilege existed. However, Rule 501 directs federal courts to apply "the principles of common law as they may be i n t e r p r e t e d . . -in light of reason and e x p e r i e n c e " . F.R.E. Rule 501 (emphasis added). - 9 - 12725 Rather than attempting to set one rule by which privilege questions should be determined in all cases, Rule 501 permits a more flexible, case-by-case approach. See Lora v. Board of Education of the City of N e w York, 74 F.R.D. 565, 578 (E.D.N.Y. 1977) where Judge Weinstein recognized that, in developing privileges on a case-by-case basis, "'reason and experience' dictate a balancing of the public and private interests involved". Id. See a l s o , United States v. King, 73 F.R.D. 103, 105 (E.D.N.Y. 1976). In L o r a , this court formulated a balance test to determine whether a psychiatrist-patient privilege would apply to diagnostic and referral records used by the Board of Education in its procedures for placing children in schools for emotionally disturbed children. The "most constant" factor in the balancing equation is the "need for full development of the facts in federal litigation in order that the paramount interest in fair administration of justice be s e r v e d " . Lora v. Board of E d u c a t i o n , 74 F.R.D. at 578. The court also identified other public interest factors such as the public's interest in civil rights cases generally and in particular the public's interest in the effects on society of discriminaton in remedial schools. Id. at 579. - 10- 12726 Private interests, such as an individual's "justifiable privilege expectations", must be considered too. See Lora v. Board of Education, 74 F.R.D. at 579. In Lora this court isolated four factors designed to narrow, as much as possible, potential intrusion into the privacy of the students whose records were being sought: "First, is the identification of the individuals required for effective use of the data? Second, is the invasion of privacy and risk of psychological harm being limited to the narrowest possible extent? Third, will the data be supplied only to qualified personnel under strict controls over confidentiality? Fourth, is the data necessary or simply desirable?" Id. Finally, even though state law may not supply the rule of decision, a federal court may look at state law to determine what the state's law is with respect to the privilege in question. See, e .g ., Lora v. Board of Education, 74 F.R.D. at 576; United States v. King, 73 F.R.D. at 105: "A strong p o l i c y of comity between the state and federal sovereignties impels federal courts to recognize state privileges where this can be accomplished at no substantial cost to federal substantive and procedural policy". Recommendation As indicated above, the Special Master recommends that Dow's employee medical and workers' compensation records which -11- 12727 arise out of alleged claims of industrial exposure to phenoxy herbicides from 1953 to 1970 be produced to plaintiffs with the names, addresses and other such identifying information redacted. "'The public...has a right to every man's evidence' except for those persons protected by a constitutional, common-law, or statutory privilege." Branzburg v. Hayes, 408 U.S. 665, 688, 92 S .C t . 2646 (1972) (citation omitted). As no physician-patient privilege exists in federal common law, one should be reluctant to recommend this court to adopt one in this case. See In re D o e , 97 F.R.D. 640, 645-46 (S.D.N.Y. 1983), affirmed 711 F.2d 1187 (2d Cir. 1983) where the court ordered production of a psychiatrist's patients' records because, after an in camera examination, it found that the records contained only information which would be found in records of a non-psychiatrist physician, and, there being no physician-patient privilege in federal common law, such records were not protected from disclosure. In addition, the physician-patient privilege has been often criticized by leading authorities. See McCormick, Evidence, 105 at 228 (Cleary 2d.ed. 1972). It is worth noting, too, that the Advisory Committee to the Federal Rules of Evidence included rules defining nine specific privileges in the original Article -12- 12728 V of the Federal Rules of Evidence, however, the Committee rejected the physician--patient privilege, adopting, instead, a narrow privilege for psychiatrist-patient communications. See, Salzburg, Federal Rules of Evidence Manual, Rule 501 at 231 (3d Ed. 1982). See a l s o , In re Doe, 97 F.R.D. at 644-46. As was stated in Lora v. Board of Education, 74 F.R.D. at 578, the most constant factor in the balancing test is "the need for full development of the facts in federal litigation". Also, as in L o r a , there are other public interest factors in this case weighing in favor of disclosure of Dow employee medical and workers' compensation records. The need to have all relevant information before the court is heightened here where the public has a particular interest in the resolution of claims which involve United States servicemen alleging serious injuries as a result of a product manufactured in the United States by every major chemical manufacturer and used by the government during a war which has not yet ceased to provoke controversy. Dow argues that the medical and workers' compensation records of present and former Dow workers should not be produced just because their employer has been sued in federal court. Dow maintains that Dow employees, having no interest or involvement in this litigation, stand nothing to gain but "an invasion of their p r i v a c y " . Memorandum of Dow Chemical -13- 12723 Company, dated December 30, 1983, at 7-8. However, D o w also indicates in its papers its willingness to supply the information sought by plaintiffs. Id. at 6-7. Rather than having Dow extract the data, however, it seems preferable that the records themselves be provided. Dow's employees' privacy will be protected by blocking out the names, addresses and any other identifying information on the individual records and files. See E.E.O.C. v. U n i v ersity of Notre Dame Du L a c , 715 F.2d 331, 338 (7th Cir. 1983). See a l s o , Marrese v. American Aca d e m y of Orthopaedic S u r g e o n s , 52 U.S.L.W. 2399 (7th Cir. January 3, 19 8 4 ) (en b a n c ) . Further, the material should be disclosed under a protective order which will limit the use of the records solely for purposes of this lawsuit. While the general purpose of the physician-patient privilege is to encourage a patient in need of medical assistance to communicate freely with his or her doctor, this policy will not be impaired in the instant case where the records to be produced retain their confidentiality, inasmuch as all identifying information will be redacted. Plaintiffs have shown a compelling need for this data. The information contained in these records m a y be of great importance in determining whether, when and to what 14- extent Dow knew that its product might cause harm to human health. Accordingly, it is m y recommendation that these records, redacted as indicated, be produced forthwith, under the terms of a protective order as described above. Dated: New York, New York January 31, 1984 Respectfully submitted, :i b e r Master -15- . 9 ^ ^ 1 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE "AGENT ORANGE" PRODUCT L IA B IL IT Y LITIGATION X X MEMORANDUM OF DEFENDANT MONSANTO COMPANY IN SUPPORT OF IT S MOTION FOR A PROTECTIVE ORDER MDL N o. 381 (A ll Cases) rrr p j| r~' r\i r trr \/'c. -- il.V.. ; I-' To w n ley & U pd ik e CHRYSLER BUILDING 4 0 5 LEXINGTON AVENUE N E W Y O R K , N . Y. 1 0 1 7 4 TELEPHONE (212) 6 8 2 - 4 5 6 7 12600 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK ----------------------------------- x IN RE "AGENT ORANGE" PRODUCT LIABILITY LITIGATION ------------------------------ X MDL No. 381 (All Cases) MEMORANDUM OF DEFENDANT MONSANTO COMPANY IN SUPPORT OF ITS MOTION __________ FOR A P R O T E C T IVE ORDER__________ Defendant Monsanto Company ("Monsanto") submits this memorandum in support of its motion, pursuant to Fed. R. Civ. P. 26(c), for an order barring plaintiffs from deposing the twenty present or former Monsanto employees named in plaintiffs' most recent "preliminary list" of so-called "priority witnesses," dated February 13, 1984. With trial only eleven weeks away, to permit these twenty additional depositions would be to impose on Monsanto a heavy and unjustifiable burden -- unjustifiable because plaintiffs have had two years to take the depositions they now so belatedly request. This Court should not allow plaintiffs' deliberate delay to prejudice Monsanto. Relevant Procedural History To put plaintiffs' eleventh-hour request in its proper light, a concise account of the course of discovery in this case is required. In Pretrial Order No. 26 the Court ordered 12601 first-wave discovery on the then undefined government contract defense. See 506 F. Supp. 762, 797, 799 (E.D.N.Y. 1980). In January, 1981 plaintiffs served interrogatories on defendants. In February, 1981 Monsanto, pursuant to Fed. R. Civ. P. 33(c), produced documents responsive to those interrogatories which pertained to the government contract defense as interpreted by defendants. In Pretrial Order No. 33 the Court explicitly defined the elements of the government contract defense. See 534 F. Supp 1046, 1055 (E.D.N.Y. 1982). The Court's definition made relevant the issue of each defendant's knowledge of the human health hazards, if any, that accompanied the use of Agent Orange -- an issue that remains the focus of plaintiffs' theory of defendants' liability. See, e .g ., Pretrial Order No. 51, 565 F. Supp. 1263, 1276 (E.D.N.Y. 1983) ("Plaintiffs undoubtedly will strongly emphasize a negligent failure to warn as a basis for liability."). The Court also ordered "intensive discovery" on the now defined government contract defense. 534 F. Supp. at 1058. On July 9, 1982 Monsanto served supplemental answers to plaintiffs' interrogatories. See Exhibit A hereto. In addition to producing documents relevant to the government contract defense, Monsanto identified -- by name, address, and relevant job title -- 76 present or former Monsanto employees with relevant knowledge. Thus for over nineteen months plaintiffs have known the identities and whereabouts of 76 persons from Monsanto with knowledge about the critical issues -2- 12602 in this case, e . g . , the formation of dioxin in the 2,4,5-T production process; the identification, detection, and measurement of dioxin; the toxicity of dioxin; and the means of avoiding or minimizing the presence of dioxin in 2,4,5-T. What have plaintiffs done with this information? During the nine-month period preceding the Court's announcement on May 12, 1983 adjourning the trial scheduled for June 27, plaintiffs deposed only six of the 76 persons identified by Monsanto. During the five-month period after the adjournment, plaintiffs deposed no one presently or formerly employed by Monsanto. In September, 1983 Special Master Schreiber established a deposition schedule for the rest of the year pursuant to which plaintiffs, during three of every four weeks, would each week take the depositions of three of each defendant's present or former employees. During each such three-week period, defendants would not be permitted to depose anyone. The Special Master clearly stated the purpose of this schedule: "to give the plaintiffs catch up time." See T r . of Hearing on September 7, 1983 at 6470-74, 6476-78, 6483-84 (Exhibit B hereto). The Court affirmed this schedule, noting that "plaintiffs' failure thus far to undertake a regular program of depositions makes appropriate the program directed by the special master." Pretrial Order No. 59 at 3 (September 15, 1983). This program, pursuant to which plaintiffs were -3- 12603 permitted to take 27 Monsanto depositions by year's end, was slated to begin October 3, 1983. See Pretrial Order No. 59 at 7; T r . of Hearing on September 15, 1983 at 6561. Plaintiffs' counsel, however, who had known about the "catch up" deposition program since early September, delayed three weeks in sending counsel for Monsanto a witness list. See letter dated September 27, 1983 from David J. Dean to John Sabetta (Exhibit C hereto). That list contained the names of seven present and thirteen former employees. After witnesses were located and arrangements made, the deposition program finally began on October 17, 1983. In October, six Monsanto depositions were taken. In November six were taken; two more had been scheduled but were adjourned by Special. Master Schreiber at the request of plaintiffs' counsel and over Monsanto's objection. In December two depositions were taken. In January three were taken; thus far in February one has been taken, and one witness has been re-deposed. Thus during the four and a half months since the Court-approved deposition "catch up" program began, plaintiffs have deposed eighteen Monsanto witnesses. On February 9, 1984 plaintiffs submitted a deposition witness list containing 203 names, 98 of which were purported present or former employees of defendants, including seven from Monsanto. See Plaintiffs' Response to Paragraph No. 7 of the 12604 -4 - Magistrate's Pretrial Order No. 1 (Exhibit D hereto), at 3. In their submission plaintiffs assured the Court that the number of depositions they actually planned to take would "of necessity be but a fraction" -- less than half, perhaps even less than a quarter -- of the number listed. In this regard plaintiffs undertook to submit a second list of "priority witnesses" from the first list. I d . at 1-2. Plaintiffs' counsel reiterated these assurances at the hearing before Magistrate Scheindlin on February 9. See T r . at 9200 ("But I am sure that these [lists] will be pared down. I know ours will."), 9211, 9215 (Exhibit E hereto). Plaintiffs' "priority list" was received by counsel for Monsanto on February 15. The list contains 111 names, 60 of which are purported present or former employees of defendants. See letter dated February 13, 1984 from Schlegel & Trafelet, Ltd. to Hon. Shira Scheindlin (Exhibit F hereto). The extent of plaintiffs' prioritization of each defendant's employees is as follows: Number on First List Number on "Priority" List Diamond Dow Hercules Monsanto T-H Thompson Uniroyal 14 40 9 7 22 6 0 6 15 5 22* 6 6 0 * Of these 22 names, one, Louis Schwartz, was never a Monsanto employee, and another, L.C. Weger (identified incorrectly by plaintiffs as E. Weger), is deceased. 12605 -5- With respect to Monsanto employees, plaintiffs have plainly not prioritized -- they have multiplied, more than tripling the number of depositions they seek to take. During the past two years of discovery in this case, plaintiffs have taken 28 Monsanto depositions. They now propose to take 22 more during the month of March. ARGUMENT THIS COURT SHOULD REJECT PLAINTIFFS' BELATED REQUEST FOR TWENTY MORE MONSANTO DEPOSITIONS AS UNJUSTIFIABLE AND HIGHLY PREJUDICIAL The original complaint in this case was filed over five years ago. There has been intensive discovery during the past two years. The Court has made plain its firm intention that the trial will begin May 7, eleven weeks away. Because this litigation is so big, so complex, and so important, there is much to do before trial and little time in which to do it. Plaintiffs want to force Monsanto to spend a good deal of this precious time preparing for and defending twenty depositions they could have taken many months ago. Eleven of the twenty names on plaintiffs' "priority list" were specifically identified by Monsanto over nineteen months ago as persons having knowledge relevant to the core issues of liability in this case. All names on the list have been identified in relevant documents produced by Monsanto as long as three years ago. 12806 -6- Plaintiffs have deposed twenty-five present or former Monsanto employees during the past two years. That they have not deposed a greater number is not an accident but rather a litigation decision. Plaintiffs' counsel have often proclaimed their readiness for trial without need for any further discovery of defendants. See, e.g., Ex. B at 6468. Plaintiffs' deliberate inattention to deposition discovery of defendants did, however, concern Special Master Schreiber. As a result he required plaintiffs to take depositions and prohibited defendants from taking depositions during 75% of the last three months of 1983. The Special Master, in announcing this deposition "catch up" program, and the Court, in approving it, were careful to consider whether it would prejudice defendants' preparation for trial. Because the program was slated to end well in advance of the then unfixed trial date, both concluded that no such prejudice would result. See Ex. B at 6473-74, 6478, 6483-84; Pretrial Order No. 59 at 5. Plaintiffs in large part availed themselves of this unusual opportunity to "catch u p " . At the beginning of the three-month period they had taken only eight Monsanto depositions; during that period they took fourteen more. Since the beginning of 1984, however, plaintiffs have shown little interest or initiative in taking more Monsanto depositions, with the notable exception of Dr. R. Emmet Kelly, whom they 12807 -7- regard as very important and have been permitted to depose on three separate occasions. Otherwise, they have apparently again decided to concentrate their trial preparation efforts elsewhere. On February 9 plaintiffs served a deposition witness list containing the names of seven purported present or former Monsanto employees. Monsanto objected only to the deposition of two of the seven on the ground that plaintiffs had already deposed them. See letter dated February 15, 1984 from John C. Sabetta to Stephen J. Schlegel (Exhibit G hereto). When plaintiffs last week served their so-called "priority list" of deposition witnesses, the number of Monsanto employees they wish to depose suddenly tripled. Moreover, because only one name appears on both lists, the first list has turned out to be a sham. In light of plaintiffs' counsel's repeated assurances to this Court -- both in writing and at the hearing before Magistrate Scheindlin on February 9 -- that they would pare down and prioritize their deposition requests, the conclusion is inescapable that their conduct with regard to Monsanto has worked a fraud on Monsanto and on the Court. Indeed, plaintiffs' new list is a creature of litigation tactics, not legitimate need. It is difficult to imagine a stratagem more disruptive of Monsanto's preparation for trial than an eleventh-hour odyssey of nationwide deposition defense. If plaintiffs really thought they needed 12S08 -8- twenty more Monsanto depositions, they would have taken them during the past two years. They chose not to take them. That was a litigation decision, an exercise of their counsel's discretion. Now they want to take them. This is a litigation ploy that the Court should not enforce. Judge Weinstein on prior occasions has, in light of the rapidly approaching trial, drastically reduced the number of depositions requested by the parties. For example, last November defendants requested 61 depositions of government causation experts. The Court, citing the "enormous amount of work" to be done in the time remaining before trial, limited the number to ten. See T r . of Hearing on November 21, 1983 at 65-67, 72-75, 77-78 (Exhibit H hereto). Similarly, last week plaintiffs proposed to take the depositions of scores of government contract officers. Judge Weinstein reserved decision on whether to allow any such depositions and made it clear that he would in any event permit only a few. See T r . of Hearing on February 15, 1983 at 39-40, 45 (Exhibit I hereto). The Court recognizes there is no time on the eve of trial for a large number of depositions -- all of which could have been taken months ago. The "catch up" program has ended, and there is no time for another. Moreover, based on our preliminary review, many of the twenty Monsanto witnesses plaintiffs now seek to depose have knowledge that, if relevant, is at best merely cumulative of that of the twenty-five Monsanto witnesses whom plaintiffs have already deposed. In 12SG9 -9- such circumstances, the Court should recognize plaintiffs' omnibus request for twenty more Monsanto depositions as the mere device that it is. Because plaintiffs' deliberately belated request is completely unjustifiable and very prejudicial to Monsanto's preparation for the now imminent trial, it should be denied in its entirety. At the very least, plaintiffs should be required to explain to the Court's satisfaction, for each of the twenty Monsanto witnesses, why he was not noticed for deposition last year or before, what information plaintiffs expect to obtain from him, and why they have not been able to obtain that information from their extensive discovery of Monsanto over the past three years. C O N C L U S ION For the reasons stated above, Monsanto's motion for a protective order should be granted. Dated: New York, New York February 21, 1984 Respectfully submitted, TOWNLEY & UPDIKE Attorneys for the Defendant Monsanto Company 405 Lexington Avenue New York, New York 10174 (212) 682-4567 12610 10- UNITED STATES D I S T R I C T COURT EASTERN DI ST R I C T OF NEW YORK ---------- ------------------- x I N RE "AGENT ORANGE" : PRODUCT L I A B I L I T Y LI TIG AT ION ----------------------------------------------------------------------x Bound Fil MDL N o . 3 8 1 SUPPLEMENTAL ANSWERS OF DEFENDANT MONSANTO COMPANY TO P L A I N T I F F S ' INTERROGATORIES TO DEFENDANTS _______________( F I R S T WAVE)________________ To w n l e y & U p d ik e CHRYSLER B u il d in g 405 LEXINGTON a v e n u e N E W Y O R K , N . Y. 1 0 1 7 4 TClCPh O m E <2i2> 662- 4567 12611 UNITED STATES D I S T R I C T COURT EASTERN D I S T R I C T OF NEW YORK ---------------------------------------------------- -x I N RE MDL N o . 3 8 1 "AGENT ORANGE" : SUPPLEMENTAL ANSWERS OF DEFENDANT MONSANTO COMPANY PRODUCT L I A B I L I T Y LI TIGATION : TO P L A I N T I F F S ' INTERROGATORIES TO DEFENDANTS ( F I R S T WAVE) ---------------------------------------------------------------------- x M onsanto Company (" M on san to"), in a cco rd a n ce w ith P r e t r i a l Order No. 33 and M onsanto's February 11, 1981 Answers to P l a i n t i f f s ' " I n te r r o g a to r ie s to D efendants ( F ir s t W ave)," dated January, 1981 ( " P la in t if f s ' I n te r r o g a to r ie s " ), p ro v id es the fo llo w in g supplem ental answers to P la in t if f s ' I n t e r r o g a t o r i e s . The su p p lem en ta l answ ers c o n s i s t o f (1) l i s t s o f th e names o f p r e s e n t and p a s t M onsanto e m p lo y ees who h e ld m anagerial or su p ervisory p o s itio n s p rio r to January 1, 1971, p o s s e s s p e r t in e n t in fo r m a tio n , and are b e lie v e d to be l i v i n g ; and (2 ) 13 s c h e d u l e s o f a d d i t i o n a l M onsanto d ocu m en ts c o n ta in in g in fo r m a tio n r e sp o n siv e to one or more o f th e in te r r o g a to r ie s . Each such Monsanto document i s id e n t i f ie d by a n i n e - d i g i t number. B ecau se o f th e o v e r la p p in g n a tu r e o f some o f th e in t e r r o g a t o r ie s , some o f th e document sc h e d u le s are r e sp o n siv e to more than one in te r r o g a to r y . In an A ppendix annexed h e r e t o , th e names o f a l l Monsanto em ployees id e n t if ie d in resp on se to th e in te r r o g a to r ie s are lis te d a lp h a b e tic a lly , togeth er w ith, for each, h is r e le v a n t job t i t l e or t i t l e s h eld p r io r to January 1, 1971 and, i f h e i s n o t p r e s e n t l y em ployed by M onsanto, h i s l a s t known address. The docum ents i d e n t i f i e d h e r e in have been seg reg a ted a c c o r d in g t o t h e 13 s c h e d u l e s and a re a v a i l a b l e f o r i n s p e c t i o n and cop yin g a t th e o f f i c e s o f M onsanto's a tto r n e y s , Townley & Updike, upon reason ab le n o tic e . .otCc'O!.13 - 2- ANSWERS INTERROGATORY NUMBER 2 Provide a ta b le o f o rg a n iza tio n o f the answering D efen d a n t Company s e t t i n g f o r t h th e f o llo w in g : I n t e r r o g a t o r y 2A A. The name and l o c a t i o n o f e a c h d i v i s i o n o f t h e defendant r e sp o n sib le fo r or which p a r tic ip a te d in the d esig n , p ro d u ctio n and s a le to th e U n ited S t a te s Government o f th e h e r b ic id e known as A gent Orange f o r u s e in S o u th e a st A sia in clu d in g Vietnam during th e p erio d 1960 through 1971. S u p p le m e n ta l Answ er t o I n t e r r o g a t o r y 2A See a tta ch ed S ch ed u les 1 and 3. I n t e r r o g a t o r y 2B B. The name, a d d r e ss, te le p h o n e number, t i t l e and d u tie s o f every person employed by, under c o n tra c t w ith or o t h e r w i s e r e l a t e d t o e a c h D e fe n d a n t who was r e s p o n s i b l e f o r , p a r tic ip a te d in or fa m ilia r w ith any of the follow in g: Interrogatory 2B(i) ( i ) N e g o t ia t io n s and c o n t r a c t w ith th e U n ited S t a t e s Government fo r th e s a le o f the Agent Orange h e r b ic id e for use in S ou th east A sia in c lu d in g Vietnam during the p erio d 1960 through 1971, in clu d in g , but not lim ite d to a ll persons id e n tifie d in or fa m ilia r w ith the m atters sta ted i n D e f e n d a n t s ' M o tio n s f o r Summary Judgm ent i n t h i s c a s e and th e docum ents r e fe r r e d to t h e r e in . -3- Supplemental Answer to Interrogatory 2B(i) Robert Baynard John Bush James Connaughton Donald F isch er G. H. G r i f f i n P. N. H offman W illiam J. M cC arville Dan M id d leton R o b e r t Rumer C e c i l H. R u s s e l l M ilt Smid C. P. Z o r sc h Interrogatory 2B(ii) (ii) D esign o f th e Agent Orange h e r b ic id e w hich was the su b ject of the government co n tra ct. Supplem ental Answer to I n te r r o g a to r y 2 B ( i i ) Donald Cayard Tom G reenm an Fred Matthews D onald Mayer William J. M cC arville Dan M id d le to n R o b er t Rumer C e c i l H. R u s s e l l D. B. Sharp -cola -4- Interrogatory 2B(iil) (iii) The p ro d u ctio n o f th e Agent Orange h erb icid e which was th e s u b je c t o f th e government c o n tr a c t. Supplem ental Answer to In ter r o g a to ry 2 B ( i i i ) Rick A tkinson P h ilip B. B a ld erso n Edmund B au er Tom B o c h John Boehm Carl Bohl Donald Cayard James Connaughton Eugene C utw right Eugene Dotson Fred Edmonds Donald F isch er H. M a x w e ll G a l l o w a y Tom G reenm an R o b e r t M. H a m l e t t Paul H eisler Frank J. Helmer F. J. H o lz a p fe l P eter H owell Hal K ir tle y W i ll ia m A. Kuhn Arthur L eisy 12616 -5- Darwin E. Lewis C harles F. Lueeke Fred Matthews Donald Mayer W illiam J. M cC arville Dan M id dleton John M ullendore Roy Payne Homer P ayton J. T. Pebworth D a rrell Rainey V ernon L. Rhodes R o b e r t Rumer C e c i l H. R u s s e l l Herbert Sachs Carl Schumacher Robert Sido R o n a ld R. S m ith Robert Soden James S p rin ggate Ed S te w a r t Frank E. Take, J r . Henry F. T r a il W illiam U dell H. E. Webb, J r . R ob ert Webber Toby W hite H ill W illiam s Robert Yoder C. P. Z o r sc h Interrogatory 2B(iv) ( i v ) The s t a t e o f th e a r t and tec h n o lo g y d uring th e p e r io d o f tim e when D e fe n d a n ts were under c o n t r a c t w ith th e U n ited S t a te s Government to supp ly th e Agent Orange herb icid e w ith resp ect to the form ulation, design, m an u factu rin g, method or p r o c e s s and p r o d u c tio n o f th e Agent Orange h e r b ic id e . Supplem ental Answer to In te r r o g a to r y 2B(iv) See Supplem ental Answers to I n t e r r o g a t o r ie s Numbers 2 B ( i i ) , ( i i i ) and ( v i i ) . Interrogatory 2B(v) (v) The r is k s o f d io x in c o n ta m in a tio n a s s o c ia t e d w ith th e d e s ig n and p r o d u c tio n o f th e Agent Orange h e r b ic id e , th e m ethods o f d io x in c o n tr o l r e d u c tio n or e lim in a t io n and the co sts th ereof. Supplem ental Answer to In te r r o g a to r y 2B(v) P . G. A r v a n Rick A tkinson P h i l i p B. B a ld e r so n Carl Bohl Owen E. D o l i n -7- Jack D. E a rly P eter Howell R. Emmet K e l l y Darwin E. L ew is W illiam J. M cC arville John M ullendore Roy Payne V ernon L. R hodes F r e d e r i c k L. R u p el C e c i l H. R u s s e l l D. B. Sh arp A. J . S p e z i a l e J. A. S te p h a n s William U dell Elmer W heeler Interrogatory 2B(vi) (vi) Warning to th e U n ited S t a te s Government, i f an w ith regard to the m atters sta te d in the p reced in g item (v). Supplem ental Answer to I n te r r o g a to r y 2B (vi) M o n sa n to p r e s e n t l y know s o f no r e p r e s e n t a t i v e who was r e s p o n s ib le fo r , p a r t ic ip a te d in or was f a m i li a r w ith warnings to the U nited S ta tes government w ith regard to the risk s of d io x in contam ination a s s o c ia te d w ith Agent Orange, or the m e t h o d s o f d i o x i n c o n t r o l . H o w e v e r , R. Emmet K e l l y communicated w ith government r e p r e s e n ta tiv e s con cern in g h e a lth 12619 -8- e f f e c t s to w orkers exp osed to 2 , 4 , 5 - T and i t s p r e c u r so r s, and John M ullendore communicated w ith government r e p r e se n ta tiv e s concerning the d io x in conten t of ch lorin ated phenols. Interrogatory 2B(vii) (vii) The m anufacturing p ro cess proposed to be u t il i z e d or u t i l i z e d in the production of Agent Orange. Supplem ental Answer to In ter r o g a to ry 2 B ( v i i ) Rick A tkinson P h i l i p B. B a ld e r so n D. E. B a ld u s Edmund Bauer Tom R. B o c h John Boehm Carl Bohl Donald Cayard James Connaughton Eugene Cutwright Owen E. D o l i n Eugene Dotson Fred Edmonds H. M a x w ell G a llo w a y Jack G arrett Tom G reenm an R o b e r t M. H a m l e t t L. P. H a r ic h r 1 nri a -9- H. C. Heineman Paul H eiBler Frank J. Helmer P eter Howell Darwin E. Lewis C h a rles F. Luecke ,D. Lynch Fred Matthews Donald Mayer W illiam J. M cC arville Dan M id d leto n John M ullendore R. L. N u ll Roy Payne Homer P a y to n J. T. Pebw orth Wayne P h i l l i p s V ernon L. Rhodes James N. Roark R o b er t Rumer F r e d e r i c k L. R u p el C e c i l H. R u s s e l l Herbert Sachs V. N. S c h r o d t D. B. Sharp -10- 12621 Ronald R. Smith A. J. S p e z ia le J. A. Stephans Ed S te w a r t Frank E. Take, J r . M arrine A. T e r p stra W illiam U d ell H. E. Webb, J r . R obert Webber Toby White Robert Yoder INTERROGATORY NUMBER 3 I d e n t i f y by name and l a s t known a d d r e s s , and i f r e t i r e d so s t a t e and su p p ly th e l a s t known a d d r e ss o f each and every person, s c i e n t i f i c , medical, or otherw ise, reta in ed by or known to t h i s d e fen d a n t or known by t h i s d e fen d a n t to have been r e t a i n e d by or known to any o f th e o t h e r d e fe n d a n ts who h as stu d ied , evaluated, or reported or d ir e c tly or in d ir e c tly communicated any fin d in g s r e fe r a b le to w hatever e f f e c t s were so fou n d upon a n im a ls or human b e i n g s r e s u l t i n g from e x p o s u r e , d ir e c tly or in d ir e c tly , in the form ulation, d esign , m anufacture and p rod u ction o f phenoxy h e r b ic id e s such as 2 , 4 , 5 -T r ic h lo r o phenoxy A lip h a tics containing but not lim ited to the sy n th etic o r g a n i c c h e m i c a l 2 , 3 , 7 , 8 - T e t r a c h l o r D i b e n z o p - d i o x i n (TCDD o r "D ioxin") and oth er h e r b ic id e s c o n ta in in g P o ly c h lo r in a te d Dibenzo-p-dioxins (PCDDs) and Polychlorinated Dibenzo furans (PCDFs) including the ultimate users of those expected to be exposed to same. Supplemental Answer to Interrogatory 3 See attached Schedule 7. INTERROGATORY NUMBER 4 (FIRST) Provide a table or organization as to the United States Government showing: Interrogatory 4A (First) A. The division or units of such division of the United States Government with whom Defendants contracted to supply the Agent Orange herbicide to be used in Southeast Asia including Vietnam during the period 1960 through 1971. Supplemental Answer to Interrogatory 4A (First) See attached Schedule 1. Interrogatory 4B (First) B. The name, address, telephone number, title and duties of every person employed by, under contract with or otherwise related to said division or units of the United States Government with whom the Defendants, or any of their agents, servants, or employees dealt in connection with the negotiations and contract for the supply of the Agent Orange herbicide, including the design and production of such herbicide. 12623 -12- Supplemental Answer to Interrogatory 4B (First) See attached Schedule 1. Interrogatory 4C (First) C. The name, address, telephone number, title and duties of every person employed by said division and units whom Defendants claim were knowledgeable with respect to the following: Interrogatory 4C(i) (First) (i) The state of the art and technology at the time the Defendants were under contract with the United States Government to supply the Agent Orange herbicide with respect to the design and method of process of production including manufacturing process of the Agent Orange herbicide. Supplemental Answer to Interrogatory 4C(i) (First) See attached Schedule 3. Interrogatory 4C(ii) (First) (ii) The risks of dioxin contamination associated with the design and production of the Agent Orange herbicide, the methods of dioxin control, reduction or elimination and the costs thereof. Supplemental Answer to Interrogatory 4C(ii) (First) See attached Schedule 4. -13- i? rj Interrogatory 4C(iii) (First) (iii) Warning to the U n i t e d States Government, if any, with regard to the matters stated in the preceding item (ii). Supplemental Answer to Interrogatory 4C(iii) (First) Monsanto is presently unable to identify any such person. Interrogatory 4C(iv) (First) (iv) The process utilized or proposed to be utilized by defendant to manufacture Agent Orange. Supplemental Answer to Interrogatory 4C(iv) (First) See attached Schedule 3. INTERROGATORY NUMBER 4 (SECOND) Identify all documents, their location and the name, title, address and telphone number of the custodian in possession or control of, or known to the Defendants which relate to the items 1 through 3 supra, including: Interrogatory 4A (Second) A. Any and all research, analyses, tests, testing procedures relative to the manufacture, advertising, sale, promotion, and marketing of phenoxy herbicides such as 2,4,5-Trichlorophenoxy Aliphatics containing but not limited to the synthetic organic chemical 2,3,7,8-Tetracholor Dibenzo p-dioxin (TCDD or "Dioxin") and other herbicides containing Polychlorinated Dibeno-p-dioxins (PCDDs) and Polychlorinated Dibenzo furans (PCDFs), hereinafter simply "Phenoxy herbicides." ; ip, -14- Supplemental Answer to Interrogatory 4A (Second) See attached Schedule 6. Interrogatory 4B (Second) B. Analysis, studies, experiments, results of such experiments, including but not limited to the recommendations concerning the results of experiments relative to the formulation, production, manufacture, sale, marketing, promotion, and advertising of phenoxy herbicides. Supplemental Answer to Interrogatory 4B (Second) See attached Schedule 6. Interrogatory 4C (Second) C. Anyone acting by or on behalf of this defendant or known to be acting by or on behalf of any of the other defendants relative to the research, testing, analysis, evaluation, and recommendations relative to the manufacture, sale, distribution, advertising, and promotion of phenoxy herbicides. Supplemental Answer to Interrogatory 4C (Second) See attached Schedule 6. Interrogatory 4D (Second) D. Effects of exposure of whatever nature and under whatever circumstances or conditions to phenoxy herbicides. Supplemental Answer to Interrogatory 4D (Second) See attached Schedule 7. -15- 28?O 3 J8. W Interrogatory 4E (Second) E. The dates, places and times of measuring and testing exposure in animals (identify by animal) of phenoxy herbicides. Supplemental Answer to Interrogatory 4E (Second) See attached Schedule 8. Interrogatory 4F (Second) F. The dates, times, places, and results of exposure to humans in whatever form of phenoxy herbicides. Supplemental Answer to Interrogatory 4F (Second) See attached Schedule 9. Interrogatory 4G (Second) G. Any studies conducted by this defendant or known by this defendant to have been conducted by any of the other defendants or by anyone or by any independent organization retained by this defendant or known by this defendant to have been retained by other defendants with respect to the effects, if any, upon the employees of this defendant or the employees of other defendants known to this defendant or their spouses and children who were in any manner, shape, or form associated with or exposed to the manufacture, production and shipment of phenoxy herbicides. Supplemental Answer to Interrogatory 4G (Second) See attached Schedule 10. -16- -i r>o ^ Jr: fC' vO Interrogatory 4H (Second) H. A n y and all accidents in the production and manufacturing, shipping, and distribution of phenoxy herbicides including the results of any inquiry by this defendant or known by this defendant to have been made by other defendants or any inquiry by any public or private agency relative to such accident or accidents. Supplemental Answer to Interrogatory 4H (Second) See attached Schedule 11. Interrogatory 41 (Second) I. Identify and set forth the process utilized for the manfacture of phenoxy herbicides. Supplemental Answer to Interrogatory 41 (Second) See attached Schedule 3. Interrogatory 4J (Second) J. If the process in response to the above was changed from time to time, identify and set forth each and every process and the dates of changes, if any, to date. Supplemental Answer to Interrogatory 4J (Second) See attached Schedule 3. Interrogatory 4K (Second) K. The existence of Dioxin in the manufacture and production of phenoxy herbicides. Supplemental Answer to Interrogatory 4K (Second) See attached Schedule 4. 12628 -17- Interrogatory 4L (Second) L. Warranties, representations, and assurances, made by this defendant or known by this defendant to have been made by other defendants to the United States Government in respect of phenoxy herbicides. Supplemental Answer to Interrogatory 4L (Second) See attached Schedule 2. Interrogatory 4M (Second) M. The company's knowledge of the existence of Dioxin in the production, manufacture, distribution, sale, marketing, and promotion of phenoxy herbicides. Supplemental Answer to Interrogatory 4M (Second) See attached Schedule 4. Interrogatory 4N (Second) N. Warranties, representations, assurances, and/or promises made by this defendant or known to this defendant to have been made by other defendants to the United States Government relative to the existence or non-existence of Dioxin in phenoxy herbicides. Supplemental Answer to Interrogatory 4N (Second) Monsanto has no such documents. Interrogatory 40 (Second) O. Negotiations between this defendant or known by this defendant to have been undertaken by or on behalf of the 12829 -18- other defendants between this and/or the other defendants and the United States Government with respect to the existence of Dioxin in the manfacture, production, marketing, promotion, sale, advertising, and distribution, on [sic] phenoxy herbicides. Supplemental Answer to Interrogatory 40 (Second) See attached Schedule 2. Interrogatory 4P (Second) P. The manufacturing process from beginning to end in the production of phenoxy herbicides. Supplemental Answer to Interrogatory 4P (Second) See attached Schedule 3. Interrogatory 4Q (Second) Q. All documents which refer or relate, directly or indirectly, to any action, investigation, analysis, study, report, or statements by or on behalf of the company or received by the company or known by this company in respect of the other defendants relating to incidents of medical signs, symptoms, and conditions claimed, suggested, or suspected of being related to exposure in any form to phenoxy herbicides from in or about 1945 to date including but not limited to activities of any treatment organization, study organization and its groups. Supplemental Answer to Interrogatory 4Q (Second) See attached Schedule 7. 12630 -19- Interrogatory 4R (Second) R. All documents which refer or relate, directly or indirectly, to claims filed against this defendant in any local, State or Federal Court, agency, board, or any other entity established to hear such claims for medical conditions claimed to have resulted or be connected directly or indirectly to the formulation, design, production and manufacture of phenoxy herbicides. Supplemental Answer to Interrogatory 4R (Second) See attached Schedule 13. Interrogatory 4S (Second) S. All documents relative to studies of the effects of phenoxy herbicides when used in Southeast Asia including Vietnam including the dates, times, and places and amounts of use and conditions i n c i u u m y our not limited to meteorological conditions for use and any and all instructions, directions, suggestions, indications, and contraindications relative to the use of phenoxy herbicides in Southeast Asia from 1960 to 1971. Supplemental Answer to Interrogatory 4S (Second) See attached Schedule 12. Interrogatory 4T (Second) T. A n y and all such documents relating to any private organizations, conferences, foundations, which have conducted any studies, experiments, evaluations, or analyses 12631 -20- either independently or by and on behalf of the answering defendant or known to have been conducted by or on behalf of the other defendants with respect to the effects, if any, of exposure to phenoxy herbicides on animals and humans and the conclusions and recommendations drawn therefrom and the actions, if any, taken in respect thereto by this defendant or known by this defendant to have been taken by other defendants. Supplemental Answer to Interrogatory 4T (Second) See attached Schedule 5. Interrogatory 4U (Second) U. The funding by this defendant or known by this defendant to have been funded by any or all of the other defendants of any organizations commissioned, encouraged, suffered, and/or directed to undertake studies relative to the medical, genetic, and systematic effects and any other medical effects upon animals and humans exposed by whatever means under whatever conditions and circumstances to phenoxy herbicides. Supplemental Answer to Interrogatory 4U (Second) See attached Schedule 5. INTERROGATORY NUMBER 5 Provide an idex to and summary of each of said documents and provide and indicate their means of identification such as file number, case, etc. Supplemental Answer to Interrogatory 5 See attached Schedules. 12032 -21- INTERROGATORY NUMBER 6 Identify the name, title, address and telephone number of those persons employed by or under contract with, or otherwise related to the Defendants, who were authors of said documents and those persons who are familiar with such documents. Supplemental Answer to Interrogatory 6 See attached Schedules. Dated: New York, New York July 9, 1982 TO: SEE ATTACHED SERVICE LIST 405 Lexington Avenue New York, New York 10174 (212) 582-4567 12G33 - 22- APPENDIX P.G. ARVAN Director of Marketing,- Agricultural Division 420 North Maple Greenwich, CT 06348 RICK ATKINSON Process Research Chemist Monsanto PHILIP B. BALDERSON Chemist, Nitro Monsanto D.E. BALDUS Research Chemist, Agricultural Division Monsanto EDMUND BAUER General Manager, Agricultural Division Monsanto ROBERT BAYNARD Product Supervisor, New York 231 Jeffrey Lane Newtown Square, PA 19073 TOM R. BOCH Production Supervisor, Nitro Monsanto 12634 JOHN BOEHM Engineer, W.G. Krummrich Monsanto CARL BOHL Industrial Hygienist Monsanto JOHN BUSH Manager and Director of Governmental Marketing, Washington, D.C. 2232 North Military Road Arlington, VA 22207 DONALD CAYARD Manager of Guest Operations, Agricultural Products Company Monsanto JAMES CONNAUGHTON Manufacturing Superintendent, Agricultural Division Nitro and Krummrich 9905 Roundstone Trace Louisville, KY 40223 EUGENE CUTWRIGHT Guest Manufacturing Superintendent, Nitro 1474 Maplewood Dr. Macon, GA 31210 OWEN E. DOLIN Research Supervisor, Nitro Monsanto 1 -2- i\y EUGENE DOTSON Operations Supervisor, Nitro Foote Mineral Company Gover Road Kingsmountain, NC 28086 JACK D. EARLY Director of Technical Services, Agricultural Division and EnviroChem, Washington, D.C. 8024 Lakenheath Way Potomac, MD 20854 FRED EDMONDS Foreman, W.G. Krummrich Monsanto DONALD FISCHER Manager of Proprietary Pesticides, Director of Agricultural Chemicals Monsanto H. MAXWELL GALLOWAY Engineer, Technical Services Department Monsanto JACK GARRETT Manager, Industrial Hygiene & Pollution Abatement Monsanto TOM GREENMAN Superintendent, Technical Services Department Monsanto -3- ?L PV O" 1 R G.H. GRIFFIN Legal Department, St. Louis Monsanto ROBERT M. HAMLETT Manufacturing Supervisor, W.G. Kruitunrich 24 Queensbrook St. Louis, MO 63132 L.P. HARICH Production Supervisor, Nitro Monsanto H.C. HEINEMAN Production Superintendent, W.G. Krummrich Monsanto PAUL HEISLER General Manufacturing Superintendent, W.G. Krummrich Monsanto FRANK J. HELMER Engineering Services and Process Engineering Superintendent, Nitro Monsanto P.N. HOFFMAN Product Manager for Agricultural Chemicals, Agricultural Division 1202 Lakeshore Dr. North Barrington, IL 60010 3?-4- fr , ..4. \ F.J. HOLZAPFEL Director of Engineering, Queeny 12124 St. Clement St. Louis, MO 63131 PETER HOWELL Engineer, Nitro Monsanto R. Emmet KELLY Director, Medical Department 665 S. Skinker St. Louis, MO 63105 HAL KIRTLEY Shipping Superintendent, Nitro 835 Hughes Drive St. Albans, WV 25177 WILLIAM A. KUHN Superintendent, W.G. Krummrich 11915 Paradise Lane St. Louis, MO 63131 ARTHUR LEISY Guest Superintendent, W.G. Krummrich 3609 Tibet Drive Gulf Breeze, FL 32561 -5- 12338 DARWIN E . LEWIS E n g in eerin g S u p ervisor and A s s is ta n t T ech n ica l S e r v ic e s S u p erin ten d en t 3235 B ainburry C t. S t . L o u i s , MO 6 3 1 2 9 CHARLES F . LUECKE A s s ista n t D ir e cto r o f M anufacturing, A g r ic u ltu r a l D iv isio n M onsanto D . LYNCH S en io r R esearch C hem ist and R esearch S p e c ia lis t in p r o c e ss d e v e l o p m e n t and im p r o v e m e n t , Q u e e n y an d W.G. K ru m m rich M onsanto FRED MATTHEWS P r o d u c t i o n a n d O p e r a t i n g S u p e r v i s o r , W.G. K ru m m rich M onsanto DONALD MAYER P r o d u c t i o n C o o r d i n a t o r , W.G. K rum m rich M onsanto WILLIAM J . McCARVILLE D irecto r of Product S a les, A g ricu ltu ra l D iv isio n M onsanto DAN MIDDLETON P r o d u c t i o n S u p e r v i s o r , W.G. K rum m rich M onsanto 12339 -6- JOHN MULLENDORE E n g i n e e r i n g a n d T e c h n i c a l S e r v i c e s S u p e r i n t e n d e n t , W.C. K ru n u n rich 1020 Grove E v a n sto n , IL 60201 R . L . NULL T e c h n ic a l S e r v ic e s D epartm ent E n g in eer, A rea M aintenance S u p erv iso r and T e c h n ic a l P ro d u ctio n S u p erin ten d en t, N itr o M onsanto ROY PAYNE Head O perator and B u ild in g Forem an, N itr o M onsanto HOMER PAYTON D ir e c to r o f M anufacturing, S t. L ouis 1 7 5 3 H a g g in G rove Way C a r m i c h a e l , CA 9 5 6 0 8 J . T . PEBWORTH O perating S u p ervisor, N itro . E th y l A s ia P a c i f i c Company 1 S c ie n c e C en tre Rd. 0 6 -0 5 U n ity House Singapore, 2260 WAYNE P H I L L I P S P r o c e ss C hem ist and M an u factu rin g S u p er v iso r, N itr o M onsanto < ,r> -L -7- DARRELL RAINEY F o r e m a n , W.G. K rum m rich 1070 G eorgia Avenue E n g le w o o d , FL 3 3 5 3 3 VERNON L . RHODES P rod u ction S u p erv iso r, N itro M onsanto JAMES N . ROARK C h ief A n a ly tic a l C hem ist, N itro M onsanto ROBERT RUMER V ic e -P r e s id e n t and G eneral M anager, A g r ic u ltu r a l D iv is io n 2620 Q uail H i l l P i t t s b u r g h , PA 1 5 2 4 1 FREDERICK L. RUPEL S u p erv iso r o f P roduct Q u a lity , S t. L ou is M onsanto CECIL H. RUSSELL D irecto r o f Product Q u ality 46 W in gfield S t . L o u i s , MO 6 3 1 2 2 HERBERT SACHS M a n u f a c t u r in g S u p e r i n t e n d e n t , W.G. K rum m rich 4322 Stone C rest S t . J o s e p h , MO 6 4 5 0 5 -e - for* 41 V.N. SCHRODT Senior Research Engineer Monsanto CARL SCHUMACHER O p eration S u p er v iso r, A d m in istr a tiv e S e r v ic e s and P ro d u ctio n Sch ed u lin g P lan n in g, A g ricu ltu ra l D iv isio n M onsanto D . B . SHARP R esearch D ir e c to r , S t. L ouis M onsanto ROBERT SIDO L a b e llin g M anager, S t. L ouis M onsanto MILT SMID M a t e r i a l s H a n d l in g and P a c k a g i n g E n g i n e e r i n g S p e c i a l i s t , W.G. K ru m m rich M onsanto RONALD R . SMITH Head O p era to r, N itr o M onsanto ROBERT SODEN P l a n t M a n a g er, W.G. K rum m rich M onsanto 1 <*>.-T X A* -9- A.J. SPEZIALE Director of Research, Agricultural Division 311 Northumberland Redwood City, CA 94061 JAMES SPRINGGATE P la n t M anager, N itro 13060 E. S u n set D rive L o s A l t o s H i l l s , CA 9 4 0 2 2 J . A . STEPHANS D irector of R esearch M onsanto ED STEWART S e n i o r E n g in e e r , W.G. K rum m rich M onsanto FRANK E . TAKE, J R . M anufacturing S u p erin ten d en t, N itr o 480 H illb ro o k Dr. B a l l w i n , MO 6 3 0 1 1 MARRINE A . TERPSTRA R esearch Group L ead er, S t . L o u is 515 Andrews S t . L o u i s , MO 6 3 1 2 2 -10- 123 HENRY F . TRAIL E n gin eerin g M anager, S t. L ou is Box 239, Watson Hill Freedom, NH 03836 WILLIAM UDELL R esearch C hem ist, A g r ic u ltu r a l D iv is io n M onsanto H . E . WEBB, J R . S a fety D irecto r, N itro 1141 New Hope Road S p r i n g H i l l , FL 3 3 5 1 2 ROBERT WEBBER A ssista n t D irecto r o f E n gin eerin g, A g ricu ltu ra l D iv isio n M onsanto ELMER WHEELER In d u str ia l H y g ie n ist, S t. L ou is 110 Cool S p rin gs Dr. C a m d e n , SC 2 9 0 2 0 TOBY WHITE P la n t E n gin eer, T ech n ica l S e r v ic e s D epartm ent, N itro 5015 Town C e n tr e D r. S t . L o u i s , M0 6 3 1 2 8 -11- C/u 4 HILL WILLIAMS E n g in eerin g , Queeny M onsanto ROBERT YODER S en io r E n gin eer, S t. L ouis M onsanto C . P . ZORSCH Product S u p ervisor, A g ricu ltu ra l D iv isio n R t. 2 Box 30 P a c i f i c , MO 6 3 0 6 9 -12- VERIFICATION STATE OF MISSOURI ) ) COUNTY OF S T . LO U IS) s s .: _ J . R. B le y , J r . , b e in g d u ly sw orn, d e p o se s and sa y s t h a t he i s an a s s is t a n t s e c r e t a r y o f d e fen d a n t M onsanto Company, a co r p o r a tio n ; th a t he h as read th e fo r e g o in g Supplem ental A nsw ers o f D efen d a n t M onsanto Company t o P l a i n t i f f s ' I n t e r r o g a t o r i e s t o D e fe n d a n ts ( F i r s t Wave) and i s f a m ilia r w it h the co n ten ts th ereo f; th a t deponent i s w ith ou t p erson al know ledge o f th e m a tte rs s ta te d in th e fo r e g o in g S u p p lem en tal A nsw ers, and i s in form ed and b e lie v e s th a t no o f f i c e r or em ployee o f M onsanto Company h a s p e r s o n a l k n o w led g e o f a l l su c h m a tt e r s ; th a t th e fo reg o in g Sup plem ental Answers have been assem b led by a u th o r iz e d em p loyees and c o u n se l o f M onsanto Company, who have inform ed deponent th a t th e fo re g o in g Su p p lem en tal Answers are tr u e ; and th a t to th e b e s t o f d e p o n e n t's know ledge th o se Sup plem ental Answers are tr u e . Sw orn t o b e f o r e me t h i s 7 ^ , day o f J u ly , 1982 VIRGINIA SGHRGEDER HOTARY PUBLIC. STATE OF MISSOURI MY COMMISSION EXPIRES 8/29/RB J . R. B l e y , J r UNITED STATES DISTRICT COURT 1 Pc*nA o ifctrfttrfitg fUtTi3f*Irnr\T1ftxl nv/err ulur un ViuftrDsiVs 2 3 In re: 4 "AGENT ORANGE" 5 Product L iability L itigation 6 7 X : : : X MDL No.381 8 United States Courthouse U n i o n d a l e , Long I s l a n d 9 New York 10 September 7 , 1983 1:30 o ' c l o c k P.M. 11 12 13 U BEFORE: 15 HONORABLE SOL SCHREIBER, S p e c i a l Master 16 17 18 19 20 21 HENRY SHAPIRO 22 HARRY RAPAPORT OffTcTal Court Reporters 23 24 .26 47 25 6401 1 2 APPEARANCES : 3 4 YANNACONE & YANNACONE, ESCS. 5 Post O f f i c e Drawer 109 P a t c h o g u e , New York 11772 6 BY: VICTOR J. YANNACONE, ESQ. 7 8 9 10 P l a i n t i f f s ' Management Committee: 11 IRVING LIKE, ESQ. 12 13 14 15 16 ASHCRAFT & GEREL, ESOS. 2000 L S t r e e t , M. W. 17 Washi ngton, 0. C. 20038 18 BY: ROBERT A. TAYLOR, J R . , ESQ. 19 20 21 22 23 c o n t i nued__ 24 25 1 6402 2 A P P E A R A N C E S : (continued) 3 4 RIVKIN, LEFF, SHERMAN & RADLER, ESQS. 5 A t t o r n e y s f o r De f e n da n t Dow Chemical 100 Garden C i t y Plaza Garden C i t y , New York 11530 7 BY: LEONARD RIVKIN, ESQ. MARJORIE MINTZER, ESQ. 3 STANLEY PIERCE, ESQ. 9 ROBIN STALBOV, ESQ. 10 l 12 13 CADWALADER, WICKERSHAM & TAFT, ESQS. A t t o r n e y s f o r De f e n dan t Diamond Shamrock 14 One Hall S t r e e t New York, New York 10005 15 BY: KENDELL B. ALCORN, JR. , ESQ. 16 MICHAEL M. GORDON, ESQ. JEANNE P. BOLGER, ESQ. 17 18 19 20 TOHNLEY & UPDIKE, ESQS. A t t o r n e y s f o r De f endant Monsanto Company 21 405 L e x i n g t o n Avenue New York, New York 10017 22 BY: PHILIP PAKULA, ESQ. 23 JOHN C. SABETTA, ESQ. JAMES E. TYRRELL, ESQ. 24 25 c o n t i nued. . . EASTERN nTSTOTCT POTTO-T t a n o T c n e 6403 1 2 A P P E A R A N C E S : (continued) 3 4 CLARK, SAGLIARDI & MILLER, ESQS. 5 A t t o r n e y s f o r De f enda nt T. H. A g r i c u l t u r e & Nutrition Co., Ic. 6 The Inns o f Court 99 Court S t r e e t 7 White P l a i n s , New York 10607 a BY: MORTON SILBERMAN, ESQ. JOHN J . BURKE, ESQ. 9 io n 12 KELLEY, DRYE & WARREN, ESQS. 13 A t t o r n e y s f o r De f endant H e r c u l e s , Inc. 101 Park Avenue u New York, New York 10178 13 BY: PATRICIA TUOHEY, ESQ. 16 17 18 ARTHUR, DRY & KALISH, P.C. 19 Attorneys for Defendant UniRoyal 1230 Avenue o f t h e Americas 20 New York, New York 10020 BY: THOMAS A. BECK, ESQ. 21 MARILYN NEIMAN, ESQ. 22 23 continued -- id 'J 24 25 1 6404 2 A P P E A R A N C E S : (continued) 3 4 SHEA, GOULD, ESQS. Attorneys for Defendant UniRoyal 5 330 Madison Avenue New York, New York 10017 6 BY: RICHARD GOLDSTEIN, ESO. 7 3 9 10 BUDD, LARNER, KENT, GROSS, PICILLO 4 ROSENBAUM, ESQS. 11 A t t o r n e y s f o r De f endant Thompson Chemi cal s 33 Washington S t r e e t 12 Newark, New J e r s e y 0 7 102 13 BY: EDWIN R. MATTHEWS, ESQ. DAVID GROSS, ESQ. 14 _ 15 15 17 UNITED STATES OF AMERICA Civil D i v i s i o n , Department of J u s t ic e 18 521 12th S t r e e t , Nort hwest Rnom 822 19 Washi ngton, D. C. 20530 20 BY: ARVIN MASKIN, ESQ. 21 22 continued. . . 23 24 25 Ea s t e r n district c o u r t -r e p o r t * 1 2 A P P E A R A N C E S : (continued) 3 4 5 ALSO PRESENT: JOY BEANE, ESQ. 7 A s s i s t a n t to Sp eci al Master a 9 i 10 11 12 oOo 13 14 13 16 17 18 19 20 21 22 23 24 23 6505 VV D . 1 6468 time t o c ompl et e i t . There were a number o f 2 3 problems t h a t have a r i s e n and t h e r e were some 4 a d d i t i o n a l documents and c o uns e l saw f i t In good faith to continue the discovery. 5 However, I do b e l i e v e t h a t I t 1s n e c e s s a r y 6 to g i v e t he p l a i n t i f f s some o p p o r t u n i t y to conduct 7 some d e p o s i t i o n d i s c o v e r y . And I r e c o g ni z e d t h a t 8 e a r l i e r In the proceedings p l a i n t i f f s have 9 I n d i c a t e d t h a t they were ready to go to t r i a l 10 and t h a t they did not need any o t h e r d i s c o v e r y 11 on the government c o n t r a c t d e f e n s e , but with the 12 summary judgments and wi th the enl argement o f the 13 case taken Into account the Issue of general 14 causation, I did not view the e a r l ie r statements 15 by the p l a i n t i f f s t h a t they had completed 16 di sc ov ery as meaning that they could not 17 c o n t i nu e to make t h a t d i s c o v e r y now. 18 My guess i s t h a t t hey must have conducted 19 t o dat e maybe f i v e or ten d e p o s i t i o n s o f a l l 20 def endant s on government c o n t r a c t d e f e n s e and, 21 frankly, while I recognize counsel for the 22 defense continually raise that Issue, I find It 23 hol ds no m e r i t t h a t we have wai ved. 24 I t shoul d be a l s o noted t h a t a number o f 25 Ea s t e r n district c o u r t reporters UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST 0 . 1 6478 2 HR. RIVKIN: I have no problem wi t h t h a t . 3 The o t h e r problem I have, f o r c l a r i f i c a t i o n , 4 s i r , 1s you are s a y i n g we cannot conduct 5 d e p o s i t i o n s o t h e r than a f f i r m a t i v e l y more than one week a month? 6 7 SPECIAL MASTER: Yes. MR. RIVKIN: Is t h e r e a reason f o r t hat ? 8 9 SPECIAL MASTER: Yes. The reason 1s you conducted f i f t e e n months 10 of depositions. 11 MR. RIVKIN: Not one week on l i a b i l i t y or 12 causation. 13 SPECIAL MASTER: You w i l l g e t I n t o 1 t . 14 At t h i s s t a g e I want to g i v e the p l a i n t i f f s 15 catch up t i me . Ue have oirly' been t a k i n g d e f e n d a n t s ' 16 d e p o s i ti o n s o f government w i t n e s s e s . 17 MR. RIVKIN: I am throwing t h e s e out 18 not necessarily - - 19 SPECIAL MASTER: I n c i d e n t a l l y , I d o n ' t 20 what the d i s c o v e r y 1s on misuse and c a u s a t i o n y e t 21 as f ar as the d e f e n d a n t s , because I have given 22 them a d d i t i o n a l time t o prepare t h e i r b r i e f s 23 on t h a t . 24 MR. PAKULA: Th a t ' s mi s us e . 12S54 25 eastern district c o u r t reporters UNITED STATES DISTRICT COURT TiS C A D M A N Pf A7A t*rr 6483 1 1t. 2 SPECIAL MASTER: Not any l o n g e r . I t 1s 3 a l r e a dy p a s t September 1 s t now. September 1 s t 4 was the new h o r i z o n , so to speak. We were going 5 to take another approach. 6 MR. RIVKIN: Then I take i t you w i l l 7 e n t e r t a i n document r e q u e s t s from the Government? 8 SPECIAL MASTER: By a l l means. 9 I would prefer to get that as soon as p o s s i b l e . 10 But not onl y on the I s s u e o f c a u s a t i o n . 11 MR. RIVKIN : L i a b i l i t y a l s o ? 12 SPECIAL MASTER: The I s s u e o f mi s u s e . 13 MR. RIVKIN: Very d e f i n i t e l y , y e s , s i r . 14 MR. PAKULA: A q u e s t i o n , s i r . 15 SPECIAL MASTER: Yes. 16 MR. PAKULA: On the f o u r t h week, what are 17 the l i m i t s , 1f any, on how many d e p o s i t i o n s 18 the de f e ndant s can take on each o f t h o s e weeks? 19 You may have s a i d t h a t . 20 SPECIAL MASTER: No, I d i d n ' t . But I 21 would think somewhere in the area o f t hr ee or 22 four. 23 MR. PAKULA: Three or four d e p o s i t i o n s ? 24 SPECIAL MASTER: Yes. p- r. 25 Eastern district court reporters UNITED STATES DISTRICT COURT 484 1 2 MR. PAKULA: A week? 3 SPECIAL MASTER: Yes. 4 MS. MINTZER: A week? 5 SPECIAL MASTER: Yes. 6 MR. RIVKIN: There are t we l v e t o f i f t e e n , s i r , 7 going -- 8 SPECIAL MASTER: Ye s. I w a n t t h e p l a i n t i f f s 9 to have a l i t t l e c a t c h up t i me . You have had 10 160 d e p o s i t i o n s . We are not goi ng t o t r i a l 11 1n October or November. MR. SILBERMAN: What 1s the f i r s t date 12 13 o f d e p o s i t i o n s ? SPECIAL MASTER: September 22nd. 14 MR. SILBERMAN: T h a t ' s a Thursday? 15 SPECIAL MASTER: No, 1t 1s n o t . 16 MR. SILBERMAN: Then you have the wrong da t e . 17 SPECIAL MASTER: The 2 6 t h , I'm s o r r y . 18 MR. SILBERMAN: All r i g h t . 19 SPECIAL MASTER: Now, one f u r t h e r a d d i t i o n . 20 I f couns el cannot agree on w i t n e s s e s f o r the 21 f i r s t few weeks, I e x p e c t to meet with them next 22 week and r e s o l v e the d i s p u t e s . 23 MS. MINTZER: S p e c i a l Mast er, may I ask 24 a q u e s t i o n on PSAC w i t n e s s e s ? Where w i l l they 25 12656 eastern district c o u r t reporters UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST DAVIO JOHN OEAN ANTHONY J. FALANOA JOSEPH COVELLO NORMAN ROSE JOSEPH M. Re y n o ld s MONROE FMK COUNSELLORS AT LAW ONE OLD COUNTRY ROAD CARLE PLACE, NEW YORK 11514 September 27, 1983 ( t it ) 24S -M U m<) 741-4411 (212)343-4114 BY HAND Townly & Updike, Esqs. 405 Lexington Avenue New York, New York Re: Agent Orange Product Liability Litigation MDL # 3 8 1 Attention: John Sabetta, Esq. Dear John: The following is a partial list of those past and present Monsanto employees whom we now wish to depose: Past: Robert Rumer A. J. Speziale Frank E. Take, Jr. Elmer Wheeler Peter G. Arvan Paul N. Hoffman R. Emmett Kelly, M.D Present: Vernon L. Rhodes D. B. Sharp J. A. Stephans Owen E. Dolin Unknown: James Springgate Jack D. Early J. L. Sims John Mason George Kempson J. C. Strum Eugene Outright L. E. Dotson L. T. Webber With professional respect, we remain, Very truly yours, DEAN, FALANGA & ROSE D J D :at DAVID J. DEAN 12857 UNITED STATES DI S T RI CT COURT EASTERN DI S T RI C T OF NEW YORK In re "AGENT ORANGE" Product L ia b ility L itig a tio n * * * MDL N o . 3 8 1 * * Judge Jack B. W e in s t e in P L A I N T I F F S ' RESPONSE TO PARAGRAPH NO. 7 OF THE MAGISTRATE'S PRETRIAL ORDER NO. 1___________________________________ The u n d e r s i g n e d , S te p h e n J . S c h l e g e l , member o f t h e P l a i n t i f f s ' Management Committee, subm its the f o llo w in g names o f w i t n e s s e s which t h e P l a i n t i f f s may w i s h to be d e p o s e d i n c o n f o r m i t y w i t h P a r a g r a p h No. 7 o f the M a g i s t r a t e ' s P r e t r i a l Order No. 1. PRELIMINARY STATEMENT The u n d e r s ig n e d r e c e i v e d th e M a g i s t r a t e ' s P r e t r i a l O rder No. 1 on T u e s d a y , F eb ru ary 7 , 1 9 8 4 . The l i s t w h ic h f o l l o w s i s t h e r e s u l t o f c o m p ilin g the names o f w i t n e s s e s an d /or d ep a rtm en ts and o r g a n i z a t i o n s who e i t h e r h a v e n o t b e e n p r e v i o u s l y d e p o s e d a t a l l o r who h ave n o t been d ep o sed on c a u s a t i o n i s s u e s . I t c o n t a i n s a p p r o x i m ately 200 p r o s p e c tiv e w i t n e s s e s . A lth o u g h P l a i n t i f f s w i s h , in c o n f o r m i t y w i t h th e O rd er, to be a b le to supplem ent t h i s l i s t w ith a d d it io n a l w i t n e s s e s as they become known, P l a i n t i f f s a ls o wish to a d v ise the M a g istra te that 1 they b e lie v e that d iscovery w i l l only of n e c e s s it y be but a fra ctio n o f t h e t o t a l number shown h e r e a f t e r . The u n d e r s ig n e d e s t i m a t e s t h a t d e p o s i t i o n d i s c o v e r y sh o u ld n ot exceed o n e - h a l f and p erhaps w i l l not exceed any more than one-quarter of the total number of witnesses listed. We request 7 to 10 days additional time to provide the Magistrate with a list of priority witnesses from this number. The Magistrate should know that the first nine witnesses listed are shown in conformity with the Court's prior wishes regarding the names of up to ten Government causation witnesses the Plaintiffs wish to depose. It is not anticipated that any reduction in the number of those witnesses' depositions will be effectuated. Plaintiffs acknowledge that by their calculations there are approxi mately sixty normal working days available for the purpose of taking depositions between the time of this submission and the commencement of trial. They also submit to this Court that they have previously demonstrated their ability to engage in a multiple-track deposition schedule. They represent to this Court that they continue to be able to appear at multiple depositions in a variety of locales on the same day and in successive days and that they have the ability to complete the discovery they need to be ready for trial on May 7, 1984. The names of witnesses are as follows: Debdas Mukerjee, EPA - D.C. Philip J. Landrigan, CDC, NIOSH Janet Springer, EPA - D.C. Vernon N. Houk, CDC - Atl. James Mason, CDC - Atl. Dr. Diane Courtney, EPA - D.C. Peter Infante, NIOSH - D.C. Umberto Saffiotti, NCI - D.C. Donald Barnes, EPA - D.C. MONSANTO WITNESSES I. Contracting officers R i c h m o n d , Virginia: Edward E. Adams W. B. Bells William Blumenauer John Blish George Collins Val K. Gaertner Jesse Gershberg George Kline Frank Lemak Francis 0. Panneton L. P. Seitz R. D. Thompson II. Monsanto inspectors St. Louis region: Ten Eyck R. D. Fisher Me McCalley Roy Meyers N. Wirz R. Wright III. Monsanto employees: Robert E. Baynard S. S. Daniels W. J. McCarvelle Lapin 0. Scott T o m K . Smi th John S. Sullivan Charles Zorsch IV. Miscellaneous witnesses Johnston Chemical Laboratories, Des Moines, Iowa Dr. Oettel 12G60 -3- UNIROYAL, INC. WITNESSES I. Government witnesses - Defense General Supply Center - Richmond, Virginia: William Fenner H. G. Fredericks William Kidd II. Defense Contract Administration Service Office: F. H. Placet (Process inspector) A. Matasauage - Industrial Specialist M. Dojny - Quality Assurance Rep. (Chemical inspector) A. W. Glenn - Preservation Packing Specialist J. F. O'Connor - Transportation officer Harold A. Llo y - Administration Contracting officer W. Maloney - Transportation officer Wayne Vandervendor - Specialist for Technical Orange Orange Herbicides. -4- 12G61 HERCULES' WITNESSES I. Hercules' employees: J. G. Copeland C . L . Dunn J. R. Fisher Thomas R. Hunt Rafael H. Huston A. E. Sidwell A. L. Treisback H. E. Wilder R. T. Yates II. Defense Personnel Supply Center - Contracting officers: Government witnesses Thomas P. Dalby Jacob L. Bolton Ellis Cash J. R. Mallet J. M. Kirgis L. K. Woolfolk J. E. Pallard Donald Elmore W. Schuback L. A. Pardee J. G. Charlton E. D. Baumgartner P. R. Little L. E. Faist III. Miscellaneous witnesses: Dr. L. L. Danielsson, NACA Otis Fancher, Industrial Biotests Laboratories G. Holsing, Hazelton Laboratories J. Klingman, NACA -5- 12562 HERCULES' WITNESSES - CONT. III. Miscellaneous witnesses: Paul Mayfield, NACA Charles E. Minarick, U.S. Army - Chemicals Biologies William Lee Popham - U.S.D.A. Mitcher Zavon - University of Cincinnati IV. Depositions Duces Tecum of the Custodian of Records of the following facilities: NACA - National Agricultural Chemicals Association, Washington, D.C. Bionetics Research Laboratories, Methesda, Maryland Hazleton Laboratories, Falls Church, Virginia Industrial Biotests Laboratories, Illinois Jacksonville Arkansas Laboratories V -6- fO^ 1o -Q-J T-H AGRICULTURE & NUTRITION CO. WITNESSES I. Government witnesses: Edward E. Adams, St. Louis, Missouri A. A. Block, Kansas City, Missouri James E. Bowers, St. Louis, Missouri Charles Dilley, Kansas City, Missouri A. A. Pello, Kansas City, Missouri L. W. Stenzel, Kansas City, Missouri Frank W. Kleman, St. Louis, Missouri Joseph W. Fowler, Kansas City, Missouri A. Y. Kistner, Kansas City, Missouri K. M. LeFever, Kansas City, Missouri Employees : R. E. Ballinger Bob Brooks George Carmack Dale Carpenter L. S. DeAtley Mr. Damaunas Bill Schirley Art Wilson John Ferris Bob Greer Jack Hallen John Hughes Bill Kates Dr. Charles Lewis Bill Sulzen Gary Linderman Sam Long Bob Mayer Bob Perry Harold Page Chet Roberts Tom Terlly e>f> jf -7- THOMPSON- ' - CHEMICAL COMPANY _________ W I T N E S S E S Employees : John Mayer Leo Crivello D. Halleck Cecil McGill James Reagan F. Vargas II. Government witnesses: Director Commander, DCSR - St. Louis, Missouri Director of Procurement and Production - Defense General Supply Center - Richmond, Virginia III. Miscellaneous witnesses: Kosciusko Medical Clinic - St. Louis, Missouri Dr. Earnest Velasco Dr. A. J. Reichas Dr. Raymond Simpson' American Mutual Liability Insurance Company St. Louis, Missouri Custodian of Records - Division of Worker's Compensation Dept, of Labor and Industrial Relations Jefferson City, Missouri - Local office, St. Louis, MO. Mr. Jack Randall n.r*o rr u D -8- DIAMOND-SHAMROCK WITNESSES I. Diamond-Shamrock employees: J. 0. King Lex Creamer Howard E. Edison S. B. Honour David J. Ponter Cy Perkins J. J. Lusardi Melvin Hochberg R. F. Lindeman John J. Brennan Peter Celli William Goodloe Harry E. Klepp Milton Rosenfeld II. Government witnesses: M. Isele, DCAS - contracting officer J. K. Murphy, Chief - Contracts branch E. R. Sabala, DCAS - contracting officer R. J. Schlesinger - Transportation officer I. Wolin, DCAS - Cleveland, Ohio -9- 12368 DIAMOND-SHAMROCK WITNESSES - CONT. II. Government witnesses (Cont.) Inspector, DCASRO - Contracting officer Schenectady Army Depot Petroleum Division Schenectady, New York Chief DSASD - Newark 240 Route 22 Springfield, New Jersey 07081 Commander, DCASR Contracting officer 1367 E. 6th Cleveland, Ohio -10- JtL/OPu QO P DOW WITNESSES I. Dow employees: George E. Lynn Paul Orrefice Ray Holmes R. D. Wilcox Ross Mulholland Larry G. Silverstein H. R. Hoyle Julius Johnson V. K. Rowe Patricia Keeler G. Goergen Chester Otis S. E. Sadek F. H. Riley R. N. Smiley L. B. Grant C. 0. Hutchenrenther F. C. Amstutz D. E. Pletcher W. L. Corbin D. D. Irish J. C. Tucker J. W. Harris E. C. Staehling K. Y. Hansen R. C. Hoff W. J. McCoy K. C. Barrons Joseph Temple Earl Farnham W'ade VanValkenberg Roy Van Horn Fred Chase Harold DeLong C. A. Highhill J. L. Spalding Dr. Keith Barrons, retired 142 W. Bay Cove Holmes Beach, FL K. Y. Hanson, retired Ocala, FL Sam Birkman John Barber ' 12068 DOW WITNESSES fCONT.) II. Government witnesses: Inspection Commander, DSACR Detroit, Michigan George C. Slagle, Jr. - Contract Administrator August Barbarine J. L. Brinser, Middleton, PA Welton Bills - Defense General Supply Center John Boyce - Defense General Supply Center Brigadier General John D. Hines Edward R. Killam R. G. Knott - DSACR Inspector C. E. Raub - Middletown, PA Hon. Richard M. Nixon - Former President of the United States John Baldeschweiler (continuation of deposition) The aforesaid list is submitted in accordance with the terms of the Magistrate's Pretrial Order No. 1 and is subject to the r e p r e sentations and requests contained in the preamble first above written. Respectfully, -12- UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re: "AGENT ORANGE" PRODUCT LIABILITY LITIGATION x : : : x 9164 MDL No.381 United States Courthouse Brooklyn, New York February 9, 1934 3:00 o'clock p.m. Before : HONORABLE SHIRA SCHEINDLIN, Magistrate HENRY SHAPIRO JOSEPH BARBELLA SHELDON SILVERMAN OFFICIAL COURT REPORTERS EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 12870 1 2 PLAINTIFFS' MANAGEMENT COMMITTEE 3 DAVID DEAN, ESQ. STEPHEN J. SCHLEGEL, ESQ. 4 5 91G5" 6 RIVKIN, LEFF, SHERMAN & RADLER, E S Q S . 7 Attorneys for Dow Chemical 100 Garden City Plaza 8 Garden City, New York 11530 9 BY: MARJORIE MINTZER, ESQ. Of Counsel 10 11 12 CADWALADER, W I C K ERSHAM & TAFT, ESQS. Attorneys for Defendant Diamond Shamrock 13 1 Wall Street 14 N e w York, N e w York 10005 BY: MICHAEL M. GORDON,' ESQ. 15 GRANT HERING, ESQ. JOSEPH SCHIAVONE, ESQ. 16 Of Counsel 17 EDWARD J. J1ASEK, ESQ. Counsel for Diamond Shamrock 18 19 TOWNLEY & UPDIKE, ESOS. 20 Attorneys for Defendant Monsanto Comoany 405 Lexington Avenue 21 New York, New York 10017 22 BY: PHILIP PAKULA, ESO. JOHN C. SABETTA, ESQ. 23 JAMES E. TYRRELL, ESQ. EDV7ARD FERGUSON, ESQ. 24 Of Counsel 25 12^71 1 APPEARANCES : 2 3 SHEA, GOULD, E S Q S . 4 Attorneys for UniRoyal 330 Madison Avenue 5 New York, New York 9160 6 BY: MEGAN LESS E R LEVINE, ESQ. Of Counsel 7 8 9 BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, ESQS. Attorneys for Defendant Thompson Chemicals 10 33 Washington Street Newark, New Jersey 07102 11 BY: EDWIN R. MATTHEWS, ESQ. 12 DAVID GROSS, ESQ. WIL L I A M J. MARCONI, ESQ. 13 SUSAL O L N E Y , ESO. Of Counsel 14 15 UNITED STATES DEPARTMENT OF JUSTICE 16 Civil Division 17 BY: GRETCHIN WITT, ESQ. Special Attorney 18 19 Also present: 20 JOY BEAN, ESQ. 21 Assi s t a n t to Special Mast e r 22 23 24 J1LCotu *10 I 25 1 2 APPEARANCES : 3 4 CLARK, GAGLIARDI & HILLER, ESOS. 5 Attorneys for Defendant T.H. Agriculture & Nutrition C o . , Inc. 6 The Inns of Court 99 Court Street 7 White Plains, New York 10607 8 BY: JOHN J. BURKE, ESQ. Of Counsel 9 10 11 KELLEY, DRYE & WARREN, ESOS. Attorneys for D e f e n d a n t Hercules, Inc. 12 101 Park Avenue New York, New York 10178 13 14 BY: W I L L IA M A. KROHLEY, ESQ. PATRICIA TUQHEY, ESQ. Of Counsel 15 16 17 ARTHUR, DRY & K A L I S H , P.C. 18 Attorneys for Defendant UniRoyal 1230 Avenue of the Americas 19 New York, New York 10020 20 BY: THOMAS A. BECK, ESO. MARILYN NEIMAN, ESO. 21 Of Counsel 22 23 24 25 9xv 12G73 9200 1 MR. DEAN: While we are on the topic, can we just 2 go into it a little further. 3 THE COURT: Sure. 4 MR. DEAN: Your Honor has outlined one hopeful 5 ground. And that's five days. THE COURT: From the day after they are served 6 with a notice, yes. 7 MR. DEAN: But I am still troubled by -- and wh e n 8 I see the unlimited nature of the proposed deposition, 9 and, your Honor -- 10 THE COURT: On both sides. 11 MR. DEAN: Your Honor understands and considers 12 if this is done and w e are here -- that w e m a y not 13 be allowed and then we w o u l d have to apply for other 14 names. Other names, you know, that w o u l d be an 15 inevitable result of a request. But I am sure that 16 these will be pared down. I know ours will. And I 17 must, be forthright w i t h your Honor and tell y o u that 18 there are more names here than we are going to call. 19 We are just fearful of not us i n g the one or two that -- 20 THE COURT: We could get a duplicate set of books 21 if you will give me the real list. 22 MR. DEAN: There isn't any real list. Every one 23 of the names that we have submitted are valid names. 24 But w h a t we are saying -- 22G74 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 9211 1 the treating physicians. We were very clear. We heard 2 you say that y o u have the right to add to these. 3 We expect they m a y have to do so. But the treating 4 physician -- this is the list that we have. We have 5 taken them all. We may pair that one down, but the 6 rest are absolutely -- 7 THE COURT: I am glad you brought me back. I hadn't known in the past that there had been a preferred 8 9 and not preferred list. I suggested the same thing. I like the idea. I would ask that the plaintiff do 10 that without any fear or risk of notice or preclusion. 11 But just to give the notice of who the must do list 12 is and then -13 MR. SCHLEGEL: We have our own preamble to that. 14 It's within seven to ten days. 15 THE COURT: Great. Within seven to ten days. 16 Is that acceptable to the defendants. 17 MR. SCHLEGEL: We refer to it as a priority list. 18 THE COURT: Great. The second list, you will 19 get them. 20 MR. SCHLEGEL: Yes. 21 THE COURT: Great. 22 MS. MINTZER: And the cutoff date as of now for 23 the deposition of the defendant's w itnesses is 24 March 30th. 25 * 2 ^7'' eastern district c o u r t reporters UNITED STATES DISTRICT COURT 9214 1 counsel will in fact on five day's notice present any 2 one of these people w h o is available to go to two or 3 three tracks just on the one defendant. 4 THE COURT: Sure. 5 MR. SCHLEGEL: I can take 90 in M a r c h alone. 6 THE COURT: Well -- 7 MR. SCHLEGEL: I can do that. 8 THE COURT: It's not a boast. He may have to 9 take 90 in M a r c h alone. I think that is a reality. 10 Well, is there any p o ssibility to get us that 11 priority list? But if you could, and since w e are 12 h a v i n g -- 13 MR. SCHLEGEL: I am going to have it for the 14 m e e t i n g on the 15th. 15 THE COURT: That's the m o s t we can ask. 16 MS. MINTZER: If we could have it before the 17 meeting, then we can deal w i t h it at the meeting. I 18 can't argue about a list of 35, and apparently it is 19 a m e a n i n g f u l list -- THE COURT: No. Y o u k n o w it's 35. Y o u can find 20 out who they are when he comes in with the priority 21 list. Then you can do it on the spot. You will have 22 the big list to work with. 23 X2: 78 MR. SCHLEGEL: I think you have one thing that 24 is apparent as to wha t we did and w h a t they did. They 25 eastern district c o u r t reporters UNITED STATES DISTRICT COURT 9 921b 1 are giving an essential list, but they are telling 2 y o u that I've got the right to take 200 more. I am 3 giving 200 more and even m a y b e a couple of more as 4 an inclusion and saying I want to cut it down to a 5 quarter or to a half of that. It's just a difference 6 of approach. 7 THE COURT: Okay. I appreciate that, Mr. Schlegel. 8 And I hope that you are wrong about the defendants. 9 Is there any thought y o u are going to have 200 10 m o r e or are y o u talking about a small addition where 11 needed? 12 MR. SCHLEGEL: I am just suggesting -- 13 MR. K R O H L E Y : I haven't reviewed this list from 14 top to bottom. I am familiar w i t h mos t of the names 15 on it. I think one thing y o u have to bear in m i n d 16 is that we were really begi n n i n g to try six cases. 17 Six cases w h i c h have just been identified not that 18 long ago. We are getting into compl i c a t e d m edical 19 and scientific issues. Ordinarily y o u have use to do what we are trying to do in a period of months. 20 THE COURT: I know that. 21 MR. KROHLEY: We are serious and I am agraid that 22 the -- 23 THE COURT: But my question is, I said y ou could 24 make additions. Dow expects them to be fast or just 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST 12377 STEPHEN J . SCIILCUBL CAN M. T r a k k l k t Iva R. A z m i s S teven P. P o i.icn J ames A. Romanyak S c H i.r .O F .i. & T r a p e l e t . Lt d . A t t o r n e y s a t Law O ne North La Saule St r e e t C hicao o . Illin o is GOG02 . February 13, 1984 f-?- *ltiet - if r ' S u it e n iH X ) (3 I ) 708*1001 Honorable Shira Schneindlin Magistrate & Special Master United States District Court Eastern District of New York 225 Cadman Plaza East Brooklyn, New York 11201 Re: In re "Agent Oran g e " Product Liability Litigation - MDL No. 381 Dear Magistrate Scheindlin: In conformity with the representation made by the Plaintiffs to you at the hearing he d on February 9, 1984, we are tendering the.following as our preliminary list of our priority witnesses. Plaintiffs wish to depose: Debdas Mukerjee, EPA - D.C. Philip J. Landrigan, CDC, NIOSH Janet Springer, EPA - D.C. Vernon N. Houk, CDC - Atl. James Mason, CDC - Atl. Dr. Diane Courtney, EPA - D.C. Peter Infante, NICSH, D.C. Umberto Saffiotti, NCI - D.C. Donald Barnes, EPA - D.C. 12678 DIAMOND-SHAMROCK WITNESSES I . Diamond-Shamrock employees : David J. Porter S. B. Honour J. 0. King Melvin Hochberg Howard E. Edison Lex Creamer (Would like to depose, but unable to locate) II. Government witnesses : M. Isele, DCAS - Contracting officer J. K. Murphy, Chief - Contracts branch E. R. Sabala, DCAS - Contracing officer I. Wolin, DCAS - Cleveland, Ohio DCASR - Commander Contracting officer 1367 E. 6th Cleveland, Ohio 12G79 -2- I . Employees: DOW CHEMICAL COMPANY George E. Lynn Julius Johnson H. R. Hoyle Ross Mulholland Larry G. Silverstein Ray Holmes R. D. Wilcox V. K. Rowe G. Goergen Paul Orrefice Sam Birkman John Barber Joseph G. Temple, Jr. Etcyl H. Blair David L. Rooke -3- 12680 HERCULES' WITNESSES I. First priority list : C . L . Dunn T. Eagon A. E. Sidwell A. L. Triesback H. E. Wilder I I . Second priority list : J. G. Copeland Rafael H. Huston Charles E. Minarick, U.S. Army - Biochemical Custodian of Records of NACA - National Agriculture Chemicals Association, Washington, D.C. Custodian of Records of Bionetics Research Laboratories, Bethesda, Maryland III. Third priority list : Otis Fancher, Industrial Biotests Laboratories Custodian of Records of Industrial Biotests Laboratories, Illinois R. T. Yates Custodian of Records of Hazleton Laboratories, Falls Church, Virginia 2S81 HERCULES' WITNESSES cont. IV. Defense Personnel Supple Center - Contra c t i n g officers: Government witnesses Donald Elmore Thomas P. Dalby Jacob L. Bolton Ellis Cash ILC.'? QjO MONSANTO WITNESSES Charles Luecke John Mullendore Carl Bohl Phillip Balderson Homer Payton Frederick L. Rupel Ronald R. Smith R. L. Payne T o m K. Smith Richard Wallace, M.D. Nel Putzel Louis Schwartz Robert R. Rumer (Recall) U. L. Sims R. L. Null Toby White Howard Minkler E. Weger Nick Machacrola Paul Ekberg Jim Starrett Bruce Ely MONSANTO WITNESSES cont. II. Contracting officers - R i c h m o n d . Virginia : John Blish George Collins Jesse Gershberg III. Monsanto inspectors - S t . L o u i s .region : Ten Eyck R. D. Fisher M. McCallev Roy Meyers N. Wirz R. Wright 1223 4 -7- THOMPSON CHEMICAL COMPANY WITNESSES Employees : John Mayer Leo Crivello D. Halleek Cecil McGill James Reagan F. Vargas II. Government witnesses : DCSR, Director Commander - St. Louis, Missouri III. Miscellaneous witnesses: Dr. Earnest Velasco Kosciusko Medical Clinic St. Louis, Missouri American Mutual Liability Insurance Company St. Louis, Missouri UNIROYAL, INC. WITNESSES I. Defense Contract Administration Service O f f i c e : F. F. Placet (Process inspector) A. Matasauage - Industrial Specialist M. Dojny - Quality Assurance Rep. (Chemical inspector) A. W. Glenn - Preservation Packing Specialist Harold A. Lloy - Administration Contracting officer Wayne Vandervendor - Specialist for Technical Orange Herbicides 12G86 -9- T-H AGRICULTURE & NUTRITION CO. WITNESSES T-H Agriculture & Nutrition Co. e m p l o y e e s : L. S. DeAtley Bill Sulzen Art Wilson Dr. Charles Lewis Bob Mayer Jack Hallen Government witnesses: Edward E. Adams - St. Louis, Missouri A. A. Block - Kansis City, Missouri James E. Bowers - St. Louis, Missouri Charles Dilley - Kansas City, Missouri Frank W. Kleman - St. Louis, Missouri Joseph W. Fowler - Kansis City, Missouri Respectfully submitted, On behalf of the Plaintiffs' Management Committee If f^c"O*OQ J Wendall B. Alcorn. Jr.. Esq. ** Cadwalader, Wickersham & Tafc One Wall Street New York. New York 10005 Thomas Beck, Esq. ** Arthur. Dry & Kalish, P.C. 1230 Avenue of the Americas New York, New York 10020 Judith !.. Spanier, Esq. Shea & Gould 330 Madison Avenue New York, New York 10017 ** Morton B. Silberman, Esq. ** Clark, Gagliardi & Miller 99 Court Street White Plains, New York 10601 William A. Krohley, Esq. ** Kelley. Drye & Warren 101 Park Avenue New York. New York 10178 David R. Cross, Esq. ** Budd, L a m e r , Kent, Gross, Picillo & Rosenthal 33 Washington Street Newark, New Jersey 17102 Herbert L. Fenster, Esq. McKenna, Conner & Cunes 1575 Eye Street, N.W. Washington, D.C. 20005 * John M. Fitzpatrick, Esq. Stillworth, Paxson, Kalish & Levy 2600 Fidelity Building Philadelphia, Pa. 19109 * Paul V. Esposito, Esq. Lewis, Overbeck & Furman 135 S. LaSalle Street Suite 1060 Chicago. Illinois 60603 Howard Lester, Esq. ** Lester, Schwab, Katz & Dwy^r 120 Broadway New York, New York 10271 Michael V. Corrigan, F.sq. ** Simpson, Thatcher & Bartlett One Battery Park Plaza New York, New York 10004 Mr. Robert Heinemann ** Clerk of the United States District Court 225 Cadman Plaza East Brooklyn, New York 11201 *** - Hand Delivered ** - Delivery by Federal Express Delivered regular mail to everyone else. 88 t AGENT ORANGE SERVICE LIST Judge Jack B. Weinstein ** United States District Court Eastern District of New York 225 Cadman Plaza East Brooklyn, New York 11201 Honorable Shira Schneidlin ** Magistrate - Special Master United States District Court 225 Cadman Plaza East. Rm. 235 Brooklyn, New York 11201 Honorable Sol Schreiber Milberg. Weiss. Bershad & Specthrie One Penn Plaza New York, New York 10019 Stephen J. Schlegel. Esq. Schlegel & Trafelet, Ltd. One N. LaSalle St., Ste. 3900 Chicago. Illinois 60602 Thomas W. Henderson, Esq. Henderson & Goldberg Frick Building, Rpi- 1601 Pittsburgh, Pa. 15219 ** David J. Dean, Esq. ** Dean, Falanga & Rose 1 Old Country Road Carle Place, New York 11514 Benton Musslewhite, Esq. ** 609 Fannin - Suite 517 Houston, Texas 77002 Newton B. Schwartz, P.C. Houston Bar Center Bldg. 723 Main, Suite 325 Houston, Texas 77002 Stanley M. Chesley, Esq. Waite, Schneider. Bayless & Chesley Co., L.P.A. 1318 Central Trust Tower Fourth & Vine Streets Cincinnati, Ohio 45202 Neil Peterson, Esq. ** Gene Locks, Esq. Creitzer & Locks 1500 Walnut St., 21st FI. Philadelphia, Pa. 19102 Phillip E. Brown, Esq. Hoberg. Finger, Brovm. Cox & Molligan, P.C. Central Tower 703 Market Street San Francisco, Calif. 94103 John O 'Quinn, Esq. O'Quinn, Hagans & Wettman 3200 Texas Commerce Tower Houston, Texas 77002 Plaintiffs' Management Commit: c/o Jan Levien, Esq. ** 26 Court S t . , Suite 905 Brooklyn, New York 11242 Irving Like, Esq. ** Reilly, Like & Schneider 200 West Main Street Babylon, New York 11702 Clerk of the Panel ** Judicial Panel on M u l t i district Litigation 1120 Vermont Avenue, N.W. Suite 1002 Washington, D.C. 20005 Arvin Maskin, Esq. ** United States Attorney United States Dept, of Justice Safeway Bldg. - Room 904D Washington, D.C. 20530 Leonard Rivkin, Esq. ** Rivkin, Leff, Sherman & Radler 100 Garden City Plaza Garden City. New York 11530 12389John C. Sabetta, Esq. ** Townlcy i Updike 405 Lexington Avenue New York. New York 10017 j o h n m. m cM OCM C. jn . JO H N J. LEIOHTON h o c h n eid EDW ARD M. M H E * A N DREW L. H U O H C S MHILR D. MHUL iviC n a n w A S A n fifc RICHARD m . LUTZ JO H N RAUL REIN ER R M tU ft. OLICK MAHR O. O E R A O M TY JO H N 0. CANON' M A R IE V. D R tS C O L L RICHARD C. RULLEN. JA . ROBERT C. MANOONE WILLIAM O C MANNI&CH J A M Q & BW IRE R C N N C T H J . McC U L L O C H DOUOLAS C. rA lN H O N ST ELUQT R A SR O Ff RERCZ C . CHNICH JO H N C. ABETTA J A M E S R. L E A O E R rN C O C R lC R O. E N R O N J E N O M E N. C O L E M A N R E N N E T H M. H A RT JA M E S E. TYRRELL. J * . BY COURIER To w n le y & U p d ik e C h r y sl e r Building 4 0 5 LEXINGTON AVENUE NEW YORK. N. Y. 10174 teleph o n e (12) S S 2 - 4 S S 7 CA BLE: TU CARRO TELEX: WUO I2-7B IB RCA * 2 5 0 7 7 T E L E C O PIE R (zi*)es7-3oei February 15, 1984 cdwaro w . sc h a ll COUNSEL Stephen J. Schlegel, Esq. Schlegel & Trafelet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 RE: "Agent Orange" Product Liability Litigation Dear Mr. Schlegel: I write to state the objections of defendant Monsanto Company ("Monsanto") to Plaintiffs' Response to Paragraph No. 7 of the Magistrate's Pretrial Order No. 1, which was served at the hearing before Magistrate Scheindlin on February 9, 1984. Monsanto recognizes that plaintiffs have requested additional time in which to submit a prioritized list of potential deposition witnesses. See Plaintiffs' Response at 1-2. Accordingly, Monsanto reserves its right to make further objections, if appropriate, when such a list is submitted. Monsanto objects to the depositions of William J. McCarville and Charles P. Zorsch on the ground that both have already been deposed by plaintiffs in this litigation. McCarville was deposed on February 11, 1983; Zorsch, on May 3, 1983. Plaintiffs have demonstrated no special need for redeposing them on the eve of trial. Nor have plaintiffs offered any explanation for their long delay -- about a year and about nine and a half months, respectively -- in noticing the redepositions of Messrs. McCarville and Zorsch. Because the defense of these unjustified redepositions would prejudice 12390 Town let & Upd ik e M o n s a n t o 's prepa r a t i o n for t h e rapidly approaching trial, plaintiffs' inexcusable delay should not be condoned by the Court. W i t h respect to the deposition of Lapin O. Scott, Monsanto has thus far not found any information in its files on such an individual. Thus at this time it appears that no such person was ever an employee of Monsanto. Sincerely, TOWNLEY & UPDIKE Attorneys for Defendant Monsanto Company 405 Lexington Avenue New York, New York 10174 (212) 682-4567 cc (by courier): attached service list Hon. Shira Schleindlin SERVICE LIST Michael M. Gordon, Esg. Cadvalader, Wickersham & Taft One Wall Street New York, New York 10005 Leonard L. Rivkin, Esg. Rivkin, Leff, Sherman & Radler 100 Garden City Plaza Garden City, New York 11530 William Krohley, Esg. Kelley Drye & Warren 101 Park Avenue New York, New York 10178 Howard Lester, Esg. Lester Schwab Katz & Dwyer 120 Broadway New York, New York 10005 Paul V. Esposito, Esg. Lewis, Overbeck & Furman 135 South LaSalle Street Suite 1060 Chicago, Illinois 60303 David R. Gross, Esg. Budd, Lamer, Kent, Gross, PiciIlo & Rosenbaum 33 Washington Street Newark, New Jersey 07102 Judge Morton B. Silberman Clark, Gagliardi & Miller 99 Court Street White Plains, New York 10601 Thomas Beck, Esg. Arthur, Dry & Kalish 1230 Avenue of the Americas New York, New York 10020 Richard M. Goldstein, Esg. Shea 6 Gould 330 Madison Avenue New York, New York 10017 L. Kenneth Sheridan, Esg. Executive Assistant D.S. Attorney United States Attorney's Office 225 Cadman Plaza East Brooklyn, New York 11201 Stephen J. Schlegel, Esg. Schlegel & Trafelet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Benton Musselwhite, Esg. Law Offices of Benton Musselwhite, Inc. Suite 517 609 Fannin Houston, Texas 77002 Thomas W. Henderson, Esg. Baskin & Sears * Frick Building, 10th Floor Pittsburgh, Pennsylvania 15219 Victor J. Yannacone, Jr., Esg., Yannacone & Yannacone Post Office Drawer #109 Patchogue, New York 11772 David J. Dean, Esg. Dean, Falanga, Sinrod & Rose One Old Country Road Carle Place, New York 11514 Irving Like, Esg., Reilly, Like and Schneider 200 West Main Street Babylon, New York 11772 Arvin Maskin, Esg. Trial Attorney, Torts Branch, Civil Div., U.S. Department of Justice Safeway Building Washington, D.C. 20530 Clerk of Panel Judicial Panel on -inn q o Multidistrict Litigation I & o o & 1120 Vermont Avenue, N.W. Suite 1002 Washington, D.C. 20005 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE: "AGENT ORANGE" PRODUCT LIABILITY LITIGATION X : : : X MDL NO.381 United States Courhouse Brooklyn, New York N o v ember 21, 1983 1:00 P.M. Before : HONORABLE JACK B. WEINSTEIN, CHIEF U.S.D.J. s'Ki.l'ii:" 12393 1 Appearances : 2 3 4 SOL SCHREIBER, THE SPECIAL MASTER 5 6 JOY BEANE, ESQ. Assistant to Special Master 7 8 9 10 PLAINTIFFS' M A N A G E M E N T COMMITTEE 11 DAVID DEAN, ESQ. STEPHEN SCHLEGEL, ESQ. 12 THOMAS W. HENDERSON, ESQ. N E W T O N B. SCHWARTZ, ESQ. 13 NICHOLAS A L T I M A R I , ESQ. STANLEY CHESLEY, ESQ. 14 IRVING LIKE, ESQ. BENTON MUSSELWHITE, ESQ. 15 A A R O N T W E R S K I , E S Q . 16 17 18 RIVKIN, LEFF, SHERMAN & RADLER, ESQS. 19 Attorneys for D o w Chemical 100 Garden City Plaza 20 Garden City, N e w Y o r k 11530 21 BY : LEONARD R I V K I N , E S Q . , of Counsel 22 MARJO R I E MINTZER, ESQ., of Counsel 23 24 25 eastern district court reporters UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. N EW YORK 11201 I2C94 1 Appearances (Continued) 2 3 4 CADWALADER, WICKERSHAM & TAFT, E S Q S . Attorneys for Diamond Shamrock 5 One Wall Street New York, New York 10005 6 BY: W E N D E L L B. ALCORN, JR., ESQ. 7 of Counsel M I C H A E L M. GORDON, ESQ., 8 of Counsel JOHN MARIANI, ESQ., 9 of Counsel 10 11 II 12 BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM, ESC 13 Attorneys for D e fendant Thompson Chemicals 13 W a s h i n g t o n Street 14 Newark, N e w J e r s e y 07102 15 BY: DAVID GROSS, ESQ., of Counsel 16 EDWIN R. MATTHEWS, ESQ. of Counsel 17 18 19 20 ARTHUR DRY & K A L I S H , ESQS. 21 A ttorneys for Defe n d a n t UniRoyal 1230 Avenue of the Americas 22 N e w York, N e w Y ork 10020 23 BY: THOMAS A. BECK, ESQ., of Counsel 24 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 2 2 2 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 12G95 "~ 1 Appearances (continued) 2 3 4 TOWNLEY & UPDIKE, ESQS. 5 Attorneys for Defendant Monsanto Company 405 Lexington Avenue New York, New York 10017 7 BY: PHILIP PAKULA, ESQ., of Counsel 8 JAMES E. TYRRELL, ESQ., of Counsel 9 10 11 12 ROBERT T. BERENDT, ESQ. In House Counsel - Monsanto 13 14 15 i 16 CLARK, GAGLIARDI & MILLER, ESQS. 17 Attorneys for Defe n d a n t T. H. A g riculture & Nutrition Company 18 The Inns of Court 99 Court Street 19 W h i t e Plains, N e w York 10607 20 BY: MORT O N SILBERMAN, ESQ., of Counsel 21 JOHN J. BURKE, ESQ., of Counsel 22 LAWRENCE D' ALOISE, ESQ., of Counsel 23 24 25 EASTERN DISTRICT COURT REPORTERS 1.2G96 UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 1 Appearances (Continued) 2 3 4 5 KELLEY, DRYE & WARREN, ESQS. A t torneys for D e f e n d a n t Hercules, Inc. 6 101 Park Avnue New York, New York 10178 7 BY: W I L L I A M A. KROHLEY, E S Q . , 8 of Counsel PATRICIA TOUHY, ESQ., 9 of Counsel WIL L I A M C. HECK, ESQ., 10 of Counsel 11 12 13 UNITED STATES OF AMERICA 14 Civil Division, D e p a r t m e n t of Justice 521 12th Street, Northwest 15 Washington, D. C. 20530 16 BY: ARVIN MASKIN, ESQ. GRETCHEN WITT, ESQ. 17 18 19 ASHCRAFT & GEREL, ESQS. 20 2000 L Street, N o r t h w e s t Washington, D. C. 20038 21 BY: ROBERT A. TAYLOR, JR., ESQ. 22 of Counsel 23 24 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 9 65 1 and over the rapids without destruction. 2 MR. GROSS: I am over the rapids now. I am now 3 over the waterfall. 4 I would respectfully request the same certification 5 by this court to take to the Second Circuit as done 6 by Hercules. 7 THE COURT: Denied. 8 MR. GROSS: Thank you. 9 THE COURT: For the same reasons. I 10 Dia m o n d Shamrock? 11 MR. ALCORN: Wendell Alcorn, a m e m b e r of the 12 Cadwalader, W i c k e r s h a m & Taft representing Diamond 13 Shamrock Chemicals Company. 14 To my knowledge, the m o t i o n to change the name 15 of the party is unopposed. 16 THE COURT: Nobody being he a r d in opposition, 17 w o u l d y o u submit an order w i t h i n forty-eight hours? 18 MR. ALCORN: Yes, your Honor. 19 THE COURT: Granted. 20 Item 4, appeal from the r e c o m m endation of the 21 Special Master on Government causation witnesses. 22 MR. MASKIN: Your Honor, Arvin M askin on behalf 23 of the Unit e d States. 24 The UnitedStates begins w i t h its recognition of 25 one truth in this case; and that is, this trial is going EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST innri vxi utw YOftK 11201 10 1 to go forward on My 7th. 66 2 We would also add that the interests of acceleratinjg 3 discovery of identifying all information for which there 4 is a genuine n eed of m i n i m i z i n g discovery disputes and of accomodating the United States' legitimate 5 interests in discovery are not mutually exclusive. 6 The United States has demonstrated, at least in 7 the context of the deliberative process, privilege 8 issues and state secrets privilege issues, that care 9 fully considered procedures resolving privilege 10 disputes do work and our experience has been that they 11 worked in the past. 12 Virtually none of the 18 witness who have been 13 identified by the parties could be considered fact 14 witnesses. 15 THE COURT: Would be considered what? 16 MR. MASKIN: Could be considered fact witnesses. 17 Each and every one of those witnesses are described 18 as "expert." 19 THE COURT: Let me suggest this to you and get 20 your reaction to it. 21 We have to move ahead quickly. They are not going 22 to have a lot of time to depose these people. 23 I do not know whether they are going to come 24 forward with other lists, but I would suggest that each 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 2 2 i CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 12039 11 67 1 side have ten. If they overlap, that is fine. And 2 that they be limited to one or two days deposition as 3 to anything they want to take. Let's say two days. 4 Fact, opinion, anything. One day for the party who 5 wants the witness and the other -- most of the other 6 day for the opposing party and then just a little 7 rebuttal. 8 I understand your point. You cannot have these 9 experts constantly annoyed with this, but let's see 10 if we keep it to a bar e minimum, let them ask them n anything they want to. If they want to waste their 12 day asking them about things they don't need, that's 13 up to them. 14 Then I w o u l d suggest, too, that if -- before the witness testifies or gives his deposition, that they 15 16 tell the witness w h a t they are going to use in the way 17 of documents so the witness doesn't'come in cold. 18 That is i t . 19 MR. MASKIN: M a y I respond? 20 THE COURT: Yes. MR. MASKIN: Your Honor, the procedures that we 21 suggested while at first glance seem cumbersome I 22 envision that with respect to the same number of people 23 you have suggested, the information that we requested 24 could be in our hands by this Friday. Government could 25 EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 2 2 5 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 12700 16 72 1 case, your Honor, and it's worked absolutely fine. 2 If there is a p r o b l e m that's asked at the time, 3 the Special Master can rule as to whether that question 4 makes any sense. 5 To set up 6 THE COURT: Excuse me. I do not care whether it 7 makes sense or not. I do not need the Master to tell 8 me whether it makes sense. 9 If you want to ask a question that does not make 10 sense, m y ruling n o w is, ask it. 11 The witness will be entitled to say, I cannot 12 answer it or I will be delighted to answer that senseles 13 question. 14 That is all. I do not want you coming in here 15 m a king applications to the M a s t e r whe n we have five 16 months to prepare a c o mplicated trial. 17 You want ten witnesses? Give them ten witnesses. 18 MS. MINTZER: Let me clarify that, please. 19 The Special M a s t e r requ e s t e d an initial list 20 of fen witnesses, w h i c h is what we have provided. That 21 is by no means our complete list. 22 THE COURT: I am telling you, it is your complete 23 list. You can take ten and they will take ten. 24 I am not going to have the Government denuded of 25 witnesses. If after four years you do not k n o w who EASTERN DISTRICT COURT REPORTERS U N IT E D STATES D IS TR IC T C O U RT 223 C A D M A N P L A Z A EAST B R O O K L Y N . N E W Y O R K 11201 1 Z i 1 17 73 1 the best ten people are in the Government, then you are 2 not prepared. 3 MS. MINTZER: Your Honor, this is very, very 4 important and please let me address that issue. 5 For one thing, I believe today my office received 6 and all offices received the names of the plaintiffs 7 that are actually going to be litigated, the cases that 8 will be litigated so up until this date we haven't 9 even known the particular medical issues that will be 10 at issue. i 11 Number two, and that's exceedingly important, 12 the Government -- 13 THE COURT: I understand. 14 I myself think you may want to delay a little while 15 in putting in those names. 16 (Continued on next page.) 17 18 19 20 21 22 23 24 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 12702 1 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 71 MS. MINTZER: We have already submitted ten, but the -- THE COURT: You can withdraw them. MS. MINTZER: I understand that. The other point that I want to make, is very important here, is the Government's papers admit that the Government -- Congress has expended vast suns of money on causation and energy and knowledge is amassed within the Government today on the very issues that this Judge and the jury in this case will decide. I think it is incredibly unfair to the jury and to the Court not to have that testimony before the Court. THE COURT: You can have all the reports. They are giving you every report that was made. Any report that is finished before the trial, you can have that, too. You can have ten experts free, plus all the experts you have. MS. MINTZER: I submit to your Honor that this -- THE COURT: I am not going to be drowning in experts. MS. MINTZER: I understand that, but at this point in the litigation, when we are just beginning causation discovery, when we don't know yet what issues we face -- EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST 1270-1 1 THE COURT: Hold off. Do not give them a full 2 ten names. 3 MS. MINTZER: May I request that you please not 4 be so firm on that number ten? I just doesn't make 5 sense. It is an arbitrary number, your Honor. 6 THE COURT: Yes. You are going to find that we 7 will be arbitrary time after time here because that 8 is the way it goes. 9 MS. MINTZER: There may well be ten different 10 injuries that are being focused upon here. There may 11 well be far more than that number of causation witnesses 12 required. 13 THE COURT: If you need more, you will go to 14 the Special Mastern. My inclination would be to give you ten each. 15 16 If I were in your position, I w o u l d n ' t use my 17 whole ten. 18 MS. MINTZER: I am not sure that the -- you might 19 w a n t to rethink that. 20 Can I just ask you one question? I am not clear on your ruling with regard to Page 34. 21 THE COURT: Yes. 22 MS. MINTZER: It is my understanding that the 23 information that the Government is requesting on 24 Page 34 you are suggesting that we do supply that, but 25 EASTERN DISTRICT C O U R T r e p o r t e r s UNITED STATES DISTRICT COURT 2 2 } CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 n XCt *704 4 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 77 THE SPECIAL MASTER: Your Honor, if I may be heard for a moment? I have carefully studies the submissions of the defendants. As you know, they submitted 61 names. I reviewed those both by their comments and my own research and I tend to suggest to your Honor, without being impolite, that a number of somewhere between 15 and 20, and the time is sufficient, w o u l d give the defendant appropriate attack upon or -- THE COURT: 15 or 20 for each? THE SPECIAL MASTER: No, no. the plaintiffs have indicated that they only have eight. THE COURT: They may want -- THE SPECIAL MASTER: Even 15 or 20, your Honor, we can easily get it in. I give -- MR. DEAN: Respectfully, may we -- THE COURT: Excuse me. I just want to p o i n t out to you, that 20 plus even ten is 30 witnesses. That's 30 solid days of depositions. There are five months. You've got to depose all of the plaintiffs. You probably -- that are going to be tested. You will probably have to depose their doctors. You are going to have to -- there is an enormous amount of work. EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST ROOKLYN. NEW YORK 11201 1 THE SPECIAL MASTER: Different teams. There will 2 not be one deposition team. 3 MR. DEAN: May I rise respectfully to uphold the 4 desire of the Special Master, whom I have the highest 5 regard for and who mandates we have often followed. 6 Always followed, how is that? 7 We will certainly abide by your Honor's direction 8 with him and we ask the defendants do the same. 9 THE COURT: All right. I will rule, in view of 10 m y special respect for the Special Master, I will rule 11 ten on each side with the .Master having the authority 12 subject to an appeal to me to add an extra five on each 13 s i d e . 14 MR. PAKULA: I tried to rise, I did rise but I 15 didn't get a chance to speak before your Honor ruled. 16 Right now we are looking at a list of 46 p roposed 17 named plaintiffs, w h i c h we just received, which they 18 say they will reduce at some time in the future. 19 THE COURT: We are going to have to get to that. 20 We must get to that and get to it fast because that 21 is step number one. 22 Until they give us those names, we are not going 23 to be able to proceed. 24 I underst nd your problem. 25 MR. PAKULA: Second point, and I think Ms. Mintzer EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 X & 0 K) UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In r e : "AGENT ORANGE" PRODUCT LIABILITY LITIGATION x : : : X MDL No.381 United States Courthouse Brooklyn, New York February 15, 1984 2:00 o' clock p.m. B e f or e : HONORABLE J A C K B. WEINSTEIN, Chief U.S.D.J. HENRY SHAPIRO ILENE GINSBERG SHELDON SILVERMAN OFFICIAL COURT REPORTERS EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 22J CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 1 2 APPEARANCES : t 2 3 4 Plaintiffs' Management Committee 5 THOMAS HENDERSON, ESO. BENTON MUSSELWHITE, ESQ. GENE LOCKS, ESO. 6 7 8 9 RIVKIN, LEFF, SHERMAN & RADLER, ESQS. 10 Attorneys for Dow Chemical 100 Garden City Plaza 11 Garden City, New York 11530 12 BY: MARJO R I E MINTZER, ESQ. STEVEN BROCK, ESQ. 13 Of Counsel 14 15 16 CADWALADER, W I C K ERSHAM & TAFT, ESQS. Attorneys for Defendant Diamond Shamrock 17 One Wall Street New York, New York 10005 18 BY: MICHAEL M. GORDON, ESQ. 19 GRANT B. HERING, ESQ. 20 21 22 23 24 25 127 0 9 3i 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 APPEARANCES : 3 TOWNLEY a UPDIKE, E S Q S . Attorneys for Defendant Monsanto 405 Lexington Avenue New York, New York 10017 Company BY: PHILIP PAKULA, ESQ. JAMES E. TYRRELL, ESQ. JOHN C. SABETTA, ESQ. JOSEPH SCHIAVONE, ESQ. BRUCE G. SHEFFLER, ESQ. Of Counsel CLARK, GAGLIARDI & MILLER, ESQS. Attorneys for Defendant T.H. Agriculture & Nutrition Co.,Inc. The Inns of Court 99 Court Street White Plains, New York 10607 BY: MORTON S I L E E R M A N , ESQ. JOHN J. BURKE, ESQ. Of Counsel KELLEY, DRYE & WARREN, ESQS. Attorneys for Defendant Hercules, 101 Park Avenue New York, New York 10178 Inc. BY: W ILLIAM A. KROHLEY, ESQ. PATRICIA T U O H E Y , ESQ. WILLIAM HECK, ESQ. Of Counsel 12709 1 APPEARANCES : 2 41 r 3 ARTHUR, DRY i KALISH, F.C. Attorneys for Defendant UniRoyal 4 1230 Avenue of the Americas 5 New York, New York 10020 BY: THOM A S A. BECK, ESQ. 6 MARILYN NEIMAN, ESQ. Of Counsel 7 8 9 BUDD, LARNER, KENT, GROSS, PICILLO & 10 ROSENBAUM, ESQS. Attorneys for Defendant Thompson Chemicals 11 33 Wa s h i n g t o n Street Newark, New Jersey 07102 12 BY: E D W I N R. MATTHEWS, ESQ. 13 DAVID GROSS, ESQ. SUSAN O L N E Y , ESQ. 14 Of Counsel 15 16 17 UNITED STATES OF AME R I C A Civil Division, Department of Justice 18 521 12th Street, Northwest Room 822 19 Washington, D.C. 20530 20 BY: AR V I N MASKIN, ESQ. GRETCHIN LEAH WITT, ESQ. 21 Special Attorneys 22 23 24 25 12710 1 2 Also present: 3 4 HONORABLE SHIRA SCHEINDLIN, Magistrate 5 SOL SCHREIBER, E S Q . , Special Master 6 JOY BEAN, Assistant to Special Master 7 8 NANCY PETRILLO, Clerk of Court 9 10 11 12 13 14 15 16 17 18 19 20 21 5 I &. **> | 3.9 1 2 But I take it that ultimately they are goino to 3 contest it if they don't concede it -- 4 MR. MASKIN: Your Honor, I am not sure -- 5 THE COURT: (Continuing) -- because if they 6 concede it, y o u may be able to, almost as a matter of 7 summary judgment, have a third-party judgment against 8 them for any judgment the plaintiffs get against you. 9 That is the posture of the case, as I understand 10 it. 11 Now, if that is an open issue as to the third 12 party, then it is an issue in the case. 13 MR. KROHLEY: Apart from whe t h e r it is an open 14 issue in the case or not and whether it needs to be 15 decided again or not, there is a practical d imension 16 to this, too. 17 We spent four, four and a half years on the 18 Government contract defense prior to trial in June. 19 That -- A t least that aspect of the case, in terms of the first two elements, and the third element was 20 discussed into at substantial length and hundreds of 21 depositions were taken. 22 If we now go back and try to go back to issues 23 one and two in the Government contract defense and 24 depose 40, 50, 60 additional witnesses in the time 25 12712 1 remaining -- 40 2 THE COURT: I am g o i n g t o i n s t r u c t t h e M a g i s t r a t e 3 t o p u t i t on t h e b a c k b u r n e r a n d c u t i t way, way dow n. 4 A couple of witnesses are all you are going to get. 5 I am not going to, a month and a half before trial, 6 allow a whole big discovery. There is not enough 7 energy left in all the plaintiffs' and defendants' bars 8 in the country for that. We have to be realistic. 9 But the issue is between the defendants and the 10 third-party plaintiffs. 11 MR. GROSS: I think Mr. Maskin was about to say 12 that the Government may indeed not oppose or contest the 13 m a t t e r . 14 THE COURT: I didn't hear him'say that. 15 Did you say that? 16 MR. MASKIN: No. The Government again assumes no 17 posture whatever, and n othing happened to day to require 18 us to take a position. 19 THE COURT: F r o m a tactical point of view, it would be a very serious concession. 20 MR. KROHLEY: I don't see how this is an issue 21 at all between the defendants and the Government. 22 The Government contract defense is the claim the 23 plaintiffs are asserting against us. 24 THE COURT: If the Government ordered something 25 f(T1 45 MR. MUSSELWHITE: Your Honor, may I ask you a Jl 2 question? 3 Due to the time element -- all we are asking for, 4 basically, from the Government, are the contracts, the 5 officers and inspectors. They are not going to be long depositions. 6 7 THE COURT: You had better get it cut down. I will put it down for February 27th. 8 9 MR. GROSS: May we have two weeks beyo n d that? THE COURT:- M a r c h 5th. 10 MR. MUSSELWHITE: Can we go ahead and start taking 11 some of these depositions? 12 THE COURT: N o . 13 You have got plenty of other things to do. You 14 have not done so great on getting you r experts in. 15 MR. LOCKS: Gene Locks on behalf of the Plaintiffs. 16 I think I might have something to do with that. 17 I agree with Mr. Gross. May we go to the 12th rather 18 than the 5th? 19 You have got another hearing date scheduled on 20 the 12th. 21 THE COURT: You are speaking for the plaintiffs. 22 You are the ones they want. 23 MR. LOCKS: Yes. 24 THE COURT: March 12th. Government specifications e a s t e r n district c o u r t reporters UNITED STATES DISTRICT COURT 223 CADMAN PLATA EAST 12? 14 CERTIFICATE OF SERVICE I HEREBY AFFIRM that I am an attorney duly admitted to practice in the State of New York and in the Eastern District of New York. I HEREBY CERTIFY that on February 21, 1984 I caused to be served a true and correct copy of the Notice of Motion and the Memorandum of Defendant Monsanto Company in Support of its Motion for a Protective Order on all counsel on the attached service list -- by hand on Mr. Dean and on all counsel in Manhattan, by courier on all others. 1 SERVICE LIST Michael M. Gordon, Esq. Cadwalader, Wickersham & Taft One Wall Street New York, New York 10005 Leonard L. Rivkin, Esq. Rivkin, Leff, Sherman & Radler 100 Garden City Plaza Garden City, New York 11530 William Krohley, Esq. Kelley Drye & Warren 101 Park Avenue New York, New York 10178 Howard Lester, Esq. Lester Schwab Katz & Dwyer 120 Broadway New York, New York 10005 Paul V. Esposito, Esq. Lewis, Overbeck & Furman 135 South LaSalle Street Suite 1060 Chicago, Illinois 60303 David R. Gross, Esq. Budd, L a m e r , Kent, Gross, Picillo & Rosenbaum 33 Washington Street Newark, New Jersey 07102 Judge Morton B. Silberman Clark, Gagliardi & Miller 99 Court Street White Plains, New York 10601 Thomas Beck, Esq. Arthur, Dry & Kalish 1230 Avenue of the Americas New York, New York 10020 Richard M. Goldstein, Esq. Shea & Gould 330 Madison Avenue New York, New York 10017 L. Kenneth Sheridan, Esq. Executive Assistant U.S. Attorney United States Attorney's Office 225 Cadman Plaza East Brooklyn, New York 11201 Stephen J. Schlegel, Esq. Schlegel & Trafelet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Benton Musselwhite, Esq. Law Offices of Benton Musselwhite, Inc. Suite 517 609 Fannin Houston, Texas 77002 Thomas W. Henderson, Esq. Baskin & Sears 'J Frick Building, 10th Floor Pittsburgh, Pennsylvania 15219 Victor J. Yannacone, Jr., Esq. , Yannacone & Yannacone Post Office Drawer #109 Patchogue, New York 11772 David J. Dean, Esq. Dean, Falanga, Sinrod & Rose One Old Country Road Carle Place, New York 11514 Irving Like, Esq., Reilly, Like and Schneider 200 West Main Street Babylon, New York 11772 Arvin Maskin, Esq. Trial Attorney, Torts Branch, Civil Div., U.S. Department of Justice Safeway Building Washington, D.C. 20530 Clerk of Panel Judicial Panel on Multidistrict Litigation 1120 Vermont Avenue, N.W. Suite 1002 Washington, D.C. 20005 I UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK x In re: Agent Orange" Product Liability Litigation MDL No. JOi (All Cases) ' - SPECIAL MASTER'S FINAL AMENDED RECOMMENDATION RE: SCHEDULING ORDER FOR THE COMPLETION OF DISCOVERY AND THE PREPARATION OF A PRETRIAL ORDER AS APPROVED BY JUDGE WEINSTEIN -----------------x Pursuant to the direction of the Court, as set forth in its Pretrial Order #69, the Special Master met with opposing counsel to review their recommendations concerning the completion of discovery and the preparation of a pretrial order. On December 16, 1983, the Special Master's recommendation concerning these matters was sent to the Court with copies to counsel. Thereafter, on December 19, 1983, at a hearing before the Court, the recommendation was reviewed and substantially approved by the Court, and the Special Master was asked to meet again with counsel in an attempt to resolve a few remaining issues. This hearing took place immediately after the Court's hearing on December 19, 1983. A draft of the Special M a s t e r 's amended scheduling order was thereafter circulated among the interested parties and a further review hearing was held on December 28, 1983. At this hearing, the views of counsel were further examined by the Special Master, and additional requested changes by plaintiffs', defendants' and government's counsel were reviewed. A number of these changes were accepted by the Special Master and are incorporated herein. The following is the amended scheduling order which is recommended for the Court's consideration: I . Interrogatories Served by Respective Parties A. Plaintiffs' Interrogatories The interrogatories served by the plaintiffs upon the defendants and reviewed by the Court at its hearing on December 12, 1983 are to be served in amended form upon the defendants not later than Thursday, December 22, 1983. Defendants will serve and file their responsive answers not later than Monday, January 16, 1984. Plaintiffs' interrogatories dealing with the Government Contract Defense, which were recently served upon the defendants will be reviewed by the Special Master at a hearing to be held on Thursday, December 29, 1983 at 2:00 p.m . , tinless prior meetings of counsel resolve the outstanding conflicts. The interrogatories agreed upon by counsel or approved by the Special Master will be served upon the defendants, in amended form, by Wednesday, January 4, 1984 and will be answered by the defendants not later than January 30, 1984 . 12733 B . Defendants' Interrogatories The interrogatories served by the defendants were reviewed by the Special Master and thereafter his recommendations were examined by the Judge at a hearing on December 12, 1983. The Special Master's recommendations were approved by the Court with a few modifications. These revised interrogatories are to be served upon the plaintiffs by December 22, 1983. Plaintiffs will serve and file their answers to these interrogatories not later than Monday, January 16, 1984. Any disputes concerning these amended interrogatories were resolved at the Special Master's hearing of December 29, 1983 II. Interrogatory Requests Served Upon United States Re Causation Documents____________________________ Defendants' documentary requests of December 1, 1983 entitled "Notice to Produce Documents re Causation Issue", and served upon the United States were reviewed by the Special Master at a hearing on December 20, 1983. At this hearing all disputed requests were resolved by the Special Master whose recommendations are contained in the transcript of the hearing. The Special Master advised counsel that if any of the recommendations were to be appealed they were to notify opposing counsel and set forth their objections in written form within a few days after the December 20th hearing; thereafter, the Special Master would hold a hearing to determine the 12734 -3- validity of such objections before submitting his recommendations to the Court. At the December 28, 1983 hearing before the Special Master counsel were requested to state their objections to the Special Master's rulings of December 20, 1983. No objections were raised and defendants were directed to serve an amended documentary request (re: causation issues) upon the government by January 4, 1984. The government was directed to produce documents as soon as they were assembled and not to wait for the final date of Jainuary 16, 1984 to make production. Ill. Depositions A. Plaintiffs' Depositions Plaintiffs' depositions of defendants' present and/or prior employees will continue on a daily basis and end by March 30, 1984 unless good cause be shown for a short extension of this cut-off date. Plaintiffs' depositions of other non-party witnesses, except expert witnesses, discussed below, will be completed by the same date. Plaintiffs' depositions of government experts or persons knowledgeable on the issue of causation and liability will be taken between January 15, 1984 and March 12, 1984. These depositions will be preceded by the plaintiffs' serving upon the government and opposing counsel at least seven (7) days prior to the scheduled depositions a list of documents upon which these government witnesses will be | ni^ -4- J A deposed. In addition, both plaintiffs' and defendants' counsel, in seeking depositions of such government witnesses, must comply with Judge Weinstein's directions concerning preliminary notice and information to be given to the government. (See transcript of proceedings before Judge Weinstein of November 21, 1983, pp. 69 & 71.) This information must also be supplied at least seven (7) days prior to the scheduled depositions. B. Defendants' Depositions of Plaintiffs' Representative Parties and Non-Party Fact Witnesses_________________________ Prior to their taking depositions of plaintiffs' representative parties, defendants may serve on plaintiffs a limited number of interrogatories. These interrogatories should be served not later than December 22, 1983; responses due not later than January 11, 1984. Depositions of the plaintiffs' representative parties, their wives, children, relatives and legal representatives will begin on January 16, 1984 and will be completed by April 6, 1984, unless good cause be shown for a short extension of this date. The April 6, 1984 cut-off date also applies to non-party fact witnesses. The government is directed to locate and produce all service and medical records of the representative plaintiffs by January 6, 1984. In addition, all medical records of treating doctors and medical institutions which counsel for the representative plaintiffs have in their possession will be turned over to the defendants by January 6, 1984. Defendants' medical o i -5- # >'**'ri JL J f. ` i 4 Af*fC A4I W Wf their wives. children and relatives will begin on January 17, 1984 and notice of the said examination will be given to plaintiffs' counsel at least ten (10) days prior to the examination date. In the event that plaintiffs object to the type or place of the said medical examination, these objections will be heard by the Special Master within 48 hours. Defendants will exert all efforts to complete these examinations by March 6, 1984 and will further advise all doctors or institutions conducting such examination that they must submit their reports in writing to the defendants' counsel not later than March 12, 1984. It is expected, however, that these reports will be delivered to counsel as soon as the examinations are completed. This same instruction (i.e., staggered delivery of reports) is applicable to plaintiffs' medical experts. C. Defendants' Depositions of Government Witnesses on All Issues Including Causation _________ These depositions will begin on January 15, 1984 and be completed by March 30, 1984 unless good cause be shown for a further short extension of this date. Prior to taking the depositions of government witnesses, defendants will deliver to counsel for the government and plaintiffs, copies of documents upon which the said witnesses will be deposed. Such documents -6- must be r e ceiv ed by counsel at le a s t seven (7) days p r io r to the d ep o sitio n . Defendants w ill a lso provide government's co u n sel w ith th e a d d itio n a l n o t ic e and inform ation , as d iscu ssed in paragraph III above. IV. Expert W itnesses A. P l a i n t i f f s w i l l d e l i v e r t o th e d e f e n d a n t s summaries of p l a in t i f f s ' t r e a tin g d octors' reports pursuant to Rule 2 6 ( b ) ( 4 ) (A)( i) of the Federal Rules of C iv il Procedure. Such summaries or cop ies o f th e d o cto rs' w r itte n r e p o r ts w i l l be d e liv e r e d not la te r than January 16, 1984. In a d d itio n , p l a i n t i f f s w i l l d e l i v e r t o d e f e n d a n t s ' c o u n se l summary r e p o r t s o f o t h e r e x p e r t s who a r e e x p e c t e d t o b e c a l l e d t o t e s t i f y on b e h a l f o f p l a i n t i f f s , pursuant to t h e R u l e 2 6 ( b ) ( 4 ( A ) ( i ) o f t h e Federal Rules of Civil Procedure or copies of the ex p erts' w r itte n rep o rts by January 23, 1984. All rep orts or summaries w i l l be accompanied by any documents, in clu d in g m edical t e s t s and/or r e s u l t s , upon which th e s a id rep o rts are b ased . A ll m edical examinations of rep resen ta tiv e p l a i n t i f f s th at p l a i n t i f f s w i l l conduct b efore t r i a l sh a ll be com pleted in tim e to furnish the resu lts thereof to the defendants by January 23, 1984. Defendants' d ep osition s of p l a i n t i f f s ' expert w itn esses w i l l b e g in on February 1, 1984 and be com pleted by March 13, 1984, u n le s s good cause be shown for a sh ort e x t e n s io n o f t h i s date. B. D efendants w i l l subm it e it h e r summaries o f t h e i r ex p erts' testim ony pursuant to Rule 26 (b (4 )(A )(i) or 3a l t e r n a t i v e l y , c o p i e s o f t h e i r e x p e r t s ' w r i t t e n r e p o r t s n o t ' p " g -7- I later than March 13, 1384. All reports or summaries will be accompanied by any documents, including medical tests and/or results, upon which these reports are based. Defendants' experts will be deposed by plaintiffs' counsel between March 20, 1984, and April 15, 1984. C. If counsel cannot agree upon reasonable expenses to be paid for the appearance of opposing counsel's experts, the Special Master will recommend the appropriate fee to be paid. V. P r e t r i a l O rder Counsel are directed to meet with the Special Master at a date to be set within the next few weeks but prior to February 1, 1984 in an attempt to agree upon a schedule for the completion and filing of a pretrial order not later than April 24, 1984. V I . Other Matters A. All fact witnesses who will give testimony in support of the claims of the respective parties will be listed by name, present address and a description of the general nature of the testimony. This information will be exchanged by the parties not later than February 29, 1984. In addition, counsel for the respective parties will have an additional ten (10) days thereafter to supplement their earlier lists. -8- B. A scheduling order for in limine or pretrial evidentiary rulings, special interrogatories to the jury, preliminary and interim jury instructions and the dates for the submission of trial briefs will be recommended to the Court by the Special Master by February 1, 1984 after consultation with counsel. Dated: New York, New York January 10, 1984 Respectfully submitted. Dated: Brooklyn, New York January/" , 1984 Special Master -9- i 1 MR. GORDON: Well, access will be permitted 2 according to the order. 3 THE SPECIAL MASTER: Well, we can say that the 4 list will be made available to both parties under seal 5 of the Court. 6 So, the Government will supply a list to plaint.: 7 defendants and to the Court, under seal.. MR. PAKULA: What will be filed that purports 8 9 to be proof of -- MR. DEAN: We w ill file -- no matter what is 10 informally agreed today -- we will file affidavits 11 of service w ith regard to everyone who m we have mailc 12 notices, including those on the Agent Orange registry 13 THE SPECIAL MASTER: You can say those on the 14 Agent Orange registry but your affidavits of service 15 can only be appropriate to those not on the Agent 16 Orange registry because the Post Office will make the 17 mailing and stuff and supply the stamps. 18 MR. DEAN: And supply their own affidavits of 19 service. They agreed to do that? 20 THE SPECIAL MASTER: Y e s , 21 MR. H E I N E M A N N : May I request the information' 22 as to what Post Office person received these tapes 23 since I am going to be the conduit? 24 THE SPECIAL MASTER: I think you ought to get 25 EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 > ^ v,, i -L ,h. % I I cnose as quiciciy as possiDie. 2 Will you write to Mr. Heinemann by tomorrow? 3 MR. HEINEMANN: Then we can do it immediately 4 in case it happens suddenly. 5 THE SPECIAL MASTER: We now have -- unless anyon 6 has another m a tter to be taken up -- the final order 7 of the business, which Mr. Pakula will address himself 8 to. 9 MR. PAKULA: Thank you. 10 Dates and status of disclosure matters that 11 are the subject of the order, scheduling order entered 12 in this case. 13 January 6th, the Government was to produce all service and medical records of representative plaintiff 14 As of this morning, we do not have the following 15 records: Danny Ford, we don't have his 201 file -16 that is his service record. We don't have his military 17 medical file. 18 Michael Ryan -19 THE SPECIAL MASTER: Let's go one at a time. 20 Does the Govenrment know all of this information" 21 Is this the first time they are hearing it? 22 MR. PAKULA: This is the first time they are 23 hearing it and I think a convenient time on a day-to24 day proposition -25 EASTERN DISTRICT C O U R T REPORTERS U N IT E D STATES D IS TR IC T COURT 223 C A D M A N P L A Z A EAST B R O O K L Y N . N E W Y O R K 11201 330-7687 y^ A L^ 5 T* 1 .Lin- AiitK: n a n we asK tne government to respond to each one? 2 HR. PAKULA: I am not suggesting we have an 3 argument about who shot John. 4 THE SPECIAL MASTER: You are just posting the 5 record. 6 MR. PAKULA: I feel you should have a status 7 report regularly. 8 I didn't raise it to stick a knife in them, 9 but 10 THE SPECIAL MASTER: Let's do all the service 11 and medical records and we will find out what is 12 happening. 13 MR. PAKULA: Michael Ryan. We don't have his 14 military medical file. 15 Mr. Ewault -- we don't have his military 16 medical file. 17 Next date 18 THE SPECIAL MASTER: L e t 's stop here for a mome: 19 Can Government counsel illuminate for us where 20 we are? 21 MS. WITT: As to Danny Ford, the problem here - 22 I stood here and said we had not been able to find 23 any record and at that time Danny Ford was dropped 24 from the case and therefore we stopped looking for 25 him. EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 I j a u ^ c ictsL w e e s uney nave Degun to cry a n a locate 2 his records again. 3 Hopefully they will be found quickly, but they 4 were having difficulty before in locating any records 5 pertaining to Mr. Ford. 6 As to Mr. Ryan and Mr. Ewault, the military 7 records records, I am not aware of the status of those 8 My belief is that those files were contained 9 within the VA Claims Files and I may be mistaken on 10 that, but most of the veterans whose files we have 11 found, their military medical records, have not been contained with their military file and already forwarc 12 on to VA, as is normally the case when somebody 13 applies for VA benefits. 14 I will have to go back and look at the records 15 but I thought those records were already contained -16 MR. PAKULA: I imagine that you can guess that 17 I have not looked at every page of these records and 18 we too will look and see if we -- we will check and 19 see if we were wrong. 20 THE SPECIAL MASTER: If it i s n 't, y o u will let 21 counsel know immediately. 22 MR. PAKULA: Of course immediately. 23 THE SPECIAL MASTER: Ewault is the same. 24 MR. PAKULA: Schaeffer. That was January 11th 25 EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 I 3T1Q I t O C CflcLIlgSG t O JcLriTJ.cLI'y I ^ L U w u i u i i w a o 2 plaintiffs were to answer defendant's limited 3 interrogatories re representative plaintiff and that 4 is the subject of objections by the defendant to the 5 answers that were served which will be heard at a 6 later time. 7 January 15th -- I'll skip that -- that's the 8 deposition date we talked about before. 9 January 16th, plaintiffs were to answer defends:, 10 general interrogatories. 11 Those answers have been received. Objections 12 to the answers have been made. That will be the subjt 13 of a later hearing. 14 January 16th was also the last day for the 15 Government to respond to defendant's document request 16 re causation. 17 As you can tell the documents are still rolling 18 in and I think we resolved a lot of problems because of your ruling, but that is the status of that -- the> 19 are coming in as they come in. 20 January 16th, the plaintiffs were to produce 21 Rule 26(b) -- y o u always straighten me out on this -22 THE SPECIAL MASTER: (b)(4)(a)(1) -- because 23 I have u sed it so long. 24 MR. PAKULA: For their treating physicians and 25 EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 ^ -,u A fe * p 1 none have been received. 2 THE SPECIAL MASTER: I received a letter from 3 Mr. Musselwhite which I assume counsel -- which was 4 addressed to the Court and I am not sure -- would y ou 5 check, Mr. Dean, to make s u r e 'that Mr. Musselwhite 6 has the Magistrate on the mailing list because I am 7 not sure that the Magistrate received a copy. 8 MR. DEAN: The Magistrate did not get 9 Mr. M u s s e l w h i t e 's communication and we will remedy 10 t h a t . 11 THE SPECIAL MASTER: That dealt wit h not only 12 the medical expert but also experts. 13 Frankly, I was troubled not so muc h that the 14 deadline was not met but there was no indication of 15 a date. 16 MR. DEAN: Mr. Musselwhite told me a couple of 17 days ago he had written a letter and I have not seen 18 i t . 19 THE SPECIAL MASTER: More important than that, when are the plaintiffs going-to select their experts. 20 MR. DEAN: I know that plaintiffs have now 21 some names of experts. 22 I will tell you that I spoke to Mr. Henderson 23 this morning and he alerted me that he assumed this 24 was going to be discussed. 25 EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 ^A ^^ * 1 ' I said, thanks a lot. 2 He wanted me to convey to you the fact that I 3 k n o w his office has received -- had sent out many, many 4 many requests for medical reports from the treating 5 physicians. 6 A number of those reports -- so the defendants 7 are not n o w prejudiced -- a number of those reports 8 are found within the medical records themselves and 9 I tell you, if there was a way to duplicate those 10 reports -11 (Continued on next page.) 12 13 14 15 16 17 18 19 20 21 22 23 24 25 EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-7687 i-iV I THE SPECIAL MASTER: But even assuming that the i t 2 key seems to me that it is your expert medical 3 witness -- 4 MR. DEAN: We are not talking about expert 5 witnesses at all. Mr. Pakula was talking about 6 treating physicians. 7 THE SPECIAL MASTER: But they are also -- he 8 is also talking about expert medical. And Mr.-M us se 9 white's letter says he is sorry, we m issed all 10 deadli ne s but we are trying our best. 11 That's fine, but somebody has to be in a p o s i 12 tion by Monday to ask w h e n is this going to be done. 13 The whole structure of discove ry depends on the 14 plaintiff's going first and making proper production. 15 Now, you know the judge's feeling that time is 16 short and people are doing their best, he u n d e r 17 stands it and recognizes it and sympathizes w i t h it. 18 But you better get that done and you should be in a 19 position by Mond ay to say, Judge, you will get it 20 by Tuesday or Wednesday. And if you don't have a 21 date by then you will be jumping into the frying pa; 22 or into the fire, which ever is w o r s e . 23 MR. PAKULA: You have covered the whole subject 24 And we don't have any 26(b) reports of any sort 25 whatsoever. Until we get that there are things that EASTERN DISTRICT COURT REPORTERS UNITED STATES DISTRICT COURT 223 CADMAN PLAZA E.AST BROOKLYN. NEW YORK 11201 330-7687 I3 2 THE SPECIAL MASTER: I agree, counsel. j 3 MR. PAKULA: Those are the only dates that have ' 4 passed. j 5 So the only other thing that I wanted to mentic 6 and this is something that the defendants just workc 7 out yesterday or the day before -- yesterday, really 8 and that is that we are scheduling in New York our 9 medical examinations for the period March 1st thro 10 March 5th. You probably don't know that yet, Mr. he- 11 New York is the place and Albert Einstein is the 12 location. 13 THE SPECIAL MASTER: The hospital? 14 MR. PAKULA: Yes. 15 THE SPECIAL MASTER: In the Bronx? 16 MR PAKULA: And the dates are March 1st thr cup:'. 17 March 5th for the examinations, he will provide 18 other information as well, but I am conveying that 19 date to you now, Dave. I am.not asking you to comrm 20 on it unless you want to. 21 THE SPECIAL MASTER: I t 's a fine institution. 22 I once represented them. 23 MR. PAKULA: At the soonest possible time I 24 would like to know if there is anybody that cannot 25 go there or cannot be there at that time. Because EASTERN DISTRICT C O U R T REPORTERS UNITED STATES DISTRICT COURT 225 CADMAN PLAZA EAST BROOKLYN. NEW YORK 11201 330-768/ ^_ 1JLPKvX*u4asI j ; [ ! ! UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re jj "AGENT ORANGE" |I|* Product Liability Litigation x MDL No. 381 DEFENDANTS' INTERROGATORIES TO ELEVEN PROPOSED REPRESENTATIVE PLAINTIFFS. P L E A S E T A K E N O T I C E t h a t p u r s u a n t to the d i r e c t i o n s of Special Master Schreiber, you are hereby required to answer each : of the following interrogatories for each of the eleven proposed representative plaintiffs and for each other person claiming d e r i v atively through him as a result of his exposure to Agent Orange in V i et n am under oath on or before January 11., 1984. Th e s e I n t e r r o g a t o r i e s shall be d e e m e d s e r v e d only on behalf of those defendants who have properly been made parties hereto by service of the sum mo ns and complaint in accordance with the Federal Rules of Civil P r o c e d u r e and shall not be d e e m e d an a p p e a r a n c e , a d m i s s i o n of s e r v i c e or c o n s e n t to j u r i s d i c t i o n by !, any defendant not so m a d e a party to this action. !' j! T h e s e I n t e r r o g a t o r i e s a re c o n t i n u i n g interrogatories. ji |j If at any time after service of answers hereto plaintiff obtains !; ji or becomes aware of additional information pertaining to any of i\:j ! the Interrogatories, plaintiff shall immediately serve supplemental sworn written answers setting forth such additional information. f A vv I. GENERAT, State your name, social security number, military service number, and each address at which you have ever lived (excluding time during active military service), starting w i t h your current address, and give the dates you lived at each address. Identify each educational institution you attended, the d a t e s of y o u r a t t e n d a n c e , and d e s c r i b e any p h y s i c a l or m e n t a l e x a m i n a t i o n you received at or in connection with your attendance at each institution, stating with respect to each such examination: a) the date of the examination; b) the hospital or institution where such examination was given; and c) the n a m e a nd a d d r e s s of the p e r s o n c o n d u c t i n g the examination. If you have ever applied for life, health or accident insur ance, state with respect to each such application: a) the date of the application; b) the kind of insurance applied for; c) the name and address of the insurance company to which the application was made; d) w h e t h e r s u c h a p p l i c a t i o n wa s a c c e p t e d and if not, w h y not; and e) whether a medical examination was given in connection w i t h the a p p l i c a t i o n , and, if so, i d e n t i f y the p e r s o n conducting the examination and the medical institution wher e the examination was given. If you have ever made a claim for benefits for any medical condition (including worker's compensation, veteran's bene fits, state or federal disability or insurance or union or third party medical plans) state with respect to each such claim: a) the type of c l a i m (worker's c o m p e n s a t i o n , ve teran's benefits, etc.); -2- >*V i#* I si -i* b) t h e d a t e o f t h e c la im ; c) th e c la im number or o th er i d e n t i f i c a t i o n of the cla im ; d) t h e e n t i t y t o whom t h e c l a i m w a s m a d e , i n c l u d i n g t h e nam g and address; e) t h e m e d ic a l c o n d it io n f o r w h ich th e c la im was made; and f) the d isp o sitio n of claim . I f you have ever f i l e d or o th e r w ise commenced a le g a l a ctio r in c o n n e c tio n w ith any m ed ica l c o n d itio n (other than th is action) s ta te as to each such action : a) th e d a te th a t a c tio n was f i l e d or o th e r w is e commenced th e co u rt or a d m in is tr a tiv e body, th e f u ll t i t l e o f tht a c t i o n , th e in d ex or o th e r i d e n t i f y in g number, and the id e n tity of a ll p arties to the action; b) a d e s c r i p t i o n o f t h e m e d i c a l c o n d i t i o n in c o n n e c t i o r w it h w h ic h th e a c t io n w as f i l e d , and how you b e l ie v e th at m edical condition occurred; c) a d e s c r i p t i o n o f th e o u tco m e o f th e a c t i o n , or o f i t t p r e s e n t s t a t u s i f i t i s s t i l l p ending; and d) t h e d a t e s and a m o u n ts o f any p a y m e n ts , e i t h e r a s i r e s u lt o f a judgm ent or s e t t le m e n t , w hich you have r e c e iv e d or w hich you are scheduled to r e ce iv e. I I . EMPLOYMENT HISTORY I d e n t if y and d e s c r ib e each job you have h e ld , w hether em ployed by o th e r s or s e lf -e m p lo y e d , and s t a t e as to each: a) t h e name and a d d r e ss o f you r e m p lo y e r , th e a d d r e s s of your w o r k p la c e , th e n a tu re o f the b u s in e s s and your jo t title ; b) your d u t i e s and r e s p o n s i b i l i t i e s ; c) th e d a te th e job began and ended and th e r e a so n s fo r te r m in a tio n o f the job; and d) th e d a te and p la c e o f ea ch p h y s ic a l or m en tal e x a m in a tio n th a t you underwent in co n n ection w ith such job, i d e n t i f y i n g th e name and a d d r e ss o f each m e d ic a l p r a c t i t i o n e r c o n d u c tin g th e e x a m in a tio n and th e name n! . -3- and a d d ress o f any m ed ica l i n s t i t u t i o n a t w h ich such exam ination was conducted. 7. W i t h r e s p e c t to e a c h job i d e n t i f i e d in r e s p o n s e to Inter- r n o i f n r v Hn^ . f*i.r iH. o. .n H f v M r h n n - f h p- - i_ /o b i n ^ mf u ~ r ~~ v J .r mevdmi*/'v al* condition or accident that you experienced, and state sepa rately as to each: a) a description of the injury, medical condition or acci dent; b) the dates of the injury, medical condition or accident; and c) the treatment received, including the treating physi cian's name and address and all hospitalizations, oper ations and medication received. I I I . FAMILY MEDICAL HISTORY 8. S t a t e t h e n a m e s a n d a d d r e s s e s o f y o u r s p o u s e , c h i l d r e n , b ro th ers, s is t e r s , parents, grandparents, aunts, un cles, c o u s in s , n i e c e s , nephews and g r a n d c h ild r e n , and w ith r e sp e c t to each: a) i f any o f them are d e c e a se d , s t a t e h is or her age at th e tim e of d eath and th e tim e , p la c e and ca u se of death; b) id e n t if y each i l l n e s s , d is e a s e , d i s a b i l i t y , or m ed ical c o n d it io n ev er had by ea ch d u rin g h is or her l i f e t i m e which required p r o fe ssio n a l m edical a tten tio n ; c) identify any birth or genetic defects or miscarriages wh i c h they had; and d) w i t h r e s p e c t to e a c h r e la ti ve , i d e n t i f y ea ch m e d i c a l practitioner and medical institution that treated them, and set forth the diagnosis. I V . VETERAN'S MEDICAL HISTORY 9. State: a) the date of your birth; -4- b) the name and address of the hospital or other facility where you were born, and the name and address of each attending physician or other medical practitioner; and c) each birth defect that you had and each medical co mpli c a t i o n c o n n e c t e d w i t h yo u r b i r t h (e.g.> p r e m a t u r e birth, breech birth, jaundice, fetal alcoholism), and each medical complication or health problem that your m o ther had in connection with her pregnancy or your birth (e.g.. toxemia, long period of labor). 10. Identify each injury, illness, disability or other physical or mental condition which you have ever had, whether tempo rary or permanent, and state separately as to each: a) e a c h m e d i c a l p r a c t i t i o n e r and/or m e d i c a l i n s t i t u t i o n seen or visited by you for the purposes of c o n s u l t a tion, diagnosis, prognosis, x-rays, treatment or other care, specifying the dates of all hospitalizations; b) t h e d i a g n o s i s or p r o g n o s i s m a d e b y e a c h m e d i c a l practitioner and medical institution; and c) t h e n a t u r e a n d e x t e n t of t h e c a r e a n d t r e a t m e n t received in each medical institution and from each medical practitioner. 11. W i t h respect to e a c h injury, illness, disabili t y , or other physical or mental condition identified in response to In terrogatory 10, identify each such condition that you claiir or believe was caused by or arose out of exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin or some combination thereof, and state separately as to each: a) a description of each symptom; b) whether you contend that such injury, illness disabili ty or other physical or mental condition was caused by e x p o s u r e to A g e n t O r a n g e , 2,4,5-T, 2,4-D, dioxin, or some combination thereof; c) the date and m a n n e r i n w h i c h e a c h s u c h s y m p t o m first manifested itself or was made known to you; and d) the bas is for yo u r c l a i m or b e l i e f that the c on d i t i o n was caused by or arose out of exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin or some c o m b i n a t i o n thereof, including the name and address of each person whc f u r n i s h e d i n f o r m a t i o n c o n t r i b u t i n g to said c l a i m or belief, and the substance of that information. -5- II 1 i; I 12. i j ! Identify each drug or medication ever used or taken by you, i n c l u d i n g , but not l i m i t e d to, illegal, r e c r e a t i o n a l and over-the counter drugs, and for each drug or medication, set forth the following with respect to each: a) the bra nd n a m e , g e n e r i c name, or " s t r e e t n a m e " of the drug; b) the dates of use; c) the amount used during each period of use; d) the n a m e a n d a d d r e s s of the p h y s i c i a n , if any, who prescribed the drug; e) a description of reasons for your use of the drug; and ' i i i i 13. | I 1 f) whether you have ever received any medical treatment or counseling in connection with your use of such drugs. Identify each skin condition that you have ever had, and with respect to each such condition: a) state the dates during which you had that condition; b) d e s c r i b e a n y d i a g n o s i s or m e d i c a l t r e a t m e n t you i ceived for the condition, and state: i) the n a m e and a d d r e s s of the p e r s o n r e n d e r i n g the diagnosis or treatment; | ii) the name and address of the medical institution(s) I at which you were diagnosed or treated; | iii) the dates of the diagnosis or treatment; and i iv) the effect of the treatment. 14. If you have ever s m o k e d c i g a r e t t e s or o t h e r w i s e used a tobacco product: a) i d e n t i f y e a c h type of p r o d u c t fe.a.. cigars, c i g a rettes, chewing tobacco); b) i d e n t i f y the t i m e p e r i o d d u r i n g w h i c h y o u used that tobacco product; c) i d e n t i f y the a m o u n t used on a d a i l y b a s i s (e.g., packs of cigarettes/day); and d) st a t e w h e t h e r an y p h y s i c i a n or o t h e r h e a l t h care professional has ever advised you to stop or reduce your use of cigarettes or other tobacco products, and, I -6- 3 ft^ if if 4 ; wJ i if so, s t a t e the n a m e and a d d r e s s of the p h y s i c i a n or other health care professional and the date of the advice. 15. If you have ever consumed or drunk alcohol, state separately w i t h respect to each type of alcohol (e.g.. liquor, beer, wine, etc.) consumed: a) at what age consumption began; b) the amount and frequency of such consumption; c) if consumption ceased at any time, the reasons for such cessation and the reasons for any resumption; and d) wheth er you were ever hospitalized or institutionalized for alcohol use, or advised to l i m i t or stop alcohol use, and, if so, state the name(s) of ea ch such h o s p i tal or institution or medical practitioner who treated or advised you. 16. If a n y i n s e c t i c i d e s (e . g . . C h l o r d a n e , L i n d a n e , DDT), r o d e n t i c i d e s (e.g.. rat poison), i n s e c t r e p e l l e n t s (e.g.. DEET) or other pest control compounds were ever used by you or o t h e r s a r o u n d y o u r livin g or w o r k i n g q u a r t e rs , st a te as to each: a) the brand n a m e or generic name of the chemical; b) a d e s c r i p t i o n of the c h e m i c a l (e.g.. p o wd er , liquid, color, smell); c) a d e s c r i p t i o n of the c o n t a i n e r for the c h e m i c a l (e.g.. shape, color, markings) d) the dates of use: e) the metho d of application; f) the place it was applied; g) the frequency of application; and h) w h e t h e r y o u e x p e r i e n c e d any a d v e r s e r e a c t i o n to the compound and, if so, describe the reaction. V I . M ILITARY SERVICE 17. S t a t e w i t h r e s p e c t to y o u r m i l i t a r y s e r v i c e : -7- r- fi Jt i.'ai)o a) th e b ran ch o f th e arm ed s e r v i c e s in w h ic h you served ? b) th e i n c lu s i v e d a te s o f your se r v ic e ? c) th e in c lu s iv e d a te s of s e r v ic e in or near Vietnam? d) t h e name o f e a c h m i l i t a r y u n i t t o w h ic h you w e r e a s s ig n e d w h ile s e r v in g in or near Vietnam ? and the d ates during which you were assign ed to each such unit? e) th e name and l o c a t i o n o f each p la c e or area a t w h ich you w ere p h y s ic a lly p r e se n t in or near Vietnam and the d a tes during w hich you w ere p resen t a t each such p lace or area? f) your im m e d ia te s u p e r io r o f f i c e r ' s name and rank w h ile in or near Vietnam ? and g) th e type of d isc h a r g e you r e c e iv e d . w ith r e sp e c t to each i l l n e s s , in ju r y , wound, or other m e d ic a l or p s y c h o l o g ic a l c o n d it io n e x p e r ie n c e d by you d u rin g your m ilit a r y s e r v ic e in or near Vietnam , sta te : a) th e d a te o f your i l l n e s s , in ju r y , wound, or o th e r m edical or p sy c h o lo g ic a l con d ition ; b) a d e s c r i p t i o n o f t h e i l l n e s s , i n j u r y , w ound, or o th e r m ed ica l or p s y c h o lo g ic a l c o n d itio n , in c lu d in g a de s c r ip t io n o f a l l symptoms? c) th e ca u se o f th e i l l n e s s , in ju r y , wound, or o th er m ed ical or p s y c h o lo g ic a l con d ition ? d) t h e name and rank o f t h e p e r s o n t o whom y o u f i r s t r e p o r te d th e i l l n e s s , in ju r y , wound, or oth er m ed ica l or p s y c h o lo g ic a l c o n d itio n ( i f anyone); e) the date th a t you f i r s t rep o rted th e i l l n e s s , in ju r y , wound, or other p sy ch o lo g ica l or m edical condition? f) th e name, rank and lo c a t io n of each p h y sic ia n or other h e a lth c a re p r o f e s s io n a l who tr e a te d your i l l n e s s , in ju r y , wound, or other p s y c h o lo g ic a l or m ed ical con d i t io n , in c lu d in g th e d a te s and p l a c e s o f tr e a tm e n t, and a d e s c r ip tio n o f the trea tm en t you receiv ed ; and g) th e name and lo c a t io n o f each h o s p it a l or oth er h e a lth c a r e f a c i l i t y w h ich t r e a t e d your p s y c h o lo g ic a l or m e d ic a l c o n d itio n , th e d a te s o f tr e a tm e n t, and a d e sc r ip tio n of the treatm ent th at you received . - 8 - P C; 19. Describe any other medication taken by you during your military service (e.g., Dapsone, Chloroquine, Primaquine, Binoctal), stating as to each: a-;\ the brand name or generic name of the medication; b) the form of the m e d i c a t i o n (e.g., pill/ capsule, injection, etc.); c) the color, shape, and size of any pill or capsule taken; d) the reasons for taking the medication; e) the name and rank of the person(s) who gave you the medication; f) the dates you took the medication; g) the amount of the medication taken (e.g.. pills/day) and h) whether you experienced any adverse reaction to th medication and, if so, describe the reaction. 20. State whether you ever received any training, instructions warnings or health and safety information concerning herbi cides during your military service, and identify as to each a) the dates you received the foregoing; b) the location where received; c) the name and rank of the person(s) from who it was received; d) the substance of any oral information received; and e) the title, date, author or source, and content of an: written material received. 21. Set forth with respect to each time you claim to have beer exposed to herbicides: a) the date of the alleged herbicide exposure; b) the time of day of the alleged exposure; -9- I*,w,# v <3 c) the closest geographical or political reference point (e.g., hill, to w n , l a n d i n g zone) to the p l a c e yot believe you were exposed; d) a d e s c r i p t i o n of the t e r r a i n at the p l a c e of allge exposure; e) a d e s c r i p t i o n of h o w t h e h e r b i c i d e w a s be i n g a p p l i e d (e.g., h e l i c o p t e r , a i r c r a f t , hand, f) a description of your activities at the time of allge exposure; g) the manner you believe your body was physically exposec to the h e r b i c i d e (e.g.. s k i n contact, i n h a l a t i o n , i n ge s t i o n or s w a l l o w i n g ) , and, if you b elieve you were exposed by contact on your skin, identify the areas o: skin that came in contact with the herbicide; h) the n a m e and rank of o t h e r p e o p l e p r e s e n t at the tim< of alleged exposure; and i) w i t h r e s pe ct to an y d e c e a s e d p r o p o s e d r ep re se n ta ti v e plaintiff, state how such plaintiff will demonstrate any of the information requested in subparts a) throug] h) of this interrogatory, identifying any persons wit: such i n f o r mation w h o w i l l testify as to such p l a i n tiff's exposure to herbicides. ONLY IF YOU CONTEND THAT ANY OF YOUR CHILDREN HAS A BIRTH DEFEC'. CAUSED BY YOUR EXPOSURE TO AGENT ORANGE, 2,4-D, 2,4,5-T, DIOXIr OR SOME COMBINATION THEREOF, ANSWER THE FOLLOWING INTERROGATO RIES. 22. I d e n t i f y the c h i l d r e n th a t y o u have fathe re d, inclu di ng n a m e , dat e and p l a c e of b i r t h of each such child, a nd the name and address of each child's mother. 23. Identify each of your children w h o m you contend has birth o: genetic defects allegedly caused by your exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin or some combination thereof and identify; a) th e b i r t h or g e n e t i c d e f e c t s w h i c h y o u c o n t e n d we re caused by your exposure to Agent Orange, 2,4-D, 2,4,5T, dioxin, or s o m e c o m b i n a t i o n th er eo f, and s t a t e the ba s i s for y o u r belief, i n c l u d i n g o p i n i o n s of anj physicians; b) any other birth or genetic defects which the child has; -10- Vi * 4 ii C c) each medical practitioner and medical institution seen or visited by the child or in w h i c h the child was confined for p urposes of consultation, diagnosis, prognosis, treatment or other care, and the dates, purposes and results of such consulation, diagnosis, prognosis, treatment or other care; and d) the identity of the mother of each child. 24. I d e n t i f y each and e v e r y c h i l d of each m o t h e r i d e n t i f i e d in response to Interrogatory 22 and state as to each: a) the child's na m e , a d d r e s s , date of b i r t h and p l a c e of birth, including the name and address of the hospital or other place where delivery occurred? and b) t h e p h y s i c i a n ( s ) w h o t r e a t e d t h e m o t h e r d u r i n g pregnancy and/or delivered the child. 25. W i t h respect to each mother identified in response to Inter rogatory 23(d), identify her brothers, sisters, parents, grandparents, aunts, uncles, cousins, nieces, nephews, and grandchildren, and: a) if any of t h e m are de c e a s e d , state his or her age at the time of death and the time, place, and cause of death; b) identify each illness, disease, disability, or medical condition ever had by each during his or her li f e t i m e which required professional medical attention; c) identify each medical practitioner and medical institu tion that treated them, and set forth the diagnosis of each, stating the same as to each relative. 26. W i t h respect to each pregnancy, for each mother identified in response to Interrogatory 23(d), state: a) w h e t h e r the m o t h e r w a s e x p o s e d to or c o n t r a c t e d any vi ral or b a c t e r i a l i n f e c t i o n or d i s e a s e d u r i n g or s h o r t l y b e f o r e the p r e g n a n c y fe.a.. G e r m a n m e a s l e s , flu, i.) and if so, i d e n t i f y the i n f e c t i o n or illness, the period during which it occurred, and any medication or treatment given therefor; b) whether the mother incurred any injury during pregnan cy, and, if so, d e s c r i b e the injury, the t r e a t m e n t -i- V F*& r\ fe y received, any examining or treating physicians, and any institutions at which treatment occurred; c) w h e t h e r the m o t h e r or f a t h e r ever h a d any v e n e r e a l dise ase , and, if so, d e s c r i b e the di s e a s e , the t r e a t m e n t received, any e x a m i n i n g or t r e a t i n g physicians, and any institutions at which treatment occurred; d) w h e t h e r d i a g n o s t i c p r o c e d u r e s , i n c l u d i n g , but not l i m i t e d to, a b d o m i n a l x - r a y or p e l v i m e t r y , amniocentesis, and/or ultrasound were used, and, if so, set forth the date of the procedure, describe the procedure, the examining or treating physician and any institutions at which the procedure occurred; and e) w h e t h e r any m e d i c a l p r o b l e m s or c o m p l i c a t i o n s a r o s e d u r i n g p r e g n a n c y (e.g.. t o x e m i a ) , and, if so, d e s c r i b e the p r o b l e m s or c o m p l i c a t i o n s and the t r e a t m e n t received. 27. An sw er Interrogatories 6, 7, 12, 14, 15, and 16 with respect to each mother identified in response to Interrogatory 23(d). 28. For ea c h m o t h e r i d e n t i f i e d in r e s p o n s e to I n t e r r o g a t o r y 22 identify each and every pregnancy not resulting in a live birth, and state with respect to each: a) w h e t h e r t h e r e w a s a m i s c a r r i a g e a n d / o r s p o n t a n e o u s a b ort io n, and, if so, state the date and d e s c r i b e the reason for the miscarriage and/or spontaneous abortion and identify any examining or treating physicians, and any institutions at whi ch it occurred; b) if the r e s p o n s e to a) a b o v e is a f f i r m a t i v e , state whether you contend that such miscarriage and s p o n t a n e o u s a b o r t i o n w a s c a u s e d by y o u r e x p o s u r e to A g e n t Orange, 2,4-D, 2,4,5-T, dioxin, or s o m e combination thereof; c) whether there was a .voluntary or therapeutic abortion, and, if so, s t a t e the da t e and d e s c r i b e the reason for the voluntary or therapeutic abortion, and identify any examining or treating physicians, and any institutions at whic h the abortion occurred; and d) if the r e s p o n s e to c) a b o v e is a f f i r m a t i v e , s ta te whether you contend that such voluntary or therapeutic abortion was caused or necessitated by your exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin, or some combina tion thereof. Dated: New York, New York December 23, 1983 CADWALADER, WICKERSHAM & TAFT * w v w j > v * v^ w Diamond Shamrock Chemicals One Wall Street New York, New York 10005 (212) 908-7000 Company TOWNLEY & UPDIKE Attorneys for Defendant Monsanto Company 405 Lexington Avenue New York,. New York 10174 (212) 682-4567 RIVKIN, LEFF, SHERMAN & RADLER Attorneys for Defendant The Dow Chemical Company 100 Garden City Plaza Garden City, New York 11530 (516) 746-7500 CLARK, GAGLIARDI & MILLER Attorneys for Defendant T H Agriculture & Nutrition Company, Inc. The Inns of Court 99 Court Street White Plains, New York 10601 (914) 946-8900 -13- ARTHUR, DRY & KALISH Attorneys for Defendant Uniroyal, Inc. 1230 Avenue of the Americas New York, New York 10020 (212) 841-9300 BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM Attorneys for Defendant Thompson Chemicals Company 33 Washington Street Newark, New Jersey (201) 622-7400 -14- 12763 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK __ ___________ ____ -- ________ _ _ _ ____ In r e "AGENT ORANGE" : Product L ia b ility L itig a tio n : MDL N o . 3 8 1 ANSWERS OF DAVID GENE LAMBIOTTE TO DEFENDANT'S INTERROGATORIES TO PROPOSED REPRESENTATIVE P L A IN T IF FS P L A I N T I F F ' S MANAGEMENT COMMITTEE P h i l l i p E. Brown, E sq. H o b e r g , F i n g e r , B r o w n , Cox it Mol 1 i gan 703 Market S tr e e t (18th F loor) San F ra n cisco , C a lifo r n ia 94103 S t a n l e y M. C h e s l e y , E s q . W aite, Schneider, B ayless and C h esle y Co. L .P .A . 1513 C entral T ru st Tower F ourth and V ine S t r e e t s C in c in n a ti, Ohio 45202 David J. Dean, Esq. D e a n , F a l a n g a it R o s e One Old Country Road C a r l e P l a c e , New York 11514 New ton B. S c h w a r tz , E sq . H ouston Bar C enter B u ild in g 7 2 3 Main ( S u ite 325) Houston, Texas 77002 T h o m a s W. H e n d e r s o n , E s q . B a s k i n it S e a r s F rick B u ild in g (10th F I.) P i t t s b u r g h , PA. 15219 Benton M u sselw h ite, Esq. John 0. O'Quinn, Esq. 609 Fannin (S u ite 517) Houston, Texas 77002 Stephen J. S c h le g e l, Esq. S c h l e g e l it T r a - f e l e t , L t d . One N orth L a S a lle S t r e e t S u ite 3900 C hicago, I l l i n o i s 60602 Gene L ocks, Esq. N eil P eterson Esq. G r e i t z e r Sc L o c k s , E s q s . 1500 Walnut S t r e e t P h i l a d e l p h i a , PA 1 9 1 0 2 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" __________ I . GENERAL MDL No. 381 1. S t a te your name, s o c ia l s e c u r it y number, m ilit a r y s e r v ic e number, and each a d d r e ss a t which you have e v e r liv e d (excluding tim e during a c tiv e m ilita r y s e r v ic e ), sta r tin g w ith your c u r r en t a d d r e ss, and g iv e th e d a te s you liv e d at each address. D avid Gene L am b iotte 223-68-8395 44 W estover Road Newport News, V ir g in ia 1983 551 Logan P la ce Newport N ew s,' V ir g ini a , 1980-1983 York, Maine 1978-1980 220 Paen Ave. Newport News, V ir g in ia 1975 304 Hurley Ave. Newport News, V ir g in ia 1974 River Drive Apartments Newport News, V ir g in ia 1973 44 W estover Road Newport News, V ir g in ia 1947-1969 2. I d e n tify each ed u ca tio n a l in s t i t u t i o n you a tten d ed , the d a t e s of your a tte n d a n c e , and d e s c r ib e any p h y s ic a l or mental exam ination you re ce iv ed at or in con n ection with your attendance at each in s titu tio n , s ta tin g with resp ect to each such exam ination . a) th e date of th e exam ination; b ) . th e h o sp ita l or in s titu tio n where such exam ination was giv en ; and c) t h e name and a d d r e s s o f t h e p e r so n c o n d u c tin g th e exam ination. <i r* r* <"* ? " _l ; D O JL 2 . A tten d ed C h r is to p h e r Newport Community C o lle g e , 19681 9 7 1 . No p h y s i c a l exam r e q u i r e d . 3 . I f you h a v e e v e r a p p l i e d -for l i f e , h e a l t h o r a c c i d e n t in su ran ce, s t a t e with resp ect to each such a p p lica tio n : a) th e d a te of th e a p p lic a tio n ; b) th e kind o f in su r a n c e a p p lie d fo r; c) t h e name, and a d d r e s s o f t h e in s u r a n c e company t o w hich t h e a p p l i c a t i o n was made; d) w h e th e r s u c h a p p l i c a t i o n was a c c e p t e d and i f n o t , why n o t; and e) w hether a m edical exam in ation was g iv en in co n n ectio n w ith the a p p lic a tio n , and, i f so, id e n tif y th e person c o n d u c tin g th e exam in ation and th e m edical i n s t i t u t i o n where th e exam ination was g iv en . 3. Interrogatory d eleted . 4. I f you have e v e r made a c la im fo r b e n e f i t s f o r any m edical co n d itio n (in clu d in g worker' s com pensation, v e te r a n ' s b e n e f it s , s t a t e or fe d e r a l d i s a b i l i t y or in su ran ce or union or th ird party m edical p lan s) s ta te with resp ect t o each such claim : a) t h e ty p e o f c la im (w ork er' s co m p en sa tio n , v e t e r a n ' s b e n e fits , e t c . ); b) th e d a te o f th e claim ; c) th e c la im number of o th er i d e n t i f i c a t i o n of th e claim d) t h e e n t i t y t o whom t h e c l a i m w as m ad e, i n c l u d i n g t h e name and a d d r e s s ; e) t h e m ed ical c o n d it io n fo r which th e c la im was made; and f) the d isp o sitio n of claim . j r% 'b o 4. W i t h V e t e r a n s A d m i n i s t r a t i o n -fo r d i s a b i l i t y , 1 9 7 9 , J a n u a r y . Lymphoma in c o n n e c t i o n w it h A g en t O range e x p o s u r e . N o n -serv ice d is a b ilit y awarded. 5. If you have ever f i l e d or o th e r w ise commenced a le g a l a c tio n in con n ection w ith any m edical co n d itio n (other than t h i s action ) s ta te as to each such a ctio n : a) th e d a te t h a t a c tio n was -filed or o th e r w is e commenced, th e court or a d m in istr a tiv e body, th e -full t i t l e of th e a c tio n , th e index or other i d e n t i f y i n g number, and t h e id e n t i t y , of a l l p a r t i e s to the action; b) a d e s c r i p t i o n of t h e m ed ical c o n d it io n in c o n n e c tio n w ith w h ich t h e a c t i o n was f i l e d , and how you b e l i e v e th at m edical co n d itio n occurred; c) a d e s c r ip tio n of th e outcome of th e a c tio n , or of i t s p r e s e n t s t a t u s i f i t i s s t i l l pending; and d) t h e d a t e s and am ounts o f any p aym en ts, e i t h e r a s a r e s u lt o f a judgment or s e tt le m e n t, which you have r e c e iv e d or which you are sch ed u led to r e c e iv e . 5. Auto a c c id e n t sp r a in ed back and w h ip la sh , s e t t l e d out court. Auto a c c id e n t, m u ltip le b r u ise s - s e t t le d out of court. I I . EMPLOYMENT HISTORY I d e n tify and d e sc r ib e each job you have h e ld , whether em ployed by o th e r s or s e lf-e m p lo y e d , and s t a t e a s t o each: a) t h e name and a d d r e ss of your em p lo y er, th e a d d r e ss of your w o rk p lace, th e n a tu re of th e b u s in e s s and your job t i t l e ; b) your d u t i e s and r e s p o n s i b i l i t i e s ; c) t h e d a te t h e job began and ended and th e r e a s o n s fo r t e r m in a t io n o f th e jo b ; and d) th e d a te and p la c e o f each p h y s ic a l and m ental exam ination th a t you underwent in con n ection 5 UM .iu'. h / w ith su ch jo b , i d e n t i f y i n g th e name and a d d r e ss of each m edical p r a c titio n e r conducting th e e x a m in a tio n and t h e name and a d d r e s s of any m ed ical i n s t i t u t i o n at which such ex a m in a tio n s was conducted. 6. C i t y o f N e w p o r t N e w s , V i r g i n i a , l i f e g u a r d a n d s w i m m i n g in s tr u c t o r - life g u a r d 1965, no exam ination r eq u ired . Job was f o r t h e summer o n ly . V arious sh ort exam ination. - term jo b s one of which r e q u ir e d an S h erw in W i l l i a m s F'a i n t C o m p a n y , C onsolidated Carpet I n s t a lla t io n , E n virotech , o f f i c e work, tim e keeper/book keeper, payroll clerk, e tc . 6W i t h r e s p e c t t o e a c h j o b i d e n t i f i e d i n r e s p o n s e t o I n t e r r o g a t o r y No. , id e n tify each on-th e-job inju ry, m ed ic a l c o n d i t i o n or a c c id e n t t h a t you e x p e r ie n c e d , and s ta te sep arately as to each: a) a d e s c r ip tio n of th e in ju r y , m edical c o n d itio n or a c c id e n t; b) th e d a te s o f th e in ju r y , m edical c o n d itio n or a c c id e n t; c) th e treatm ent receiv ed , inclu d in g the trea tin g p h y s i c i a n ' s name and a d d r e s s and a l l h o s p i t a l i z a t i o n s , o p e r a tio n s and m ed ic a tio n r e c e iv e d . 7 . No on t h e j o b i n j u r i e s e x c e p t p r e v i o u s l y m e n tio n e d a u t o a c c id e n t which occu rred while' d r iv in g a company tru ck . I I I . FAMILY MEDICAL HISTORY S t a t e th e names and a d d r e s s e s of your sp o u se , c h ild r e n , 1b r o t h e r s , s i s t e r s , p a r e n t s , g r a n d p a r e n t s , a u n t s , u n c l e s , c o u s in s , n ie c e s , nephews and g r a n d c h i dren, and w ith resp ect to each: a) i f any o f them are d e c e a se d , s t a t e h i s or her age a t th e tim e of death and th e tim e , p la c e and ca u se of death; b) id e n t if y each i l l n e s s , d is e a s e , d i s a b i l i t y , or m edical c o n d itio n ev er had by each during h i s or her l if e t i m e which r e q u ire d p r o fe ssio n a l m edical atten tion . c) id e n tif y any b ir th or g en etic d e fe c ts or m is c a r r ia g e s which t h e y had; and d) w ith r e s p e c t t o each r e l a t i v e , id e n t if y each m edical p r a c t i t io n e r and m ed ical i n s t i t u t i o n th a t t r e a t e d them , and s e t f o r t h t h e d ia g n o s is . B. h a r r i e d f i v e y e a r s t o E l i s a b e t h Bugg, no c h i l d r e n . B r o t h e r s : A r t h u r G. L a m b i o t t e , 2 0 8 S . M u h l e n b e r g S t . , W o o d s t o c k , V i r g i n i a 2 2 6 6 4 ; M i c h a e l G. L a m b i o t t e , 18 M i l f o r d Road, Newport News, V i r g i n i a , ; S id n e y P. L a m b io tte , 2753 H igh gate Court, W heelersburg, Ohio, 45694. F ather: Arthur J. Lam biotte M oth er: D o ro th y T. L a m b io t t e . I V . VETERAN' S MEDICAL HISTORY S ta te : a) th e date of your b ir th ; b) t h e name and a d d r e s s o f t h e h o s p i t a l or o th e r f a c i l i t y w here you w ere b o rn , and t h e name and ad d ress of each a tte n d in g p h y sicia n or other m edical p r a c t i t i o n e r ; and c) each b ir t h d e f e c t t h a t you had and each m ed ical co m p lica tio n connected w ith your b irth ( e .g ., premature b ir th , breech b ir th , jaundice, f e t a l a lc o h o lis m ) , and each m ed ical c o m p lic a tio n or h e a lth problem th a t you mother had in co n n e c tio n w ith her pregnancy of your b irth ( e .g ., toxem ia, long period of la b o r). 9 . a. November 1, 1947. b. R iv e r s id e H o s p it a l, Newport News, V ir g in ia , Dr. Bland (deceased). c . No b i r t h d e f e c t s , m other had anem ic c o n d i t i o n , s h o r t , easy labor. 10. Id e n tify each in ju ry , illn e s s , d is a b ilit y or other p h y sic a l or m ental c o n d itio n which you have ev er had, w hether tem porary or perm anent, and s t a t e s e p a r a t e ly as to each: a) ' each m edical p r a c titio n e r and/or m edical in s t i t u t io n seen or v i s i t e d by you fo r th e p u rp oses of c o n s u l ta tio n , d ia g n o s is , p ro g n o sis, x -ra y s, treatm en t or other care, sp e c ify in g the dates of a ll h o s p ita l ization s; b) t h e d i a g n o s i s or p r o g n o s i s made by each m e d ic a l p r a c t i t io n e r and m edical i n s t i t u t i o n ; and c) th e n a tu re and e x te n t of th e ca re and tre a tm e n t r e c e iv e d in each m ed ical i n s t i t u t i o n and from each m edical p r a c t it io n e r . 1 0 . O th e r t h a n a s e n u m e r a t e d i n 11 i n f r a , o n l y o c c a s i o n a l c o ld , so re th r o a t, and sin u s in fe c t io n . 11. With r e s p e c t t o each in ju r y , i l l n e s s , d i s a b i l i t y , or oth er p h y sica l or mental co n d itio n id e n tif ie d in resp on se to In terrogatory 10, id e n tify each such c o n d itio n th at you claim or b e lie v e was caused by or a r o s e out of exp osu re t o Agent Orange, 2 ,4 -D , 2 ,4 ,5 - T , d io x in or some com bination t h e r e o f , and s t a t e s e p a r a te ly as t o each: a) a d e s c r i p t io n o f each symptom; b) whether you conten d th a t such in ju r y , i l l n e s s d i s a b il i t y or oth er p h y sica l or mental c o n d i t io n was cau sed by exp osu re to Agent Orange, 2 , 4 - D , 2 , 4 , 5 --T , d i o x i n o r s o m e c o m b i n a t i o n thereof ; c) th e d a te and manner in which each such symptom f i r s t m a n if e s t e d i t s e l f o r was made known t o you; and d) th e b a s i s f o r your c la im or b e l i e f th a t t h e c o n d i t io n was caused by or a ro se out of exp osu re t o 6 fr.y Agent Orange, 2 ,4 -D , 2 ,4 ,5 - T , d io x in or some c o m b in a tio n t h e r e o f , in c lu d in g t h e name and a d d r e s s o f ea ch p e r s o n who fu rn ish ed in fo r m a tio n c o n t r ib u t in g t o s a id c la im or b e l i e f , and th e substance of th at inform ation. a. L ym phocytic Lymphoma, w ith p e r io d s o f e x a c e r b a t io n , rash, night sw eats, lo ss of w eight, s e n s it iv it y to 1s u n l i g h t , m e m o r y l o s s , i r r i t a b i i t y , a n x i e t y , a n d s e i z u r e s . b . d e l e t e d .. c . S e iz u r e s began in 1972 or 1973. I d e n t if y each drug or m ed ica tio n ev e r used or tak en by you, in clu d in g, but not lim ited to , ille g a l, recreation al and o v e r -t h e -c o u n te r d rugs, and fo r each drug or m edication, s e t fo rth th e follow in g with resp ect to each: a) t h e brand name, g e n e r ic name, or " s t r e e t name" of the drug; b) th e d a te o f u se; c) th e amount used during each p erio d of use; d) t h e name and a d d r e s s o f t h e p h y s i c i a n , i f a n y, who p rescrib ed the drug; e) a d escrip tio n of reasons for your use of the drug; and f) whether you have ever receiv ed any m edical treatm ent or co u n selin g in con n ection w ith your use of such drugs. 12. a. Valium , D ila n t in , P h n o b a r b ita l, and T e g r e to l, and o c c a sio n a l m arijuana. b. Valium s in c e s h o r tly a fte r p l a i n t i f f ' s retu r n from Vietnam. A ll o th e rs to co n tro l th e s e iz u r e s . c . D rs. Warren, M attern, S a lte r , S avin , th e N e u r o lo g ist at VA H o s p i t a l . f l r jf JL d. For p l a i n t i f f ' s s t r e s s problem s and t o c o n tro l p la in tiff 's seizu res. 13. I d e n t i f y ea ch s k in c o n d it io n t h a t you h a v e e v e r had, and with resp ect to each such con d ition : a) s t a t e th e d a te s during which you had th a t co n d tio n ; b) d e s c r ib e any d ia g n o s is or m edical trea tm en t you r e c e i v e d -for t h e c o n d i t i o n , and s t a t e : i ) th e name and a d d ress of th e person ren d erin g th e d ia g n o sis or treatm ent; f i i ) t h e n a m e a n d a d d r e s s o-f t h e m e d i c a l i n s t i t u t i o n is) at which you were diagnosed or trea ted ; i i i ) th e d a te s of the d ia g n o sis or treatm ent; iv ) and t h e e f f e c t of th e tre a tm e n t. 13. a. s k in c a n c e r on f a c e . b. Dr. N eal 321 Main S t r e e t , N ew port News, V i r g i n i a , 2 3 6 0 1 . 14. If you have ev er smoked c i g a r e t t e s or o th e r w is e used a tobacco product: a) id e n t if y each typ e of product ( e .g ., c ig a r s , c ig a r e t t e s , chewing tob acco); b) i d e n t i f y t h e tim e p e r io d d u rin g which you used that tobacco product; c) i d e n t i f y t h e amount used on a d a i l y b a s i s ( e . g . , p a ck s o f c i g a r e t t e s / d a y ); and d) s t a t e w hether any p h y s ic ia n or o th e r h e a lth care p r o fe ssio n a l has ever ad vised you to stop or reduce your use of c ig a r e t t e s or other tobacco products, and, i f so, s ta te the name and a d d r e s s o f t h e p h y s i c ia n or o th e r h e a lth c a r e p r o fe s s io n a l and th e d a te of th e a d v ic e . J ks.. 1 i ,6 8 14. a. yes clgarettes. b. 1965 to p resen t. c. One and one h a lf p a c k s per d a y . d . Y e s , c e r t a i n d o c t o r s p l a i n t i f f h-as s e e n . 15. If you have ever consumed or drunk a lc o h o l, s t a t e sep a ra tely w ith resp ect to each type of alcohol (e .g ., liq u o r , b e e r ,, w ine, e t c .) consumed: ' a) a t what age consum ption began; b) th e amount and freq u en cy of such consum ption; c) if consum ption ceased at any tim e, th e reason s fo r such c e s s a t io n and th e r e a so n s fo r any resu m p tion ; and d) w hether you were ev er h o s p i t a l i s e d or in s titu tio n a liz e d for alcohol use, or advised to lim it or stop alcoh ol use, and, i f so, s ta te the nam e(s) of each such h o sp ita l or in s titu tio n or m e d ic a l p r a c t i t i o n e r who t r e a t e d or a d v is e d you. 15. a. E ighteen or n in eteen . b. S o c i a l l y and m o d era tely . c. Has not c e a se d , has le s s e n e d . d. No. 16. I f any i n s e c t i c i d e s ( e . g . , C h lo rd a n e, L in d an e, DDT), rod en ticid es (e .g ., rat poison), in sect rep ellen ts (e .g ., DEET) o r o t h e r p e s t c o n t r o l c o m p o u n d s w e r e e v e r u s e d b y you or o th e r s around your liv i n g or working q u a rters, s ta te as to each: a) t h e brand name or g e n e r ic name o f t h e c h e m ic a l; b) a d e s c r ip t io n of th e chem ical ( e . g . , powder, liq u id , color, sm ell); \ 9 V. c> a d e s c r i p t i o n o f t h e c o n t a i n e r f o r t h e c h e m ic a l ( e . g . , shape, c o lo r , m arkings) d) t h e d a t e o f u se ; e) th e method of a p p lic a tio n ; f ) th e p la c e i t was a p p lied ; 9> t h e f r e q u e n c y o f a p p l i c a t i o n ; a n d h) f whether you ex p erien ced any a d verse r e a c tio n to the compound and, i f so , d e s c r ib e th e r e a c tio n . 16. Yes. P la in t if f has used in s e c t ic id e s to control f l i e s , f l e a s , e tc . Apartment com plexes use in s e c t ic id e s to co n tro l in s e c t s however, p l a i n t i f f i s not aware of neme brands o f th e p r o d u c ts th e y u se d . P l a i n t i f f o r d in a r y s t o r e brand powder fo r f l e a s and sp ra y fo r w ith no r e a c tio n from such u se. ants, a lso the used ants V I. MILITARY SERVICE 17. S ta te w ith r e sp e c t to your m ilita r y s e r v ic e : a) th e branch of th e armed s e r v i c e s in which you served; b) th e i n c l u s i v e d a te s o f your s e r v i c e ; c) the in c lu s iv e d ates of se r v ic e in or near Vi etnam ; d) th e name o f each m i l i t a r y u n it tD which you were assign ed w hile servin g in or near Vietnam; and th e d a te s during w hich you were assign ed to each such u n its; e) th e name and lo c a t io n o f each p la c e or area at which you were p h y s ic a lly p r e se n t in or near Vietnam and th e d a te s d u rin g which you were p resen t at each such p la ce or area; f ) your im m ed iate s u p e r io r o f f i c e r ' s name and rank w h ile in or near Vietnam ; and 9> t h e t y p e o f d i s c h a r g e y o u r e c e i v e d . -jr L - . i ' 17 a. Army b. December 1966 - September 1968. c . May 1 9 6 7 - A p r i l 1 9 6 8 . d . S t a t i o n e d o n Cam R a h n B a y a n d w e n t wi t h c o n v o y s e . d e l i v e r i n g s u p p l i e s t o v a r i o u s a r e a s on t h e m aini and. f . P l a i n t i f f d oes not remember any s p e c if ic names of p la c e s , he d e liv e r e d th e s u p p lie s and l e f t . g. H onorable. 18. W ith r e s p e c t t o each i l l n e s s , i n j u r y , wound or o t h e r m edical or p sy c h o lo g ic a l c o n d itio n experienced by you d uring your m ilit a r y s e r v ic e in or near Vietnam, s t a t e : a) t h e d a t e o f your i l l n e s s , i n j u r y , wound, or other m edical or p sy c h o lo g ic a l con d ition ; b ) a d e s c r i p t i o n o-f t h e i l l n e s s , i n j u r y , w o u n d , o r other m edical or p sy c h o lo g ic a l co n d itio n , in clu d in g a d e s c r i p t i o n o-f a l l s y m p t o m s ; c ) t h e c a u s e o-f t h e i l l n e s s , i n j u r y , w o u n d , o r o t h e r m edical or p sy ch o lo g ica l c o n d itio n ; d> t h e n a m e a n d r a n k o-f t h e p e r s o n t o whom y o u - f i r s t r e p o r te d th e i l l n e s s , in j u r y , wound, or oth er m edical or p sy ch o lo g ica l co n d itio n ( if anyone): e) th e d ate th a t you f i r s t rep o rted the illn e s s , in ju ry , wound, or oth er p sy ch o lo g ica l' or medical c o n d itio n ; f ) th e name, rank and lo c a t io n o f each p h y sic ia n or o th e r h e a lt h c a r e p r o f e s s i o n a l who tr e a te d your i l l n e s s , in ju r y , wound, or o th e r p sy c h o lo g ic a l or m ed ica l c o n d i t i o n , in c lu d in g t h e d a t e s and p l a c e s o f tr e a tm e n t, and a d e s c r i p t io n o f th e trea tm en t you r e c e i v e d ; and g> t h e nam e a n d l o c a t i o n o f e a c h h o s p i t a l o r o t h e r h e a lth ca re f a c i l i t y which t r e a t e d your p sy ch o lo g ic a l or m edical c o n d itio n , th e d ates of treatm ent, and a d e s c r ip t io n of th e tr e a tm e n t th a t you r e c e iv e d . ?)r*V* 11 IB. The o n ly in ju r y p l a i n t i f f r e c ie v e d was in th e warehouse where he was w orking. P la in ti-f f was s i t t i n g a t a desk doing paper work when a l i e u t e n a n t who had not been c le a r e d t o do so began t o u se a -fo r k lift,, he l o s t c o n tr o l of i t and th e f o r k l i f t pinned p l a i n t i f f to th e w all and in ju red p l a i n t i f f ' s sh in from which p l a i n t i f f has a sc a r . 19. D e s c r ib e any oth er m ed ic a tio n taken by you d uring your m ilita r y s e r v ic e ( e .g ., Dapsone, Chloroquine, Prim aquine, B in o cta l), sta tin g as to each: a) t h e brand name or g e n e r i c name o f t h e m e d ic a t io n ; / b) t h e form o f th e m e d ic a tio n ( e . g . , p i l l , c a p s u le , in jection , etc.); c) th e c o lo r , shape, and s i r e of any p i l l or c a p su le taken; d) t h e r e a s o n s f o r t a k i n g t h e m e d ic a t io n ; e) t h e name and rank o f t h e p e r s o n ( s ) who g a v e you th e m edication; f > th e d a te s you took th e m ed ication; g> t h e a m o u n t o f t h e m e d i c a t i o n t a k e n ( e . g . , p i l l s / d a y ) ; and h) w h eth er you e x p e r ie n c e d any a d v e r se r e a c t io n t o t h e m ed ication and, i f so , d e sc r ib e the r e a c tio n . 19. The o n ly m ed ic a tio n p l a i n t i f f had was fo r a headache, p l a i n t i f f does not r e c a ll what m edicine i t was. 20. S ta te whether you ever r e ce iv ed any tr a in in g , i n s t r u c t i o n s , w arnings or h e a lth and s a f e t y in fo r m a tio n c o n c e r n in g h e r b ic id e s d u rin g your m ilit a r y s e r v i c e , and id e n tify as to each: a) th e d a te s you r e c e iv e d th e fo r e g o in g ; b) t h e l o c a t i o n where r e c e i v e d ; c) t h e name and rank o f t h e p erso n (s) from who r : ry _L<4 i ( O 12 it was received; d> t h e s u b s t a n c e o f a n y o r a l i n - f o r m a t i o n r e c e i v e d ; and e) t h e t i t l e , d a t e , a u th o r or s o u r c e , and c o n t e n t o-f a n y w r i t t e n m a t e r i a l r e c e i v e d . 20. No. 21. S et -forth w ith r e s p e c t to each tim e you claim to have been exposed to h e r b icie s: a) t h e d a t e o-f t h e a l l e g e d h e r b i c i d e e x p o s u r e ; b) th e tim e of day o f th e a lle g e d exposure; c) th e c lo s e s t geograp h ical or p o lit ic a l r e fe r e n c e p oin t ( e .g ., h i l l , town, landing zone) to th e p la c e you b e lie v e you were exposed; d) a d e s c r i p t i o n o f t h e t e r r a i n a t t h e p la c e o f a lle g e d exposure; e) a d e s c r i p t i o n o f how t h e h e r b i c i d e was b e in g a p p lied ( e .g ., h e lic o p t e r , a ir c r a ft , hand, e t c .) ; f) a d escrip tio n of your a c t i v i t i e s at the tim e of alleged exposure; g) th e manner you b e l i e v e your body was p h y s i c a l l y exposed to the h erb icid e ( e .g ., skin con tact, in h a la tio n , in g e stio n or sw allow in g), and, i f you b e l ie v e you were exp osed by c o n ta c t on your s k in , i d e n t i f y th e a r e a s o f sk in th a t came in con tact with th e h erb icid e; h) t h e name and rank o f o th e r p e o p le p r e s e n t a t t h e tim e of a lle g e d e x p o su re; and i) with resp ect to any deceased proposed rep re s e n t a t i v e p l a i n t i f f , s t a t e how su c h p l a i n t i f f w ill dem onstrate any of th e inform ation r e q u e s t e d i n s u b p a r t s a) t h r o u g h h ) o f t h i s in te r r o g a to r y , id e n tify in g any persons w ith such in fo r m a tio n who w i l l t e s t i f y a s t o such p l a i n t i f f ' s exposure to h erb icid es. L&' i'( 2 1 . Cam R a h n w a s d e f o l i a t e d , p l a i n t i f f l i v e d t h e s o i l t h e r e , a l s o t h e a r e a s on th e m ainland Cam Rahn w e r e d e f o l i a t e d a n d t h e c o n v o y s w e n t th e north and t o th e sou th , som etim es o v ern ig h t and worked in a c r o s s -from to areas to runs. ONLY I F YOU CONTEND THAT ANY OF YOUR CHILDREN HAS A BIRTH DEFECT CAUSED BY YOUR EXPOSURE TO AGENT ORANGE, 2 , 4 - D , 2 , 4 , 5 - T , DI O XI N OR SOME COMBINATION THEREOF, ANSWER THE FOLLOWING INTERROGATORIES. I d e n tify th e c h ild r e n th a t you have fa th e r e d , in clu d in g name, d a te and p l a c e of b ir t h of each such c h i l d , and th e name and a d d r e s s o f each c h i l d ' s m other. 22. Not a p p lic a b le . I d e n t i f y e a c h o f y o u r c h i l d r e n whom y o u c o n t e n d h a s b i r t h or g e n e tic d e f e c t s a lle g e d ly caused by your exposure to Agent Orange, 2 .4 -D , 2 ,4 ,5 - T , d io x in or some other com b in ation t h e r e o f , and i d e n t if y : a) th e b ir th or g e n e tic d e f e c t s which you contend were caused by your exposure to Agent Orange, 2,4-D , 2 , 4 , 5 - T , d i o x i n , or some c o m b in a tio n t h e r e o f , and s ta te the b a s is for your b e lie f , includ ing opinions of any p h y sic ia n s; b) any oth er b ir th or g e n e tic d e f e c t s which th e c h ild has; c) each m ed ical p r a c t i t i o n e r and m ed ical i n s t i t u t i o n seen or v i s i t e d by th e c h ild or in which th e c h ild was co n fin ed fo r purposes of c o n s u lta tio n , d i a g n o s is , p r o g n o s is , tr e a tm e n t or o th e r c a r e , and th e d a t e s , p u r p o se s and r e s u l t s of such c o n s u lt a t io n , d i a g n o s is , p r o g n o s is , tr e a tm e n t or o th e r c a r e ; and d) th e i d e n t i t y o f th e mother of each c h ild . 23. Not a p p lic a b le . 24. I d e n t i f y e a c h a n d e v e r y c h i l d o f e a c h m o t h e r i d e n t i f i e d in r e s p o n s e t o I n t e r r o g a t o r y 22 and s t a t e as t o each : a) th e c h i l d ' s name, a d d r e ss, d a te o f b ir th and p la c e of b i r t h , in c lu d in g th e name and a d d r e s s o f th e h o s p it a l or oth er p la c e where d e l iv e r y o c cu rred ; and b) t h e p h y s i c i a n ( s ) who t r e a t e d t h e m other d u rin g pregnancy and/or d e liv e r ed the c h ild . 24. Not a p p lic a b le . With r e s p e c t t o each mother i d e n t i f i e d in respcn&ft- t o In terrogatory 23 (d ), id e n tif y her b roth ers, s i s t e r s , 1p a r e n t s , g r a n d p a r e n t s , a u n t s , u n c l e s , c o u s i n s , n i e c e s , nephew s, and g r a n d c h i d r e n , and: a) i f any of them a re d e c e a se d , s t a t e h is or her age a t t h e tim e of d ea th and t h e tim e , p l a c e and cause of death; b) i d e n t i f y each i l l n e s s , d i s e a s e , d i s a b i l i t y , or m edical c o n d itio n ever had by each during h i s or her l i f e t i m e which req u ired p r o fe s s io n a l m edical attention ; c) i d e n t i f y each m edical p r a c t i t io n e r and m edical i n s t i t u t i o n th a t t r e a t e d them, and s e t f o r th th e d ia g n o s is of each, s t a t in g th e same as to each r e la tiv e . 25. Not a p p lic a b le . 26. With r e s p e c t t o each p regnancy, fo r each mother id e n tifie d in response to Interrogatory 23(d ), sta te : a) w hether th e mother was exposed t o or c o n tr a c te d any v ir a l or b a c te r ia l in fe c t io n or d is e a s e during or s h o r t l y b e f o r e t h e p r e g n a n c y ( e . g . , German m e a s l e s , f l u , e t c . ) and i f s o , i d e n t i f y th e i n f e c t i o n or i l l n e s s , th e p eriod during which i t o ccu rred , and any m edication or treatm ent given th e re fo r ; b) whether th e mother in c u r re d any in ju r y d u rin g l.?7 73 pregnancy, and, if so, d escrib e th e inju ry, the treatm en t r e c e iv e d , any exam ining or tr e a tin g p h y s ic ia n s , and any i n s t i t u t i o n s a t which t r e a t ment occu rred ; c) w hether th e mother or fa th e r ev er had any v en era i d ise a se , and, if so, d escrib e th e d isea se , the treatm en t r e c e iv e d , any exam ining or tr e a tin g p h y s ic ia n s , and any i n s t i t u t i o n s a t which treatm ent occurred; d) w h eth er d i a g n o s t i c p r o c e d u r e s , i n c lu d in g , b u t n o t lim ite d t o , abdominal x -r a y s or p elv im etry , a m n io cen tesis, and/or ultrasound were used, and, i f so, se t forth the date of the procedure, describe th e procedure, the exam ining or tr e a tin g p h y sicia n and any i n s t i t u t i o n s at which th e p rocedure o ccu rred ; and e) whether any m edical problems or co m p lica tio n s arose during pregnancy ( e .g ., to x em ia ), and, i f so, d e s c r ib e t h e problem s or c o m p lic a tio n s and th e treatm ent received. 26. Not a p p lic a b le . 62 7 . A n s w e r I n t e r r o g a t o r i e s , 7 , 1 2 , 1 4 , 1 5 , a n d 1 6 w i t h respect to each mother i d e n t i f ie d in r e sp o n se to Interrogatory 23(d). 27. Not a p p lic a b le . 222 8 . F o r e a c h m o t h e r i d e n t i f i e d i n r e s p o n s e t o I n t e r r o g a t o r y i d e n t i f y each and e v e r y p regn an cy n ot r e s u l t i n g in a l i v e b i r t h , and s t a t e w ith r e s p e c t t o each: a) w hether th e r e was a m isc a r r ia g e and/or spontaneous abortion, and, if so, s ta te the d a te and d e s c r ib e th e reason fo r th e m is c a r r ia g e and/or sp on tan eou s a b o r tio n and id e n tif y any examining or tr e a tin g p h y sic ia n s, and any i n s t i t u t i o n s at which i t occurred; b) i f t h e r e sp o n s e t o a) above i s a f f ir m a t iv e , s t a t e whether you contend th a t such m isc a r r ia g e and sp on tan eou s ab ortion was caused by your exp osu re 16 t o Agent Orange, 2 ,4 -D , 2 ,4 ,5 - T , d io x in , or some com bination th ereo f; c) whether th e r e was a v o lu n ta r y or th e r a p e u tic a b o r tio n , and, i f s o , s t a t e th e d a te and d e s c r ib e t h e r e a s o n -for t h e v o l u n t a r y or t h e r a p e u t i c a b o r tio n , and i d e n t i f y any exam ining or t r e a t in g p h y s ic ia n s , and any i n s t i t u t i o n s a t which th e a b o r tio n o ccu rred ; and d) i f th e r e sp o n se to c) above i s a f fir m a t iv e , s t a t e whether 'you contend th a t such v o lu n ta ry or th e r a p e u tic a b o rtio n was caused or n e c e s s ita te d by your exposure to Agent Orange, 2,4-D , 2 ,4 ,5 -T , d io x in , or some com b in ation t h e r e o f , 28. Not a p p lic a b le . Dated: Carle Place, New York January 14, 1984 PLAINTIFFS' MANAGEMENT COMMITTEE DAVID J. DEAN, ESQ. DEAN, FALANGA & ROSE, ESQS. One Old Country Road Carle Place, New York 1151 (516) 248-9888 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product Liability Litigation : MDL No. 381 ANSWERS OF DANNY GENE JORDAN TO DEFENDANT'S INTERROGATORIES TO PROPOSED REPRESENTATIVE PLAINTIFFS PLAINTIFF'S MANAGEMENT COMMITTEE: Phillip E. Brown, Esq. Hoberg, Finger, Brown, Cox S< Mol 1igan 703 Market Street (13th Floor) San Francisco, California 94103 Stanley M. Chesiey, Esq. Waite, Schneider. Bayless and Chesiey Co. L.P.A. 1513 Central Trust Tower Fourth and Vine Streets Cincinnati, Ohio 45202 David J. Dean, Esq. Dean, Fa1anga ?< Rose One Old Country Road Carle Place, New York 11514 Newton B. Schwartz, Esq. Houston Bar Center Building 723 Main (Suite 325) Houston, Texas 77002 Thomas W. Henderson, Esq. Baskin ?< Sears Frick Building (10th FI.) Pittsburgh, PA. 15219 Benton Mussel white, Esq. John 0. 0 'Quinn, Esq. 09 Fannin (Suite 517) Houston, Tex as 77002 Stephen J. Schlegel, Esq. Schlegel S< Trafelet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Gene Locks, Esq. Neil Peterson Esq. Greitzer 2< Locks, Esqs. 1500 Walnut Street Philadelphia, PA 19102 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product Liability Litigation MDL No. 381 I. GENERAL 1. State your name, social security number, military service number, and each address at which you have ever lived (excluding time during active military service), starting with your current address, and give the dates you lived at each address. Danny Gene Jordan SSN 443-70-2511 MSN US54665959 7212 Sir Gawain, Austin, Texas 321 William Cannon, Austin, Texas 6049A Karen Circle, Fort Worth, Texas 1204 Scotland, Azle, Texas 3809 Delaware, Fort Worth, Texas 6215 Lloydhill, Fort Worth, Texas SpringbrooK, Fort Worth, Texas 215 Folk Street, Mangum, Oklahoma 404 Alpha, Mangum, Oklahoma U.S. Army Georgia Street, Mangum, Oklahoma Lincoln Street, Mangum, Oklahoma 1705 1/2 E. Broad, Lake Charles, LA Gueydan, Louisiana 1705 1/2 E. Broad, Lake Charles, La Big Lake. Texas Glendive, Montana Newtown, North Dakota Dickinson, North Dakota Bismarck, North Dakota Mi note, nORTH Dakota Chickasota, Oklahoma Mangum, Oklahoma 1/80 to present 8/78 to 1/B0 6/75 to 8/78 1/75 to 6/75 4/73 to 1/75 9/72 to 4/73 5/71 to 9/72 1/70 to 5/71 .2/69 to 1/70 6/67 to 2/69 11 /65 to 6/67 8/65 to 11/65 9/60 to 8/65 9/59 to 1/60 5/57 to 9/59 1/57 to 5/57 5/55 to 1/57 10/54 to 5/55 8/54 to 10/54 5/54 to 8/54 1/54 to 5/54 12/53 to 1/54 9/53 to 12/53 Identify each educational institution you attended, the dates of your attendance, and describe any physical or mental examination you received at or in connection with your attendance at each institution, stating with respect to each such examination. a) the date of the examination; b) the hospital or institution where such examination was given; and c) the name and address of the person conducting the ex ami nati on. University of Texas. Auston, Texas No physical or mental exam given 9/78 to 12/78 lexas Wesleyan university. Fort Worth, TX No physical or mental exam required / w> U> rW\ - / *7 A Altus Jr. College, Altus, Oklahoma Physical by Dr. Pierson <in office) Mangum, Oklahoma 73554 9/69 to 5/71 Lake Charles High School, Lake Charles, LA 9/61 to 5/65 Physical by dR. Charles Woodard (in o-f-fice) Lake Charles, La. Central Elementary, Lake Charles, La. 'physical by Dr. Charles Woodard Lake Charles, La. 9/60 to 5/61 and 8/57 to 9/59 Catholic School Gueydan, Louisana Do not remember any medical exams -for school. 9/59 to 9/60 I-f you have ever applied -for li-fe, health or accident insurance, state with respect to each such application: a) the date of the application; b) the rind of insurance applied for; c ) the name and address o,: the insurance company to which the application was made; d) whether such application was accepted and if not. why not; and e) whether a medical examination was given in connection with the application, and, if so, identify the person conducting the examination and the medical institution where the examination was given. INTERROGATORY DELETED If you have ever made a claim for benefits for any medical condition (including worker's compensation, veteran's benefits, state or federal disability or insurance or union or third party medical plans) state with respect to each such claim: a) the type of claim (worker's compensation, veteran's benefits, etc.); b) the date of the claim; c) the claim number of other identification of the claim d) the entity to whom the claim was made, including the name and address; e) the medical condition for which the claim was made; and f) the disposition of claim. a. Workman's Compensation b. Spring 1975 c. Moody F'rint ing ,Fort Worth, Texas d. Farmers Insurance Group, Fort Worth, Texas e. Ruptured disk f. Awarded 1007. disability with settlement a. Social Security Disability b. 3/77 c. SSN 443-70-2511 d. Social Security Agency, Fort worth, Texas e. Neck: and back injuries f . Awar ded 1007. disability a. Veterans Disability b. October, 197S c. C 24880850 d. Veteran's Administration Olin Teague Hospital, Temple, Texas e. Exposure to Toxins (including Agent Orange), Choracne, loss of feeling extremities, birth defects in children and wounds received in combat, including shrapnel and loss of hearing. f. Awarded service connected disability. 107. for wounds, denied symptoms of toxin exposure, citing lack of medical proof. 5. If you have ever filed or otherwise commenced a legal action in connection with any medical condition (other than this action) state as to each such action; a) the date that action was filed or otherwise commenced, the court or administrative body, the full title of the action, the index or other identifying number, and the identity of all parties t to the action; b> a description of the medical condition in connection with which the action was filed, and how you believe that medical condition occurred; c> a description of the outcome of the action, or of its present status if it is still pending; and d) the dates and amounts of any payments, either as a result of a judgment or settlement, which you have received or which you are scheduled to receive. See answer to 4-A. No lawsuit actually -filed. II. EMPLOYMENT HISTORY 6. Identi-fy and describe each job you have held, whether employed by others or self-employed, and state as to each: aT1 the name and address of your employer, the address of your workplace, the nature of the business and your job title; b > your duties and responsibilities; c) the date the job began and ended and the reasons for termination of the job; and d) the date and place of each physical and mental examination that you underwent in connection with such job, identifying the name and address of each medical practitioner conducting the examination and the name and address of any medical institution at which such examinations was conducted. A. Part-time janitor employed by others Central Elementary School, Lake Charles, La. Helping sweep and mop cafeteria in exchange for free lunches. during school terms from 1957 to 1960 graduated to high school unknown. B. Newspaper Delivery Boy - employed by others Lake Charles American Press Daily Newspaper Del ivery Boy ^ 30 4 Delivery o-f papers 7 days a week, collections, etc. Fall 1957 to 1959 - moved Unknown C. School Student Aide - employed by others St. Josephs Catholic School Gueydan, Louisiana Cleaning classrooms and mowing church grounds 10/59 to 5/61 - moved away Unknown D. Summer jobs in High School - construction worker employed by others Richard Construction Co., Lake Charles, La.; residential and commercial construction; part-time 1abcrer 'job site cleanup Summers o-f 1963 and 1964; returned to school N/A E. Seismograph Worker - employed by others Western Drilling Co.; Oil Exploration Big Lake, Texas; Jug Lineman Laying seismophones along blast sites and driving water truck. Summer of 1961; returned to school Unknown F. Seismograph Driller's Helper - Employed by others Fhillips Petroleum Co. Bart1esvi11e, Oklahoma; hermi t , Texas and Jal, New Mexico; Petrikeyn Ex loration, Driller's helper To help the driller in punching test holes for seismic exploration. Summer of 1962; returned to school Unknown G. Fast Food Worker - employed by others Slick's Drive-In, Mangum, Oklahoma Slick Avery property Soda fountain and short order cook July 1965 to October 1965; better job N/A H. Grocery Employee - employed by others United Supermarket, Mangum, Oklahoma Wade Ridley, Manager, Grocery Sales, Clerk Checking, stocking, sacking, ordering and building sales displays. ^ Of October, 1969 to June, 1967; Drafted into army Unknown I. Police O-f-ficer - employed by others City of Mangum, Oklahoma; Mangum Police Station. Law Enforcement; patrolman Car patrol; enforcement of the law June, 1969 to August, 1969; enrolled in college Unknown J. Work study employee - employed by others Altus Jr. College, Altus, Oklahoma, education,' student aide Helping in computer lab grading papers, etc. During school sessions from 1969 to May, 1971; Graduated N/A K. Laborer, summer - employed by others City of Mangum, Oklahoma Street Department Road and street maintenance; laborer Drove dump trucks and ran tractors with mowers on City right-of-way. Part-time Fall 1969 to Spring, 1970; Fall, 1971; moved Unknown L. Gas Station Attendant - employed by others Bill's Shamrock Station, Mangum, Oklahoma; service station; Bill Van Vacter, Owner; cashier attendant Pumping gas, repairing flats, etc. February, 1971 to May 1971; moved No exam M. Retail sales - employed by others k>Mart Sporting Goods, Fort Worth, Texas Bruce Watson District Manager, Stockboy, Assistant Manager and Manager Buying, selling, merchandising sporting goods; hiring, and firing personnel; accounting, inventory, etc. September, 1971, to June, 1974; resigned Unknown N. Retail Grocery; employed by others Safeway Grocery Co. , Lake Worth, Texas Groceries; night Stocker Ordering and restocking grocery supply September, 1974, to October, 1974; better job Unknown P. Warehouse and delivery; employed by others Moody Printing Company, Main Street, Fort Worth, Texas; Ed Moody prop.; warehouse man Inventory control paper warehouse -for printing company January - June, 1975; injury, then fired Unknown Q. Convenience Store Clerk; employed by others McClouds Food Stores, Fort Worth, Texas; Manager trainee Stocking, checking in convenience store August-September 1975; health problems Unknown R. Warehouse Work; employed by others Wap 1es/F'l at ter, Inc., Fort Worth, Texas wholesale groceries; order puller Filling orders, loading trucks October - November, 1975; health Unknown 7. With respect to each job identified in response to Interrogatory No. 6, identify each on-the-job injury, medical condition or accident that you experienced, and state separately as to each; a) a description of the injury, medical condition or acci dent; b) the dates of the injury, medical condition or accident; c) the treatment received, including the treating physician's name and address and all hospital izations, operations and medication received. See answer to Interrogatory No. 4 supra. -fSyt to. 7 III. FAMILY MEDICAL HISTORY 8. State the names and addresses of your spouse, children, brothers, sisters, parents, grandparents, aunts, uncles, cousins, nieces, nephews and grandchi1dren, and with respect to each: a) if any o-f them are deceased, state his or her age at the time o-f death and the time, place and cause o-f death; b) identify each illness, disease, disability, or medical condition ever had by each during his or her lifetime which required professional medical attent ion. c) identify any birth or genetic defects or miscarriages which they had; and d) with respect to each relative, identify each medical practitioner and medical institution that treated them, and set forth the diagnosis. Spouse - Donna Frances Hukill Jordan 7212 Sir Gawain, Austin, Texas a. Living b. Normal childhood diseases; none other known c. Had one spontaneous abortion d. Obstetricians involved with the birth of two sons: Chad - 09 was Dr. Kingery, but he did not deliver. Dr. Funell delivered baby by Caesarean section at Mercy Hospital in Oklahoma City, Okla. Michael -09 was Dr. Darwin Fielder who deli vered the baby at All Saints Hospi tal, Ft. Worth, Texas. Son - Chad Alan Jordan 7212 Sir Gawain, Austin, Texas a. Li vi ng b. Sronchitis; Various birth defects c . Medical problems involving missing wrist bones, absence of thumb on either hand with an extra digit on the left hand. d. Scottish Rite Hospital for Children, Dr. Aston and l.<c Dr. Senevey it Ft. Worth made the following diagnosis among others: 8 "Bi1ateral terminal radial hemimelia with Bilateral deupi icti on of index fingers and Absence of both thumbs. " a n c ra i Son - Michael Ryan Jordan 7212 Sir Gawain, Austin, Texas Li ving Various birth defects Medical problems involving clubbed hands, thumb missing on both hands and large forearm bone missing. Scottish Rite Hospital for Children, Dr. Aston and Dr. Senevey in Ft. Worth made the following diagnosis among others: "Bilateral radial club hands, left hand has four digits (absence of left thumb) and short humerous and forearm." Sister - Sheryl Lynette Jordan Gonder 4009 Shawnee Trail, Lake Worth, Texas Li vi ng Unknown None Unknown other - Billie Marie Thompson Jordan Bell 4004 Bonnie Drive, Ft. Worth, Texas Li vi ng Other than birth of children and one miscarriage, had none Born with a weak joint (next to nail) on each thumb; She did have one miscarriage and did have one infant die a few days after birth Dr. Ohl in each instance treated her at the Chickasha Memorial in Chickasha, Oklahoma n cx cu 3: a n o j i n. a n c r a "0 cl n c r tn Father - Harold Eugene Jordan LeBleu Road, Lake Charles, Louisiana . Living . Unknown . No birth defects . Unknown aternal Grandfather - Joseph Jordan Miami Beach, Florida . Deceased; Age 58; 1953; Miami Beach, Florida Heart Attack . Unknown . No birth defects Unknown 9 12791 Paternal Grandmother - Hester Dunham Jordan Baird, Texas a. Deceased; Age 60; or thereabout; 1969; Baird, Cause of death was cancer (Type unknown) b. Unknown c. Unknown c. Unknown Texas; Maternal Grandfather - George Hancel Thompson Mangum, Oklahoma a. Deceased; Age 65; 1970; Mangum, Oklahoma; Cause o-f death were complications resulting -from a stroke b. See c. . Did have trait o-f both thumbs with -frozen joints. . Dr. Sellers, Mangum, Oklahoma aternal Grandmother - Mable Cordelia Miller Thompson Mangum, Oklahoma . Living . Good health, other -facts unknown c. Did have -four or -five miscarriages and one stillbirth Also had one child born witn frozen joint in thumb d. Unknown cr tu 3 a n IV. VETERAN'S MEDICAL HISTORY State: a ) . the date of your birth; b) the name and address of the hospital or other facility where you were born, and the name and address of each attending physician or other medical practitioner; and c) each birth defect that you had and each medical complication connected with your birth (e.g., premature birth, breech birth, jaundice, fetal alcoholism), and each medical complication or health problem that your mother had in connection with her pregnancy of your birth (e.g., toxemia, long period of labor). f a. February 4, 1947 b. Chickasha Memorial Hospital Chickasha, Oklahoma 1 _L u %J ''& 10 Dr. Ohl Chi ckasha, Ok1ahorna c. Birth-complications -for him? None Birth complications for mother? None 10. Identify each injury, illness, disability or other physical or mental condition which you have ever had, whether temporary or permanent, and state separately as to each: a) each medical practitioner and/or medical institution seen or visited by you for the purposes of consul tation, diagnosis, prognosis, x-rays, treatment or other care, specifying the dates of all hospital izations ; Doesn't remember b ) the di agnosi s or prognosis made by each medi cal practitioner and medical institution; and Unknown c) the nature and extent of the care and treatment received in each medical institution and from each medical practitioner. Did have to wear casts and braces on legs temporarily, Gueton, Louisiana See answer to question no. 4 11. With respect to each injury, illness, disability, or other physical or mental condition identified in response to Interrogatory 10, identify each such condition that you claim or believe was caused by or arose out of exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin or some combination thereof, and state separately as to each: a) a description of each symptom; Chloracene, fatigue, elevated red blood count, low blood pressure, rectal bleeding, spastic colon, liver disfunction, loss of sensory feelings, disrupted immune system b) whether you contend that such injury, illness 11 disability or other physical or mental condi tion was caused by exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin or some combination thereof ; c) the date and manner in which each such symptom -first manifested itself or was made known to you; and Rash (Tentatively diagnosed as chloracene) April, 1968; Fatigue, March 1969; Elevated Red Blood Count, March 1969; Low blood pressure, March 1969; Rectal bleeding, 1976; Spastic colon, 1979; Liver disfunction, around 197S; Loss of sensory feelings in arms beginning in 1973 and has now extended to toes and feet beginning around 1978 or 1979; disrupted immune system, March 1969. 12. Identify each drug or medication ever used or taken by y-ou, including, but not limited to, illegal, recreational and over-the-counter drugs, and for each drug or medication, set forth the following with respect to each: a) the brand name, generic name, or "street name" of the drug; b > the date of use; c.< the amount used during each period of use; d) the name and address of the physician, if any, who prescribed the drug; - e) a description of reasons for your use of the drug; and f) whether you have ever received any medical treatment or counseling in connection with your use of such drugs. D. Plaintiff is not aware of all drugs taken during childhood, but has listed the following as those taken in his adult life: 1. (Not aware of name) b . October or November, 1967 c. Not aware of amount d. Female Major located at the Ft. Polk army hospital e. Had double pneumonia with 107 degree temperature f . No 12 an ro cl n cr c i -+. ro cl n cr t-j Mari juana Not aware of dates; used approximately fifteen times in a one year period <1968) Joints <YZ> Not applicable Recreati on No Dexadrene Not aware of dates; seldom used depending upon patrol assignment in 1968 Amount - 2 tabs per day Issued by Army Medic Drug used -for alertness on patrol no cl n era) + u a n tr \i -*111 cl n cr o +> m a n cr u +. (ti a n u i> Dapsone Daily used 1968 1 small tablet Issued by the Army Medic This is an anti-malarial drug no (Not aware o-f name) Taken 1 time weekly 1 orange tablet Issued by the Army Medic This is an anti-malarial drug no Iodine tablets Placed in cantene each time it was -filled 1 tablet Issued by Army Medic Water purification no Vali urn 4X daily 1 tablet; 5 mg. Issued by Dr. Van Zant and Dr. Bernel1 Muscle relaxant yes Fercodan As needed, probably took 35 tablets over a 6 or 7 month period 1 tablet Issued by Doctors' VanZant and Bernel1 e-. This drug is a pain killer a,.- r\ w 9. Rob a::son b. 4 X daily-for 3 months c. i tablet d. Issued by DrsJ VanZant and Bernell e. Muscle relaxer f . . No 10. El evil b. 1 or 2 tablets daily for 6 or 7 months c. see (b) d. Issued by Drs' VanZant and Bernell e. To aid in giving up the Valium f . No 11. Antibiotics <Erythromycin) b. 2 tablets daily for 1 month; 250 mg. c. 1 tablet d. Issued by VA Hospital in Temple, Texas; Dr. Redman e. skin rash f . No 13. Identify each skin condition that you have ever had, and with respect to each such condition: a) state the dates during which you had that condition; b) describe any diagnosis or medical treatment you received for the condition, and state: i) the name and address of the person rendering the diagnosis or treatment; ii) the name and address of the medical institution is) at which you were diagnosed or treated; iii) the dates of the diagnosis or treatment; iv) and the effect of the treatment. From April 1968 to present, Plaintiff has had a skin condition tentatis'ely diagnosed by Dr. Sonstein and the VA Hospital (Dr. Temple) as chloracene. Dr. Sonstein is located at 7201 Manachaca Road, Austin, Texas 78745 and the VA Hospital is located at 1902 South 1st, Temple, Texas 76501. Treatment? Diff. Scrubbs; ointment 14. I f y o u h a v e e v e r s m o k e d c i g a r e t t e s o r o t h e r w i s e u s e d a tobacco product: 14 a) identify each type of product (e.g., cigars, cigarettes, chewing tobacco); Cigarettes b) identify the time period during which you used that tobacco product; From the time he was seventeen years of age c) identify the amount used on a daily basis (e.g., packs of cigarettes/day); and one and a half packs a day d) state whether any physician or other healh care professional has ever advised you to stop or reduce your use of cigarettes or other tobacco products, and, if so, state the name and address of the physician or other health care professional and the date of the advi ce. Dr. Daum located in Hackensack, New Jersey, advised him in November of 1933 to quit smoking. If you have ever consumed or drunk alcohol, state separately with respect to each type of alcohol (e.g., liquor, beer, wine, etc.) consumed: a) at what age consumption began; Drank for the first time when he was approximately sixteen or seventeen years old b) the amount and frequency of such consumption; Possibly once a week, during high school and thereafter soci al1y c) if consumption ceased at any time, the reasons for such cessation and the reasons for any resumption; and Stopped drinking in 1974 or 1975 due to the fact that he was having blackouts. Other reasons included; alcohol made him violent, he was tired of it, health problems and his father was an alcoholic. d) whether you were ever hospitalised or r* institutionalized -for alcohol use, or advised to limit or stop alcohol use, and, if so, state the name(s) of each such hospital or institution or medical practitioner who treated or advised you. No 16. If any insecticides (e.g., Chlordane, Lindane, DDT), rodenticides (e.g., rat poison), insect repellents (e.g., DEET) or other pest control compounds were ever used by you or others around your living or working quarters, sta te as to each: a) the brand nam e or generic name of the chemical; b) a description of the chemical (e.g., powder, liquid, color, smell) 1 c) a description of the container for the chemical (e.g., shape, color, markings) d > the date of u 35 e ) the method of appiicati on ; f ) the place it was appiie d ; 9> the frequency of application; and h> whether you experienced any adverse reaction to the compound and, if so, describe the reaction. To his knowledge, he was never exposed to the listed insecticides prior to Vietnam. Since Vietnam, he has used the various foggers (Raid, Holiday) a couple of times in his home. Never directly handled on the job. Knows specifically, he did not use those listed. VI. MILITARY SERVICE 17. State with respect to your military service: a) the branch of the armed services in which you served; Army 16 h the inclusive dates of your service; June 1967 through February 1969 the inclusive dates o-f service in or near Vi etnam; February 1968 through February 1969 the name o-f each military unit to which you were assigned while serving in or near Vietnam; and the dates during which you were assigned to each such units; Delta Company 1/5 First Air Cavalry (February 1968 through October 1968) Echo Company 1/5 First Air Calvary (October 1968 through February 1969) the name and location o-f each place or area at which you were physically present in or near Vietnam and the dates during which you were present at each such place or area; Quang Tri Province (February, 1968 through November 1963) and Tua Thien Province (same dates). I-Ccrps Located at the -following landing zones (L2); Hue, Red Beach, LZ Jane, LZ STud, LZ Wharton, LZ Butcher, khe Sahn VAlley, LZ Peanuts, LZ Barbara, Con Tien, Cua Viet, Dong Ha, A Shau Valley, Lang Vei, and An Khe base camp. These were areas they worked out o-f as base camps. This is not a conclusive list. Also, -from November 1968 through February 1969, with III Corps in Tail Ninh Province and Quan Loi Province. These included the -following areas "Katum Special Forces (SF) camp, Chien Lien (SF); War Zone C & D. the Iron Triangle region, Hobo Wood and Vietnam/Cambodia border. your immediate superior officer's name and rank while in or near Vietnam; and Delta Company - Sgt. E5 John Willis (Platoon Sergeant) Echo Company - Staff Sergeant Timothy Meador (Platoon Sergent) Dan had 6 or 7 different commanding officers, but is unable to remember particular names of each. the type of discharge you received. Honorable rf, Ufe* 1 fyJ t IS. With respect to each illness, injury, wound or other medical or psychological condition experienced by you during your military service in or near Vietnam, state: a) the date o-f your illness, injury, wound, or other medical or psychological condition; b < a description o-f the illness, injury, wound, or other medical or psychological condition, including a description o-f all symptoms; c) the cause o-f the illness, injury, wound, or other medical or psychological condicin; d) the name and rank o-f the person to whom you -first reported the illness, injury, wound, or other medical or psychological condition (if anyone): e) the date that you -first reported the illness, injury, wound, or other psychological or medical condition; -f) the name, rank and location o-f each physician or other health care professional who treated your illness, injury, wound, or other psychological or medical condition, including the dates and places o-f treatment, and a description o-f the treatment you received; and g) the name and location of each hospital or otherhealth care facility which treated your psycholo gical or medical condition, the dates of treatment, and a description of the treatment that you received. a. 1967 b. Pneumonia c. Does not know d. Doesn't recall e. Approximately October or November, 1967 f. Fort Polk physician g. Fort Polk Army Base; Does not recall the treatment for this illness due to high temperature. He was delirious but does remember alcohol and ice dips. cr a> November, 1968 (Was nit pulled from field) Shrapnel wound to left shoulder ie 12830 *> u cl n ci +. ij a n u ii to Enemy -fire Army company medic November, 1968 Army company medic treated Flaintiff, by giving him a tetanus shot, cleaning wound and using butterfly bandages with field dressing, k'atum Special Forces Camp October, 1968 (Was not pulled from field) Pneumonia, flu like illness Cause unknown, but whole company had it Army company medic October, 1968 Army company medic diagnosed, but they treated for it. LZ Barbara with Echo Company were never July, August of 1968 (taken from field) Heat Stroke Weather conditions Army company medic July or August 1968 Battalion Aid Unit doctored him; He was given a glucose and saline solution (several IVJs of each) LZ Jane with Delta Company April or Hay of 1968 ( Was not pulled from field) Dysentary c. Not known, but was located in heavily defoliated area at time. The whole company had this for approximately 2 weeks. d. Army company medic thought it was dysentary, but this was not actually diagnosed. e. April or Hay 1968 f. Army company medic g. Delta Company LZ Jane er m e + u Q. n cr ii 19. Describe any other medication taken by you during your military service (e.g., Dapsone, Chloroquine, Primaquine, Binoctal), stating as to each: a) the brand name or generi c name of the medication; b) the form of the medication (e.g., pill, capsule, injection, etc.); c) the color, shape, and size of any pill or capsule taken ; * p ;(\* A. V V A 19 d) the reasons for taking the medication; e) the name and rank of the person(s) who gave you the medication; f ) the dates you took the medication; 9> the amount of the medication taken (e.g pills/day); and h) whether you experienced any adverse reaction to the medication and, if so, describe the reaction. See Question 12 1 through 6 items for the answers to a) through g ). h. The dey.adrene made him nervous and edgy. He also experienced some chest pains. This drug was taken as needed for patrol duty. The iodine which they put in the water for purification purposes seemed to make everyone nauseous. He is not sure if this was due to iodine or the water. State whether you ever received any training, instructions, warnings or health and safety information concerning herbicides during your military service, and identify as to each: a) the dates you received the foregoing; b> the location where received; c) the name and rank of the person(s) from who it was received; d) the substance of any oral information received; and e) the title, date, author or source, and content of any written material received. Plaintiff never received any information concerning herbicides They were told that the planes were spraying the foliage to hinder the enemy. <rS {\r) i.W V 20 Set -forth with respect to each time you claim to have been exposed to herbicies: a) the date o-f the alleged herbicide exposure; b) the time o-f day o-f the alleged exposure; c) the closest geographical or political reference point (e.g., hill, town, landing zone) to the place you believe you were exposed; d) a description o-f the terrain at the place o-f alleged exposure; e) a description o-f how the herbicide was being applied (e.g., helicopter, aircra-ft, hand, etc.); f) a description o-f your activities at the time o-f alleged exposure; g) the manner you believe your body was physically exposed to the herbicide (e.g., skin contact, inhalation, ingestion or swallowing), and, if you believe you were exposed by contact on your skin, identify the areas of skin that came in contact with the herbicide; h) the name and rank of other people present at the time of alleged exposure; and i) with respect to any deceased proposed repre sentative plaintiff, state how such plaintiff will demonstrate any of the information requested in subparts a) through h) of this interrogatory, identifying any persons with such information who will testify as to such plaintiff's exposure to herbicides. a. Khe Sahn Valley and A Shau Valley April, 1968 through June, 1968 b. Usually early a.m. and late afternoon, dusk c. Khe Sahn Valley, A Shau Valley, LZ Jane, LZ Barbara, LZ Stud, LZ Wharton, LZ Peanut, Dong Ha, Con Tien, Qua Viet, Lan Vei SF d. Mountainous; mostly jungle; some rice paddies e. Aircraft f. Usually eating breakfast and dinner g. Body exposed in each instance listed; Contact with skin to exposed parts of body (face, hairline, hands) v r- -'7 21 h. IV Delta Company I-Corps; Sergeant J. Willis i. E-5 Bob Brown; Bitch Westerland, Gene Cummings, et al. a. November, 1968 through February 1969 b. Usually early a.m. and late afternoon, dusk Occasionally at midday c. War Zones C S< D; Iron Triangle; Hobo Wood; Michel in Rubber Plantation; Katum SF; Chi Lien SF; Ho Chi Mien Trail d. Mostly rice paddies; terrain was flatter; Jungles were five or si:: canopies thick e. Aircraft f. Usually eating breakfast and dinner g. Same as above h. Sgt. Timothy Meddor, Sgt. E-5 Thomas O'Donnell; Ayres (Radio Operator); Some of the same people listed above. ONLY IF YOU CONTEND THAT ANY OF YOUR CHILDREN HAS A BIRTH DEFECT CAUSED BY YOUR EXPOSURE TO AGENT ORANGE, 2,4-D, 2,4,5-T, DIOXIN OR SOME COMBINATION THEREOF, ANSWER THE FOLLOW In 3 INTERROGATORIES. Identify the children that you have fathered, including name, date and place of birth of each'such child, and the name and address of each child's mother. a. Chad Allan Jordan born January 7, 1971 at Mercy Hospital in Oklahoma City, Oklahoma b. Michael Ryan Jordan born November 17, 1972 at All Saints Hospital in Fort Worth, Texas Mother: Donna Frances Hukill Jordan 7212 Sir Gawain, Austin, Texas Identify each of your children whom you contend has birth or genetic defects allegedly caused by your exposure to Agent Orange, 2.4-D, 2,4,5-T, dioxin or some other combination thereof, and identify: a) the birth or genetic defects which you contend were caused by your exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin, or some combination thereof, and state the basis for your belief, including opinions O 1 'i of any physicians; 1CUI b) any other birth or genetic defects which the child has: c) each medical practitioner and medical institution seen or visited by the child or in which the child was con-fined -for purposes of consultation, diagnosis, prognosis, treatment or other care, and the dates, purposes and results of such consultation, diagnosis, prognosis, treatment or other care; and d> the identity of the mother of each child. Chad Allan Jordan a. Missing thumbs, missing wristbones b. None c. Dr. Senevey, Dr. Aston, Texas Scottish Rite Hospital for Crippled Children in Ft. Worth, Texas. Diagnosis was bilateral terminal radial hemimelia with Bilateral duplication of index fingers and absence of both thumbs. Had various surgeries on May, 1974, July 1975, and June 1976 (list may be inconclusive) d. Donna Frances Hukill Jordan Michael Ryan Jordan a. Missing thumb, club hands, missing wristbones, missing bone in forearm b. None c. Dr. Senevey, Dr. Aston, Texas Scottish Rite Hospital for Crippled Children in Ft. Worth, Texas. Diagnosis was Bilateral radial club hands, Left hand has four digits (absence of left thumb) and short humerus and forearm. Had various surgeries on February 1975, July 1975 and June 1976. Surgeries continuing. d. Donna Frances Hukill Jordan 24. Identify each and every child of each mother identified in response to Interrogatory 22 and state as to each: a) the child's name, address, date of birth and place of birth, including the name and address of the hospital or other place where delivery occurred; and b) the physician(s) who treated the mother during pregnancy and/or delivered the child. Chad Allan Jordan 7212 Sir Gawain Austin, Texas Born January 7, 1971 Mercy Hospital in Oklahoma City, Oklahoma 12805 Mi chael Ryan Jor dan 7212 Sir Gawain Austin, Texas Born November 17, 1972 All Saints Hospital in Fort Worth, Texas b. Dr. Funel1 delivered Chad, Dr. Kingery was DB Dr. Fielder delivered Michael With respect to each mother identified in response to Interrogatory 23(d), identify her brothers, sisters, parents, grandparents, aunts, uncles, cousins, nieces, nephews, and grandchi1dren, and: a) if any of them are deceased, state his or her age at the time of death and the time, place and cause of death; b) identify each illness, disease, disability, or medical condition ever had by each during his or her lifetime which required professional medical attenti on; c) identify each medical practitioner and medical institution that treated them, and set forth the diagnosis of each, stating the same as to each relati ve. Mother - Vada Hukill Mangum, Oklahoma a. Living b. In good health; had chronic bronchitis between 1957 and 1961; Also had one miscarriage in 1954 c. Doctors' names unavailable, but both instances were treated at Gardenia Hospital, Gardenia, California. Father - F. Gerald Hukill Mangum, Oklahoma a. Living b. In good health; did have cyst cut from back (1956) and one cut from thigh (1957); Vitamin B deficiency noted in 1983 c. Doctors' names unavailable, but operations for cysts done ; at Gardenia Hospital, Gardenia, California. Vitamin B definciency noted by Dr. Troung Thach in Mangum, Oklahoma Brother - Jerry Hukill Stillwater, Oklahoma 12806 a. Living b. Good health, no other details known c. Unknown Maternal Uncle - Chester N. Anderson Commerce City, Colorado a. Living b. Disability - has a vascular and circulatory problems in legs c. Unknown Maternal Grandmother - Ada Anderson Mangum, Oklahoma a. Living b. Has high blood pressure c. Dr. Thach in Mangum, Oklahoma Dr. Lenaburg in Mangum, Oklahoma Maternal Grandfather - Chester H. Anderson a. Deceased; 1958; Age 54; Heart attack b. Unknown c. Dr. White at Bethina Hospital in Wichita Falls, Texas Maternal cousins - Larry Anderson Denver, Colorado Gary Anderson Denver, Colorado Donnie Anderson (Deceased; Dallas, Texas, murdered, early 20's) Joleyn Anderson, Commerce City, TX Angel Anderson, Commerce City, TX Denise Anderson, Commerce City, TX Melody Anderson, Ft. Worth, TX Chester Anderson, Ft. Worth, TX a. Living , exception to Donnie b. Unknown c. Unknown 1977, Paternal Grandmother - Audrey Hukill Mangum, Oklahoma a. Deceased, 1970; 70; Cerebral hemmorage b. High blood pressure, ulcers, intestinal blockage c. Dr. Laniberg, Mangum, Oklahoma Paternal Grandfather - Francis Letcher Hukill Mangum, Oklahoma a. Deceased, 1983; Age 87; Pneumonia b . Unknown c. Mangum City Hospital Paternal Uncle -Dr. Viron Hukel1 Conway, Arkansas a. Living fnp A b. Wounded severly in World War II; No other details known c. Unknown U U U 3X I a. Living b. Unknown c. Unknown u y u u u a ri~_iii.x. ri%, c_r xi ix Kansas City, Missouri 26. With respect to each preganancy, -for each mother identified in response to Interrogatory 23(d), state: a) whether the mother was exposed to or contracted any viral or bacterial infection or disease during or shortly before the pregnancy (e.g., German measles, flu, etc.) and if so, identify the infection or illness, the period during which it occurred, and any medication or treatment given therefor; b) whether the mother incurred any injury during pregnancy, and, if so, describe the injury, the treatment received, any examining or treating physicians, and any institutions at which treat ment occurred; c) whether the mother or father ever had any venerai disease, and, if so, describe the disease, the treatment received, any examining or treating physicians, and any institutions at which treatment occurred; d) whether diagnostic procedures, including, but not limited to, abdominal x-rays or pelvimetry, amniocentesis, and/or ultrasound were used, and, if so, set forth the date of the procedure, describe the procedure, the examining or treating physician and any institutions at which the procedure occurred; and e) whether any medical problems or complications arose during pregnancy (e.g., toxemia), and, if so, describe the problems or complications and the treatment received. a. Contracted Belles Palsy (a neuroligical disorder) but other than this did not contract virus and exposed to any. b. None c. No. d. Did receive x--rays in the ninth month of both 12808 26 pregnancies. Dr. Kingery ordered the ray -for Chad and Dr. Fielder for Michael, e. No Answer Interrogator!es 6, 7, 12, 14, 15, and 16 with respect to each mother identified in response to Interrogatory 23(d). J '4 O'- . See attached handwritten sheet . No on the job injuries . a. Birthcontrol (does not remember name) b. October 1967 through 196? c. 1 pill one time daily d. Dr. Kingery, Mangum, Oklahoma e. Birth contral reasons f hO a. Medication given during Bell's Palsy b. January 1971 through March 1971 c. Once daily, she did not take due to pregnancy d. Dr. Thomas Parker, Oklahoma City, Oklahoma e. Helped condition f. No a. Librium b. June, 1972 c. Once daily, she only took 2 or 3 d. Dr.: Fielder in Fort Worth, Texas e. Nervous condition f. No 12809 27 14. a. cigarettes b. Eighteen years of age to present, none during pregnancy c . 1 pack daily d. No 15. a. Eighteen years b. Infrequently - once a month c . NA d. NO 16. She used various foggers (Raid, Holiday) in the house approxi matel y 2 or 3 times a year. Never exposed due to the -fact that they totally clear the house of -fumes before entering. 28. For each mother identified in response to Interrogatory 22 identify each and every pregnancy not resulting in a live birth, and state with respect to each: a) whether there was a miscarriage and/or spontaneous abortion, and, if so, state the date and describe the reason for the miscarriage and/or spontaneous abortion and identify any examining or treating physicians, and any institutions at which it occurred; b) if the response to a) above is affirmative, state whether you contend that such miscarriage and spontaneous abortion was caused by your exposure to Agent Orange, 2,4-D, 2,4,5-T, dioxin, or some combination thereof; c) whether there was a voluntary or therapeutic abortion, and, if so, state the date and describe the reason for the voluntary or therapeutic abortion, and identify any examining or treating physicians, and any institutions at which the abortion occurred; and 12810 d) if the response to c) above is affirmative, state whether you contend that such voluntary or therapeutic abortion was caused or necessitated by an your exposure to Agent Orange, 2,4-D, 2,4,5-T, a. Spontaneous abortion Occurred around January 1972 Dr. Rhodes treated at White Settlement Austiopathic Hospital, White Settlement, Texas b. Ves, due to toxins No NA Dated: Carle Place, New York January 14, 1984 PLAINTIFFS' MANAGEMENT COMMITTEE DAVID J. DEAN, ESQ. DEAN, FALANGA & ROSE, One Old Country Road Carle Place, New York (516) 248-9888 E 11 12811 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK. In re "AGENT ORANGE" Product Liability Litigation : MDL No. 381 ANSWERS OF MICHAEL FRANCIS RYAN TO DEFENDANT'S INTERROGATORIES TO PROPOSED REPRESENTATIVE PLAINTIFFS PLAINTIFF'S MANAGEMENT COMMITTEE: Phillip E. Brown, Esq. Hoberg, Finger, Brown, Co:-: S< Mol 1igan 703 Market Street (18th Floor) San Francisco, California 94103 Stanley M. Chesley, Esq. Waite, Schneider, Bayless and Chesley Co. L.P.A. 1513 Central Trust Tower Fourth and Vine Streets Cincinnati, Ohio 45202 David J. Dean, Esq. Dean, Falanga h Rose One Old Country Road Carle Place, New York 11514 Newton B. Schwarts, Esq. Houston Bar Center Building 723 Main (Suite 325) Houston, Texas 77002 Thomas W. Henderson, Esq. Baskin ?< Sears Frick Building (10th FI.) Pittsburgh, F`A. 15219 Benton Mussel white, Esq. & John 0. 0'Quinn, Esq. 609 Fannin (Suite 517) Houston, Texas 77002 Stephen J. Schlegel, Esq. Schlegel S< Tra-felet, Ltd. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Gene Locks, Esq. Neil Peterson Esq. Greitzer ?< Locks, Esqs. 1500 Walnut Street Philadelphia, PA 19102 12812 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF FEW YORK In Re "Agent Orange" . Product Liability Litigation MDL NO. 281 I. GENERAL State your name, social security number, military service number, and each address at which you have ever lived (excluding time during active military service), starting with your current address, and give the dates you lived at each address. Michael Francis Ryan 133-34-2420 US 51579873 73 University Heights Drive Stony Brook, New York 1971 - Present 41 Juniper Road Kings Park, New York 1970 - 1971 5805 Avenue "0" Brooklyn, New York 1967 - 1970 U.S. Army 1965 - 1967 3320 Avenue "L" Brooklyn, New York Identi-fy each educational institution you attended, the dates o-f your attendance, and describe any physical or mental examination you received at or in connection with your attendance at each institution, stating with respect to each such examination. a) the date o-f the examination; b) the hospital or institution where such examination was given; and c) the name and address o-f the person conducting the examination. ur Lady Help o-f Christians 1951-1959 Brooklyn, New York 12813 1 Brooklyn Preparatory 1959 - 1961 Midwood High School 1961 - 1964 St. John's University Brooklyn, New York 1964 - 1965 Service 1965-1967 Suffolk Community College Suffolk County 1972 or 1973 Doesn't recall any examinations If you have ever applied for life, health or accident insurance, state with respect to each such application: a) the date of the application; b) the kind of insurance applied for; c) the name and address of the insurance company to which the application was made; d) whether such application was accepted and if not, why not; and e) whether a medical examination was given in connection with the application, and, if so, identify the person conducting the examination and the medical institution where the examination was given. INTERROGATORY DELETED If you have ever made a claim for benefits for any medical condition (including worker's compensation, veteran's benefits, state or federal disability or insurance or union or third party medical plans) state with respect to each such claim: a) the type of claim (worker's compensation, veteran's benefits, etc.); b) the date of the claim; 12814 c) the claim number of other identification of the claim d) the entity to whom the claim was made, including the name and address; e> the medical condition for which the claim was made; and f) the disposition of claim. 2/13/72 Suffolk County Police Department Sprained Thumb Insurance; Royal Globe 3/10/73 Concussion Insurance: Royal Globe 4/12/73 Punture Wound Right Wrist Contusion to rib cage Insurance: Royal Glote 5/19/73 Sprained ring finger Insurance: Royal Globe 12/19/73> Two chipped teeth, all teeth loosened swollen jaw Insurance: Royal Globe 1/17/77 Neck Sprain Insurance: Suffolk County 6/12/77 Abrasions on hand, arms and smoke inhalation Insurance: Suffolk County 9/22/78 Sprained left elbow, wrist and knee Insurance: Suffolk County 11/26/S1 Hematoma right wrist and elbow Insurance: Suffolk County If you have ever filed or otherwise commenced a legal action in connection with any medical condition (other than this action) state as to each such action; a) the date that action was filed or otherwise commenced, the court or administrative body, the full title of the action, the index or other 4 H o n + i i v i n n r i i m h e r . / - ta ' w. y to the action; in H f hi dsntity cf i l 1 n a r- 4- b) a description of the medical condition in connection with which the action was filed, and how you believe that medical condition occurred; c) a description of the outcome of the action, or of its present status if it is still pending; and d) the dates and amounts of any payments, either as a result of a judgment or settlement, which you have received or which you are scheduled to receive. NONE II. EMPLOYMENT HISTORY 6. Identify and describe each job you have held, whether employed by others or self-employed, and state as to each: a) the name and address of your employer, the address of your workplace, the nature of the.business and your job title; b> your duties and responsibilities; c> the date the job began and ended and the reasons for termination of the job; and d) the date and place of each physical and mental examination that you underwent in connection with such job, identifying the name and address of each medical practitioner conducting the examination and the name and address of any medical institution at which such examinations was conducted. 10/70 to present Suffolk County Police Department Physical examintion prior to hiring 10/70 - 2/70 New York City Police Physician examination prior to hiring 2/70 - 8/67 IBM Physical examination prior to hiring B/67 - 10/65 U.S. Army 12816 4 10/65 - 6/65 Service Bureau Corp. IBM Subsidiary 7. With respect to each job identified in response to Interrogatory No. 6, identify each on-the-job injury, medical condition or accident that you experienced, and state separately as to each: a) a description of the injury, medical condition or acci dent: b) the dates of the injury, medical condition or acci dent; c) the treatment received, including the treating physician's name and acdress and all hospital isations, operations and medication received. See Answer to Interrogator-, #5 supra. III. FAMILY MEDICAL HISTORY 8. State the names and addresses of your spouse, children, brothers, sisters, parents, grandparents, aunts, uncles, cousins, nieces, nephews and grandchi1dren, and with respect to each: a) if any of them are deceased, state his or her age at the time of death and the time, place and cause of death; b> identify each illness, disease, disability, or medical condition ever had by each during his or her lifetime which required professional medical attenti on. c) identify any birth or genetic defects or miscarriages which they had; and d) with respect to each relative, identify each medical practitioner and medical institution that treated them, and set forth the diagnosis. SPOUSE: Maureen Ann, 73 University Heights Dr., Stony Brook, NY 12317 t'--i'">/6S 6/>5 ..fSeov-vc-r -bunpan I rli r' 7, With respect tc each job', identified in response to Interrogatory No. />, identify each on-the-job injury, medical condition or accident, that you experienced, and state separately as to each: a) a description of the inj.ury, medical condition or ac <:ident; b) the dates of the injury, medical condition or accident; c) the trestment received, including the treating phys_i ci arc s name and acdress and all hospital izations, operations and medication received. e i if*; v i..-( _* > 1 l cr;' l > g a t o r y ' 5 s u p r a , IJ(. i-AMILY MEDICAL HISTORY 8. State the names and addresses of your spouse, children, brothers, sisters, parents, grandparents, aunts, uncles, cousins, nie.es. necnews and grandchi1dren, and with respect to each--. -) K *"' of thc-m are deceased, state his or her age at the time >vf drath and the time, place and cause of death; b> '^ id-entify g-,;h illness, disease, disability, or medical coruii >"ion ever had by each during his or .'h'er.-.,lif '-'J!-.:- ch required professional medical a11 <an.tior 1 identify y birth or genetic defects or mi y.carr : win oh they had; and :';d' with respect to each relative, identify each medical practitioner ar-d medical institution that treated and set * *th the diagnosis. 'SPOUSE: Maureen Ann, 73 University Heights Dr., Stony Brook, MY . One miscarriage before birth of first child (Kerry), two children born with birth defects, Dr. Wilton Fritz, Brooklyn NY; Dr. Baker, Stony Brook, NY; Women's Hospital, Manhattan. CHILDREN: Kerry Ann Ryan, 73 University Heights Dr., Stony Brook, NY Born with approximately 22 birth defects; Dr. Bertrand Schwartz, Brooklyn, NY; Dr. Oscar Schwartz; Dr. Benjamin, Maimonides Hospital, NY; Community Hospital, Brooklyn, NY Michael Francis Ryan (son), 73 University Heights Drive, Stony Brook, NY Born with diffuse brain atrophy, University Hospital, Stony Brook, NY PLAINTIFF'S SISTERS: Patricia Ann Stransky, South Mallard, NY One child, no complications, she is currently pregnant Deidre Stransky, Seldon, NY No children PLAINTIFF'S PARENTS: Michael Francis Ryan, Kings Park, NY; Healthy Victoria Ryan, Kings Park, NY; Hip replacement, osteoporosis, Roger Dee, M.D., Stony Brook, NY Sox miscarriages, each in the sixth month of preganancy, RH factor, Dr. Joseph E. Hall, Brooklyn, NY PATERNAL GRANDPARENTS: Michael Francis Ryan, Died 1929, stroke, Ireland. Mary Ellen Ryan, Died 1940, stroke, Ireland. Plaintiff does not recal1 doctors or the respective dates of death. MATERNAL GRANDPARENTS: William Molloy, Died Approx. 19401941, lung cancer, Brooklyn, NY Isabelle Molloy, Died approx. 1977-1976, natural causes, Brook lyn, NY 12519 IV. VETERAN'S NEDI CAL HISTORY 9. State: a) the date of your birth; b) the name and address of the hospital or other facility where you were born, and the name and address of each attending physician or other medical practitioner; and c) each birth defect that you had and each medical complication connected with your birth (e.g., premature birth, breech birth, jaundice, fetal alcoholism), and each.medical complication or health problem that you mother had in connection with her pregnancy of your birth (e.g., toxemia, long period of labor). a) 7/25/45 b) Brooklyn Hospital, Brooklyn, NY Dr. Joseph E. Hall, Dr. Thomas Lamb (believed to be deceased) c) None 10. Identify each injury, illness, disability or other physical or mental condition which you have ever had, whether temporary or permanent, and state separately as to each: a) each medical practitioner and/or medical institution seen or visited by you for the purposes of consul tation, diagnosis, prognosis, x-rays, treatment or other care, specifying the dates of all hospital ist ions; b) the diagnosis or prognosis made by each medical practitioner and medical institution; and c) the nature and extent of the care and treatment received in each medical institution and from each medical practitioner. Before 1966: Tonsils removed, broken nose, 1966-67: plaintiff was admitted to the 91st EVAC Hospital at Long Binh. for upper respiratory distress (difficulty breathing); fatigue, severe weight loss, migraine 12&20headaches, skin rash in groin, neck and facial areas. 7 i Plaintiff was hospitalised 10 days -for the above-listed symptoms in the 91st EVAC hospital in Long Binh and given penicillin and bedrest. From approx. 1966 to 1971,with periods of exacerbation remission, plaintiff suffered from a severe skin rash which left large scars, later diagnosed as chloracne, Dr. Susan Baum, N.J. and 1967 - Mirgraine headaches, hearing loss and nervous condition. VA Offices, Seventh Ave., NY. Awarded 10% disability for nervous condition, 10% disability for hearing loss. Migraine headaches - seeing Dr. Robert Dinapoli since Approximately 1983. Prescribed periactin and recently prescribed Tylenol with codeine. 11. With respect to each injury, illness, disability, or other physical or mental condition identified in response to Interrogatory 10, identify each such condition that you claim or believe was caused by or arose out of exposure to Agent Drange, 2,4-D, 2,4,5-T, dioxin or some combination thereof, and state separately as to each: a) a description of each symptom; c) the date and manner in which each such symptom first manifested itself or was made known to you; and 11a) Rapid weight loss Migrain headaches Inability to breathe Chioracne Nervous condition 1966 upper respiratory difficulties 12. Identify each drug or medication ever used or taken by you, including, but not limited to, illegal, recreational and over-- the-counter drugs, and for each drug or medication, set forth the following with respect to each: a) the brand name, generic name, or "street name" of the drug; b) the date of use; 12821 8 \ c) th e amount used during each p eriod of use; d> t h e n a m e a n d a d d r e s s o-f t h e p h y s i c i a n , i f a n y , who p rescrib ed the drug; e) a d e s c r i p t io n of reason s for your use of th e drug; and f) whether you have ever received any medical trea tm en t or c o u n se lin g in c o n n e c tio n with your use of such drugs. P laintiff to n sils. doctors. canal; he was p r e scr ib e d a n t i b i o t i c s fo r removal of h is He c a n n o t r e c a l l t h e e x a c t a n t i b i o t i c s or P l a i n t i f f was p r e scr ib e d percodan fo r a root does not re ca ll the doctor. "Catodot" - P la in t if f does not r e c a ll p rescrib in g doctor " P e r ia c t in " - Dr. Robert D i n a p o l i , P o rt J e f e r s o n S t a t i o n , NY i n a b o u t 1 9 8 3 f o r p l a i n t i f f s m i g r a i n e h e a d a c h e s Tylenol c o d e in e - Dr. Robert D in a p o li p r e s c r ib e d t y le n o l codeine w ithin the past few weeks to be taken as well as the p eria ctin for the p la in t if f 's migraine headaches. f ) - None 13. I d e n t i f y each sk in c o n d i t i o n t h a t you have ev e r had, and with resp ect to each such condition: a) s t a t e t h e d a te s during which you had t h a t con d tio n ; b) d e s c r i b e any d i a g n o s i s or m ed ical t r e a t m e n t you r e c e i v e d fo r t h e c o n d it i o n , and s t a t e : i ) t h e name and a d d r e s s of t h e p e r s o n rendering th e d ia g n o sis or treatm ent; i i ) t h e name and a d d r e s s of t h e m ed ic a l i n s t i t u t i o n ( s ) at which you were diagnosed or treated; i i i ) the dates of the diagnosis or treatm ent; iv) and th e e f f e c t of the trea tm en t. P l a i n t i f f f i r s t s u ffe r e d from a s e v e r e rash in th e groin , 12822 a neck and -facial area in 1966, t h i s same sk in p ersisted u n til at lea st 1971, leaving very large, scars. rash deep P l a i n t i f f ' s skin c o n d itio n was b e lie v e d to be ju n g le rot in 1966-1967. This c o n d itio n was l a t e r diagnosed in 1983 a s c h l o r a c n e by Dr. Susan Baum, NJ. P l a i n t i f f was not t r e a t e d by a p h y s ic ia n for t h i s skin condition. 14. If you have ever smoked c i g a r e t t e s or o th e r w ise used a tobacco product: a) i d e n t i f y each t y p e of p r o d u c t ( e . g . , c i g a r s , c ig a r e t t e s , chewing to b a c c o ); b) i d e n t i f y t h e t im e p e r i o d d u r i n g wh ich you u sed that tobacco product; c) i d e n t i f y t h e amount used on a d a i l y b a s i s ( e . g . , packs of c i g a r e t t e s / d a y ) ; and d) s t a t e w hether any p h y s i c i a n or o t h e r h e a lh care p r o fe s s io n a l has ever ad v ised you to sto p or reduce your use of c i g a r e t t e s or other tobacco products, and, i f so, s ta te the name and a d d r e ss of t h e p h y s i c i a n or o th er h e a lth c a re p r o f e s s io n a l and th e d ate of the advi ce. C ig a rettes - 1 -1 /2 pack/day sin c e 1965, with the ex cep tio n of approxim ately 5 y ea rs during which p l a i n t i f f q u i t on h i s own a c c o r d . P l a i n t i f f was never a d vised to q u it . 15. If you have ever consumed or drunk a lc o h o l, s t a t e sep arately with respect to each type of alcohol (e .g ., liq u or, beer, wine, e t c .) consumed: a) at what age consum ption began; b) t h e amount and f r e q u e n c y o f s u c h co n su m p tio n ; c) i f consumption ceased at any tim e, the reasons fo r such c e s s a t i o n and th e r e a s o n s fo r any r e su m p tio n ; and 12823 10 d) w h eth e r you were e v e r h o s p i t a l i s e d or i n s t i t u t i o n a l i s e d -for a l c o h o l u s e , or a d v i s e d to lim it or stop a lco h o l use, and, i f so, s t a t e th e name(s) of each such h o s p ita l or i n s t i t u t i o n or m e d ic a l p r a c t i t i o n e r who t r e a t e d or a d v i s e d you. a) A pproxim ately age 18. b) P l a i n t i f f drank -for a p p r o x i m a t e l y two y e a r s and consumed during t h i s p e r io d one to two s ix - p a c k s of beer per week. c) P l a i n t i f f quit drinking in 1966. P l a i n t i f f cannot d rin k now. d ) No I f any i n s e c t i c i d e s ( e . g . , C h lo r d a n e , L in d a n e , DDT), rodenticides (e.g., rat poison), insect repellents (e.g., DEET) o r o t h e r p e s t c o n t r o l c o m p o u n d s w e r e e v e r u s e d by you or o th e r s around your l iv i n g or working quarters, sta te as to each: a) t h e brand name or g e n e r i c name of t h e c h e m ic a l; 1b ) a d e s c r i p t i o n o f t h e c h e m i c a l ( e . g . , p o w d e r , l i q u i d , co l o r , s m e l ); c) a d e sc r ip tio n of th e container for the chemical ( e .g ., shape, co lo r, markings) d) t h e d a t e o f use; e) th e method of a p p lic a tio n ; f ) th e p la c e i t was a p p lie d ; g) t h e fr e q u e n c y of a p p l i c a t i o n ; and h) w h eth e r you e x p e r i e n c e d any a d v e r s e r e a c t i o n t o t h e compound and, i f so , d e s c r ib e th e r e a c tio n . P l a i n t i f f never used any i n s e c t ic id e s . V I . MILITARY SERVICE S tate with respect to your m ilita ry service: 12824 a ) t h e b r a n c h o-f t h e a r m e d s e r v i c e s i n w h i c h y o u served * b ) t h e i n c l u s i v e d a t e s o-f y o u r s e r v i c e ; c ) t h e i n c l u s i v e d a t e s o-f s e r v i c e i n o r n e a r Vi e t n a m ; d ) t h e n a m e o-f e a c h m i l i t a r y u n i t t o w h i c h y o u were assigned w h ile servin g in or near Vietnam; and t h e d a t e s during which you were assigned to each such u n its; e ) t h e n a m e a n d l o c a t i o n o-f e a c h p l a c e o r a r e a at which you were p h y s i c a l l y p r e sen t in or near Vietnam and th e d a t e s during which you were present at each such place or area; -f) your i m m e d ia t e s u p e r i o r o-f-ficer ' s name and rank w h ile in or near Vietnam; and g ) t h e t y p e o-f d i s c h a r g e y o u r e c e i v e d . e r Qi ) U . S . Army 8/66) 1 1 / 6 5 - 8 / 6 7 c) Vietnam - - 8/67 d) 11th Armored C a lv a r y Regiment 3rd Squ ad ron , H e a d q u a r te r s Co. Long B i n h , Xuan Loc 1st Sergeant Snipes Honorable D ischarge (good conduct medal) e) Long B in h , Xuan Loc f) F ' l a i n t i - f - f c a n o n l y r e c a l l - f i r s t S e r g e a n t S t r i p e s g) Honorable 18. With r e s p e c t t o each i l l n e s s , i n j u r y , wound or o t h e r medical or p s y c h o lo g ic a l c o n d itio n exp e r ie n c e d by you during your m ilit a r y s e r v ic e in or near Vietnam, s t a t e : a ) t h e d a t e o-f y o u r i l l n e s s , i n j u r y , w o u n d , o r other medical or psych ological condition; b ) a d e s c r i p t i o n o-f t h e i l l n e s s , i n j u r y , w o u n d , o r other medical or psychological con d ition , in clud ing a d e s c r i p t i o n o-f a l l s y m p t o m s ; c ) t h e c a u s e o-f t h e i l l n e s s , i n j u r y , w o u n d , o r o t h e r medical or p sych o lo g ica l con d ition ; d ) t h e n a m e a n d r a n k o-f t h e p e r s o n t o whom y o u - f i r s t * 12825 12 rep orted th e i l l n e s s , in ju r y , wound, c oth er medical or p sy c h o lo g ic a l c o n d itio n (if anyone) e) th e date th a t you -first reported th e i l l n e s s , inju ry, wound, or oth er p s y c h o lo g ic a l or medical c o n d itio n ; f ) t h e n a m e , r a n k a n d l o c a t i o n o-f e a c h p h y s i c i a n o r o t h e r h e a l t h c a r e pro-f e s s i onal who t r e a t e d your i l l n e s s , in j u r y , wound, or other p s y c h o lo g ic a l or m edical c o n d i t i o n , in c lu d in g th e d a te s and p l a c e s o-f t r e a t m e n t , a n d a d e s c r i p t i o n o-f t h e t r e a t m e n t you r e c e iv e d ; and g ) t h e n a m e a n d l o c a t i o n o-f e a c h h o s p i t a l o r o t h e r h ea lth care - f a c ilit y which tre a te d your p sy c h o lo g i c a l o r m e d i c a l c o n d i t i o n , t h e d a t e s o-f t r e a t m e n t , a n d a d e s c r i p t i o n o-f t h e t r e a t m e n t t h a t y o u r e c e i v e d . I n 1 9 6 6 F l a i n t i - f - f w a s h p i t a l i c e d i n t h e 9 1 s t EVAC h o s p i t a l in Long Binh f o r 10 days f o r upper r e s p i r a t o r y d istr e ss, severe weight lo ss, fatigu e, migraine headaches and a s k in r a s h . P l a i n t i f f d o e s n o t r e c a l 1 t h e name o f t h e p e r s o n he f i r s t reported h is medical con d ition s to. P la in tiff reported the a b o v e - lis te d problems in 1966. P l a i n t i f f h a s b een t r e a t e d f o r m i g r a i n e h e a d a c h e s by Dr. R o b e r t D i n a p o l i , P o r t J e f f e r s o n S t a t i o n , NY. 19. D escrib e any oth er m ed ication taken by you during your m ilita r y s e r v ic e ( e . g . , Dapsone, Chloroquine, Frimaquine, B in o cta l), s ta tin g as to each: a) t h e brand name o r g e n e r i c name o f t h e m e d i c a t i o n ; b) t h e fo rm o f t h e m e d i c a t i o n ( e . g . , p i l l , c a p s u l e , i nj e c t i o n , e t c . ) ; c) th e c o l o r , shape, and s i c e of any p i l l or c a p s u le taken ; d) t h e r e a s o n s f o r t a k i n g t h e m e d i c a t i o n ; e) t h e name and rank o f t h e p e r s o n ( s ) who g a v e you th e m edication; f ) the d ates you took the medication; 9> t h e a m o u n t o f t h e m e d i c a t i o n t a k e n ( e . g . , p i l l s / d a y ) ; and 12826 13 h) whether you e x p e r ie n c e d any a d v e r s e r e a c t i o n t o the m edication and, i f so, describe the reaction . P l a i n t i f f did not ta k e any drugs w h ile in Vietnam, including malaria p i ll s . S ta te whether you ever receiv ed any training, i n s t r u c t i o n s , w a rn in gs or h e a lth and s a f e t y in-formation c o n c e r n i n g h e r b i c i d e s d u r i n g your m i l i t a r y s e r v i c e , and id en tify as to each: a) th e d a te s you r e c e iv e d the fo re g o in g ; b) t h e l o c a t i o n w h er e r e c e i v e d ; c) t h e name and r a n k o f t h e p e r s o n ( s ) from who i t was r e c e iv e d ; d) t h e s u b s t a n c e o f any o r a l i n f o r m a t i o n r e c e i v e d ; and e) th e t i t l e , d a t e , author or s o u r c e , and c o n te n t of any w r itt e n m aterial r e c e iv e d . None. Set forth w ith r e sp e c t to each tim e you claim to have been exposed to h er b icies: a) t h e d a te o f t h e a l l e g e d h e r b i c i d e ex p o su re; b) t h e tim e o f day o f t h e a l l e g e d exposure;- c) th e c l o s e s t g e o g r a p h ic a l or p o l i t i c a l r e f e r e n c e point ( e .g ., h i l l , town, landing zone) to the p lace you b e l ie v e you were exposed; d> a d e s c r i p t i o n o f t h e t e r r a i n a t t h e p l a c e o f a l l e g e d exposure; e) a d e s c r i p t i o n of how th e h e r b i c i d e was b e in g applied ( e .g ., h e lic o p te r , a ir c r a ft, hand, e t c .) ; f) a d escrip tio n of your a c t i v i t i e s at the tim e of alleged exposure; g) th e manner you b e l i e v e your body was p h y s i c a ll y 12827 14 exposed to the herbicide (e .g ., skin contact, in h a la tio n , in g e stio n or sw allow ing), and, if you b e l i e v e you were exposed by c o n t a c t on your sk in , i d e n t i f y th e a r e a s of sk in th a t came in contact with the herbicide; h) t h e name and rank of o t h e r p e o p l e p r e s e n t a t t h e tim e of a l l e g e d e x p o su r e ; and i) with r e sp e c t to any deceased proposed rep re s e n t a t i v e p l a i n t i f f , s t a t e how s u c h p l a i n t i f f w ill dem onstrate any of the inform ation r e q u e s te d in s u b p a r t s a) through h) of t h i s i n t e r r o g a t o r y , i d e n t i f y i n g any p erso n s w ith such i n f o r m a t i o n who w i l l t e s t i f y a s t o su c h p l a i n t i f f ' s exposure to herbicides. To t h e b e s t o f p l a i n t i f f ' s r e c o l l e c t i o n he b e l i e v e s t h a t he was p h y s i c a l l y exposed t o h e r b i c i d e s through skin c o n t a c t , i n h a l a t i o n , i n g e s t i o n and s w a l l o w i n g . P l a i n t i f f b e l i e v e s he was ex p o sed t o h e r b i c i d e s in Long Binh and ad d ition al areas which he cannot r e c a ll at t h is time. ONLY I F YOU CONTEND THAT ANY OF YOUR CHILDREN HAS A BIRTH DEFECT CAUSED BY YOUR EXPOSURE TO AGENT ORANGE, 2 , 4 - D , 2 , 4 , 5 - T , DI OXI N OR SOME COMBINATION THEREOF, ANSWER THE FOLLOWING INTERROGATORIES. I d e n tify th e c h ild r e n th a t you have fa th e r e d , includ ing name, d a t e and p l a c e o f b i r t h of each such c h i l d , and t h e name and a d d r e s s o f each c h i l d ' s m oth er. K e r r y Ann 1/24/71 Community Brooklyn, Ryan H osp ital New York M ichael F r a n c i s Ryan 6/26/83 University Hospital S t o n y B r o o k , NY Mother - Maureen Ryan 73 U n iv e r sity H eights Drive S t o n y B r o o k , New York I d e n t i f y e a c h o f y o u r c h i l d r e n whom y o u c o n t e n d h a s b i r t h or g e n e tic d e f e c t s a lle g e d ly caused by your exposure to Agent Orange, 2 .4 -D , 2 ,4 ,5 - T , d io x in or some other 12828 15 combination thereof, and identify: a) t h e b i r t h or g e n e t i c d e f e c t s which you conten d were caused by your exposure to Agent Orange, 2,4 -D , 2 , 4 , 5 - T , d i o x in , or some com b in ation t h e r e o f , and s ta t e the b a sis for your b e lie f , including opinions of any physicians; b> a n y o t h e r b i r t h o r g e n e t i c d e f e c t s w h i c h t h e c h i l d has; c) each m edical p r a c t i t io n e r and medical i n s t i t u t i o n seen or v i s i t e d by th e c h ild or in which th e c h ild was c o n fin e d for purposes of c o n s u lta tio n , d i a g n o s i s , p r o g n o s i s , t r e a t m e n t or o th e r c a r e , and t h e d a t e s , p u rp oses and r e s u l t s of such c o n s u l t a t i o n , d i a g n o s i s , p r o g n o s i s , t r e a t m e n t or o th er c a r e ; and d) t h e i d e n t i t y o f t h e m other o f e a c h c h i l d . a) K erry was born w ith a p p r o x im a t e ly 22 b i r t h d e f e c t s . These include: - 4 deform ed f i n g e r s on her r i g h t hand - m i s s i n g thumb on r i g h t hand - 2 /3 of ulna bone m issing - l e f t hand i s m is s in g m u scles and nerves -h y p e r p la sia of sacrum -neurogenic bladder -duodinal atresia -h o le in heart 2- o c c u l t s p i n o b i f i d a -double reproductive organs (i.e . uterus', 2 2c e r v i x e s , v a g in a s , undeterm ined amount of ovaries) -m is sin g anus -pyloric stenosis b) d ue t o h e r o p e r a t i o n s , K er r y s u f f e r e d b r a i n damage, b l i n d n e s s , s c o l i o s i s , " h y p h o s i s ", s p e e c h , h e a r i n g and in te lle c u t a l impediments. She i s a lso permanently confined to a wheelchair. c) M aureen Ann Ryan 24. I d e n t i f y each and e v e ry c h i l d of each mother i d e n t i f i e d in r e s p o n s e t o I n t e r r o g a to r y 22 and s t a t e as t o each: a) t h e c h i l d ' s name, a d d r e s s , d a te of b ir th and p l a c e of b i r t h , i n c l u d in g t h e name and ad d ress of t h e h o s p i t a l or o th e r p l a c e where d e l i v e r y o c c u r r e d : and 12829 16 b) t h e p h y s i c i a n ( s ) who t r e a t e d t h e mother d u r in g pregnancy and/or delivered the child. K e r r y Ann Ryan, 73 U n i v e r s i t y H e i g h t s D r i v e , S t o n y Brook, NY, 1 / 2 4 / 7 1 . C o m m u n i t y H o s p i t a l , B r o o k l y n , NY. Dr. W i l t o n F r i t z , B r o o k l y n NY. Michael F r a n c is Ryan, 73 U n iv e r s it y H eights D riv e, Stony B r o o k , NY. U n i v e r s i t y H o s p i t a l , S t o n y B r o o k , NY. Dr. Baker 5. With r e s p e c t t o each mother i d e n t i f i e d in r e sp o n se to In ter r o g a to ry 2 3 (d ), id e n t i f y her b rothers, s i s t e r s , 1p a r e n t s , g r a n d p a r e n t s , a u n t s , u n c l e s , c o u s i n s , n i e c e s , nephews, and g r a n d c h i d r e n , and: a) i f any of them a r e d e c e a s e d , s t a t e h i s or her age a t t h e tim e of death and th e tim e, p l a c e and cause of death; b) i d e n t i f y ea ch i l l n e s s , d i s e a s e , d i s a b i l i t y , or m edical c o n d i t i o n ever had by each during h i s or her lif e t im e which required p rofession al medical a tte n tio n ; c) i d e n t i f y each m ed ical p r a c t i t i o n e r and m ed ical i n s t i t u t i o n t h a t t r e a t e d them, and s e t f o r t h t h e d ia g n o s is of each, s t a t i n g th e same as to each r e la ti ve. Maureen Ann Ryan PARENTS: D a n i e l O ' C o n n o r , D i e d 1 9 6 1 , P a n c r e a t i c c a n c e r , I r e l a n d and New Y o r k . H e l e n O ' C o n n o r , S t i l l l i v i n g , Br onx NY. PATERNAL GRANDPARENTS: J o h n O ' C o n n o r , D i e d i n 1 9 7 0 ' s , natural causes. Josephine O'Connor, Died in 1 9 70's, natural causes. BROTHERS AND S I S T E R S : Helen Calahan, s t i l l liv in g , healthy to th e b est of p l a i n t i f f ' s knowledge. 3 c h ild r e n , no m i s c a r r i a g e s , Howell NJ. Carol G a lla g h er, s t ill : living, 4 children, no 17 m isca rria g es, Lakewood, NJ. L o r r a i n e R e i l l y , b o r n w i t h a t u r n e d - f o o t (NY O r t h o p e d i c H o s p i t a l ) , 3 c h i l d r e n , o n e m i s c a r r i a g e , New R o c h e l l e , NY. Bernadette Miesner, B a r d o n i a , NY. 2 children, no m is c a r r ia g e s , Gayle S tapleton, 2 ch ild ren , m i s c a r r i a g e s , B a r d o n i a , NY. currently pregnant, no Daniel O'Connor, no c h ild r e n , l i v e s in V irg in ia . J o h n O ' C o n n o r , u n m a r r i e d , n o c h i l d r e n , B r o n x , NY. B r i a n O ' C o n n o r , u n m a r r i e d , n o c h i l d r e n , B r o n x , NY. With r e sp e c t to each preganancy, -for e a c h m o th e r id e n tifie d in response to Interrogatory 23(d), sta te : a) whether th e mother was exposed to or c o n tra c te d any v ira l or b a c te r ia l in f e c t io n or d is e a s e during or s h o r t l y b e f o r e t h e p r e g n a n c y ( e . g . , German m e a s l e s , flu, e t c . ) and i f s o , i d e n t i f y t h e i n f e c t i o n or i l l n e s s , th e p e r io d during which i t occurred, and any m edication or treatm ent given th erefor; b) whether t h e mother i n c u r r e d any i n j u r y during pregnancy, and, if so, describe the injury, the treatm ent r e c e iv e d , any examining or t r e a t in g p h y s ic ia n s , and any i n s t i t u t i o n s at which t r e a t ment occurred; c) whether th e mother or f a t h e r ever had any v e n e r a i d is e a s e , and, i f so, d e sc rib e the d ise a se , the treatm ent r e c e i v e d , any examining or t r e a t i n g p h y s ic ia n s , and any i n s t i t u t i o n s at which treatment occurred; d) w h eth er d i a g n o s t i c p r o c e d u r e s , i n c l u d i n g , b u t n o t lim ite d to , abdominal x -ra y s or pelvim etry, am niocentesis, and/or ultrasound were used, and, i f so, set forth the date of the procedure, describe the procedure, th e examining or tr e a tin g p h y sic ia n and any i n s t i t u t i o n s a t which t h e procedure occurred; and e) whether any medical problems or com p lication s a rose during pregnancy ( e .g ., toxem ia), and, i f so, d e s c r ib e th e problem s or c o m p lic a tio n s and th e treatment received. .28 31 18 PI a i n t i f f ' s w i f e Maureen had a normal p r e g n a n c y w h i l e carrying Kerry. Neither P laintiff or P l a i n t i f f ' s wife c o m p lic a tio n s ever had ven ereal d is e a s e . w ith no 67 . A n s w e r I n t e r r o g a t o r i e s . 7 , 1 2 , 1 4 , 1 5 , a n d 1 6 w i t h resp ect to each mother id e n t if ie d in resp onse to Interrogatory 23(d). N Maureen worked for th e fo llo w in g : A $< P F o o d S t o r e , 1 9 6 2 - 1 9 6 4 , New R o c h e l l e S e r v i c e B u r e a u C o r p . , 1 9 6 5 - 1 9 7 1 / 7 2 , NV NY K i n g s P a r k H o s p i t a l , K i n g s P a r k , NY In 19B2 Maureen Ryan s u f f e r e d a s e v e r e a s t h m a t i c a t t a c k . She has been h o s p ita liz e d seven or e ig h t tim es at U n i v e r s i t y H o s p i t a l , S t o n y B r o o k , NY f o r h e r r e s p i r a t o r y condition. She i s now on d i s a b i l i t y f o r a s e v e r e a s th m a tic c o n d i t i o n d ia g n o se d by Dr. Michael Sampson, U n iv ersity H osp ital, Stony Brook. To t h e b e s t o f P l a i n t i f f ' s k n ow led g e, Maureen Ryan taken the follow ing medications: A llu p en t - 2 sp ra y s, 4 tim es a day Theodur - 2000 mg/day Steroi ds Bennet p o s it iv e p ressu re b reath ing machine 4 tim es a has day. Her t r e a t i n g p h y s i c i a n i s M ichael Sampson, U n i v e r s i t y H o s p i t a l , S t o n y B r o o k , NY Maureen Ryan d o e s n o t smoke and h as drunk a p p r o x m a te ly f i v e drinks in her l i f e t i m e . P l a i n t i f f ' s w ife has been exposed to in s e c t ic id e s b eginning approxim ately in 1979 or 1980 at th e K ings Park H o s p i t a l . The i n s e c t i c i d e was u sed by t h e h o s p i t a l . She d o e s n o t know t h e brand name but r e c a l l s i t b e i n g used approxim ately once a month in th e h o s p it a l. 8. F o r e a c h m o t h e r i d e n t i f i e d i n r e s p o n s e t o I n t e r r o g a t o r y 22 i d e n t i f y e a c h a n d e v e r y p r e g n a n c y n o t r e s u l t i n g i n a l i v e b i r t h , and s t a t e w ith r e s p e c t t o each: 1^^32 19 a) whether t h e r e was a m isc a r r ia g e and/or spontaneous a b o r tio n , and, i f so, s t a t e the d a t e and d e s c r i b e t h e r e a s o n -for t h e m is c a r r ia g e a n d /or sp on tan eou s a b o r tio n and id e n tif y any examining or tr e a tin g p h y sicia n s, and any i n s t i t u t i o n s at which i t oc c u r re d ; b) i f t h e r e s p o n s e t o a) above i s a f f i r m a t i v e , s t a t e whether you c o n te n d t h a t such m is c a r r i a g e and spontaneous a b o r tio n was caused by your exposure t o Agent Orange, 2 ,4 - D , 2 , 4 , 5 - T , d i o x i n , or some combination thereof; c) whether t h e r e was a vo lu n ta ry or t h e r a p e u tic a b o r t i o n , and, i f s o , s t a t e t h e d a t e and d e s c r i b e the reason for the voluntary or therap eu tic a b o r tio n , and i d e n t i f y any exam ining or t r e a t in g p h y s i c i a n s , and any i n s t i t u t i o n s a t which th e a b o r tio n o cc u r re d ; and d) i f t h e r e s p o n s e t o c) above i s a f f i r m a t i v e , s t a t e whether you contend that such voluntary or t h e r a p e u t i c a b o r t io n was c a u se d or n e c e s s i t a t e d by your exposure to Agent Orange, 2,4-D , 2 ,4 ,5 -T , d io x in , or some com bination th e r e o f . a) P l a i n t i f f had one m i s c a r r i a g e b e f o r e t h e b i r t h of Kerry in 1971. Dated: Carle Place, New York J anuary 14, 1984 PLAINTIFFS' MANAGEMENT COMMITTEE DAVID J. DEAN, ESQ. DEAN, FALANGA & ROSE, ESC One Old Country Road Carle Place, N e w York 115 (516) 248-9888 20 12833 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In r e "AGENT ORANGE" Product L ia b ility L itig a tio n x : : MDL N o . 3B1 ANSWERS OF DANNY LEE FORD TO DEFENDANT' S INTERROGATORIES TO PROPOSED REPRESENTATIVE P L A I N T I F F S - P L A I N T I F F ' S MANAGEMENT COMMITTEE: P h i l l i p E. Brown, Esq. H o b e r g , F i n g e r , B r o w n , Cox i< Mol 1 i g a n 703 Market S tr e e t <18th F loor) San F r a n c is c o , C a l i f o r n i a 94103 S t a n l e y M. C h e s l e y , E s q . Waite, Schneider, B ayless and C h e s l e y Co. L .P .A . 1513 C en tral Trust Tower Fourth and Vine S t r e e t s C in c in n a ti, Ohio 45202 David J. Dean, Esq. Dean, Falanga & Rose One Old C o u n try Road C a r l e P l a c e , New Yor k 11514 Newton B. S ch w artz, Esq. Houston Bar Center B u ild in g 723 Main ( S u ite 325) Houston, Texas 77002 T h o m a s W. H e n d e r s o n , E s q . B a s k i n !< S e a r s Frick B uilding (10th F I.) P i t t s b u r g h , PA. 15219 Benton M usselwhite, Esq. John 0. 0 ' Quinn, Esq. 609 Fannin (S u ite 517) Houston, Texas 77002 !< Stephen J. S ch leg el, Esq. Schlegel & Tra-felet, Ltd. One N o r th L a S a l l e S t r e e t Suite 3900 Chicago, I l l i n o is 60602 Gene Locks, Esq. Neil Peterson Esq. G reitzer & Locks, Esqs. 1500 Walnut S tr e e t P h i l a d e l p h i a , PA 1 9 1 0 2 12834 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product Liability Litigation. X X MDL No. 381 I. GENERAL 1. S t a t e your name, s o c ia l s e c u r i t y number, m il it a r y s e r v i c e number, and each a d d r e ss at which you have ever liv e d (excluding time during a c tiv e m ilita ry se rv ic e), sta rtin g w ith your c u r r en t a d d r e s s , and g i v e t h e d a te s you l i v e d at each address. Da n ny L e e F o r d 3 6 5 - 5 2 - 1 7 9 4 US 5 4 9 7 6 2 7 5 3 5 0 7 S t . A n t h o n y R'd. T e m p e r a n c e , MI . 4 B 4 1 2 1 9 7 4 - P r e s e n t ; 6 5 0 7 S e c o r Rd . T o l e d o , OH. 43613 1973-1974; 13478 South C o u n t y L i n e Hwy. O t t a w a L a k e , MI 4 9 2 6 7 1 9 5 3 - 7 3 ; 5 0 2 4 T r e l l i s Way, S y l v a n i a , OH 1 9 4 8 - 1 9 5 3 I d e n tify each ed u ca tion al i n s t i t u t i o n you attended, the d a te s of your a tte n d a n c e , and d e s c r i b e any p h y s ic a l or mental exam ination you rece iv ed at or in connection with your attendance at each i n s t it u t io n , s ta tin g with resp ect to each such exam ination. a) th e d a te of th e exam in ation ; b) t h e h o s p i t a l or i n s t i t u t i o n where such exam in ation was g iv en ; and c) t h e name and a d d r e s s o f t h e p e r s o n c o n d u c t in g t h e ex am in ation . W hiteford A g ricu ltu ra l High S chool, a. b. c.r none 3. Interrogatory d eleted . 4. If you have ever made a c la im f o r b e n e f i t s fo r any medical condition (including worker's 3 5c o m p e n s a t i o n , I ~ v e te r a n ' s b e n e f i t s , s t a t e or fe d e r a l d i s a b i l i t y or 1 insurance or union or th ird party medical plans) s ta te with resp ect to each such claim : a ) t h e t y p e o-f c l a i m ( w o r k e r ' s c o m p e n s a t i o n , v e t e r a n ' s benefits, etc. ) ; b ) t h e d a t e o-f t h e c l a i m ; c ) t h e c l a i m n u m b e r o-f o t h e r i d e n t i f i c a t i o n o f t h e claim d) t h e e n t i t y t o whom t h e c l a i m w a s made, i n c l u d i n g t h e name and a d d r e s s ; e) t h e m ed ica l c o n d i t i o n f o r which t h e cla im was made; and f) the d isp o sitio n of claim. V e t e r a n s B e n e f i t s - m a l a r i a - 10/1 d i s a b i l i t y , Bureau o f Workmans C om pensation S tate of Ohio Back in ju r y - Feb. 1973, cla im allow ed Carbon monoxide p o iso n in g , approx, 1975 - claim allow ed S em i-truck a c c id e n t - November 5, 1979 - la c e r a tio n l e f t knee, abdominal con tu sio n s - claim allow ed. May 1 9 8 3 - r e s e c t i o n o f s m a l l b o w e l - c l a i m a l l o w e d - AMC J e e p Corporation insurance ca rrier Aetna 1974 - removal of p l a t e and screw s r ig h t leg 1976 - Flower H ospital crushed b ig to e I960 -T o led o H osp ital biop sy and surgery 1980 - chemotherapy, r a d ia tio n therapy 19B1 - T o l e d o H o s p i t a l s t r e s s f r a c t u r e A p r il, 1981 - b iop sy r ig h t leg January, 1982 - bone g ra ft r ig h t leg May, 1 9 8 3 - s u r g e r y r i g h t l e g . F l o w e r H o s p i t a l j 12836 2 Summer, 1983 - chem otherapy - D rs. Horvath and S c h a fe r R a d i a t i o n - F l o w e r H o s p i t a l - - f a l l o f 1 9 83 - D e v i l b i s s CompanIn su ra n ce c a r r i e r unknown a t t h i s tim e. T o n s ille c t o m y - d a te unknown a t t h i s tim e F r a c t u r e d r i g h t -femur 1 9 6 6 i 1 9 6 7 - r e m o v e d rod - r i g h t -femur B ankers Li-fe, Des Moine, Iowa - Agent - Gary B a r r ic k lo w - B e ll B u i l d i n g , T o l e d o , DH 1970 - compound -fracture r ig h t t i b i a 1972 - Appendectomy 5 . I-f y o u h a v e e v e r - f i l e d o r o t h e r w i s e c o m m e n c e d a l e g a l action in connection with any medical condition (other than t h i s action ) s t a t e as to each such action: a) th e d a te th a t a c t io n was f i l e d or oth erw ise commenced, the court or a d m in istra tiv e body, th e f u l l t i t l e of th e a c t i o n , th e index or other i d e n t i f y i n g number, and t h e i d e n t i t y of a l l p a r t ie s to the action; b) a d e s c r i p t i o n o f t h e m ed ic a l c o n d i t i o n in c o n n e c t i o n w i t h w h ic h t h e a c t i o n w as f i l e d , and how y o u b e l i e v e th at medical co n d itio n occurred; c) a d e sc r ip tio n of th e outcome of the a ctio n , or of i t s p r e s e n t s t a t u s i f i t i s s t i l l pending; and d) t h e d a t e s and am ounts o f any paym ents, e i t h e r as a r e s u lt of a judgment or s e ttle m e n t, which you have r e ce iv ed or which you are scheduled to r e c e iv e . Out o f c o u r t s e t t l e m e n t in c o n n e c t io n w ith m o t o r c y c le /a u t o a ccid en t in 1970 - *15,000 awarded in 1972. Workers com pensation s u i t - Danny Ford 1982 No. 81-2872 - l o s t c a s e in v o lv in g Chatham, O ntario Canada. vs. Jeep sem i-tru ck Corporation accident in 12837 II. EMPLOYMENT HISTORY I d e n t i f y and d e s c r i b e e a c h job you have h e ld , whether employed by o t h e r s or s e lf -e m p lo y e d , and s t a t e as to each: a) t h e name and a d d r e s s o f your em p loyer, t h e a d d r e s s of your w o r k p la c e , t h e n a tu r e of t h e b u s i n e s s and your job t i t l e ; b) your d u t i e s and r e s p o n s i b i 1i t i e s ; c) t h e d a te t h e job began and ended and th e r e a s o n s f o r t e r m i n a t i o n of t h e j o b ; and d) t h e d a t e and p l a c e o f each p h y s ic a l and m ental exam ination that you underwent in connection w it h su c h j o b , i d e n t i f y i n g t h e name and a d d r e s s of each medical p r a c titio n e r conducting the ex a m in a tio n and t h e name and a d d ress of any m edical i n s t i t u t i o n at which such exam in ation s was conducted. S tu b n itz, d iv is io n of Hoover Ball Bearing 1966-1967 Adrain, MI. W e ld e r , went i n t o s e r v i c e . J o - J o ' s F iz z a r ia , Monroe S t . , Toledo, O h io ,1966 deliverym an - went t o work at S t ib n it z . Aamco T r a n sm issio n Monroe S t . , T oledo, Ohio - t r a n s m is s io n i n s t a l l e r - d o e sn ' t remember when. Landmark farm bureau - Berkey, Ohio - d eliverym an d o e s n ' t remember d a t e s or pay. E d d y ' s g a s and o i l S y l v a n i a - P e t e r s b u r g Rd. S y l v a n i a , Ohio 4 3 5 6 0 t r u c k d r i v e r 1 9 6 9 - 1 9 7 3 $ 1 3 5 . W e e k l y w e n t t o AMC J e e p ] 2 AMC J e e p C o r p o r a t i o n , p r e s s o p e r a t o r , i n s p e c t o r , s e m i - t r u c k d r iv e r - $ 6 1 5 .0 0 w eekly -- p h y sica l January, 1973 - Dr. Berber, 9 4 0 N. Cove B l v d . T o l e d o , O hio accident; b) t h e d a te s of th e i n j u r y , m edical c o n d itio n or acci dent ; c) the treatm ent re c e iv e d , including the tre a tin g p h y s i c i a n ' s name and a d d r e s s and a l l h o s p i t a l i s a t i o n s , o p e r a t io n s and m ed ication r e c e iv e d . See answer to question #4. D r . R o b e r t C o o k e H o l l s n d - S y l v a n i a R d . S y l v a n i a , OH 4 3 5 6 0 Farafon -forte Dr. Randall Finken, Sun-forest Court, Toledo, Ohio 43612 S t. J o s e p h 's H o s p it a l, Chatham, O ntario, Canada Dr. E r n s t S t e r n - f e l d , S e c o r Rd. , T o l e d o , O hio 4 3 6 1 3 Dr. E r n s t S t e r n -f e ld F lo w er H o s p it a l Harroun Rd. S y s l a n i a , OH 4 3 5 6 0 I I I . FAMILY MEDICAL HISTORY B. S t a t e t h e n a m e s a n d a d d r e s s e s o-f y o u r s p o u s e , c h i l d r e n , brothers, s is t e r s , parents, grandparents, aunts, uncles, c o u s in s , n i e c e s , nephews and g r a n d c h i1dren, and with respect to each: a ) i-f a n y o-f t h e m a r e d e c e a s e d , s t a t e h i s o r h e r a g e a t t h e t i m e o-f d e a t h a n d t h e t i m e , p l a c e a n d c a u s e o-f d e a t h ; b) i d e n t i f y each i l l n e s s , d i s e a s e , d i s a b i l i t y , or medical c o n d i t i o n ever had by each during h i s or her lif e t im e which required p ro fessio n a l medical a tte n tio n . c> i d e n t i f y a n y b ir th or g e n e tic m is c a r r ia g e s which t h e y had; and defects or d) w ith r e s p e c t t o each r e l a t i v e , i d e n t i f y each medical p r a c titio n e r and medical in s t it u t io n th a t trea ted them, and s e t f o r t h t h e d ia g n o s is . .12839 W i f e C h r i s t i n a M a r g a r e t C r a w f i s Ford 3 5 0 7 S t . A n th o n y Rd. T e m p e r a n c e . MI 4 8 1 8 3 . M i t r a l v a l v e i n s u - f f i e n c y - D r . T h o ma s A b o u n d S e c t o r R d . , T o l e d o OH. B r e a s t t u m o r b e n i g n - D r . Abraham S t e in b e r g , P h i l l i p s A v e ., T o led o , Ohio. F a th e r - Raymond Ford, 13478 South County L in e Hwy., Ottowa L a k e , MI 4 9 2 6 7 - N o n e Mother - Rose Ford, 13478 South County Line Hwy., Ottowa Lake, Ml - b a c k s u r g e r y - D r . R o b t C o o k e - h y s t e r e c t o m y D r . Wm. Me w b o r n B r o t h e r - T e r r y F o r d , 6 5 0 7 S e c t o r R d . , T o l e d o , OH 4 3 6 1 3 - C u t o n h a n d - F l o w e r H o s p i t a l , T o n s i l l e c t o m y - D r . Wm. M e w b o r n B r o t h e r - R a n d y F o r d , R t # 2 O t t o w a L a k e , MI 4 9 2 6 7 - t o n s i l l e c t o m y D r . Wm. M e w b o r n A u n t M i l d r e d B a r r i c k l o w Wo o d r o w S t . S y l v a n i a , OH 4 3 5 6 0 h y s t e r e c t o m y D r . R a n d a l F i n k e n S u n - f o r e s t C t . T o l e d o , OH 4 3 6 1 2 Aunt B u ela h Sou th ard d ie d January 2 6, 1964 a t home ca n cer U n c l e M o r g a n F o r d T e c u m s e h , MI 3 0 0 o u t e r D r . U n c l e G a r l a n d F o r d 2 9 6 9 E a s t b r o o k T o l e d o , OH n o n e U n c l e A r t h u r Ford d e c e a s e d June 1971 h e a r t a t t a c k a t home 61 yrs. G rand-father Lyman Ford d e c e a s e d 1953 s t r o k e a t home 74 y r s . G randmother S u s i e Ford d e c e a s e d 5 - 4 5 h e a r t a t t a c k a t home 60 years Grand-father E ar l Capron d e c e a s e d 1 1 - 2 1 - 5 0 ca r a c c i d e n t 61 years G r a n d m o t h e r E s t h e r C a p r o n 5 3 1 9 S e c o r R d . T o l e d o , OH. N o n e A u n t H e l e n P r i c e 5 3 1 9 S e c o r R d . T o l e d o , OH. 4 3 6 2 3 a b d o m i n a l adhesions Toledo H ospital - doesn't reca ll date Aunt J e r r y Hoyt R t # 2 O ttow a L ak e, MI. 4 9 2 6 7 - Appendectomy c o u ld n o t r e c a l l D r . ' s name U n c l e E a r l Capron 1 3 4 6 0 S o u t h C o u n ty L i n e Hwy, O tto w a Lak e. MI. 4 9 2 6 7 U n c l e R o n C a p r o n 4 8 1 4 B o w s e r D r . , T o l e d o , OH. 3 2 6 1 3 N i e c e Mandy F o rd R t # 2 O t t o w a L a k e, MI. n o n e 12840 6 Nephew Andy Ford Rt#2 Ottowa Lake, MI.49267 none I V . VETERAN' S MEDICAL HISTORY 9. State: a) th e d a te of your b ir th ; b) t h e name and a d d r e s s of t h e h o s p i t a l or o t h e r f a c i l i t y w here you were born, and t h e name and a d d r e s s o-f e a c h a t t e n d i n g p h y s i c i a n o r o t h e r m ed ical p r a c t i t i o n e r ; and c) each b i r t h d e f e c t t h a t you had and each m ed ica l c o m p lic a tio n connected with your b ir th ( e . g . , premature b irth , breech birth, jaundice, fe ta l a l c o h o l i s m ) , and each medical c o m p lic a tio n or h e a lth problem th a t you mother had in c o n n e c tio n with her pregnancy of your b irth ( e . g . , toxem ia, long period of la b o r). 8 - 2 3 - 4 8 T o l e d o H o s p i t a l N. Cove B l v d . M e w b o r n S u n f o r e s t C t . T o l e d o , OH 4 3 6 1 2 Toledo, OH D r . Wm. c. none 10. I d e n t if y each in ju r y , i l l n e s s , d i s a b i l i t y or other p h y s ic a l or mental c o n d itio n which you have ever had, whether tem p orary or permanent, and s t a t e s e p a r a t e l y as to each: a) each m edical p r a c t i t io n e r and/or m edical i n s t i t u t i o n seen or v i s i t e d by you for the purposes of c o n su l t a t i o n , d i a g n o s i s , p r o g n o sis, x - r a y s , trea tm en t or other care, sp ecifyin g the dates of a ll h o sp ita l iz a tio n s; b) t h e d i a g n o s i s or p r o g n o s i s made by e a c h m e d ic a l p r a c t i t i o n e r and m edical i n s t i t u t i o n ; and c) th e n a tu r e and e x t e n t of th e c a r e and tre a tm e n t r e c e i v e d in each m edical i n s t i t u t i o n and from each medical p ra ctitio n er. T o n s i l e c t o m y D r . Wm. Me w b o r n 12841 F r a c t u r e d r i g h t Femur F ebruary 1966 Dr. Robt Cooke T o le d o i H osp ital -fourteen days open red u ction with Schneider rod crutches-one year-temporary T oledo H o sp ita l Dr. Robert Cooke removed rod - receiv ed p h ysical therapy-T oledo c lin ic temporary 1 9 7 0 T o l e d o H o s p i t a l D r . R o b e r t C o o k e c o m p o u n d - f r a c t u r e o-f r i g h t t i b i a - 14 days h o s p i t a l i s a t i o n , -fracture plated temporary 1 9 7 2 a p p e n d e c t o m y D r . Wm. M e w b o r n - t e n d a y s - T o l e d o H o s p i t a l temporary 1 9 7 4 r e m o v a l o-f p l a t e -from r i g h t t i b i a - t e m p o r a r y - T o l e d o H o s p ita l-a p p r o x im a te 3 d a y -s ta y Dr. Robert Cooke 1974 Dr. Randal Finken -- high blood p ressu re -- re ce iv ed m edication 1976 Flower H o s p i t a l - Dr. Fred Hawkens-- crushed b ig t o e o b s e r v a tio n and x -ra y s November 5 , 1979 Chatham, O ntario S t. J o se p h ' s H o s p it a lo b s e r v a t i o n a n d s u t e r i n g o-f l e f t k n e e l a c e r a t i o n Transferred Sternfeld 1979 by ambulance t o Flower H osp ital - Dr. Ernst November 7, 1 9 7 9 - o b s e r v a t io n -r e le a s e d November 10, Flower H o sp ita l-D r . Ernst S te rn fe ld -N o v . 12, 1 9 7 9 -p o s sib le bowel o b s tr u c tio n due to truck a c c id e n t-1 0 day sta y O ffic e v is it - D r . Robert Cooke-pain lower rig h t le g - x-rays both 1egs-Novem ber 27, 1 9 7 9 -r e fe r r e d t o Dr. Paul Clark O f f ic e v i s i t Dr. Paul C la r 1- p o s s i b l e s o f t t i s s u e i n f e c t i o n e l e v a t i o n o f l e g , w a r m s o a k s - k e f 1 e x 5 0 0 mg D e c em b er 1 9 7 9 T o l e d o H o s p i t a l - o u t p a t i e n t 1 ami n o g r a m s Dr. Paul C lark O.V. p o s s i b l e p h l e b i t i s , s i g v a r i s s t o c k in g s Toledo H ospital tomagraphs, xero radiographs January 1980 Gallium scan, p o ssib le abscess R eferred back t o Robert Cooke by Dr. Paul Cooke O u tp a tien t b io p s y - Toledo Hospi ta l-F e b r u a r y 22, Robert Cooke-M alignant mass in r ig h t le g 1980- Dr. 12842 Admitted to Toledo Hospital February 22, 1980 for further su r g e ry Dr. Robert Cooke Feb. 27, 1980 r a d ic a l r e s e c t i o n of r i g h t l e g - o n c o l o g i s t c a l l e d i n - r e g i m i n e o-f c h e m o t h e r a p y started Six weeks chem otherapy-Dr. s Horvath and S c h a f e r 's o-f-fice Radiation therapy-3 treatm ents-Flow er Hospital Dr. S ta n ley cancer Zupnick, P sy c h o lo g ist, mental adjustm ent to S tress -fracture right leg-T oledo H osp ital-x-rays Dr. Stephen K iech el-ca sted leg Continued chemotherapy Dr. s Scha-fer and Horvath Flower H osp ital-A p ri1 19Bl-biopsy righ t leg . Stephen Kiechel n e g a tiv e , Dr. F in is h e d chemotherapy August 1981 F l o w e r H o s p i t a l D r . S . Ki e c h e l b o n e g r a - f t J a n . 1 9 8 2 F o l l o w up o-f-fice v i s i t s - D r . s H o r v a t h and Scha-fer Chest x-ray Flower H ospital Flower H ospital-D r. S. Kiechel-M ay 16, 1983-mass in lower thigh, extensive surgery on th ig h , resection o-f r e tr o p e r to n e a la r e a , v ein gra-ft, tumors in le g and abdomen, r e s e c t i o n small bowel due t o tru ck a c c id e n t in 1979 Chemotherapy, D r .s Horvath and Scha-fer--3 months 11. With r e s p e c t t o each i n j u r y , i l l n e s s , d i s a b i l i t y , other p h ysical or mental co n d itio n i d e n t if ie d in response to Interrogatory 10, id e n tif y each such con d ition that you c la im or b e l i e v e was caused by or a r o se out of exposure t o Agent Orange, 2 ,4 -D , 2 ,4 ,5 - T , d io x in or some com b ination t h e r e o f , and s t a t e s e p a r a t e l y as t o each: a) a d e s c r i p t i o n o f e a c h s y m p t o m ; or c) t h e d a te and manner in which each such symptom f i r s t m a n if e s te d i t s e l f or was made known t o you; and Embryonal rhabdomyosarcoma February 22, 1980 ou tp atien t biopsy 190 Intolerance to alcohol 1974-1975 Rash in th ig h s and b u tto ck s 1969 Joint pain 1974-1975 Memory l o s s 1976 Headaches 1969-1970 I d e n t if y each drug or m ed ication ever used or taken by you, in clu d in g , but not lim ite d to , i l l e g a l , r e cr e a tio n a l and o v e r -t h e -c o u n te r d rugs, and -for e a c h drug or m edication, set forth the follow in g with respect to each: a) t h e brand name, g e n e r i c name, or " s t r e e t name" of the drug; b) t h e d a t e of use; c) th e amount used during each p e r io d of use; d) t h e name and a d d r e s s o f t h e p h y s i c i a n , i f a n y , who prescribed the drug; e) a d escrip tio n of reasons for your use of the drug; and f ) whether you have ever r e c e iv e d any medical treatm ent or co u n sellin g in connection with your use of such drugs. f is p ir in ,p e r io d ic a lly through p r e s e n t ,f o r headaches and j o in t pain HCTZ 2 t i m e s d a i l y p r e s c r i b e d , D r . T h o m a s A b o u n d S e c t o r R d . T o l e d o , OH 4 3 6 1 3 , h y p e r t e n s i o n K e f l e x 5 0 0 mg D r . P a u l C l a r k 3 9 3 0 S u n f o r e s t C t . T o l e d o , OH 43612-possible soft tissu e infection T y l e n o l 3 D r . S t e p h e n K i e c h e l S e c o r R d . T o l e d o , OH 4 3 6 1 3 Parafon f o r t e Dr. Robert Cooke H olland- S ylv a n ia , S ylvan ia, OH 4 3 5 6 0 - b a c k i n j u r y 12344 A n ti-m alarial drug p rescrib ed in Vietnam Marijuana o c c a s io n a lly in Vietnam 13. I d e n t i f y e a ch s k i n c o n d i t i o n t h a t you have e v e r had, and with respect to each such condition: a) s t a t e th e d a t e s during which you had th a t co n d tio n ; b) d e s c r i b e any d i a g n o s i s or m ed ical tre a tm e n t you received for the condition,and state: i> t h e name and a d d r e s s o f t h e p erso n rendering the d ia g n o s is or treatm ent; i i ) t h e name and a d d r e s s of t h e m edical i n s t i t u t i o n ( s ) at which you were diagnosed or tr e a te d ; i i i ) the d ates of the d ia g n o s is or treatment; iv ) and t h e e f f e c t of t h e tr e a tm e n t. Rash on t h i g h s and b u t t o c k s - 1 9 6 9 - p r e s e n t n e v e r s e e n by p h y s i c i an 14. If you have ever smoked c i g a r e t t e s or o th e r w ise used a tobacco product: a) i d e n t i f y each ty p e of product ( e . g . , c ig a r s , c ig a r e tt e s , chewing to b a c c o ); b) i d e n t i f y t h e tim e p e r io d d u rin g which you used that tobacco product; c) i d e n t i f y t h e amount used on a d a i l y b a s is ( e . g . , packs of c i g a r e t t e s / d a y ); and d) s t a t e whether any p h y s i c ia n or o th e r h e a lth care p r o fe s s io n a l has ever a d v ised you to sto p or reduce your u se of c i g a r e t t e s or other tobacco products, and, i f so, sta te the name and a d d r e s s o f t h e p h y s i c i a n or o th e r h e a lth c a r e p r o f e s s io n a l and t h e d a te of th e advice. C i g a r e t t e s l e s s than one pack d a i l y f o r f i v e y e a r s - q u i t on own a c c o r d If you have ever consumed or drunk separately with resp ect to each type of liq u o r, b eer, wine, e t c . ) consumed: alcohol, state alcohol (e.g., a) at what age consum ption began; b) t h e amount and f r e q u e n c y of such consum ption; c) i f consumption ceased at any tim e, the reason s for such c e s s a t i o n and th e re a so n s for any resum ption; and d) w h eth er you w e r e e v e r h o s p i t a l i s e d or in s t it u t io n a lis e d for alcohol use, or advised to lim it or stop alcoh ol use, and, i f so, s t a t e th e nameCs) of each such h o s p i t a l or i n s t i t u t i o n or m e d ic a l p r a c t i t i o n e r who t r e a t e d or a d v i s e d you. Beer l e s s than 3 per week. D i s t i l le d s p i r i t s l e s s than per week. Stopped due to d ig e s t iv e d istu rb an ces I f any i n s e c t i c i d e s ( e . g . , C h lo r d a n e , L in d a n e , DDT), rodenticides (e.g ., rat poison), insect rep ellen ts (e.g., DEED or o th e r p e s t c o n t r o l compounds were e v e r used by you or o th e r s around your l i v i n g or working q u a r te r s , sta te as to each: a) t h e brand name or g e n e r i c name o f t h e c h e m i c a l ; b) a d e s c r i p t i o n o f t h e chem ical ( e . g . , powder, l i q u i d , col o r, smel1); c) a d escrip tio n of the container for the chemical ( e .g ., shape, c o lo r , markings) d) t h e d a t e o f u s e ; e) t h e m e t h o d o f a p p l i c a t i o n ; f) th e p lace i t was applied ; g) th e freq u en cy of a p p lic a t io n ; and h) whether you e x p e r ie n c e d any ad v erse r e a c t io n t o th e compound and, i f s o , d e s c r i b e t h e r e a c t i o n . None VI. MILITARY SERVICE 17. S t a te with r e s p e c t t o your m ilita r y s e r v ic e : a ) t h e b r a n c h o-f t h e a r m e d s e r v i c e s i n w h i c h y o u served: b> t h e i n c l u s i v e d a t e s o-f y o u r s e r v i c e ; c> t h e i n c l u s i v e d a t e s o-f s e - v i c e i n o r n e a r Vietnam; d) the name o-f each military unit to which you were assiQned while serving in or near Vietnam; and the dates during which you were assigned to each such units; e ) t h e n a m e a n d l o c a t i o n o-f e a c h p l a c e o r a r e a at which you were p h y sic a lly p resen t in or near Vietnam and th e dates during which you were p resen t at each such p lace or area; f) y o u r i m m e d i a t e s u p e r i o r o - f - f i c e r ' s n a m e a n d r a n k w h ile in or near Vietnam; and g ) t h e t y p e o-f d i s c h a r g e y o u r e c e i v e d . f ' Ar my ! 1-15-6B - 9-18-67 j Sept. 1968 - Sept. 1969 I C harlie B attery F ir s t B attalion 92nd A r t ille r y I S e p t . 1 9 6 8 Cameron Bay. pa e i k u , Kontum, Bambi t o Landing Zone Marylou, Firebase 13, I Blackhawk, c a n ' t remember d a te s I Capt. Farmer Honorable T u i t , Dak Firebase 18. With r e s p e c t t o each i l i n e s - , i n j u r y , wound or o th e r m edical or p s y c h o lo g ic a l con d ition e x p e r ie n c e d by you during your m ilit a r y s e r v ic e in or near Vietnam, s t a t e : a ) t h e d a t e o-f y o u r i l l n e s s , i n j u r y , w o u n d , o r other medical or psychological co n d itio n ; b ) a d e s c r i p t i o n o-f t h e i l l n e s s , i n j u r y , w o u n d , o r other medical or psychological co n d itio n , including a d e s c r i p t i o n o-f a l l s y m p t o m s ; c ) t h e c a u s e o-f t h e i l l n e s s , i n j u r y , w o u n d , o r o t h e r 12847 medical or psychological condition; d) t h e name an d r a n k o f t h e p e r s o n t o whom y o u - f i r s t re p o r te d th e i l l n e s s , in ju ry, wound, or o th e r medical or p sy c h o lo g ic a l condition (if anyone): e) the date th a t you f i r s t reported the i l l n e s s , in ju ry, wound, or o th e r p sy c h o lo g ic a l or m edical c o n d itio n ; f) t h e name, rank and lo c a t io n of each p h y s i c ia n or o t h e r h e a l t h c a r e p r o f e s s i o n a l who t r e a t e d your i l l n e s s , i n j u r y , wound, or o t h e r p s y c h o l o g i c a l or m edical c o n d it io n , in clu d in g th e d a te s and p la c e s of t r e a t m e n t , and a d e s c r ip t io n of th e tre a tm e n t you r e c e i v e d ; and g) t h e name and l o c a t i o n of each h o s p i t a l or o t h e r h e a lth c a r e f a c i l i t y which t r e a t e d your p s y c h o lo g ic a l or m edical c o n d itio n , th e d a te s of tre a tm e n t, and a d e s c r i p t i o n of t h e tr e a tm e n t t h a t you r e c e i v e d . Schrapnel r ig h t lower leg, L.2. Marylou, don't r e c a ll d a t e t r e a t e d by army medical s t a t i o n on p e r i m e t e r M a l a r i a c o n t r a c t e d i n Kontum, s e n t t o a i d e s t a t i o n and then t o Cameron Bay and h o s p i t a l i z e d . Don't r e c a ll date. 19. D escrib e any other m edication taken by you during your m ilita r y s e r v i c e ( e . g . , Dapsone, C hloroquine, Primaquine, B in o c ta l), s t a t in g as to each: a) t h e b r a n d name or g e n e r i c name o f t h e m e d i c a t i o n ; b) t h e form of t h e m ed ication ( e . g . , p i l l , c a p s u l e , in j e c t io n , e t c . ); c) t h e c o l o r , sh a p e, and s i z e of any p i l l or c a p s u l e taken; d) th e r e a s o n s fo r ta k in g the m ed ic a tio n ; e) t h e name and rank o f t h e person (s) who g a v e you th e m edication; f) the d a te s you took the medication; g) th e amount of the medication taken ( e . g . , p i l l s / d a y ) ; and h> w h e t h e r y o u e x p e r i e n c e d any a d v e r s e r e a c t i o n t o t h e m edication and, i f so, describe th e r e a c tio n . 12343 Some s o r t of a n t i - m a l a r i a l d rug. Took m e d ic a tio n f o r e n t i r e s t a y , r e a c tio n . Don't r e c a ll type. Did not have ad v erse 20. S t a te whether you ever re ce iv ed any t r a in in g , i n s t r u c t i o n s , warnings or h e a lth and s a f e t y in-formation c o n c e r n in g h e r b i c i d e s during your m i l i t a r y s e r v i c e , and identi-fy as to each: Cl ) t h e d a t e s y o u r e c e i v e d t h e - f o r e g o i n g ; b) t h e l o c a t i o n where r e c e i v e d ; c ) t h e n a m e a n d r a n k o-f t h e p e r s o n ( s ) -from wh o i t was r e c e iv e d ; d> t h e s u b s t a n c e o-f a n y o r a l i n - f o r m a t i o n r e c e i v e d ; and e) th e t i t l e , d a te , author or so u r c e , and c o n ten t o-f a n y w r i t t e n m a t e r i a l r e c e i v e d . No 21. S et forth w ith r e s p e c t t o each tim e you c la im t o have been exposed to herb icies: a ) t h e d a t e o-f t h e a l l e g e d h e r b i c i d e e x p o s u r e ; b ) t h e t i m e o-f d a y o f t h e a l l e g e d e x p o s u r e ; c) th e c l o s e s t geographical or p o l i t i c a l r e fe r en ce point ( e .g ., h i l l , town, landing zone) to the p la c e you b e lie v e you were exposed; d) a d e s c r i p t i o n o f t h e t e r r a i n a t t h e p l a c e o f a l l e g e d exposure; e) a d e s c r i p t i o n of how t h e h e r b i c i d e was b e in g a pplied ( e . g . , h e lic o p te r , a i r c r a f t , hand, e t c . ) ; f ) a d e s c r ip tio n of your a c t i v i t i e s at the tim e of alleged exposure; g> t h e m a n n e r y o u b e l i e v e y o u r b o d y w a s p h y s i c a l l y exposed to the herbicide (e .g ., skin contact, in h a la tio n , in g e stio n or sw allow in g), and, i f you b e l i e v e you were exposed by c o n t a c t on your s k in , i d e n t i f y th e areas of s k in th a t came in contact with the herbicide; 12849 h> t h e n a m e a n d r a n k o f o t h e r p e o p l e p r e s e n t a t t h e 15 time o-f alleged exposure; and i> w ith r e s p e c t t o any d e c e a s e d proposed r e p r e s e n t a t i v e p l a i n t i f f , s t a t e how such p l a i n t i f f w ill dem onstrate any of th e in form ation r e q u e s t e d i n s u b p a r t s a ) t h r o u g h h> o f ^ i s in te r r o g a to r y , i d e n t i f y in g any persons With such i n f o r m a t i o n who w i l l t e s t i f y a s t o such p l a i n t i f f ' s exposure to h erbicides. _ Exposed at v a rio u s tim e s u n it was a i r l i f t e d in to v a rio u s areas sprayed with d e f o i l i a n t , drank water from r ic e p a d d ie s in a r e a s w ith dead and dying f o l i a g e , chopped down dead and d y i n g f o l i a g e , went t o bathroom i n dead and d ying f o l i a g e . L .2 . Marylou and o th e r a r e a s p reviou sly mentioned in Question 17. Fred F a l a n a , R o b e r t S n o d g r a s s , S g t . Brown Worked and o f t e n l i v e d i n a r e a s s p r a y e d w i t h dead a n d / o r dying fo ila g e . Dated: Carle Place, New York January 14, 1984 H .1 Si - J : PLAINTIFFS' MANAGEMENT COMMITTEE BY:A ______ DAVID J. DEAN, ESQ. DEAN", F A L A N G A & ROSE, ESQS. One Old Country Road r Carle Place, New York 11514 (516) 248-9888 , t . or. r .-r aD -iT ^tur -y ;.e 12.850 16 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product L ia b ility L itig a tio n : : MDL N o . 3B1 ANSWERS OF Stephen John Z ardis TO DEFENDANT' S INTERROGATORIES TO PROPOSED REPRESENTATIVE PLAINTIFFS P L A I N T I F F ' S MANAGEMENT COMMITTEE: P h i l l i p E. Brown. Esq. H o t - e r g , F i n g e r , B r o w n , Cox S-. Mol 1 i g a n 703 Market S t r e e t (18th Floor) San F r a n c isc o , C a l i f o r n i a 94103 S t a n l e y M. C h e s l e y , E s q . Waite, Schneider, B eyless and C h e s le y Co. L .P .A . 1513 Central Trust Tower Fourth and Vine S t r e e t s C in c in n a ti, Ohio 45202 David J. Dean, Esq. Dean, Falanga & Rose One Old C ountry Road C a r l e P l a c e , New York 11514 Newton B. S c h w a r t s , Esq. Houston Bar Center B u ild in g 723 Main ( S u i t e 325) Houston, Texas 77002 T h o m a s W. H e n d e r s o n , E s q . B a s k i n S< S e a r s Frick Building (10th FI.) P i t t s b u r g h , PA. 1 5 2 1 9 Benton Mussel w hite, Esq. John 0. 0 ' Quinn, Esq. 609 Fannin (S u ite 517) Houston, Texas 77002 Stephen J. S c h le g el, Esq. S c h l e g e l V. T r a f e l e t , L t d . One North L a S a l l e S t r e e t S u ite 3900 Chicago, I l l i n o is 60602 Gene Locks, Esq. N eil Peterson Esq. G r e i t s e r Sc L o c k s , E s q s . 1500 Walnut S t r e e t P h i l a d e l p h i a , PA 1 9 1 0 2 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In Re "Agent Orange" Product L ia b ility L itia g a tio n . MDL N o . 381 I . GENERAL 1. S t a t e your name, s o c i a l s e c u r i t y number, m ilit a r y s e r v i c e number, and each a d d r e s s at which you have ever l iv e d (excluding time during a c tiv e m ilitary se rv ic e), sta rtin g w ith your c u r r e n t a d d r e s s , and g i v e th e d a te s you l i v e d at each address. S t e p h e n J o h n Z a r d i s , 0 1 3 - 3 4 - S S 0 9 , RA 1 1 6 2 1 8 4 6 . Addresses: 5 2 Pitm an Road M a r b l e h e a d , MA PRESENT - S e p t e m b e r , 1981 141 Front S t r e e t M a r b l e h e a d , MA February, 1972 - June, 1971 IB M erritt S t r e e t M a r b l e h e a d , MA S e p t . , 1981 - S e p t . , 1981 35 Baker S tr ee t M a l d e n , MA June, 1971 - June, 1970 One Crocker Park M a r b l e h e a d , MA S e p t., 1980 - S e p t., 1979 ACTIVE SERVICE US Army June, 1970 - June, 1967 141 Front S t r e e t M a r b l e h e a d , MA S e p t . , 1 9 7 9 - May, 1 9 7 6 35 Baker S treet M a l d e n , MA June, 1967 - 1956 5 0 Holden Road S t e r l i n g J u n c t i o n , MA May, 1 9 7 6 - May, 1 9 7 5 G o r e N u r s i n g Home W o l l a s t o n , MA 1956 - 1954 Clintwood V illage Bldg. 3, A p t., 5 C l i n t o n , MA May, 1975 - Feb. 1972 Cook S t r e e t C h a r l e s t o w n , MA 1954 - 1948 2. I d e n t i f y each e d u c a tio n a l i n s t i t u t i o n you a tte n d e d , the d a t e s of your a tte n d a n c e , and d e s c r ib e any p h y s ic a l or mental examination you received at or in connection with your attendance at each in s titu tio n , statin g with respect t o each such exam ination. a) th e d a te of th e exam ination ; b) t h e h o s p i t a l or i n s t i t u t i o n where such e x a m in a tio n was g iv e n ; and c ) t h e n a m e a n d a d d r e s s o-f t h e p e r s o n c o n d u c t i n g t h e exam in ation . Salem S ta te C o lle tg e , Salem M assachusetts Fall Sem ester, 1976 Worcester S ta te C ollege, Worchester, M assachusetts Spring, 1975; F a ll, 1974; Spring, 1974; F a ll, 1973 Salem S ta te C o lleg e, Salem, M assachusetts Spring, 1972; Fai 1,'1971 Eoston C ollege, Chestnut H ill, M assachusetts F a ll, 1965; Spring, 1967 4 . I-f y o u h a v e e v e r m a d e a c l a i m -for b e n e - f i t s -for a n y medical condition (including worker's comipensati on, v e t e r a n ' s b en e-fits, s t a t e or -federal d i s a b i l i t y or insurance or union or th ir d party medical plans) s ta t e with resp ect to each such claim: a ) t h e t y p e o-f c l a i m ( w o r k e r ' s c o m p e n s a t i o n , v e t e r a n ' s bene-fits, etc. ) ; b ) t h e d a t e o-f t h e c l a i m ; c ) t h e c l a i m n u m b e r o-f o t h e r i d e n t i f i c a t i o n o-f t h e cl ai m d) t h e e n t i t y t o whom t h e c l a i m wa s made, i n c l u d i n g t h e name and a d d r e ss; e ) t h e m e d i c a l c o n d i t i o n -for w h ic h t h e c l a i m was made; and f ) t h e d i s p o s i t i o n o-f c l a i m . A) V e t e r a n ' s b e n e - f i t s B> J u l y , 1 9 7 0 ; Mar cK 7 , 1 9 7 7 C) C - 2 6 0 8 3 3 1 1 D) V e t e r a n ' s A d m i n i s t r a t i o n R e g i o n a l O f f i c e , Federal Building, Boston, M assachusetts 2 12333 I E) J u l y . 1 9 7 0 -- I n j u r y t o j a w a s a r e s u l t o f combat in Vietnam and u rin a ry t r a c t problem incurred w h ile in Vietnam. March 7, 1977 -- com p en sation f o r n e u r o l o g ic a l damage F) A l l c l a i m s a p p r o v e d 10 p e r c e n t j a w , 40 p e r c e n t urinary tr a c t problem, 100 percent neurological problem. If you have ever f i l e d or o th e r w ise commenced a le g a l a c tio n in c o n n e c tio n w ith any m edical c o n d itio n (other than t h i s a ctio n ) s t a t e as to each such action : a) th e d a t e t h a t a c t i o n was f i l e d or o t h e r w is e commenced, th e court or a d m in is tr a tiv e body, th e f u l l t i t l e of t h e a c t i o n , t h e inde:; or o th er i d e n t i f y i n g number, and th e i d e n t i t y of a l l p a r t i e s to the action; b) a d e s c r i p t i o n o f t h e m ed ica l c o n d i t i o n in c o n n e c t i o n w ith w hich t h e a c t i o n was f i l e d , and how you b e l i e v e that medical con dition occurred; c) a d e s c r ip tio n of th e outcome of th e a c tio n , or of i t s p r e s e n t s t a t u s i f i t i s s t i l l pending; and d) t h e d a t e s and amounts of any p aym ents, e i t h e r as a r e s u lt of a judgment or s e ttle m e n t, which you have r e c e iv e d or which you are scheduled to r e c e iv e . F l a i n t i f f has never f i l e d or commenced any oth er leg a l a c tio n with regard to any medical c o n d itio n which p l a i n t i f f has had other than t h i s la w s u it. 12854 II. EMPLOYMENT HISTORY 6. I d e n t if y and d e s c r ib e each job you have h eld , whether em ployed by o t h e r s or s e l f - e m p l o y e d , and s t a t e as t o each: a) th e name and a d d ress of your em ployer, th e address of your w o r k p la c e , t h e n a t u r e of t h e b u s i n e s s and your job t i t l e ; b> y o u r d u t i e s a n d r e s p o n s i b i l i t i e s ; c) th e d a t e th e job began and ended and the r e a so n s fo r t e r m in a t io n of th e job; and d) t h e d a t e and p l a c e o f e a c h p h y s i c a l and m en tal exam ination th at you underwent in connection w ith su ch jo b , i d e n t i f y i n g t h e name and a d d r e s s of each medical p r a c titio n e r conducting the e x a m in a t io n and t h e name and a d d r e s s of any medical i n s t i t u t i o n at which such ex a m in a tio n s was conducted. Commonwealth of M assach u setts, Department of S o c ia l S e r v ic e s . 150 Causeway S t r e e t , Poston, M assachusetts, S o c ia l Worker, March, 1979 through September, 1978. Terminated because of n eu ro lo g ica l problem. Could not walk t o make home v i s i t s . P l a i n t i f f d id not h a v e any p h y s ic a l or mental e x a m in a tio n s perform ed upon him. Robert F. Kennedy A ction C orp s., A s s is t a n t D irector of R e sid e n tia l D iagnostic Center, Lancaster, M a ssa ch u setts. Child Care Worker, September, 1970 t h r o u g h May, 1 9 7 6 . Home f o r e m o t i o n a l l y d i s t u r b e d c h ild r e n . P l a i n t i f f did not have any p h y sica l or mental e x a m in tio n s performed upon him. M ilitary S erv ice, physical examination at Boston Army B a s e , B o s t o n , M a s s a c h u s e t t s , 1 9 6 7 - 1 9 7 0 . Boston C ollege, Chestnut H ill, M assachusetts, f u l l time stu d en t, 1965-1976. Revere K n it t in g M ills , Ferry S t r e e t , Malden, M a s s a c h u s e t t s , Summer, 1966. F i l l i n g o r d e r s in warehouse for clothing shipped to r e ta il customers. 7 With r e s p e c t t o each job i d e n t i f i e d in re sp o n se to I n t e r r o g a t o r y No. 6, i d e n t i f y ea ch o n - t h e - j o b i nj u r ^ 2 8 5 5 medical c o n d itio n or a c c id e n t th a t you exp erien ced , s ta te sep arately as to each: and a> a d e s c r i p t i o n o f t h e i n j u r y , m e d i c a l c o n d i t i o n or acci dent ; b ) t h e d a t e s o-f t h e i n j u r y , m e d i c a l c o n d i t i o n o r acci dent ; c) th e treatm ent r e ce iv ed , in c lu d in g th e t r e a t in g p h y s i c i a n ' s name and a d d r e s s and a l l h o s p i t a l i r a t i o n s , o p e r a tio n s and m ed ic a tio n r e c e iv e d . NONE III. FAMILY MEDICAL HISTORY 8 . . S t a t e t h e n a m e s a n d a d d r e s s e s o-f y o u r s p o u s e , c h i l d r e n , brothers, siste r s, parents, grandparents, aunts, uncles, c o u s i n s , n i e c e s , nephews and g r a n d c h i 1d r e n , and with respect to each: a ) i-f a n y o-f t h e m a r e d e c e a s e d , s t a t e h i s o r h e r a g e a t t h e t i m e o-f d e a t h a n d t h e t i m e , p l a c e a n d c a u s e o-f d e a t h ; b) i d e n t i - f y e a ch i l l n e s s , d i s e a s e , d i s a b i l i t y , or m edical c o n d i t i o n ever had by each during h i s or her li-fetim e which required pro-fessional medical a t t e n t i on. c) identi-fy any b irth or g e n e tic de-fects or m is c a r r ia g e s which they had; and d> w i t h r e s p e c t t o e a c h r e l a t i v e , i d e n t i - f y e a c h m e d i c a l p r a c t i t i o n e r and medical i n s t i t u t i o n th a t t r e a t e d them, and s e t -forth th e d i a g n o s i s . Plainti-f-f has no sp o u s e , c h i l d r e n , no s i s t e r s and no b r o t h e r s . T o t h e b e s t o-f p l a i n t i f f ' s r e c o l l e c t i o n , t h e r e have been no b ir th d e f e c t s . Both of p l a i n t i f f ' s p a ren ts are s t i l l l iv i n g . They are as fo llo w s: FATHER: Emmanuel Z a r d i s , Age 61 P o ly p s removed from t h r o a t , 1981 Harvard Community H ea lth Program Cambridge, M assachusetts a ~ j_& O D MOTHER: Iren e Z ardis, Age 60 Cancer of b rea st, 1980 Mastectomy performed B r ig h a m and Women' s H o s p i t a l Boston, Massachusetts MATERNAL GRANDMOTHER: C atherine MacFarlane D e c e a s e d - Summer, 1978 C o m p l i c a t i o n s -from d i a b e t e s E verett. Massachusetts MATERNAL GRANDFATHER: John MacFarlane Deceased - 1962 C a n c e r o-f C o l o n Chelsea, Massachusetts PATERNAL GRANDMOTHER: Mary Z a r d i s Deceased - 1930 Com plications at Q u e e n s . New York childbirth PATERNAL GRANDFATHER: John Zardis Deceased - 1943 Q u e e n s , New York FAMILY P HYS I C I A NS : Dr. H alpin (deceased) Dr. Finnegan I V . VETERAN' S MEDICAL HISTORY State: a ) t h e d a t e o-f y o u r b i r t h ; b ) t h e n a m e a n d a d d r e s s o-f t h e h o s p i t a l o r o t h e r - f a c i l i t y w h ere you w e r e b o r n , and t h e name and a d d r e s s o-f e a c h a t t e n d i n g p h y s i c i a n o r o t h e r m edical p r a c t i t i o n e r ; and c) each b i r t h d e f e c t t h a t you had and each m edical com p lication connected with your birth ( e .g ., premature birth, breech b irth , jaundice, fe ta l a l c o h o l i s m ) , and each m edical c o m p lic a tio n or h e a lth problem th a t you mother had in c o n n e c tio n with her pregnancy of your b ir th ( e .g ., toxem ia, long period of la b o r). January 26, 194B C h elsea Memorial H o s p it a l, C h elsea, M assachu setts P h y s i c i a n unknown No b i r t h d e - f e c t s or m e d i c a l c o m p l i c a t i o n s . Id en tify each in ju ry, i l l n e s s , d i s a b i l i t y or other p h y s ic a l or mental c o n d it io n which you have ever had, w hether tem porary or perm anent, and s t a t e s e p a r a t e l y as to each: a) each m edical p r a c t i t i o n e r and/or medical i n s t i t u t i o n s e e n o r s ' i s i t e d b y y o u -for t h e p u r p o s e s o-f c o n s u l t a t i o n , d ia g n o s is , p ro g n o sis, x -ra y s, treatm ent or other c a r e , s p e c i f y i n g t h e d a t e s o-f a l l h o s p i t a l i c a t i o n s ; b) t h e d i a g n o s i s or p r o g n o s i s made by each m ed ical p r a c t i t i o n e r and m edical i n s t i t u t i o n ; and c ) t h e n a t u r e a n d e x t e n t o-f t h e c a r e a n d t r e a t m e n t r e c e i v e d i n e a c h m e d i c a l i n s t i t u t i o n and -from each medical p r a c tit io n e r . November, 1959 -- broken a n k le . Dr. H alpin. T reated a t Law rence Memorial H o s p i t a l , Med-ford, M a s s a c h u s e t t s . Ankle s e t and c a s t made. A ugust, 1960 -- Chest x - r a y . Dr. H alpin. T reated at L aw ren ce Memorial H o s p i t a l , Med-ford, M a s s a c h u s e t t s . F e l l on c h e s t , had t r o u b l e b r e a th in g and p h y s ic ia n took x-ray which was n e g a tiv e . February 22, 1977 -- Jamaica P lain Veterans Adminis t r a t i o n H osp ital and West Roxbury V eterans A d m i n i s t r a t i o n H o s p i t a l . E a c h p e r i o d o-f h o s p i t a l i z a t i o n s i n c e t h i s t i m e h a s b e e n -for n e u r o l o g i c a l p r o b l e m s . The h o s p i t a l i z a t i o n are so numerous th a t plainti-f-f cannot r e c a l l each and every h o s p i t a l i z a t i o n , which d a t e s a r e s e t -forth in p ia in ti-f-f"s v a r io u s h o s p i t a l records. I n t h e R e p u b l i c o-f V i e t n a m , p l a i n t i - f - f h a d a - f e v e r o-f 12858 unknown o r i g i n and was h o s p i t a l i z e d a t th e lB 7 th E v a c u a t i o n H o s p i t a l a n d t h e n M e d i v a c e d t o Cu Chi 2 5 t h E v a cu a tio n H o s p it a l and seen at Tay Ninh H o s p i t a l . Agent Orange Exposure: R esulting in a severe, progressive dem yelination d isease, which has been diagnosed as m u ltip le s c l e r o s i s , with p e r ip h e r a ln e u r o p a th y , marked lower e x t r e m it y and back r i g i d i t y and s e v e r e s p a s t i c i t y (re q u ir in g L l- S l a n te r io r rhizotom y), p r o g r e ssiv e lower extrem ity weakness, lo s s of movement and marked se n so r y a t a x i a , s t i f f n e s s of lower e x tr e m itie s , r ig h t fo o t drop, in tr a c ta b le pain syndrome of lower e x tr e m itie s, in te r m itte n t numbness of the f e e t , p a r a p le g ia , s e v e r e s p a s t i c i t y and l i m i t a t i o n of movement of upper e x t r e m i t i e s , marked decreased s e n s a tio n of both upper extrem ities, in te r m itte n t numbness of both hands, s ig n ific a n timpairment in stren gth , d e x ter ity and p rop rio cep tio n in upper e x tr e m itie s , r e s u lt in g in low le v e l "quadraplegia", recurrent urinary tract in fe c tio n s, interm ittent renal fa ilu r e , bladder dysfunction with i n c o n t i n e n c e , b l a d d e r s p h i n c t e r d y s y n e r g i a ( r e q u i r i n g TURF' a n d TURBN w i t h s p h i n c t e r o t o m y ) , in t e r m it t e n t bowel incontinence, prolap sin g of rectum, enlargement of p rostate, sacral decubiti, le f t ischial ulcer (requiring left is c h ie c to m y u l c e r e x c i s i o n ) . sex u a l d y s f u n c t i o n , marked visual disturbances and d e f i c i t , severe diplopia, i n t e r n u c l e a r o p h t h a lm o p le g ia and a t a x i a , marked l e f t l a t e r a l nystagmus, l e f t greater than r ig h t, severe lo s s of v isio n , decreased visual acuity, abdominal mass (requiring ex cisio n ), chloracne, chronic urinary tra ct in fectio n s, r e c u r r e n t f e v e r o f unknown o r i g i n , i n a b i l i t y t o sw a llo w , drastic weight lo ss, disanthenia, emotional overlay depression, lethargy, depressive n eu r itis, lo ss of appetite, speech incoordination, chronic fa tig u e, p er sisten t headaches and j o i n t and m u scle p a in , i r r a s c i b i 1 i t y , e r r a t i c b eh a v io r d i f f i c u l t i e s and i r r i t a b i 1i t y . O Co iJQO 11. With r e s p e c t t o each in j u r y , i l l n e s s , d i s a b i l i t y , or other p h ysical or mental co n d itio n i d e n t if ie d in response to In terrogatory 10, id e n tify each such con d ition that you c la im or b e l i e v e was caused by or a r o se out of e x p o s u r e t o Agent Orange, 2 ,4 - B , 2 , 4 , 5 - T , d i o x i n or some co m b in a tio n t h e r e o f , and s t a t e s e p a r a t e l y as t o each: a) a d e s c r i p t i o n o f ea ch symptom; c) t h e d a t e and manner in which each such symptom f i r s t m a n i f e s t e d i t s e l f or was made known t o you; and See P l a i n t i f f ' s answer t o q u e s t io n number 10 supra re: Agent Orange Exposure. 12. I d e n t i f y each drug or m ed ic a tio n ever used or taken by yc"_., i n c l u d i n g , b u t n o t l i m i t e d t o , i l l e g a l , r e c r e a t i o n a l and o v e r - t h e - c o u n t e r drugs, and fo r each drug or m edication, set forth the follow ing with resp ect to each: a'' t h e b r a n d name, g e n e r i c name, or " s t r e e t name" of the drug; b> t h e d a t e o f u s e ; c) th e amount used during each p erio d of use; d) t h e name and a d d r e s s o f t h e p h y s i c i a n , i f a n y , who p rescrib ed the drug; e> a d e s c r i p t i o n o f r e a s o n s f o r y o u r u s e o f t h e drug; and f) whether you have ever receiv ed any medical treatm ent or counseling in connection with your use of such drugs. Pain m ed ication , morphine, valium. Various tim es w h ile h o s p ita lis e d from 1977 onward. See medical records. Various d o cto rs at Jamaica P lain V eteran 's A dm inistration H o s p i t a l , Jam aica P l a in , M a s s a c h u s e tts , and West Roxbury' V e t e r a n 's A d m in is t r a tio n , West Roxbury, M a s s a c h u s e tts . P r e s c r i p t i o n t o e a s e pain, fo r m uscle s p a s t i c i t y and l o s s of sieep No 9 13. I d e n t i f y each sk in c o n d i t i o n t h a t you have ev er had, and with resp ect to each such condition: a) s t a t e t h e d a t e s during which you had th a t c o n d tio n ; b) d e s c r i b e any d i a g n o s i s or m ed ical tr e a tm e n t you r e c e i v e d fo r t h e c o n d it i o n , and s t a t e : I) t h e name and a d d r e s s of t h e p erso n rendering the d ia g n o sis or treatm ent; II) t h e name and a d d r e ss of th e m edical i n s t i t u t i o n (s ) at which you were diagnosed or treated ; III) th e d a te s of the d ia g n o s is or treatm ent; IV) and t h e e f f e c t o f t h e t r e a t m e n t . In 1* t 1968 or e a r l y 1969 w h i l e in Vietnam , p l a i n t i f f d e v e lo p e d a rash on h i s arms and c h e s t . P l a i n t i f f was seen by a p h y s ic ia n at t h e 1 8 7 th A s s a u l t H e l i c o p t e r Company H o s p ita l in Tay Ninh. A w h ite ointm ent, which P l a i n t i f f b e l i e v e s t o be c o r t is o n e was giv en by sa id p h y s i c i a n , who b e l i e v e d P l a i n t i f f may h a v e b e e n s u f f e r i n g from an a l l e r g y t o d i e s e l f u e l . The o in tm en t was i n e f f e c t i v e . The c o n d i t i o n , e x p e r ie n c in g p e r i o d s of e x a c e r v a t i o n and r e m i s s i o n , r em ain s. 14. If you have ever smoked c i g a r e t t e s or o th e r w is e used a tobacco product: a) i d e n t i f y each ty p e of product ( e . g . , c ig a r s , c ig a r e tt e s , chewing to b a c co ); b) i d e n t i f y t h e tim e p erio d during which you used that tobacco product; c) i d e n t i f y t h e amount used on a d a i l y b a s i s ( e . g . , p a ck s of c i g a r e t t e s / d a y ); and d) s t a t e w hether any p h y s ic ia n or o th e r h ea lh care p r o fe ssio n a l has ever advised you to sto p or reduce your use of c i g a r e t t e s or other tobacco products, and, i f so, s t a t e the name and a d d r e s s o f t h e p h y s i c i a n or o th e r h e a lth c a re p r o f e s s io n a l and th e d a te of th e advi ce C ig a r e tte s -- January, 196B. Two p a c k s / d a y . December, 19B2. No. 1 5 . I-f y o u h a v e e v e r c o n s u m e d o r d r u n k a l c o h o l , s t a t e s e p a r a t e l y w i t h r e s p e c t t o e a c h t y p e o-f a l c o h o l ( e . g . , liq u o r, b eer, wine, e t c .) consumed: a) at what age consumption began; b ) t h e a m o u n t a n d f r e q u e n c y o-f s u c h c o n s u m p t i o n : c) i-f c o n s u m p t i o n c e a s e d a t any t i m e , t h e r e a s o n s for s u c h c e s s a t i o n a n d t h e r e a s o n s -fob a n y resu m p tio n ; and d> w h e t h e r y o u w e r e e v e r h o s p i t a l i s e d o r i n s t i t u t i o n a l i s e d -for a l c o h o l u s e , or a d v i s e d t o l i m i t o r s t o p a l c o h o l u s e , a n d , i-f s o , s t a t e t h e n a m e ( s ) o-f e a c h s u c h h o s p i t a l o r i n s t i t u t i o n or m e d ic a l p r a c t i t i o n e r who t r e a t e d or a d v i s e d you. 1 7 y e a r s o-f a g e . Beer - in -f r e q u e n t 1y . Consummed v e r y l i t t l e a l c o h o l , p e r h a p s a s i x pack/m onth w h i l e in t h e s e r v i c e . Wine a n d o c c a s i o n a l l i q u o r n o w l e s s t h a n o n e ( 1 ) b o t t l e o-f wine/m onth. L ess than ten (10) c o c k t a i 1s/m onth. C onsum ption c e a s e d -for e x t e n d e d p e r i o d s w h i l e hospi t a lis e d . No. r; Qhs;O tA**' i0 & 1 6 . I-f a n y i n s e c t i c i d e s ( e . g . , C h l o r d a n e , L i n d a n e , D D T ) , r o d e n t ic id e s ( e . g . , ra t p o is o n ), in s e c t repel 1e n ts < e .g ., DEET) o r o t h e r p e s t c o n t r o l c o m p o u n d s w e r e e v e r u s e d b y you or o th e rs around your l iv i n g or working q u arters, sta te as to each: a ) t h e b r a n d n a m e o r g e n e r i c n a m e o-f ' t h e c h e m i c a l ; b ) a d e s c r i p t i o n o-f t h e c h e m i c a l ( e . g . , . p o w d e r , l i q u i d , col o r , smel1); c ) a d e s c r i p t i o n o-f t h e c o n t a i n e r - f o r t h e c h e m i c a l ( e .g ., shape, co lo r, markings) d ) t h e d a t e o-f u s e ; e ) t h e m e t h o d o-f a p p l i c a t i o n ; -f ) t h e p l a c e i t w a s a p p l i e d ; g ) t h e - f r e q u e n c y o-f a p p l i c a t i o n ; a n d h) w h e t h e r you. e x p e r i e n c e d a n y a d v e r s e r e a c t i o n t o t h e compound and, i-f s o , d e s c r i b e t h e r e a c t i o n . N o n e t o t h e b e s t o-f PI a i n t i - f - f ' s k n o w l e d g e . V I . MILITARY SERVICE S ta te with resp ect to your m ilita r y serv ice: a ) t h e b r a n c h o-f t h e a r m e d s e r v i c e s i n w h i c h y o u served; b ) t h e i n c l u s i v e d a t e s o-f y o u r s e r v i c e ; c ) t h e i n c l u s i v e d a t e s o-f s e r v i c e i n o r n e a r Vi etnam; d ) t h e n a m e o-f e a c h m i l i t a r y u n i t t o w h i c h y o u were assigned w hile serving in or near Vietnam; and th e d a te s during which you were assigned to each such u n its; e ) t h e n a m e a n d l o c a t i o n o-f e a c h p l a c e o r a r e a at which you were p h y s ic a lly p resen t in or near Vietnam and th e d a t e s du rin g which you were present at each such p lace or area; f) y o u r i m m e d i a t e s u p e r i o r o - f - f i c e r ' s n a m e a n d r a n k w h ile in or near Vietnam; and g) the type o-f discharge you received U n it e d S t a t e s Army. June 25, 1967 through June 26, 1970. April 4, 1968 through April 7, 1969. 362nd A v ia tio h Support Detachment a tta c h e d t o 2nd Brigade 25th In-fantry D iv isio n ; 1 st Air Cavalry D iv isio n , 228th 2 2 9 t h C o m p a n i e s ; A e r o - S c o u t D e t a c h m e n t o-f t h e 1 1 t h Armored Cavalry at Tay Ninh; B-32 Fi-fth S p ecial F orces Group; A d v i s o r y Team 9 0 , M i l i t a r y A s s i s t a n c e Command, V i e t n a m 1 8 7 t h A s s a u l t H e l i c o p t e r C o m p a n y o-f F i r s t A v i a t i o n B rig a d e. Unit plain ti-f-f was a s s ig n e d t o was r e s p o n s i b l e for a i r s p a c e s e c u r i t y o r g r o u n d c o n t r o l o-f a i r c r a - f t t o in s u r e p la n e s and h e l i c o p t e r s did not -fly in t o each o t h e r . C l e a r a n c e -for a i r s t r i k e s and s p r a y i n g m i s s i o n s , m e d i c a l e v a c u a t i o n s , i n s e r t i o n a n d e x t r a c t i o n o-f t r o o p s , t a c t i c a l and l o g i s t i c a l a i r - f l i g h t s . Tay Ninh P r o v i n c e , E a s t and W est, Dau T i e n g , Trang Bang, Cu Chi t o C a m b o d i a . P l a i n t i - f - f ws i n t h i s g e n e r a l a r e a t h e e n t i r e w h ile he was in Vietnam. Plainti-f-f was on th e g r o u n d t h e e n t i r e p e r i o d o-f t i m e e x c e p t - for a c o u p l e o-f h o u r s p e r month when b e i n g t r a n s p o r t e d -from o n e p l a c e to another. Major B e l l , Major S c u l ly . F ie ld Grade 0-f-ficers. were oth ers which plainti-f-f cannot r e c a ll. There Honorable. 18. With r e s p e c t t o e a ch i l l n e s s , i n j u r y , wound or o t h e r medical or p sy c h o lo g ic a l c o n d itio n experienced by you during your m ilita r y s e r v ic e in or near Vietnam, s ta te ; a ) t h e d a t e o-f y o u r i l l n e s s , i n j u r y , w o u n d , o r other medical or p sych ological condition; b ) a d e s c r i p t i o n o-f t h e i l l n e s s , i n j u r y , w o u n d , o r other medical or p sych ological con d ition , in clud ing a d e s c r i p t i o n o-f a l l s y m p t o m s ; c ) t h e c a u s e o-f t h e i l l n e s s , i n j u r y , w o u n d , o r o t h e r medical or p sy c h o lo g ic a l c o n d itio n ; ?4tj l,2 b ^ 13 d) t h e na me a n d r a n k o f t h e p e r s o n t o whom y o u f i r s t re p o r te d th e i l l n e s s , in ju r y , wound, or o th e r m edical or p sy c h o lo g ic a l c o n d itio n ( if anyone): e> t h e d a t e t h a t y o u f i r s t r e p o r t e d t h e i l l n e s s , i n j u r y , wound, or oth er p s y c h o l o g i c a l or m edical c o n d i t i o n ; f) th e name, rank and l o c a t i o n of each p h y s ic ia n or ; o th e r h e a l t h c a r e p r o f e s s i o n a l who t r e a t e d your i l l n e s s , in ju ry , wound, or other p s y c h o lo g ic a l or m edical c o n d it io n , in c lu d in g th e d a te s and p la c e s of tre a tm e n t, and a d e s c r i p t io n of th e tre a tm e n t you r e c e iv e d ; and g) t h e name and l o c a t i o n of each h o s p i t a l or o t h e r h ealth care f a c i l i t y which tr e a te d your p sy c h o lo g ica l or medical c o n d itio n , the d ates of treatm ent, and a d e s c r i p t i o n o f t h e tre a tm e n t t h a t you r e c e i v e d . July, 1968, injured jaw from rocket exp losion . Urinary tr a c t in f e c t io n s from August, 1868, onward. Pain e s p e c i a l l y when u r i n a t i n g , but a lm ost c o n t in u o u s . Sometime around September through November, 1968, P l a i n t i f f w a s m e d i v a c e d t o Cu Chi f o r t h r o a t exam ination. P l a i n t i f f was unable to swallow. P l a i n t i f f w a s t a k e n t o T a y N i n h B a s e Camp H o s p i t a l . P l a i n t i f f ws e v a l u a t e d p s y c h o l o g i c a l l y in or ab o u t January, 1869, for f i t n e s s fo r duty in combat rone. Combat. Throat, f e v e r of unknown o r i g i n , and jaw in ju r y -- Doctor a t 187th A s s a u l t H e l i c o p t e r Company, who referred to 25th Infantry H ospital. H ospitalired 4 t o 5 days f o r f e v e r of unknown o r i g i n and t h r o a t . Jaw -- o u t - p a t i e n t , 1 8 7 th A s s a u l t H e l i c o p t e r Company H ospital. P sychological - o u t-p a tie n t, 187th A ssault H e l i c o p t e r Company H o s p i t a l . January, 1969, p sy c h o lo g ic a l. September through November, 196B, t h r o a t , f e v e r of unknown o r i g i n , and jaw in ju r y . Unknown. 187th A s s a u l t H e l i c o p t e r Company H o s p it a l f o r a l l i n j u r i e s . The jaw and p s y c h o lo g ic a l ex a m in a tio n s were on an o u t p a t ie n t b a s i s and p l a i n t i f f was re tu r n e d t o d u ty t h a t same day. The sw a llo w in g d i f f i c u l t i e s and f e v e r of unknown o r i g i n o c c u r r e d s i m u l t a n e o u s l y , and p l a i n t i f f was s e n t t o th e 25th I n f a n tr y H o sp ita l and h o s p i t a l i z e d 12385 for several days. 1A J 19. D e s c r ib e any o th e r m ed ic a tio n taken by you during your m ilita r y s e r v ic e ( e .g ., Dapsone, Chloroquine, Primaquine, B in o cta l), sta tin g as to each: a ) t h e b r a n d n a m e o r g e n e r i c n a m e o-f t h e m e d i c a t i o n ; b ) t h e -form o-f t h e m e d i c a t i o n ( e . g . , p i l l , c a p s u l e , in je c t io n , e t c . ); c ) t h e c o l o r , s h a p e , a n d s i z e o-f a n y p i l l o r c a p s u l e taken; d) t h e r e a s o n s -for t a k i n g t h e m e d i c a t i o n ; e ) t h e n a m e a n d r a n k o-f t h e p e r s o n ( s ) who g a v e you th e m edication; f) t h e d a t e s you. t o o k t h e m e d i c a t i o n ; g ) t h e a m o u n t o-f t h e m e d i c a t i o n t a k e n ( e . g . , p i l l s / d a y ) ; and h) w h e th e r you e x p e r i e n c e d any a d v e r s e r e a c t i o n t o t h e m e d i c a t i o n a n d , i-f s o , d e s c r i b e t h e r e a c t i o n . PI a i n t i -f -f n e v e r t o o k a n y o-f t h e m e d i c a t i o n s d e s c r i b e d e x c e p t a s a l m o n - c o l o r e d (p in k ) h o r s e t a b l e t -for a n t i m a l a r i a w h i c h P l a i n t i - f - f t o o k a -few t i m e s upon - f i r s t a rriv in g in Vietnam in A p ril, 1968. One S g t . F r e e m a n w a s i n c h a r g e o-f d i s p e r s i n g t h e m e d ic a tio n , which he u s u a l ly did by le a v in g in th e sleeping quarters. P l a i n t i - f - f c o n s u m e d a c o u p l e o-f p i l l s u p o n a r r i v a l i n Vietnam, then stopped. Di a r r h e a . 20. S ta te whether you ever received any tra in in g , i n s t r u c t i o n s , w arnings or h e a lth and sa-fety in-formation c o n c e r n in g h e r b i c i d e s d u rin g your m i l i t a r y s e r v i c e , and identi-fy as to each: a) t h e d a t e s y o u r e c e i v e d t h e - f o r e g o i n g ; b) t h e l o c a t i o n where r e c e iv e d ; c ) t h e n a m e a n d r a n k o-f t h e p e r s o n ( s ) -from wh o i t was r e ce iv ed ; * <$0 15 d> t h e s u b s t a n c e o f a n y o r a l i n f o r m a t i o n r e c e i v e d ; and e) t h e t i t l e , d a t e , author or so u r c e , and c o n te n t of any w ritten m aterial received. NONE 1. Set f o r t h w ith r e s p e c t t o each tim e you claim t o have been exposed to h erb icies: a) t h e d a t e o f t h e a l l e g e d h e r b i c i d e exposure; b) t h e tim e o f day of t h e a l l e g e d exposure; c) th e c l o s e s t geographical or p o l i t i c a l r e fe r e n c e point ( e .g ., h i l l , town, landing zone) to the p la c e you b e lie v e you were exposed; d) a d escrip tio n of the terrain at the place of alleged exposure; e) a d e s c r i p t i o n o f how t h e h e r b i c i d e was b ein g applied ( e . g . , h e lic o p te r , a ir c r a ft, hand, e t c . ) ; f ) a d e s c r ip tio n of your a c t i v i t i e s at the time of alleged exposure; g> t h e m a n n e r y o u b e l i e v e y o u r b o d y w a s p h y s i c a l l y exposed to the herbicide (e.g ., skin contact, in h a la tio n , in g e s t io n or sw allow in g), and, i f you b e l i e v e you were exposed by c o n t a c t on your s k in , i d e n t i f y th e a r e a s of skin th a t came in contact with the herbicide; h) t h e name and rank o f o t h e r p e o p l e p r e s e n t a t t h e t im e o f a l l e g e d e x p o su r e ; and i ) with r e sp ec t to any deceased proposed repre s e n t a t i v e p l a i n t i f f , s t a t e how su c h p l a i n t i f f w ill dem onstrate any of the information r e q u e s t e d i n s u b p a r t s a) through h) of t h i s in te r r o g a to r y , id e n tif y in g any persons with such in fo r m a tio n who w i l l t e s t i f y a s t o such p l a i n t i f f ' s exposure to herbicides. Nui Ba D in h , T rang Bang, Dau T ie n g -- t h i s i s t h e g e n e r a l a r e a w h e r e p l a i n t i f f r e c a l l s b e i n g s p r a y e d d i r e c t l y . On two o c c a sio n s in th e e a r ly morning, p l a i n t i f f remembers being caught in a d r ift of foggy, foul sm elling chemical sprayed by U n ite d S t a t e ' s p la n e s . The f i r s t o c c a s i o n , was e i t h e r June or J u ly of 1968, and s h o r t ly a fte r w a r d s , th e 16 P l a i n t i f f vom ited. The second o c c a s io n , th e P l a i n t i f f d e v e lo p e d a f e v e r of unknown o r i g i n a week or s o t h e r e a f t e r . On t w o o t h e r o c c a s i o n s , o n e w h e n a UC 1 2 3 g o t h i t w i t h g r o u n d f i r e and dumped i t s lo a d o f c h e m i c a l s , P l a i n t i f f was sprayed d i r e c t ly . This occurred around November, 196B. The o th e r o c c a sio n was a f l y b y 50-100 m eters from me. P l a i n t i f f was a g a in sp r a y e d d i r e c t l y . A ll sp ra y in g were by a i r c r a f t . P l a i n t i f f was walking on th e ground. Head, arms and c h e s t were exposed. O n l y t w e n t y - t w o men i n U n i t . P l a i n t i f f w o r k e d on g e n e r a t o r s by h i m s e l f . Exposed w it h E4 s o l d i e r on i n i t i a l s p r a y i n g a n d w i t h RVN r e g u l a r s s e c o n d t i m e . P l a i n t i f f was exposed by h im s e lf on t h e n ext two occasi ons. Dated: C a r l e P l a c e , New York January 14, 1984 P L A I N T I F F S ' MANAGEMENT COMMITTEE BY DAVID J . DEAN, ESQ. DEAN, FALANGA & ROSE, ESQS. One Old C ou ntry Road C a r l e P l a c e , New York 1 1 5 1 4 (5U>) 2 4 0 -9 3 3 9 CO 12 17 UNITED STATES D I S T R I C T COURT EASTERN D I S T R I C T OF NEW YORK In re "AGENT ORANGE" Product L ia b ility L itig a tio n : r MDL N o . 3 0 1 ANSWERS OF GEORGE W. EWALT, J R . TO DEFENDANT' S INTERROGATORIES TO PROPOSED REPRESENTATIVE PLAINTIFFS P L A I N T I F F ' S MANAGEMENT COMMITTEE: P h i l l i p E. Brown, Esq. H o b e r g , F i n g e r , Br ow n, Cox & Mol 1 i g a n 703 Market S t r e e t (18th Floor) San F r a n c is c o , C a l i f o r n i a 94103 S t a n l e y M. C h e s l e y , E s q . Waite, Schneider, B ayless and C h e s le y Co. L .P .A . 1513 C en tral T ru st Tower Fourth and Vine S t r e e t s C in cin n a ti, Ohio 45202 David J. Dean, Esq. D e a n , F a l a n g a t< R o s e One Old C o u n tr y Road C a r l e P l a c e , New York 11514 Newton B. S c h w a r ts , Esq. Houston Bar Center B uilding 723 Main ( S u i t e 325) Houston, Texas 77002 T h o m a s W. H e n d e r s o n , E s q . B a s k i n !< S e a r s Frick Building (10th FI.) P i t t s b u r g h , PA. 1 5 2 1 9 Benton Mussel w h ite, Esq. John 0. 0 ' Quinn, Esq. 609 Fannin (S u ite 517) Houston, Texas 77002 & Stephen J. S c h le g e l, Esq. S c h l e g e l ?< T r a f e l e t , L t d . One North L a S a l l e S t r e e t S u ite 3900 Chicago, I l l i n o i s 0602 Gene Locks, Esq. Neil Peterson Esq. G reitser & Locks, Esqs. 1500 Walnut S t r e e t P h i l a d e l p h i a , PA 19102 12869 UNI TED STATES D I S T R I C T COURT EASTERN D I S T R I C T OF NEW YORK In re X "AGENT ORANGE" Product Liability Litigation. X MDL No. 381 '.Vf I . GENERAL ]. S t a te your name, s o c ia l s e c u r i t y number, m il it a r y s e r v i c e - nomc e**, n d e a c h a d o 'e = c a t w h i c h y o u h a v e e v e r l i v e d (excluding time during active m ilitary serv ice), sta r tin g w ith your curren t a d d r e ss. and g iv e the d a te s you l i v e d at each address. e c - a W. Ew>j t . J r . : = . = . fc 1 6 9 - 3 3 - 4 5 3 8 ; M . S . # U S 5 2 8 0 7 8 4 5 . a c t A r d r e s i . e c : Ft e c e n i . at 4 331 Lau*"is t r , P h i l a d e l p h i a , PA : - ovg=- 4 y e a r =. P - i o r t o t h a t 7 0 1 Summi t A v e n u e , Kr - sc e l p h i a . PA i 9 1 2 r . = y e s : s : 5 3 0 0 b l o c k R i d g e A v e n u e , F : 1 c hi a .. 3 year: block J a m e s t o w n S t r e e t , F . rdclphi a, 1 yes*: 200 b ) ock W e n d o v e r Street, -:Lscsi phi a, 2 year: "21 Fenn Pin e s B o u l e v a r d , C l i f t o n u ::chtz, FA appro:-1 msts I y 2 years; m i l i t a r y s e r v i c e , 2 \ s ? - = : 731 Fenn Pines Foulevard 6 y e a r s ; 7 2 9 W e s t Wood i. . . a , Clifton Heights. FA, 2 years; 1 3 4 R i d g e w a y A v e n u e , I-,r-.-coc. FA B or 9 yea~s; Greenway Avenue i n S h a r o n H i l l Fs " s . ' l vcinis. Born in ger aid Mercy H o s p i t a l , D a r b y , F'A sc camber 34. 1947. I d e n t if y each ed u ca tio n a l i n s t i t u t i o n you atten d ed , th e c a t e s of your a t te n d a n c e , and d e s c r ib e any p h y s ic a l or mental exam ination you r e ce iv ed at or in connection with y o u 1- a t t e n d a n c e a t e a c h i n s t i t u t i o n , s t a t i n g w i t h r e s p e c t t o each such ex a n d n a tio n . G r a d e S c h o o l a t S t . G a b r i e l ' s , No r w o o d, PA f r o m 1 s t t o 6 t h g r a d e ; 7 t h and 8 t h g r a d s B l e s s e d V i r g i n Mary i n D a r b y , PA; f o u r y e a r s o f h i g h s c h o o l a t M o n s e n i o r B o n n e r In . D r e x e l H i l l , PA a f t e r s e r v i c e . n i g h t s c h o o l i n a p p r o x i m a t e l y 1 9 7 8 or 1979 a t C h e s t n u t H i l l C o l l e g e . No r e c o l l e c t i o n ' : o f any s p e c i f i c t e s t i n g , p h y s i c a l l y or m en ta lly , d u rin g^ th e above period other than regular s c h o la s tic te stin g such as SAT's. Hs h a s n o p r e s e n t r e c a l l o f t h e d a t e s o f t h e SAT' s . R o u t i n e p h .s i c a l s , d a te s unknown. . :- a/ t h e d a te of th e exan: n a ti on; 4'12-370 1 b ) tf"iE h o s p i t a l o r i n E t i t u t i o n w h e r e s u c h e x a m i n a t i o n was g : ven; and c) t h e name and a d d r e s s o f t h e p e r s o n c o n d u c t i n g t h e e x ami ns'.; o n . A. I f you h a v e e v e r made a c l a i m -for b e n e - f i t s -for any medical condition (including worker's compensation, veteran's bene-fits, sta te or -federal d i s a b i l i t y or i n s u r a n c e o r u n i o n c-r t h : r d p a r t y m e d i c a l p l a n s ) s t a t e with resp ect to each such claim : a c =. - -f: t s . e t c . : t '* t h e d a t e o f t h e c l a i m c ' t^-e c l a i m n u m b e r o r o t h e r i d e n t i -fi c a t i o n o-f t h e c l a i m d> the entity to whom the claim was made, including the name and address: e> she medical corrriit.io~ for which the claimi was made: f ans t*-e di spc-ci to* of the claim. C l a i m -for V e t e r a n Adm:i r. i = t r a t i o n b e n e f i t s f o r l e f t k n e e , f r a c t u r e d i n Tsn.ar w h i l e i n t h e s e r v i c e . F o r t Hood, T e x a s in 1 9 o 2 . T h e r e a f t e r . a c l a i m f o r p o e t - t r a umat i o s t r e s s . F'ric-r to f i l i n g the p o st-tra u m a tic s t r e s s claim -and subsequerrt to t h e f r a c t u r e d I-.nee c l a i m i . P l a n t i f f f i l e d an Agent Orange c la im . C l a i m s h a v e bee- n ma d e u n d e r G e o r g e W. E w a l t , n o J r . C e r t a i n h a d W o r k e r ' s Comip . c l a i m s w i t h t h e B e l l T e l e p h o n e Co. Appr o-:i me.tel y 6 t o E y e a r s a g o Mr. E w a l t b r o k e a f in g e r on th e job . The c la im was made w ith B e ll Telephone, medical b i l l s were paid. Approximately 4 ot 5 y e a r s ago, a d d i t i o n a l 1 y, l e f t arm, elb o w , s h o u ld e r s tr u c k b y v a n . M e d ic a l b i l l s w e r e p a i d , No r e c o l l e c t i o n o f l o s t time for eith er. l) , , 12571}I'"' w. I f y o u h a v e e v e r f i l e d o r o t h e r w i s e c o m m e n c e d a l e g a l i fi a c t i o n i n c o n n e c t i o n w i t h n.- m e d ic a l c o n d i t i o n than th is action) s t a t e as tc each such action: (other a) the date that action was -filed or otherwise commenced, trie court c* admi ni strati ve body, ^tht- -i11 title cef the action, the index or other ident l -fyi nc number, and the identity o-f all parties to the action; b> s description o-f the medical condition in connection with which the act ion was -filed, and how you believe that medical condition occurred: r a. ce s c" l p t . on o s t \ s - o u t c o t .s o-f t h e a c t i o n , o r o-f i t s p - - e i s t a t u s i -f i t . = s t i l l p e n d i n g ; arc- e > the cates and amount s o- any payments, ei the-" as a res. It c-f s- judgment o** sett 1ement, which ye: ha-e re:.=:'-s-d or which vc-u -:e scheduled to recei-s. Automobile accids-nt e-.c-pro; imstely 10 years ago, and cut o-f wor k -for some wee! s. jury to neck and uppe- tad . Emergene, treatment and !-?:= st Roxborough Memorial Hospital. th-erea-fter. -followed b . his -family ph.siciar-. r-r. Joan riurlock. The case was settled with carrier. In approx :mat el y l=6t-, had ar- accident while a passenger in car. Injur - to head end r,e: :. lost little -.-.pensea, No recollection c- attorney's name. I I . EMPL-jVrtENT HISTORY . Identi-fy employee each: arid d e s c r i b e e a c h j o b you h a v e h e l d , w h e t h e r by o t h e r s o r s e l - f - e m p l e y e d , a n d s t a t e a s t o a ) t h e n a m e a n d a d d r e s s o-f y c u r e m p l o y e r , t h e a d d - e s s o-f y o u r w o r k p l a c e , t h e n a t u r e o-f t h e b u s i n e s s a n d your job t i t l e ; b) your d u t ie s and r e s p o n s i b i l i t i e s ; c) t h e d a te th e jo b began and ended and t h e r e a s o n s for t e r m i r . a t i o n o-f t h e j o b ; a n d d ) the* d a t e arid p l a c e o-f e =: : h p h y s i c a l a n d m e n t a l e x am: n e t i or. t h a t y o u u n d e r w e n t i n c o n n e c t i o n w ith such jo b , i d e n t i f y i n g th e name and a d d r e ss of each medical p r a c titio n e r conducting the e x a m i n a t i o n a n d t h e n a m e a n d a d d r e s s o-f a n y m e d i c a l i n s t i t u t i o n at which such exam inations was conducted. While in high school in approxim ately 1964 worked p a r t - t i m e f o r Adams C a d i l l a c , 2 0 t h and Sansom S t r e e t s , P h i l a d e l p h i a . W a s h i n g a n d c l e a n i n g t h e a u t o m o b i l e s . He was te r m in a te d when he graduated from h igh school and went in to f u l l l i n e employment. While in high s c h o o l , George a l s o was a vendor f o r t h e Nylon B r o th e r s food co n cessio n s at the stadiums s e ll in g hot dogs, candy bare, cokes, 7-Ups and r o o t beer b e v e r a g e s . After high s c h o o l, accep ted f u l l - t i m e work - C u rtis P u b li s h in g Co. in June of 1965 t o January of 1966. o p e r a te d an a u t o m a t ic l a b e l i n g m achine. He Left Curti / o p* p o r t u n i t -, in the military. P u b l i s h i n g Co. fo r a b e t t e r 'em p lo y m e n t an. S o r e n s o n I n d u s t r y . C o l w i n , PA. a n d w o r k e d : r e s h o p as mat a! man, ( b r i n g i n g m a t e r i a l t o The c h e n d s : ,-.heo he wa s d r a f t e d i n t o v h e In 1968, r e tu r n e d t o Sorenson I n d u s t r i e s as m a c h i n i s t . f c r 3 o: 4 m o n t h s . He l e f t i n t e n d i n g b a c i t o s c h o o l . " h e r e-af Le*". e m p l o y e d b y W i n g s a n d as a p a r t-tim e drive*- for a fr e ig h t company. a to go Wneel s In 1769. he became a f u l l - t i m e em ployee w ith the U.S. P o s t a l E-fc'-vice f o r 1 y ea r i n Wayne. PA. a s a r e g u l a r mai . mari d e l i v e r n o mai 1 . In 9 7 0 , became em ployed w ith the t e l e p h o n e compa.-y, B e l l c>f PA. He s t a g e d a.s s p l i c e r - h e l p e r , a n d w a s t h e n p r o m o t e d a f t e r 13 m o n t h s t o l i n e m a n . Was a l i n e m a n u n t i l 1 9 5 3 . - A l t h o u g h h e w a s a. t i t l e d l i n e m a n u n t i l 1 9 8 3 , in 1981 t c 1953 due t o h i s h e a l t h p r o b le m s he perform ed f u n c t i o n o f o f f i c e w o r k e r . He b e c a m e a f a c i l i t y a s s i g n e r in 1983 and i s p r e s e n t l v employed at B e ll Telephone at that p osition . P la n t if f b e lie v e s he i s p resen tly employed by Bell Avantic, although has not yet received f i r s t chect after telephone companies reorgan ization. Any p h y s i c a l exam inations during th e period of employment with S o r e n s o n I n d u s t r i e s and many o f t h e p a r t - t i m e j o b s b e f o r e were performed by fa m ily doctor, Dr. Marvin W erlinsky, A l d e n , PA. 7. With r e s p e c t t o each jot- i d e n t i f i e d in r e sp o n se t o I n t e r r o g a t o r y No. 6, i d e n t i f y each o n - t h e - j o b in ju r y , m edical c o n d i t i o n or a c c id e n t th a t you e x p e r ie n c e d , and s ta te sep arately as to each: 4 a) a d e s c r i p t i o n of th e i n j u r y , m edical c o n d i t i o n or acci dent : b) t h e d a t e ; - c-f t h e i n . i u r v , m e d i c a l c o n d i t i o n o r acci dent : c) he, treatm ent r e c e iv e d , in c lu d in e th e t r e a t in g p h y s i c i a n ' s nane and a d d r e ss and a l l h o s p i t a l i e n t i o n s , e p e r a t i ons. a nd m e d i c a t i o n r e c e i v e d . Each on t h e jot- i n j u r y r e c a l l e d has been s t a t e d . U-.j i s a t S o r e r s o n * s . h e d i d h a v e a n o t j o b r e l a t e d i n j u r - , A* none - , h e s l i c e d t h e t o p o-' h i s -f: n g e r . T r e a t e d a t ? : : w*e-- e l a Me- c Ho: ;-i t a. l i n r=-.rbv, PA. family medical history E l a t e t h e n a m e s a n d a d d r e s s e s , o-f v o u r s p o u s e , c h i l d r e n , t'cthei's. s iste r s, parents, grandparents, aunts, uncles, c c . - c i n s , n i e c e s . n e p h e w s a.r-d g r a n d c h i l d r e n , a n d w i t h >- a s p e c t t c - e a c h : a'* i-f a n y o-f t h e m are- d e c e a s e d , s t a t e h i s o r h e r a g e a t t h e t i m e o-f d e a t h a n d t h e t i m e , p l a c e `a n d c a u s e o-f d e a t h : : b) i d e n t i - f y each i l l n e s s , d i s e a s e , . d i s a b i l i t y , or m edical c o n d itio n ever had by each during h i s or h e r l i - f e t i m e w h i c h r e q u i r e d p r o-f e s s i o n a l m e d i c a l a t t e n t i on. c) i d e n t i - f y any t i r t h or g e n e t i c d e - fe c ts or m i s c a r r i a g e s which th e y had; and d) w i t h r e s p e c t t o e a c h r e l a t i v e , i d e n t i - f y e a c h m e d ic a l p r a c t i t i o n e r and m ed ical i n s t i t u t i o n t h a t t r e a t e d them, and s e t -forth th e d i a g n o s is . R e s i d e s w ith husband w i f e ' s name i s S h i e l a S. E w a lt. One c h i l d , a d a u g h t e r , 12, Tara C a t h e r i n e , who a l s e r e s i d e s a t home w ith her mother and -fath er. PI a i nti-f-f h a s n o b r o t h e r s , and h a s t w o s i s t e r s . S u s a n arc Maroaret Scanlon. Marcaret i s th e o l d e s t and married t o P e t e r F o r l a n o , S t a f f S a r g e n t , U . 5 . Army, s t a t i o n e d a t Ft. Dix. There- a r e no o t h e r b r o t h e r s and s i s t e r s . . P a r e n t George and E u n ic e , r e s i d e at 733 Penn P in e s B o u le v a r d . Father, g r a n d - f a t h e r a n d g r e a t g r a n d f a t h e r we**e a l l e x t e n d e d c a r e e r s c - l d i e r s . The heal th of p a r e n t s and s is t e r s is good. Grandparents: fa th er's side: Ch a r 1 e y ' E w a l t , b o r ri J a n u a r y 2 9 , 3 3 7 c , d i e d J u l y 1 8 , 1 9 6 8 , Er y e a r s o l d . F a . t h e - *s m other rs name i s H azel F o r c e Ewal t , b o rn Juris 1, 1 358. D ied S e p te m b e r 10, 1923. Mother's side; S-- a n o f Jul , 2, K*1 C: :r-r e t 4 --^ ~ p a s s e d ,-h li J o h n H. A K Ha n -I a. i.n in iij d;-:c -- ---- tr - r z . Mo t h e r ' s mo the. -- i s E u n i c e r* Hj v c - t t t- t :r* - t h e r Cecemfc e r 17 o r 2 6 , e.Wr r 1 . . "7JV c--4 -/r2 y e a r s Of f O t , i'>t ff ' s fa tha-t ' s o*a.r z : c th e- 1i ed to be 9, and -father * s gr a->df at,her 1; .ec to be 89 1FI : r11iff ' s father's oranz*at her t a *d / brothers and s i tnrs and t-is-y ail lived be-.-ond 30. Fattier is frc-m ha !-.iria.i~ Cit y. K.cfjiuan. n i s and J n c le s : M other's s i c s . F 1 a i n t i f f r s mc- t ner h a d 7 b r o t h e r s a n d 5 s i s t e r s . . T.vc- b r o t h e r s a r e d e c e a s s d . 1 *== h i l l e d i n t h e K o r e a n War , t h e o th e r had an i n d u s t r i a l a c c i d e n t som etim e in t h e 7 0 ' s . B e l i e v e s t h a t c-ne c-- h i s u n c l e s h a s d i a b e t e s , t h e r e s t of them a r e in good h e a l t h . Knows o f no major i l l n e s e s , i f any. with the excep tion of one of h is aunts on h i s m o th e r 's; s i d e who h a s d e v e l o p e d leuhemie. i n t h e p a s t y e a r . Her name i s Ne"-e>*st J o h n s o n ar.d s h e l i v e s i n N o r w o o d , PA on Amos] and F o a d . W i t h r e f e r e n c e t o n i e c e s and nephews, has 3 n i e c e s and 1 nephew. Their names are Michele Scanlon, 13, good health? Stephen Scanlon, a p p ro x im a tely 7 or 8 years o ld , good h e a lth ; Yolanda F o r l a n o , appro;-:imetel y 12 y e a r s o l d , gc-od h e a l t h e x c e p t for s c o l i o s i s l a s t year and A l i c e F o r la n o , a p p r o x im a te ly 1 0 y e a r s o l d . fJc- g r a n d c h i 3 c** er.-. I V . VETERAN' S MEE'ICAL HISTORY t X, 9. St at e: a) t h e da te b ; t h e n e me i 1i t y * 2 r e s e. m e d i c a l pr <cti t i o n e r ; e nd tal or other I t hit n e 'Tie!' c*rc! c) e fc h b i r t h d e f e c t t h a t you had and each medical : cmpl i c a t i on c o n n e c t e d w i t h your b i r t h ( e . g . , C'i' s v r t s . i r e b i r t h , b r e e c h b i r t h , . i a u n c i o e . - f e t a l a I c oh. ..1 i = t. > . a n d e a r r,i e c c o a l c on if i . c ; t : o n or protls*. that vou mother had : connect:on f r 1 i ob j a ho** - . -, r ..al-_- t.*.s.-^. d r-i-, c !i{i.=.r-'.A la . C. t . * ar..e.-r,ru*y , r.o o t h o r Kr . --1rjC.i : i.- . . C-1 rth ci f*'"t.r-r 10. Ice-c:- y Gri-C.h 1njU'- y, il iries= , diSr ph-=:cal or men t=.' conditi on yo. w k5;*.s ' + ".O*1"cif** or pe-mar.ent ar-c! sta to sa: : or o th e r eve'- had. *r a t e 1 y a s a) each medi cel pr act iti oner end/or med seer, o r v i s i t e d by you. -for t h e p u r p o s e s o - c o n s u l t a t i o n , d i a g n o s i s , p r o g n o s i s , r - r s y i . `t r e a t m e n t or o t o e - c a r e , s p e c i f y i n g t h e d a t e s c-f a i l h o s e i t e l ica tio n s: t ) t h e d i a g n o s i s or p r o g n o s i s made by e a c h m e d i c a l p r a c t i t i o n e r and m ed ical i n s t i t u t i o n : and c ) t h e n a t u r e a n d e . : t e n t o-f t h e c a r e a n d t r e a t m e n t r e c e i v e d i n e a c h m e d i c a l : r. = t i t u t i or. . a^d - from each medical p r a c t it io n e r . i^ O t h e r t h an t h e c o n d i t i o n s a s e n u m e r a t e d i n 11 i n f r a , p l a i n t i f f s u s t a i r.ec a b r o k e r l e f t w r i s t a t 10 y e a r s of a g e . F i t z g e r a l d M e r c y He s c i t a l ; l e n g t h o f d i s a b i l i t y g u e s s s c a t 6 t o 8 w e e k s . ' Ri g h t e a r m a s t o i d o p e r a t i o n appr o:-:lm a t e l y 6 y e a r s o l d , F i t z g e r a l d 1 Merc v Hos c i t e l . d i s a b i l i t y unknown. b e l i e v e s he was i n t h e h o s p i t a l f o r fQ JL> ?'\ it I appro: . 1 month. At a g e 10. b e c a u s e o f c o n t i n u i n g e a r a c h e s , he was t r e a t e d w ith r a d i a t i o n on r i g h t ear and removed s k i n t h a t had or own o v e r t h e s c a r t i s s u e and no p r o b l e m s s i n c e t h e n . He h a d n o r m a l r o u t i n e - r a y s . - f o r t h e a u t o a c c i d e n t o f h i a n e e I:. ' - r e - s o-f h i s b a c k i n t h e V . f i . H o s p i t a l w h e n t h e y t r i e d a s p i n a l t a p , x - r a y s o-f h i s l e - f t k n e e . Apid: t j o n a 1 1 y , h e b r o k e l e - f t w r i s t i n t h e s u mme r o-f 1 9 3 3 when he - f e l l w h i l e p l a y i n g s o f t b a l l . He was x - r a y e d i n W i l k e s t a r r e M e d i c a l C e n t e - H o s p i t a l , W i l k e s B a r r e , PA and at Rc-rbr o u g h M e m o r ia l H o s p i t a l i n Phi 1 a d e l p h i a . FI anti-f-f r e c a l l s t h e - f i r s t d o c t o r s i s B r . P a u l Keenan, Norwood, FA; D*` . P a t t o n , A l d e n , FA; D r . Wor kl i n s '>v , A l d e n , PA; D r . J o a n H u r i o c k , P h i l a d e l p h i a , PA a t F a x t O'* o-ugh M e d i c a l B u i l d i n g . T h e r i g h t e a r p r o b l e m a t c - - e - c : s c u s s e d w;.:s h a n d l e d c D r . M c C o n n e l l i n P i l g r i m 2c r `* v `i i . FA. the c c e r a t i o r - -as at Fitrgeral-r M~rc> Ho? p i t a l c-nd t r e a t m e n t a l s : ' i n D a r b y , PA. D r . J o a n H u r l o c i i r more- or l e s s ar.d n = s b e e n PI s i n t i -f -f ?s f a m i l y d o c t o r s i n c e - l a t e r 0 ' s o r s a ' l y r 7 0 ! s . D r . G s c ' g e M. W ilson, al sur g e o n , Fa .borough Memorial - o s p it a .l r e m o v e d *= s k i n gr c - w t h s i ri - . he h e a d , r i g h t a r m . l e - f t l e g s , t s -C: a n d t h r o a t . F 2 .* r,*.: -f -f w a s r e f e r r e d to- D r . Wi 1 s o n D Dr. i c e ! . R e c e n t 1 > h a ? c s e n s e e n b> R o n a l d D c d a r i o , M.D. f c - i s A g e n t O r a n g e p - - c o l errs, a n d h a s b e e n s e e n b y e n u m e r a b l e d o c t o r t . the- V'.A. Add: Xi o n e ! 1 y , Pi a.i n t i -f f ad h i s t o n s i l s o u t a i a g e 4 o r s c a t F : t c c-er a 1 d Me - c y H c - s c i t a l . P e r h a p s t : -i s a m e p h y s i c : a" t h a t d i d h i s e=- *. F'i a i n t i - f - f s t i l l h a s h l s- append!Opthamologist, i s D r . C - o r o c o , F.o o o r o u g n Medical B u ild in g . Has been seen by Dr. Barbara R ockett i n i t i a l l y w ith t h e V.fi. , and her p r i v a t e p r a c t i c e at Philadelphia In stitu te. 11. With r e s p e c t t o e a c h i n j u r y , i l l n e s s , d i s a b i l i t y , or o t h e r p h y s i c a l or m ental c o n d i t i o n i d e n t i f i e d in r e s p o n s e to Interrogatory 10, id e n tify each such condition that y o u c l a i m o r b e l i e v e w a s c a u s e d b y o r a r o s e o u t o-f exposure to Agent Orange, 2 ,4 -D . 2 ,4 ,5 - T , d io x in or some com bination t h e r e o f , and s t a t e s e p a r a te ly as to each: i See #11 fo r Agent 0 - a n g e p o i s o n i n g prob lem s, a.' a d e s c r i p t i o n o f e a c h s y m p t o m ; I c) th e d ate and manner inwhich each such symptom f i r s t m a n i f e s t e d i t s e l f or was made known t o you; and enO r*rj 1 tCi <J * * s Hc>c! se-vC-re stomach pains at base- camp in Phuc-Vinh requirino reassignment ir o n t combat arid treatment. Skin growths, including a basal cell carcinoma, shingles, chi or acne, elevated porp.'-.et in level. Numbness: in hands and -feet, pains in joints. pesine along the Lack. muscle pains concentrated in his legs, but all through oodv; muscle spasms all through Jr-ody: p: ne and needles sensations in scalp, pains that -feel as. if hot needles are being inserted in hie. body, revere rearti one to beer and alcohol; fatigue, chest pai ne, peripheral neuropathy, eyes are sensitive to Ii. i unnatural aging of nails; Nausea; Numbness on the la-ii side of his jh. High blood pressure, nervousness, ds> :essi on, other associ ated mental problems, greater sus espiib:1 1 1v io di seas* s , illnesses, and ange-*. t s . :rromr: a , delated stress syndrome; c e d i n e in p 1 sir i. ::th . ii f i ci.l i-, wi th memo- - and l o~ :ent: at ;on .. an. :e t . ri oslie-es. that the symptoms -firs". became when he auffe-ed severe pains in the field, and was trc-a.eJ in the field f or toils and growths on h_ = r- k*". Jd-.'tit v each drug or m e d i c a t i o n ever used or nal.en by y c . . ir-cl udi *i c. but not limited lO, i l l e g a l , rec-eat i ona.i arc! O'!"-the-: ountov cirugs. and f o r each drug or fTiircicat io n , set forth the following with respect to each: a ' the -brand name, generic name, or "street nans" of the drug; b' the date of use: c > the amount usee during each period o f use; d> the name and address of the physician, i f any, who prescribed the drug; e ) a description of reasons for your u s e o f t h e drug; and f> whether you have ever received any medical treatment or counseling in connection w i t h your use of drugs. Marijuana, de.edrine pills,, tai.en in Vietnam, net before 12378 9 ; or a f te r . The d e x e d r i n e was handed o u t by t h e Army'. In a d d i t i o n . P l a i n t i f f had p r e s c r i b e d -for him a t r a n q u i 3i : er in t h e 7 0 ' s. It was p r e s c r i b e d by a p h y s i c i a n w*- c s u t s t i l u t e d -for h i s - f a m i l y p h y s i c i a n , D r . Hu*"loc* . For a p p r o x i m a t e l y one year d u r in g 1980 P l a i n t i f f was on fje r d il p r e s c r i b e d by V.A. p h y s i c i a n s . A d d i t i o n a I d r u g s i n l c u d e d T y l e n o l for m u s c l e p a i n s , p e n i c i l l i n ; \ : t a.-.i n B 1 2 -for s h i n g l e s . The V.A. a ls o p rescrib ed a high regimer of vitamins including vitam in B a n d -f p i i c : : d . I d e n t : -f . e wi t h r5s; . *f . ; i 2-. c o n d a t i o n tnat you h a v e e v e r s. . . c h c. o : d ~ o n : had, and a s i a 4. < i n a c : - : : dur i r,g w r j c h >. c-u h a d t h a t c o n d i i o n ; t d e s c r : h s f - . c i f or. o s i s o r m e d i c a l t r e a t m e n t y o u r e : e i . t d -'c- i n a c o n d i t i cr , ano s t a t e : ; ) .!1 11It..?. r r ' .-d a d d r e s s o f t h e p e r s o n ! a n d " - ~ V *. h c c i e g n o e i s or t r e a t m e n t ; i / ill! t h e r , ; : ; a-id a d d " e s s of the m ed ical i n s t i l . C*1\ & > a t w h i c h y Ou. w e r e d i a s - r. t r e r t e c i ; t h e C; s' 1 D*f t h e d l s c - n o = i s o r t r e a t m e n t i v i a n d t h i s e - f - f e c t o-f t h e t r e a t m e n t . The sh in c o n d itio n s t a r t e d in Vietnam and has continu ed s p o ^ a d i c a l 1> t o t h e p r e s e n t t i m e . It included pustules, b o ils, s h i n g l e s . chi or a c n e and o t h e r s k i n g r o w th s. T r e a t m e n t i n c l u d e s l a n c i n g o-f t . he b o i l s i n V i e t n a m , c o n t i n u i n g t r e s t m e - n t i n t h e U n i t e d S t a t e s , r e m o v a l o-f b o i l s , r e m o v a l o f c y s t s , a n d s u r g i c a l r e m o v a l o-f t h e g r o w t h s a t Ro.: t o** o u g n M e m o r i a l H o s p i t a l u n d e r G e o r g e M. W i l s o n i n 1 9 7 5 o" 7t-, 1 9 7 9 or 8 0 , and 1 9 8 1 . P l a i n t i f f p r e s e n t l y h a s some g r o w th s on h i s l e f t l e g which w i l l require surgical removal. In a d d i t i o n , B a s a l c e l l carcinom a on t h e r i g h t s i d e of th e P l a i n t i f f ' s head was rem oved by Dr. W ils o n i n 1975 or 1976. ! 14. If you have ever smoked c i g a r e t t e s or o th e r w is e used tobacco product: l 10 ) j denta fy each t y p e of product -!e.g., c ig a r e , c io a r e tte s , chewino tobacco': b > identify the time period during wh;c that tobacco product; c) ident if y the- amount use:. c-n a d ai1 y : e .<, g . . pac 1;s of c igar et tes/dav': and d) state whether any physician c* other car e pr of es s ion a 1 has- s-y er ad-ised y E t OD c-r reduce your use of cigarette ccher t ci. acc p c-c' u c t s . arid, i* so. r. --.'a c r c a c dr t.-s*.; o f i f ie .J: - v Ei 1 *. c ' i C(* t - c;<' P--c- era: on a; =".0 Cic-t o ac v c a par1, ar c a h a ,,f a o a . . O n c e ;a-: when ne oot out c-* the sa* ce ar c r i t h e 1 a t a = . ear] , t- ;7=, resumed i-i-i-k:no rier = :: s . p ; : r e : i r n a t l e y 5r' amoi ! as be-f or e. Dr. Coc-anc- n a s 5V3 s e d h i m etc. sTiC-i'to ci qe-e c e . le. I* i h* .*e ?. e?r c o n s u m e d or druni a l c o h o l . s c a l e e a r a r a i a l , i - i t h r e s p e c t t c e a c h t y p e o-f a l c o h o l ' " e . g . , l i q - . - o r , b e e r , wine, e t c . ) c o n s u m e s : a.1 at what age consumption began; fc> the amount and -frequency o-f such con sump 11 o n ; c) i-f consumption ceased at any time, the reasons for such cessation and the ree.sons -for. an. resume i io n ; and d) whether you were e v e r h o s p i t a l i c e d or i n s t i t u t i o n a l i z e d -for a l c o h o l u s e , or a d v i s e d t o l i m i t o r s t o p a l c o h o l u s e , a n d , i -f s o , s t a t e t h e n a m e ( s ) o-f e a c h s u c h h o s p i t a l o r i n s t i t u t i o n or m e d i c a l p r a c t i t i o n e r who t r e a t e d or a d v i s e d you. F la n t if f consumed b efo re se -v ic e in Vietnam. In Vietnam h e c o u l d d r i n k a. s i ; . - p a c k o-f b e e r . After Vietnam 11 12880 c o n c u m p t : o n o f b e e r c e n s e d t h e FI a n t i f f t o b e c o m e i l l a n d produced severe headaches. A d v ised t o d i s c o n t i n u e when on N a r d i1. If an. i n s e c t i c i d e s ( e . g . , C h lordane, Lindane, DDT/, r o d e n tic ides ( e .g ., rat p oison), in sect r ep ellen ts ( e .g ., DEET) c r o t h e r p e s t c o n t r o l c o m p o u n d s w e r e e v e r u s e d by y o u o-- o t h e r s a r o u n d y o u r l i v i n g o r w o r k i n g q u a r t e r s , s ta t e as to each: a- t h e b r a n d name- o r g e n e r i c n a m e o f t h e c h e m i c a l ; t 1 s d e sc rip tio n cf the chemical ( e .g ., ponder, liq u id . - L..1r.2c <j p l :.*i :*- ii.-t container for the chemical *. i:'t s' r->-. markings) - -:--:- cats r~>- i-si. e. tr.-s m-fthod of r-pp-1'icat ion ; * - t hi. pla-.s- it wii appl iecJ: r t -, e frequency of appli cation : and r.i 'T,r-1her you ex per ienced any adverse reaction to comp :<Ltnd and., i- so, describe the reaction. P lain tiff h as never a p p l i e d or know ingly used any c h l o r d a n e , l i n d a n e . DDT. He h a s u s e d D e c o n m o u s e t r a p s i n h i s h o u s e or- s e v e r a l o c c a s i o n s . While in Vietnam i n s e c t r e p e l 1ant was used by P l a i n t i f f i n f r e q u e n t l y , f o u n d o u t i t d i d n ' t w o rk . He was a l s o g iv en i n s e c t repel 1ant t o rub on h i s hands and neck area, which was i n f r e q u e n t l y u se d . The c a n s were o . d . , g r e e n c a n s a b o u t 6 - 8 in c h e s t a l l , a p p r o x im a te ly 3 i n c h e s and looked l i k e a shaving cream can. The rub-on rep el 1ant came in a c l e a r p l a s t i c b o t t l e about 2 i n c h e s , h ig h , rounded r e c t a n g u l a r shape- w i t h b l a c k l e t t e r i n g . V I . MILITARY SERVICE JL&o 17 State wit!-i respect to /our militar / service: a ' t h e b r a n c h o f t h e ar med s e r v i c e o i n w h i c h y o u Sic*- \ e-::- ; b> t h e i n c l u s i v e t a t e s o f y o u r s e r v i c e ; c : th e in c lu s i ve dates of se r v ic e i n or near Vi etna*!;: d' / z. t he- name- c-f e a c h m i l i t a r y u n i t t o w h i c h were a ss ig n e d w h ile se rv in g in or near 1V i - t - a ' : a r i d t h e d a t a s o r : n g wh i c h y o u *-;.t,,' s f.s c r i e d! t o e a c h s u Ch Uiii ^ S--T you t h e T i r , . . s,:.t l o c a t i o n o f e a c h c-i a c e o r area-. a. w- i . vou were physically r''eEer*t- in or *.te-ar Vi e I n s m a n d the clr.lt; du'~: n g w h i c h >ou `-- e p:- eter i at east, eucv: pi act. or area.; c.".." (Tir.ee. i a t e suc-e r v i ec-r u f f i c a r ' s name a n d r e - r. while /in Vietnam, a* d u - th e t -pa c-f d is c h a r g e \ oc r e c e v e d triced Eli-tee Arn.-, 9.-'1A :'6 - 9 / 1 7 t-E. February IS. !'&" to I-i, 1568. First Ir.-frantry Division, Cr-cp-mv E, 0 5 ''=+ Batcal ic-n, 26th In-fa.ntr First Brigade. For a few months he was attached to headouarters o-f that unit. He a r r i v e d i n V i e t N'arr. o n t h e 2 5 t h o f F e b r u a r y , 1 ? : " a t E-:e-r. H o e . FI 5 j n t : f-i ? e g r o u p s t a v e d a t t h e r e p l a c e m e n t d e c o t -for -5 or 5 d a v s trier- t h e y w e r e s p l i t i n t o i n d i v i d u a l u n i t s and G eo r g e 's u n it wee s e n t t o th e F i r s t In-fantry D iv is io n at D i o - - . A- ^t e r a we e ! t o a w e e k a n d a. h a l f P l a n t i - f - f w a s s e n t t o h i s u n i t a t FTruc V i n h . He w a s " t h e r e - f or appro:-: i m a t e ! y 3 t o A weel e . Then h e j o i n e d h i s u n i t i n quan Lo: w h e -e he rem ained in o p e r a t i o n s i n t h a t a r e a , i . e . , the Iron T r i a n g l e , L o c N i n h , a . n l o c , L a i Kai , B o i L o i W o o d s , Ph.u L o i . so n g B a i , Nue Boi B ia ( E n g lis h name B lack V ir g in M o u n t a i n ) i n T a y n i n h P r o v i n c e , P h u c Wa.i. T h e r e a f t e r G e c i - g e l e - f t Qua.n L o i a n d w e n t t o K i o n t h a n b a c k t c t h e r e p l a c e m e n t c e n t e r n e a r De n Wa.i t h e n t o T o n S e n N h u t a: i-p or t t o O a k la n d , C a l i f o r n i a . Captain Pederson; th e r e a fte r Captain Smith; F ir st L i e u t e n a n t S m ith . The E5 squad l e a d e r ' s name was S s ^ g e r . t J ^ B D: a.c. T h e b r i g a d e c o mma n d e r w a s L i e u t e n a n t C o l o n e l 33 A] e - e.r-de?- M. H a i g , J r . e n d t N e r e s U e r C o l o n e l Ho-f-fman. Ho n e * ' al. 1 e d i s c h a r g e - . 1 3 . W i t h r e s p e c t t o e a c h illness. injury, wound o r other medical z'~ psychological condition experienced pv you during vc-ur a :I-it ar y service m or near Vietnam, state: i Kc c a t e o ' y o u r i l l n e s s , i n j u r y , w o u n d , o r other medical or psycho! og: cal co n d itio n ; the illn ess p s . c !c I o g i c err c-f i n j u r y , wound, or c ondi t i o n , ir.r 1. y t` fT.^rV' i t hfc i ] I r*e-s s . i n j u r ' , - , w o u n d , o r e t h e r p e y c h o l o o i c a 1 c c n d i t : tins tht *>.-- and 'au,!- o-f t:a- person to whom you -first r t-. r - .* n * r . i i 1 n e s s . i. 1 ; y . w o u n d , o r o t h e 1* m e d i c a l o- j- = . ; i g i cal c o n d i a : . ( i f a n y o n e ! : 6> s tnr-.t VO*. f l : * S t ! ep-or t e d t h e i l l n e s s . i n j L T > , . c o t h a- c a. -, c h c l o g i c a l o r m e d i c a l c o r d : t : ori ; t h e r a - f c . r a n k a.r-d l o c a t i o n o-f e a c h p h y s i c i a n c** h e a l t h ca* e p r o - f e s s i c n a l w h o t r e a t e d vou** i l l n e s s , i n j u r y , w o u n d . O'* o t h e r p s y c h o l o g i c a l o r medical c o n d it io n , in c lu d in g th e d a te s and p la c e s o-f t r e a t m e n t , a n d a d e s c r i p t i o n o-f t h e t r e a t m e n t vc-u. r e c e : u ? o : a n d g t Lie -ar-e a n d l o c a t i o n o-f e a c h h o s p i t a l o r o t h e r h ea lth ca^e -fa c ility which tre a te d your psycho! og i c a l o r m e d i c a l c o n d i t i o n , t h e d a t e s o-f t r e a t m e n t , a n d a d e s c r i p t i o n o-f t h e t r e a t m e n t t h a t y o u r e c e i v e d . T h e s t o m a c h p r o b l e m a r o s e i n a p p r o x i m a t e l y O c t o b e r o-f 1 9 6 7 and t h e s h i n p r o b l e m s were- s e e n monsoon s e a s o n i n V i e t n a m a r o u n d m i d - s u m m e r o-f 1 9 6 7 . W h i l e P l a n t i - f - f w a s a t an L.F. p o s i t i o n o u t s id e h i s p e r im e te r and he was s tr u c k i n t h e l i p b* a b u l l e t . This went unreported and no p u r p le h e a r t was r e c e i v e d . F 1 a i n t i -f1 ' s s t o m a c h a n d s k i n p r o b l e m s h a v e b e e n d e s c r i b e e . FI a: r,t i-f f was - f i r s t t r e a t e d a t Auan Loi and t h e n wa = s e n t t c Fru. c V i n h . o O 14 19. D e s c r i b e sn v e th e r medi c a t i on taker. by you d u r in g your m ilita r y service- ( a .g ., Dapsone. Chloroquine, Primaquine, P in o cta l), sta tin g as to each: * ) the brand ns-me or generic name o-f t h e m e d i c a t i o n ; b) the -form o* the medi cat ion ie.g.. p i l l , c a p s u l e , inject iori. ct i . ) ; c ) thi color, shape-, and size of any p i l l o r c a p s u l e taker; d'1 the reason? -for tal-ring the medication; the ne ms r".r rani: of the person's' who gave t'Oi- \ :at ion : f the dates .zv too! the medi cat ion; the and -; che medi c at ien ts.i en (e.g.. pills cay); r. w h i t h e r . a-per i enced a n y a d v e r s e r e a c t i o n t o t h e m e d i c a t io- s-r. if so. describe t h e r e a c t i o n . F l a i n t i f f t a:. *r or a n g e p i l l we e k l . a n d a w h i t e mj r = c fte n bctii d ie* - p the medics. P l a i n t i f f h a d r.o a d v e r s e r e s i t i j,ri t e a i t'-e*- . Was t a k e n b v P l a i n t i f f d u r i n g t h a s n t i r e t : me h e ws s i n Vi a t r . i u 2 0 . Sc a t e w h eth e r you e v e r r e c e i v e d a n y t r a i n i n g , i n s t r u c t i o n s . w a-nings or h e a lth and s a f e t y inform ation c o n c e r n in g h e r b ic id e s , d u r in g your ^m ilitary s e r v i c e , and id e n tify as tc each: a) th e d a t e s you r e c e i v e d th e fo r e g o in g ; b> t h e l o c a t i o n w h e r e r e c e i v e d ; c ) t h e name a n d r a n k o f t h e p e r s o n i s ) f r o m who i t was r e c e iv e d : d> t h e s u b s t a n c e o f a n y o r a l i n f o r m a t i o n r e c e i v e d ; and 123 15 e> t h e t i t l e . d ? t e , au th o r o r s o u r c e , and c o n t e n t of anv w r itte n m aterial r e c e iv e d . No 21. Set -forth w ith r e s p e c t t o each tim e you cla im t o have been exposed sc h e r b ic ies: a ) t he - d a 4. e o f t h e a l l e g e d h e r b i c i d e e x p o s u r e ; ' b! t h e t i r e c - ca>- o-f t h e a l l e g e d e:-. p c s u r e ; c- the _* :--T- ge on- ar-hjc ai or political refer e*-cs point ' .c .. hill, town, 3ending zone) to the pi m: e c-.- c-ieve you we-re exposed: a decor ir -- o-f the ie'-r c.in a.t the pi ace of a.lIeged e) a cie=c-ip: . c<i hot; the herbicide was being applied a .g ., helicopter, aircra-ft, hand, etc.); f> a. deec *1 1 1:rr o-f you'* activities at the time o-f alleged e co=-'.rs:. g) the n.a*irie- v o j believe your body was physically exposed tc the herbicide (e .q . , stin contact, inhalation, ingestion or swallowing), and, if you. belie-, -r- you were exposed by contact c>r. your shin, identify the areas o-f shin that cams in contact with the herbiciti; h ) t h e n a m e a**d r a n k o-f o t h e r p e o p l e p r e s e n t a t t h e < t i m e o-f a l l e g e d e x p o s u r e ; a n d i ) w ith r e s p e c t t o any d e cea sed proposed r e p r e - t s e n t a t i v e p i a i n t i -f -f , s t a t e h o w s u c h p l a i n t i f f w i l l d e m o n s t r a t e a n y o-f t h e i n - f o r m a t i o n . .-J-.A-'. r e q u e s t e d i n s u b p a r t s a.) t h r o u g h h ) o-f t h i s i n t e r r o g a t o r y , i d e n t i f y i n g a n y p e r s o n s w i t h such ;K , i n f o r m a t i o n who w i l l t e s t i f y a s t c s u c h p l a i n t i f f ' -s exposure to herbicides. iii 12335 \ 1 P l a i n t i f f was s u b j e c t e d t o h e r b i c i d e exp osu re t h e e n t i r e time he was in Vietnam. S p e c i ( i c c a t e s a n d t i m e s a r e p r e s e n tly u n a v a ila b le , e-.cept as to a spraying m ission which w a s c o n d u c t e - d a t F'huc V : n h , Ma r c h 7 , 3= r ~ . Plaintiff was consistently and repes t e d i - . i n p e r i m e t e r areas that had cS'iousiv been recent I v d e t o n a t e d ,,and h e repeated! ; saw the Vs einemese civil i a n a r my e m p l o y e e s 1spray a.round mess Lai Is, barrac hs. t e n t s a n d h o o t c h e s . Additionally, "thunder " bases- and t Qh wc. y 1 3 we r e defoliated for 1C!1 meters on each s: ds-. I n m i d - 1 9 6 7 , Pi ai nt iff 's bat all ion went to Lai La:, A i t e r h e l i c o p t e r drop off in lav N: nh Province, his t a t t a l i o n m a r c h e d through jung I e tn des 1 3n ati on i-,i1]to p . P i a.i n t i -f -f r e c a . i l s thr". theae- areas hs-:' ci; v sut s.tartce c*i - f r e s h l y d y i n g T t c w a s n o or e o a r i c u i a r l - c l o s e s * . geo-g** a p h i c a l o r p : t : c r ' r n-f c- s *>r e p c : n t o t h e r t h a - , t n s j u n g l e arid t h e Ks-e.r i 0 1 ; i s d a t PL.- c '.'3 rill a n d L-us." L e i a n d t h e I r c - n T r i a n g l e . Gec- e l s e a r s &! t o +01 i t . T h e t o r i * a i n i r. c 1 . r t ! j L-ng I t . i OK- *' 1 s *. l a n d s ? r i c e p a e d : e s ; !i.- c h e l i r r .r.'!>sr p 1 ar. t a t i o n e . C 1 ->!*& was t nr c u l t s !.3 n c o n t s c *. . . :rhalat:o n . ingestion and [`.` e peop-le- present irii udc-o Let 'voter, E 4 ; Staff Sergeant Ds so : Lieutenant Smith; Colonel Haig: Colonel Ho-f-fman; Captain Fede**sc-n: Captain Smith; enumerable otter soldier's names presently unknown.. ONLY I F YOU CONTEND THAT ANY OP YOUR CHILDREN HAS A BIRTH DEFECT CAUSED F 'r YOUR EXF n5UF:E TO AGENT ORANGE, 2 , 4 - D , 2 , 4 , 5 - T . DI OVI N OR SOME COMBINATION THEREOF, ANSWER THE FOLLOWING INTERROGATORIES. 22. I d e n tify the c h ild r e n th a t you have -fathered, in clu d in g name, d a te and p la c e of b i r t h of each such c h i l d , and th e name an d a d d r e s s o f e a c h c h i l d ' s mot he**. Tara C a th e r in e E w alt, 8 / 2 7 / 7 1 , Ro-.-boro.gh Memorial H o s p it a l, P h ila d e lp h ia . Mother S.hiela Ewalt. All r e s i d e t o g e t h e r . tX 0fVW 1 I d e n t i f y e a c h o-f y o u r c h i l d r e n whom y o u c o n t e n d h a s b i r t h or c e ~ e t i c d e f e c t s a lle g e d ! ' c ? u ie d by your e x p o s u r e t o 1Accent Ora n g e * . 2 . 4 - D . 2 , 4 . 5 - T , d i o x i n on s o m e o t h e r combi r.ai i on the* e o - f . and i d e n t f . : a) the d :rth or genetic defects- which you contend were caused by you- e :posure to Agent Or ar.ge, 2,4-D, die in. or some combi rial ior. thereof, and state the basis -for you- belief, including opinions o-f cip; physicians; b ' S.r- Z-i h o b . i - i h : = QC-r,ei i C d e f e c t s w h i c h t h e C h i l d cica! pr :-ct:1 ic-= arid modi Csi institution visited b the c :ld or in wrier, the child W s C f ift1-C TO* 1V.rpOr of consul tet ion. diagnosis, is. t- Si tmunt D * the*- irre. - the dates, = and ts - -c l. consul t s t : o n . di acr.usi =. .t: t c- t* Ti of each c n ld, Tr-i c-feie. nt ! r o w "; d e f e c t ? . r c 1 ud;.- e a r p r o b l e m s r e q - . i r i n g a i r "-' - r i t e '. . f o.** f i v e : r-r.ei e a - o p e ? a t i o n s , r a s n e s . pyl o*" i o s t e n o s i s a t b i r t h w h i c h " e o L ' i r t d c lo s e ttantion during -first th ree wee s of l i f e . Temper e . i d a n c e d by p e r s o n a l i t y c h a n g e s r e q u i r i n g p= . chu! c i i cal c o u n s e lin g . She was h , p e r - a c t i v e, and a l t h o u g h she- h a s t h e i n t e l l i g e n c e o f a - g i f t e d c h i l d . s h e doe? net wo-k c l o s e t o her a b i l i t y . -'She i s e a s i l y d i s t r e c t e d and has a rash or her a n k le s , w r i s t s and hands, l o c i s l i i e d ried sl-in which sometimes breaks, open, f l a r e s up and becomes i n f e c t e d . The s k in around her a n k l e s i s le a t h e r y . Whenever she becomes s i c k l y . which i s often , she complains of jo in t pain. F'h v s i c i a n s i n c l u d e D r . C c - n s u e l o S a u l k a . P e n n s y l v a n i a Medical C o lle g e . Henry Avenue, P h ila d e lp h ia - d e liv e r e d T a - a . The p e d i a t r i c i a n was Dr. J e a n Gal w i n , who i s p r e s e n t l y r e t i r e d . Dr. Joan H u -lo c l, Dr. S a bina, West Park H o sp ita l. 3500 block Conshohocken Avenue, P h ila d elp h ia . FA 1 9 1 3 1 . Her a l l e r g i s t i s D - . J e f f r e y G r e e n , C h i l d r e n ' s H o sp ita l, P h ila d e lp h ia . Present p e d ia tr ic ia n - Dr. Carolyn V e r ie r . C h ild r e n 's h o s p i t a l . Dr. Paul Honig for sk in problems at Children's. Latest skin doctor is Dr. Kol bl er.zer, Spruce Street, F'hi Iedel phi a. Dr. Cor or a teles cere of her e\ e problems - F>:o.'.borough Medical Center, piv'chc! ogi st is Dr . Annet te Lvcic*"i. School house Lane, F'h: ]adc 1phi a . Ht r1 1 -f. t-;r11 -rii e el'i chi Id of ee ch mother lder t if res;-or, =e t** Ini err c-gat l r\ I! and state as to each-: t`-f chi :-J' a - , hd"o:r Qc'tfc.` of birth and pi are o* t ;r . ir r3ud: ... Xlu`i- ra--.-.' ar,d addr ess of tr.s ! 111 :t . : c iKe* r ijc. i i-'` e de ] iver . oc cu.rrcd: a the p : nol- t e.-:1e toe mother during del _ er the child. 1:,ti ro;?- :.r n e p ' i f ? ^ = , c - . r Cj o : car*- m e t ho- i d e n t i f i e d in reI : d . ice -t : her brothers, c ts . urc 2es, cousins .orb i : j dr e-o. a.od : if a n y c-f the*- ere d e c e a s e d . s t a t e his or her age at the. i ime c.-f death end the time,- p i e c e end c au.s C'f death : b) idw.nt if y ea-rb. illness. disease, disability. or medic.a.1 cone j1 1 on trier had bv each: during his or her 1 i-fet jme which required pr o-fes si onel medical ett enl i or,; c) identify each medical practitioner and medical institution that treated them, and set forth the diagnosis o-f each, stating the same as to each relat iv e . Previously answered. See #S supra. <5 0 r' JL s-*' Wit!', respect. to each p e ganenc >. -for each motner lG'eiiti-fitd 3 r- '*f rEpori se to I r. p er- r oy a t o r y 2 3 < d / , d a t e : ivf i r l h e r t h ez mo X'. 1k. e r wi s e .p o = e d t o o r c o n t r a c t e d an v v i r a l o r t - + - '* Xa i l M e c t i c r o r d i s e a s e d u r i n g c s h o r 1 1 y b e t z i* p `l. h e p r e g n a n e > er. y G e r m a n m e e s l e = . f l u . e t L . . r,.* j f s o . ) Cjt- i"i u i t v t h e i r r f e c t i o n or : 1 3 n e s = . t he F`e 1 Od d u r i n g whi ch i t o c c u r r e d , an. - =n V m e d : c a \ ; rt:, r t r (rc ufist-Ti 1 u: \fS r, t h e r e f o r ; K-J-eths r j.'* c.' "J i'i- *. * t h C" V. u e>' .. ,i a I r. - --; i n c u r r e d a-r.y i n j u r y d u r i n g EO. c: i z r i be t h e i n j u r y , t h e . e a - * " r.g o r t r e a t i n g 'J ' - ' - '-r|'- c_*jw. wh . i c h t r e i c - - - - r... J - A! - - - . e ha d a n y v e n c - *a J. --. ._ V- . C- * - 4 i O, dCC. r r . z-e t r ;e d i E c - e s e , t h e t r i.a : ve-r:t *-e wf i ZC*. c*Tr>' *. l n i n u o r t r e a t i n g l~'~ = - ~ : f-' ir -" 7 a-. - i r - s t i t o p : o n e a.t w h i c h t 11 n . - "iv l : ; d: a i* r-s 1 1 c pr `- c e d v r e s . i n c l u d i n g , b u t 'rt j j Hi - t _- t 1*`. c l Z1:" j Tif i - --r a . r C,r p e l v i m e t r y , e i - n j u c f r t s i i 5. and/or ul t " a so--nd were u se d , i*c-. i e :-. r eh * -i -.* *.nt; c 1 & o- t h e p r o c e d u r e , d e s c r i b e t ''U pr C'Ce . * h e e a,' . n ; r>g or t r e a t i n g p h y s i c ; a * a n d ar, v 1 n = t : u l : o n e a t which, t h e p r o c e d u r e occurred: arc e whet he1- an. medical problems wi compl "cat ione areas during p- eg " ar- (e .g .. t o .emj a., and , it so, describe the pr obi eos c-*` cc-r-ij. Iicatior.s and the t>ai tment received. Fos. e i t i l i t - c - a n e a r l v mi = c a-- r i a g e a t t h e W o m e n ' s Medical Coll see i n 1970 and 1971. D iagnosis not c o n - f i r m e d . F i a : r . t i -f -f ' s d o n o t b e l i e v e t h a t t h e m o t h e r w a s e.-.posed t o or c o n tr a c te d any v ir a l b a c t e r i a , in-fectior. or d i s e a s e d u r in g or s h o r t l y b e f o r e t h e pregn an cy. Answer In ter r o g e io r : es 6 , 1". 14, 1 and 1 th af.fj,t'Ori re-spt. et le each mother Interi c ic ie r y 2~id). identified in response Noi cppj icebi e. to 2 5 . F o 1' e a c h m o t h e r i d e n t i -f i eci i n r e s p o n s e t o I n t e r r o g a t o r y 22 i d e n t i f y each and e v e r y pregnancy not r e s u l t i n g in a l i v e L-.'rth, anu : li.lt' w i t h r e s p e c t t o e a c h : 'i w h e t h e r t h e r e wa r a mi s c a n - i a g e a n d / o r >_{. eni r ri./uui. at*or l i o n . ar i d, i f s o . s t a t e t h e d a l e a n u dt.-i. c i i t - t h e r e a s o n f c*r t h e fiilr-. .1 dip!- and.- or s p e n t oi ic-vus a b o r t i o n arid i d e n t i f v any. e a n i i n i rig or t r e a t i n g p h y s i c i a n s , and any i n s t i t u t i o n s at which i t occurred; b ) i f th e r e sp o n se to a) s b o v E is a f f i r m a t i v e , s t a t e whether you contend th a t such m isc a r ria g e and sp o n ta n e o u s a b o r tio n was caused by your e x p o s u r e t o A g en t O r a n g e , 2 , 4 - D , 2 , 4 , 5 - T, d i o x i n , o r some combi nati on t h e r e o f ; c) whether th e r e was a v o lu n ta ry or t h e r a p e u tic a b o r tio n , and, i f so , s t a t e the' d a te and d e s c r ib e the reason for th e volu n tary or th e r a p e u tic a b o r t io n , and i d e n t i f y any ex a m ining or t r e a t i n g p h y s i c i a n s , and any i n s t i t u t i o n s a t which t h e a b o r tio n occu rred ; and i f the- r e s p o n s e t o c> a b o v e i s a f f i r m a t i v e , s t a t e whether you contend that such voluntary t h e r a p e u t i c a b o r t i o n was c a u s e d or n e c e s s i t a t e d by y o u r e x p o s u r e t o A g e n t O r a n g e , 2 , 4 - D , 2 , 4 , 5 --T , d i o x i n , or somie c o m b i n a t i o n t h e r e o f . or Dated: Carle Place, New York January 14, 1984 12390 PLAINTIFFS' MANAGEMENT COMMITTEE v'x- B DAVID J. DEAN, ESQ. DEAN, FALANGA & ROSE, ESQS. One Old Country Road Carle Place, New York 11514 / c i t \ . o n o D O Defendants' interrogatories to Plaintiffs dated December 22, 1983 and Plaintiffs' answers thereto dated January 16,1984 12891 Defendants' Interrogatory 1. Separately as to each person identified as required by Paragraph "1" of Pretrial Order No. 65, specify each illness or injury you contend was caused to him or her by exposure to Agent Orange and the date of onset of each such illness or injury. Plaintiffs' Response 1. See answers to interrogatories filed as to each plaintiff on January 16, 1984. Defendants' Interrogatory 2. Separately as to each p e r s o n .referred to in Interrogatory 1 and each illness or injury specified in your answer to that interrogatory: (a) specify each component, ingredient or impurity of Agent Orange you contend caused or contributed to each such illness or injury; Plaintiffs' Response 2. (a) 2,3,7,8 tetrachlorodibenzo-p-dioxin ( T C D D ) , dichlorophenoxyacetic acid (2,4-D), trichlorophenoxyacetic acid and tetrachlorodibenzofuran (2,3,7,8-TCDF) and all other isomers of polychlorinated dibenzo-p-dioxin, of which TCDD appears to be the most hazardous. These chemical compositions are all hereinafter referred to as "material". -2- Defendants' Interrogatory 2. (b) State all facts as to the amount, manner, type and dates of exposures to Agent Orange, any component, ingredient or impurity of Agent Orange or any other substance you contend caused or contributed to each such illness or injury; Plaintiffs' Response 2. (b) Such facts as are known concerning his exposure by each plaintiff have been set forth in their answers to interrogatories filed as to each plaintiff on Jan u a r y 16, 1984 . -3- Defendants' Interrogatory 2. (c) State all facts as to the amounts and routes of absorption and manner and rates of elimination of Agent Orange or any component, ingredient or impurity of Agent Orange or of any other substance you contend caused or contributed to each such illness or injury; Plaintiffs' Response 2. (c) No plaintiff has sufficient knowledge as to the amount of material which be absorbed, or the routes and manner of its absorption. Suffice it to say that each plaintiff absorbed sufficient material to produce his illness or injury, or to produce the untoward side-effects it did in his children. The plaintiffs like-wise have no information as to how much material was eliminated from their systems or what amount still remains therein. -4- t I ^to-v OQ K0 Defendants' Interrogatory 2. (d) Fully describe each scientific theory upon which you base your contention that exposure to each component, ingredient or impurity of Agent Orange caused or contributed to each such illness or injury; Plaintiffs' Response 2. (d) These theories will be a matter of presentation in the expert witness statements to be filed by the plaintiffs on J anuary 23, 1984. -5- Defendants' Interrogatory 2. (e) State all facts as to the medical, military and occupational history of each such person. Plaintiffs' Response 2. (e) The pertinent facts are that each veteran plaintiff was p h y s ically present in South Viet N a m and was exposed to the material in some amount through any or all of several methods. The medical history of each person is available through the medical records of each plaintiff which are being produced as rapidly as they become available and which plaintiffs have authorized the defendants to obtain. To the best of the knowledge of each veteran plaintiff, no occupational history is relevant because there was no known exposure to the material by any verteran plaintiff other than in South Viet Nam. 1239? -6- Defendants' Interrogatory 3. Do you intend to support your claims as to the persons referred to in Interrogatory 1 with evidence that exposure to Agent Orange caused any illnesses or injuries other than those illnesses or injuries specified in your answer to Interrogatory 1? If so: (a) specify each such other illness or injury; Plaintiffs' Response 3. (a) Chloracne; porphyria cutanea tarda; hyperpigmentation; hyperkeratosis; hirsutism; asthenia; weakness in low expremities; loss of strength; easy fatigability; fatigue; headaches; peripheral neurophathy; polyneuropathy; intolerance to cold; other neurological deficits; irritation to eyes; impairment of sight; impairment of hearing; impairment of smell; impairment of taste; loss of weight; loss of appetite; anorexia; loss of sexual drive; sleep disturbances; orthostatic hypotension; abdominal pain; nausea; vomiting; diarrhea; other gastrointestinal disorders; nerasthenia; depression; violent behavior; other psychobehavioral disorders; myocardial infarction; atherosclerosis; other cardiovascular disorders; liver damage; pancreatic dysfunction; kidney disorders; urinary tract disorders; pulmonary pathologies; other respiratory disorders; 12893 -7- fat metabolism disorders; carbohydrate metabolism disorders; cholangiocarcinoma; other liver cancers; kidney cancer; bladder cancer; pancreatic cancer; colon cancer; stomach cancer; other gastrointestinal cancers; lung cancer; fibrosarcoma; leiomyosarcoma; liposarcoma; rhabomyosarcoma; myofibrosarcoma; neurofibrosarcoma; fibrous histiocytoma; retroperitoneal neurogenic sarcoma; fib?" sarcomatous mesothelioma; other soft-tissue sarcomas; leukemia; angiosarcoma; other blood cancers; hepatoma; lymphoma; squamous cell carcinoma of skin; other skin cancers; thyroid cancer; other glandular cancers; cancer of tongue; cancer of hard palate; other cancers of mouth, chronic lympphocytic leukemia; various brain cancers; ischemic heart disease; lung fibrosis; loss of body weight; loss of lymphoid tissue; loss of thymus tissue; sensitivity to infections; immune system disturbancees; brain cancer; multiple sclerosis; testicular cancer; DNA disturbances; RNA disturbances; skin eruptions and cysts; slowing of nerve impulses; hypertension; elevated blood lipid levels; elevated cholesterol levels; prediabetic and diabetic states; abnormal cell proliferations; organ enlargements; cellular atrophy; decreased cell proliferation; birth defects in offspring; miscarriages; increased white blood cell counts; elevation of eosinophil; decrease in IgM and IgD; decrease in B-cell and T-cell capabilities; skin rash; scalp tumors; aching muscles; bleph a ro-conjunctivitis; porphyria. This list is not meant to be total or exclusive. 8- - 12399 Defendants' Interrogatory 3. (b) Fully describe each scientific theory upon which you base your contention that the occurrences of the injuries specified in answer to Interrogatory 3(a) support your claims as to the persons referred to in Interrogatory 1. Plaintiffs' Response 3. (b) See answer to 1(d) 12900 -9- Defendants' Interrogatory 4. Separately as to each illness or injury specified in your answers to Interrogatories 1 and 3(a): (a) State the m inimum amount of a single exposure to and the minimum amount of a single absorption of each component, ingredient or impurity of Agent Orange y o u contend causes or contributes to such illness or injury; Plaintiffs' Response 4. (a) This question cannot be answered because it contains an invalid assumption that the amount of the material which produced the harm in any given case was the result of a single exposure and a single absorption. Each plaintiff contends that the totality of the material and/or any part thereof to which he was exposed and which he absorbed was what caused the harm he experienced. - 1 0 - 12301 Defendants' Interrogatory 4. (b) State the minimum amount and minimum number of multiple exposures to and the minimum amount and minimum number of multiple absorptions of each such component, ingredient or impurity you contend causes or conributes to such illness or injury; Plaintiffs' Response 4. (b) This question cannot be answered because it asks for data which has never been satisfactorily investigated, since there has been no true epidemiologic study in humans to determine whether there is a no-effect level for the material. Given the fact that the material appears to b io-accumulate in humans, minimum levels for exposure as to amount or times cannot be given with precision, nor need they be. The same is true with absorptions. Obviously, each plaintiff contends that the total exposure and/or any part thereof he had to the material in South Viet Nam was responsible for the har m caused him. -11- 12302 Defendants' Interrogatory 4. (c) State what you contend is the minimum time interval between exposure to each component, ingredient or impurity of Agent Orange and the onset of such illness or injury; Plaintiffs' Response 4. (c) This question cannot be answered as phrased, since it asks a medical question in a legal context. The answer will vary depending upon whether the question asks for the first cellular or pathologic illness or injury, or the first diagnosable illness or injury, or the first symptomatic illness or injury of which the individual is aware. If defendants will define what sort of latency period they are referring to, plaintiffs will endeavor to give a more specific response. In any event, such information can be obtained and clarified in the depositions of plaintiffs' experts which will be taken. 12303 -12- Defendants' Interrogatory 4. (d) Fully desc r i b e each scientific th e o r y upon which you base your contention that exposure to each component, ingredient or impurity of Agent Orange causes or contributes to each such illness or injury. Plaintiffs' Response 4. (d) See answer to 2(d). \ -13- J1L9Kt 0 0\J4M- Defendants' Interrogatory 10. Do y o u intend to support your claims as to the persons referred to in Interrogatory 1 with evidence that any persons sustained illnesses or injuries by exposure to substances other than Agent Orange? If so: (a) identify each such person; (b) spe c i f y each injury or illness you contend he or she sustained and the date of its onset; (c) s pecify each substance you contend caused each such illness or injury; (d) state all facts as to the amount, manner, type and dates of expos u r e of each such person to each such substance; (e) state all facts as to the amounts and routes of absorption and mann e r and rates of elimination of each such substance by each such person; (f) state all facts as to the medical, occupational and (if applicable) military history of each such person; (g) state what you contend is the minimum time interval between exposure to each such substance and the onset of each such illness or injury; (h) fully describe each scientific theory upon which you base your contentions that exposure to each such substance caused each such illness or injury; 1 (i) fully describe each scientific theory upon which you base your contentions that the occurrences of the illnesses or injuries specified in answer to Interrogatory 10(b) support your claims as to the persons referred to in Interrogatory 1. Plaintiffs' Response 10. (a)-(i) The persons who may be referred to by expert witnesses are again generally part of statistical accumulations of cases and incidents. Plaintiffs simply do not have access to revelant individualizing data. The specific other substances will be set out in the expert witness summaries and by the expert witnesses in their depositions, but include at a minimum all the materials set forth in response to Interrogatory 2(a) above as well as other substances which are chemically and/or structually related thereto and/or produce the same sort of results. -26- 12 SOB Defendants* Interrogatory 11. Have you determined that any person referred to in Interrogatory 1 or identified in response to Interrogatories 5(b) or 7 was exposed to Agent Orange manufactured by a particular manufacturer? If so, identify each such pers o n and the manufacturer to whose product you have determined he or she has been exposed, and state all the facts upon which that determination was made. Plaintiffs* Response 11. Nn such determination has been made. 12307 -27- Defendants' Interrogatory 12. State whether plaintiffs contend that the prevalence rate of any illness identified in response to Interrogatories 1 or 3(a) is greater in persons exposed to Agent Orange than in other persons. If so, set forth: (a) a complete description of the population you contend was exposed to Agent Orange; (b) a complete description of the population against which you compare persons exposed to Agent Orange; (c) the increase in the prevalence of the illness in the population identified in (a) above that in the population identified in (b) which you contend resulted from exposure to Agent Orange; (d) the facts upon which you base your response to this interrogatory and the method by which you reached your conclusion. Plaintiffs' Response 12. (a)-(d) Obviously plaintiffs do contend that there is a higher incidence of the stated illnesses in persons exposed to the material than in the general population. General references will be made in the expert witness summaries and any specifics will be furnished in their depositions in response to appropriate questions. fOQO-S -28- Defendants' Interrogatory 13. State whether plaintiffs, or any persons acting on their behalf or at their request, have performed or are in the process of performing any tests, experiments, studies or analyses of any description that support plaintiffs' position or contentions or which they intend to introduce at trial. If so, for .each such test, experiment, study or analysis: (a) fully describe it and its results; (b) identify the substance involved, if any, the source from which it was obtained and when it was obtained; (c) identify each person participating in the test, experiment, study or analysis and state the nature of his or her participation; (d) identify all documents referring or relating to or resulting from the test, experiment, study or analysis. Plaintiffs' Response 13. (a)-(d) No such are contemplated. -29- Defendants' Interrogatory Plaintiffs' Response 14-16. No questions so numbered. -30- Defendants' Interrogatory 17. Identify each test, experiment, study or analysis not identified in answer to the preceding interrogatories which you contend supports any fact or contention stated in your answer to any of the preceding interrogatories and specify the fact or contention which the study or analysis supports. Plaintiffs' Response 17. See second sentence to response to 12(a)-(d). -31- <o jL c ^ 1 1 Defendants' Interrogatory 18. Except to the extent identified in answer to one of th preceding interrogatories, identify all documents that support your answers to the preceding interrogatories, that contain information requested by the preceding interrogatories or that you used or consulted in answering the preceding interrogatories. As to each such document, specify the interrogatory to which pertains. Plaintiffs' Response 18. Any relevant and appropriate documents as support the preceding answers, to the extent they are not part of general scientific and/or medical literature or publicly available reports will be identified by plaintiffs' experts in response to appropriate questions at their depositions. *2812 -32- Defendants' Interrogatory 19. Identify each person you intend to call as a trial witness to give evidence other than expert opinion as to any of the facts or contentions stated in your answers to these interrogatories. As to each such person: (a) state the substance of his or her testimony; Plaintiffs' Response 19. (a) To be supplied in expert witness summaries. 12313 -33- Defendants' Interrogatory 19. (b) identify each document you anticipate will be referred to in his or her testimomy. (The court directed that the information sought in Interrogatory number 19 be provided in connection with the Special Master's planned exchange of witness lists. Special Master's planned exchanges of witness lists. See T r . of December 12, 1983 at 24-26). Plaintiffs' Response 19. (b) See answer to 18. -34- w n :;: :5. district court f a s h ;:: r :ft :3CT OF n e w y 0 rk MICHAEL F. RYAN and MAUREEN RYAN , his $ spouse, individually and as parents S and next friends of their child, KERRY S RYAN, a minor: CHAP.L0T7F BLACKMON, as surviving spouse and as the personal $ representative of ORVILLE B. BLACKMON, (5 deceased, individually and as mother and next friend of their children, $ RF.BECCA BLACKMON, BRENT BLACKMON, VALERIE BLACKMON and KAREN BLACKMON; |S CAROLYN CHAMPION, as surviving spouse and as the personal representative of THOMAS B. CHAMPION, deceased, S individually and as mother and next friend of their children, THOMAS B. 5 CHAMP IO N , JR. , JOY CHAMPION and C DFDRICK CHAMPION; GEORGE FLA! 7 and C SHF.ILA EWALT, his spouse, individually S and as parents and next friends of S their child, TERA CATHERINE EWALT; (5 DAVID G. LAMBIOTTE; CAROL QUINN, as surviving spouse and as the personal representative of BRIAN T. OUINN, 5 deceased, individually and as mother c and next friend of their child, KEVIN S QUINN; DAN G. JORDAN and DONNA JORDAN, S his spouse, individually and as parents and next friends of their S children, CHAD JORDAN and MICHAEL JORDAN; EARLY ROBINSON and SHEILA ANN 5 ROBINSON, his spouse, individually S and as parents and next friends of $ their child, MICHAEL ANTHONY POBINSON; S WILLIAM SINGLEY and DIANE SINGLEY, his spouse, individually and as the sur- viving parents of their child, WILLIAM; 5 and STEVE ZARDIS; S S on behalf of themselves and all others 5 siit.ilarly situated, IS Plaintiffs s -v- S now CHEMICAL CON; A'-'Y, a pel evare cor- c C pcrat icn; MONSA.N 7'' COi.rCI-ATI C`:,a 5 DOCKET NO. 79 C 7^7 1Q Dr] awar i corpcrs; h : L : : ic , i n CORPORATE D, a Pel awo m c o: : c ra t ior,; T-H AGRICULTURE >. r:OT? :: ]r-: cr."p/-t:y , INC., a Delaware corporation: DIAMOND SHAMROCK CORPORATI Or:, a Delaware corporation; UNIROYAL, INC., a New Jersey corporation; THOMPSON CHEMICAL CORPORATION, a Missouri corporation, and THE UNITED STATES OF AMERICA, Defendants. t s $ $ RESPONSE TO THE COURT CONCERNING EXPERT WITNESSES COME NOW the Plaintiffs in the above entitled and numbere cause and in response to the order of the Court to furnish a list c expert witnesses by the 23rd day of January, 1984, would respect fully show the Court: I. The expert witnesses concerning general causation are beim furnished under separate cover by the Honorable Torn Henderson, o m of the Members of the Plaintiffs Management Committee. The Court should receive the list cf those experts, together with initial sum maries, under such separate cover. 11. With respect to the ether expert witnesses, your Plaintiffs would show that tirn.e and circumstances has made it impossible tc finalize the designs tier, cf those witnesses and to obtain summaries. r\ Howl vt r , youi j 1a i 1<, since the Court decided in Ft-[ terbe t tc set the care ic: *,:;:.l cn all aspects of the case, have proceeded with due diligence to make arrangments for the designation of such experts, in the categories hereinafter listed, and to have them pre pare initial summaries. We hope to be able to conclude our efforts in that regard within the next few days. As the Court knows, our time and attention has presently been occupied with the more pres sing matters of designating the Plaintiffs, obtaining the necessary information in order to finalize a designation of Flaintiffs, final izing the general causation witnesses and other matters to which the Court seers tc have given more priority. Therefore, we respect fully request the Court that we he permitted at U.i s time tc indicate to the Defendants the various areas of concern relative to which we will probably be designating expert witnesses and to permit us a few additional days in which to actually designate those witnesses and come forward with preliminary reports. Ill. The arc-as of concern relative to which we will in all pro bability be designating expert witnesses are as follows: 1. economist - tc testify concerning economic loss with, respect to the various Plaintiffs. 2. Clinical Psychcicist - to testify with respect to the mental anguish, intangible loss, and psychological ef fects cc :,ct rr;ino tc the various Plaintiffs. f-iicty Engineer - to testily with m card tc proper safety precautions and types of warnings that wouic have been proper under the circumstances of this case and other aspects relative to safety. Industrial Hygenist - to testify as to safety aspects of production, distribution and dissemination of such pr ducts in general and the kinds of protection that could have been afforded persons on the ground who were ex posed to the spraying of the Agent Orange. Hunan Factor Engineer - this expert will testify witr regard tc those kind of things, that should have b e t : forseen and/or anticipated by the Defendants in the manufacturing of their product, as to hew it would be used, as to any forseeable misuse, and the other human factor considerations that contribute to the equation of safe or unsafe practices. A team composed of a mechanical engineer, chemist, e botanist, a toxicologist and a chemical engineer tc lay out various alternative means of producing a herbicide tc accomplish the coal which the government sought, that is the defoliation in Vietnam, without the risk of harm and danger posed by the manufacture and sale of the product sold by the Defendants. This team will in all probability work together tc core ut with not only alternative rears of defoliation but alternative ways of process 3 rig :n a safer n.anner the products specified. An expert on governmental authority, lines of authority and responsibilities. This person will testify with respect to various executive orders, statutes, direc tives, regulations, and practices of the various g o vernment agencies, which relate to the lines of auth ority and as to who had the ultimate legal authority to make decisions with regard to the use and continued use of Agent Orange in Vietnan and with regard to who had authority to negotiate spec 1 fications. Statistician - to provide us with various statistics with regard to exposures, number of veterans serving in Vietnam, and other statistics relavant to the var ious factors of the case. A expert on exposure - to utilize the Erbst tapes and maps, and other information from the government and put together a profile of what amount of chemicals was sprayed where, at what tiir.es and on what occasions - that is tc provide the jury and the Court with an organized summary of exposure opportunities. Financial analyst. To testify, concerning punitive damages, about the profits rrade by the Defendants off the sale of the Agent Pi ange to the government end to provide ether financial analyser as may hi relevant. 11. All medical doctors who may have treated any of the Plaintiffs. It is our understanding that Mr. Henderson will be providing summaries of medical records which will indicate the hinds of treatment and opinions of the various treating doctors. However, to the extent that those are not sufficient we will be specifying in more detail those treating doctors we plan to call as witnesses and providing any further summaries that may be required by the Court in that regard. 12. Employees, past and present, of the Defendants and the Government, who may be able to testify about any of the above matters. IV. Plaintiffs recognize their responsibility to provide these names and summaries as soon as possible. Plaintiffs assure the Court that they will be provided in sufficient time for the Defendants to take the depositions of these various experts and to obtain counter experts of their own if it is their desire to cc sc. Flaintiffs would show' that no prejudice will be sustained by either party to allow an additional reasonable time in which to provide the names cf these expert witnesses and sumrriaries in regard thereto. 12320 WHEREFORE, Plairtili* urut the Court tc grant such exte s ion of t i m e . Respectfully submitted, PLAINTIFFS MANAGEMENT COMMITTEE Stephen J. Schlegel, Esq. SCHLEGEL t TRAFELFT One North LaSalle Street Suite 390C Chicago, Illinois 60602 Thomas Henderson, Esq. BASKIN & SEARS Frick Building - 10th Floor Pittsburgh, Pennsylvania 15219 Phillip E. Provn, Esq. HOBERG, FINGER, BROWN , COX i, MOLLIGA 703 Market Street, 16th Floor Sar. Francisco, California 94 1C David Dean, Esq. DEAN AND FALANGA One Old Country Road Carle Place, New York 11514 Stanley Chesley, Esq. WAITE, SCHNIDER, BAYLEFF f, CHESLEY 1318 Central Trust Tower Cincinnati, Ohio 45202 N. R. Peterson, Esq. GREITZER 6 LOCKS 1500 Walnut Street, 22nd Philadelphia, Pennsylvania Floe 1910 John O'O'-'inn, Esq. O'QUINN, HAGANS i WETTM.AN3200 Texas Commerce Tower Houston, Texas 77002 Newton B. Schwartz, Esc. NEWTON B. SCHWARTZ, P.C. 723 Main, Suite 325 Houston, Texas 77C:? 1m i . t o' , Kuss-j ewh, j t t , Lsq. l ;.: o r n c r s of bekton KUS5LEWHITF, INC. 609 Fannin, Suite 517 Houston, Texas 77002 B y : i X >-n-TT Benton Musslewhite 12322 -e- CFKTIFK'ATf OP SFKV1CF I hereby certify that a true and correct copy of the foregoing pleading was forwarded, via Courier, on this the 21st day of January, 1984, to the following: Morton B. Silberman, Esq. CLARK, GAGLIARDI i. MILLER The Inns of Court 99 Court Street White Plains, New York 10601 Wendell B. Alcorn, Jr., Esq. CADWALADER, KlCKERSHAM b TAFT One Wall Street New York, New York 10005 John Sabetta, Fso. TOWNLEY k UFD1KE 405 Lexington Avenue New York, New York 10174 William Krohley, Esq. KELLEY, DRYE & WARREN 101 Park Avenue New York, New York 10178 David R. Gross, Esq. BUDD, LARNER, KENT, GROSS, PICILLO & ROSENBAUM 3 3 Washington Avenue Newark, New Jersey 07102 Thomas A. Beck, Esq. ARTHUR, DRY & K A L I S H , P.C. 1230 Avenue of the Americas New York, New York 10020 Arvin Maskin, Esq. DEPARTMENT OF JUSTICE Safeway Building Rocn 904 D Washington, D.C. 20530 Howard Lester, Fsq. LESTER. SCHV.'A B , KATZ i DWYER 120 Broadway New York, New York 10271 Stephen J. Schlegel, Esq. SCHLEGEL & TRAFELET, LTD. One North LaSalle Street Suite 3900 Chicago, Illinois 60602 Leonard Rivkin, Esq. RIYKiN, LEFF, SHERMAN & RADLER ICC: Garden City Plaza Garden City, New York 11530 Thomas Henderson, Esq. BASKIN fc SEARS Frick Building, 10th Floor Pittsburgh, Pennsylvania 15219 Victor J. Yannacone, Jr., Esq. YANNACONE i YANNACONE Post Office Box 109 Patchogue, New York 11722 David Dean, Esq. DEAN AND FALANGA One Old Country Road Carle Place, New York 11514 Sol Schreiber, Esq. Special Master MILBERG, WEISS, BERSHAD i SPFCTHRIE One Pennsylvania Place Peon 4915, 4Sth Floor New York, New York 10019 I& co -9- Judy Spanier, Fsq. SHEA i, COULD 3 3C Madison Avo m u 15th Floor New York, New York 10017 Paul Esposito, Esq. LEWIS, OVERDECK fc FURMAN 135 South La Salle Street Suite 1060 Chicago, Illinois 60603 Stanley Chesley, Esq. WAITE, SCHNIDER, BAYLEFF f. CHESLEY 1318 Central Trust Tower Cincinnati, Ohio 45202 John 0. O'Quinn, Esq. O'OUINN, HAGANS & WETTMAN 3200 Texas Commerce Tower Houston, Texas 77002 N. P.. Peterson, Esq. CF.E1TZER f> LOCKS 1500 Walnut St., 22nd Floor Philadelphia, Pa. 19102 Clerk oi the Panel Judicial Panel on Multidistr Li tiga t ion 1120 Vermont Avenue, N.K. Suite 1002 Washington, D.C. 20005 Newton D. Schwartz, Esq. Houston Bar Center Building 723 Main, Suite 325 Houston, Texas 77002 Phillip E. Brown, Esq. ` HOBERG, FINGER, BROWN, COX & MOLLIGA 703 Market Street, 18th Floor San Francisco, California 941 Robert A. Taylor, Jr., Esq. ASHCRAFT f. GEREL 2000 L Street N.W. , Suite 700 Washington, D.C. 20036 District Clerk United States District Court Eastern District of New York 220 Cadman Plaza Brooklyn, New York 11201 Benton Musslewhite 12324 UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK In re "AGENT ORANGE" Product Liability Litigation MDL No. 381 PRESENT LIST OF PLAINTIFFS' CAUSATION WITNESSES WITH ATTACHED SUMMARIES IN ACCORDANCE WITH FRCP 26(b)(A)(A)(i) 1. Charles Baron, M.D. 2. Deborah Anne Barsotti, Ph.D. 3. Ronald Codario, M.D. 4. Arthur W. Galston, Ph.D. 5. John Garofalo, M.D. 6. Lennart Hardell, M.D. 7. Maureen C. Hatch, Ph.D. 8. Alastair W.M. Hay, Ph.D. 9. Herbert Kay, Ph.D. 10. Ronald H. Kerman, Ph.D. 11. Marvin S. Legator, Ph.D. 12. Alan Scott Levin, M.D. 13. Peter Orris, M.D., M.P.H. 14. Marvin A. Schneiderman, Ph.D. 15. Ellen K. Silbergeld, Ph.D. lfi. Raymond Singer, Ph.D. 17. Theodor D. Sterling, Ph.D. 18. Biostatistician/Mathematician (Additional) Exhibit "A" Exhibit "B" Exhibit "C" Exhibit "D" Exhibit "E" Exhibit "F" Exhibit "G" Exhibit "H" Exhibit "I" Exhibit "J" Exhibit "K" Exhibit "L" Exhibit "M" Exhibit "N" Exhibit "0" Exhibit "P" Exhibit "Q" Exhibit "R" PLAINTIFFS' MANAGEMENT COMMITTEE Thomas W. Henderson, Esquire 12325 Dr. Charles M. Baron, M . D . , is a p h y s i a t r i s t pr a c t i c i n g in Philadelphia, Pennsylvania. His curriculum vitae will be supplied. Dr. Baron will testify as to the performance and interpretation of various tests in the veterans. These will include an eltroencephalogram on both sleep and waking states with nasopharyngeal leads. He will also perfrom electromyograms, nerve conduction velocity tests, and somato sensory evoked potentials of the upper and lower extemities. Dr. Baron will then testify as to the mechanisms by which toxins produce the changes noted in the tests and what the various tests are capable of determining as to the medical status of the patient. Then he will relate the results obtained in the testing of each plaintiff examined, give opinions as to the causation of those results where possible from the evidence revealed by the tests, and state the prognosis for the individual plaintiff for further deterioration in test results and/or for the individual's condition as a whole. 12326 Dr. D e b o r a h A n n e B a r sotti is an A s s i s t a n t P r o f e s sor of Toxicology in the Department of Pharmacology and Toxicology of the Philadelphia College of Pharmacy and Science in Phila delphia, Pennsylvania. Her curriculum vitae is attached. Dr. Barsotti is a toxicologist who has done substantial personal investigative work with halogenated aromatic hydrocarbons. This category of chemicals includes various biphenyls and dioxins, and specifically includes tetrachlorodibenzo-p-dioxin (TCDD). She will testify as to the relative chemical stability and lipophilicity of these chem i c a l s as w e l l as their r e s i s t a n c e to degradation, and will testify that these qualities are what account for the perceived and documented bioaccumulation of the chemicals in the human system. Dr. Barsotti will emphasize the difference in results between chron ic and acute exposures to these chemicals, testifying as to the varying types of responses to acute and chronic exposures. Dr. B a r s o t t i w i l l discuss her o w n w o r k as w ell as r e v i e w the literature in these areas, noting differences in routes of administration, and in the species and genetic strain of the animals involved. She will explain these variations and where they permit extrapolation of results from animals to humans. In particular, Dr. Barsotti will also testify as to the similarities in response to these chemicals by rhesus monkeys and by humans, and will explain how the similarities permit extrapolation in this instance. Dr. Barsotti will also discuss reproductive toxicity, 12827 teratology and post-natal toxicity, including instances where no gross or clinical signes of maternal toxicity could be detected. CD CURRICULUM VITAE DEBORAH ANNE BARSOTTI ADDRESS: Home - 4818 T r i n i t y Place Ph il a. , PA 19143 215-724-5387 Business - Phi l a . C o llege o f Pharmacy & Science Dept, o f Pharmacology & Toxicology 43rd & Kingsessing Mall Ph il a. , PA 19104 215-596-8978 CITIZENSHIP: USA BIRTHDATE: September 1 4 , 1949 MARITAL STATUS: M a rrie d ; no c h ild r e n EDUCATION: Humboldt S ta te U n iv e r s it y Areata, C a lifo rn ia - 1967-1972 Bachelor o f Arts Biology-Medical Technology Humboldt S ta te U n iv e r s it y Areata, C a lifo rn ia - 1972-1973 Graduate School Coursework: Electron microscopy Endocrinology Instrumentation U n iversity o f Wisconsin Madison, Wisconsin - 1973-1980 Doctor o f Philosophy Pathology Thesis T it le : Gross, C lin ic a l & Reproductive Effects o f P o ly c h lo rin a te d Biphenyls (PCBs) in th e Rhesus Monkey EXPERIENCE: Phil a. C o lle g e o f Pharmacy & Science Phil a . , PA - J an u ary, 1983 to Present Asst. Professor, Dept, of Pharmacology/Toxicology In s tr u c t B io lo g ic a l Methods in T o x ic o lo g y , Toxico logy I I I & Techniques in Electron Microscopy Advise undergraduate students Faculty adviso r f o r Tox Club Member, Ad visory Committe f o r fo u r graduate studen ts Conduct independent research S23 A s s is ta n t S c i e n t i s t - J u ly , 1982 to January, P ro je c t A s s o c ia te - June, 1980 to June, 1982 U n iv e rs ity o f Wisconsin Dept, of Pathology Madison, Wisconsin 1983 Coordinated m ultifaceted research projects involving over 120 rhesus monkeys exposed to low l e v e l s o f t o x in s ( h a l o genated a ro m a tic hydrocarbons) and i n te g r a te d the c l i n i c a l data and o b s e rv a tio n s w ith the residue analyses o f tis s u e s and f l u i d s o b ta in e d by gas chromatography (GC) and con firm ed by mass spectrometry (MS). Supervised th e c l i n i c a l and reprodu ctive e v a lu a tio n s as w ell as th e care o f la b o r a to r y animals. Developed d a t a management and word processing systems u t i l i z i n g o n - s i t e computers and t i e - i n s to a Sperry Univac 1100 to s o r t , c o l l a t e and s t a t i s t i c a l l y e v a lu a te d a ta . Conducted gross necropsies and m icroscopic e v a lu a t io n s and prepared necropsy reports. Research A s s is ta n t - 1976-1980 U n iversity o f Wisconsin Dept, o f Pathology Madison, Wisconsin Conducted radioimmunoassays f o r serum progesterone and e s t r a d io l fo r use in evaluating the reproductive parameters in rhesus monkeys. Performed c l i n i c a l assessments on la b . animals in c lu d in g hematology and c l i n i c a l chem istries. Supervised and e v a lu a te d data and prepared r e p o r t s f o r contra c tu ra l work. Separated c e l l u l a r fra c tio n s o f tis s u e homogenates by u l t r a c e n t r i f u g a t i o n and assayed homogenates and r e s u l t a n t f r a c tio n s f o r co n te n t o f various components. Provided animal husbandry f o r rhesus monkey and r a t co lonies Supervised u n i t members on protocols f o r e x p e r im e n ta tio n and proper methods o f conducting basic la b o ra to ry analyses. Pre-Doctoral Fellow - 1974-1976 U n iversity of Wisconsin Dept, o f Pathology Madison, Wisconsin Stocked and o rg an ized a la b o ra to ry f o r the c l i n i c a l and re p r ductive analyses of laboratory animals. -2 - Prepared protocols fo r long-term feeding studies in the laboratory animals including those fo r gross, c lin ic a l and re p ro d u c tiv e assessments. Developed radioimmunoassay procedures f o r serum proges te ro n e and e s t r a d i o l . Conducted metabolism and d i s t r i b u t i o n s tu d ie s in r a t s and rhesus monkeys using r a d io la b e le d isomers o f halogenated aro m a tic hydrocarbons and o th e r chem icals. Laboratory Assistant - 1970-1972 Humboldt S ta te U n iv e rs ity Student Health Center Areata, California Duties included assisting in routine c lin ic a l laboratory practices involved in u r in a ly s is , gonococcal screening, VDRLs, h e te ro p h ile s f o r mononucleosis, t h r o a t c u ltu re s and pregnancy t e s t s . AWARDS/HONORS: N a tio n a l Sea Grant Graduate Student o f th e Year - 1976. PROFESSIONAL SOCIETIES: American Society fo r Prim atologists M id -A tlan tic Chapter, Society of Toxicology SEMINARS/MEETINGS: P a rtic ip a n t - Federation of American S o cieties fo r Experi mental Biology (FASEB), A t la n t ic C i t y , NJ, A p r i l , 1976. T o p ic : " E f fe c ts o f p o ly c h lo r in a t e d b ip h e n y ls on re p ro duction in the primate". P a r t i c i p a n t - American A s s o c ia tio n o f P a th o lo g is t s and B a c t e r i o l o g i s t s , Boston, MA, March, 1976. Topic: "The A s s o c ia tio n o f T ra n s p la c e n ta l and Mammary Movement o f PCBs w it h In fa n t M o r b id ity and M o r t a l i t y " . I n v i t e d Speaker - 9th Annual Sea G rant A s s o c ia tio n M e e tin g , Los A n g e le s , CA, November, 1976. T o p ic : "Toxicology o f PCBs in th e A d ult and I n f a n t Rhesus Monkey". P a r t i c i p a n t - FASEB, Chicago, I L , A p r i l , 1977. Topic: " E f f e c t s o f p o ly c h lo r in a t e d b ipheny ls in nonhuman p rim a te s " . P a r t i c ip a n t - American Chemical S o c ie ty , 11th Great Lakes Regional Meeting, Stevens P o in t, W I, June, 1977. Topic: "Responses o f i n f a n t prim ates to i n t e r u t e r i n e and neonatal exposure to polychTorinated biphenyls". I n v i t e d Speaker - Community Meeting on PCBs, U n i v e r s i t y o f Wisconsin, Parkside, March, 1977. - 3 12331 P a r t i c i p a n t - I n t e r n a t io n a l Symposium on Pathobiology o f Environmental P o llu ta n ts , S to rrs , CT, June, 1977. Topics: "Pathology o r rhesus macaques (Macaca m u la tt a ) exposed to t e t r a c h lo r o d ib e n z o - p - d io x in (TCDD)" and "Exposure o f p o ly c h lo r in a t e d biphenyl (PCB) to i n f a n t rhesus macaques (Macaca m ulatta)". I n v i t e d Speaker - Community Meeting on PCBs, Door County, WI, September, 1977. In v it e d Speaker - 45th Annual Convention o f A s s o c ia tio n o f Midwest Fish and W i l d l i f e A gencies, M ilwaukee, W I, J u l y , 1978. T o p ic : "Consequences o f d i e t a r y PCB consumption in rhesus monkeys". I n v i t e d C o n su lta n t - Symposium on PBB L i t i g a t i o n , T rave rse C i t y , M I, J u l y , 1978. Topic: "PBB t o x i c i t y in th e rhesus monkey". In v ite d Speaker - Smerkee's Conservation C lub, Sheboygan, WI, F e b ru a r y , 1979. Topic: "PCBs and t h e i r e f f e c t s on rhesus monkeys". P a r t i c i p a n t - FASEB, D a l l a s , TX, A p r i l , 1979. Top ic: "Residual e f f e c t s o f p o ly c h lo r in a t e d biphenyls on a d u lt nonhuman prim ates and t h e i r o f f s p r i n g " . Expert Witness - State of North C aro lin a, H alifax County; te s tim o n y on t o x i c i t y o f PCBs, June, 1979. P a r t i c i p a n t - Sea Grant Symposium on T o x ic M a t e r i a l s and t h e i r E f f e c t s on Marine Resources, Madison, W I, J u l y , 1979. PUBLICATIONS: B a r s o t t i , D. A. and Van M i l l e r , J. P . : Reproductive assessments o f rhesus monkeys housed in c l im a t e c o n t r o lle d c o n d itio n s . Amer. J. P r i m a t o l . , submitted 1983. B a r s o t t i , D. A . : Long term r e p ro d u c tiv e assessment o f rhesus monkeys exposed to c h lo r in a t e d b ipheny ls ( A r o c lo r 124 8). Fd. Cosmet. T o x i c o l . , subm itted 1983. B a r s o t t i , D. A. and Van M i l l e r , J. P. : Accumulation o f a commercial p o l y c h lo r in a t e d biphenyl m ix tu r e ( A r o c lo r 1010) in a d u lt rhesus monkeys and th e ir nursing o ffs p rin g . Toxicology. In press. Bowman, R. E. , H eironim us, M. P. and B a r s o t t i , D. A . : Locomotor h y p e r a c t i v i t y in PCB-exposed rhesus monkeys. N e u r o to x ic o l. 2 : 2 5 1 - 2 6 8 , 1981. B a r s o t t i , D. A. , Abrahamson, L. J. , M a r l a r , R. J. and A l l e n , J. R . : The e f f e c t o f c lim a te c o n t r o l l e d housing on the r e p ro d u c tiv e p o t e n t i a l o f the rhesus monkey. J. Reprod. F e r t i l . 5 9 : 1 5 - 2 0 , 1980. d B a r s o t t i , D. A. and A l l e n , J. R . : nursing rhesus monkey i n f a n t s . (Abstract). Health i m p lic a t io n s o f A r o c lo r 1016 on Toxicol. Appl. Pharmacol. 52:135, 1980 A l l e n , J. R . , B a r s o t t i , D. A. and C a rs te n s , L. A . : Residual e f f e c t s o f p o ly c h lo r in a t e d b ipheny ls on a d u lt nonhuman p rim ates and t h e i r o f f s p r i n g . J. T o xico l. Environ. H lth . 6 :5 5 -6 6 , 1980. A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J. P . : T o x ic o lo g ic a l e f f e c t s o f A r o c lo r 1016 on nonhuman p rim a te s . EPA Report # 6 8 - 0 2 : 2 4 6 4 , 1980. B a r s o t t i , D. A . , Abrahamson, L. J. and A l l e n , J. R. : Hormonal a l t e r a t i o n s in fem ale rhesus monkeys fe d d i e t s c o n ta in in g 2 , 3 , 7 , 8 - t e t r a c h lo r o d ib e n z o l - d i o x i n . B u l l . E nviron. Contain. T o x ic o l. 2 1 : 4 6 3 - 4 6 9 , 1979. B a r s o t t i , D. A . , C a rs te n s , L. A. and A l l e n , J. R . : Residual e f f e c t s o f p o ly c h lo r in a t e d b ipheny ls on a d u lt nonhuman p rim a tes and t h e i r o f f s p r i n g . Fed. Proc. 38:11 19, 1979 (A b s tra c t). A l l e n , J. R. , B a r s o t t i , D. A. and Lambrecht, L. K . : R e p ro d u ctive e f f e c t s o f halogenated a ro m a tic hydrocarbons on nonhuman p r im a te s . New York Academy o f Sciences, 320:419-427, 1979. A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J . P . : P a tho logy o f rhesus macagques (Macaca m u la tt a ) exposed to t e tr a c h lo r o d ib e n z o - ]D -d io x in (TCDD). I n t e r n a t i o n a l Symposium on Pathology o f Environmental P o l l u t a n t s , N a tio n a l Research C ouncil, 346-355, 1979. A l l e n , J. R . , Van M i l l e r , J. P. and B a r s o t t i , D. A . : T o x ic o lo g i c a l responses o f nonhuman p rim ates to 1 , 2 , 4 , 6 ,7 ,8 - h e x a c h l o r o d i b e n z o - - d i o x i n (HCDD). T o x ic o l. Appl. Pharmacol. 47 :1 7 9 , 1979 (A b s tr a c t). C a rs te n s , L. A . , B a r s o t t i , D. A. and A l l e n , J . R . : Exposure o f p o l y c h l o r i n ated biphenyl (PCB) to i n f a n t rhesus macaques (Macaca m u l a t t a ) . I n t e r n a t io n a l Symposium on P ath o b io lo g y o f Environmental P o l l u t a n t s , .N atio n a l Research Council , 339-345, 1979. S c h a n tz, S. L. , B a r s o t t i , D. A. and A l l e n , J . R . : T o x ic o lo g i c a l e f f e c t s pro duced in nonhuman p rim ates c h r o n ic a ll y exposed to f i f t y p a r t s per t r i l l i o n 2 ,3 ,7 ,8 -te tr a c h lo r o d ib e n z o -p -d io x in (TCDD). T o x ic o l. Appl. Pharmacol. 46:180, 1979 (A b s tra c t). A l l e n , J. R. , Lambrecht, L. K. and B a r s o t t i , D. A . : Some gen eral e f f e c t s o f polybrom inated biphenyls in nonhuman p rim a te s . J. Am. V e t. Med. Assoc. 173 1 1 :1 4 8 5 -1 4 8 9 , 1978. Lambrecht, L. K. , B a r s o t t i , D. A. and A l l e n , J. R. : Responses o f nonhuman primates to a polybrominated mixture. Environ. Health Perspec. 23:139147, 1978. A l l e n , J. R. , B a r s o t t i , D. A . , Van M i l l e r , J. P . , Abrahamson, L. J. and L a l i c h , J. J . : Morphological changes in monkeys consuming a d i e t c o n ta in ing low l e v e l s o f 2 , 3 , 7 ,8 -te tr a c h lo r o d ib e n z o - _ -d io x in . Fd. Cosmet. , Toxicol. 15:401-410, 1977/ A l l e n , J. R. and B a r s o t t i , D. A . : Responses o f i n f a n t primates to i n t e r u t e r i n e and neonatal exposure o f p o ly c h lo r in a t e d b ip h e n y ls . American Chemical So c i e t y , Proceedings o f 11th Great Lakes Regional M eeting, June, 1977 (Ab stract). A l l e n , J. R . , B a r s o t t i , D. A. and Van M i l l e r , J. P . : Reproductive dysfunc t i o n in nonhuman primates exposed to d io x in s . T o x ic o l. A p pl. Pharmacol. 4 1 :1 7 9 , 1977 (A b s tra c t). Norback, D. H. and B a r s o t t i , D. A . : E f f e c t s o f p o ly c h lo r in a t e d biphenyls in nonhuman p rim ates. Fed. Proc. 3 6 5 :3 9 6 , 1977 ( A b s t r a c t ) . B a r s o t t i , D. A . , M a r l a r , R. J. and A l l e n , J. R . : Reproductive dysfun ctions in rhesus monkeys exposed to low l e v e l s o f p o ly c h lo r in a t e d biphenyls ( A r o c lo r 1248). Fd. Cosmet. T o x ic o l. 1 4 : 9 9 - 1 0 3 , 1976. B a r s o t t i , D. A. and A l l e n , J. R . : The a s s o c ia tio n o f t r a n s p la c e n ta l and mammary movement o f PCBs w ith i n f a n t m o r b id it y and m o r t a l i t y . Amer. -J. Path. 82:21a, 1976 (A b s tra c t). A l l e n , J . R. and B a r s o t t i , D. A . : The e f f e c t s o f tra n s p la c e n ta l and mammary movement o f PCBs on i n f a n t rhesus monkeys. T oxico logy 6 : 3 3 1 -3 4 0 , 1976. A l l e n , J. R. , B a r s o t t i , D. A. and C a r s te n s , L. A . : Residual e f f e c t s o f s h o rt t e r m , low le v e l exposure o f nonhuman p rim ates to p o ly c h lo r in a t e d biphenyls. Toxicol. Appl. Pharmacol. 30:440-451 , 1974. -6- >' 3 Dr. Ron a l d Corderio, M . D . , is an internist p r a cticing in Philadelphia, Pennsylvania. His curriculum vitae will be supplied. Dr. C o r d e r i o will t e s t i f y that he is c u r r e n t l y e n g a g e d in the p r i v a t e p r a c t i c e of m e d i c i n e as an internist. He will testify that he personally has examined and/or treated over five hundred Vietnam veterans for complaints related to Agent Orange. He will testify as to the type of interview he has conducted with each veteran, the type of tests that each veteran should have performed, and the clinical significance of positive or negative findings on each of those tests. He will also discuss how toxins, and specifically Agent Orange, can cause changes in each of the tests and what such changes portend for the individual. Dr. Corderio will next discuss some of the available medical literature in both animals and humans to further v a l i d a t e his own work. Dr. Corderio will then outline in detail the results obtained from his own extensive investigation into Agent Orange toxicity based upon his examination of more than five hundred veterans, and will present those conclusions which he feels are reasonably appropriate based upon an analysis of his investigative work. W i t h this material as background, Dr. C o r d e r i o will then proceed to present the test results which have been obtained for each court-approved representative veteran plaintiff. He will ,ai * / interpret each of the test results in terms of those individual plaintiffs. Finally, he will testify on generic causation and specific proximate causation in relation to each representative veteran plaintiff. He will also testify as to prognosis for each representative veteran plaintiff. n 12836 ARTHUR W. GALSTON, Ph.D. Dr. Galston is Eaton Professor of Botany, Department of Biology, at Yale University. His Curriculum Vitae will be supplied. Dr. Galston is a plant physiologist and has personally observed the effect of the spraying of Agent Orange on the Vietnam ecosystem, i.e. the devastation of the Vietnamese countryside. Dr. Galston has been in Vietnam on four occasions between 1971 and 1982, and will describe those observations while in Vietnam, with such pictorial evidence as is available. Dr. Galston will testify to the potential and actual effects of phenoxy herbicides and their contaminants, both in Vietnam and elsewhere, including the United States and Sweden, and other places. The testimony will include the chemistry and the mechanisms of action of such chemicals on plant life. In addition, Dr. Galston will testify to the fate of Agent Orange and other phenoxy herbicides and their contaminants, especially TCDD, in the environment generally and in Vietnam in particular. Dr. Galston will testify to the persistence of such chemicals on plants, in water, and in soil, such that exposure to the phenoxy herbicides and their contaminants, especially TCDD, by the veterans in sprayed areas in Vietnam is presumed. The bases or grounds for Dr. Galston's testimony as to any facts and opinions expressed are a review of the scientific literature and his personal research and experience. 12337 Dr. John Garofalo is a immunologist practicing in Philadelphia, Pennsylvania. His curriculum vitae will be supplied. Dr. Garofalo will testify to the performance of certain tests on the veteran plaintiffs and their wives and children and to the interpretation of those test results. Specifically, he will be conducting phenotyping assay tests for, among others, B -lymphocytes, K cells, T -lymphocytes, T-helper cells, T-cytotoxic cells, and T-suppressor cells. The purpose of these tests is to determine antigen levels, antibody levels, and the presence of a viral defenses and immune surveillance s y s t e m s , and to identify various types of cells that may be indicators of and/or precursors of malignancy. Not only will the tests determine the presence of such factors, but they will also include functional assays of each. LENNART HARDELL, M.D. Dr. Hardell is employed by the University Hospital in its Department O of Oncology in Umea, Sweden, where he specializes in internal medicine and oncology. His work includes diagnosis, treatment, and evaluation of possible causes of cancer, and education of medical students. Dr. Hardell will testify to several epidemiological studies which he and colleagues have conducted in Sweden. This research includes investigations concerning the relationship between the risk for different types of cancer and exposure to phenoxy herbicides and chlorophenols. The research has been published in the medical and scientific literature. .These studies utilized the case-control study as the vehicle for investigation. Certain methodological aspects, such as selection of cases, selection of controls, assessment of exposure, and statistical methods, were considered; and then utilization was based upon thoroughly considered aspects of bias, all of which were well controlled. Specifically, these studies, four in number, involved soft tissue sarcomas, malignant lymphomas, and colon cancer. Highly statistically significant risks of soft tissue sarcomas and malignant lymphoma were found, whereas no association was found for colon cancer. In point of fact, the negative finding for colon cancer strongly supports the statistical significance of the increased risk demonstrated for soft tissue sarcomas and malignant lymphomas, i.e. a presumed causal relationship between exposure to phenoxy herbicides and human cancer particularly of soft tissue sarcoma and malignant lymphoma. 12S39 Dr. Hardell has also seen in his clinical practice basal cell carcinoma of persons previously exposed to phenoxy herbicides, with no other known confounding variables. With respect to those cases with soft tissue sarcoma, malignant lymphoma, and basal cell carcinomas, Dr. Hardell will testify that the presumed exposure to Agent Orange caused, in significant part, such neoplastic processes. The bases for Dr. Hardell?s testimony as to various facts and opinion include: educational background; professional training and experience; review of the applicable medical and scientific literature; personal research; and a review of the pertinent medical data of the relevant representative plaintiffs. < o o 2- - MAUREEN C. HATCH, Ph.D. Dr. Hatch is Assistant Professor of Epidemiology at Columbia University, School of Public Health, in New York City. Her Curriculum Vitae will be supplied. The subject matter about which Dr. Hatch will testify is reproductive toxicology and its specific applicability to miscarriages and congenital malformations (birth defects) in the wives and children of Vietnam veterans. Dr. Hatch will testify at length to the data collected in Vietnam regarding untoward pregnancy outcomes. Dr. Hatch is one of two investigators who are to publish that portion of the International Symposium held in Ho Chi Minh City in January, 1983 having to do with reproductive toxicology as a result of exposure to Agent Orange and other phenoxy herbicide spraying in Vietnam. The results of these data demonstrate a statistically significant increase in certain congenital malformations, e.g. cleft palate, limb deformaties, and anencephaly, as a result of paternal mediated reproductive effects. The exposure of the fathers was to the spraying of Agent Orange in Vietnam. The mothers were not exposed. These human data are coupled with positive, consistent animal data. For example, such studies where males were exposed indicate the following; the male gonads are a target site of 2,3,7,8-TCDD action; at the endocrinological level, there has been demonstrated a major effect, i.e., AHH receptor in male gonads; which very nicely provides a mechanistic linkage; and finally, abnormal biochemical and morphologic characteristics of the sperm have been lil|ejwi'je| X. demonstrated. ALASTAIR W.M. HAY, Ph.D. Dr. Hay is a lecturer on Chemical Pathology, Department of Chemical Pathology, Old Medical School, University of Leeds, Leeds, England. His partial Curriculum Vitae is attached. Dr. Hay will testify to a broad spectrum of matters related to Agent Orange, phenoxy herbicides, and their contaminants, including dioxins, especially 2,3,7,8-TCDD. Dr. Hay will discuss in detail his knowledge of the various phenoxy herbicides and their contaminants, including but not limited to the various aspects of: chemistry; biochemistry; manufacture and/or production; fate in the environment, animals, and humans; modes of exposure, i.e. absorption, ingestion and inhalation, specifically by the veterans who served in Vietnam; toxicity; and the state of the medical and scientific literature at various times since at least 1957 forward. The medical and scientific literature, attendance and participation in various symposia, review of various documents of certain defendants, personal research, and experience form the bases of whatever facts and opinions to which Dr. Hay will testify. Dr. Hay's testimony regarding the medical and scientific literature will" include an exposition of the definitions and explanations, and their applicability to the troops exposed in Vietnam, of the phenoxy herbicides and their contaminants, in the following areas: plant physiology; toxicology; neuro-toxicology, both neurological and psychological; epidemiology; immunology; mutagenicity; teratology; reproductive toxicology; and carcinogenicity. More specifically, the phenoxy herbicides, including Agent Orange, 2,4-D and 2,4,5-T, and their contaminants, including dioxins, especially TCDD are highly toxic, neuro-toxic, immuno-suppressive, teratogenic, potentially mutagenic, and certainly carcinogenic. As a carcinogen, e.g. TCDD, it has no safe level and indeed any single exposure may prove to result in human cancer many years later; said in another way, there is no "no effect" level that can be established. Dr. Hay will testify to examples of the grounds which support the above, including: knowledge of spraying Agent Orange, especially its effect on the Vietnamese countryside; the purpose and historical tracing of the animal studies; historical tracing of the human data, including the various industrial incidents since 1949; references to specific documents, such as the EPA Dioxin document (presently in Draft form); various cancer epidemiology; pertinent teratology epidemiology; various studies of the Vietnamese, especially in area of reproductive toxicology; and those reports of the symptoms and diagnoses of the U.S. Vietnam veterans. . P QO' 2- - Name: Alastair Watt Macintyre HAY D.O.B.: 21 April 1947 Marital Status: Married Children: 1 son (Tom) Place of Birth: Glasgow, Scotland Nationality: British Degrees : B.Sc.(Hons), Chemistry IIA - London 1969 Ph.D., Biochemistry, London 1973 Home Address: School House, A r t hington Lane, Arthington, Leeds LS21 1PE England. Work Address: Department of Chemical Old Medical School, University of Leeds, Leeds LS2 9NL England. Pathology, Place of Secondary Education: Gifford Technical High School, Bulowayo, Zimbabwe (formerly Rhodesia) Present Appointment: University lecturer in Chemical Pathology since April 1979 (University of Leeds) Leeds, England. Former Appointments: Research Fellow - Zoological Soc. of London September 1972 - November 1977 Research Fellow - University of Leeds, Department of Animal Physiology and Nutritic December 1977 - March 1979 PUBLICATIONS Books "(i) A l a s t a i r Hay. The Chemical Scythe: Les s o n s of 2,4,5-T ' - and Dioxin. Plenum Press. 265pp. August 1982 (ii) Sean Murphy, Alastair Hay and Steven Rose. No Fire: No Thunder. The threat of chemical and biological warfare. Pluto Press. (To be published in January 1984). 135pp. Scientific Papers Some 50 scientific papers including: (i) Hay, A.W.M., Mawer, E.B., Hassan, A . G., Crawford, M.A., & Stevens, P.A. The role of essential fatty acids in vitamin dependent calcium absorption infhe intestine. Proc. of 5th V i t a m i n D Workshop. W i l l i a m s b u r g U S A n o w in Vitamin D, Chemical, Biochemical and Clinical Endocrinology of Calcium # 2 Metabolism. Walter de Gruyter. Berlin. 1982 pp309-311. (ii) Hay, Alastair. V i t a m i n D: Sunli g h t and precursors. Nature. 2 9 7 , 364 (1982) (iii) Hay, A. Herbicides, T r i c h l orophenols and sof t tissue sarcomas. L a n c e t I, 1240, (1982). (iv) Hay, A. It kills weeds, but what about people? New Scientist. 94., N o . 1314. ppl5 8-161 (1982). (v) H a y , A ., Murphy, S., Robinson, J.P., and S. Rose. The poisor c l o u d h a n g i n g ove r Europe. N e w Scientist. 93., No. 1296 pp6 635 (1982). (vi) Hay, Alastair. New Pathways for clorinated dioxins. Nature, 294, 514-515 (1981). (vii) Hay, A. Experimental Toxicology and cytogenetics: an overview. In "Herbicides and War" to be published by S t o c k h o l m I n t e r n a t i o n a l Peace R e s earch Institute. (1984) A. Westing, Ed. (viii) Hay,A. The M u t a g e n i c p r o p erties of 2 , 3 , 7 , 8-Tet rachlorodibenzo-p-dioxin in "Chlorinated Dioxins and Dibenzofurans in,the Total Environment. Vol II" Edit, by Keith, L.H. et. al to be p u b l i s h e d in 1984. Other Publications I h a v e w r i t t e n some 90 odd articles for the News, News and Views and books review section of the scientific journal Nature since 1976. &o \oJ: D Dr. H e r b e r t Kaye, Ph.D., is a p s y c h o l o g i s t in the D e p a r t ment of Psychology at the State University of New York at Stoneybrook, Long Island and a visiting Associate Professor in the De partment of Psychiatry at New York University Medical Center. His curriculum vitae will be supplied. Dr. Kaye will testify concerning the significance of a battery of q u a n t i t a t i v e n e u r o p h y s i o l o g i c a l tests c a l l e d n e u r o m e t r i e s will which be performed on the veteran, wife and children plaintiffs. The procedures were developed in part by Dr. Kaye in conjunction with medical and psychological researchers from this and other coun tries. He will testify that neurometries, on which he has written extensively, is a s o p h i s t i c a t e d battery of e l e c t r i c a l tests in u se for about fifty years, which are highly efficient in determing cortical EEG and evoked responses. Dr. Kay will explain the model used in the computeriza tion against which the test results are compared and will explain how deviations from normal produce certain effects. Dr. Kaye will also discuss the mechanism by which toxins produce these altered responses, and what effect those altered re sponses have upon the individual veterans at present, and the prog nosis for any additional changes or deterioration in the future based upon an assumed bioaccumulation of the toxic materials in the system. In doing so, he will rely on his experience in diagnosing many Vietnam veterans exposed to Agent Orange. f n o 1,a- RONALD H. KERMAN. Ph.D. Dr. Kerman is Associate Professor, and Chief, Cellular Immunology, Clinical Immunology Laboratories, the University of Texas Medical School at Houston. His Curriculum Vitae is attached. Dr. Kerman will testify that 2,3,7,8-TCDD in particular causes, among others, immuno-suppressive effects, as reported in the literature regarding the various animal species studies. Specifically, TCDD has been demonstrated to suppress T-cell mediated immunity in such species. This effect likewise has been demonstrated in humans by Bekesi, specifically an alteration of mature T-cells. Dr. Kerman will testify that the special scientific discipline involved is immuno-toxicology which has been defined as "the undesirable effects of an inappropriate response of the immune system". The bases for the facts and opinions to which Dr. Kerman will testify include a review of the applicable medical and scientific literature, his educational and professional background, and his work in connection with the Texas Agent Orange Study. Dr. Kerman will discuss the following in his testimony: the immune system, with its organic, cellular, and humoral components - most especially with regard to the latter, T-helper cells, B-cells, plasma cells and immunoglobulin production; immune response, both beneficial and harmful; the various experimental studies, particularly those demonstrating atrophy of the thymus, weight loss, depletion of lymphoid organs, lymphopenia, cutaneous type delayed hypersensitivity (skin thickness) and altered bacterial immunity. e o A *7 1CJ i D r . Kerman will testify that on the basis of the above a person exposed to TCDD might have increased predisposition to increased infection and neoplasm (cancer). OQ 2- - CURRICULUM VITAE Ronald EL Kerman, Ph.D. DATE OF BIRTH: June 10, 1943 PLACE OF BIRTH: Chicago, Illinois NATIONALITY : U.S. C itizen SEX: Male EDUCATION: 1965 1967 1969 University of Illinois, B.S. (with Honors) U niversity o f Illinois, M.S. University of Illinois, Ph.D. in Immunology HONORS: 1965 1967-1969 1967 1969-1971 1970 Bachelor of Science w ith G eneral Honors in the College Recipient of Public Health Service Predoctoral Traineeship Phi Sigma N ational Biological Honorary Recipient of Public Health Service Postdoctoral Traineeship Society of Sigma Xi RESEARCH AND PROFESSIONAL EXPERIENCE: 19831981- 19771977-1980 1974-1977 1973-1977 1972-1973 1969-1971 Associate Professor D epartm ent of Pathology, and Chief, C ellular Im munology, Clinical Immunology Laboratories, The Uni versity of Texas Medical School a t Houston Associate Professor D epartm ent of Surgery, and Head, Histocom patibility and Immune Evaluation Laboratories, Division o f Organ Transplantation, The University of Texas Medical School at Houston Member, Program in Immunology, G raduate School o f Bio m edical Sciences, The University of Texas H ealth Science C enter at Houston Assistant Professor D epartm ent of Surgery, and Head, H istocom patibility and Immune Evaluation Laboratories, Division of Organ Transplantation, The University of Texas Medical School a t Houston Assistant Professor D epartm ent of Surgery, Loyola University S tritch School of Medicine, Maywood, Illinois Research Immunologist Chief, Immunobiology Research Laboratory, R esearch Service, V. A. H ospital, Hines, Illinois Assistant Professor D epartm ent of Microbiology, Jefferson M edical College Postdoctoral Fellow, (Immunology) 12349. Children^ Hospital of Philadelphia and The U niversity of Pennsylvania School of Medicine  Curriculum Vitae Ronald H. Kerman, Ph.D. 2 PROFESSIONAL SOCIETIES: RESEARCH INTERESTS: RESEARCH SUPPORT: 1974-1978 1976-1979 1976- 1980 1977- 1978 197719771983-1984 OTHER ACTIVITIES: The Transplantation Society (Editorial Board, Trans plantation and M ember, Symposium Com m ittee) Am erican Association of Immunologists American Association for Cancer Research New York Academy of Sciences American Society of Transplant Physicians (Member, and Vice Chairman, Scientific Studies Com m ittee) Society for Experim ental Biology and Medicine International Society for H eart Transplantation American Association for the Advancement of Science American Society for Histocom patibility and Immuno- genetics (Chairman, Finance and Audit C om m ittee, and Member, Laboratory A ccreditation Committee) Immunologic response to allotransplantation and malignancy Evaluation of immunocompetency Co-principal Investigator: Bronchogenic Carcinoma: Immu nologic P rofile, Radio and Im m unotherapy - V.A. M edical R esearch G rant No. MRIS-8121-08. $213,000 Co-principal Investigator: Immunotherapy Adjuvant to R adiotherapy of Head and Neck C ancer - V.A. M edical R esearch G rant No. MRIS-8121-06. $73,814 Co-principal Investigator: Factors Influencing Immuno co m p ten ce in H um an T ran sp lan tatio n - V.A. M edical R esearch G rant No. MRIS-3068. $68,770 Principal Investigator: Functional and Surface R eceptor D ifferences of Human T-lymphocyte Subpopulations General Research Support Funds, The University of Texas Medical School a t Houston. $5,000 Principal Investigator: The Role of HLA Typing in R enal Transplantation, ESRD Program , No. 450068. $377,400 (last year) Principal Investigator: Immune Monitoring for the Diagnosis of Renal A llograft Rejection, ESRD Program , No. 450068. $544,800 (last year) Principal Investigator: Immune Evaluation of V eterans Exposed to Agent Orange. Texas Veterans Agent Orange A ssistance Program , IAC(83-84)1266. $93,352 Special C onsultant in Immunology to the Epidem iology and D isease C ontrol Study S ection, NIH C o n su ltan t in Immunology and H isto co m p atib ility T estin g to th e D epartm ent of L aboratory M edicine, M.D. Anderson Hospital and Tumor Institute Editorial Board, Transplantation Review of m anuscripts for the journal Human Immunology Review of manuscripts for the journal Transplantation Review of manuscripts for the journal H eart Transplantation Book review er for Journal of American Medical Association L iterature Reviewer for The American Association of C linical H istocom patibility T esting -- AACHTion News 12950 . Curriculum Vitae Ronald H. Kerman, Ph.D. 3 G rant Reviewer for the Kidney Foundation of Canada G ra n t R eview er in T ran sp lan tatio n Immunology fo r The March of Dimes - B irth D efects Foundation O utside R eview er of R ese arch Proposals in Immunology fo r the Research and Development C om m ittee, The Vet erans Administration Research Service Invited P a rtic ip a n t (as a te stin g laboratory) in The Third A m erican HLA Workshop Invited P articip an t (as a testin g laboratory) in The Eighth International H istocom patibility Workshop "R elevance of DR typing to renal allograft survival" Invited P a rtic ip a n t (as a te stin g lab o rato ry ) in The In te r national Transfusion and T ransplantation Workshop Invited P articip an t (as a testing laboratory) for the Ninth International H istocom patibility Workshop Invited P re se n te r a t an NIH Workshop, 'T h e B iological R elevance of Immune Suppression as Induced by G enetic, Therapeutic and Environmental Factors" Invited P articip an t (as a testin g laboratory) in the In ter national Collaborative Transplant Study Laboratory Inspector for Clinical Laboratory A ccreditation in H isto co m p atib ility fo r The A m erican S ociety fo r His tocom patibility and Immunogenetics and The College of American Pathologists Chairm an, Finance and Audit C om m ittee for The American Society for Histocom patibility and Immunogenetics M ember, Symposium and A ffiliations C om m ittee, The Transplantation Society Member and Vice-Chairm an, Scientific Studies C om m ittee, American Society of Transplant Physicians M em ber, A cquired Im m une D eficiency Syndrom e (AIDS) Working Group for the Houston Area Chairm an, Organizing C om m ittee and Host for The Fourth International Immune Monitoring Symposium: Im munological Evaluation and Monitoring of the Transplant R ec ip ie n t (1983) M ember, Organizing C om m ittee for the International Sym posium on R elev an t Im m unological F a c to rs in C linical Kidney T ran sp lan tatio n , H eidelberg, West G erm any, 1985 M em ber, UTMSH Admissions Interview C o m m ittee M em ber, UTMSH Admissions C o m m itte e Member, Medical Review Board, Organ Transplantation C e n te r, UTMSH M em ber, C om m ittee on Subject Selection for The U niversity of Texas System Agent Orange Study M ember, Steering C om m ittee, Program in Immunology, UT-GS3S C hairm an, By-Laws C om m ittee, Program in Immunology, UT-GSBS C ourse D irecto r, "M ethods in C ellu lar Immunology," a P ro gram in Immunology C ourse, UT-GSBS fO T " 4t O 'l BIBLIOGRAPHY Ronald H. Kerman, Ph.D. Publications 1. K erm an, R ., Segre, D. and Myers, W.L.: A lte re d response to pneum ococcal polysaccharide in offspring of im m unologically paraly zed m ice. Science 156:1514, 1967. 2. K erm an, R ., Segre, D. and M yers, W.L.: The role of im m une and n a tu ra l sp ecific antibodies in immunologic paralysis and immunity of mice to pneum ococcal polysac charide Type IE. J . Immunol. 104:655, 1970. 3. K erm an, R. and Segre, D.: A nti-pneum ococcal polysaccharide Type IH hem olytic plaques in mice: C ellular response in im m unity and im m unologic paralysis. J . Immunol. 104:1262, 1970. 4. Kerman, R. and H arris, T.N.: R esistance to denaturation by periodate of a dialyzable histocom patibility antigen. Proc. Soc. Exp. Biol. Med. 141:179-183, 1972. 5. Kerman, R.H., H arris, T.N. and H arris, S.: Preparation of a dialyzable histocom pati bility antigen from balb/c mice. Proc. Natl. Acad. Sci. 69:223-227, 1972. 6. Smith, R.A., Kerman, R., Ezdinli, E. and S tefani, S.: A modified assay for the detection of human adult active ro sette forming cells. J. Immunol. Meth. 8:175-184, 1975.- 7. Kerman, R. and Stefani, S.: Immunological evaluation of patients with solid tum ors before and a fte r radiotherapy. In Crispen, R.G. (ed.): Neoplasm Immunity: Mecha nisms, pp. 109-120. U niversity of Illinois Press, 1976. 8. Stefani, S., Kerman, R. and A bbate, J.: Immune evaluation of lung cancer patients undergoing radiation therapy. C ancer 37:2792-2796, 1976. 9. Stefani, S., Kerman, R. and A bbate, J.: Serial studies of im m unocom petence of patients undergoing radiotherapy for malignancies of the head and neck. Am. J. Roentgenol. 126:880-886, 1976. 10. Kerman, R.H. and Geis, W.P.: T otal and activ e T-cell kinetics in renal allograft recipients. Surgery 79:398-407, 1976. H . Kerman, R., Smith, R., S tefani, S. and Ezdinli, E.: A ctive T -ro se tte form ing cells in the peripheral blood of cancer patients. C ancer Res. 36:3274-3278, 1976. 12. Kerman, R ., Smith, R., Ezdinli, E. and Stefani, S.: U nification and technical aspects of to tal T, active T and B lym phocyte rosette assays. Immunol. Comm. 5(7-S):685694, 1976. 13. Dodson, M.G., Kerman, R.H., Lange, C.F., S tefani, S. and O 'Leary, J.A .: T and B cells in pregnancy. O b stet. G ynecol. 49:299-302, 1977. Bibliography Ronald H. Kerman, Ph.D. 2 14. K erm an, R.H . and S te fa n i, S.: PHA stim u latio n of lym phocytes from p a tie n ts w ith lung cancer. Oncology 34:10-12, 1977. 15. K erm an, R .H . and S te fa n i, S.: Radio and im m unotherapy of lung can cer: A prelim inary rep o rt. In C rispen, R.G. (ed.): Neoplasm Im m unity-Solid Tumor T herapy, pp. 29-35. Franklin In stitu te Press, 1977. 16. S tefan i, S. and K erm an, R.H.: Lym phocyte response to PHA before and a fte r radiation therapy in patients with carcinom as of the head and neck. J. Laryngol. O tol. 91:605-609, 1977. 17. Kerm an, R .H ., Ing, T.S., Hano, J.E . and Geis, W.P.: Prognostic significance of the activ e T-RFC in ren al allo g raft survival. Surgery 82:607-612, 1977. 18. M arshack, M., T o to , P. and K erm an, R.H.: D elayed h y p ersen sitiv ity in the h a m ster cheek pouch. J . Im m unol. M eth. 3^5:325-330, 1977. 19. M arshack, M., T o to , P. and K erm an, R.H.: Im m unotherapy of chem ically-induced tum ors in the h am ster cheek pouch with dinitrochlorobenezene. J . D ental Res. 57:625-630, 1978. 20. S tefan i, S. and K erm an, R.: Prognostic significance of p re-th erap y delayed hypersen sitiv ity and T -ce ll levels in p a tie n ts with lung c an c e r. In N ieburgs, H.E. (ed.): Proceedings of the Third International Symposium on the D etection and Prevention of C a n c e r, Vol. 1, P a rt II, pp. 785-797. M arcel D ekker, Inc., 1978. 21. G eis, W.P., Iw atsuki, S., M olnar, Z., G iacchino, J .L ., K erm an, R.H., Ing, T.S. and Hano, J.E .: Im m unoblastic pseudo-lymphoma in renal allo g raft recipients. A rch. Surg. U3:461-466, 1978. 22. Dodson, M., K legerm an, M., K erm an, R.H., L ange, C., T essler, J . and O 'Leary, J .: B echet syndrome: With immunologic evaluation. O bstet. Gynecol. 5D621-625, 1978. 23. Dodson, M.G., K legerm an, M.E., Menon, M., K erm an, R .H ., Lange, C .F. and O'L eary , J.A .: Establishm ent and characterization of a squamous cell carcinom a of the vulva in tissue culture and immunological evaluation of the host. Am. J. Obstet. Gynecol. 131:606-619, 1978. 24. Kerm an, R.H. and Geis, W.P.: T-RFC m onitoring of CMI events in renal allo g raft recipients. Transpl. Proc. 10(3):633-635, 1978. 25. Kerm an, R.H., Ing, T.S., Hano, J.E . and Geis, W.P.: P redictive value of active T-RFC in ren al a llo g ra ft survival. T ranspl. Proc. j10(3):637-638, 1978. 26. Kerman, R.H. and S tefani, S.S.: E ffect of BCG im m unotherapy on the active T and to ta l T-RFC in p a tie n ts with lung cancer. C ancer Immunol. Imm unother. 4:41-47, 1978. 27. Kahan, B.D., Kerman, R.H. and McConnell, R.: Com bination of immunological and radionuclide techniques to diagnose allograft rejection. Surgical Forum. 29:364-366, 1978.  Bibliography Ronald H. Kerman, Ph.D. 3 28. Stfani, S. and K erm an, R.H.: Prognostic value of the immunologic profile in inoperable lung cancer p atien ts treated by radiation. In Muggia, F. and Rozencweig, M. (eds.): Lung C an cer (Progess in C ancer R ese arch and Therapy), Vol. 11, pp. 465470. Raven Press, Inc., New York, 1979. 29. Kerman, R.H.: Identification of human T and B lym phocytes. In Natelson, S., Pesce, A .J. and D ietz, A.A.: Clinical Immunochemistry: Chem ical and Cellular Bases ana A pplications in D isease, pp. 12-20. A m erican A ssociation for Clinical C hem istry, 1979. 30. Kahan, B.D., Floyd, M., Oka, T ., Van Buren, C.T. and K erm an, R.H.: Im m unological techniques in clinical renal transplantation. I. Cross-M atch Methods, Jap. J . Trans plant. 14:1-13, 1979. 31. Kahan, B.D., Floyd, M., Oka, T., Van Buren, C .T. and Kerm an, R.H.: Im m unological techniques in clin ical ren al tran sp lan tatio n . EL Im m unological M onitoring P o st allografting. Jap . J . T ransplant. 14:14-25, 1979. 32. K erm an, R .H ., Floyd, M., C onner, W., M cConnell, R., M cConnell, B .J., Van B uren, C.T. and Kahan, B.D.: Combined immunological and radionuclide techniques to monitor ren al allo g raft rejection. Transpi. Proc. Ll:1229-1231, 1979. 33. Geis, W.P., G iacchino, J.L ., Buckingham, J.M ., Bansal, V.K., Iwatsuki, S., Kerman, R.H., Ing, T.S. and Hano, J.E .: Does suppression of T-RFC determ ine in vivo immunosuppressive e ffe c t of ATG? Transpl. Proc. Tl:1433-1434, 1979. 34. Kerman, R .H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allo g ra ft survival of strong immune responder-high risk recipients with adjuvant ATG therapy. Transplantation 30:450-454, 1980. 35. Kerman, R. and Kahan, B.D.: C linical h isto co m p atib ility te stin g in renal tra n sp la n ta tion: P otential keys to alloimmune specificity and reactivity. In Reisfeld, R. and Ferrone, S. (eds.): C u rre n t Trends in H isto co m p atib ility , Vol. 2, pp. 201-226. Plenum Press, 1981. 36. Kerman, R.H. and Kahan, B.D.: Assessment of immune param eters of transplant recip ien ts on im m unosuppressive therapy. In D ean, J . and Padarathsingh, M. (eds.): Biological Relevance of Immune Suppression as Induced by Genetic Therapeutic and Environm ental F a c to rs, pp. 82-97. Van N ostrand Reinhold Co., New York, 1981. 37. Kerman, R .H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Prolonged allo g ra ft survival of strong pretransplant immune responders treated with ATG. Transpl. Proc. 13:332-335, 1981. 38. Kerman, R .H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: C orrelation of non specific immune monitoring with rejection or impaired function of renal allografts. Transplantation 32:16-23, 1981. 39. Kerman, R .H ., Floyd, M., Van Buren, C.T., and Kahan, B.D.: Prediction of cadaveric allograft survival based on pretransplant nonspecific immunocomptence; Transpl. Proc. 13:1533-1535, 1981. ,,^ . Bibliography Ronald H. Kerman, Ph.D. 4 40. K erm an, R .H ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Serial m easu rem en t of nonspecific immune param eters of chronically hemodialyzed renal failure patients. J . Clin. Immunol. 1:163-168, 1981. 41. K erm an, R .H .: New developm ents in tra n sp lan tatio n immunology. The C an cer Bulletin 33(6):281-286, 1981. 42. Kerman, R.H.: E ffect of blood transfusion on renal allograft survival: Imm unological considerations. Am. J. Kidney Diseases 2:125-127, 1981. 43. Kerman, R.H. and Kahan, B.D.: Immunological evaluation of transplant rejection: Pre and postoperative indices detectin g immune responsiveness. In Hayry, P. (ed.): P rese n t and F uture Trends in C linical T ran sp lan tatio n . Ann. Clin. Res. 13:244-263, 1981. 44. K erm an, R.H ., Van Buren, C., Payne, W., F lechner, S., A gostino, G., C onley, S., Brewer, E. and Kahan, B.D.: Influence of blood transfusions on immune responsive ness. Transpi. Proc. 14:335-337, 1982. 45. Kahan, B.D., Van Buren, C.T., Lin, S.N., Ono, Y., Agostino, G., LeGrue, S., Boileau, M., Payne, W. and Kerman, R.H.: Im m unopharm acologic m onitoring of C yclo sporin A -treated recipients of cadaveric kidney allografts. Transplantation 34:36-45, 1982. 46. Ono, Y., Kerman, R.H. and Kahan, B.D.: N atural cell-m ediated cytotoxicity and suppressor a c tiv ity for n atu ral c ell-m e d iate d c y to to x ic ity in long-term re n a l tra n s plant patients. Transplantation 34:103-107, 1982. 47. Van Buren, C.T., K erm an, R.H., A gostino, G., Payne, W., Flechner, S. and K ahan, B.D.: The cellu lar ta rg e t of C yclosporin A actio n in man. Surgery 92:167-174, 1982. 48. Kahan, B.D., K erm an, R.H., A gostino, G., Friedm an, A. and LeG rue, S .J.: T he actio n of Cyclosporin A on human lym phocytes. In White, D .J.G . (ed.): C yclosporin A, pp. 281-293. Elsevier - Biomedical Press, A m sterdam , 1982. 49. Agostino, G .J., Kahan, B.D. and Kerman, R.H.: Suppression of mixed leu co cy te culture using leucocytes from norm al individuals, urem ic individuals and allograft recipients. Transplantation 34:367-371, 1982. 50. K erm an, R.H ., Conklin, R., C ahall, D., Van Buren, C.T. and Kahan, B.D.: CMV and renal allo g raft survival. In Eisenstein, T. and Friedm an, H. (eds.): Host Defenses to Intracellular Pathogens, pp. 517-519. Plenum Press, Inc., New York, 1983. 51. E ttenger, R.B., Kerman, R., Jordan, S.C., Warshaw, B.L., H arris, R. and Fine, R.: Sensitization following donor-specific transfusions for living related renal transplan tation. Transpl. Proc. 15:943-945, 1983. 52. Van Buren, C.T., K erm an, R.H., A gostino, G., Flechner, S., Payne, W., and K ahan, B.D.: E ffe ct of cyclosporine on im m unoregulatory cells of renal allo g raft recip ien ts. Transpl. Proc. 15:527-530, 1983. Bibliography Ronald H. Kerman, Ph.D. 5 53. K erm an, R .H ., Van B uren, C .T ., P ay n e, W., F lech n er, S. and K ahan, B.D.: M onitoring T cell subsets and immune events in renal allograft recipients. Transpl. P ro c. 15:1170-1172,1983. 54. F le c h n er, S., K erm an, R ., Van B uren, C .T., Payne, W., and Kahan, B.D.: The use of cyclosporine and prednisone fo r high MLC haploidentical living re la te d renal tra n s plants. Transpl. Proc. 15:442-445, 1983. 55. Agostino, G., Kahan, B.D. and K erm an, R.: D etection of nonspecific suppressor cells from normal individuals, urem ic patients and allograft recipients. Transpl. Proc. 15:724-728, 1983. 56. K erm an, R .H ., A gostino, G ., Van B uren, C .T., Payne, W., F lech n er, S., C onley, S., B rew er, S. and Kahan, B.D.: E ffe c t of blood transfusions on g ra ft survival and immune responsiveness. Transpl. Proc. 15:1022-1025, 1983. 57. K erm an, R .H ., Van B uren, C ., P ay n e, W., F lech n er, S., A gostino, G., C onley, S., B rew er, S. and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune p a ram eters affectin g cadaveric allo g raft survival. T rans plantation 36:50-54, 1983. 58. K erm an, R .H ., F lech n er, S., Van B uren, C .T., Payne, W., and Kahan, B.D.: C yclo sporine im proves a llo g ra ft survival in im m unologically high-risk renal a llo g ra ft recipients. Transpl. Proc. 15:1909-1911, 1983. 59. K erm an, R .H ., Van B uren, C .T ., P ay n e, W., F lech n er, S., and Kahan, B.D.: Im m une monitoring of renal allograft recipients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. Transpl. Proc. 15:1971-1973, 1983. 60. K erm an, R .H ., Payne, W., Van B uren, C .T., F lech n er, S., and Kahan, B.D.: D e tec tio n of host presensitization to donor alloantigens utilizing a comprehensive immune crossm atch. Transpl. Proc. 15:1815-1816, 1983. 61. Flechner, S.M., Payne, W.D., Van B uren, C., Kerman, R., and Kahan, B.D.: The e ffe c t of cyclosporine on early g ra ft function. T ransplantation 38:268-272, 1983. 62. Verani, R .R ., B ergm an, D., and Kerm an, R.H.: G lom erulopathy in acu te and chronic rejection: U ltrastructural characteristics and relationship to graft survival. Am. J . Nephrol. 3:253-256, 1983. 63L K erm an, R .H .: E ditorial: In flu en ce of HLA A, B and DR antigen m atch in g in transfused cadaver renal transplant patients. Cleveland Clinic Q uarterly 50:216-217, 1983. 64. K erm an, R .H ., F lech n er, S., Van B uren, C .T., Payne, W. and Kahan, B.D.: Im m uno logical monitoring of renal allograft recipients treated with cyclosporine. T ranspl. Proc. 16:2302-2305, 1983. Bibliography Ronald H. Kerman, Ph.D. 6 65. Van Buren, C., K erm an, R ., Agostino, G., Flechner, S., Payne, W.D., and Kahan, B.: E ffe c t of cyclosporine on im m ucoregulatory cells of renal allo g ra ft re c ip ien ts. Transpi. Proc. 16:2293-2297, 1983. 66. Kahan, B.D ., Van B uren, C ., F lechner, S., Payne, W.D., and Kerman, R.: C yclosporine im m unosuppression m itig a te s imm unologic risk fa c to rs in renal allo tra n sp lan ta tio n . Transpl. Proc. 16:2469-2478, 1983. 67. Flechner, S.M., Van Buren, C., Kerman, R.H., and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal tra n sp la n ta tio n . T ranspl. Proc. 16:2689-2694, 1983. 68. F lechner, S.M., Van Buren, C .T., Kerman, R., and Kahan, B.D.: The e ffe c t of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. T ranspl. P ro c., 1983 (In press). 69. Flechner, S.M., Kerman, R.H., Van Buren, C., and Kahan, B.D.: Successful trans plantation of cyclosporine treated haploidentical living related renal recipients w ithout blood transfusions. T ran sp lan tatio n , 1984 (In press). 70. Kerman, R.H., Van Buren, C.T., Flechner, S.M., and Kahan, B.D.: C orrelation of visual, 5 lQ r-release, and flow cytom etry crossm atch results to g ra ft survival. T ranspl. P ro c., 1984 (In press). 71. Rogers, A .J., Kerman, R.H., and Kahan, B.D.: The pharm acokinetic and immunobiological a c tiv ity of cyclosporine in man. Transpl. P ro c., 1984 (In press). 72. Van B uren, C .T ., F lech n er, S.M ., Kerman, R.H., Vaughn, W., and Kahan, B.D.: C yclosporine im proves outcom e in high risk cadaveric renal a llo g raft recip ien ts. T ranspl. P ro c. 1984 (In press). 73. K erm an, R.H ., M anner, C., Ford, K., and Hoots, K.: Com prehensive immune evaluation of 78 hem ophiliacs. Ann. N. Y. Acad. Sc. 1984 (In press). t O A t )( Bibliography Ronald H. Kerman, Ph.D. 7 A bstracts and Presentations 1. Kerman, R., C lark, J . and Wheelock, E.F.: Mononuclear in filtra te into an air pouch: A new in v itro c ell m ed iated im m une assay. F ed. P ro c. 32:973, A tla n tic C ity , New Jersey , April 1973. 2. W heelock, E .F ., K erm an, R .H ., C lark, J . and Toy, S.: C ell m ed iated im m unity in dorm ant friend virus infections. Proc. Am. Assoc. Cancer Res. H :68, A tlantic City, New Jersey, April 1973. 3. S te fa n i, S., K erm an, R. and A bbate, J .: S erial studies of im m unocom petence in head and neck cancer patients undergoing radiotherapy. A bstract, American Radium Society M eeting, San Juan, P u erto Rico, May 1975. 4. K erm an, R., S tefani, S. and Geis, W.P.: T o tal and activ e T -cell dynam ics in renal allograft recipients. A bstracts of the American Society Transplant Surgeons, Chicago, Illinois, May 1976. 5. Kerm an, R., S tefani, S., Sm ith, R., Ezdinli, E. and Geis, W.P.: Imm unological evaluation of patients with solid tumors and hem atological m alignancies. Presented a t th e 1975 C ancer Sym posium , Neoplasm Im m unity: M echanism , C hicago, Illinois, Septem ber 1975. 6. Stefani, S., Kerman, R. and Abbate, J.: Immunological evaluation of patients with bronchogenic carcinom a. Presented at the American Society of Therapeutic Radi ology, San Francisco, C alifornia, October 1975. 7. Stefani, S. and Kerman, R.: D eterm ination and prognostic value of immunocompe te n c e in p a tien ts w ith lung c a n c e r tre a te d by rad io th erap y . A b stra cts of th e Third International Symposium on D etection and Prevention of C ancer, New York, April 1976. 8. Geis, W.P., Vaz, A.L. and K erm an, R.H.: Steroid sparing e ffe c t of ATG in high risk renal allograft survival. Presented at the American Society of Transplant Surgeons M eeting, Chicago, Illinois, May 1976. 9. K erm an, R.H ., and Geis, W.P.: Prognostic significance of the activ e T -cell in renal allograft survival. Presented at the American Society Transplant Surgeons Meeting, Chicago, Illinois, May 1976. 10. S te fa n i, S. and K erm an, R .: BCG and rad io th erap y in bronchogenic carcinom a: Prelim inary report. Presented at the American Society of Therapeutic Radiology, .A tlanta, Georgia, O ctober 1976. 11. K erm an, R. and Geis, W.P.: T-RFC m onitoring of CMI events in renal allograft recipients. Presented at the Sixth International Congress of the Transplantation Society Special Session Immunological Monitoring of Transplant R ecipient, New York, August 1976. 12. Kerm an, R. and Stefani, S.: Radio and im m unotherapy of lung cancer: A prelim inary rep o rt. Presented a t the 1977 Chicago Symposium: Im m unotherapy of Solid Tumors, Chicago Illinois, February 24-25, 1977. 12358 Bibliography Ronald H. Kerman, Ph.D. 8 13. S tefan i, S. and K erm an, R .H .: R elevance of immunologic analysis for p atien ts w ith inoperable lung cancer tre a ted by radiotherapy. Presented at an NCI sponsored Symposium 'T h e Second C o n feren ce on Lung C ancer T rea tm e n t," a t A irlie House, Virginia, May 22-24, 1977. 14. Kerman, R.H ., Ing, T.S., Hano, J.E . and Geis, W.P.: Prognostic significance of active T -R F C in ren al a llo g ra ft survival. A bstracts of F irst In te rn a tio n a l Symposium on Immunological M onitoring of the Transplant Recipient. London, O ntario, June 8-10, 1977. 15. K erm an, R .H . and G eis, W.P.: T -R F C m onitoring of CMI ev en ts in renal a llo g ra ft re c ip ie n ts. A b stra cts of F irs t In tern atio n al Symposium on Im m unological M onitoring of the Transplant R ecipient. London, Ontario, June 8-10, 1977. 16. Ezdinli, E., Simonson, K., Icli, F. and Kerman, R.: E ffects of single vs. m ultiple agent therapy on cell-m ediated immunity. Proc. Amer. Assoc. Clin. Oncol. 18:355, D enver, Colorado, May 1977. 17. Geis, W.P., Iw atsuki, S., M olnar, Z., Giacchino, J.L ., Kerm an, R.H., Ing, T.S. and H ano, J.E .: Im m unoblastic pseudo-lym phom a in renal a llo g ra ft re cip ien ts. P rese n ted a t the W estern Surgical A ssociation, Las Vegas, Nevada, November 15, 1977. 18. Kerman, R.H., R oesler, H. and K ahan,B.D .: Specific stim ulation of active T -R osette form ing cells by 3M KC1 solubilized antigen. Fed. P ro c., 1978. P resen ted a t th e FASEB-AAI M eeting, A tlanta, Georgia, June 1978. 19. K erm an, R .H ., Floyd, M., C onner, W., M cConnell, B .J., M cConnell, R . and Kahan, B . D.: C orrelation of a ctiv e T -R F C and spontaneous blastogenesis with decreased renal allograft function. A bstracts of the American Association for Clinical H istocom patibility Testing, Boston, M assachusetts, June 1978. 20. Kerman, R .H ., R oesler, H. and Kahan, B.D.: Increased activ e T-RFC with in vitro stim ulation by soluble donor antigen. A bstracts of the Amer. Assoc, of Clin. Histocomp.. Testing, Boston, M assachusetts, June 1978. 21. K erm an, R .H .,' Floyd, M., C onner, W., M cConnell, R ., M cConnell, B .J., Van B uren, C. T. and Kahan, B.D.: Combined immunological and radionuclide techniques to m onitor ren al a llo g ra ft re je c tio n . P resen ted a t th e VII In te rn a tio n a l Congress of T he Transplantation Society, Rome, Italy, Septem ber 1978. 22. Kerman, R.H.: Invited speaker to a special workshop "Immunological Monitoring of th e T ran sp lan t P a tie n ts " , VII In tern atio n al C ongress of The T ran sp lan tatio n S o ciety , Rome, Italy, Septem ber 1978. 23. Kahan, B.D., Kerman, R. and McConnell, R.: Combination of immunological and radionuclide techniques diagnoses allograft rejection. Presented a t the American College of Surgeons, San Francisco, California, O ctober 1978. 24. M ichelson, J ., M cConell, Kerm an, R. and Kahan, B.: Association of acute rejection episodes in renal tran sp lan t p atien ts with scored results of com puter analyzed d ata. P resented a t the Southw est Society of Nuclear M edicine M eeting, March 16, 1979, San Antonio, Texas. f O0 KQ JL Ac* o O Bibliography Ronald H. Kerman, Ph.D. 9 25. Kerman, R .H ., M acek, C. and Kahan, B.D.: Increase in 3 d ifferen t E -ro sette m arkers on human T cells follow ing PHA activ atio n . F ed. P ro c. 38 (No. 3, P a rt n):1282. Presented at the Annual M eeting of The American Association of Immunologists, Dallas, Texas, April 1979. 26. K erm an, R .H .: Im m unological considerations in renal tran sp lan tatio n . C lin ical Oncology Grand Rounds, M.D. Anderson H ospital and Tum or In stitu te, Septem ber 1979. 27. Kerman, R.H . and Kahan, B.D.: Assessment of immune param eters of transplant rec ip ien ts on im m unosuppressive therapy. P resen ted a t an NIH Workshop on "The Biological R elevance of Immune Suppression as Induced by G enetic Therapy and Environm ental F actors," Williamsburg, Virginia, November 1979. 28. Invited p a rtic ip a n t in a working cadre for th e NIH to develop a "Consensus On Immunotoxicology" for the National Toxicology Program , November 1979, R esearch Triangle P ark, N .C ., NIEHS, NIH. 29. K erm an, R .H .: H isto co m p atib ility testin g in tran sp lan tatio n . Pathology G rand Rounds, S t. Luke's H ospital, January 1980. 30. Van Buren, C .T., Kerman, R.H. VanBuren, D. and Kahan, B.D.: C orrelation of immune responsiveness with n u tritional indices in chronic renal failure p a tie n ts. Presented at the American Society for Parenteral and Enteral Nutrition, Annual Meeting, Chicago, Illinois, January - February 1980. 31. Kerman, R.H.: Immune monitoring of renal allograft recipients. Surgical Grand Rounds, University of Miami School of Medicine, March 1980. 32. Kerman, R.H.: P re- and postoperative immune monitoring of allograft recipients. Medical Grand Rounds, Division of Dialysis and Transplantation, Children's H ospital of Los Angeles, April 1980. 33. Kerman, R.H. and Semchuk, R.: Delineation of a radioresistant T cell subpopulation. Fed. Proc. 39(3):945. Presented a t the Annual M eeting of The American Association of Immunologists, Anaheim, California, April 1980. 34. Kerm an, R.H.: E ffe c t of h eat on the ability of human T cells to express the a ctiv e T and to ta l T recep to rs. Fed. Proc. 39(3):1137. P resented a t the Annual M eeting of The American Association of Immunologists, April 1980, Anaheim, California. >. Kerm an, R ., Peddada, L. and Kahan, B.D.: C orrelation of hyperacute rejection with ` .LDA and CDA vs. 5 1 c r-la b e le d donor T and B cell ta rg e ts. P resen ted a t T he American Association for Clinical H istocom patibility Testing, St. Louis, Missouri, April 1980. 36. Kerm an, R ., Floyd, M., Van Buren, C.T. and Kahan, B.D.: Improved allograft survival of strong responder-high risk cadaver recipients with adjuvant immunosuppressive therapy. Presented a t the Annual Meeting of The American Association for C linical H istocom patibility Testing, April 1980. 12360 Bibliography Ronald H. Kerman, Ph.D. 10 37. Kerman, R., Conklin, R., Cahall, D. and Kahan, B.D.: Association of cytom egalovirus and renal allograft survival. Presented at the m eeting of the American Association for C linical H istocom patibility Testing, St. Louis, Missouri, April 1980. 38. K erm an, R ., Floyd, M., V anB uren, C .T. and Kahan, B.D.: D elineation o f donor specific and nonspecific pretransplant immunocomptence as a predictor for LRD allograft survival. Presented at the Meeting of The American Association of Clinical H istocom patibility Testing, St. Louis, Missouri, April 1980. 39. K erm an, R .H ., Floyd, M., V anB uren, C.T. and Kahan, B.D.: Im proved a llo g ra ft survived of strong immune responder-high risk recipients with adjuvant immuno suppressive therapy. Presented a t the annual m eeting of The American Society of T ransplant Surgeons, Chicago, Illinois, May 1980. 40. K erm an, R.H ., Floyd, M., V anB uren, C.T. and Kahan, B.D.: C o rrelatio n of nonspecific immune monitoring of renal allograft recipients with rejection and impaired renal function. Presented at the Annual Meeting of The American Society of T ransplant Surgeons, Chicago, Illinois, May 1980. 41. K erm an, R ., Floyd, M., V anB uren, C.T. and Kahan, B.D.: Prolonged a llo g raft survival of strong pretransplant immune responders treated with ATG. P resented at the Vinth International Congress of The T ransplantation Society, Boston, M assachu setts, June 1980. 42. K erm an, R ., Floyd, M., Van B uren, C.T. and Kahan, B.D.: P red ictio n of renal a llo g ra ft survival based on p re tra n sp lan t non-specific im m unocom ptence. P re se n te d a t The Second International Symposium on Imm unological M onitoring of th e T rans plant R ecipient, Leiden, The N etherlands, Septem ber 1980. 43. K erm an, R .H ., Floyd, M., Van B uren, C .T., M cConnell, B .J., M cConnell, R . and Kahan, B.D.: Delineation of renal allograft rejection and impaired renal function by serial m easurem ent of non-specific immune param eters. Presented a t The Second In ternational Symposium on Imm unological M onitoring of the T ransplant R ecip ien t, Leiden, The N etherlands, Septem ber 1980. 44. Kerman, R.H. and Kahan, B.D.: Increased expression of the active T-RFC recep to r as a m easure of allosensitization following in v itro stim ulation of rec ip ien t lym pho c y te s by soluble donor HLA antigens. P re se n te d a t The Second In te rn a tio n a l Symposium on Immunological Monitoring of the Transplant R ecipient, Leiden, The N etherlands, Septem ber 1980. 45. K erm an, R .H ., Floyd, M., Van Buren, C.T. and Kahan, 3.D .: C o rrelatio n of HLA A,B and DR typing to cadaveric and living related renal allograft survival. Presented at The Second In tern atio n al Symposium on Im m unological Monitoring of the T ransplant R ecipient, Leiden, The Netherlands, Septem ber 1980. 46. Floyd, M., K erm an, R ., Woo, J ., Van Buren, C .T . and Kahan, B.D.: R elatio n sh ip s of beta-2-m icroglobulin metabolism, immune reactivity and renal allograft rejection. P resen ted a t The Second International Symposium on Imm unological M onitoring of the T ransplant R ecipient, Leiden, The N etherlands, Septem ber 1980. f O ^ -i 1 4 iifcl Bibliography Ronald H. Kerman, Ph.D. 1: 47. Kerm an, R.H.: Immune m onitoring of renal allograft recipients. Surgical Grand Rounds, University of Chicago, June 1981. 48. K erm an, R .H ., Van Buren, C.T., LeG rue, S .J. and Kahan, B.D.: Im m unopharm acological monitoring of cadaveric renal allograft recipients receiving Cyclosporin A. Presented at the Annual M eeting of the American Society of Transplant Surgeons, C hicago, Illinois, June 1981. 49. K erm an, R .H ., Conklin, R ., C ahall, D ., Van B uren, C .T. and Kahan, B.D.: CMV and renal allo g raft rejection. P resented a t a Symposium on Host D efenses to Intra cellular Pathogens, Franklin Plaza Hotel, Philadelphia, Pennsylvania, June 1981. 50. Schoenberg, L.P., Kahan, B.D. and Kerm an, R.H.: The use of Cyclosporin A as im m unosuppressive m edication in ren al tra n sp lan tatio n . P rese n ted a t The N ational Kidney Foundation, Inc., W ashington, D .C., November 1981. Amer. J . Kidney D iseases, Program for C linical Dialysis and T ransplantation Forum , p. 29. 51. E tten g e r, R ., Kerman, R., A rnett, J ., Jordan, S., Warshaw, B., H arris, R., Wassner, S. and Fine, R.: Sensitization following donor-specific transfusions for live-related renal transplantation. American Society of Nephrology, Washington, D.C., November 1981. 52. F le c h n e r, S., B oileau, M., Payne, W., Van B uren, C., K erm an, R. and Kahan, B.: The use of Cyclosporin A in stro n g im m une responder, high risk ren al tran sp lan t re c i pients. Am erican Urological A ssociation, Kansas City, Kansas, 1982. 53. K erm an, R ., Van Buren, C ., Payne, W., F lech n er, S., A gostino, G., C onley, S., B rew er, E. and Kahan, B.: Influence of blood transfusions on immune responsiveness. Presented a t The Transfusion and Transplantation C onference, Los Angeles, Cali fornia, January - February 1982. 54. Agostino, G., Kahan, B.D. and Kerman, R.H.: Suppression of mixed leucocyte culture using mononuclear leukocytes from normals, urmies and allograft recipients. P re sented a t the Annual M eeting of The Am erican Association of Immunologists, FASEB, New O rleans, Louisiana, April 1982. 55. Agostino, G .J., Kahan, B.D. and Kerman, R.H.: M easurement of suppressor cell statu s in potential allograft recipients. Presented at the Annual M eeting of The Am erican Association of Clinical H istocom patibility Testing, San Francisco, Cali fornia, April 1982. 56. K erm an, R .H .: Invited p re se n te r a t tw o workshops on 1) Im m une m onitoring of . a llo g ra ft re c ip ien ts and 2) The e ffe c t of tran sfu sed blood and blood products on urem ic hosts. Presented a t the Annual M eeting of The North American Transplant C oordinators O rganization, San Antonio, Texas, May 1982. 57. K erm an, R.H., Van Buren, C., Flechner, S., Agostino, G., Conley, S., .Brewer, E. and Kahan, B.D.: The influence of pretransplant blood transfusions from random donors on immune param eters affecting cadaveric allograft survival. Presented at The Annual M eeting of The American Society of Transplant Surgeons, Chicago, Illinois, June 1982. *-****** O > V 0 -w Bibliography Ronald H. Kerman, Ph.D. 12 58. A gostino, G., Kahan, B.D. and Kerm an, R.H.: Suppression of mixed leucocyte culture using leucocytes from normal individuals, urem ic individuals, and allograft recipients. P resented at The Annual M eeting of The American Society of Transplant Surgeons, C hicago, Illinois, June 1982. 59. K erm an, R.H.: Invited p resen ter a t a workshop on "Human T lym phocyte subpopula tio ns: T h eir role in rejectio n and im m unosuppression." P resen ted a t th e In te rn a tio n a l C ongress of The Transplantation Society, Brighton, England, August 1982. 60. K erm an, R.H.: Invited p resen ter a t a workshop on "Mechanisms responsible for blood transfusion effects." Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 61. E tte n g e r, R.B., Kerman, R ., Jo rd an , S.C., Warshaw, B.L., H arris, R. and Fine, R.: Sensitization after donor-specific transfusions for live-related renal transplantation. Presented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 62. Van B uren, C .T., K erm an, R .H ., A gostino, G., F lech n er, S. Payne, W. and Kahan, B.D.: E ffe c t of cyclosporine on im m unoregulatory cells of renal allo g raft recipients. P resented at The International Congress of The Transplantation Society, Brighton, England, August 1982. 63. K erm an, R .H ., Van B uren, C .T ., P ay n e, W., F lech n er, S. and K ahan, B.D.: M onitoring T c ell subsets and im m une ev en ts in renal a llo g ra ft recipients,. P rese n ted a t T he International Congress of The Transplantation Society, Brighton, England, August 1982. 64. F le c h n e r, S., K erm an, R ., Van B uren, C .T., Payne, W. and Kahan, B.D.: The use of cyclosporine and prednisone for high MLC haploidentical living re la te d renal tra n s plants. Presented at The International Congress of The Transplantation Society, B righton, England, August 1982. 65. A gostino, G., Kahan, B.D. and Kerman, R.: D etection of nonspecific suppressor cells from norm al individuals, urem ic patients and allograft recipients. Presented a t The International Congress of The Transplantation Society, Brighton, England, August 1982. 66. K erm an, R .H ., A gostino, G., Van Buren, C .T., Payne, W., F lech n er, S., C onley, S., B rew er, E. and Kahan, B.D.: E ffe c t of blood transfusions on g ra ft survival and immune responsiveness. Presented at The International Congress of The T ransplantation Society, Brighton, England, August 1982. 67. K ahan, B .D ., Kerm an, R ., Payne, W.D., Flechner, S. and Van Buren, C.T.: Immunopharm acologic studies of cyclosporine-treated renal allograft recipients. Fifth T rip artite Meeting, Society of University Surgeons, Salzburg, A ustria, Septem ber 1982. JfL J -J14 J Bibliography Ronald H. Kerman, Ph.D. 13 68. K erm an, R .H ., F lech n er, S., Van Buren, C .T., Payne, W., and Kahan, B.D.: C yclo sporine im proves a llo g ra ft survival in im m unologically high-risk ren al a llo g ra ft recipients. Presented at the Third International Immunological Monitoring Sym posium, K eyB iscayne, Florida, November 1982. 69. K erm an, R .H ., Van B uren, C .T ., Payne, W., F lech n er, S., and Kahan, B.D.: D etectio n of host presensitization to donor alloantigens utilizing a com prehensive immune crossm atch. Presented at the Third International Immunological Monitoring Sym posium, K eyBiscayne, Florida, November 1982. 70. K erm an, R .H ., Payne, W., Van B uren, C .T., F lech n er, S., and Kahan, B.D .: Immune monitoring of renal allograft recipients treated with cyclosporine or azathioprine using donor-specific and nonspecific assays as well as monoclonal T cell reagents. P resented a t the Third International Immunological Monitoring Symposium, Key Biscayne, Florida, November 1982. 71. Kerman, R.H.: Invited plenary speaker at the F irst Annual M eeting of The American Society of T ransplant Physicians, "Optimizing immunosuppression: Mode of action of cyclosporine." Chicago, D ecem ber 1982. 72. K erm an, R .H ., Van Buren, C .T., Payne, W., F lechner, S., and Kahan, B.D.: Cyclo sporine im proves allo g ra ft survival in im m unologically high-risk renal a llo g raft recipients. Presented a t The Annual M eeting, N ational Kidney Foundation, Clinical Dialysis and Transplant Forum , Chicago, D ecem ber 1982. 73. Kerm an, R.H.: Role of immune evaluation in clinical medicine. C linical Immunology Grand Rounds, The Children's Memorial Hospital, Chicago, Illinois, Decem ber 1982. 74. Kerman, R.H.: Immunologic effects of toxic m aterials. Presented a t Toxicology Clinical U pdate, University of Texas Medical Branch, Galveston, Texas, January 1983. 75. K erm an, R .H .: C yclosporine im proves a llo g ra ft survival in im m unologically high risk renal allograft recipients. Presented at Pathology Grand Rounds, University of Pittsburgh School of M edicine, February 1983. 76. Kerman, R.H.: Immune evaluation of renal failure patients and allograft recipients. Presented a t Surgical Grand Rounds, St. Louis University Medical C enter, St. Louis, M issouri, March 1983. 77. K erm an, R.H.: Immunological evaluation of hemophiliacs. Presented at a Symposium on C urrent Problem s in the M anagem ent of Hem ophiliac Com plications, Houston, Texas, April 1983. 78. F le c h n er, S ., K erm an, R .H ., Van B uren, C .T ., Payne, W., and Kahan, B.D.: Successful transplantation of high mixed lymphocyte culture haplo-identical living related donors using cyclosporine and prednisone. Presented a t the Annual American Urological Association, Las Vegas, Nevada, April 1983. 79. K erm an, R .H ., F lech n er, S., Van Buren, C .T., Payne, W., and K ahan, B.D.: Imm unolo gical monitoring of renal allograft recipients treated with cyclosporine. Presented at The F irst International Congress on Cyclosporine, Houston, Texas, May 1983. Bibliography Ronald H. Kerman, Ph.D. 14 80. Van Buren, C., Kerm an, R., A gostino, G., Flechner, S., Payne, W.D., and Kahan, B.: E ffe c t of cyclosporine on im m unoregulatory cells of renal allo g raft recipients. P rese n ted a t The F irst In tern a tio n a l C ongress on C yclosporine, Houston, Texas, May 1983. 81. Kahan, B.D., Van Buren, C., F lechner, S., Payne, W.D., and Kerm an, R.: Improved outcom e of 150 renal a llo g ra fts in im m unologically high risk recip ien ts tre a te d with cyclosporine. P resented a t The F irst In tern atio n al Congress on Cyclosporine, H ouston, Texas, May 1983. 82. Flechner, S.M., Van Buren, C., Kerm an, R.H., and Kahan, B.D.: The nephrotoxicity of cyclosporine in renal tra n sp la n ta tio n . P resen ted a t The F irs t In tern atio n al Congress on Cyclosporine, Houston, Texas, May 1983. 83. Flechner, S.M., Van Buren, C .T., Kerman, R., and Kahan, B.D.: The e ffe ct of conversion from cyclosporine to azathioprine immunosuppression for intractable nephrotoxicity. P resented a t The F irst In tern atio n al Congress on Cyclosporine, H ouston, T exas, May 1983. 84. K erm an, R .H ., F lechner, S., Van B uren, C .T., Payne, W., and Kahan, B.D.: C yclo sporine immunosuppression overcom es immunologic risk factors for recipients of cadaveric renal allografts. Presented at the Annual M eeting of The American Society of Transplant Physicians, Chicago, Illinois, June 1983. 85. Flechner, S.M., Kerman, R .H ., Van Buren, C .T., and Kahan, B.D.: The high risk haploidentical living related recipient: T ransplantation w ithout blood transfusions and steroid withdrawal using cyclosporine. Presented a t the Annual Meeting of The Am erican Society of T ransplant Physicians, Chicago, Illinois, June 1983. 86. Kerman, R.H.: Relationship of im m unocom ptence of hemophiliac patients and acquired immune deficiency syndrom e (AIDS). P re se n te d a t th e Gulf C oast Hemo philia Chapter Meeting, Houston, Texas, O ctober 1983. 87. Kerm an, R ., Van Buren, C .T., Flechner, S., and Kahan, B.D.: C orrelation of visual, ST-Cr-release and flow cytom etry crossm atch results to g ra ft survival. Presented at The Fourth International Symposium: Immune M onitoring of The Transplant Re cipient, Houston, Texas, November 1983. 88. Rogers, A .J., Kerman, R.H., and Kahan, B.D.: The pharm acokinetic and immunobiological a ctiv ity of cyclosporine in man. P re se n te d a t T he F ourth In tern atio n al Symposium: Immune M onitoring of The Transplant R ecipient, Houston, Texas, Novem ber 1983. 89. K erm an, R.H., Manner, C ., Ford, K., and H oots, K.: C om prehensive immune evaluation of 78 hem ophiliacs. P resen ted a t th e New York A cadem y of Sciences Symposium on Acquired Im m une D eficiency Syndrom e, New York, New York, Novem ber 1983. 90. K erm an, R., Van Buren, C .T., Flechner, S.M., and Kahan, B.D.: DRW6 and DR3 phenotypes correlating with immune response. Presented a t the Annual Meeting of The American Association for Clinical H istocom patibility Testing, Chicago, Illinois, N ovem ber 1983. Bibliography Ronald H. Kerman, Ph.D. 15 91. Van Buren, C .T., F lech n er, S.M ., K erm an, R .H ., Vaughn, W., and Kahan, B.D .: C yclosporine im proves outco m e in high risk cad av eric renal a llo g raft re cip ien ts. Presented at the F irst Meeting of The European Society for Organ Transplantation, Zurich, Switzerland, November 1983. 92. Kerman, R.H.: Cyclosporine immunosuppression for renal transplantation. Presented to Sandoz P harm aceuticals, Inc., E ast Hanover, New Jersey, Decem ber 1983. 93. K erm an, R.H.: New horizons in transplantation: Influence of cyclosporine on renal transplantation. Invited presenter at the W estern Dialysis and Transplantation Society, Park City, U tah, January 1984. 94. Sterling, R.P., Bradley, B.B., Khalil, K.G., Kerman, R.H., and Conklin, R.H.: Com pari son of biopsy proven pneum ocystis pneum onia in acquired im m une deficiency syndrom e (AIDS) p a tie n ts versus renal a llo g ra ft p a tie n ts. P rese n ted a t The S ociety fo r T h o racic Surgeons, San Antonio, Texas, January 1984. 95. Rogers, A.J., Kerman, R.H., and Kahan, B.D.: C orrelation of immunopharmacokinetic profiles of cyclosporine-treated allograft recipients and rejection. Presented at The Society for University Surgeons - Residents' M eeting, Chicago, Illinois, February 1984. MARVIN S. LEGATOR, Ph.D. Dr. Legator is Professor of Environmental Toxicology, University of Texas Medical School at Galveston. His Curriculum Vitae will be supplied. The subject matter of Dr. Legator's testimony will include: the teratogenic and carcinogenic effects of TCDD, as well as its mutagenic potential; the multi-system effects of TCDD at extremely low concentrations; the demonstrable effects, both gross and more subtle, of TCDD on animals; the extrapolition of the animal studies to humans, that is, the inherent, intended predictive aspects of the animal data to man; and finally to his work as a geneticist with respect to reproductive toxicology, i.e. male (Vietnam Veterans) - mediated birth defects and certain untoward pregnancy outcomes. Dr. Legator will testify to the extreme toxicity of dioxins, particularly 2,3,7,8-TCDD. Specifically, his testimony will indicate that TCDD is a complete carcinogen based upon certain animal studies, and that as a carcinogen, there is no safe level and does not have therefore a so-called no effect level. With respect to that, Dr. Legator will describe the extra ordinary precautions which are taken, and the fears of the researchers, in connection with the laboratory use of TCDD. In addition, Dr. Legator will testify to the reproductive toxicological effects, i.e. birth defects, and miscarriages of the children and wives of the exposed Vietnam veterans. The animal data in this regard are positive and consistent and provide a mechanistic linkage which confirms the Vietnamese epidemiological study of Hatch and others. Specifically, therefore Dr. Legator will testify that the X. & iJ 0 8 of Mrs. Dan G. Jordan and the congenital malformations of the children of Dan G. Jordan, as well as those of Kerry Ryan, daughter of Michael F. Ryan, were caused by the presumed exposure of representative plaintiffs Jordan and Ryan to phenoxy herbicides and dioxins - specifically 2,3,7,8-TCDD -- while serving in Vietnam. The bases or grounds for such facts and opinions include Dr. Legator's: educational and professional experience; personal researches; review of the applicable medical and scientific literature; and a review of the medical records and/or data of the Jordan and Ryan families. 7- - ALAN SCOTT LEVIN, M.D. Dr. Levin is engaged in tfie practice of medicine in San Francisco, His Curriculum Vitae is attached. Dr. Levin will testify that phenoxy herbicides and their contaminants, including dioxins, most especially 2,3,7,8-TCDD, cause an assortment of immunological responses, i.e. immuno-toxicity, which predispose persons exposed by absorption and/or ingestion and/or inhalation - to such chemicals to a whole host of adverse health effects, such as: chloracne or other skin rashes; various neuro-toxic effects;' reproductive effects; and neoplasm. In connection with the carcinogenic effect, Dr. Levin will state there is no safe level for this or any other carcinogen, and that a single exposure several years earlier can result in human cancer many.years later. The bases for such facts and opinions expressed herein by Dr. Levin include: review of the medical and scientific literature, including both animal and human data; his personal researches; his clinical experiences; and his personal knowledge of the defoliation of Vietnam by such phenoxyherbicides and dioxins, with such chemicals in the presence of the veterans andtheir presumed exposure thereby; and review of all pertinent medical data of the representative plaintiffs. Dr. Levin will discuss the following in his testimony: the immune system, with its organic, cellular, and humoral components - most especially with regard to the latter, T-helper cells, B-cells, plasma cells and immuno globulin production; immune response, both beneficial and harmful; the various experimental studies, particularly those demonstrating atrophy of the thymus, weight loss, depletion of lymphoid organs, lymphopenia, cutaneous type delayed hypersensitivity (skin thickness) and altered bacterial immunity. < o n n n In addition, Dr. Levin will discuss the following and their significance: immunology as molecular biology; chemical-induced immune disregulation; T-cells (lymphocytes from thymus) acting as immune modulators, (for which again there is no "no effect" level); immune surveillance; the similarity of the immune, neurologic, and endocrine systems and their significance in the area of immuno-toxicity; the relationship of immune disregulation caused by chemicals and carcinogenicity. Dr. Levin will then testify to the causal relationship of the various Agent Orange/dioxin related adverse health effects of the representative plaintiffs, including: chloracne; neuro-toxic effects, both neurological and psychological; reproductive toxic effects, both miscarriages and birth defects; and such neoplastic processes as soft tissue sarcoma, as here a rhabdomyosarcoma, lymphocytic lymphoma and basal cell carcinoma. <* f** !*** t*'\ (U -2- \r CURRICULUM VITAE Alan Scott Levin, M.D. .Born: High School: College: Graduate School: Masters Thesis: Medical School: Internship: Fellowships: Specialty Board Certifications: Military: Marital Status: January 12, 1938. Chicago, Illinois. Austin, Chicago, Illinois University of Illinois, Champaign-Urbana, Illinois 1956-1960 B.S. Chemistry in L.A. with Honors. University of Illinois (Chicago Medical Center) M.S. in Biochemistry, 1963. Metabolism of Serum Albumin in Rats with Cirrhosis of the Liver, 1963. University of Illinois (Chicago Medical Center) M.D. 1964 Alpha Omega Alpha Honor Medical Society, 1963 Children's Hospital Medical Center, Boston, Mass. Traineeship Grant, Harvard Medical School 1964 Research Assistant, Children's Hospital Boston, 1965. USPHS Hematology Training Grant, University of California San Francisco, Medical Center 1969-1971 (Pediatric and General Immunology). American Cancer Society Faculty Research Award, 1971-- 197-- 1. Certified Diplomnte American Board of Allergy and Immunology, 1975. 2. Certified Diplomate American Board of Pathology-Ciinicr Pathology, 1977. 3. Fellow in the American College of Emergency Physicians. 4. Fellow College of American Pathologists. 5. Fellow American Society -o'( Clinical Pathologists. 6. Member American Academy of Allergy. 7. Member American Association of Clinical Chemists. USN attached to USMC as Flight Surgeon 1966-1968 Viet Nam Campaign ribbons and unit citation, Navy and Marine Corps Commendation, First through Fourth Air Medals Bronze Scar Medal wich Combat "V", Silver Star Medal, Honorable Discharge November 1969. 12371 M a r r i e d to Vera S. Byers, P h .D ., M.D. fio c h i l d r e n . fI ad emic po intments : Adjunct Instructor in Pediatrics University of California San Francisco Medical Center 1971 - 1972 Assistant Professor of Immunology in Dermatology University of California San Francisco Medical Center 1972 - 1978 Adjunct Associate Professor of Immunology University of California San Francisco Medical Center 1978 - Director of Laboratory of Immunology University of California and Kaiser Foundation Research Institute Joint Program Project San Francisco, California 1971 - 1974 Director of Division of Immunology Western Laboratories 2945 Webster Street Oakland, California 1974 - 1977 Medical Director MML/Sclano Laboratories 2920 Telegraph Avenue Berkeley, California 1977 - 1979 Medical Director Levin Clinical Laboratories, 326 bth Streex San Francisco, California 1979 - 1981 Inc. Private Practice of Medicine 450 Sutter, Suite 1138 San Francisco, California,. 941U8 1981 - Member, Medical Quality Review Committee, #4 Board of Medical Quality Assurance State of California I ALAN SCOTT LEVIN, M.D. BIBLIOGRAPHY (Abstracts not included) 1. Levin, A.S., and Jeffay, H.: Metabolism of serum albumin in rats with cirrhosis of the liver. J. Lab & Clin. Med. 63: 776-733, 1964. 2. Klemperer, M.R., Cotoff, S.P., Alper, C.A., Levin, A.S., and Rosen, F.S.: Estimation of serum beta 1-C globulin concentration: Its relation to the serum hemolytic complement titre. Pediatrics 36: 766-769, 1965. 3. Alper, C.A., Levin, A.S., and Rosen, F.S.: Beta-IC-globulin: Metabolism in Glomerulonephritis. Science 153 (3732): 180-182, 1966. 4. Vyas, G.N., Levin, A.S., Fudenberg, H.H.: Intrauterine isoimmunization caused by transplacental passage of maternal IGA. Nature 225: 275-276, 1970 5. Levin, A.S., Pipkins, M.O., and Fudenberg, H.H.: A rapid radioimmunoassay for measuring nanogram levels of antigens. Vox. Sane. 18:459-466, 1970. 6. Levin, A.S., Spitler, L.E., Stites, D.P., and Fudenberg, H.H.: A gene tically determined cellular immunologic deficiency: Clinical and laboratory responses to therapy with transfer factor. Proc. Natl. Acad. Sci.USA 67: 321-828, October, 1970. 7. Stites, D.P., Levin, A.S., Austin, K.E., and Fudenberg, H.H.: Immuno biology of Human Lymphoid Cell Lines. Immunoglobulin biosyntheseis in cultures from Hypogamma-globulincmias and Paraproteinemia. J. Immunol. 107: 1376-1381, November, 1971 8. Levin, A.S., Fudenberg, H.H., Hopper, J.E., Nisonoff, A., and Wilson, S.K.: Immunofluorescent evidence for control of synthesis of variable regions of light and heavy chains of IgG and IgM by^the same gene. Proc. Natl. Acad. Sci. USA 6 8 : 169-171, 1971 9. Fudenberg, H.H., Wang, A.C., Pink, J.R.L., and Levin, A.S.: Studies of an Unusual Biclonal Gammopnthy. Ann. N.Y. Acad. Sci. 190:501-506, 1971. 10.. Levin, A.S., Fudenberg, H.H., Pete, L.D., and Sharp, G.C.: IgG levels in Cerebrospinal Fluid of Patients with Central Nervous System Lupus. Clin. Immunol, and J. Immunopath. 1: 1-5, 1972 11. Spitler, L.E., Levin, A.S., Huber, H . , and Fudenberg, H.H.: Prediction of Results of Transfer Factor Therapy in the Wiskott-Aldrich Syndrome by Monocyte IgG Receptors. In Proceedings of the Sixth Leukocyte Culture Conference. Academic Press, Inc., New York and London, P.795-803, 1972. 12373 ( 12. Spieler, L.E., Levin, A.S., Stites, D.P., Fudenberg, H.H., Pirofsky, C.S., August, E.R., Stiehm, W.H., Hitzig, H., and Cacti, R.A. : The WiskottAldrich Syndrome Results of Transfer Factor Therapy. J. Clir., Invest. 51: 3216- 3224, 1972 13. Spat'n, P., Garraty, G., Levin, A.S., Petz, L.D. , Fudenberg, H.H.: Immunhematologisc'ne Vernderungen bei Cephalosporin-therapie. Verhandlungen der Duetschen Gesselschaft fr innere Medizin, Vol. 78, 914-916, 1972. 14. Fudenberg, H.H., Spitler, L.E., and Levin, A.S.: Treatment of Immune Deficiency Disorders. Amer. J. Pathol. 69:529-536, 1972 15. Stites, D.P., Levin, A.S., Lauer, B., Costora, B.H., Fudenberg, H.H. : Selective "Dysgammaglobulineraia" with elevated serum IgA and chronic salmonellosis. Amer. J. Med. 54:260, 1973 16. Spieler, L.E., Levin, A.S., and Fudenberg, H.H.: Agammaglobulinemia and Lymphopenia without infection: A demonstration of immunologic unknowns. Amer. J. Med. 54: 371-377, 1973. 17. Raubitschek, A.S., Levin, A.S., Stites, D.P., Shaw, E.B., and Fudenberg, H.H.: Normal Granulocyte Infusion Therapy for Aspergillosis in a Patient with Chronic Granulomatous Disease. Pediatrics 51-230-233, February 1973. IS. Wybran, J. , Levin, A.S., Spitler, L.E., and Fudenberg, H.H.: Rosette Forming Cells, Immunological Diseases and Transfer Factor. New England Journal of Med. 228:710-713, 1973. 19. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: Human Lymphocyte Transfer Factor in "Methods in Cancer Research", H. Busch (ed.) Acad. Press. Ill 5th Ave., New York, N.Y., 59-106, 1973. 20. Levin, A.S., Spitler, L.E., and Fudenberg, H.H.: Transfer Factor Therapy in Immune Deficiency States. Ann. Rev. Med, (invited Review) 2h_: 1973 21. Levin, A.S., Spitler, L.E., and Fudenberg, H.H.: Immune Deficiency States. Introduction to Clinical Allergy (ed.: B. Feingold) Charles Thomas, Springfield, Illinois, Chapcer 19, 346-359, 1973. 22. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: The Wiskott-Aldrich Syndrome. In the Science and Practice of Clinical Medicine. J.M. Dietschy, L.E. Early, H.H. Fudenberg, A. Renold, C.A. Sanders, and J.P. Sanford (ed.) New York, 1974. 23. Spicier, L.E., Levin, A.S., Fudenberg, H.H.: Transfer.Factor. Clinical Immunology Volume M. (ed. R.A. Good & Bach), 2: 153-175, Academic Press, N.Y. 1974. r r%.t*} A K ... / 24. Fudenberg, H.H., Levin, A.S., Spitler, L.E., Wybran, J.E., and Byers, V.S. Therapeutic Uses of Transfer Factor. llosoital Practice 9:95-104, 1974 \ 25. Levin, A.S., Transfer Factor Therapy: Current Status. So. Med. Journal (invited editorial) _68_, 1465-1466, 1975 26. Fudenberg, H.K., Byers, V.S., Levin, A.S., and Hackett, A.J.: Additional evidence for viral etiology of certain human tumors in A.A. Gottlieb, M.D., Fundamental Aspects of Neoplasia. New York: SpringerVerlag, 1974 27. Fudenberg, H.H., Byers, V.S., and Levin, A.S., : Immunologic Evidence for a Viral Etiology of Certain Malignant Tumors, in Perspectives in Virology (Gustav Stern Symposium), New York, February 4-5, 1974. 28. Levin, A.S., Byers, V.S., Fudenberg, H.H., and Wybran, J.: Immunologic Parameters for monitoring immunotherapy with tumor-specific transfer factor. Trans. Assoc. Amer, Phys.,_8_7, 153-158, 1974 29. -Fudenberg, H.H., Byers, V.S., Levin, A.S., and Hackett, A.J.: Immunologic Evidence for a Viral Etiology of Certain Human Malignant Tumors. Ann. N.Y. Acad. Sci. (In Press, 1975) 30. Wybran, J., Levin, A.S., Fudenberg, H.H., and Goldstein, A.L.: Thymosin: Effects on Normal Human Blood T Cells. Ann. N.Y. Acad. Sci. 249/. 301-307, 1975 31. Carter, J.B., Ponce, B., Byers, V.S., Barr, G.D., Fudenberg, H.H. and Levin, A.S.: Standardization of tissue culture conditions for spontan eous thymidine^I^C incorporation by unstimulated lyr.phocytes : Circadian rhythm in Human Lymphocytes. J. of Allergy and Clinical Immunology 56, 191-196, 1975. 32. Byers, V.S., Levin, A.S., Hackett, A.J., and Fudenberg, H.H.: Tumor specific cell mediated immunity in household contacts of cancer patients. J. of Clin. Invest. 55-500-517, 1975. 33. Levin, A.S., Byers, V.S., Fudenberg, H.H., Hacket/:% A.J., Johnston, J.O., and J.E. Wybran: Osteogenic sarcoma: Immunologic' parameters before and during therapy with tumor specific transfer factor. J. Clin. Invest 55: 487-499, 1975. 34. Levin, A.S., Spitler, L.E., and Fudenberg, H.U.p/ Transfer Factor 1. Methods of Therapy, (end Int. Conf. on Immunodeficiency in Man. St. Petersburg, Fla. 1973), in ETRTII DEFECTS: Original Article Series (Editors: D. Bergsma and R.A. Good), Sinauer, Assoc., Inc., N.Y., 1975. 35. Spitler, L.E., Levin, A.S., and Fudenberg, H.H.: Transfer Factor II. Results of Therapy. (2nd Inc. Conf. on Immunodeficiency Disease in Man, St. Petersburg, Fla., 1973), in BIRTH DEFECTS:. Original Article Series (Editors: D. Eergsmn and R.A. Cood) , Sinauer Assoc., Inc., N.Y., 1975. s s :-* 75 \ 36. Fisher, J., Evers, V.S., Shafrin, M., and Levin, A.S.: Relationship of Cu and Zn levels to metastatic events in human bone sarcomas. Cancer, 37, 356-364, 1976. 37. Spitler, L.E., Levin, A.S., and Fudenberg, H.K.: The Wiskott-Aldrich Syndrome: Immunological Studies in Patients and Family Members Cellular Immunology, 19, 201-218, 1975. 33. Byers, V.S., Levin, A.S., Hackett, A.J., and Johnston, J.W.: Quantitative Immunofluorescent Studies on the Tumor Antigen Bearing Cell in Giant Cell Tumor of Bone and Osteogenic Sarcoma, Cancer Research, 35:2520 2531, 1975. 39. Jones, L.W., Levin, A.S., and Fudenberg, H.K.: Glomerular Antigen Complexes Associated with Transitional Cell Carcinoma. Surgery, Gynecology and Obstetrics 140:896-898, 1975 40. Kaplan, M.A., Byers, V.S., Levin, A.S., German, D., Fudenberg, H.H., and LeCam, L.: Circadian Rhythm in Human Lymphocyte Function. J. Allergy and Clinical Immunology: 58 I, 180-189, 1976. 41. Spitler, L.E., Levin, A.S., and Wybran, J.: Adjuvant Immunotherapy for Malignant Melanoma with BCG and Transfer Factor. Cellular Immunology 21, 1 - 19, 1976. 42. Levin, A.S., Byers, V.S., Hackett, A.J., Johnston, J.O., and LeCam, L.M. Tumor Specific Transfer Factor Therapy in Osteogenic Sarcoma, Immunotherapy in Cancer, Proceedings of ITR-C'nicago, 1975. 43. Byers, V.S., Levin, A.S., Hackett, A.J., Johnston, J.O., and LeCam, L.M. Tumor Specific Transfer Factor Therapy in Osteogenic Sarcoma, A Two-Year Followup Study, Annals of New York Academy of Science, 277, 621-627, 1976. 44. Byers, V.S. and Levin, A.S., Tumor Immunology, in Easic and Clinical Immunology: Eds. Caldwell, J., Fudenberg, H.H., .-tites, D.P. and Wang, A.S., Lange Books, 1976. 45. "Levin, A.S., Byers, V.S., LeCam, L.M., and Johnston, J.O., An Unusual , Metastasis in an Osteogenic Sarcoma Patient on Tumor Specific Transfer Factor Therapy, Transfer Factor, 537-542, Acad*ermic Press, 1976. 46. Byers, V.S., LeCam, L.M., Hackett, A.J., Johnston, J.O. and Levin, A.S.: Familial Incidence of Breast Carcinoma Immunity - A Statistical Survey. Cancer Immunology and Immunotherapy. 2, 163-172, 1977 47. Byers, .S., and Levin, A.S.: Tumor Antigen Density on Osteogenic Sarcoma Cells in Vitro. Cancer Research. 37, 3173-3183, 1977. *?^ ^ ^ J,.. \j i O I Chen. Shi-Han, Scott, C.R., Giblctt, E.F,., Levin, A.S.: Adenosine Deaminase Deficiency: Another Family with a "Silent" Ada Allele and Ni:nr.l Ada Activity in Two Hetcrozygotes. American Journal of Human Genetics. Vol. 29, 642-644, 1977. 49. Marmor, M.D., Nelson, J.W., Levin, A.S.,: Copper Metabolism in American Retinitis Pigmentosa Patients: British Journal of Opthalmologv. Vol. 62. 163-171, 1973. 50. Byers, V.S.,, LeCam, L., Levin, A.S., Johnston, J.O., and Hackett, A.J.: Osteogenic Sarcoma: Immunotherapy of Clinically Disease Free Patients with Transfer Factor: Long-Term Follow-up. Cancer Immunology and Ir.munotheranv - 243-251, 1979. 51. Byers, V.S., Levin, A.S.: Poison Oak III: Genetic Restriction in T Cell Mediated reaccivity-Journal of Clinical Investigation.-Submitted. 52. Newman, B.R., Byers, V.S., German, D., and Levin, A.S.: Variability of Lymphocyte Function by Serum Factors. Journal of Clinical Laboratory Immunology 2, 151-154, 1979. 53. McGovern, J.J.,Jr., Lazaroni, J.L., Saifer, Phyllis, Levin, A.S., Rapp, D.J., Gardner, R.W.: Clinical Evaluation of the Major Plasma and Cellular Measures of Immunity. Journal of Orthomolecular Psychiatry. VoL. 12, No. 1., 1933. 54 . Byers, V .S., Baldwin. R..W . , Levin, A.S., Embleton, M.J , and Price, M.R.: Monoclonal A.ntibodies : Their Use in the Diagnosis and Treatment of Cancer - In probability Models and Cancer, pp. 15--3^*. L. LeCam and J. Neyman (Eds.) North-Holland, 1932. 55. Binder, R.L., Callaway, E., Levin, A.S., Stites, D.P.: Relationship between Creatine Phosphokinase and Immunoglobulins in Unmedicated Caucasian Schizophrenics. Biological Psychiatry. In Press. 1983. 56. McGovern, J.J.,Jr., Rapp, D.J., Levin, A.S.: Phgnol Provokes Abnormal Immune Response During Double-Blind Testing. J ,'A,M.A . Submitted 1983. 0 f 4 <I ALAN SCOTT LEVIN, M.D. BIBLIOGRAPHY (Abstracts Only) 1. Alper, C.A., Levin, A.S., and Rosen, F.S.: Turnover of an I complement component. J. Clin. Invest. May 1965. labeled 4 2 Levin, A.S., Pete, L.D., Fudenberg, H.H.: Immunoglobulins and C Levels in Normal and CNS-SLE -'Cerebrospinal fluids using new micro radio immuno assays. Abstract presented ASCR Western Regional Meetings. 3. Levin, A.S., Stites, D.P., Spitler, L.E., Sahud, M.A. and Fudenberg, H.H.: Induction of "delayed hypersensitivity" in Wiskott-Aldrich pacient by transfer factor. Clin. Res. 18;426, April, 1970. 4. Vyas, G.N., Levin, A.S., and Fudenberg, H.H.: Isoimmunization to human IgA in pregnancy. Clin. Res. 18:157, April 1970. 5. Levin, A.S., Petz, L., and Fudenberg, H.H.: IgG and C^ levels in CSF of patients with active CNS-SLE. Clin. Res. 19:137, June 1971 6. Levin, A.S., Fudenberg, H.H., Hopper, J.., and Nisonoff, A.: Immunohistologic investigations of a Eiclonal Camopachy: Detection of identical antigen in variable regions of IgG and IgM producing cells. Presented at ASH Meeting, San Juan, P.R. Blood XXXVI (6), 831, 1970. 7. Spitler, L.W., Levin, A.S., Stites, D.P., and Fudenberg, H.H.: Current status of transfer factor therapy in Wiskott-Aldrich Syndrome. Presented at ASCI Western Regional Meetings, Carmel, Jan. 1971 Clin. Res. XIX (i ) 162, 1971 8. Levin, A.S., Weiner, R.S., Fudenberg, H.H., Spath, and Petz, L.: Granulocytopenia caused by anticep'nalothin antibodies. Clin. Res. XIX (2) 424, 1971 9. Levin, A.S,Spitler, L.E., Stites, D.P., and Fudenberg, H.H.: Molecular intervention in genetically determined cellular immune deficiency disorders. J. Clin. Invest. 50:59a, 1971 10. Spitler, L.E., Levin, A.S., Fudenberg, H.H., Huber, H.: Abnormal monocyte IgG receptors in the Wiskott-Aldrich Syndrome. Sixth Annual Leukocyte Culture Conference. Academic Press, 1972. 11. Spitler, L.E., Levin, A.S., Stites, D.P., Pirofsky, Fudenberg, H.U.: Transfer Factor Therapy in Mucocutaneous Candidiasis. Sixth Annual Leukocyte Culture Conference. Academic Press, 1972 12. Wybran, J., Spitler, L.E., Levin, A.S., and Fudenberg, II.H.: The Rosette Forming Cell ns an Indicator of Successful Transfer Factor Therapy in Immuno Deficiencies. Clin, Res. XX (3), 1972 12878 13. Levin, A.S., Spicier, L.E., Wybran, J., and Fudenberg, H.H. : Treatment: of Osteogenic Sarcoma with Tumor Specific Transfer Factor. Clin. Res. XX (3), 56S, 1972. 1m . Spicier, L.E., Levin, A.S., and Fudenberg, H.H.: Immunologic Evaluation of Patiencs with Micocutaneous Candidiasis and Results of Transfer Factor Therapy. Clin. Res. XX (3), 519, 1972. 15. Spider, L.E., Levin, A.S., Blois, M.S., Epstein, W. , Fudenberg, H.H., Hellstrom, I., and Hellstrom, K.E.: Lymphocyte Responses to Tumor Specific Antigens in Patients with Malignant Melanoma and Results of Transfer Factor Therapy. J. Clin. Invest. 16. Wybran, J., Levin, A.S., Spider, L.E., and Fudenberg, H.H.: The Human Rosette Forming Cell, Transfer Factor and Prognosis of Cancer. Clin. Res. XX, (3) 635, 1972. 17. Fcnes, D.W. , Mogerman, S.N., Spider, L.E., Stites, D.P., Shinefield, H.R., Fudenberg, H.H., and Levin, A.S.: Graft Versus Host (GVH) in A Di George Patient: Probable Accelerated Induction of T Cell Competence. Clin. Res. XXI (2) 309. 13. Mogerman, S.N., Levin, A.S., Spider, L.W. , Scites, D.P., Fudenberg, H.H. and Shinefield, H.R.: Transfer Factor Therapy in X-Linked Recessive Severe Combined Dual System Immune Deficiency Disorder (SCID). Clin. Res. XXI (2) 310. 19. Carter, J.B., Ponce, B.E., Stites, D.P., Levin, A.S., German, D.F., and Fudenberg, H.H.: Spontaneous Thymidine - 2-^-~t C Incorporation by Unstimulaced Normal Human Peripheral Lymphocytes Tn Vitro: Tissue Culture Conditions and Quantitative Measurements. 20. Carter, J.B., Ponce, B.E., Stites, D.P., Levin, A.S., German, D.Z., and Fudenberg, H.H.: Circadian Cycle of Spontaneous Thymidine-2^ C Incorporation by L'nstimulated Normal Human Peripheral Lymphocytes In Vitro. -------- 21. Fones, D.W., Levin, A.S., Mogerman, S.M., Spitler, L. E. , Stites, D.P., Shinefield, H.R., and Fudenberg, H.H.: Graft Versus Host Followed by Host Versus Graft: Evidence for Accelerated Induction of T-Cell Competence. /. 22: Levin, A. S',y '<Spider, L.E'. , Wybran, J., Byers, V.S., and Fudenberg, H.H.: Treatment of Osteogenic Sarcoma (OS) with Tumor Specific Dialysablc Transfer Factor (TF). Clinical Research, 1973 23. Levin, A.S., Byers, V.S., Fudenberg, H.H., and Wybran, J.E.: Immunologic Parameters for Monitoring Immunotherapy with Tumor Specific Transfer Factor. Clin. Res. 1974. 24. Gardner, R.D., Byers, V.S., Levin, A.S., and Fudenberg, H.H.: Frozen Human Lymphocytes: Dissociation between Tumor Specific Cytotoxicity and Mixed Leukocvte Reactivitv (MI.C Renctivitv). r* ->*?Q Clin. Res. 1974 . ' ' X6 25. Byers, V.S., Levin, A.S., and Fudenberg, H.H.: Detection of Tumor Specific Immunity in Normal Household Contacts of Tumor Bearing Patients. Clin. Res. 1974. 26. Levin, A.S., Byers, V.S., Johnston, J.O., Hackett, A.J., and Fudenberg, H.H.: Host-Tumor Relationships in Giant Cell Sarcoma of Bone (GCS): Measurement by Quantitative Immunofluorescence. Clin. Res. 1974 27. Fudenberg, H.H., Byers, V.S., Levin, A.S., and Hackett, A.J.: Evidence for Viral Etiology of Human Hypernophroma and Osteosarcoma. Perspectives in Virology. In Press, 1974 28. Levin, A.S., Byers, V.S., LeCam, L., and Johnston, J.O.: Evidence for Regression in Osteogenic Sarcoma Induced by Tumor Specific Transfer Factor. 2nd International Workshop on Transfer Factor. Frederick, MD., 1975. 29. Hackett, A., Springer, L., Levin, A.S., and Fink, M.: Transmission and Scanning Electron Microscopic Studies on Osteo Sarcoma Before and After Transfer Factor Therapy. Cancer Research 16:193, 1975 30. Levin, A.S., LeCam, L.M., Hackett, A.J. and Johnston, J.O.: Osteosarcoma (O.S.): 5 Year Followup of Epidemiology and Tumor Specific Transfer Factor Therapy (TSTF). Clin. Res. 1976 31. Levin, A.S., LeCam, L.M., and Agraz, J.M.: Dip-Stick Method of Quanti tative Immunofluorescence. Clin. Res. 1976, 32. Neuman, B.R., Byers, V.S., Levin, A.S., and Jerman, D.: Circadian Influences on T. Lymphocyte Function Mediacec by Serum Factors. Clin. Res. 1976 33. Levin, A.S., Kassel, S.D., and Flam, M . , A New Diagnostic Index: Collagen Disease vs. Malignancy vs. Infectious Disease. J.A.M.A. 237, 1916, 1977. > 34. Levin, A.S., and Baldwin, R.W.: Solid Phase Fl'uoroimmunoassay to Detect Serum Immune Complexes. 6th International Congress on Immunofluorescence, Vienna, Austria. 1973 35, Levin, A.S., McGovern, J.J.,Jr., Miller, J.B., LeCam, L.L., and Lazaroni, J.: Non-Anaphylactic Food Allergies Mediated by Immune Complexes: Ann. Allergy, Abstract in Press. 1981 & 4/' Dr. Peter Orris is an internist practicing in Chicago, Illinois. His curriculum vitae will be supplied. Dr. Orris w i l l testify as to the clinical aspects of the diseases in the representative plaintiff veterans. His testimony will be based upon a medical records review and an analysis of various test results that will have been performed upon the repre sentative plaintiffs. Dr. Orris will also testify on generic causation and specific proximate causation in relation to each representative veteran plaintiff. He will also testify as to prognosis for each representative veteran plaintiff 12981